PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
1698905-6	1990	The present study demonstrates the applicability of the BEI of 5"-Nase reaction to SEM histochemistry of lymphatic capillaries stained with heavy metal.	Metals	146-151	5'-nucleotidase ecto	Homo sapiens	63-70
2137649-0	1990	Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5"-nucleotidase (CD73).	Glycosylphosphatidylinositols	64-93	5'-nucleotidase ecto	Homo sapiens	138-158
2137649-0	1990	Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5"-nucleotidase (CD73).	Glycosylphosphatidylinositols	64-93	5'-nucleotidase ecto	Homo sapiens	160-164
2137649-1	1990	A panel of monoclonal antibodies to the 69 kDa glycosyl phosphatidylinositol anchored lymphocyte differentiation antigen ecto-5"-nucleotidase (ecto-5"-NT, CD73) was produced using highly purified human placental 5"-NT as immunogen.	Glycosylphosphatidylinositols	47-76	5'-nucleotidase ecto	Homo sapiens	121-141
2137649-1	1990	A panel of monoclonal antibodies to the 69 kDa glycosyl phosphatidylinositol anchored lymphocyte differentiation antigen ecto-5"-nucleotidase (ecto-5"-NT, CD73) was produced using highly purified human placental 5"-NT as immunogen.	Glycosylphosphatidylinositols	47-76	5'-nucleotidase ecto	Homo sapiens	143-153
2137649-1	1990	A panel of monoclonal antibodies to the 69 kDa glycosyl phosphatidylinositol anchored lymphocyte differentiation antigen ecto-5"-nucleotidase (ecto-5"-NT, CD73) was produced using highly purified human placental 5"-NT as immunogen.	Glycosylphosphatidylinositols	47-76	5'-nucleotidase ecto	Homo sapiens	155-159
2137649-10	1990	Given the tissue distribution of CD73, along with its glycosyl phosphatidylinositol membrane anchoring and the observation that some CD73 antibodies are mitogenic, we propose that this interesting antigen may play a role in cell activation, lymphocyte homing, and/or cell adhesion.	Glycosylphosphatidylinositols	54-83	5'-nucleotidase ecto	Homo sapiens	33-37
33799762-5	2021	Structural and functional studies have demonstrated that silencing or inhibition of ABCC6 with probenecid changed the expression of several genes and proteins such as NT5E and TNAP, as well as Lamin, and CDK1, which are involved in cell motility and cell cycle.	Probenecid	95-105	5'-nucleotidase ecto	Homo sapiens	167-171
33973110-2	2021	Mice lacking adenosine A2A receptors (A2AR) develop spontaneous OA by 16 weeks of age, a finding relevant to human OA since loss of adenosine signaling due to diminished adenosine production (NT5E deficiency) also leads to development of OA in mice and humans.	Adenosine	13-22	5'-nucleotidase ecto	Homo sapiens	192-196
33973110-2	2021	Mice lacking adenosine A2A receptors (A2AR) develop spontaneous OA by 16 weeks of age, a finding relevant to human OA since loss of adenosine signaling due to diminished adenosine production (NT5E deficiency) also leads to development of OA in mice and humans.	Adenosine	132-141	5'-nucleotidase ecto	Homo sapiens	192-196
33973110-2	2021	Mice lacking adenosine A2A receptors (A2AR) develop spontaneous OA by 16 weeks of age, a finding relevant to human OA since loss of adenosine signaling due to diminished adenosine production (NT5E deficiency) also leads to development of OA in mice and humans.	Adenosine	132-141	5'-nucleotidase ecto	Homo sapiens	192-196
29274390-3	2018	Sequential hydrolysis of extracellular ATP catalyzed by ectonucleotidases (e.g. CD39, CD73) is the main pathway for the generation of adenosine, which in turn activates P1 receptors.	Adenosine Triphosphate	39-42	5'-nucleotidase ecto	Homo sapiens	86-90
29274390-3	2018	Sequential hydrolysis of extracellular ATP catalyzed by ectonucleotidases (e.g. CD39, CD73) is the main pathway for the generation of adenosine, which in turn activates P1 receptors.	Adenosine	134-143	5'-nucleotidase ecto	Homo sapiens	86-90
25589619-6	2015	Dabrafenib and trametinib in BRAF V600E/K, and trametinib in BRAF wild-type tumor cells induced apoptosis markers, upregulated HLA molecule expression, and downregulated certain immunosuppressive factors such as PD-L1, IL1, IL8, NT5E, and VEGFA.	trametinib	47-57	5'-nucleotidase ecto	Homo sapiens	229-233
29745882-3	2018	Therefore, the extracellular purinergic microenvironment is under control of ectonucleotidases CD39 and CD73 degrading pro-inflammatory adenosine triphosphate (ATP) to anti-inflammatory adenosine as well as adenosine deaminase bound to CD26 deactivating adenosine.	Adenosine Triphosphate	136-158	5'-nucleotidase ecto	Homo sapiens	104-108
29745882-3	2018	Therefore, the extracellular purinergic microenvironment is under control of ectonucleotidases CD39 and CD73 degrading pro-inflammatory adenosine triphosphate (ATP) to anti-inflammatory adenosine as well as adenosine deaminase bound to CD26 deactivating adenosine.	Adenosine Triphosphate	160-163	5'-nucleotidase ecto	Homo sapiens	104-108
29745882-3	2018	Therefore, the extracellular purinergic microenvironment is under control of ectonucleotidases CD39 and CD73 degrading pro-inflammatory adenosine triphosphate (ATP) to anti-inflammatory adenosine as well as adenosine deaminase bound to CD26 deactivating adenosine.	Adenosine	136-145	5'-nucleotidase ecto	Homo sapiens	104-108
29745882-3	2018	Therefore, the extracellular purinergic microenvironment is under control of ectonucleotidases CD39 and CD73 degrading pro-inflammatory adenosine triphosphate (ATP) to anti-inflammatory adenosine as well as adenosine deaminase bound to CD26 deactivating adenosine.	Adenosine	186-195	5'-nucleotidase ecto	Homo sapiens	104-108
34922916-4	2022	Here, CD39 first converts ATP and adenosine diphosphate(ADP) into AMP, after which AMP is dephosphorylated into adenosine by CD73.	Adenosine Monophosphate	83-86	5'-nucleotidase ecto	Homo sapiens	125-129
25589619-6	2015	Dabrafenib and trametinib in BRAF V600E/K, and trametinib in BRAF wild-type tumor cells induced apoptosis markers, upregulated HLA molecule expression, and downregulated certain immunosuppressive factors such as PD-L1, IL1, IL8, NT5E, and VEGFA.	dabrafenib	0-10	5'-nucleotidase ecto	Homo sapiens	229-233
23770243-5	2013	Plasma membrane ectonucleoside triphosphate diphosphohydrolase 1 CD39 and ecto-5"-nucleotidase CD73 hydrolyze ATP to adenosine, which induces CSR in B cells in an autonomous fashion.	Adenosine Triphosphate	110-113	5'-nucleotidase ecto	Homo sapiens	74-94
23770243-5	2013	Plasma membrane ectonucleoside triphosphate diphosphohydrolase 1 CD39 and ecto-5"-nucleotidase CD73 hydrolyze ATP to adenosine, which induces CSR in B cells in an autonomous fashion.	Adenosine Triphosphate	110-113	5'-nucleotidase ecto	Homo sapiens	95-99
23770243-5	2013	Plasma membrane ectonucleoside triphosphate diphosphohydrolase 1 CD39 and ecto-5"-nucleotidase CD73 hydrolyze ATP to adenosine, which induces CSR in B cells in an autonomous fashion.	Adenosine	117-126	5'-nucleotidase ecto	Homo sapiens	74-94
23770243-5	2013	Plasma membrane ectonucleoside triphosphate diphosphohydrolase 1 CD39 and ecto-5"-nucleotidase CD73 hydrolyze ATP to adenosine, which induces CSR in B cells in an autonomous fashion.	Adenosine	117-126	5'-nucleotidase ecto	Homo sapiens	95-99
23770243-6	2013	Notably, CVID patients with impaired class-switched antibody responses are selectively deficient in CD73 expression in B cells, suggesting that CD73-dependent adenosine generation contributes to the pathogenesis of this disease.	Adenosine	159-168	5'-nucleotidase ecto	Homo sapiens	100-104
23770243-6	2013	Notably, CVID patients with impaired class-switched antibody responses are selectively deficient in CD73 expression in B cells, suggesting that CD73-dependent adenosine generation contributes to the pathogenesis of this disease.	Adenosine	159-168	5'-nucleotidase ecto	Homo sapiens	144-148
34922916-0	2022	Crowding within synaptic junctions influence the degradation of adenoside nucleotides by CD39 and CD73 ectonucleotidases.	adenoside nucleotides	64-85	5'-nucleotidase ecto	Homo sapiens	98-102
34922916-3	2022	Oftentimes nucleotide degradation occures in a sequential manner, of which ATP degradation by CD39 and CD73 are representative example.	Adenosine Triphosphate	75-78	5'-nucleotidase ecto	Homo sapiens	103-107
34922916-4	2022	Here, CD39 first converts ATP and adenosine diphosphate(ADP) into AMP, after which AMP is dephosphorylated into adenosine by CD73.	Adenosine Triphosphate	26-29	5'-nucleotidase ecto	Homo sapiens	125-129
34922916-4	2022	Here, CD39 first converts ATP and adenosine diphosphate(ADP) into AMP, after which AMP is dephosphorylated into adenosine by CD73.	Adenosine	34-43	5'-nucleotidase ecto	Homo sapiens	125-129
34922916-4	2022	Here, CD39 first converts ATP and adenosine diphosphate(ADP) into AMP, after which AMP is dephosphorylated into adenosine by CD73.	Adenosine Diphosphate	56-59	5'-nucleotidase ecto	Homo sapiens	125-129
34922916-4	2022	Here, CD39 first converts ATP and adenosine diphosphate(ADP) into AMP, after which AMP is dephosphorylated into adenosine by CD73.	Adenosine Monophosphate	66-69	5'-nucleotidase ecto	Homo sapiens	125-129
34922916-4	2022	Here, CD39 first converts ATP and adenosine diphosphate(ADP) into AMP, after which AMP is dephosphorylated into adenosine by CD73.	Adenosine	112-121	5'-nucleotidase ecto	Homo sapiens	125-129
34922916-5	2022	Hence, the concerted activity of CD39 and CD73 can help shape cellular responses to extracellular ATP.	Adenosine Triphosphate	98-101	5'-nucleotidase ecto	Homo sapiens	42-46
34922916-7	2022	In this study, we demonstrate that crowders within synaptic junctions, which can include globular proteins like cytokines and membrane-bound proteins, impact coupled CD39/CD73 electronucleotidase activity and in turn, the availability of intrasynapse ATP.	Adenosine Triphosphate	251-254	5'-nucleotidase ecto	Homo sapiens	171-175
34961895-2	2022	Damage-associated stimuli, such as hypoxia and mechanical stress, induce the cellular release of ATP and NAD+ and upregulate the expression of the nucleotide-degrading purinergic ectoenzyme cascade, including adenosine-generating CD73.	Adenosine	209-218	5'-nucleotidase ecto	Homo sapiens	230-234
34862113-0	2022	Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study.	Cisplatin	114-123	5'-nucleotidase ecto	Homo sapiens	26-30
34862113-8	2022	KEY FINDINGS: CD73-siRNA transfection has significantly decreased the cell viability and enhanced the chemosensitivity of A-549 and NCI-H1299 cells to cisplatin.	Cisplatin	151-160	5'-nucleotidase ecto	Homo sapiens	14-18
34862113-10	2022	Besides, combined cisplatin therapy with CD73-siRNA transfection has potentiated the aforementioned anti-tumoral effects of cisplatin on NSCLC cells.	Cisplatin	18-27	5'-nucleotidase ecto	Homo sapiens	41-45
34862113-10	2022	Besides, combined cisplatin therapy with CD73-siRNA transfection has potentiated the aforementioned anti-tumoral effects of cisplatin on NSCLC cells.	Cisplatin	124-133	5'-nucleotidase ecto	Homo sapiens	41-45
34862113-11	2022	SIGNIFICANCE: Besides suppressing anti-tumoral immune responses, tumor-intrinsic CD73 can facilitate NSCLC development, and the combined cisplatin therapy with CD73-siRNA transfection can substantially enhance the chemosensitivity of NSCLC to cisplatin and potentiates cisplatin-induced anti-tumoral effects on NSCLC.	Cisplatin	137-146	5'-nucleotidase ecto	Homo sapiens	160-164
34862113-11	2022	SIGNIFICANCE: Besides suppressing anti-tumoral immune responses, tumor-intrinsic CD73 can facilitate NSCLC development, and the combined cisplatin therapy with CD73-siRNA transfection can substantially enhance the chemosensitivity of NSCLC to cisplatin and potentiates cisplatin-induced anti-tumoral effects on NSCLC.	Cisplatin	243-252	5'-nucleotidase ecto	Homo sapiens	81-85
34862113-11	2022	SIGNIFICANCE: Besides suppressing anti-tumoral immune responses, tumor-intrinsic CD73 can facilitate NSCLC development, and the combined cisplatin therapy with CD73-siRNA transfection can substantially enhance the chemosensitivity of NSCLC to cisplatin and potentiates cisplatin-induced anti-tumoral effects on NSCLC.	Cisplatin	243-252	5'-nucleotidase ecto	Homo sapiens	160-164
34862113-11	2022	SIGNIFICANCE: Besides suppressing anti-tumoral immune responses, tumor-intrinsic CD73 can facilitate NSCLC development, and the combined cisplatin therapy with CD73-siRNA transfection can substantially enhance the chemosensitivity of NSCLC to cisplatin and potentiates cisplatin-induced anti-tumoral effects on NSCLC.	Cisplatin	269-278	5'-nucleotidase ecto	Homo sapiens	81-85
34862113-11	2022	SIGNIFICANCE: Besides suppressing anti-tumoral immune responses, tumor-intrinsic CD73 can facilitate NSCLC development, and the combined cisplatin therapy with CD73-siRNA transfection can substantially enhance the chemosensitivity of NSCLC to cisplatin and potentiates cisplatin-induced anti-tumoral effects on NSCLC.	Cisplatin	269-278	5'-nucleotidase ecto	Homo sapiens	160-164
34961895-0	2022	Mono-ADP-ribosylation sites of human CD73 inhibit its adenosine-generating enzymatic activity.	Adenosine	54-63	5'-nucleotidase ecto	Homo sapiens	37-41
34961895-1	2022	CD73-derived adenosine plays a major role in damage-induced tissue responses by inhibiting inflammation.	Adenosine	13-22	5'-nucleotidase ecto	Homo sapiens	0-4
34961895-5	2022	Multi-colour immunoblotting with an anti-etheno-adenosine antibody showed ARTC1-mediated transfer of ADP-ribose together with the etheno label to CD73.	etheno	41-47	5'-nucleotidase ecto	Homo sapiens	146-150
34961895-5	2022	Multi-colour immunoblotting with an anti-etheno-adenosine antibody showed ARTC1-mediated transfer of ADP-ribose together with the etheno label to CD73.	Adenosine	48-57	5'-nucleotidase ecto	Homo sapiens	146-150
34961895-6	2022	HPLC analysis of the enzymatic activity of in vitro-ribosylated CD73 revealed strong inhibition of adenosine generation in comparison to non-ribosylated CD73.	Adenosine	99-108	5'-nucleotidase ecto	Homo sapiens	64-68
34961895-9	2022	Our study identifies human CD73 as target for ARTC1-mediated mono-ADP-ribosylation, which can profoundly modulate its adenosine-generating activity.	Mono-S	61-65	5'-nucleotidase ecto	Homo sapiens	27-31
34961895-9	2022	Our study identifies human CD73 as target for ARTC1-mediated mono-ADP-ribosylation, which can profoundly modulate its adenosine-generating activity.	Adenosine Diphosphate	66-69	5'-nucleotidase ecto	Homo sapiens	27-31
34961895-9	2022	Our study identifies human CD73 as target for ARTC1-mediated mono-ADP-ribosylation, which can profoundly modulate its adenosine-generating activity.	Adenosine	118-127	5'-nucleotidase ecto	Homo sapiens	27-31
34403084-0	2021	Substrate binding modes of purine and pyrimidine nucleotides to human ecto-5"-nucleotidase (CD73) and inhibition by their bisphosphonic acid derivatives.	purine	27-33	5'-nucleotidase ecto	Homo sapiens	70-90
34948316-4	2021	Adenosine is produced starting from the highly immunostimulatory ATP, which is progressively hydrolyzed to ADP and adenosine by CD39 and CD73.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	137-141
34948316-4	2021	Adenosine is produced starting from the highly immunostimulatory ATP, which is progressively hydrolyzed to ADP and adenosine by CD39 and CD73.	Adenosine Triphosphate	65-68	5'-nucleotidase ecto	Homo sapiens	137-141
34948316-4	2021	Adenosine is produced starting from the highly immunostimulatory ATP, which is progressively hydrolyzed to ADP and adenosine by CD39 and CD73.	Adenosine Diphosphate	107-110	5'-nucleotidase ecto	Homo sapiens	137-141
34948316-4	2021	Adenosine is produced starting from the highly immunostimulatory ATP, which is progressively hydrolyzed to ADP and adenosine by CD39 and CD73.	Adenosine	115-124	5'-nucleotidase ecto	Homo sapiens	137-141
34948316-5	2021	Cancer cells express high levels of CD39 and CD73 ectoenzymes, thus converting immunostimulatory purinergic signal of ATP into an immunosuppressive signal.	Adenosine Triphosphate	118-121	5'-nucleotidase ecto	Homo sapiens	45-49
34697820-3	2021	CD39 catalyzes the extracellular hydrolysis of nucleoside tri- and diphosphates, mainly adenosine 5"-triphosphate (ATP) and ADP, yielding adenosine monophosphate, which is further hydrolyzed by ecto-5"-nucleotidase (CD73) to produce adenosine.	Adenosine Triphosphate	115-118	5'-nucleotidase ecto	Homo sapiens	216-220
34697820-3	2021	CD39 catalyzes the extracellular hydrolysis of nucleoside tri- and diphosphates, mainly adenosine 5"-triphosphate (ATP) and ADP, yielding adenosine monophosphate, which is further hydrolyzed by ecto-5"-nucleotidase (CD73) to produce adenosine.	Adenosine Diphosphate	124-127	5'-nucleotidase ecto	Homo sapiens	194-214
34697820-3	2021	CD39 catalyzes the extracellular hydrolysis of nucleoside tri- and diphosphates, mainly adenosine 5"-triphosphate (ATP) and ADP, yielding adenosine monophosphate, which is further hydrolyzed by ecto-5"-nucleotidase (CD73) to produce adenosine.	Adenosine Diphosphate	124-127	5'-nucleotidase ecto	Homo sapiens	216-220
34697820-3	2021	CD39 catalyzes the extracellular hydrolysis of nucleoside tri- and diphosphates, mainly adenosine 5"-triphosphate (ATP) and ADP, yielding adenosine monophosphate, which is further hydrolyzed by ecto-5"-nucleotidase (CD73) to produce adenosine.	Adenosine	138-147	5'-nucleotidase ecto	Homo sapiens	194-214
34697820-3	2021	CD39 catalyzes the extracellular hydrolysis of nucleoside tri- and diphosphates, mainly adenosine 5"-triphosphate (ATP) and ADP, yielding adenosine monophosphate, which is further hydrolyzed by ecto-5"-nucleotidase (CD73) to produce adenosine.	Adenosine	138-147	5'-nucleotidase ecto	Homo sapiens	216-220
34697820-3	2021	CD39 catalyzes the extracellular hydrolysis of nucleoside tri- and diphosphates, mainly adenosine 5"-triphosphate (ATP) and ADP, yielding adenosine monophosphate, which is further hydrolyzed by ecto-5"-nucleotidase (CD73) to produce adenosine.	Adenosine	233-242	5'-nucleotidase ecto	Homo sapiens	194-214
34697820-3	2021	CD39 catalyzes the extracellular hydrolysis of nucleoside tri- and diphosphates, mainly adenosine 5"-triphosphate (ATP) and ADP, yielding adenosine monophosphate, which is further hydrolyzed by ecto-5"-nucleotidase (CD73) to produce adenosine.	Adenosine	233-242	5'-nucleotidase ecto	Homo sapiens	216-220
34476674-2	2021	Abeta can affect astrocytic gliotransmitters release, namely ATP, which is rapidly metabolized into adenosine by ecto-5"-nucleotidase, CD73, resulting in adenosine A2A receptors (A2AR) activation that bolsters neurodegeneration.	Adenosine Triphosphate	61-64	5'-nucleotidase ecto	Homo sapiens	113-133
34476674-2	2021	Abeta can affect astrocytic gliotransmitters release, namely ATP, which is rapidly metabolized into adenosine by ecto-5"-nucleotidase, CD73, resulting in adenosine A2A receptors (A2AR) activation that bolsters neurodegeneration.	Adenosine Triphosphate	61-64	5'-nucleotidase ecto	Homo sapiens	135-139
34476674-2	2021	Abeta can affect astrocytic gliotransmitters release, namely ATP, which is rapidly metabolized into adenosine by ecto-5"-nucleotidase, CD73, resulting in adenosine A2A receptors (A2AR) activation that bolsters neurodegeneration.	Adenosine	100-109	5'-nucleotidase ecto	Homo sapiens	113-133
34476674-2	2021	Abeta can affect astrocytic gliotransmitters release, namely ATP, which is rapidly metabolized into adenosine by ecto-5"-nucleotidase, CD73, resulting in adenosine A2A receptors (A2AR) activation that bolsters neurodegeneration.	Adenosine	100-109	5'-nucleotidase ecto	Homo sapiens	135-139
34476674-2	2021	Abeta can affect astrocytic gliotransmitters release, namely ATP, which is rapidly metabolized into adenosine by ecto-5"-nucleotidase, CD73, resulting in adenosine A2A receptors (A2AR) activation that bolsters neurodegeneration.	Adenosine	154-163	5'-nucleotidase ecto	Homo sapiens	113-133
34476674-2	2021	Abeta can affect astrocytic gliotransmitters release, namely ATP, which is rapidly metabolized into adenosine by ecto-5"-nucleotidase, CD73, resulting in adenosine A2A receptors (A2AR) activation that bolsters neurodegeneration.	Adenosine	154-163	5'-nucleotidase ecto	Homo sapiens	135-139
34476674-9	2021	Finally, the blockade of CD73-mediated extracellular formation of ATP-derived adenosine prevented the Abeta-induced increase of Cx43 hemichannel activity and of ATP release.	Adenosine Triphosphate	66-69	5'-nucleotidase ecto	Homo sapiens	25-29
34476674-9	2021	Finally, the blockade of CD73-mediated extracellular formation of ATP-derived adenosine prevented the Abeta-induced increase of Cx43 hemichannel activity and of ATP release.	Adenosine	78-87	5'-nucleotidase ecto	Homo sapiens	25-29
34476674-9	2021	Finally, the blockade of CD73-mediated extracellular formation of ATP-derived adenosine prevented the Abeta-induced increase of Cx43 hemichannel activity and of ATP release.	Adenosine Triphosphate	161-164	5'-nucleotidase ecto	Homo sapiens	25-29
34476674-10	2021	Overall, the data identify a feed-forward loop involving astrocytic A2AR and Cx43 hemichannels, whereby A2AR increase Cx43 hemichannel activity leading to increased ATP release, which is converted into adenosine by CD73, sustaining the increased astrocytic A2AR activity in AD-like conditions.	Adenosine Triphosphate	165-168	5'-nucleotidase ecto	Homo sapiens	215-219
34476674-10	2021	Overall, the data identify a feed-forward loop involving astrocytic A2AR and Cx43 hemichannels, whereby A2AR increase Cx43 hemichannel activity leading to increased ATP release, which is converted into adenosine by CD73, sustaining the increased astrocytic A2AR activity in AD-like conditions.	Adenosine	202-211	5'-nucleotidase ecto	Homo sapiens	215-219
34697820-3	2021	CD39 catalyzes the extracellular hydrolysis of nucleoside tri- and diphosphates, mainly adenosine 5"-triphosphate (ATP) and ADP, yielding adenosine monophosphate, which is further hydrolyzed by ecto-5"-nucleotidase (CD73) to produce adenosine.	Nucleosides	47-57	5'-nucleotidase ecto	Homo sapiens	194-214
34697820-3	2021	CD39 catalyzes the extracellular hydrolysis of nucleoside tri- and diphosphates, mainly adenosine 5"-triphosphate (ATP) and ADP, yielding adenosine monophosphate, which is further hydrolyzed by ecto-5"-nucleotidase (CD73) to produce adenosine.	Nucleosides	47-57	5'-nucleotidase ecto	Homo sapiens	216-220
34697820-3	2021	CD39 catalyzes the extracellular hydrolysis of nucleoside tri- and diphosphates, mainly adenosine 5"-triphosphate (ATP) and ADP, yielding adenosine monophosphate, which is further hydrolyzed by ecto-5"-nucleotidase (CD73) to produce adenosine.	tri- and diphosphates	58-79	5'-nucleotidase ecto	Homo sapiens	194-214
34697820-3	2021	CD39 catalyzes the extracellular hydrolysis of nucleoside tri- and diphosphates, mainly adenosine 5"-triphosphate (ATP) and ADP, yielding adenosine monophosphate, which is further hydrolyzed by ecto-5"-nucleotidase (CD73) to produce adenosine.	tri- and diphosphates	58-79	5'-nucleotidase ecto	Homo sapiens	216-220
34697820-3	2021	CD39 catalyzes the extracellular hydrolysis of nucleoside tri- and diphosphates, mainly adenosine 5"-triphosphate (ATP) and ADP, yielding adenosine monophosphate, which is further hydrolyzed by ecto-5"-nucleotidase (CD73) to produce adenosine.	Adenosine	88-97	5'-nucleotidase ecto	Homo sapiens	194-214
34697820-3	2021	CD39 catalyzes the extracellular hydrolysis of nucleoside tri- and diphosphates, mainly adenosine 5"-triphosphate (ATP) and ADP, yielding adenosine monophosphate, which is further hydrolyzed by ecto-5"-nucleotidase (CD73) to produce adenosine.	Adenosine	88-97	5'-nucleotidase ecto	Homo sapiens	216-220
34697820-3	2021	CD39 catalyzes the extracellular hydrolysis of nucleoside tri- and diphosphates, mainly adenosine 5"-triphosphate (ATP) and ADP, yielding adenosine monophosphate, which is further hydrolyzed by ecto-5"-nucleotidase (CD73) to produce adenosine.	Adenosine Triphosphate	115-118	5'-nucleotidase ecto	Homo sapiens	194-214
34403084-5	2021	While AMP is the major substrate of the enzyme, CD73 has been reported to hydrolyse other 5"-nucleoside monophosphates.	Adenosine Monophosphate	6-9	5'-nucleotidase ecto	Homo sapiens	48-52
34403084-5	2021	While AMP is the major substrate of the enzyme, CD73 has been reported to hydrolyse other 5"-nucleoside monophosphates.	5"-nucleoside monophosphates	90-118	5'-nucleotidase ecto	Homo sapiens	48-52
34403084-8	2021	We characterised the initial step of AMP hydrolysis, the binding mode of AMP to the open conformation of CD73 and compared that to other monophosphate substrates.	Adenosine Monophosphate	73-76	5'-nucleotidase ecto	Homo sapiens	105-109
34403084-8	2021	We characterised the initial step of AMP hydrolysis, the binding mode of AMP to the open conformation of CD73 and compared that to other monophosphate substrates.	monophosphate	137-150	5'-nucleotidase ecto	Homo sapiens	105-109
34403084-0	2021	Substrate binding modes of purine and pyrimidine nucleotides to human ecto-5"-nucleotidase (CD73) and inhibition by their bisphosphonic acid derivatives.	purine	27-33	5'-nucleotidase ecto	Homo sapiens	92-96
34403084-0	2021	Substrate binding modes of purine and pyrimidine nucleotides to human ecto-5"-nucleotidase (CD73) and inhibition by their bisphosphonic acid derivatives.	Pyrimidine Nucleotides	38-60	5'-nucleotidase ecto	Homo sapiens	70-90
34403084-0	2021	Substrate binding modes of purine and pyrimidine nucleotides to human ecto-5"-nucleotidase (CD73) and inhibition by their bisphosphonic acid derivatives.	Pyrimidine Nucleotides	38-60	5'-nucleotidase ecto	Homo sapiens	92-96
34403084-0	2021	Substrate binding modes of purine and pyrimidine nucleotides to human ecto-5"-nucleotidase (CD73) and inhibition by their bisphosphonic acid derivatives.	bisphosphonic acid	122-140	5'-nucleotidase ecto	Homo sapiens	70-90
34403084-2	2021	CD73 hydrolyses AMP and is the major control point for the levels of extracellular adenosine.	Adenosine Monophosphate	16-19	5'-nucleotidase ecto	Homo sapiens	0-4
34403084-2	2021	CD73 hydrolyses AMP and is the major control point for the levels of extracellular adenosine.	Adenosine	83-92	5'-nucleotidase ecto	Homo sapiens	0-4
34403084-3	2021	Inhibitors of CD73 thus block the immunosuppressive action of adenosine, a promising approach for cancer immunotherapy.	Adenosine	62-71	5'-nucleotidase ecto	Homo sapiens	14-18
34403084-4	2021	Interestingly, ADP and ATP are competitive inhibitors of CD73, with the most potent small-molecule inhibitors to date being non-hydrolysable ADP analogues.	Adenosine Diphosphate	15-18	5'-nucleotidase ecto	Homo sapiens	57-61
34403084-4	2021	Interestingly, ADP and ATP are competitive inhibitors of CD73, with the most potent small-molecule inhibitors to date being non-hydrolysable ADP analogues.	Adenosine Triphosphate	23-26	5'-nucleotidase ecto	Homo sapiens	57-61
34403084-4	2021	Interestingly, ADP and ATP are competitive inhibitors of CD73, with the most potent small-molecule inhibitors to date being non-hydrolysable ADP analogues.	Adenosine Diphosphate	141-144	5'-nucleotidase ecto	Homo sapiens	57-61
34838121-13	2021	We discovered that cell-specific CD39 expression in macrophages and CD73 expression in HCC cells synergistically activated the eATP-adenosine pathway and produced more adenosine, thereby impairing CD8+ T cell function and driving anti-PD1 resistance.	eatp	127-131	5'-nucleotidase ecto	Homo sapiens	68-72
34838121-13	2021	We discovered that cell-specific CD39 expression in macrophages and CD73 expression in HCC cells synergistically activated the eATP-adenosine pathway and produced more adenosine, thereby impairing CD8+ T cell function and driving anti-PD1 resistance.	Adenosine	132-141	5'-nucleotidase ecto	Homo sapiens	68-72
34838121-13	2021	We discovered that cell-specific CD39 expression in macrophages and CD73 expression in HCC cells synergistically activated the eATP-adenosine pathway and produced more adenosine, thereby impairing CD8+ T cell function and driving anti-PD1 resistance.	Adenosine	168-177	5'-nucleotidase ecto	Homo sapiens	68-72
34758173-4	2022	Inactivating mutations in ABCC6, ENPP1 and NT5E are the genetic cause of these diseases, respectively, and all of them result in reduced inorganic pyrophosphate (PPi ) concentration in the circulation.	diphosphoric acid	147-160	5'-nucleotidase ecto	Homo sapiens	43-47
34884548-4	2021	Under these circumstances, an increasing level of extracellular adenosine via the activation of ecto-5"-nucleotidase (CD73) and consequent adenosine receptor signalling is a typical mechanism that tumours use to evade immune surveillance.	Adenosine	64-73	5'-nucleotidase ecto	Homo sapiens	96-116
34884548-4	2021	Under these circumstances, an increasing level of extracellular adenosine via the activation of ecto-5"-nucleotidase (CD73) and consequent adenosine receptor signalling is a typical mechanism that tumours use to evade immune surveillance.	Adenosine	64-73	5'-nucleotidase ecto	Homo sapiens	118-122
34884548-4	2021	Under these circumstances, an increasing level of extracellular adenosine via the activation of ecto-5"-nucleotidase (CD73) and consequent adenosine receptor signalling is a typical mechanism that tumours use to evade immune surveillance.	Adenosine	139-148	5'-nucleotidase ecto	Homo sapiens	96-116
34884548-4	2021	Under these circumstances, an increasing level of extracellular adenosine via the activation of ecto-5"-nucleotidase (CD73) and consequent adenosine receptor signalling is a typical mechanism that tumours use to evade immune surveillance.	Adenosine	139-148	5'-nucleotidase ecto	Homo sapiens	118-122
34884548-5	2021	CD73 is responsible for the conversion of adenosine monophosphate to adenosine.	Adenosine	42-51	5'-nucleotidase ecto	Homo sapiens	0-4
34884548-5	2021	CD73 is responsible for the conversion of adenosine monophosphate to adenosine.	Adenosine	69-78	5'-nucleotidase ecto	Homo sapiens	0-4
34884548-7	2021	Hence, targetting CD73"s signalling is important for the reversal of adenosine-facilitated immune suppression.	Adenosine	69-78	5'-nucleotidase ecto	Homo sapiens	18-22
34884993-4	2021	We first reveal that CD73 protein level specifically accumulates in CAF-S1 in breast cancer patients.	caf-s1	68-74	5'-nucleotidase ecto	Homo sapiens	21-25
34884993-8	2021	CONCLUSIONS: Our data support the potential clinical benefit of using both anti-CD73 and immune-checkpoint inhibitors in breast cancer patients for inhibiting CAF-S1-mediated immunosuppression and enhancing anti-tumor immune response.	caf-s1	159-165	5'-nucleotidase ecto	Homo sapiens	80-84
34508993-11	2021	In addition, CD73high tumours indicated better chemotherapeutic responsiveness to fluorouracil yet a worse objective response rate to pembrolizumab in GC.	Fluorouracil	82-94	5'-nucleotidase ecto	Homo sapiens	13-17
34741235-11	2022	Altogether, data suggest that the regulation of NT5E by miRNAs in MCF7 lineage may direct the molecular profile of luminal BC.	Phenobarbital	115-122	5'-nucleotidase ecto	Homo sapiens	48-52
34666225-0	2021	Profound inhibition of CD73-dependent formation of anti-inflammatory adenosine in B cells of SLE patients.	Adenosine	69-78	5'-nucleotidase ecto	Homo sapiens	23-27
34482286-0	2021	A novel antagonistic CD73 antibody for inhibition of the immunosuppressive adenosine pathway.	Adenosine	75-84	5'-nucleotidase ecto	Homo sapiens	21-25
34666225-2	2021	The anti-inflammatory activity of CD73-derived adenosine is well documented, however, its role in SLE pathogenesis is unknown.	Adenosine	47-56	5'-nucleotidase ecto	Homo sapiens	34-38
34666225-12	2021	INTERPRETATION: We describe a new pathomechanism for SLE, by which inactivation of CD73 on B cells produces less anti-inflammatory adenosine, resulting in immune cell activation.	Adenosine	131-140	5'-nucleotidase ecto	Homo sapiens	83-87
34482286-9	2021	Adenosine levels were found to be elevated upon doxorubicin treatment in vivo, which could be blocked by CD73 inhibition.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	105-109
34482286-9	2021	Adenosine levels were found to be elevated upon doxorubicin treatment in vivo, which could be blocked by CD73 inhibition.	Doxorubicin	48-59	5'-nucleotidase ecto	Homo sapiens	105-109
34482286-11	2021	Furthermore, a retrospective analysis of rectal cancer patient samples demonstrated an upregulation of the adenosine pathway upon chemoradiation, providing further rationale for combining CD73 inhibition with chemotherapeutic agents.	Adenosine	107-116	5'-nucleotidase ecto	Homo sapiens	188-192
34482286-12	2021	This study demonstrates the ability of a novel CD73 antibody to enhance T-cell function through the potent suppression of adenosine levels.	Adenosine	122-131	5'-nucleotidase ecto	Homo sapiens	47-51
34302921-0	2021	CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms.	gemcitabine	13-24	5'-nucleotidase ecto	Homo sapiens	0-4
34302921-1	2021	CD73, a cell surface-localized ecto-5"-nucleotidase, is the major enzymatic source of extracellular adenosine.	Adenosine	100-109	5'-nucleotidase ecto	Homo sapiens	0-4
34302921-1	2021	CD73, a cell surface-localized ecto-5"-nucleotidase, is the major enzymatic source of extracellular adenosine.	Adenosine	100-109	5'-nucleotidase ecto	Homo sapiens	31-51
34302921-5	2021	Our findings support that the elevated expression of CD73 in PDAC cells promotes gemcitabine (GEM) resistance by activating AKT.	gemcitabine	81-92	5'-nucleotidase ecto	Homo sapiens	53-57
34302921-5	2021	Our findings support that the elevated expression of CD73 in PDAC cells promotes gemcitabine (GEM) resistance by activating AKT.	gemcitabine	94-97	5'-nucleotidase ecto	Homo sapiens	53-57
34302921-8	2021	Troglitazone (TGZ) is a peroxisome proliferator-activated receptor gamma agonist that could inhibit the expression of CD73.	Troglitazone	0-12	5'-nucleotidase ecto	Homo sapiens	118-122
34302921-8	2021	Troglitazone (TGZ) is a peroxisome proliferator-activated receptor gamma agonist that could inhibit the expression of CD73.	Troglitazone	14-17	5'-nucleotidase ecto	Homo sapiens	118-122
34302921-9	2021	The administration of TGZ markedly enhances sensitivity to GEM via downregulating CD73 in PDAC.	Troglitazone	22-25	5'-nucleotidase ecto	Homo sapiens	82-86
34302921-9	2021	The administration of TGZ markedly enhances sensitivity to GEM via downregulating CD73 in PDAC.	gemcitabine	59-62	5'-nucleotidase ecto	Homo sapiens	82-86
34712389-5	2021	Dietary Zn levels had on effect on egg production and fertility (P > 0.05), whereas dietary Zn deficiency decreased breeder plasma Zn concentration and erythrocytic alkaline phosphatase activity at week 6 and inhibited erythrocytic 5"-nucleotidase (5"-NT) activity at weeks 2, 4, and 6 (P < 0.05), indicating that marginal Zn-deficient status occurred after Zn depletion.	Zinc	92-94	5'-nucleotidase ecto	Homo sapiens	232-247
34650224-3	2021	By comparing their function, phenotype and transcriptomic profile against ex vivo Tregs, we demonstrate that expanded human Tregs switch their metabolism to aerobic glycolysis and show enhanced suppressive function through hypoxia-inducible factor 1-alpha (HIF1A) driven acquisition of CD73 expression.	tregs	124-129	5'-nucleotidase ecto	Homo sapiens	286-290
34650224-4	2021	In conjunction with CD39, CD73 expression enables expanded Tregs to convert ATP to immunosuppressive adenosine.	tregs	59-64	5'-nucleotidase ecto	Homo sapiens	26-30
34650224-4	2021	In conjunction with CD39, CD73 expression enables expanded Tregs to convert ATP to immunosuppressive adenosine.	Adenosine Triphosphate	76-79	5'-nucleotidase ecto	Homo sapiens	26-30
34650224-4	2021	In conjunction with CD39, CD73 expression enables expanded Tregs to convert ATP to immunosuppressive adenosine.	Adenosine	101-110	5'-nucleotidase ecto	Homo sapiens	26-30
34612808-1	2022	cN-II is a cytosolic 5"-nucleotidase with preference for IMP and GMP over AMP.	Adenosine Monophosphate	74-77	5'-nucleotidase ecto	Homo sapiens	21-36
34482286-3	2021	CD73 is a key enzyme involved in adenosine production.	Adenosine	33-42	5'-nucleotidase ecto	Homo sapiens	0-4
34482286-5	2021	mAb19 potently inhibits the enzymatic activity of CD73 in vitro, resulting in an inhibition of adenosine formation and enhanced T cell activation.	Adenosine	95-104	5'-nucleotidase ecto	Homo sapiens	50-54
34216588-5	2021	Results show that Caco-2 cells regulate the metabolism of eATP and by-products by ecto-nucleoside triphosphate diphosphohydrolase-1 and -2, a neutral ecto-phosphatase and ecto-5"-nucleotidase.	eatp	58-62	5'-nucleotidase ecto	Homo sapiens	171-191
34089473-2	2021	The enzymes CD39 and CD73 produce adenosine in the extracellular milieu that has a very important role in tumor development.	Adenosine	34-43	5'-nucleotidase ecto	Homo sapiens	21-25
34265363-4	2021	Growing evidence indicates that CD39 and CD73, as novel checkpoints, can transform adenosine triphosphate (ATP)-mediated pro-inflammatory tumor microenvironment into an adenosine-mediated immunosuppressive one via the purinergic signaling pathway.	Adenosine	83-92	5'-nucleotidase ecto	Homo sapiens	41-45
34265363-4	2021	Growing evidence indicates that CD39 and CD73, as novel checkpoints, can transform adenosine triphosphate (ATP)-mediated pro-inflammatory tumor microenvironment into an adenosine-mediated immunosuppressive one via the purinergic signaling pathway.	Adenosine Triphosphate	107-110	5'-nucleotidase ecto	Homo sapiens	41-45
34265363-4	2021	Growing evidence indicates that CD39 and CD73, as novel checkpoints, can transform adenosine triphosphate (ATP)-mediated pro-inflammatory tumor microenvironment into an adenosine-mediated immunosuppressive one via the purinergic signaling pathway.	Adenosine	169-178	5'-nucleotidase ecto	Homo sapiens	41-45
34089473-10	2021	The results with APCP, a specific CD73 inhibitor, showed that the AMP hydrolysis was inhibited in all conditions evaluated.	Adenosine Monophosphate	66-69	5'-nucleotidase ecto	Homo sapiens	34-38
34116887-2	2021	A key component of the purinergic system, the enzyme ecto-5"-nucleotidase (CD73) catalyzes the last step in the extracellular metabolism of ATP to form adenosine.	Adenosine Triphosphate	140-143	5'-nucleotidase ecto	Homo sapiens	53-73
34116887-2	2021	A key component of the purinergic system, the enzyme ecto-5"-nucleotidase (CD73) catalyzes the last step in the extracellular metabolism of ATP to form adenosine.	Adenosine Triphosphate	140-143	5'-nucleotidase ecto	Homo sapiens	75-79
34116887-2	2021	A key component of the purinergic system, the enzyme ecto-5"-nucleotidase (CD73) catalyzes the last step in the extracellular metabolism of ATP to form adenosine.	Adenosine	152-161	5'-nucleotidase ecto	Homo sapiens	53-73
34116887-2	2021	A key component of the purinergic system, the enzyme ecto-5"-nucleotidase (CD73) catalyzes the last step in the extracellular metabolism of ATP to form adenosine.	Adenosine	152-161	5'-nucleotidase ecto	Homo sapiens	75-79
34274385-6	2021	The anti-CD73 antibody prevents the immunosuppression phenomenon in tumors by blocking the adenosine pathway, and it is emerging as a sufficient immune checkpoint blockade when combined with ICD-elicited tumor therapies.	Adenosine	91-100	5'-nucleotidase ecto	Homo sapiens	9-13
34575580-6	2021	Their enzymatic properties result in the generation of AMP, which is further degraded by CD73 to adenosine, an anti-inflammatory and anti-platelet reagent.	Adenosine Monophosphate	55-58	5'-nucleotidase ecto	Homo sapiens	89-93
34575580-6	2021	Their enzymatic properties result in the generation of AMP, which is further degraded by CD73 to adenosine, an anti-inflammatory and anti-platelet reagent.	Adenosine	97-106	5'-nucleotidase ecto	Homo sapiens	89-93
34274385-7	2021	As cancer membrane camouflaged nanoparticles CM@UCNP-RB/PTD combined with anti-CD73 antibodies, synergistic efficacy of chemotherapy and PDT not only destroys the orthotopic tumors by DOX and cytotoxic ROS but also prevents abscopal tumor metastasis via inducing systemic cytotoxic T cell responses with CD73 blockade.	Doxorubicin	184-187	5'-nucleotidase ecto	Homo sapiens	79-83
34274385-7	2021	As cancer membrane camouflaged nanoparticles CM@UCNP-RB/PTD combined with anti-CD73 antibodies, synergistic efficacy of chemotherapy and PDT not only destroys the orthotopic tumors by DOX and cytotoxic ROS but also prevents abscopal tumor metastasis via inducing systemic cytotoxic T cell responses with CD73 blockade.	Doxorubicin	184-187	5'-nucleotidase ecto	Homo sapiens	304-308
34274385-7	2021	As cancer membrane camouflaged nanoparticles CM@UCNP-RB/PTD combined with anti-CD73 antibodies, synergistic efficacy of chemotherapy and PDT not only destroys the orthotopic tumors by DOX and cytotoxic ROS but also prevents abscopal tumor metastasis via inducing systemic cytotoxic T cell responses with CD73 blockade.	Reactive Oxygen Species	202-205	5'-nucleotidase ecto	Homo sapiens	79-83
34274385-7	2021	As cancer membrane camouflaged nanoparticles CM@UCNP-RB/PTD combined with anti-CD73 antibodies, synergistic efficacy of chemotherapy and PDT not only destroys the orthotopic tumors by DOX and cytotoxic ROS but also prevents abscopal tumor metastasis via inducing systemic cytotoxic T cell responses with CD73 blockade.	Reactive Oxygen Species	202-205	5'-nucleotidase ecto	Homo sapiens	304-308
34496892-1	2021	BACKGROUND: Spinal cord injury (SCI) is an inflammatory condition, and excessive adenosine triphosphate (ATP) is released into the extracellular space, which can be catabolized into adenosine by CD73.	Adenosine	81-90	5'-nucleotidase ecto	Homo sapiens	195-199
34977618-9	2021	FACS analysis revealed high positivity rates (>95%) of CTP-specific surface epitopes (CD105, CD90, and CD73) and low positivity rates (<1.3%) of negative markers (CD45, CD31).	Cytidine Triphosphate	55-58	5'-nucleotidase ecto	Homo sapiens	103-107
34496892-1	2021	BACKGROUND: Spinal cord injury (SCI) is an inflammatory condition, and excessive adenosine triphosphate (ATP) is released into the extracellular space, which can be catabolized into adenosine by CD73.	Adenosine Triphosphate	105-108	5'-nucleotidase ecto	Homo sapiens	195-199
34496892-1	2021	BACKGROUND: Spinal cord injury (SCI) is an inflammatory condition, and excessive adenosine triphosphate (ATP) is released into the extracellular space, which can be catabolized into adenosine by CD73.	Adenosine	182-191	5'-nucleotidase ecto	Homo sapiens	195-199
34496892-6	2021	Effects of CD73+ hucMSC-EVs on hydrolyzing ATP into adenosine were detected.	Adenosine Triphosphate	43-46	5'-nucleotidase ecto	Homo sapiens	11-15
34496892-6	2021	Effects of CD73+ hucMSC-EVs on hydrolyzing ATP into adenosine were detected.	Adenosine	52-61	5'-nucleotidase ecto	Homo sapiens	11-15
34496892-11	2021	RESULTS: CD73+ hucMSC-EVs reduced concentration of ATP and promoted the level of adenosine.	Adenosine Triphosphate	51-54	5'-nucleotidase ecto	Homo sapiens	9-13
34496892-11	2021	RESULTS: CD73+ hucMSC-EVs reduced concentration of ATP and promoted the level of adenosine.	Adenosine	81-90	5'-nucleotidase ecto	Homo sapiens	9-13
34496892-12	2021	In vitro experiments, CD73+ hucMSC-EVs increased macrophages/microglia M2:M1 polarization, activated adenosine 2b receptor (A2bR), and then promoted cAMP/PKA signaling pathway.	Adenosine	101-110	5'-nucleotidase ecto	Homo sapiens	22-26
34496892-12	2021	In vitro experiments, CD73+ hucMSC-EVs increased macrophages/microglia M2:M1 polarization, activated adenosine 2b receptor (A2bR), and then promoted cAMP/PKA signaling pathway.	Cyclic AMP	149-153	5'-nucleotidase ecto	Homo sapiens	22-26
34571872-6	2021	Ectonucleoside triphosphate diphosphohydrolase-1 (NTPDase1)/CD39 dephosphorylates ATP to ADP and to AMP, which in turn, is hydrolysed to adenosine by ecto-5"-nucleotidase (CD73).	Adenosine Triphosphate	82-85	5'-nucleotidase ecto	Homo sapiens	150-170
34659527-10	2021	Importantly, pharmacological inhibition of CD73 activity by APCP inhibits tumor growth, which can be largely compromised by the addition of adenosine, suggesting an enzyme activity-dependent effect of CD73 in gastric cancer.	Adenosine	140-149	5'-nucleotidase ecto	Homo sapiens	43-47
34659527-10	2021	Importantly, pharmacological inhibition of CD73 activity by APCP inhibits tumor growth, which can be largely compromised by the addition of adenosine, suggesting an enzyme activity-dependent effect of CD73 in gastric cancer.	Adenosine	140-149	5'-nucleotidase ecto	Homo sapiens	201-205
34659527-11	2021	Furthermore, hijacking tumor glycolysis by 2-DG or galactose largely abrogated the oncogenic roles of CD73, indicating that CD73 promotes tumor growth in a glycolysis-dependent manner in gastric cancer.	Deoxyglucose	43-47	5'-nucleotidase ecto	Homo sapiens	102-106
34659527-11	2021	Furthermore, hijacking tumor glycolysis by 2-DG or galactose largely abrogated the oncogenic roles of CD73, indicating that CD73 promotes tumor growth in a glycolysis-dependent manner in gastric cancer.	Deoxyglucose	43-47	5'-nucleotidase ecto	Homo sapiens	124-128
34659527-11	2021	Furthermore, hijacking tumor glycolysis by 2-DG or galactose largely abrogated the oncogenic roles of CD73, indicating that CD73 promotes tumor growth in a glycolysis-dependent manner in gastric cancer.	Galactose	51-60	5'-nucleotidase ecto	Homo sapiens	102-106
34659527-11	2021	Furthermore, hijacking tumor glycolysis by 2-DG or galactose largely abrogated the oncogenic roles of CD73, indicating that CD73 promotes tumor growth in a glycolysis-dependent manner in gastric cancer.	Galactose	51-60	5'-nucleotidase ecto	Homo sapiens	124-128
34464670-0	2021	Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles.	Adenosine	56-65	5'-nucleotidase ecto	Homo sapiens	20-24
34464670-2	2021	A significant part of the immunoinhibitory activity of EVs is attributable to CD73, a GPI-anchored ecto-5"-nucleotidase involved in the conversion of tumor-derived proinflammatory extracellular ATP (eATP) to immunosuppressive adenosine (ADO).	Adenosine Triphosphate	194-197	5'-nucleotidase ecto	Homo sapiens	78-82
34464670-2	2021	A significant part of the immunoinhibitory activity of EVs is attributable to CD73, a GPI-anchored ecto-5"-nucleotidase involved in the conversion of tumor-derived proinflammatory extracellular ATP (eATP) to immunosuppressive adenosine (ADO).	Adenosine Triphosphate	194-197	5'-nucleotidase ecto	Homo sapiens	99-119
34464670-2	2021	A significant part of the immunoinhibitory activity of EVs is attributable to CD73, a GPI-anchored ecto-5"-nucleotidase involved in the conversion of tumor-derived proinflammatory extracellular ATP (eATP) to immunosuppressive adenosine (ADO).	Adenosine	226-235	5'-nucleotidase ecto	Homo sapiens	78-82
34464670-2	2021	A significant part of the immunoinhibitory activity of EVs is attributable to CD73, a GPI-anchored ecto-5"-nucleotidase involved in the conversion of tumor-derived proinflammatory extracellular ATP (eATP) to immunosuppressive adenosine (ADO).	Adenosine	226-235	5'-nucleotidase ecto	Homo sapiens	99-119
34464670-2	2021	A significant part of the immunoinhibitory activity of EVs is attributable to CD73, a GPI-anchored ecto-5"-nucleotidase involved in the conversion of tumor-derived proinflammatory extracellular ATP (eATP) to immunosuppressive adenosine (ADO).	Adenosine	237-240	5'-nucleotidase ecto	Homo sapiens	78-82
34464670-2	2021	A significant part of the immunoinhibitory activity of EVs is attributable to CD73, a GPI-anchored ecto-5"-nucleotidase involved in the conversion of tumor-derived proinflammatory extracellular ATP (eATP) to immunosuppressive adenosine (ADO).	Adenosine	237-240	5'-nucleotidase ecto	Homo sapiens	99-119
34625545-0	2021	CD73-mediated adenosine production by CD8 T cell-derived extracellular vesicles constitutes an intrinsic mechanism of immune suppression.	Adenosine	14-23	5'-nucleotidase ecto	Homo sapiens	0-4
34625545-2	2021	The stepwise hydrolysis of extracellular ATP by ectonucleotidases CD39 and CD73 generates adenosine, a potent immune suppressor.	Adenosine Triphosphate	41-44	5'-nucleotidase ecto	Homo sapiens	75-79
34625545-2	2021	The stepwise hydrolysis of extracellular ATP by ectonucleotidases CD39 and CD73 generates adenosine, a potent immune suppressor.	Adenosine	90-99	5'-nucleotidase ecto	Homo sapiens	75-79
34625545-3	2021	Here we report that human effector CD8 T cells contribute to adenosine production by releasing CD73-containing extracellular vesicles upon activation.	Adenosine	61-70	5'-nucleotidase ecto	Homo sapiens	95-99
34245737-3	2021	In this study, we designed and generated a novel nanocarrier composed of chitosan lactate nanoparticles (NPs) functionalized by HIV-1 derived TAT peptide (Transactivating transcriptional activator) and hyaluronate (HA) to deliver CD73 siRNA and doxorubicin to 4T1 and CT26 cancer cells, both in vivo and in vitro, as a novel combinatorial treatment strategy.	Lactic Acid	82-89	5'-nucleotidase ecto	Homo sapiens	230-234
34245737-3	2021	In this study, we designed and generated a novel nanocarrier composed of chitosan lactate nanoparticles (NPs) functionalized by HIV-1 derived TAT peptide (Transactivating transcriptional activator) and hyaluronate (HA) to deliver CD73 siRNA and doxorubicin to 4T1 and CT26 cancer cells, both in vivo and in vitro, as a novel combinatorial treatment strategy.	hyaluronate	202-213	5'-nucleotidase ecto	Homo sapiens	230-234
34571872-6	2021	Ectonucleoside triphosphate diphosphohydrolase-1 (NTPDase1)/CD39 dephosphorylates ATP to ADP and to AMP, which in turn, is hydrolysed to adenosine by ecto-5"-nucleotidase (CD73).	Adenosine	137-146	5'-nucleotidase ecto	Homo sapiens	150-170
34571872-6	2021	Ectonucleoside triphosphate diphosphohydrolase-1 (NTPDase1)/CD39 dephosphorylates ATP to ADP and to AMP, which in turn, is hydrolysed to adenosine by ecto-5"-nucleotidase (CD73).	Adenosine	137-146	5'-nucleotidase ecto	Homo sapiens	172-176
34571872-6	2021	Ectonucleoside triphosphate diphosphohydrolase-1 (NTPDase1)/CD39 dephosphorylates ATP to ADP and to AMP, which in turn, is hydrolysed to adenosine by ecto-5"-nucleotidase (CD73).	Adenosine Triphosphate	82-85	5'-nucleotidase ecto	Homo sapiens	172-176
34571872-6	2021	Ectonucleoside triphosphate diphosphohydrolase-1 (NTPDase1)/CD39 dephosphorylates ATP to ADP and to AMP, which in turn, is hydrolysed to adenosine by ecto-5"-nucleotidase (CD73).	Adenosine Diphosphate	89-92	5'-nucleotidase ecto	Homo sapiens	150-170
34571872-6	2021	Ectonucleoside triphosphate diphosphohydrolase-1 (NTPDase1)/CD39 dephosphorylates ATP to ADP and to AMP, which in turn, is hydrolysed to adenosine by ecto-5"-nucleotidase (CD73).	Adenosine Diphosphate	89-92	5'-nucleotidase ecto	Homo sapiens	172-176
34571872-6	2021	Ectonucleoside triphosphate diphosphohydrolase-1 (NTPDase1)/CD39 dephosphorylates ATP to ADP and to AMP, which in turn, is hydrolysed to adenosine by ecto-5"-nucleotidase (CD73).	Adenosine Monophosphate	100-103	5'-nucleotidase ecto	Homo sapiens	150-170
34571872-6	2021	Ectonucleoside triphosphate diphosphohydrolase-1 (NTPDase1)/CD39 dephosphorylates ATP to ADP and to AMP, which in turn, is hydrolysed to adenosine by ecto-5"-nucleotidase (CD73).	Adenosine Monophosphate	100-103	5'-nucleotidase ecto	Homo sapiens	172-176
34407878-9	2021	Generation of LPS-EEMos induced a lower percentage of CD14+ monocyte subsets that were CD16+, CD73+, CD86+, or CD206+ but a higher percentage of PD-L1+ cells.	eemos	18-23	5'-nucleotidase ecto	Homo sapiens	94-98
34445661-4	2021	Both OA and RA cells expressed CD39 (converts ATP to AMP), CD73 (converts AMP to adenosine), ADA (converts adenosine to inosine), ENT1/2 (adenosine transporters), all AR subtypes (A1, A2A, A2B and A3) and synthesized predominantly adenosine.	Adenosine Monophosphate	74-77	5'-nucleotidase ecto	Homo sapiens	59-63
34439161-1	2021	Cluster of differentiation (CD)-73 plays pivotal roles in the regulation of immune reactions via the production of extracellular adenosine, and the overexpression of CD73 is associated with worse outcomes in several types of cancers.	Adenosine	129-138	5'-nucleotidase ecto	Homo sapiens	0-34
34445661-4	2021	Both OA and RA cells expressed CD39 (converts ATP to AMP), CD73 (converts AMP to adenosine), ADA (converts adenosine to inosine), ENT1/2 (adenosine transporters), all AR subtypes (A1, A2A, A2B and A3) and synthesized predominantly adenosine.	Adenosine	81-90	5'-nucleotidase ecto	Homo sapiens	59-63
34445661-5	2021	The CD73 inhibitor AMPCP significantly increased IL-6 and decreased IL-10 in both cell types, while TNF only increased in RA cells.	alpha,beta-methyleneadenosine 5'-diphosphate	19-24	5'-nucleotidase ecto	Homo sapiens	4-8
34381563-2	2021	The ectonucleotidases CD39 and CD73 play strategic roles in calibrating purinergic signals via an extracellular balance between ATP and adenosine.	Adenosine Triphosphate	128-131	5'-nucleotidase ecto	Homo sapiens	31-35
34381563-2	2021	The ectonucleotidases CD39 and CD73 play strategic roles in calibrating purinergic signals via an extracellular balance between ATP and adenosine.	Adenosine	136-145	5'-nucleotidase ecto	Homo sapiens	31-35
34360833-1	2021	CD39 is an enzyme which is responsible, together with CD73, for a cascade converting adenosine triphosphate into adenosine diphosphate and cyclic adenosine monophosphate, ultimately leading to the release of an immunosuppressive form of adenosine in the tumor microenvironment.	Adenosine	85-94	5'-nucleotidase ecto	Homo sapiens	54-58
34105986-10	2021	Dampening of these danger signals and organ protection largely depends upon activities of vascular and immune cell-expressed ectonucleotidases (CD39 and CD73), which convert ATP and ADP into anti-inflammatory adenosine.	Adenosine Triphosphate	174-177	5'-nucleotidase ecto	Homo sapiens	153-157
34105986-10	2021	Dampening of these danger signals and organ protection largely depends upon activities of vascular and immune cell-expressed ectonucleotidases (CD39 and CD73), which convert ATP and ADP into anti-inflammatory adenosine.	Adenosine Diphosphate	182-185	5'-nucleotidase ecto	Homo sapiens	153-157
34105986-10	2021	Dampening of these danger signals and organ protection largely depends upon activities of vascular and immune cell-expressed ectonucleotidases (CD39 and CD73), which convert ATP and ADP into anti-inflammatory adenosine.	Adenosine	209-218	5'-nucleotidase ecto	Homo sapiens	153-157
34442398-3	2021	MATERIAL AND METHODS: Tr1 were generated in co-cultures of CD4+CD25neg T cells, autologous immature dendritic cells (iDC), and irradiated ADO-producing CD73+ or non-producing CD73neg breast cancer (BrCa) cell lines (TU).	Adenosine	138-141	5'-nucleotidase ecto	Homo sapiens	152-156
34442398-13	2021	CONCLUSION: BrCa producing ADO (CD73+ TU) favor the induction of Tr1, which expresses CD39 and CD73, hydrolyzes ATP to ADO, and effectively suppresses anti-tumor immunity.	Adenosine	27-30	5'-nucleotidase ecto	Homo sapiens	32-36
34442398-13	2021	CONCLUSION: BrCa producing ADO (CD73+ TU) favor the induction of Tr1, which expresses CD39 and CD73, hydrolyzes ATP to ADO, and effectively suppresses anti-tumor immunity.	Adenosine	27-30	5'-nucleotidase ecto	Homo sapiens	95-99
34442398-13	2021	CONCLUSION: BrCa producing ADO (CD73+ TU) favor the induction of Tr1, which expresses CD39 and CD73, hydrolyzes ATP to ADO, and effectively suppresses anti-tumor immunity.	Adenosine Triphosphate	112-115	5'-nucleotidase ecto	Homo sapiens	32-36
34360833-1	2021	CD39 is an enzyme which is responsible, together with CD73, for a cascade converting adenosine triphosphate into adenosine diphosphate and cyclic adenosine monophosphate, ultimately leading to the release of an immunosuppressive form of adenosine in the tumor microenvironment.	Adenosine	113-122	5'-nucleotidase ecto	Homo sapiens	54-58
34360833-1	2021	CD39 is an enzyme which is responsible, together with CD73, for a cascade converting adenosine triphosphate into adenosine diphosphate and cyclic adenosine monophosphate, ultimately leading to the release of an immunosuppressive form of adenosine in the tumor microenvironment.	Adenosine	146-155	5'-nucleotidase ecto	Homo sapiens	54-58
34360833-1	2021	CD39 is an enzyme which is responsible, together with CD73, for a cascade converting adenosine triphosphate into adenosine diphosphate and cyclic adenosine monophosphate, ultimately leading to the release of an immunosuppressive form of adenosine in the tumor microenvironment.	Adenosine	237-246	5'-nucleotidase ecto	Homo sapiens	54-58
34393062-7	2022	In the adenosine pathway, the prevalence of positive staining for CD39, CD73, and A2AR was 4.9%, 2.5%, and 69.2%, in TETs and 0%, 1.7%, and 50.8%, in SCLC.	Adenosine	7-16	5'-nucleotidase ecto	Homo sapiens	72-76
34097876-8	2021	Interestingly, silencing the NAD+-sensor enzyme SIRT1 prevented eNAD+-dependent transcriptional repression of CD73, Slc12a8, and NRK1, as well as iNAD+ resetting.	NAD	29-33	5'-nucleotidase ecto	Homo sapiens	110-114
34290905-5	2021	Our results highlight the bidirectional interaction between T cells and CAFs in promoting components of the immunosuppressive CD39, CD73 adenosine pathway and demonstrate IL-27 production can be induced in CAF by activated T cells.	Adenosine	137-146	5'-nucleotidase ecto	Homo sapiens	132-136
34356618-7	2021	Purinergic signaling is an endogenous molecular pathway in which the enzymes CD39 and CD73 catabolize extracellular adenosine triphosphate (eATP) to adenosine.	Adenosine	116-125	5'-nucleotidase ecto	Homo sapiens	86-90
34356618-7	2021	Purinergic signaling is an endogenous molecular pathway in which the enzymes CD39 and CD73 catabolize extracellular adenosine triphosphate (eATP) to adenosine.	eatp	140-144	5'-nucleotidase ecto	Homo sapiens	86-90
34356618-7	2021	Purinergic signaling is an endogenous molecular pathway in which the enzymes CD39 and CD73 catabolize extracellular adenosine triphosphate (eATP) to adenosine.	Adenosine	149-158	5'-nucleotidase ecto	Homo sapiens	86-90
34159634-2	2021	The ectonucleotidases CD39 and CD73 are responsible for the sequential catabolism of ATP to adenosine via AMP, thus promoting an anti-inflammatory milieu induced by the "adenosine halo".	Adenosine Triphosphate	85-88	5'-nucleotidase ecto	Homo sapiens	31-35
34159634-2	2021	The ectonucleotidases CD39 and CD73 are responsible for the sequential catabolism of ATP to adenosine via AMP, thus promoting an anti-inflammatory milieu induced by the "adenosine halo".	Adenosine	92-101	5'-nucleotidase ecto	Homo sapiens	31-35
34159634-2	2021	The ectonucleotidases CD39 and CD73 are responsible for the sequential catabolism of ATP to adenosine via AMP, thus promoting an anti-inflammatory milieu induced by the "adenosine halo".	Adenosine Monophosphate	106-109	5'-nucleotidase ecto	Homo sapiens	31-35
34159634-2	2021	The ectonucleotidases CD39 and CD73 are responsible for the sequential catabolism of ATP to adenosine via AMP, thus promoting an anti-inflammatory milieu induced by the "adenosine halo".	Adenosine	170-179	5'-nucleotidase ecto	Homo sapiens	31-35
34142751-0	2021	The new insight into extracellular NAD+ degradation-the contribution of CD38 and CD73 in calcific aortic valve disease.	NAD	35-39	5'-nucleotidase ecto	Homo sapiens	81-85
34442398-13	2021	CONCLUSION: BrCa producing ADO (CD73+ TU) favor the induction of Tr1, which expresses CD39 and CD73, hydrolyzes ATP to ADO, and effectively suppresses anti-tumor immunity.	Adenosine	119-122	5'-nucleotidase ecto	Homo sapiens	32-36
34142751-4	2021	Human non-stenotic valves (n = 10) actively converted NAD+ and NMN via both CD73 and NAD+ -glycohydrolase (CD38) according to our analysis with RP-HPLC and immunofluorescence.	NAD	54-58	5'-nucleotidase ecto	Homo sapiens	76-80
34142751-5	2021	In stenotic valves (n = 50), due to reduced CD73 activity, NAD+ was degraded predominantly by CD38 and additionally by ALP and eNPP1.	NAD	59-63	5'-nucleotidase ecto	Homo sapiens	44-48
35405741-0	2022	Targeting CD73 with AB680 (Quemliclustat), a novel and potent small molecule CD73 inhibitor, restores immune functionality and facilitates anti-tumor immunity.	AB-680	20-25	5'-nucleotidase ecto	Homo sapiens	10-14
34355184-3	2021	Together with ecto-5"-nucleotidase (CD73), NPP3 produces immunosuppressive, cancer-promoting adenosine, and has therefore been proposed as a target for cancer therapy.	Adenosine	93-102	5'-nucleotidase ecto	Homo sapiens	14-34
34355184-3	2021	Together with ecto-5"-nucleotidase (CD73), NPP3 produces immunosuppressive, cancer-promoting adenosine, and has therefore been proposed as a target for cancer therapy.	Adenosine	93-102	5'-nucleotidase ecto	Homo sapiens	36-40
34208001-11	2021	The combined treatment with SB431542 and siRNA-mediated PD-L1 or CD73 knockdown effectively enhanced the cytotoxicity of Sorafenib against the CSC population compared to Sorafenib alone, as evidenced by the reduced size and proliferation of spheres.	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	28-36	5'-nucleotidase ecto	Homo sapiens	65-69
34208001-11	2021	The combined treatment with SB431542 and siRNA-mediated PD-L1 or CD73 knockdown effectively enhanced the cytotoxicity of Sorafenib against the CSC population compared to Sorafenib alone, as evidenced by the reduced size and proliferation of spheres.	Sorafenib	121-130	5'-nucleotidase ecto	Homo sapiens	65-69
34208001-12	2021	Furthermore, the combination treatment of Sorafenib with SB431542 and PD-L1 or CD73 siRNA resulted in an increased proportion of an apoptotic population, as evidenced by flow cytometry analysis.	Sorafenib	42-51	5'-nucleotidase ecto	Homo sapiens	79-83
35550530-3	2022	With several clinical strategies currently being explored to modulating the eADO pathway in patients with cancer, recent clinical data with antagonists targeting CD73 and A2A receptor have demonstrated a promising therapeutic potential in cancer.	eado	76-80	5'-nucleotidase ecto	Homo sapiens	162-166
35405741-0	2022	Targeting CD73 with AB680 (Quemliclustat), a novel and potent small molecule CD73 inhibitor, restores immune functionality and facilitates anti-tumor immunity.	AB-680	20-25	5'-nucleotidase ecto	Homo sapiens	77-81
35405741-0	2022	Targeting CD73 with AB680 (Quemliclustat), a novel and potent small molecule CD73 inhibitor, restores immune functionality and facilitates anti-tumor immunity.	AB-680	27-40	5'-nucleotidase ecto	Homo sapiens	10-14
35405741-0	2022	Targeting CD73 with AB680 (Quemliclustat), a novel and potent small molecule CD73 inhibitor, restores immune functionality and facilitates anti-tumor immunity.	AB-680	27-40	5'-nucleotidase ecto	Homo sapiens	77-81
35405741-4	2022	Adenosine has emerged as a potent immune suppressant within the TME and CD73 is the major enzyme responsible for its extracellular production.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	72-76
35405741-6	2022	To target this pathway and block the formation of adenosine, we designed a novel, selective and potent class of small-molecule inhibitors of CD73, including AB680 (quemliclustat), which is currently being tested in cancer patients.	Adenosine	50-59	5'-nucleotidase ecto	Homo sapiens	141-145
35405741-6	2022	To target this pathway and block the formation of adenosine, we designed a novel, selective and potent class of small-molecule inhibitors of CD73, including AB680 (quemliclustat), which is currently being tested in cancer patients.	AB-680	157-162	5'-nucleotidase ecto	Homo sapiens	141-145
35405741-6	2022	To target this pathway and block the formation of adenosine, we designed a novel, selective and potent class of small-molecule inhibitors of CD73, including AB680 (quemliclustat), which is currently being tested in cancer patients.	AB-680	164-177	5'-nucleotidase ecto	Homo sapiens	141-145
35405741-7	2022	AB680 effectively restored T cell proliferation, cytokine secretion and cytotoxicity that were dampened by the formation of immunosuppressive adenosine by CD73.	AB-680	0-5	5'-nucleotidase ecto	Homo sapiens	155-159
35405741-7	2022	AB680 effectively restored T cell proliferation, cytokine secretion and cytotoxicity that were dampened by the formation of immunosuppressive adenosine by CD73.	Adenosine	142-151	5'-nucleotidase ecto	Homo sapiens	155-159
35405741-8	2022	Furthermore, in an allogeneic mixed lymphocyte reaction where CD73-derived adenosine had a dominant suppressive effect in the presence of PD-1 blockade, AB680 restored T cell activation and function.	Adenosine	75-84	5'-nucleotidase ecto	Homo sapiens	62-66
35405741-8	2022	Furthermore, in an allogeneic mixed lymphocyte reaction where CD73-derived adenosine had a dominant suppressive effect in the presence of PD-1 blockade, AB680 restored T cell activation and function.	AB-680	153-158	5'-nucleotidase ecto	Homo sapiens	62-66
35622118-1	2022	The production of adenosine by CD73 on cancer cells in the tumor microenvironment is a recognized immunosuppressive mechanism contributing to immune evasion in many solid tumors.	Adenosine	18-27	5'-nucleotidase ecto	Homo sapiens	31-35
35598361-3	2022	Besides the low tumor mutational burden, PD-L1 expression and CD8+ tumor-infiltrating T cells, upregulation of CD73/adenosine pathway also contributes to the immune-inert microenvironment of EGFR-mutant NSCLC.	Adenosine	116-125	5'-nucleotidase ecto	Homo sapiens	111-115
35508221-2	2022	However, the immune-stimulating ATP may be rapidly degraded into immunosuppressive adenosine by highly expressed CD39 and CD73 in the tumor microenvironment, which leads to immune escape.	Adenosine Triphosphate	32-35	5'-nucleotidase ecto	Homo sapiens	122-126
34079223-12	2021	Docking results revealed that among the selected oncotargets, Chk1, CD73, Nrf2, PCAF and AT tip60 were more vulnerable to wedelolactone than their respective standard inhibitors.	wedelolactone	122-135	5'-nucleotidase ecto	Homo sapiens	68-72
35508221-2	2022	However, the immune-stimulating ATP may be rapidly degraded into immunosuppressive adenosine by highly expressed CD39 and CD73 in the tumor microenvironment, which leads to immune escape.	Adenosine	83-92	5'-nucleotidase ecto	Homo sapiens	122-126
35563517-0	2022	CD73/Adenosine Pathway Involvement in the Interaction of Non-Small Cell Lung Cancer Stem Cells and Bone Cells in the Pre-Metastatic Niche.	Adenosine	5-14	5'-nucleotidase ecto	Homo sapiens	0-4
35462304-5	2022	Moreover, this design significantly downregulates CD39 and CD73 expression than DCA or MnFe2O4 alone, which consequently decreases the extracellular ATP catabolism.	Dichloroacetic Acid	80-83	5'-nucleotidase ecto	Homo sapiens	59-63
35563553-3	2022	CD73 is one of the key enzymes catalyzing the conversion of extracellular ATP into adenosine, which in turn exerts potent immune suppressive effects.	Adenosine Triphosphate	74-77	5'-nucleotidase ecto	Homo sapiens	0-4
35563553-3	2022	CD73 is one of the key enzymes catalyzing the conversion of extracellular ATP into adenosine, which in turn exerts potent immune suppressive effects.	Adenosine	83-92	5'-nucleotidase ecto	Homo sapiens	0-4
35182493-4	2022	These hereditary disorders, caused by mutations in genes encoding ABCC6, ENPP1, CD73, ANK, and LMNA proteins, respectively, are inorganic pyrophosphate (PPi) deficiency syndromes with reduced circulating levels of PPi, the principal physiological inhibitor of calcium hydroxyapatite deposition in soft connective tissues.	diphosphoric acid	138-151	5'-nucleotidase ecto	Homo sapiens	80-84
35182493-4	2022	These hereditary disorders, caused by mutations in genes encoding ABCC6, ENPP1, CD73, ANK, and LMNA proteins, respectively, are inorganic pyrophosphate (PPi) deficiency syndromes with reduced circulating levels of PPi, the principal physiological inhibitor of calcium hydroxyapatite deposition in soft connective tissues.	Durapatite	260-282	5'-nucleotidase ecto	Homo sapiens	80-84
35462304-5	2022	Moreover, this design significantly downregulates CD39 and CD73 expression than DCA or MnFe2O4 alone, which consequently decreases the extracellular ATP catabolism.	manganese ferrite	87-94	5'-nucleotidase ecto	Homo sapiens	59-63
35462304-5	2022	Moreover, this design significantly downregulates CD39 and CD73 expression than DCA or MnFe2O4 alone, which consequently decreases the extracellular ATP catabolism.	Adenosine Triphosphate	149-152	5'-nucleotidase ecto	Homo sapiens	59-63
35573239-0	2022	CD73-Positive Small Extracellular Vesicles Derived From Umbilical Cord Mesenchymal Stem Cells Promote the Proliferation and Migration of Pediatric Urethral Smooth Muscle Cells Through Adenosine Pathway.	Adenosine	184-193	5'-nucleotidase ecto	Homo sapiens	0-4
35573239-6	2022	Conversely, the effect of UCMSC-sEV on the proliferation and migration of PUSMCs were no longer observed with addition of the PSB12379 as a CD73 inhibitor.	psb12379	126-134	5'-nucleotidase ecto	Homo sapiens	140-144
35573239-8	2022	In summary, UCMSC-sEV promoted proliferation and migration of PUSMCs in vitro by activating CD73/adenosine signaling axis and downstream PI3K/AKT pathway.	Adenosine	97-106	5'-nucleotidase ecto	Homo sapiens	92-96
35529864-2	2022	The ectonucleotidase CD39 is part of the purinergic pathway that regulates immune responses by degradation of pro-inflammatory ATP in concert with CD73.	Adenosine Triphosphate	127-130	5'-nucleotidase ecto	Homo sapiens	147-151
35510041-4	2022	The hypoxia-adenosine pathway, in which CD73 encoded by the NT5E gene is a key enzyme for adenosine production, has been identified as an immune checkpoint of great potential.	Adenosine	12-21	5'-nucleotidase ecto	Homo sapiens	40-44
35510041-4	2022	The hypoxia-adenosine pathway, in which CD73 encoded by the NT5E gene is a key enzyme for adenosine production, has been identified as an immune checkpoint of great potential.	Adenosine	12-21	5'-nucleotidase ecto	Homo sapiens	60-64
35510041-4	2022	The hypoxia-adenosine pathway, in which CD73 encoded by the NT5E gene is a key enzyme for adenosine production, has been identified as an immune checkpoint of great potential.	Adenosine	90-99	5'-nucleotidase ecto	Homo sapiens	40-44
35510041-4	2022	The hypoxia-adenosine pathway, in which CD73 encoded by the NT5E gene is a key enzyme for adenosine production, has been identified as an immune checkpoint of great potential.	Adenosine	90-99	5'-nucleotidase ecto	Homo sapiens	60-64
35217359-0	2022	Discovery and optimization of betulinic acid derivatives as novel potent CD73 inhibitors.	betulinic acid	30-44	5'-nucleotidase ecto	Homo sapiens	73-77
35479074-4	2022	The cAMP-adenosine pathway is a biochemical mechanism mediated by ATP-binding cassette transporters that facilitate cAMP efflux and by specific ectoenzymes that convert cAMP to AMP (ecto-PDEs) and AMP to adenosine (ecto-nucleotidases such as CD73).	Cyclic AMP	4-8	5'-nucleotidase ecto	Homo sapiens	242-246
35479074-4	2022	The cAMP-adenosine pathway is a biochemical mechanism mediated by ATP-binding cassette transporters that facilitate cAMP efflux and by specific ectoenzymes that convert cAMP to AMP (ecto-PDEs) and AMP to adenosine (ecto-nucleotidases such as CD73).	Adenosine	9-18	5'-nucleotidase ecto	Homo sapiens	242-246
35479074-4	2022	The cAMP-adenosine pathway is a biochemical mechanism mediated by ATP-binding cassette transporters that facilitate cAMP efflux and by specific ectoenzymes that convert cAMP to AMP (ecto-PDEs) and AMP to adenosine (ecto-nucleotidases such as CD73).	Cyclic AMP	116-120	5'-nucleotidase ecto	Homo sapiens	242-246
35479074-4	2022	The cAMP-adenosine pathway is a biochemical mechanism mediated by ATP-binding cassette transporters that facilitate cAMP efflux and by specific ectoenzymes that convert cAMP to AMP (ecto-PDEs) and AMP to adenosine (ecto-nucleotidases such as CD73).	Cyclic AMP	169-173	5'-nucleotidase ecto	Homo sapiens	242-246
35479074-4	2022	The cAMP-adenosine pathway is a biochemical mechanism mediated by ATP-binding cassette transporters that facilitate cAMP efflux and by specific ectoenzymes that convert cAMP to AMP (ecto-PDEs) and AMP to adenosine (ecto-nucleotidases such as CD73).	Adenosine Monophosphate	177-180	5'-nucleotidase ecto	Homo sapiens	242-246
35479074-4	2022	The cAMP-adenosine pathway is a biochemical mechanism mediated by ATP-binding cassette transporters that facilitate cAMP efflux and by specific ectoenzymes that convert cAMP to AMP (ecto-PDEs) and AMP to adenosine (ecto-nucleotidases such as CD73).	Adenosine Monophosphate	197-200	5'-nucleotidase ecto	Homo sapiens	242-246
35479074-4	2022	The cAMP-adenosine pathway is a biochemical mechanism mediated by ATP-binding cassette transporters that facilitate cAMP efflux and by specific ectoenzymes that convert cAMP to AMP (ecto-PDEs) and AMP to adenosine (ecto-nucleotidases such as CD73).	Adenosine	204-213	5'-nucleotidase ecto	Homo sapiens	242-246
35444646-7	2022	CD73, both a soluble and a membrane-bound form, display immunosuppressive effects through producing adenosine (ADO).	Adenosine	100-109	5'-nucleotidase ecto	Homo sapiens	0-4
35444646-7	2022	CD73, both a soluble and a membrane-bound form, display immunosuppressive effects through producing adenosine (ADO).	Adenosine	111-114	5'-nucleotidase ecto	Homo sapiens	0-4
35444646-10	2022	Both the frequency of CD73+ DNT cells and the level of plasma sCD73 recovered after ART treatment.	art	84-87	5'-nucleotidase ecto	Homo sapiens	22-26
35485681-7	2022	In the PDAC group, CD73 overexpression was significantly associated with longer overall survival (p = 0.018).	pdac	7-11	5'-nucleotidase ecto	Homo sapiens	19-23
35485681-11	2022	The prognostic role of tumor immune response in the PDAC group was strongly modulated by CD73 and A2AR expression.	pdac	52-56	5'-nucleotidase ecto	Homo sapiens	89-93
35217359-3	2022	Adenosine is a potent immune-modulating molecule and overexpression of CD73 on tumor leads to the high concentration of adenosine.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	71-75
35365613-5	2022	Using our pDC-MM coculture models, we found that blockade of CD73 with anti-CD73 Abs: decreases adenosine levels; activates MM patient pDCs; triggers cytotoxic T lymphocytes (CTL) activity against autologous patient MM cells.	Adenosine	96-105	5'-nucleotidase ecto	Homo sapiens	61-65
35217359-3	2022	Adenosine is a potent immune-modulating molecule and overexpression of CD73 on tumor leads to the high concentration of adenosine.	Adenosine	120-129	5'-nucleotidase ecto	Homo sapiens	71-75
35365613-5	2022	Using our pDC-MM coculture models, we found that blockade of CD73 with anti-CD73 Abs: decreases adenosine levels; activates MM patient pDCs; triggers cytotoxic T lymphocytes (CTL) activity against autologous patient MM cells.	Adenosine	96-105	5'-nucleotidase ecto	Homo sapiens	76-80
35217359-4	2022	Blockade of the key adenosine-generating enzyme CD73 can be a promising strategy for cancer immunotherapy.	Adenosine	20-29	5'-nucleotidase ecto	Homo sapiens	48-52
35217359-5	2022	Here, we report the discovery of betulinic acid as a novel CD73 inhibitor lead compound by a hit-based substructure search strategy.	betulinic acid	33-47	5'-nucleotidase ecto	Homo sapiens	59-63
35218567-7	2022	We showed that HASC-P10 and P100 were able to intrinsically produce ATP, which was further converted to adenosine by 5"-nucleotidase (CD73) and ectonucleoside triphosphate diphosphohydrolase-1 (CD39).	hasc-p10	15-23	5'-nucleotidase ecto	Homo sapiens	117-132
35218567-7	2022	We showed that HASC-P10 and P100 were able to intrinsically produce ATP, which was further converted to adenosine by 5"-nucleotidase (CD73) and ectonucleoside triphosphate diphosphohydrolase-1 (CD39).	hasc-p10	15-23	5'-nucleotidase ecto	Homo sapiens	134-138
35218567-7	2022	We showed that HASC-P10 and P100 were able to intrinsically produce ATP, which was further converted to adenosine by 5"-nucleotidase (CD73) and ectonucleoside triphosphate diphosphohydrolase-1 (CD39).	Adenosine Triphosphate	68-71	5'-nucleotidase ecto	Homo sapiens	117-132
35218567-7	2022	We showed that HASC-P10 and P100 were able to intrinsically produce ATP, which was further converted to adenosine by 5"-nucleotidase (CD73) and ectonucleoside triphosphate diphosphohydrolase-1 (CD39).	Adenosine Triphosphate	68-71	5'-nucleotidase ecto	Homo sapiens	134-138
35218567-7	2022	We showed that HASC-P10 and P100 were able to intrinsically produce ATP, which was further converted to adenosine by 5"-nucleotidase (CD73) and ectonucleoside triphosphate diphosphohydrolase-1 (CD39).	Adenosine	104-113	5'-nucleotidase ecto	Homo sapiens	117-132
35218567-7	2022	We showed that HASC-P10 and P100 were able to intrinsically produce ATP, which was further converted to adenosine by 5"-nucleotidase (CD73) and ectonucleoside triphosphate diphosphohydrolase-1 (CD39).	Adenosine	104-113	5'-nucleotidase ecto	Homo sapiens	134-138
35078640-3	2022	The ectoenzymes CD39 and CD73, also expressed by CD4 T lymphocytes, are involved in the hydrolysis of pro-inflammatory extracellular ATP and generation of immunosuppressive adenosine and seem to be modulated in some arthritogenic pathologies.	Adenosine Triphosphate	133-136	5'-nucleotidase ecto	Homo sapiens	25-29
35078640-3	2022	The ectoenzymes CD39 and CD73, also expressed by CD4 T lymphocytes, are involved in the hydrolysis of pro-inflammatory extracellular ATP and generation of immunosuppressive adenosine and seem to be modulated in some arthritogenic pathologies.	Adenosine	173-182	5'-nucleotidase ecto	Homo sapiens	25-29
35078640-8	2022	Finally, reduced levels of the ectoenzymes CD39 and CD73 expression was found during the chronic phase suggesting a possible modulation of extracellular ATP and adenosine by CD4+ T cells that may be involved in the persistence of arthritogenic symptoms.	Adenosine Triphosphate	153-156	5'-nucleotidase ecto	Homo sapiens	52-56
35078640-8	2022	Finally, reduced levels of the ectoenzymes CD39 and CD73 expression was found during the chronic phase suggesting a possible modulation of extracellular ATP and adenosine by CD4+ T cells that may be involved in the persistence of arthritogenic symptoms.	Adenosine	161-170	5'-nucleotidase ecto	Homo sapiens	52-56
35365585-1	2022	BACKGROUND: Targeting the PD-1/PD-L1/L2 (programmed cell death protein 1/programmed cell death ligand 1/ligand 2) pathway combined with other immunosuppressive signalings, such as CD73/A2aR (A2a adenosine receptor) adenosine signaling, has emerged as a promising strategy for cancer treatment.	Adenosine	215-224	5'-nucleotidase ecto	Homo sapiens	180-184
35325005-0	2022	Elevated ATP via enhanced miRNA-30b, 30c, and 30e downregulates the expression of CD73 in CD8+ T cells of HIV-infected individuals.	Adenosine Triphosphate	9-12	5'-nucleotidase ecto	Homo sapiens	82-86
35325005-2	2022	For example, CD73 works with CD39 to convert highly inflammatory ATP to adenosine.	Adenosine Triphosphate	65-68	5'-nucleotidase ecto	Homo sapiens	13-17
35325005-2	2022	For example, CD73 works with CD39 to convert highly inflammatory ATP to adenosine.	Adenosine	72-81	5'-nucleotidase ecto	Homo sapiens	13-17
35325005-12	2022	Therefore, we provide a novel mechanism for the downregulation of CD73 via ATP-induced upregulation of miRNA30b, 30c and 30e in HIV infection.	Adenosine Triphosphate	75-78	5'-nucleotidase ecto	Homo sapiens	66-70
35325005-13	2022	Finally, these observations imply that ATP-mediated downregulation of CD73 mainly occurs via its receptor, P2X1/P2RX1.	Adenosine Triphosphate	39-42	5'-nucleotidase ecto	Homo sapiens	70-74
35371066-3	2022	One of the described contact dependent suppressive mechanisms regulatory cells have been shown to utilize is through the production of adenosine from extracellular ATP mediated by CD39 and CD73.	Adenosine	135-144	5'-nucleotidase ecto	Homo sapiens	189-193
35371066-3	2022	One of the described contact dependent suppressive mechanisms regulatory cells have been shown to utilize is through the production of adenosine from extracellular ATP mediated by CD39 and CD73.	Adenosine Triphosphate	164-167	5'-nucleotidase ecto	Homo sapiens	189-193
35371066-9	2022	Upregulation of both CD39 and CD73 was observed post expansion and ASTRLs demonstrated extracellular hydrolysis of ATP, indicating functionality of the upregulated proteins.	Adenosine Triphosphate	115-118	5'-nucleotidase ecto	Homo sapiens	30-34
35327609-2	2022	Presently, researchers are developing approaches in immune therapy that target inhibition of adenosine or its signaling such as CD39 or CD73 inhibiting antibodies or adenosine A2A receptor antagonists.	Adenosine	93-102	5'-nucleotidase ecto	Homo sapiens	136-140
35401839-7	2022	CD73 deficiency decreased the tissue tropism, and impaired the immunosuppressive and protective function of Tregs in cardiac healing.	tregs	108-113	5'-nucleotidase ecto	Homo sapiens	0-4
35401839-8	2022	Administration of low-dose of IL-2/anti-IL-2 complex resulted in FoxP3+CD73+Tregs expansion in the heart and contributed to the recovery of cardiac function.	tregs	76-81	5'-nucleotidase ecto	Homo sapiens	71-75
35401839-9	2022	CD73 derived from FoxP3+Tregs could bind to FoxP3- effector T-cells and inhibit the production of multiple inflammatory cytokines.	tregs	24-29	5'-nucleotidase ecto	Homo sapiens	0-4
35401839-11	2022	Moreover, CD73 expressions on CD4+ T cells were negatively correlated with the levels of NT pro-BNP and myocardial zymogram in serum.	pro-bnp	92-99	5'-nucleotidase ecto	Homo sapiens	10-14
35064653-8	2022	However, superfluous ATP is converted into immunosuppressive adenosine through the CD39-CD73-A2AR pathway.	Adenosine Triphosphate	21-24	5'-nucleotidase ecto	Homo sapiens	88-92
35064653-8	2022	However, superfluous ATP is converted into immunosuppressive adenosine through the CD39-CD73-A2AR pathway.	Adenosine	61-70	5'-nucleotidase ecto	Homo sapiens	88-92
35196024-8	2022	RNA sequencing analyses highlighted modifications in the tolerant patients" transcriptomic profiles, particularly with overexpression of the ectoenzyme NT5E (encoding CD73), which could counterbalance CD38 enzymatic functions by producing adenosine.	Adenosine	239-248	5'-nucleotidase ecto	Homo sapiens	152-156
35196024-8	2022	RNA sequencing analyses highlighted modifications in the tolerant patients" transcriptomic profiles, particularly with overexpression of the ectoenzyme NT5E (encoding CD73), which could counterbalance CD38 enzymatic functions by producing adenosine.	Adenosine	239-248	5'-nucleotidase ecto	Homo sapiens	167-171
35196024-11	2022	Thus, balance between a CD38-activated immune state and CD73-related production of adenosine may be a key regulator of operational tolerance.	Adenosine	83-92	5'-nucleotidase ecto	Homo sapiens	56-60
35222389-0	2022	CD39/CD73 Dysregulation of Adenosine Metabolism Increases Decidual Natural Killer Cell Cytotoxicity: Implications in Unexplained Recurrent Spontaneous Abortion.	Adenosine	27-36	5'-nucleotidase ecto	Homo sapiens	5-9
35222389-2	2022	The ATP-adenosine metabolic pathway regulated by CD39/CD73 has recently been recognized to be important in immunosuppression.	Adenosine Triphosphate	4-7	5'-nucleotidase ecto	Homo sapiens	54-58
35222389-2	2022	The ATP-adenosine metabolic pathway regulated by CD39/CD73 has recently been recognized to be important in immunosuppression.	Adenosine	8-17	5'-nucleotidase ecto	Homo sapiens	54-58
35222389-6	2022	Similarly, inhibition of CD73 on HTR8/SVneo cells decreased the adenosine concentration in the cell culture media, increased the proportion of CD107a+ dNK cells, and decreased the invasion and proliferation capabilities of the HTR8/SVneo cells.	Adenosine	64-73	5'-nucleotidase ecto	Homo sapiens	25-29
35222389-8	2022	In summary, reduced numbers of CD39+ and CD73+ cells at the maternal-fetal interface, which may be due to downregulated TGF-beta-mTOR-HIF-1alpha pathway, results in reduced ATP-adenosine metabolism and increased dNK cytotoxicity, and potentially contributes to URSA occurrences.	Adenosine Triphosphate	173-176	5'-nucleotidase ecto	Homo sapiens	41-45
35222389-8	2022	In summary, reduced numbers of CD39+ and CD73+ cells at the maternal-fetal interface, which may be due to downregulated TGF-beta-mTOR-HIF-1alpha pathway, results in reduced ATP-adenosine metabolism and increased dNK cytotoxicity, and potentially contributes to URSA occurrences.	Adenosine	177-186	5'-nucleotidase ecto	Homo sapiens	41-45
35080883-0	2022	Structure-Activity Relationship of 3-Methylcytidine-5"-alpha,beta-methylenediphosphates as CD73 Inhibitors.	3-methylcytidine-5"-alpha,beta-methylenediphosphates	35-87	5'-nucleotidase ecto	Homo sapiens	91-95
35199627-1	2022	Extracellular adenosine is produced from ATP by CD39 and CD73, and can modulate tumor development by acting on cancer cells or immune cells.	Adenosine	14-23	5'-nucleotidase ecto	Homo sapiens	57-61
35199627-1	2022	Extracellular adenosine is produced from ATP by CD39 and CD73, and can modulate tumor development by acting on cancer cells or immune cells.	Adenosine Triphosphate	41-44	5'-nucleotidase ecto	Homo sapiens	57-61
35163096-6	2022	Fluorescence-activated cell sorting (FACS) analysis demonstrated that CD73 and CD105 were downregulated in the PEMF group at 60 Hz.	pemf	111-115	5'-nucleotidase ecto	Homo sapiens	70-74
35080883-1	2022	We recently reported N4-substituted 3-methylcytidine-5"-alpha,beta-methylenediphosphates as CD73 inhibitors, potentially useful in cancer immunotherapy.	n4-substituted 3-methylcytidine-5"-alpha,beta-methylenediphosphates	21-88	5'-nucleotidase ecto	Homo sapiens	92-96
35080883-2	2022	We now expand the structure-activity relationship of pyrimidine nucleotides as human CD73 inhibitors.	Pyrimidine Nucleotides	53-75	5'-nucleotidase ecto	Homo sapiens	85-89
35080883-5	2022	X-ray structures of hCD73 with two inhibitors indicated a ribose ring conformational adaptation, and the benzyloxyimino group (E configuration) binds to the same region (between the C-terminal and N-terminal domains) as N4-benzyl groups in adenine inhibitors.	Ribose	58-64	5'-nucleotidase ecto	Homo sapiens	20-25
35080883-5	2022	X-ray structures of hCD73 with two inhibitors indicated a ribose ring conformational adaptation, and the benzyloxyimino group (E configuration) binds to the same region (between the C-terminal and N-terminal domains) as N4-benzyl groups in adenine inhibitors.	Adenine	240-247	5'-nucleotidase ecto	Homo sapiens	20-25
35059478-7	2022	IFP-DFATs and SC-DFATs exhibited similar immunophenotypes (CD73+, CD90+, CD105+, CD31-, CD45-, HLA-DR-) and tri-lineage (adipogenic, osteogenic, and chondrogenic) differentiation potential, consistent with the minimal criteria for defining MSCs.	ifp-dfats	0-9	5'-nucleotidase ecto	Homo sapiens	59-63
35620732-2	2022	CD73, a cell-surface protein, acts as a switch of the adenosine-related signaling pathway that can cause significant immunosuppression.	Adenosine	54-63	5'-nucleotidase ecto	Homo sapiens	0-4
35069091-9	2021	Indeed, the enzyme CD73, which converts AMP to ADO, is overexpressed in glioblastoma cells; this upregulation is associated with tumor aggressiveness.	Adenosine Monophosphate	40-43	5'-nucleotidase ecto	Homo sapiens	19-23
35069091-9	2021	Indeed, the enzyme CD73, which converts AMP to ADO, is overexpressed in glioblastoma cells; this upregulation is associated with tumor aggressiveness.	Adenosine	47-50	5'-nucleotidase ecto	Homo sapiens	19-23
35069091-10	2021	Because of the crucial activity of CD73 in these cells, extracellular ADO accumulation in the TME contributes to sustaining glioblastoma immune escape while promoting A2-like activation.	Adenosine	70-73	5'-nucleotidase ecto	Homo sapiens	35-39
35108658-15	2022	Lastly, omeprazole treatment prevented the effects of IL-4 and IL-13 on the CD73+CD104+ population.	Omeprazole	8-18	5'-nucleotidase ecto	Homo sapiens	76-80
35388712-10	2022	Furthermore, Y-27632 decreased the CD73, CD90, CD105, CD166, TLR4, and NF-kappaB p65 genes expression, but increased the IL-8 gene expression.	Y 27632	13-20	5'-nucleotidase ecto	Homo sapiens	35-39
2555407-3	1989	Results from 5"-nucleotidase and (Ca2+ + Mg2+)ATPase assays using this method were compared with conventional phosphate assays and showed a high degree of correlation.	Phosphates	110-119	5'-nucleotidase ecto	Homo sapiens	13-28
2560629-1	1989	We have previously assigned human ecto-5"-nucleotidase (NT) to chromosome 6 on the basis of conversion of exogenously supplied [14C]AMP to adenosine by whole cells of human and Chinese hamster hybrids carrying chromosome 6.	Carbon-14	128-132	5'-nucleotidase ecto	Homo sapiens	34-54
2560629-1	1989	We have previously assigned human ecto-5"-nucleotidase (NT) to chromosome 6 on the basis of conversion of exogenously supplied [14C]AMP to adenosine by whole cells of human and Chinese hamster hybrids carrying chromosome 6.	Adenosine Monophosphate	132-135	5'-nucleotidase ecto	Homo sapiens	34-54
2808404-5	1989	In spite of the inhibition of 5"-nucleotidase by ADP, adenosine was produced very rapidly by smooth muscle cells.	Adenosine Diphosphate	49-52	5'-nucleotidase ecto	Homo sapiens	30-45
2561998-1	1989	The affinity of lymphocyte 5"-nucleotidase (5NT) for its substrate adenosine monophosphate (AMP) was studied in Epstein-Barr virus immortalized B-lymphocyte clones from healthy controls and patients with primary hypogammaglobulinaemia.	Adenosine Monophosphate	67-90	5'-nucleotidase ecto	Homo sapiens	27-42
2561998-1	1989	The affinity of lymphocyte 5"-nucleotidase (5NT) for its substrate adenosine monophosphate (AMP) was studied in Epstein-Barr virus immortalized B-lymphocyte clones from healthy controls and patients with primary hypogammaglobulinaemia.	Adenosine Monophosphate	67-90	5'-nucleotidase ecto	Homo sapiens	44-47
2561998-1	1989	The affinity of lymphocyte 5"-nucleotidase (5NT) for its substrate adenosine monophosphate (AMP) was studied in Epstein-Barr virus immortalized B-lymphocyte clones from healthy controls and patients with primary hypogammaglobulinaemia.	Adenosine Monophosphate	92-95	5'-nucleotidase ecto	Homo sapiens	27-42
2561998-1	1989	The affinity of lymphocyte 5"-nucleotidase (5NT) for its substrate adenosine monophosphate (AMP) was studied in Epstein-Barr virus immortalized B-lymphocyte clones from healthy controls and patients with primary hypogammaglobulinaemia.	Adenosine Monophosphate	92-95	5'-nucleotidase ecto	Homo sapiens	44-47
2561998-2	1989	Km values for AMP for 5NT in most of the patient clones were found to be significantly increased compared to B-cell clones from normal subjects, whereas Vmax values were within the normal range.	Adenosine Monophosphate	14-17	5'-nucleotidase ecto	Homo sapiens	22-25
2550355-1	1989	Human and mouse hybrids that contain fragments of human chromosome 6 as translocations were analysed for expression of ecto-5" nucleotidase enzymic activity measured by the conversion of AMP to adenosine and for antigenicity recognized by a monoclonal antibody specific for the human isozyme.	Adenosine Monophosphate	187-190	5'-nucleotidase ecto	Homo sapiens	119-139
2550355-1	1989	Human and mouse hybrids that contain fragments of human chromosome 6 as translocations were analysed for expression of ecto-5" nucleotidase enzymic activity measured by the conversion of AMP to adenosine and for antigenicity recognized by a monoclonal antibody specific for the human isozyme.	Adenosine	194-203	5'-nucleotidase ecto	Homo sapiens	119-139
2560629-1	1989	We have previously assigned human ecto-5"-nucleotidase (NT) to chromosome 6 on the basis of conversion of exogenously supplied [14C]AMP to adenosine by whole cells of human and Chinese hamster hybrids carrying chromosome 6.	Adenosine	139-148	5'-nucleotidase ecto	Homo sapiens	34-54
2553165-7	1989	The size and distribution of the 27.2 antigen on T cell subsets suggested that it might be the enzyme ecto-5" nucleotidase (NT), a phosphatidylinositol-linked enzyme that catalyzes dephosphorylation of monophosphate nucleotides to their respective nucleosides.	Phosphatidylinositols	131-151	5'-nucleotidase ecto	Homo sapiens	102-122
2553165-7	1989	The size and distribution of the 27.2 antigen on T cell subsets suggested that it might be the enzyme ecto-5" nucleotidase (NT), a phosphatidylinositol-linked enzyme that catalyzes dephosphorylation of monophosphate nucleotides to their respective nucleosides.	monophosphate nucleotides	202-227	5'-nucleotidase ecto	Homo sapiens	102-122
2553165-7	1989	The size and distribution of the 27.2 antigen on T cell subsets suggested that it might be the enzyme ecto-5" nucleotidase (NT), a phosphatidylinositol-linked enzyme that catalyzes dephosphorylation of monophosphate nucleotides to their respective nucleosides.	Nucleosides	248-259	5'-nucleotidase ecto	Homo sapiens	102-122
2559327-3	1989	In a further fractionation of the cytosol of various leukemic cells with ammonium sulfate, 5"-nucleotidase specific activity increased up to 14-fold in the 60% (NH4)2SO4 fraction, with a recovery of 1266 +/- 115%.	Ammonium Sulfate	73-89	5'-nucleotidase ecto	Homo sapiens	91-106
2559327-3	1989	In a further fractionation of the cytosol of various leukemic cells with ammonium sulfate, 5"-nucleotidase specific activity increased up to 14-fold in the 60% (NH4)2SO4 fraction, with a recovery of 1266 +/- 115%.	Ammonium Sulfate	160-169	5'-nucleotidase ecto	Homo sapiens	91-106
2546605-0	1989	Stimulation by glycerate 2,3-bisphosphate: a common property of cytosolic IMP-GMP 5"-nucleotidase in rat and human tissues.	2,3-Diphosphoglycerate	15-41	5'-nucleotidase ecto	Homo sapiens	82-97
2546605-1	1989	Glycerate 2,3-bisphosphate, a potent stimulator of the cytosolic 5"-nucleotidase which preferentially hydrolyzes IMP and GMP in human erythrocytes (Bontemps et al., 1988, Biochem.	2,3-Diphosphoglycerate	0-26	5'-nucleotidase ecto	Homo sapiens	65-80
2546605-1	1989	Glycerate 2,3-bisphosphate, a potent stimulator of the cytosolic 5"-nucleotidase which preferentially hydrolyzes IMP and GMP in human erythrocytes (Bontemps et al., 1988, Biochem.	guanosine 5'-monophosphorothioate	121-124	5'-nucleotidase ecto	Homo sapiens	65-80
2730189-11	1989	Immaturity of 5"-nucleotidase results in accumulation of adenosine monophosphate during ischemia.	Adenosine Monophosphate	57-80	5'-nucleotidase ecto	Homo sapiens	14-29
2550035-1	1989	5"-Nucleotidase is a member of a recently identified class of membrane proteins that is anchored via a phosphatidylinositol-containing glycolipid.	Phosphatidylinositols	103-123	5'-nucleotidase ecto	Homo sapiens	0-15
2539728-4	1989	Inhibition of ecto-5"-nucleotidase with 100 microM alpha, beta-methyleneadenosine 5"-diphosphate (AOPCP) reduced plasma adenosine to 22 +/- 6 nM.	beta-methyleneadenosine 5"-diphosphate	58-96	5'-nucleotidase ecto	Homo sapiens	14-34
2539728-4	1989	Inhibition of ecto-5"-nucleotidase with 100 microM alpha, beta-methyleneadenosine 5"-diphosphate (AOPCP) reduced plasma adenosine to 22 +/- 6 nM.	alpha,beta-methyleneadenosine 5'-diphosphate	98-103	5'-nucleotidase ecto	Homo sapiens	14-34
2539728-4	1989	Inhibition of ecto-5"-nucleotidase with 100 microM alpha, beta-methyleneadenosine 5"-diphosphate (AOPCP) reduced plasma adenosine to 22 +/- 6 nM.	Adenosine	72-81	5'-nucleotidase ecto	Homo sapiens	14-34
2550035-1	1989	5"-Nucleotidase is a member of a recently identified class of membrane proteins that is anchored via a phosphatidylinositol-containing glycolipid.	Glycolipids	135-145	5'-nucleotidase ecto	Homo sapiens	0-15
2550035-6	1989	Arrhenius plots of solubilized 5"-nucleotidase showed "break points" for all detergents in the temperature range 30-37 degrees C. SDS-PAGE of pure 5"-nucleotidase showed a single subunit of molecular mass 70 kilodaltons (kDa), while sucrose density gradient sedimentation gave a peak of activity corresponding to 132 kDa, indicating that the enzyme exists as a dimer.	Sodium Dodecyl Sulfate	130-133	5'-nucleotidase ecto	Homo sapiens	147-162
2550035-6	1989	Arrhenius plots of solubilized 5"-nucleotidase showed "break points" for all detergents in the temperature range 30-37 degrees C. SDS-PAGE of pure 5"-nucleotidase showed a single subunit of molecular mass 70 kilodaltons (kDa), while sucrose density gradient sedimentation gave a peak of activity corresponding to 132 kDa, indicating that the enzyme exists as a dimer.	Sucrose	233-240	5'-nucleotidase ecto	Homo sapiens	147-162
2537356-5	1989	In five separate experiments, ecto-5"-NT-T cells demonstrated an equal or better ability to incorporate [3H]TdR after PHA stimulation or in a MLR, as compared with ecto-5"-NT+ T cells.	Tritium	105-107	5'-nucleotidase ecto	Homo sapiens	30-40
2538071-3	1989	High-Km 5"-nucleotidase was eluted with 0.5 M NaCl, low-Km 5"-nucleotidase was eluted with 10 mM ADP, and nonspecific phosphatase was not retained on the column.	Sodium Chloride	46-50	5'-nucleotidase ecto	Homo sapiens	8-23
2538071-3	1989	High-Km 5"-nucleotidase was eluted with 0.5 M NaCl, low-Km 5"-nucleotidase was eluted with 10 mM ADP, and nonspecific phosphatase was not retained on the column.	Adenosine Diphosphate	97-100	5'-nucleotidase ecto	Homo sapiens	59-74
2549385-0	1989	Phosphorylation of 2",3"-dideoxyinosine by cytosolic 5"-nucleotidase of human lymphoid cells.	Didanosine	19-39	5'-nucleotidase ecto	Homo sapiens	53-68
2549385-6	1989	We now find that, in the presence of MgCl2, KCl, and inosine-5"-monophosphate as phosphate donor, purified cytosolic 5"-nucleotidase catalyzed the phosphorylation of ddlno.	Magnesium Chloride	37-42	5'-nucleotidase ecto	Homo sapiens	117-132
2549385-6	1989	We now find that, in the presence of MgCl2, KCl, and inosine-5"-monophosphate as phosphate donor, purified cytosolic 5"-nucleotidase catalyzed the phosphorylation of ddlno.	Potassium Chloride	44-47	5'-nucleotidase ecto	Homo sapiens	117-132
2549385-6	1989	We now find that, in the presence of MgCl2, KCl, and inosine-5"-monophosphate as phosphate donor, purified cytosolic 5"-nucleotidase catalyzed the phosphorylation of ddlno.	Inosine Monophosphate	53-77	5'-nucleotidase ecto	Homo sapiens	117-132
2549385-6	1989	We now find that, in the presence of MgCl2, KCl, and inosine-5"-monophosphate as phosphate donor, purified cytosolic 5"-nucleotidase catalyzed the phosphorylation of ddlno.	Phosphates	68-77	5'-nucleotidase ecto	Homo sapiens	117-132
2549385-6	1989	We now find that, in the presence of MgCl2, KCl, and inosine-5"-monophosphate as phosphate donor, purified cytosolic 5"-nucleotidase catalyzed the phosphorylation of ddlno.	ddlno	166-171	5'-nucleotidase ecto	Homo sapiens	117-132
2558531-3	1989	Using 0.5 M NaCl, 10 mM ATP and 5 mM adenosine as eluting agents, it was possible to separate on AMP-sepharose column AMP deaminase "high Km" and "low Km" 5"-nucleotidase and adenosine kinase.	Adenosine	37-46	5'-nucleotidase ecto	Homo sapiens	155-170
2540766-2	1989	In two-dimensional electrophoresis 5"-nucleotidase, purified as well as membrane bound, is resolved in up to 13 isoforms distinguished by a different content of neuraminic acid.	Neuraminic Acids	161-176	5'-nucleotidase ecto	Homo sapiens	35-50
2537356-9	1989	Ecto-5"-NT+ T cells responded to lower doses of PMA (1.0 ng/ml) than did ecto-5"-NT- T cells and showed a two- to eight-fold greater rate of [3H]TdR incorporation at 3 to 10 ng of PMA per ml.	Tritium	142-144	5'-nucleotidase ecto	Homo sapiens	0-10
2537356-9	1989	Ecto-5"-NT+ T cells responded to lower doses of PMA (1.0 ng/ml) than did ecto-5"-NT- T cells and showed a two- to eight-fold greater rate of [3H]TdR incorporation at 3 to 10 ng of PMA per ml.	Tetradecanoylphorbol Acetate	48-51	5'-nucleotidase ecto	Homo sapiens	0-10
2537356-10	1989	Ecto-5"-NT+ T cells may have a protein kinase C that is more accessible or more easily activated or may utilize an alternate pathway of activation when stimulated with low concentrations of PMA.	Tetradecanoylphorbol Acetate	190-193	5'-nucleotidase ecto	Homo sapiens	0-10
3191394-2	1988	This release was reduced by (i) the 5-HT receptor antagonist methysergide, (ii) removal of Ca2+ from the medium, (iii) inhibition of ecto-5"-nucleotidase and (iv) capsaicin pretreatment.	Methysergide	61-73	5'-nucleotidase ecto	Homo sapiens	133-153
2848805-2	1988	A human placental soluble "high Km" 5"-nucleotidase has been separated from "low Km" 5"-nucleotidase and nonspecific phosphatase by AMP-Sepharose affinity chromatography.	Adenosine Monophosphate	132-135	5'-nucleotidase ecto	Homo sapiens	36-51
2848805-2	1988	A human placental soluble "high Km" 5"-nucleotidase has been separated from "low Km" 5"-nucleotidase and nonspecific phosphatase by AMP-Sepharose affinity chromatography.	Sepharose	136-145	5'-nucleotidase ecto	Homo sapiens	36-51
2848805-5	1988	Soluble high Km 5"-nucleotidase is most active with IMP and GMP and their deoxy derivatives.	Inosine Monophosphate	52-55	5'-nucleotidase ecto	Homo sapiens	16-31
2848805-5	1988	Soluble high Km 5"-nucleotidase is most active with IMP and GMP and their deoxy derivatives.	guanosine 5'-monophosphorothioate	60-63	5'-nucleotidase ecto	Homo sapiens	16-31
2848805-16	1988	These data show that: (a) soluble human placental high Km 5"-nucleotidase coexists in human placenta with the low Km enzyme; (b) under physiological conditions the enzyme favors the hydrolysis of IMP and is critically regulated by IMP, ATP, and Pi levels; and (c) kinetic properties of ATP and IMP are each modified by the other compound suggesting complex interaction of the associated binding sites.	Inosine Monophosphate	196-199	5'-nucleotidase ecto	Homo sapiens	58-73
2848805-16	1988	These data show that: (a) soluble human placental high Km 5"-nucleotidase coexists in human placenta with the low Km enzyme; (b) under physiological conditions the enzyme favors the hydrolysis of IMP and is critically regulated by IMP, ATP, and Pi levels; and (c) kinetic properties of ATP and IMP are each modified by the other compound suggesting complex interaction of the associated binding sites.	Adenosine Triphosphate	236-239	5'-nucleotidase ecto	Homo sapiens	58-73
2848805-16	1988	These data show that: (a) soluble human placental high Km 5"-nucleotidase coexists in human placenta with the low Km enzyme; (b) under physiological conditions the enzyme favors the hydrolysis of IMP and is critically regulated by IMP, ATP, and Pi levels; and (c) kinetic properties of ATP and IMP are each modified by the other compound suggesting complex interaction of the associated binding sites.	Adenosine Triphosphate	286-289	5'-nucleotidase ecto	Homo sapiens	58-73
2844789-0	1988	5"-Nucleotidase of human placental trophoblastic microvilli possesses cobalt-stimulated FAD pyrophosphatase activity.	Cobalt	70-76	5'-nucleotidase ecto	Homo sapiens	0-15
2844789-11	1988	For 5"-nucleotidase (AMP as substrate) the Km was 4.1 x 10(-5) M and the Vmax 109 mumol/min/mg protein.	Adenosine Monophosphate	21-24	5'-nucleotidase ecto	Homo sapiens	4-19
2844789-12	1988	Hydrolysis of FMN to riboflavin was observed in partially purified detergent extracts of microvilli that contained alkaline phosphatase activity and lacked FAD pyrophosphatase and 5"-nucleotidase activity.	Flavin Mononucleotide	14-17	5'-nucleotidase ecto	Homo sapiens	180-195
2847980-0	1988	Role of inositol starvation on ecto-5"-nucleotidase activity during mitogen-induced lymphocyte activation.	Inositol	8-16	5'-nucleotidase ecto	Homo sapiens	31-51
2844789-12	1988	Hydrolysis of FMN to riboflavin was observed in partially purified detergent extracts of microvilli that contained alkaline phosphatase activity and lacked FAD pyrophosphatase and 5"-nucleotidase activity.	Riboflavin	21-31	5'-nucleotidase ecto	Homo sapiens	180-195
2558531-0	1989	The application of affinity chromatography for the separation of "high Km" and "low Km" 5"-nucleotidase and other AMP metabolizing enzymes.	Adenosine Monophosphate	114-117	5'-nucleotidase ecto	Homo sapiens	88-103
2558531-1	1989	AMP-sepharose 4B has been widely used as a general ligand affinity chromatography for purification of AMP deaminase, 5"-nucleotidase, adenosine kinase and other adenine nucleotide metabolizing enzymes.	amp-sepharose 4b	0-16	5'-nucleotidase ecto	Homo sapiens	117-132
2558531-3	1989	Using 0.5 M NaCl, 10 mM ATP and 5 mM adenosine as eluting agents, it was possible to separate on AMP-sepharose column AMP deaminase "high Km" and "low Km" 5"-nucleotidase and adenosine kinase.	Sodium Chloride	12-16	5'-nucleotidase ecto	Homo sapiens	155-170
2839245-1	1988	5"-Nucleotidase of bull seminal plasma has been spin labeled with the sulfhydryl reagent 3-maleimidoproxyl.	N-(1-oxyl-2,2,5,5-tetramethyl-3-pyrrolidinyl)maleimide	89-106	5'-nucleotidase ecto	Homo sapiens	0-15
2901726-7	1988	Ribavirin imidodiphosphate (4e) was also synthesized and tested for its inhibitory effect on ecto-5"-nucleotidase, PPRP-synthetase as well as IMP dehydrogenase.	ribavirin imidodiphosphate	0-26	5'-nucleotidase ecto	Homo sapiens	93-113
3379046-4	1988	Dipyridamole (10 mumol/liter), an inhibitor of nucleoside transport, caused a 5-7-fold increase in adenosine accumulation which was reduced by 85% on inhibition of ectophosphatases by beta-glycerophosphate and antibodies against ecto-5"-nucleotidase or alpha, beta-methylene 5"-adenosine diphosphate (10 mumol/liter), respectively, indicating that most of the adenosine is produced in the extracellular compartment.	Dipyridamole	0-12	5'-nucleotidase ecto	Homo sapiens	229-249
3379046-4	1988	Dipyridamole (10 mumol/liter), an inhibitor of nucleoside transport, caused a 5-7-fold increase in adenosine accumulation which was reduced by 85% on inhibition of ectophosphatases by beta-glycerophosphate and antibodies against ecto-5"-nucleotidase or alpha, beta-methylene 5"-adenosine diphosphate (10 mumol/liter), respectively, indicating that most of the adenosine is produced in the extracellular compartment.	Adenosine	99-108	5'-nucleotidase ecto	Homo sapiens	229-249
2836053-0	1988	Photosensitizing effects of hematoporphyrin derivative and photofrin II on the plasma membrane enzymes 5"-nucleotidase, Na+K+-ATPase, and Mg2+-ATPase in R3230AC mammary adenocarcinomas.	Hematoporphyrins	28-43	5'-nucleotidase ecto	Homo sapiens	103-118
2836053-4	1988	For 5"-nucleotidase in vitro, a 10-fold higher porphyrin concentration was required to achieve a similar rate of enzyme inhibition as that for the ion-activated ATPases.	Porphyrins	47-56	5'-nucleotidase ecto	Homo sapiens	4-19
2839245-4	1988	The second class is characterized by a shorter correlation time of the covalently bound spin labels and binding of the substrate sodium thymidine 5"-monophosphate to 5"-nucleotidase results in a reduction of their mobility.	sodium thymidine 5"-monophosphate	129-162	5'-nucleotidase ecto	Homo sapiens	166-181
2839144-1	1988	Identification of a purine 5"-nucleotidase stimulated by ATP and glycerate 2,3-bisphosphate.	Adenosine Triphosphate	57-60	5'-nucleotidase ecto	Homo sapiens	27-42
2833294-1	1988	The 5"-nucleotidase of plasma membranes of cultured skin fibroblasts from patients with Duchenne muscular dystrophy had a reduced affinity for its substrate, 5"-AMP.	Adenosine Monophosphate	158-164	5'-nucleotidase ecto	Homo sapiens	4-19
2892037-0	1987	Are children with lymphoblastic leukaemia resistant to 6-mercaptopurine because of 5"-nucleotidase?	Mercaptopurine	55-71	5'-nucleotidase ecto	Homo sapiens	83-98
2834709-3	1988	The activities of key enzymes involved in purine degradation and re-utilization (5"-nucleotidase; AMP-deaminase; hypoxanthine phosphoribosyltransferase (HPRT); xanthine dehydrogenase/oxidase) as well as the total activity of alkaline phosphatase were measured in the trophoblastic cells.	purine	42-48	5'-nucleotidase ecto	Homo sapiens	81-96
2834709-5	1988	A 40 per cent decrease was noted in the activity of 5"-nucleotidase, which, on the basis of kinetic properties, appears to have a dominant role in the dephosphorylation of placental nucleoside-5"-monophosphates.	nucleoside-5"-monophosphates	182-210	5'-nucleotidase ecto	Homo sapiens	52-67
2827918-0	1987	Loss of sialic acid from 5"-nucleotidase in human milk.	N-Acetylneuraminic Acid	8-19	5'-nucleotidase ecto	Homo sapiens	25-40
2839144-1	1988	Identification of a purine 5"-nucleotidase stimulated by ATP and glycerate 2,3-bisphosphate.	2,3-Diphosphoglycerate	65-91	5'-nucleotidase ecto	Homo sapiens	27-42
2839144-6	1988	The purine 5"-nucleotidase is inhibited by Pi, and is strongly stimulated by ATP, dATP and GTP, and by glycerate 2,3-bisphosphate.	Adenosine Triphosphate	77-80	5'-nucleotidase ecto	Homo sapiens	11-26
2839144-6	1988	The purine 5"-nucleotidase is inhibited by Pi, and is strongly stimulated by ATP, dATP and GTP, and by glycerate 2,3-bisphosphate.	2'-deoxyadenosine triphosphate	82-86	5'-nucleotidase ecto	Homo sapiens	11-26
2839144-6	1988	The purine 5"-nucleotidase is inhibited by Pi, and is strongly stimulated by ATP, dATP and GTP, and by glycerate 2,3-bisphosphate.	Guanosine Triphosphate	91-94	5'-nucleotidase ecto	Homo sapiens	11-26
2839144-6	1988	The purine 5"-nucleotidase is inhibited by Pi, and is strongly stimulated by ATP, dATP and GTP, and by glycerate 2,3-bisphosphate.	2,3-Diphosphoglycerate	103-129	5'-nucleotidase ecto	Homo sapiens	11-26
2839144-10	1988	It is concluded that the glycerate 2,3-bisphosphate-stimulated purine 5"-nucleotidase is responsible for the dephosphorylation of IMP and GMP, but not of AMP, in human erythrocytes.	2,3-Diphosphoglycerate	25-51	5'-nucleotidase ecto	Homo sapiens	70-85
2839144-10	1988	It is concluded that the glycerate 2,3-bisphosphate-stimulated purine 5"-nucleotidase is responsible for the dephosphorylation of IMP and GMP, but not of AMP, in human erythrocytes.	guanosine 5'-monophosphorothioate	138-141	5'-nucleotidase ecto	Homo sapiens	70-85
2839144-10	1988	It is concluded that the glycerate 2,3-bisphosphate-stimulated purine 5"-nucleotidase is responsible for the dephosphorylation of IMP and GMP, but not of AMP, in human erythrocytes.	Adenosine Monophosphate	154-157	5'-nucleotidase ecto	Homo sapiens	70-85
2824345-6	1987	When purine de novo synthesis of the lymphocytes is blocked by aminopterin and purine nucleotides in the extracellular medium are given as the only purine source, lymphocyte stimulation becomes dependent on the enzymatic activity of ecto-5"-nucleotidase.	purine	5-11	5'-nucleotidase ecto	Homo sapiens	233-253
2824345-6	1987	When purine de novo synthesis of the lymphocytes is blocked by aminopterin and purine nucleotides in the extracellular medium are given as the only purine source, lymphocyte stimulation becomes dependent on the enzymatic activity of ecto-5"-nucleotidase.	Aminopterin	63-74	5'-nucleotidase ecto	Homo sapiens	233-253
2824345-6	1987	When purine de novo synthesis of the lymphocytes is blocked by aminopterin and purine nucleotides in the extracellular medium are given as the only purine source, lymphocyte stimulation becomes dependent on the enzymatic activity of ecto-5"-nucleotidase.	Purine Nucleotides	79-97	5'-nucleotidase ecto	Homo sapiens	233-253
2824345-6	1987	When purine de novo synthesis of the lymphocytes is blocked by aminopterin and purine nucleotides in the extracellular medium are given as the only purine source, lymphocyte stimulation becomes dependent on the enzymatic activity of ecto-5"-nucleotidase.	purine	79-85	5'-nucleotidase ecto	Homo sapiens	233-253
2823369-0	1987	Nitrobenzylthioinosinate binding sites in HeLa cells: relationship with ecto-5"-nucleotidase.	nitrobenzylthioinosinate	0-24	5'-nucleotidase ecto	Homo sapiens	72-92
2445224-2	1987	The 5-phosphoribosyl-1-pyrophosphate (PRPP)-dependent formation of AMP from adenine is followed spectrophotometrically at 265 nm by coupling it with the following two-stage enzymatic conversion: AMP + H2O----adenosine + Pi (5"-nucleotidase); adenosine + H2O----inosine + NH3 (adenosine deaminase).	Phosphoribosyl Pyrophosphate	4-36	5'-nucleotidase ecto	Homo sapiens	224-239
2445224-2	1987	The 5-phosphoribosyl-1-pyrophosphate (PRPP)-dependent formation of AMP from adenine is followed spectrophotometrically at 265 nm by coupling it with the following two-stage enzymatic conversion: AMP + H2O----adenosine + Pi (5"-nucleotidase); adenosine + H2O----inosine + NH3 (adenosine deaminase).	Phosphoribosyl Pyrophosphate	38-42	5'-nucleotidase ecto	Homo sapiens	224-239
2445224-2	1987	The 5-phosphoribosyl-1-pyrophosphate (PRPP)-dependent formation of AMP from adenine is followed spectrophotometrically at 265 nm by coupling it with the following two-stage enzymatic conversion: AMP + H2O----adenosine + Pi (5"-nucleotidase); adenosine + H2O----inosine + NH3 (adenosine deaminase).	Adenosine Monophosphate	67-70	5'-nucleotidase ecto	Homo sapiens	224-239
2445224-2	1987	The 5-phosphoribosyl-1-pyrophosphate (PRPP)-dependent formation of AMP from adenine is followed spectrophotometrically at 265 nm by coupling it with the following two-stage enzymatic conversion: AMP + H2O----adenosine + Pi (5"-nucleotidase); adenosine + H2O----inosine + NH3 (adenosine deaminase).	Adenine	76-83	5'-nucleotidase ecto	Homo sapiens	224-239
2445224-2	1987	The 5-phosphoribosyl-1-pyrophosphate (PRPP)-dependent formation of AMP from adenine is followed spectrophotometrically at 265 nm by coupling it with the following two-stage enzymatic conversion: AMP + H2O----adenosine + Pi (5"-nucleotidase); adenosine + H2O----inosine + NH3 (adenosine deaminase).	Adenosine Monophosphate	195-198	5'-nucleotidase ecto	Homo sapiens	224-239
2445224-2	1987	The 5-phosphoribosyl-1-pyrophosphate (PRPP)-dependent formation of AMP from adenine is followed spectrophotometrically at 265 nm by coupling it with the following two-stage enzymatic conversion: AMP + H2O----adenosine + Pi (5"-nucleotidase); adenosine + H2O----inosine + NH3 (adenosine deaminase).	h2o----adenosine	201-217	5'-nucleotidase ecto	Homo sapiens	224-239
2445224-4	1987	The basis of the spectrophotometric assay is the absorbance change at 265 nm associated with the enzymatic conversion of PRPP into inosine, catalyzed by the sequential action of partially purified adenine phosphoribosyltransferase, commercial 5"-nucleotidase, and commercial adenosine deaminase, in the presence of excess adenine.	Phosphoribosyl Pyrophosphate	121-125	5'-nucleotidase ecto	Homo sapiens	243-258
2445224-4	1987	The basis of the spectrophotometric assay is the absorbance change at 265 nm associated with the enzymatic conversion of PRPP into inosine, catalyzed by the sequential action of partially purified adenine phosphoribosyltransferase, commercial 5"-nucleotidase, and commercial adenosine deaminase, in the presence of excess adenine.	Inosine	131-138	5'-nucleotidase ecto	Homo sapiens	243-258
2445224-4	1987	The basis of the spectrophotometric assay is the absorbance change at 265 nm associated with the enzymatic conversion of PRPP into inosine, catalyzed by the sequential action of partially purified adenine phosphoribosyltransferase, commercial 5"-nucleotidase, and commercial adenosine deaminase, in the presence of excess adenine.	Adenine	197-204	5'-nucleotidase ecto	Homo sapiens	243-258
3039004-3	1987	Enzyme activity is determined by colorimetric estimation of NH3 released from adenosine, the product of 5"-nucleotidase activity in the presence of adenosine deaminase.	Ammonia	60-63	5'-nucleotidase ecto	Homo sapiens	104-119
3039004-3	1987	Enzyme activity is determined by colorimetric estimation of NH3 released from adenosine, the product of 5"-nucleotidase activity in the presence of adenosine deaminase.	Adenosine	78-87	5'-nucleotidase ecto	Homo sapiens	104-119
2823369-1	1987	Nitrobenzylthioinosine (NBTI), a substrate for the ecto-5"-nucleotidase of HeLa cells, was used to probe the relationship between ecto-5"-nucleotidase dephosphorylation site and the dephosphorylated NBTI binding site.	4-nitrobenzylthioinosine	0-22	5'-nucleotidase ecto	Homo sapiens	51-71
2823369-1	1987	Nitrobenzylthioinosine (NBTI), a substrate for the ecto-5"-nucleotidase of HeLa cells, was used to probe the relationship between ecto-5"-nucleotidase dephosphorylation site and the dephosphorylated NBTI binding site.	4-nitrobenzylthioinosine	0-22	5'-nucleotidase ecto	Homo sapiens	130-150
2823369-1	1987	Nitrobenzylthioinosine (NBTI), a substrate for the ecto-5"-nucleotidase of HeLa cells, was used to probe the relationship between ecto-5"-nucleotidase dephosphorylation site and the dephosphorylated NBTI binding site.	4-nitrobenzylthioinosine	24-28	5'-nucleotidase ecto	Homo sapiens	51-71
2823369-1	1987	Nitrobenzylthioinosine (NBTI), a substrate for the ecto-5"-nucleotidase of HeLa cells, was used to probe the relationship between ecto-5"-nucleotidase dephosphorylation site and the dephosphorylated NBTI binding site.	4-nitrobenzylthioinosine	24-28	5'-nucleotidase ecto	Homo sapiens	130-150
3036115-4	1987	The soluble 5"-nucleotidase may be derived from the membrane-bound form by the action of an endogenous phospholipase C. The structural basis for the inability of some of the membrane-bound 5"-nucleotidase to be released by phosphatidylinositol-specific phospholipase C is unknown.	Phosphatidylinositols	223-243	5'-nucleotidase ecto	Homo sapiens	12-27
3036115-0	1987	Purification of 5"-nucleotidase from human placenta after release from plasma membranes by phosphatidylinositol-specific phospholipase C. 5"-Nucleotidase was purified greater than 1000-fold from human placenta by treatment of plasma membranes with S. aureus phosphatidylinositol-specific phospholipase C and affinity chromatography on Con A Sepharose and AMP-Sepharose.	Phosphatidylinositols	91-111	5'-nucleotidase ecto	Homo sapiens	16-31
3036115-0	1987	Purification of 5"-nucleotidase from human placenta after release from plasma membranes by phosphatidylinositol-specific phospholipase C. 5"-Nucleotidase was purified greater than 1000-fold from human placenta by treatment of plasma membranes with S. aureus phosphatidylinositol-specific phospholipase C and affinity chromatography on Con A Sepharose and AMP-Sepharose.	Phosphatidylinositols	91-111	5'-nucleotidase ecto	Homo sapiens	138-153
3036115-0	1987	Purification of 5"-nucleotidase from human placenta after release from plasma membranes by phosphatidylinositol-specific phospholipase C. 5"-Nucleotidase was purified greater than 1000-fold from human placenta by treatment of plasma membranes with S. aureus phosphatidylinositol-specific phospholipase C and affinity chromatography on Con A Sepharose and AMP-Sepharose.	Phosphatidylinositols	258-278	5'-nucleotidase ecto	Homo sapiens	138-153
3036115-0	1987	Purification of 5"-nucleotidase from human placenta after release from plasma membranes by phosphatidylinositol-specific phospholipase C. 5"-Nucleotidase was purified greater than 1000-fold from human placenta by treatment of plasma membranes with S. aureus phosphatidylinositol-specific phospholipase C and affinity chromatography on Con A Sepharose and AMP-Sepharose.	Sepharose	341-350	5'-nucleotidase ecto	Homo sapiens	138-153
3036115-0	1987	Purification of 5"-nucleotidase from human placenta after release from plasma membranes by phosphatidylinositol-specific phospholipase C. 5"-Nucleotidase was purified greater than 1000-fold from human placenta by treatment of plasma membranes with S. aureus phosphatidylinositol-specific phospholipase C and affinity chromatography on Con A Sepharose and AMP-Sepharose.	Adenosine Monophosphate	355-358	5'-nucleotidase ecto	Homo sapiens	138-153
3036115-0	1987	Purification of 5"-nucleotidase from human placenta after release from plasma membranes by phosphatidylinositol-specific phospholipase C. 5"-Nucleotidase was purified greater than 1000-fold from human placenta by treatment of plasma membranes with S. aureus phosphatidylinositol-specific phospholipase C and affinity chromatography on Con A Sepharose and AMP-Sepharose.	Sepharose	359-368	5'-nucleotidase ecto	Homo sapiens	138-153
3036115-4	1987	The soluble 5"-nucleotidase may be derived from the membrane-bound form by the action of an endogenous phospholipase C. The structural basis for the inability of some of the membrane-bound 5"-nucleotidase to be released by phosphatidylinositol-specific phospholipase C is unknown.	Phosphatidylinositols	223-243	5'-nucleotidase ecto	Homo sapiens	189-204
3034159-6	1987	The 5"-nucleotidase and NR phosphorylase constitute an obligatory process of the pyridine nucleotide cycle.	pyridine nucleotide	81-100	5'-nucleotidase ecto	Homo sapiens	4-19
3035286-4	1987	In these cells, RU486 fully antagonized the glucocorticoid-specific induction of 5"-nucleotidase activity by dexamethasone.	Mifepristone	16-21	5'-nucleotidase ecto	Homo sapiens	81-96
3035286-4	1987	In these cells, RU486 fully antagonized the glucocorticoid-specific induction of 5"-nucleotidase activity by dexamethasone.	Dexamethasone	109-122	5'-nucleotidase ecto	Homo sapiens	81-96
3787626-5	1986	DSF alone did not elicit these responses while DCE at the highest concentration level increased liver-to-body weight ratios and the activity of 5"-nucleotidase.	ethylene dichloride	47-50	5'-nucleotidase ecto	Homo sapiens	144-159
2954505-5	1987	There is also evidence that adenosine formation takes place intracellularly, predominantly via a cytosolic 5"-nucleotidase.	Adenosine	28-37	5'-nucleotidase ecto	Homo sapiens	107-122
3099086-3	1986	In Mg2+-prepared fractions, both 5"-nucleotidase and unoccupied receptor were distributed between plasma membrane, partially-pure nuclei and mitochondrial/microsomal pellets.	magnesium ion	3-7	5'-nucleotidase ecto	Homo sapiens	33-48
3030625-3	1987	Cephalopods showed an active adenosine deaminase and a 5"-nucleotidase which preferred AMP as the substrate.	Adenosine Monophosphate	87-90	5'-nucleotidase ecto	Homo sapiens	55-70
2945566-5	1986	In the sucrose gradient experiments it was found that [3H]ouabain, digoxin and digitoxin all initially co-distribute with the plasma membrane marker, 5"-nucleotidase, and then leave this fraction of the homogenate at a fast rate when kept at 37 degrees, to co-distribute with the lysosomal marker, beta-hexosaminidase.	Tritium	55-57	5'-nucleotidase ecto	Homo sapiens	150-165
2945566-5	1986	In the sucrose gradient experiments it was found that [3H]ouabain, digoxin and digitoxin all initially co-distribute with the plasma membrane marker, 5"-nucleotidase, and then leave this fraction of the homogenate at a fast rate when kept at 37 degrees, to co-distribute with the lysosomal marker, beta-hexosaminidase.	Digoxin	67-74	5'-nucleotidase ecto	Homo sapiens	150-165
2945566-5	1986	In the sucrose gradient experiments it was found that [3H]ouabain, digoxin and digitoxin all initially co-distribute with the plasma membrane marker, 5"-nucleotidase, and then leave this fraction of the homogenate at a fast rate when kept at 37 degrees, to co-distribute with the lysosomal marker, beta-hexosaminidase.	Digitoxin	79-88	5'-nucleotidase ecto	Homo sapiens	150-165
2985697-0	1985	Ecto-5"-nucleotidase can provide the total purine requirements of mitogen-stimulated human T cells and rapidly dividing human B lymphoblastoid cells.	purine	43-49	5'-nucleotidase ecto	Homo sapiens	0-20
3026695-3	1986	The Vmax values for the hydrolysis of AMP by 5"-nucleotidase were two orders of magnitude greater than for the uptake of adenosine itself or the uptake of adenosine from AMP by normal lymphocytes.	Adenosine	155-164	5'-nucleotidase ecto	Homo sapiens	45-60
3026695-3	1986	The Vmax values for the hydrolysis of AMP by 5"-nucleotidase were two orders of magnitude greater than for the uptake of adenosine itself or the uptake of adenosine from AMP by normal lymphocytes.	Adenosine Monophosphate	170-173	5'-nucleotidase ecto	Homo sapiens	45-60
3026695-7	1986	The uptake of adenosine moiety from AMP in CLL lymphocytes with a low Vmax for 5"-nucleotidase was also reduced, although not to the same extent as the reduction in 5"-nucleotidase activity.	Adenosine	14-23	5'-nucleotidase ecto	Homo sapiens	79-94
3026695-7	1986	The uptake of adenosine moiety from AMP in CLL lymphocytes with a low Vmax for 5"-nucleotidase was also reduced, although not to the same extent as the reduction in 5"-nucleotidase activity.	Adenosine	14-23	5'-nucleotidase ecto	Homo sapiens	165-180
3026695-7	1986	The uptake of adenosine moiety from AMP in CLL lymphocytes with a low Vmax for 5"-nucleotidase was also reduced, although not to the same extent as the reduction in 5"-nucleotidase activity.	Adenosine Monophosphate	36-39	5'-nucleotidase ecto	Homo sapiens	79-94
3026695-8	1986	One CLL patient with supranormal levels of 5"-nucleotidase activity showed elevated uptake of adenosine moiety from AMP and of free adenosine.	Adenosine	94-103	5'-nucleotidase ecto	Homo sapiens	43-58
3026695-8	1986	One CLL patient with supranormal levels of 5"-nucleotidase activity showed elevated uptake of adenosine moiety from AMP and of free adenosine.	Adenosine Monophosphate	116-119	5'-nucleotidase ecto	Homo sapiens	43-58
3026695-8	1986	One CLL patient with supranormal levels of 5"-nucleotidase activity showed elevated uptake of adenosine moiety from AMP and of free adenosine.	Adenosine	132-141	5'-nucleotidase ecto	Homo sapiens	43-58
3026695-9	1986	These results suggest that 5"-nucleotidase can influence the salvage of purine by lymphocytes from extracellular nucleotides but only when the enzyme activity is greatly reduced.	purine	72-78	5'-nucleotidase ecto	Homo sapiens	27-42
3020919-0	1986	Ecto-5"-nucleotidase can use IMP to provide the total purine requirements of mitogen-stimulated human T cells and human B lymphoblasts.	purine	54-60	5'-nucleotidase ecto	Homo sapiens	0-20
2989306-5	1985	This is the first report of a high-performance liquid chromatographic assay system which allows quantitation of the activity of pyrimidine 5"-nucleotidase isozymes using five individual pyrimidine and deoxypyrimidine nucleotides as the substrates.	pyrimidine	128-138	5'-nucleotidase ecto	Homo sapiens	139-154
2989306-5	1985	This is the first report of a high-performance liquid chromatographic assay system which allows quantitation of the activity of pyrimidine 5"-nucleotidase isozymes using five individual pyrimidine and deoxypyrimidine nucleotides as the substrates.	deoxypyrimidine nucleotides	201-228	5'-nucleotidase ecto	Homo sapiens	139-154
3026695-1	1986	The role of 5"-nucleotidase in the uptake of adenosine from AMP was investigated in lymphocytes from normal subjects and patients with common variable hypogammaglobulinaemia (CVH) and chronic lymphatic leukaemia (CLL).	Adenosine	45-54	5'-nucleotidase ecto	Homo sapiens	12-27
3026695-1	1986	The role of 5"-nucleotidase in the uptake of adenosine from AMP was investigated in lymphocytes from normal subjects and patients with common variable hypogammaglobulinaemia (CVH) and chronic lymphatic leukaemia (CLL).	Adenosine Monophosphate	60-63	5'-nucleotidase ecto	Homo sapiens	12-27
3026695-2	1986	At physiological pH, the Km values for the uptake of adenosine and of adenosine from AMP by intact cells were one order of magnitude higher than the Km values for 5"-nucleotidase.	Adenosine	53-62	5'-nucleotidase ecto	Homo sapiens	163-178
3026695-3	1986	The Vmax values for the hydrolysis of AMP by 5"-nucleotidase were two orders of magnitude greater than for the uptake of adenosine itself or the uptake of adenosine from AMP by normal lymphocytes.	Adenosine Monophosphate	38-41	5'-nucleotidase ecto	Homo sapiens	45-60
3026695-3	1986	The Vmax values for the hydrolysis of AMP by 5"-nucleotidase were two orders of magnitude greater than for the uptake of adenosine itself or the uptake of adenosine from AMP by normal lymphocytes.	Adenosine	121-130	5'-nucleotidase ecto	Homo sapiens	45-60
2956735-5	1986	Besides the physical and analytical data, all of the conjugates were demonstrated to be enzymatically hydrolyzed to the corresponding steroid and 5-fluoro-2"-deoxyuridine 5"-monophosphate (III), and the latter was further shown to be hydrolyzed to 5-fluoro-2"-deoxyuridine (II) by phosphodiesterase I, 5"-nucleotidase, and acid phosphatase.	Steroids	134-141	5'-nucleotidase ecto	Homo sapiens	302-317
2956735-5	1986	Besides the physical and analytical data, all of the conjugates were demonstrated to be enzymatically hydrolyzed to the corresponding steroid and 5-fluoro-2"-deoxyuridine 5"-monophosphate (III), and the latter was further shown to be hydrolyzed to 5-fluoro-2"-deoxyuridine (II) by phosphodiesterase I, 5"-nucleotidase, and acid phosphatase.	5-fluoro-2'-deoxyuridine	146-170	5'-nucleotidase ecto	Homo sapiens	302-317
3019308-9	1986	Within the range of adenylate energy charge observed in surviving mammalian cells (0.7-0.9), the rate of AMP-hydrolysing activity catalysed by the 5"-nucleotidase increased sharply with decreasing energy charge.	Adenosine Monophosphate	105-108	5'-nucleotidase ecto	Homo sapiens	147-162
3000575-0	1986	Tiazofurin metabolism in human lymphoblastoid cells: evidence for phosphorylation by adenosine kinase and 5"-nucleotidase.	tiazofurin	0-10	5'-nucleotidase ecto	Homo sapiens	106-121
3000575-10	1986	The monophosphate donor specificity, divalent metal, high salt requirement, and nucleoside acceptor specificity of this enzyme activity paralleled that of a 5"-nucleotidase (EC 3.1.3.5) which catalyzes inosine phosphorylation.	monophosphate	4-17	5'-nucleotidase ecto	Homo sapiens	157-172
3000575-10	1986	The monophosphate donor specificity, divalent metal, high salt requirement, and nucleoside acceptor specificity of this enzyme activity paralleled that of a 5"-nucleotidase (EC 3.1.3.5) which catalyzes inosine phosphorylation.	Metals	46-51	5'-nucleotidase ecto	Homo sapiens	157-172
3000575-10	1986	The monophosphate donor specificity, divalent metal, high salt requirement, and nucleoside acceptor specificity of this enzyme activity paralleled that of a 5"-nucleotidase (EC 3.1.3.5) which catalyzes inosine phosphorylation.	Salts	58-62	5'-nucleotidase ecto	Homo sapiens	157-172
3000575-10	1986	The monophosphate donor specificity, divalent metal, high salt requirement, and nucleoside acceptor specificity of this enzyme activity paralleled that of a 5"-nucleotidase (EC 3.1.3.5) which catalyzes inosine phosphorylation.	Nucleosides	80-90	5'-nucleotidase ecto	Homo sapiens	157-172
3000575-10	1986	The monophosphate donor specificity, divalent metal, high salt requirement, and nucleoside acceptor specificity of this enzyme activity paralleled that of a 5"-nucleotidase (EC 3.1.3.5) which catalyzes inosine phosphorylation.	Inosine	202-209	5'-nucleotidase ecto	Homo sapiens	157-172
3000575-12	1986	These results indicate that two enzymes, adenosine kinase and a cytoplasmic 5"-nucleotidase, are functionally important anabolizing enzymes for tiazofurin in human cells.	tiazofurin	144-154	5'-nucleotidase ecto	Homo sapiens	76-91
3003981-3	1985	The best ultracytochemical demonstration of 5"-nucleotidase and ATPase activities was achieved after fixation in buffered 2% formaldehyde prior to cytochemical incubation.	Formaldehyde	125-137	5'-nucleotidase ecto	Homo sapiens	44-59
2994076-2	1985	Cultured aortic smooth muscle cells which were incubated with 10 micrograms/ml of either sterol for 24 to 48 hr showed a marked decrease of 5"-nucleotidase activity in isolated crude membranes.	Sterols	89-95	5'-nucleotidase ecto	Homo sapiens	140-155
2994076-3	1985	It was further demonstrated that 5"-nucleotidase activity was also markedly decreased in plasma membrane-enriched fractions when cells were incubated with cholestane-3 beta,5 alpha,6 beta-triol.	cholestane-3,5,6-triol	155-193	5'-nucleotidase ecto	Homo sapiens	33-48
2991937-9	1985	These results show that the catalytic activity of ecto-5"-nucleotidase is sufficient to meet the total purine requirements of mitogen-stimulated human T cells or rapidly dividing human B lymphoblastoid cells and suggest that this enzyme may have functional significance when rates of purine synthesis de novo are limited and/or an extracellular source of purine nucleotides is available.	purine	103-109	5'-nucleotidase ecto	Homo sapiens	50-70
2991937-9	1985	These results show that the catalytic activity of ecto-5"-nucleotidase is sufficient to meet the total purine requirements of mitogen-stimulated human T cells or rapidly dividing human B lymphoblastoid cells and suggest that this enzyme may have functional significance when rates of purine synthesis de novo are limited and/or an extracellular source of purine nucleotides is available.	purine	284-290	5'-nucleotidase ecto	Homo sapiens	50-70
2991937-9	1985	These results show that the catalytic activity of ecto-5"-nucleotidase is sufficient to meet the total purine requirements of mitogen-stimulated human T cells or rapidly dividing human B lymphoblastoid cells and suggest that this enzyme may have functional significance when rates of purine synthesis de novo are limited and/or an extracellular source of purine nucleotides is available.	Purine Nucleotides	355-373	5'-nucleotidase ecto	Homo sapiens	50-70
2997103-2	1985	In this procedure, a mixture of AMP and NADP solution is first incubated with 5"-nucleotidase to hydrolyze AMP to adenosine and inorganic phosphate (Pi).	Adenosine Monophosphate	32-35	5'-nucleotidase ecto	Homo sapiens	78-93
2997103-2	1985	In this procedure, a mixture of AMP and NADP solution is first incubated with 5"-nucleotidase to hydrolyze AMP to adenosine and inorganic phosphate (Pi).	NADP	40-44	5'-nucleotidase ecto	Homo sapiens	78-93
2997103-2	1985	In this procedure, a mixture of AMP and NADP solution is first incubated with 5"-nucleotidase to hydrolyze AMP to adenosine and inorganic phosphate (Pi).	Adenosine Monophosphate	107-110	5'-nucleotidase ecto	Homo sapiens	78-93
2997103-2	1985	In this procedure, a mixture of AMP and NADP solution is first incubated with 5"-nucleotidase to hydrolyze AMP to adenosine and inorganic phosphate (Pi).	Adenosine	114-123	5'-nucleotidase ecto	Homo sapiens	78-93
2997103-2	1985	In this procedure, a mixture of AMP and NADP solution is first incubated with 5"-nucleotidase to hydrolyze AMP to adenosine and inorganic phosphate (Pi).	Phosphates	128-147	5'-nucleotidase ecto	Homo sapiens	78-93
2997103-4	1985	Adenosine and 5"-nucleotidase are removed by washing the column with 20 mM HCOOH.	formic acid	75-80	5'-nucleotidase ecto	Homo sapiens	14-29
2985697-2	1985	Inosine 5"-monophosphate first must be converted to inosine by the action of the enzyme ecto-5"-nucleotidase before it can be transported into the cell; inosine and hypoxanthine, however, can be transported directly.	Inosine Monophosphate	0-24	5'-nucleotidase ecto	Homo sapiens	88-108
2985697-2	1985	Inosine 5"-monophosphate first must be converted to inosine by the action of the enzyme ecto-5"-nucleotidase before it can be transported into the cell; inosine and hypoxanthine, however, can be transported directly.	Inosine	52-59	5'-nucleotidase ecto	Homo sapiens	88-108
2985697-10	1985	These results show that the catalytic activity of ecto-5"-nucleotidase is sufficient to meet the total purine requirements of mitogen-stimulated human T cells or rapidly dividing human B lymphoblastoid cells, and suggest that this enzyme may be important for purine salvage when rates of purine synthesis de novo are limited and/or an extracellular source of purine nucleotides is available.	purine	103-109	5'-nucleotidase ecto	Homo sapiens	50-70
2985697-10	1985	These results show that the catalytic activity of ecto-5"-nucleotidase is sufficient to meet the total purine requirements of mitogen-stimulated human T cells or rapidly dividing human B lymphoblastoid cells, and suggest that this enzyme may be important for purine salvage when rates of purine synthesis de novo are limited and/or an extracellular source of purine nucleotides is available.	purine	259-265	5'-nucleotidase ecto	Homo sapiens	50-70
2985697-10	1985	These results show that the catalytic activity of ecto-5"-nucleotidase is sufficient to meet the total purine requirements of mitogen-stimulated human T cells or rapidly dividing human B lymphoblastoid cells, and suggest that this enzyme may be important for purine salvage when rates of purine synthesis de novo are limited and/or an extracellular source of purine nucleotides is available.	purine	259-265	5'-nucleotidase ecto	Homo sapiens	50-70
2985697-10	1985	These results show that the catalytic activity of ecto-5"-nucleotidase is sufficient to meet the total purine requirements of mitogen-stimulated human T cells or rapidly dividing human B lymphoblastoid cells, and suggest that this enzyme may be important for purine salvage when rates of purine synthesis de novo are limited and/or an extracellular source of purine nucleotides is available.	Purine Nucleotides	359-377	5'-nucleotidase ecto	Homo sapiens	50-70
17793769-0	1985	Bacterial 5-nucleotidase in aquatic ecosystems: a novel mechanism of phosphorus regeneration.	Phosphorus	69-79	5'-nucleotidase ecto	Homo sapiens	10-24
17793769-3	1985	5-Nucleotidase rapidly generated orthophosphate from 5-nucleotide added in nanomolar amounts and could supply half the orthophosphate required by plankton.	Phosphates	33-47	5'-nucleotidase ecto	Homo sapiens	0-14
17793769-3	1985	5-Nucleotidase rapidly generated orthophosphate from 5-nucleotide added in nanomolar amounts and could supply half the orthophosphate required by plankton.	5-nucleotide	53-65	5'-nucleotidase ecto	Homo sapiens	0-14
17793769-3	1985	5-Nucleotidase rapidly generated orthophosphate from 5-nucleotide added in nanomolar amounts and could supply half the orthophosphate required by plankton.	Phosphates	119-133	5'-nucleotidase ecto	Homo sapiens	0-14
2982409-1	1985	5"-Nucleotidase from bull seminal plasma is inhibited by dithiothreitol and dithioerythritol.	Dithiothreitol	57-71	5'-nucleotidase ecto	Homo sapiens	0-15
2986260-3	1985	Adenosine formation takes place inside intact isolated cells by a pathway distinct from the cell membrane 5"-nucleotidase, which hydrolyzes only extracellular AMP.	Adenosine Monophosphate	159-162	5'-nucleotidase ecto	Homo sapiens	106-121
2986260-4	1985	Both the magnitude and the variation in the rate of adenosine formation in polymorphonuclear leukocytes undergoing ATP catabolism can be accounted for by the properties of a cytosolic 5"-nucleotidase that is also present in heart.	Adenosine	52-61	5'-nucleotidase ecto	Homo sapiens	184-199
2986260-4	1985	Both the magnitude and the variation in the rate of adenosine formation in polymorphonuclear leukocytes undergoing ATP catabolism can be accounted for by the properties of a cytosolic 5"-nucleotidase that is also present in heart.	Adenosine Triphosphate	115-118	5'-nucleotidase ecto	Homo sapiens	184-199
2982409-1	1985	5"-Nucleotidase from bull seminal plasma is inhibited by dithiothreitol and dithioerythritol.	Dithioerythritol	76-92	5'-nucleotidase ecto	Homo sapiens	0-15
2982409-2	1985	These reactives proved to dissociate the dimeric glycoprotein 5"-nucleotidase of Mr 160 000 into two subunits of apparent Mr 80 000, indicating that the subunits are held together by interchain disulfide bridges.	Disulfides	194-203	5'-nucleotidase ecto	Homo sapiens	62-77
6326439-5	1984	Nucleotides of the three types of acyclo benzimidazole nucleosides have also been prepared, and their susceptibilities to snake venom 5"-nucleotidase examined.	acyclo benzimidazole nucleosides	34-66	5'-nucleotidase ecto	Homo sapiens	134-149
6095853-0	1984	Dephosphorylation of nitrobenzylthioinosine 5"-monophosphate by ecto 5"-nucleotidase of HeLa cells.	nitrobenzylthioinosine 5'-monophosphate	21-60	5'-nucleotidase ecto	Homo sapiens	64-84
6094404-4	1984	Kinetic values of 5"-nucleotidase for 5"-AMP (Km = 3-4 microM; Amax = 3-4 mumol/min) were substantially lower than those reported in vitro but also responded predictably to the competitive inhibitor of 5"-nucleotidase, adenosine 5"-[alpha, beta-methylene]diphosphate.	Adenosine Monophosphate	38-44	5'-nucleotidase ecto	Homo sapiens	18-33
6094404-4	1984	Kinetic values of 5"-nucleotidase for 5"-AMP (Km = 3-4 microM; Amax = 3-4 mumol/min) were substantially lower than those reported in vitro but also responded predictably to the competitive inhibitor of 5"-nucleotidase, adenosine 5"-[alpha, beta-methylene]diphosphate.	Adenosine Monophosphate	38-44	5'-nucleotidase ecto	Homo sapiens	202-217
6094404-4	1984	Kinetic values of 5"-nucleotidase for 5"-AMP (Km = 3-4 microM; Amax = 3-4 mumol/min) were substantially lower than those reported in vitro but also responded predictably to the competitive inhibitor of 5"-nucleotidase, adenosine 5"-[alpha, beta-methylene]diphosphate.	alpha,beta-methyleneadenosine 5'-diphosphate	219-266	5'-nucleotidase ecto	Homo sapiens	18-33
6147383-2	1984	Low activities of the ectoenzymes ecto-5"-nucleotidase and ecto-ATPase have each been associated with deoxyadenosine sensitivity and dATP accumulation in human T-lymphoblasts.	2'-deoxyadenosine	102-116	5'-nucleotidase ecto	Homo sapiens	34-54
6147383-2	1984	Low activities of the ectoenzymes ecto-5"-nucleotidase and ecto-ATPase have each been associated with deoxyadenosine sensitivity and dATP accumulation in human T-lymphoblasts.	2'-deoxyadenosine triphosphate	133-137	5'-nucleotidase ecto	Homo sapiens	34-54
6087922-7	1984	[3H]Adenosine derived from 5"-[3H]AMP hydrolysis was further transformed into [3H]inosine by the adenosine deaminase activity of the leukemic cell lines tested; [3H]inosine was precipitated with the excess substrate and was not taken into account in the ecto-5"-nucleotidase determination, which led the authors to confuse this adenosine deaminase activity with a 5"-nucleotidase inhibitor.	[3h]adenosine	0-13	5'-nucleotidase ecto	Homo sapiens	254-274
6087922-7	1984	[3H]Adenosine derived from 5"-[3H]AMP hydrolysis was further transformed into [3H]inosine by the adenosine deaminase activity of the leukemic cell lines tested; [3H]inosine was precipitated with the excess substrate and was not taken into account in the ecto-5"-nucleotidase determination, which led the authors to confuse this adenosine deaminase activity with a 5"-nucleotidase inhibitor.	[3h]adenosine	0-13	5'-nucleotidase ecto	Homo sapiens	259-274
6087922-7	1984	[3H]Adenosine derived from 5"-[3H]AMP hydrolysis was further transformed into [3H]inosine by the adenosine deaminase activity of the leukemic cell lines tested; [3H]inosine was precipitated with the excess substrate and was not taken into account in the ecto-5"-nucleotidase determination, which led the authors to confuse this adenosine deaminase activity with a 5"-nucleotidase inhibitor.	5"-[3h]amp	27-37	5'-nucleotidase ecto	Homo sapiens	254-274
6087922-7	1984	[3H]Adenosine derived from 5"-[3H]AMP hydrolysis was further transformed into [3H]inosine by the adenosine deaminase activity of the leukemic cell lines tested; [3H]inosine was precipitated with the excess substrate and was not taken into account in the ecto-5"-nucleotidase determination, which led the authors to confuse this adenosine deaminase activity with a 5"-nucleotidase inhibitor.	5"-[3h]amp	27-37	5'-nucleotidase ecto	Homo sapiens	259-274
6087922-7	1984	[3H]Adenosine derived from 5"-[3H]AMP hydrolysis was further transformed into [3H]inosine by the adenosine deaminase activity of the leukemic cell lines tested; [3H]inosine was precipitated with the excess substrate and was not taken into account in the ecto-5"-nucleotidase determination, which led the authors to confuse this adenosine deaminase activity with a 5"-nucleotidase inhibitor.	[3h]inosine	78-89	5'-nucleotidase ecto	Homo sapiens	254-274
6087922-7	1984	[3H]Adenosine derived from 5"-[3H]AMP hydrolysis was further transformed into [3H]inosine by the adenosine deaminase activity of the leukemic cell lines tested; [3H]inosine was precipitated with the excess substrate and was not taken into account in the ecto-5"-nucleotidase determination, which led the authors to confuse this adenosine deaminase activity with a 5"-nucleotidase inhibitor.	[3h]inosine	78-89	5'-nucleotidase ecto	Homo sapiens	259-274
6087922-7	1984	[3H]Adenosine derived from 5"-[3H]AMP hydrolysis was further transformed into [3H]inosine by the adenosine deaminase activity of the leukemic cell lines tested; [3H]inosine was precipitated with the excess substrate and was not taken into account in the ecto-5"-nucleotidase determination, which led the authors to confuse this adenosine deaminase activity with a 5"-nucleotidase inhibitor.	Tritium	1-3	5'-nucleotidase ecto	Homo sapiens	254-274
6087922-7	1984	[3H]Adenosine derived from 5"-[3H]AMP hydrolysis was further transformed into [3H]inosine by the adenosine deaminase activity of the leukemic cell lines tested; [3H]inosine was precipitated with the excess substrate and was not taken into account in the ecto-5"-nucleotidase determination, which led the authors to confuse this adenosine deaminase activity with a 5"-nucleotidase inhibitor.	Tritium	1-3	5'-nucleotidase ecto	Homo sapiens	259-274
6087922-7	1984	[3H]Adenosine derived from 5"-[3H]AMP hydrolysis was further transformed into [3H]inosine by the adenosine deaminase activity of the leukemic cell lines tested; [3H]inosine was precipitated with the excess substrate and was not taken into account in the ecto-5"-nucleotidase determination, which led the authors to confuse this adenosine deaminase activity with a 5"-nucleotidase inhibitor.	Inosine	82-89	5'-nucleotidase ecto	Homo sapiens	254-274
6087922-7	1984	[3H]Adenosine derived from 5"-[3H]AMP hydrolysis was further transformed into [3H]inosine by the adenosine deaminase activity of the leukemic cell lines tested; [3H]inosine was precipitated with the excess substrate and was not taken into account in the ecto-5"-nucleotidase determination, which led the authors to confuse this adenosine deaminase activity with a 5"-nucleotidase inhibitor.	Inosine	82-89	5'-nucleotidase ecto	Homo sapiens	259-274
6086190-1	1984	The Km for AMP for 5" nucleotidase was increased in lymphocytes from patients with common variable (CVH) and sex linked (XLH) hypogammaglobulinaemia and from patients with chronic lymphatic leukaemia (CLL): the Vmax of the latter was low.	Adenosine Monophosphate	11-14	5'-nucleotidase ecto	Homo sapiens	19-34
6086190-3	1984	alpha-beta-Methylene adenosine diphosphate competitively inhibited 5" nucleotidase in lymphocytes from both healthy subjects and patients with CVH: the inhibitor constant (Ki) was higher for lymphocytes from patients with CVH than from control subjects.	alpha,beta-methyleneadenosine 5'-diphosphate	0-42	5'-nucleotidase ecto	Homo sapiens	67-82
6086190-3	1984	alpha-beta-Methylene adenosine diphosphate competitively inhibited 5" nucleotidase in lymphocytes from both healthy subjects and patients with CVH: the inhibitor constant (Ki) was higher for lymphocytes from patients with CVH than from control subjects.	cvh	143-146	5'-nucleotidase ecto	Homo sapiens	67-82
6086190-3	1984	alpha-beta-Methylene adenosine diphosphate competitively inhibited 5" nucleotidase in lymphocytes from both healthy subjects and patients with CVH: the inhibitor constant (Ki) was higher for lymphocytes from patients with CVH than from control subjects.	cvh	222-225	5'-nucleotidase ecto	Homo sapiens	67-82
6095595-0	1984	Is theophylline-induced seizures in man caused by inhibition of cerebral 5"-nucleotidase activity?	Theophylline	3-15	5'-nucleotidase ecto	Homo sapiens	73-88
6094284-2	1984	In the serum-free culture, in which TSH was administered to well-reformed follicles, this increase in 5"-nucleotidase activity concerns both the ecto-enzymic and intracellular forms of the enzyme and it coincides with the period of several days during which several glycosyltransferase activities are elevated and thyroglobulin production increased.	Thyrotropin	36-39	5'-nucleotidase ecto	Homo sapiens	102-117
6094284-3	1984	Taken together, and in view of a recent in vitro study (Brandan and Fleisher, 1982) documenting the fate of uridine diphosphate in Golgi vesicles, these results suggest that there might be a functional correlation between the stimulation of 5"-nucleotidase and an increased production of nucleoside mono- and diphosphates when the activity of a number of glycosyltransferases is increased.	Uridine Diphosphate	108-127	5'-nucleotidase ecto	Homo sapiens	241-256
6094284-3	1984	Taken together, and in view of a recent in vitro study (Brandan and Fleisher, 1982) documenting the fate of uridine diphosphate in Golgi vesicles, these results suggest that there might be a functional correlation between the stimulation of 5"-nucleotidase and an increased production of nucleoside mono- and diphosphates when the activity of a number of glycosyltransferases is increased.	nucleoside mono- and diphosphates	288-321	5'-nucleotidase ecto	Homo sapiens	241-256
6093992-0	1984	Effect of dimethylsulfoxide and butyrate on 5"-nucleotidase of human renal carcinoma cells.	Dimethyl Sulfoxide	10-27	5'-nucleotidase ecto	Homo sapiens	44-59
6093992-0	1984	Effect of dimethylsulfoxide and butyrate on 5"-nucleotidase of human renal carcinoma cells.	Butyrates	32-40	5'-nucleotidase ecto	Homo sapiens	44-59
6321242-0	1984	Identification of histidyl and cysteinyl residues essential for catalysis by 5"-nucleotidase.	histidyl	18-26	5'-nucleotidase ecto	Homo sapiens	77-92
6321242-0	1984	Identification of histidyl and cysteinyl residues essential for catalysis by 5"-nucleotidase.	lysyl-cysteinyl-cysteinyl-arginyl-cysteinyl-lysine	31-40	5'-nucleotidase ecto	Homo sapiens	77-92
6321242-1	1984	Inactivation of both cytosolic 5"-nucleotidase and ecto-5"-nucleotidase by diethylpyrocarbonate indicated the presence of an essential histidyl residue which in the cytosolic enzyme was conclusively located at the active site.	Diethyl Pyrocarbonate	75-95	5'-nucleotidase ecto	Homo sapiens	31-46
6321242-1	1984	Inactivation of both cytosolic 5"-nucleotidase and ecto-5"-nucleotidase by diethylpyrocarbonate indicated the presence of an essential histidyl residue which in the cytosolic enzyme was conclusively located at the active site.	Diethyl Pyrocarbonate	75-95	5'-nucleotidase ecto	Homo sapiens	51-71
6420881-8	1983	In PHA-responsive cell fractions (3-6), the sensitivity to inhibition of the PHA response by (deoxy)adenosine and deoxyguanosine was inversely related to the enzyme activity ratio of ecto-5"-nucleotidase to deoxycytidine kinase.	2'-deoxyadenosine	93-109	5'-nucleotidase ecto	Homo sapiens	183-203
6099286-1	1984	The glycogen-containing ascites cell line was found to have a 3-5 times higher 5"-nucleotidase specific activity than the glycogen-free variant, resulting in different substrate affinity constants of Km = 0.14 mM and Km = 0.69 mM respectively.	Glycogen	4-12	5'-nucleotidase ecto	Homo sapiens	79-94
6099286-2	1984	These activity differences were due to true 5"-nucleotidase as shown by its inactivation through specific inhibitors such as concanavalin A and alpha, beta-methylene adenosine diphosphate.	alpha,beta-methyleneadenosine 5'-diphosphate	144-187	5'-nucleotidase ecto	Homo sapiens	44-59
6320196-6	1984	Variations in substrate specificity, pH optima, kinetics, and sensitivity to inactivation by Pb2+ indicated the existence of multiple 5"-nucleotidase isozymes in normal erythrocytes: PyrNase and deoxyribonucleotidase(s) that might function physiologically in the conversion of DNA-derived nucleotides to diffusible nucleosides.	Nucleosides	315-326	5'-nucleotidase ecto	Homo sapiens	134-149
6328473-3	1984	Purified placental 5"-nucleotidase was free from non-specific or alkaline phosphatase, hydrolysed 12 to 22 mumol AMP/min/mg of protein at 30 degrees C, and was activated up to fivefold by Triton X-100.	Adenosine Monophosphate	113-116	5'-nucleotidase ecto	Homo sapiens	19-34
6328473-3	1984	Purified placental 5"-nucleotidase was free from non-specific or alkaline phosphatase, hydrolysed 12 to 22 mumol AMP/min/mg of protein at 30 degrees C, and was activated up to fivefold by Triton X-100.	Octoxynol	188-200	5'-nucleotidase ecto	Homo sapiens	19-34
6087496-3	1984	Correspondingly, there is a nearly two-fold increase in the activity of the ectoenzyme 5"-nucleotidase (a marker for plasma membrane) internally within the cytoplasm, after treatment with CD.	Cadmium	188-190	5'-nucleotidase ecto	Homo sapiens	87-102
6199001-2	1984	We applied a simple lead salt-based stain for interstitial and vascular 5"-nucleotidase to 150 muscle biopsy specimens.	lead salt	20-29	5'-nucleotidase ecto	Homo sapiens	72-87
6140031-8	1983	Although the plasma membrane could not be readily discerned in electron micrographs after the initial phase, the plasma membrane marker enzyme 5"-nucleotidase remained associated with digitonin-treated hepatocytes.	Digitonin	184-193	5'-nucleotidase ecto	Homo sapiens	143-158
6317425-6	1983	No inhibition of 5"-nucleotidase was observed by superoxide anions; however, the activity of 5"-nucleotidase was enhanced by trypsin, lysolecithin, or both in concert.	Lysophosphatidylcholines	134-146	5'-nucleotidase ecto	Homo sapiens	93-108
6420881-8	1983	In PHA-responsive cell fractions (3-6), the sensitivity to inhibition of the PHA response by (deoxy)adenosine and deoxyguanosine was inversely related to the enzyme activity ratio of ecto-5"-nucleotidase to deoxycytidine kinase.	Deoxyguanosine	114-128	5'-nucleotidase ecto	Homo sapiens	183-203
6313658-10	1983	Analysis of cAMP catabolites in granulosa cells indicated that the phosphodiesterase reaction product, 5"-AMP, was rapidly converted to adenosine by a plasma membrane 5"-nucleotidase, independent of the cellular hormonal status.	Cyclic AMP	12-16	5'-nucleotidase ecto	Homo sapiens	167-182
6313658-10	1983	Analysis of cAMP catabolites in granulosa cells indicated that the phosphodiesterase reaction product, 5"-AMP, was rapidly converted to adenosine by a plasma membrane 5"-nucleotidase, independent of the cellular hormonal status.	Adenosine Monophosphate	103-109	5'-nucleotidase ecto	Homo sapiens	167-182
6313658-10	1983	Analysis of cAMP catabolites in granulosa cells indicated that the phosphodiesterase reaction product, 5"-AMP, was rapidly converted to adenosine by a plasma membrane 5"-nucleotidase, independent of the cellular hormonal status.	Adenosine	136-145	5'-nucleotidase ecto	Homo sapiens	167-182
6311457-1	1983	We have modified a manual assay method for the determination of serum 5"-nucleotidase so that the reaction product, phosphate, is assayed colorimetrically using a continuous flow system.	Phosphates	116-125	5'-nucleotidase ecto	Homo sapiens	70-85
6603241-3	1983	We have found that non-T, non-B acute lymphoblastic leukemia cells with low ecto-5"-nucleotidase and high adenosine deaminase activities increase their dATP pools by greater than tenfold when exposed to deoxyadenosine and an inhibitor of adenosine deaminase in culture.	2'-deoxyadenosine triphosphate	152-156	5'-nucleotidase ecto	Homo sapiens	76-96
6603241-3	1983	We have found that non-T, non-B acute lymphoblastic leukemia cells with low ecto-5"-nucleotidase and high adenosine deaminase activities increase their dATP pools by greater than tenfold when exposed to deoxyadenosine and an inhibitor of adenosine deaminase in culture.	2'-deoxyadenosine	203-217	5'-nucleotidase ecto	Homo sapiens	76-96
6311457-2	1983	The contribution of non-specific phosphatase enzymes is assessed in the presence of nickel ions which specifically inhibit 5"-nucleotidase.	Nickel	84-90	5'-nucleotidase ecto	Homo sapiens	123-138
6870820-7	1983	Membrane-bound pyrophosphatases or 5"-nucleotidase are suggested as modulators of hyaluronate synthesis.	hyaluronate	82-93	5'-nucleotidase ecto	Homo sapiens	35-50
6313843-0	1983	Continuous assay of serum 5-nucleotidase activity with inosine 5"-monophosphate as substrate and total automation using a transfer-analyzer (Kem-O-Mat).	Inosine Monophosphate	55-79	5'-nucleotidase ecto	Homo sapiens	26-40
6310819-5	1983	B LCL from mothers of the patients, who were presumed to be heterozygotes, also had the same range of ecto-5"-NT activity as the control subjects.	dextramycine	2-5	5'-nucleotidase ecto	Homo sapiens	102-112
6100584-9	1983	For uptake of purine nucleotides sequential action of ecto-5"-nucleotidase (ecto-5"-NT), nucleoside carrier and intracellular metabolism is necessary.	Purine Nucleotides	14-32	5'-nucleotidase ecto	Homo sapiens	54-74
6100584-9	1983	For uptake of purine nucleotides sequential action of ecto-5"-nucleotidase (ecto-5"-NT), nucleoside carrier and intracellular metabolism is necessary.	Purine Nucleotides	14-32	5'-nucleotidase ecto	Homo sapiens	76-86
6100584-9	1983	For uptake of purine nucleotides sequential action of ecto-5"-nucleotidase (ecto-5"-NT), nucleoside carrier and intracellular metabolism is necessary.	Nucleosides	89-99	5'-nucleotidase ecto	Homo sapiens	54-74
6100584-9	1983	For uptake of purine nucleotides sequential action of ecto-5"-nucleotidase (ecto-5"-NT), nucleoside carrier and intracellular metabolism is necessary.	Nucleosides	89-99	5'-nucleotidase ecto	Homo sapiens	76-86
6291401-5	1982	Specific inhibition of plasma membrane 5"-nucleotidase with 50 microM alpha, beta-methylene adenosine diphosphate (AMPCP) did not decrease purine release during deoxyglucose-induced nucleotide degradation.	beta-methylene adenosine diphosphate	77-113	5'-nucleotidase ecto	Homo sapiens	39-54
6304549-1	1983	Treatment of the C6 glioblastoma cell with trinitrobenzenesulfonic acid (TNBS) resulted in the selective inactivation of ecto-5"-nucleotidase under conditions which maintained cell viability.	Trinitrobenzenesulfonic Acid	43-71	5'-nucleotidase ecto	Homo sapiens	121-141
6315064-4	1983	Enzyme purification can be achieved after three chromatographic steps which involve negative adsorption of 5"-nucleotidase activity on DEAE-Sephadex A-50 followed by two affinity chromatographies on concanavalin A-Sepharose 4B and ADP-agarose.	DEAE-Sephadex A-50	135-153	5'-nucleotidase ecto	Homo sapiens	107-122
6291401-5	1982	Specific inhibition of plasma membrane 5"-nucleotidase with 50 microM alpha, beta-methylene adenosine diphosphate (AMPCP) did not decrease purine release during deoxyglucose-induced nucleotide degradation.	alpha,beta-methyleneadenosine 5'-diphosphate	115-120	5'-nucleotidase ecto	Homo sapiens	39-54
6291401-10	1982	The data suggest that plasma membrane 5"-nucleotidase hydrolyzes extracellular nucleoside 5"-monophosphates only.	nucleoside 5"-monophosphates	79-107	5'-nucleotidase ecto	Homo sapiens	38-53
6291401-11	1982	Cytoplasmic 5"-nucleotidase most likely regulates the degradation of intracellular nucleoside 5"-monophosphates and may be responsible for the increased purine release observed in B-lymphoblasts.	nucleoside 5"-monophosphates	83-111	5'-nucleotidase ecto	Homo sapiens	12-27
6291401-11	1982	Cytoplasmic 5"-nucleotidase most likely regulates the degradation of intracellular nucleoside 5"-monophosphates and may be responsible for the increased purine release observed in B-lymphoblasts.	purine	153-159	5'-nucleotidase ecto	Homo sapiens	12-27
6258823-1	1981	We present a sensitive colorimetric determination of 5"-nucleotidase based on the measurement of liberated phosphate by reaction with stannous chloride/molybdenum blue.	Phosphates	107-116	5'-nucleotidase ecto	Homo sapiens	53-68
6290030-5	1982	Increasing concentrations of adenosine 5"-triphosphate and deoxyadenosine 5"-triphosphate from 0 to 3 mM enhanced 5"-nucleotidase activity up to 7-fold.	Adenosine Triphosphate	29-54	5'-nucleotidase ecto	Homo sapiens	114-129
6290030-5	1982	Increasing concentrations of adenosine 5"-triphosphate and deoxyadenosine 5"-triphosphate from 0 to 3 mM enhanced 5"-nucleotidase activity up to 7-fold.	2'-deoxyadenosine triphosphate	59-89	5'-nucleotidase ecto	Homo sapiens	114-129
6290030-8	1982	The activation of this 5"-nucleotidase by deoxyadenosine 5"-triphosphate, combined with the relative inability of the enzyme to dephosphorylate deoxyadenosine 5"-monophosphate, conceivably may contribute to the adenine nucleotide degradation induced by deoxyadenosine in normal and malignant lymphocytes.	2'-deoxyadenosine triphosphate	42-72	5'-nucleotidase ecto	Homo sapiens	23-38
6290030-8	1982	The activation of this 5"-nucleotidase by deoxyadenosine 5"-triphosphate, combined with the relative inability of the enzyme to dephosphorylate deoxyadenosine 5"-monophosphate, conceivably may contribute to the adenine nucleotide degradation induced by deoxyadenosine in normal and malignant lymphocytes.	2'-deoxy-5'-adenosine monophosphate	144-175	5'-nucleotidase ecto	Homo sapiens	23-38
6290030-8	1982	The activation of this 5"-nucleotidase by deoxyadenosine 5"-triphosphate, combined with the relative inability of the enzyme to dephosphorylate deoxyadenosine 5"-monophosphate, conceivably may contribute to the adenine nucleotide degradation induced by deoxyadenosine in normal and malignant lymphocytes.	Adenine Nucleotides	211-229	5'-nucleotidase ecto	Homo sapiens	23-38
6298338-0	1982	Effects of divalent cations on 5"-nucleotidase activity of Formosan cobra venom.	formosan	59-67	5'-nucleotidase ecto	Homo sapiens	31-46
6127180-7	1982	Thus the deficiency of ecto-5"-nucleotidase in the lymphocytes of patients with hypogammaglobulinaemia is a highly selective defect in purine metabolism.	purine	135-141	5'-nucleotidase ecto	Homo sapiens	23-43
6279335-2	1982	Inosine is formed by the hydrolysis of inosine 5"-monophosphate which is catalyzed by seric 5"-nucleotidase, and then is converted to hypoxanthine by nucleoside phosphorylase.	Inosine	0-7	5'-nucleotidase ecto	Homo sapiens	92-107
6279335-2	1982	Inosine is formed by the hydrolysis of inosine 5"-monophosphate which is catalyzed by seric 5"-nucleotidase, and then is converted to hypoxanthine by nucleoside phosphorylase.	Inosine Monophosphate	39-63	5'-nucleotidase ecto	Homo sapiens	92-107
6275991-0	1982	Relationship of 5"-nucleotidase activity and antileukemic effect in 2"-deoxycoformycin therapy.	Pentostatin	68-86	5'-nucleotidase ecto	Homo sapiens	16-31
6280163-0	1982	Isolation and partial characterization of a 5"-nucleotidase specific for orotidine-5"-monophosphate.	orotidylic acid	73-99	5'-nucleotidase ecto	Homo sapiens	44-59
6260353-3	1981	The present study confirms those observations and further documents the induction, by 16 nM phorbol myristate acetate, of 5"-nucleotidase activity, another human macrophage marker enzyme.	Tetradecanoylphorbol Acetate	92-117	5'-nucleotidase ecto	Homo sapiens	122-137
6265584-3	1981	On sucrose density gradients, the peak density of 5"-nucleotidase activity was 1.12 g/ml, and was shifted after digitonin addition to 1.15 g/ml.	Sucrose	3-10	5'-nucleotidase ecto	Homo sapiens	50-65
6265584-3	1981	On sucrose density gradients, the peak density of 5"-nucleotidase activity was 1.12 g/ml, and was shifted after digitonin addition to 1.15 g/ml.	Digitonin	112-121	5'-nucleotidase ecto	Homo sapiens	50-65
6262487-2	1981	Caffeine and theophylline inhibited the 5"-nucleotidase in both fractions, but theophylline appeared to be a more potent agent.	Caffeine	0-8	5'-nucleotidase ecto	Homo sapiens	40-55
6262487-2	1981	Caffeine and theophylline inhibited the 5"-nucleotidase in both fractions, but theophylline appeared to be a more potent agent.	Theophylline	13-25	5'-nucleotidase ecto	Homo sapiens	40-55
6262487-5	1981	The inhibitory effect of caffeine and theophylline on 5"-nucleotidase may not be related to their actions on phosphodiesterase since dipyridamole and papaverine, which are also known to inhibit phosphodiesterase, did not affect the 5"-nucleotidase activity.	Caffeine	25-33	5'-nucleotidase ecto	Homo sapiens	54-69
6262487-5	1981	The inhibitory effect of caffeine and theophylline on 5"-nucleotidase may not be related to their actions on phosphodiesterase since dipyridamole and papaverine, which are also known to inhibit phosphodiesterase, did not affect the 5"-nucleotidase activity.	Theophylline	38-50	5'-nucleotidase ecto	Homo sapiens	54-69
6262487-5	1981	The inhibitory effect of caffeine and theophylline on 5"-nucleotidase may not be related to their actions on phosphodiesterase since dipyridamole and papaverine, which are also known to inhibit phosphodiesterase, did not affect the 5"-nucleotidase activity.	Theophylline	38-50	5'-nucleotidase ecto	Homo sapiens	232-247
6262487-6	1981	It is suggested that by inhibiting 5"-nucleotidase, caffeine and theophylline may influence the production of adenosine in the myocardium and thereby may interfere with an important mechanism for the regulation of coronary blood flow.	Theophylline	65-77	5'-nucleotidase ecto	Homo sapiens	35-50
6262487-6	1981	It is suggested that by inhibiting 5"-nucleotidase, caffeine and theophylline may influence the production of adenosine in the myocardium and thereby may interfere with an important mechanism for the regulation of coronary blood flow.	Adenosine	110-119	5'-nucleotidase ecto	Homo sapiens	35-50
6261990-1	1981	Various purine and pyrimidine mononucleotides seem to be dephosphorylated by a 5"-nucleotidase complex composed of four fractions in sera from both patients with gall stones and from normal subjects.	purine	8-14	5'-nucleotidase ecto	Homo sapiens	79-94
6261990-1	1981	Various purine and pyrimidine mononucleotides seem to be dephosphorylated by a 5"-nucleotidase complex composed of four fractions in sera from both patients with gall stones and from normal subjects.	pyrimidine mononucleotides	19-45	5'-nucleotidase ecto	Homo sapiens	79-94
6290030-8	1982	The activation of this 5"-nucleotidase by deoxyadenosine 5"-triphosphate, combined with the relative inability of the enzyme to dephosphorylate deoxyadenosine 5"-monophosphate, conceivably may contribute to the adenine nucleotide degradation induced by deoxyadenosine in normal and malignant lymphocytes.	2'-deoxyadenosine	42-56	5'-nucleotidase ecto	Homo sapiens	23-38
6290262-0	1982	[5"-Nucleotidase as an "internal probe" in studying steroid hormone interaction with the plasma membranes of target cells].	Steroids	52-67	5'-nucleotidase ecto	Homo sapiens	1-16
6290262-1	1982	Changes in the activity of 5"-nucleotidase, the marker enzyme of plasma membranes, in membrane cells of the uterus and liver were examined upon action of tropic and nontropic steroid hormones.	Steroids	175-191	5'-nucleotidase ecto	Homo sapiens	27-42
6280893-0	1982	5"-Nucleotidase activity enhanced by manganese and magnesium ions with inosine monophosphate substrate.	Manganese	37-46	5'-nucleotidase ecto	Homo sapiens	0-15
6280893-0	1982	5"-Nucleotidase activity enhanced by manganese and magnesium ions with inosine monophosphate substrate.	Magnesium	51-60	5'-nucleotidase ecto	Homo sapiens	0-15
6280893-0	1982	5"-Nucleotidase activity enhanced by manganese and magnesium ions with inosine monophosphate substrate.	Inosine Monophosphate	71-92	5'-nucleotidase ecto	Homo sapiens	0-15
6279680-2	1982	Immediately following a pulse label with the glycoside, codistribution of radioactivity with the surface marker 5"-nucleotidase is found in both conventional sucrose-gradient fractionation and in fractionation following a digitonin treatment.	Glycosides	45-54	5'-nucleotidase ecto	Homo sapiens	112-127
6279680-2	1982	Immediately following a pulse label with the glycoside, codistribution of radioactivity with the surface marker 5"-nucleotidase is found in both conventional sucrose-gradient fractionation and in fractionation following a digitonin treatment.	Sucrose	158-165	5'-nucleotidase ecto	Homo sapiens	112-127
6279680-2	1982	Immediately following a pulse label with the glycoside, codistribution of radioactivity with the surface marker 5"-nucleotidase is found in both conventional sucrose-gradient fractionation and in fractionation following a digitonin treatment.	Digitonin	222-231	5'-nucleotidase ecto	Homo sapiens	112-127
6279343-7	1981	Lymphocytes, therefore, have the ability to generate AMP on their surface which can be further metabolized to adenosine by ecto-5" nucleotidase.	Adenosine Monophosphate	53-56	5'-nucleotidase ecto	Homo sapiens	123-143
6279343-7	1981	Lymphocytes, therefore, have the ability to generate AMP on their surface which can be further metabolized to adenosine by ecto-5" nucleotidase.	Adenosine	110-119	5'-nucleotidase ecto	Homo sapiens	123-143
6277136-0	1981	[Purine enzyme activities in lymphocytes from patients with impaired humoral immunity: decreased ecto-5"-nucleotidase activity in agammaglobulinemia (author"s transl)].	purine	1-7	5'-nucleotidase ecto	Homo sapiens	97-117
6793366-5	1981	In addition, methylamine seems to inhibit partially the return of the cell surface of membrane antigens and of membrane fragments bearing 5"-nucleotidase or binding sites for control IgG.	methylamine	13-24	5'-nucleotidase ecto	Homo sapiens	138-153
6269161-0	1981	[Inhibition of the cholestatic enzyme 5"-nucleotidase by high levels of bilirubin].	Bilirubin	72-81	5'-nucleotidase ecto	Homo sapiens	38-53
6258823-1	1981	We present a sensitive colorimetric determination of 5"-nucleotidase based on the measurement of liberated phosphate by reaction with stannous chloride/molybdenum blue.	stannous chloride	134-151	5'-nucleotidase ecto	Homo sapiens	53-68
6258823-1	1981	We present a sensitive colorimetric determination of 5"-nucleotidase based on the measurement of liberated phosphate by reaction with stannous chloride/molybdenum blue.	molybdenum blue	152-167	5'-nucleotidase ecto	Homo sapiens	53-68
6255990-0	1980	Stereochemistry of the hydrolysis of adenosine 5"-thiophosphate catalyzed by venom 5"-nucleotidase.	adenosine 5'-phosphorothioate	37-63	5'-nucleotidase ecto	Homo sapiens	83-98
6255990-1	1980	The stereochemical problem involving a pro-pro-prochiral phosphorus center, the hydrolysis of adenosine 5"-monophosphate to adenosine and inorganic phosphate catalyzed by the venom 5"-nucleotidase, has been studied by use of chiral [16O, 17O, 18O]thiophosphates (Psi).	pro-pro-prochiral phosphorus	39-67	5'-nucleotidase ecto	Homo sapiens	181-196
6255990-1	1980	The stereochemical problem involving a pro-pro-prochiral phosphorus center, the hydrolysis of adenosine 5"-monophosphate to adenosine and inorganic phosphate catalyzed by the venom 5"-nucleotidase, has been studied by use of chiral [16O, 17O, 18O]thiophosphates (Psi).	Adenosine Monophosphate	94-120	5'-nucleotidase ecto	Homo sapiens	181-196
6255990-1	1980	The stereochemical problem involving a pro-pro-prochiral phosphorus center, the hydrolysis of adenosine 5"-monophosphate to adenosine and inorganic phosphate catalyzed by the venom 5"-nucleotidase, has been studied by use of chiral [16O, 17O, 18O]thiophosphates (Psi).	Adenosine	94-103	5'-nucleotidase ecto	Homo sapiens	181-196
6255990-1	1980	The stereochemical problem involving a pro-pro-prochiral phosphorus center, the hydrolysis of adenosine 5"-monophosphate to adenosine and inorganic phosphate catalyzed by the venom 5"-nucleotidase, has been studied by use of chiral [16O, 17O, 18O]thiophosphates (Psi).	Phosphates	138-157	5'-nucleotidase ecto	Homo sapiens	181-196
6255990-1	1980	The stereochemical problem involving a pro-pro-prochiral phosphorus center, the hydrolysis of adenosine 5"-monophosphate to adenosine and inorganic phosphate catalyzed by the venom 5"-nucleotidase, has been studied by use of chiral [16O, 17O, 18O]thiophosphates (Psi).	[16o, 17o, 18o]thiophosphates	232-261	5'-nucleotidase ecto	Homo sapiens	181-196
6255990-3	1980	Hydrolysis of (Rp)- and (Sp)-[alpha-18O1]AMPS in H217O by 5"-nucleotidase gave two enantiomers of chiral Psi of unknown configuration.	TFF2 protein, human	25-28	5'-nucleotidase ecto	Homo sapiens	58-73
6255990-3	1980	Hydrolysis of (Rp)- and (Sp)-[alpha-18O1]AMPS in H217O by 5"-nucleotidase gave two enantiomers of chiral Psi of unknown configuration.	[alpha-18o1]amps	29-45	5'-nucleotidase ecto	Homo sapiens	58-73
6255990-3	1980	Hydrolysis of (Rp)- and (Sp)-[alpha-18O1]AMPS in H217O by 5"-nucleotidase gave two enantiomers of chiral Psi of unknown configuration.	h217o	49-54	5'-nucleotidase ecto	Homo sapiens	58-73
6255990-12	1980	Therefore the hydrolysis of AMPS catalyze by the venom 5"-nucleotidase must proceed with inversion of configuration at phosphorus, which suggests that the reaction is most likely an "in line" single displacement without involving a phosphoryl-enzyme intermediate and without pseudorotation.	adenosine 5'-phosphorothioate	28-32	5'-nucleotidase ecto	Homo sapiens	55-70
6255990-12	1980	Therefore the hydrolysis of AMPS catalyze by the venom 5"-nucleotidase must proceed with inversion of configuration at phosphorus, which suggests that the reaction is most likely an "in line" single displacement without involving a phosphoryl-enzyme intermediate and without pseudorotation.	Phosphorus	119-129	5'-nucleotidase ecto	Homo sapiens	55-70
6255057-2	1980	In combination with the enzymes nucleoside phosphorylase and xanthine oxidase, inosine, formed by hydrolysis of 5"-IMP by 5"-nucleotidase, is cleaved phosphorolytically to hypoxanthine, which is oxidized to uric acid.	Inosine	79-86	5'-nucleotidase ecto	Homo sapiens	122-137
6270328-6	1981	A possible relationship between 5"-Nucleotidase and purine metabolism in lymphocyte subpopulations is suggested by the results.	purine	52-58	5'-nucleotidase ecto	Homo sapiens	32-47
6255057-2	1980	In combination with the enzymes nucleoside phosphorylase and xanthine oxidase, inosine, formed by hydrolysis of 5"-IMP by 5"-nucleotidase, is cleaved phosphorolytically to hypoxanthine, which is oxidized to uric acid.	Inosine Monophosphate	112-118	5'-nucleotidase ecto	Homo sapiens	122-137
6255057-2	1980	In combination with the enzymes nucleoside phosphorylase and xanthine oxidase, inosine, formed by hydrolysis of 5"-IMP by 5"-nucleotidase, is cleaved phosphorolytically to hypoxanthine, which is oxidized to uric acid.	Hypoxanthine	172-184	5'-nucleotidase ecto	Homo sapiens	122-137
6255057-2	1980	In combination with the enzymes nucleoside phosphorylase and xanthine oxidase, inosine, formed by hydrolysis of 5"-IMP by 5"-nucleotidase, is cleaved phosphorolytically to hypoxanthine, which is oxidized to uric acid.	Uric Acid	207-216	5'-nucleotidase ecto	Homo sapiens	122-137
6264330-3	1980	Since rapid conversion of the nucleotides to adenosine by 5"-nucleotidase in the vicinity of the receptor might account for the responses, six experimental methods were developed to distinguish between "local conversion" and direct action of the nucleotides.	Adenosine	45-54	5'-nucleotidase ecto	Homo sapiens	58-73
6253063-4	1980	Leukemic T-lymphocytes are deficient in ecto-5"-nucleotidase (5"-ribonucleotide phosphohydrolase, EC 3.1.3.5) activity, and it has been postulated that deficiency of this enzyme decreases the capacity of these cells to degrade deoxyribonucleotides, rendering them sensitive to deoxynucleosides.	Deoxyribonucleotides	227-247	5'-nucleotidase ecto	Homo sapiens	40-60
6253063-4	1980	Leukemic T-lymphocytes are deficient in ecto-5"-nucleotidase (5"-ribonucleotide phosphohydrolase, EC 3.1.3.5) activity, and it has been postulated that deficiency of this enzyme decreases the capacity of these cells to degrade deoxyribonucleotides, rendering them sensitive to deoxynucleosides.	deoxynucleosides	277-293	5'-nucleotidase ecto	Homo sapiens	40-60
6248594-2	1980	TG cells (suppressor cells) have 39% of the ecto-5"-NT activity of Tnon-G cells (helper cells) but the increase in numbers of TG cells that occurs with age explains only about 14% of the age-related fall in T lymphocyte ecto-5"-NT activity.	Thioguanine	0-2	5'-nucleotidase ecto	Homo sapiens	44-54
6248594-2	1980	TG cells (suppressor cells) have 39% of the ecto-5"-NT activity of Tnon-G cells (helper cells) but the increase in numbers of TG cells that occurs with age explains only about 14% of the age-related fall in T lymphocyte ecto-5"-NT activity.	Thioguanine	0-2	5'-nucleotidase ecto	Homo sapiens	220-230
6162544-5	1980	Presumably, ara-AMP molecules were hydrolyzed by the nonspecific phosphatases and 5"-nucleotidase found in the serum or by the ecto-5"-nucleotidase on the outer surface of the membrane and only enter the mammalian cells as 9-beta-D-arabinofuranosyladenine.	Vidarabine Phosphate	12-19	5'-nucleotidase ecto	Homo sapiens	127-147
6252942-3	1980	The mean erythrocyte pyrimidine 5"-nucleotidase activity in 158 normal fresh blood samples was 130 +/- SD 29.8 mU/gHb.	4-hydroxybutyric acid	114-117	5'-nucleotidase ecto	Homo sapiens	32-47
6252942-11	1980	The last-mentioned technique showed that erythrocyte 5"-nucleotidase activity in reticulocytes may be as high as 1785 mU/gHb and declines rapidly as the cell ages reaching about 50 mU/gHb in the oldest cells.	4-hydroxybutyric acid	121-124	5'-nucleotidase ecto	Homo sapiens	53-68
6252942-11	1980	The last-mentioned technique showed that erythrocyte 5"-nucleotidase activity in reticulocytes may be as high as 1785 mU/gHb and declines rapidly as the cell ages reaching about 50 mU/gHb in the oldest cells.	4-hydroxybutyric acid	184-187	5'-nucleotidase ecto	Homo sapiens	53-68
6447709-9	1980	Triton X-100 (0.2%) stimulated the release of glycosyltransferases to the same extent as TPA, but also caused the release of 5"-nucleotidase.	Octoxynol	0-12	5'-nucleotidase ecto	Homo sapiens	125-140
6244908-3	1980	The properties of 5"-nucleotidase were studied by eliminating the interference of serum non-specific alkaline phosphatase by the preliminary incubation of serum in glycine-NaOH buffer containing ethylenediamine tetraacetate and magnesium.	Glycine	164-171	5'-nucleotidase ecto	Homo sapiens	18-33
6244908-3	1980	The properties of 5"-nucleotidase were studied by eliminating the interference of serum non-specific alkaline phosphatase by the preliminary incubation of serum in glycine-NaOH buffer containing ethylenediamine tetraacetate and magnesium.	Sodium Hydroxide	172-176	5'-nucleotidase ecto	Homo sapiens	18-33
6244908-3	1980	The properties of 5"-nucleotidase were studied by eliminating the interference of serum non-specific alkaline phosphatase by the preliminary incubation of serum in glycine-NaOH buffer containing ethylenediamine tetraacetate and magnesium.	Edetic Acid	195-223	5'-nucleotidase ecto	Homo sapiens	18-33
6244908-3	1980	The properties of 5"-nucleotidase were studied by eliminating the interference of serum non-specific alkaline phosphatase by the preliminary incubation of serum in glycine-NaOH buffer containing ethylenediamine tetraacetate and magnesium.	Magnesium	228-237	5'-nucleotidase ecto	Homo sapiens	18-33
6250329-0	1980	Effect of ethanol on neural cells grown in culture: interaction with plasma membrane ecto-5"-nucleotidase activity.	Ethanol	10-17	5'-nucleotidase ecto	Homo sapiens	85-105
6250329-4	1980	Chronic treatment of cells with 100 mM ethanol for 4 - 8 days also caused an increase in ecto-5"-nucleotidase activity.	Ethanol	39-46	5'-nucleotidase ecto	Homo sapiens	89-109
6264330-5	1980	(1)5"-Nucleotidase inhibitors blocked the accumulations of cyclic AMP elicited by AMP, ADP, and ATP, but did not affect the response to adenosine.	Cyclic AMP	59-69	5'-nucleotidase ecto	Homo sapiens	3-18
6264330-5	1980	(1)5"-Nucleotidase inhibitors blocked the accumulations of cyclic AMP elicited by AMP, ADP, and ATP, but did not affect the response to adenosine.	Adenosine Monophosphate	66-69	5'-nucleotidase ecto	Homo sapiens	3-18
6264330-5	1980	(1)5"-Nucleotidase inhibitors blocked the accumulations of cyclic AMP elicited by AMP, ADP, and ATP, but did not affect the response to adenosine.	Adenosine Diphosphate	87-90	5'-nucleotidase ecto	Homo sapiens	3-18
6264330-5	1980	(1)5"-Nucleotidase inhibitors blocked the accumulations of cyclic AMP elicited by AMP, ADP, and ATP, but did not affect the response to adenosine.	Adenosine Triphosphate	96-99	5'-nucleotidase ecto	Homo sapiens	3-18
6264330-12	1980	Cell lines with high levels of 5"-nucleotidase had large responses to AMP, those with intermediate levels of 5"-nucleotidase had large or intermediate responses to AMP, and those with low 5"-nucleotidase levels did not respond to AMP.	Adenosine Monophosphate	70-73	5'-nucleotidase ecto	Homo sapiens	31-46
445827-1	1979	We describe a multi-point method for the determination of the serum enzyme activity 5"-nucleotidase by means of an NADH sensor reaction.	NAD	115-119	5'-nucleotidase ecto	Homo sapiens	84-99
6250179-0	1980	Stimulation of the plasma membrane enzyme, 5"-nucleotidase, by ethanol exposure to neural cells in culture.	Ethanol	63-70	5'-nucleotidase ecto	Homo sapiens	43-58
231044-2	1979	Samples were incubated with adenosine-5"-monophosphoric acid (AMP) in a buffer of required pH, 5"-nucleotidase was inhibited with Ni2+ ions, and the phosphatase activity was determined by measuring the concentration of the reaction product, adenosine.	Nickel(2+)	130-134	5'-nucleotidase ecto	Homo sapiens	95-110
38755-6	1979	The results suggest that the enzyme which degrades nucleoside-5"-phosphate to nucleoside and inorganic phosphate is not acid phosphatase but 5"-nucleotidase.	nucleoside-5"-phosphate	51-74	5'-nucleotidase ecto	Homo sapiens	141-156
38755-6	1979	The results suggest that the enzyme which degrades nucleoside-5"-phosphate to nucleoside and inorganic phosphate is not acid phosphatase but 5"-nucleotidase.	Nucleosides	51-61	5'-nucleotidase ecto	Homo sapiens	141-156
38755-6	1979	The results suggest that the enzyme which degrades nucleoside-5"-phosphate to nucleoside and inorganic phosphate is not acid phosphatase but 5"-nucleotidase.	Phosphates	65-74	5'-nucleotidase ecto	Homo sapiens	141-156
315065-1	1979	Low activity of 5"-nucleotidase (5"-ribonucleotide phosphohydrolase, EC 3.1.3.5) in T lymphoblasts may explain the marked sensitivity of this cell to deoxynucleotide accumulation when compared to B lymphoblasts.	deoxynucleotide	150-165	5'-nucleotidase ecto	Homo sapiens	16-31
222342-5	1979	Washing of nuclei and plasma membranes twice with buffer containing 0.1% Triton X-100 resulted in gonadotropin and prostaglandin F2 alpha binding site and 5"-nucleotidase (EC 3.1.3.5) losses from nuclei that were different from those observed for plasma membranes.	Octoxynol	73-85	5'-nucleotidase ecto	Homo sapiens	155-170
923081-2	1977	This observation serves as the basis for a new method for assaying the 5"-nucleotidase activity in serum, which depends upon the difference between the enzymic hydrolysis of adenosine-5"-monophosphate in the presence and absence of concanavalin A.	5"-monophosphate	184-200	5'-nucleotidase ecto	Homo sapiens	71-86
221924-6	1979	The activity of 5"-nucleotidase (5"-ribonucleotide phosphohydrolase, EC 3.1.3.5) was increased 44-fold for AMP and 7-fold for dAMP in B lymphoblasts.	Adenosine Monophosphate	107-110	5'-nucleotidase ecto	Homo sapiens	16-31
221924-7	1979	A model for the regulation of deoxyadenosine nucleotide synthesis by 5"-nucleotidase activity is proposed on the basis of the observations.	deoxyadenosine nucleotide	30-55	5'-nucleotidase ecto	Homo sapiens	69-84
232631-0	1979	Possible role for 5"-nucleotidase in deoxyadenosine selective toxicity to cultured human lymphoblasts.	2'-deoxyadenosine	37-51	5'-nucleotidase ecto	Homo sapiens	18-33
215126-13	1978	It is suggested that 5"-nucleotidase and adenosine kinase are simultaneously active so that a substrate cycle between AMP and adenosine is produced: the difference in Km values between kinase and deaminase indicates that, via the cycle, small changes in activity of kinase or nucleotidase produce large changes in adenosine concentration.	Adenosine Monophosphate	118-121	5'-nucleotidase ecto	Homo sapiens	21-36
215126-13	1978	It is suggested that 5"-nucleotidase and adenosine kinase are simultaneously active so that a substrate cycle between AMP and adenosine is produced: the difference in Km values between kinase and deaminase indicates that, via the cycle, small changes in activity of kinase or nucleotidase produce large changes in adenosine concentration.	Adenosine	126-135	5'-nucleotidase ecto	Homo sapiens	21-36
43739-1	1978	The kinetic properties of 5"-Nucleotidase  were investigated in untreated patients with liver cirrhosis at 37 degrees C. Mg+2 and Mn+2 were found to activate both normal and liver cirrhotic 5"-Nucleotidase, but Nickel inhibited the enzyme in both systems competitively.	Nickel	211-217	5'-nucleotidase ecto	Homo sapiens	26-41
43739-2	1978	Both ATP and adenosine act as inhibitors to 5"-Nucleotidase.	Adenosine Triphosphate	5-8	5'-nucleotidase ecto	Homo sapiens	44-59
43739-2	1978	Both ATP and adenosine act as inhibitors to 5"-Nucleotidase.	Adenosine	13-22	5'-nucleotidase ecto	Homo sapiens	44-59
43739-4	1978	In our investigation, ATP was found to be a competitive inhibitor of 5"-Nucleotidase which compete the substrate (A-5"-MP) for the active site.	Adenosine Triphosphate	22-25	5'-nucleotidase ecto	Homo sapiens	69-84
43739-5	1978	Inhibition of 5"-Nucleotidase by adenosine is of non-competitive type, for both normal and liver cirrhotic sera.	Adenosine	33-42	5'-nucleotidase ecto	Homo sapiens	14-29
923081-3	1977	A denosine released by the 5"-nucleotidase reaction is deaminated by a coupled reaction with adenosine deaminase to liberate inosine and ammonia, and ammonia is measured colorimetrically by the Berthelot reaction.	Ganciclovir	2-10	5'-nucleotidase ecto	Homo sapiens	27-42
923081-3	1977	A denosine released by the 5"-nucleotidase reaction is deaminated by a coupled reaction with adenosine deaminase to liberate inosine and ammonia, and ammonia is measured colorimetrically by the Berthelot reaction.	Inosine	125-132	5'-nucleotidase ecto	Homo sapiens	27-42
923081-3	1977	A denosine released by the 5"-nucleotidase reaction is deaminated by a coupled reaction with adenosine deaminase to liberate inosine and ammonia, and ammonia is measured colorimetrically by the Berthelot reaction.	Ammonia	137-144	5'-nucleotidase ecto	Homo sapiens	27-42
923081-3	1977	A denosine released by the 5"-nucleotidase reaction is deaminated by a coupled reaction with adenosine deaminase to liberate inosine and ammonia, and ammonia is measured colorimetrically by the Berthelot reaction.	Ammonia	150-157	5'-nucleotidase ecto	Homo sapiens	27-42
923081-5	1977	In sera from 100 patients, measurements of 5"-nucleotidase activity by the new assay averaged 8% lower than by a generally accepted method in which phenyl phosphate is used to suppress hydrolysis of adenosine-5"-monophosphate by alkaline phosphatase activity.	phenylphosphate	148-164	5'-nucleotidase ecto	Homo sapiens	43-58
923081-5	1977	In sera from 100 patients, measurements of 5"-nucleotidase activity by the new assay averaged 8% lower than by a generally accepted method in which phenyl phosphate is used to suppress hydrolysis of adenosine-5"-monophosphate by alkaline phosphatase activity.	adenosine-5"-monophosphate	199-225	5'-nucleotidase ecto	Homo sapiens	43-58
923572-1	1977	The treatment of plasma membranes by a French pressure cell in sucrose medium devoid of detergents solubilized 20% of the total protein and 95--100% of 5"-nucleotidase activity.	Sucrose	63-70	5'-nucleotidase ecto	Homo sapiens	152-167
1016916-1	1976	The 5"-phosphomonoesterase activity of 5"-nucleotidase (EC 3.1.3.5) and alkaline phosphatase (EC 3.1.3.5) participates in the catabolism of purine ribonucleotides to uric acid in humans.	purine	140-146	5'-nucleotidase ecto	Homo sapiens	39-54
144099-8	1977	Pretreatment  of  frozen cryostat sections with a mixture of equal parts of chloroform and acetone give a good fixation of the plasma membrane enzymes 5"-nucleotidase, ATP-ase, alkaline phosphate and leucyl-beta-naphthylamidase.	Chloroform	76-86	5'-nucleotidase ecto	Homo sapiens	151-166
144099-8	1977	Pretreatment  of  frozen cryostat sections with a mixture of equal parts of chloroform and acetone give a good fixation of the plasma membrane enzymes 5"-nucleotidase, ATP-ase, alkaline phosphate and leucyl-beta-naphthylamidase.	Acetone	91-98	5'-nucleotidase ecto	Homo sapiens	151-166
873575-3	1977	The human neutrophil neutral peptide-generating protease was associated with the plasma membrane marker 5"-nucleotidase on sucrose density gradient centrifugation of sonicates of granule-free fractions following homogenization and velocity sedimentation.	Sucrose	123-130	5'-nucleotidase ecto	Homo sapiens	104-119
873575-5	1977	Treatment of fractions containing these enzymatic activities with 1-0 M NaCl separated the neutral peptide-generating proteasein to the eluate while leaving the 5"-nucleotidase in the pellet.	Sodium Chloride	72-76	5'-nucleotidase ecto	Homo sapiens	161-176
217998-11	1978	It is suggested that this 5"-nucleotidase plays an important role in the production of adenosine from a nucleotide pool in the synaptic cleft.	Adenosine	87-96	5'-nucleotidase ecto	Homo sapiens	26-41
894893-3	1977	In most patients with chronic coronary insufficiency an increased activity of enzymes responsible for the metabolism of adenosine, above all of 5"-nucleotidase, is registered after a graded physical exertion test.	Adenosine	120-129	5'-nucleotidase ecto	Homo sapiens	144-159
1016239-8	1976	A sensitive radiochemical assay method, using dTTP to inhibit 5"-nucleotidase activity, suitable for tissue extracts, was developed.	thymidine 5'-triphosphate	46-50	5'-nucleotidase ecto	Homo sapiens	62-77
1016916-1	1976	The 5"-phosphomonoesterase activity of 5"-nucleotidase (EC 3.1.3.5) and alkaline phosphatase (EC 3.1.3.5) participates in the catabolism of purine ribonucleotides to uric acid in humans.	Ribonucleotides	147-162	5'-nucleotidase ecto	Homo sapiens	39-54
1016916-1	1976	The 5"-phosphomonoesterase activity of 5"-nucleotidase (EC 3.1.3.5) and alkaline phosphatase (EC 3.1.3.5) participates in the catabolism of purine ribonucleotides to uric acid in humans.	Uric Acid	166-175	5'-nucleotidase ecto	Homo sapiens	39-54
1016916-2	1976	Initial velocity studies of 5"-nucleotidase suggest a sequential mechanism of interaction between AMP nad MgCl2, with a Km of 14 and 3 muM, respectively.	amp nad	98-105	5'-nucleotidase ecto	Homo sapiens	28-43
1016916-2	1976	Initial velocity studies of 5"-nucleotidase suggest a sequential mechanism of interaction between AMP nad MgCl2, with a Km of 14 and 3 muM, respectively.	Magnesium Chloride	106-111	5'-nucleotidase ecto	Homo sapiens	28-43
1016916-10	1976	These observations suggest that 5"-nucleotidase and alkaline phosphatase may be inhibited by ATP and Pi, respectively, under normal intracellular conditions, and that AMP may be preferentially hydrolyzed by 5"-nucleotidase.	Adenosine Triphosphate	93-96	5'-nucleotidase ecto	Homo sapiens	32-47
1016916-10	1976	These observations suggest that 5"-nucleotidase and alkaline phosphatase may be inhibited by ATP and Pi, respectively, under normal intracellular conditions, and that AMP may be preferentially hydrolyzed by 5"-nucleotidase.	Adenosine Monophosphate	167-170	5'-nucleotidase ecto	Homo sapiens	32-47
1016916-10	1976	These observations suggest that 5"-nucleotidase and alkaline phosphatase may be inhibited by ATP and Pi, respectively, under normal intracellular conditions, and that AMP may be preferentially hydrolyzed by 5"-nucleotidase.	Adenosine Monophosphate	167-170	5'-nucleotidase ecto	Homo sapiens	207-222
1032005-6	1976	The incorporation of Dex or MP into the plasma membranes resulted in a significant decrease in loww of 5"-nucleotidase activity of the plasma membranes in the border-zone and ischemic myocardium.	Dexamethasone	21-24	5'-nucleotidase ecto	Homo sapiens	103-118
1032005-6	1976	The incorporation of Dex or MP into the plasma membranes resulted in a significant decrease in loww of 5"-nucleotidase activity of the plasma membranes in the border-zone and ischemic myocardium.	Methylprednisolone	28-30	5'-nucleotidase ecto	Homo sapiens	103-118
1194267-0	1975	Function of 5"-nucleotidase in the uptake of adenosine from AMP by human lymphocytes.	Adenosine	45-54	5'-nucleotidase ecto	Homo sapiens	12-27
965496-1	1976	Lead intoxication is accompanied by an acquired deficiency of erythrocyte pryimidine-specific, 5"-nucleotidase.	pryimidine	74-84	5'-nucleotidase ecto	Homo sapiens	95-110
1182198-4	1975	Fibroblast enzymes were assayed using thin-layer chromatographic procedures because the high levels of 5"-nucleotidase present in this tissue interferred with the formation of LaCl3 salts.	lacl3 salts	176-187	5'-nucleotidase ecto	Homo sapiens	103-118
1182198-11	1975	Fibroblasts, with high levels of 5"-nucleotidase, have the potential to catabolize adenine nucleotides beyond the control od adenosine kinase.	Adenine Nucleotides	83-102	5'-nucleotidase ecto	Homo sapiens	33-48
6135-0	1976	Purine catabolism in man: characterization of placental microsomal 5"-nucleotidase.	purine	0-6	5'-nucleotidase ecto	Homo sapiens	67-82
6135-12	1976	Although 5"-nucleotidase was active in the absence of divalent cation, 5 mM MgCl2 stimulated the enzyme activity to 234% of control and shifted the pH optimum of 9.8 to a plateau from pH 7.4-9.8.	Magnesium Chloride	76-81	5'-nucleotidase ecto	Homo sapiens	9-24
1194267-0	1975	Function of 5"-nucleotidase in the uptake of adenosine from AMP by human lymphocytes.	Adenosine Monophosphate	60-63	5'-nucleotidase ecto	Homo sapiens	12-27
1194267-4	1975	These results indicate that phosphorylytic cleavage of AMP by 5"-nucleotidase is necessary for the uptake of the nucleotide and Pi moieties by the human lymphocyte.	Adenosine Monophosphate	55-58	5'-nucleotidase ecto	Homo sapiens	62-77
1120494-0	1975	Effect of nucleoside di-and triphosphates and MgCl2 on the activity of 5"-nucleotidase from bull seminal plasma.	nucleoside di-and triphosphates	10-41	5'-nucleotidase ecto	Homo sapiens	71-86
1148256-1	1975	Using 1-4C-labeled AMP and IMP as substrates, 5"-nucleotidase (5"-ribonucleotide phosphohydrolase, EC 3.1.3.5) activity was detected at the external surface of frog skeletal muscle with the active site facing toward the extracellular space.	Adenosine Monophosphate	19-22	5'-nucleotidase ecto	Homo sapiens	46-61
1120494-0	1975	Effect of nucleoside di-and triphosphates and MgCl2 on the activity of 5"-nucleotidase from bull seminal plasma.	Magnesium Chloride	46-51	5'-nucleotidase ecto	Homo sapiens	71-86
1147914-1	1975	Galactosyltransferase and 5"-nucleotidase were assayed in the same reaction mixture, with ovalbumin as exogenous acceptor of (14-C)galactose and with (3-H)AMP as the substrate for the 5"-nucleotidase assay.	Adenosine Monophosphate	155-158	5'-nucleotidase ecto	Homo sapiens	26-41
1197747-0	1975	The effect of epinephrine on liver 5-nucleotidase.	Epinephrine	14-25	5'-nucleotidase ecto	Homo sapiens	35-49
126626-7	1975	Under these conditions the whole chain velocity is mainly dependent on the 5"-nucleotidase concentration, because ATPases and adenylate kinase remove the nucleotidase inhibitors ATP and ADP spontanously.	Adenosine Triphosphate	114-117	5'-nucleotidase ecto	Homo sapiens	75-90
126626-7	1975	Under these conditions the whole chain velocity is mainly dependent on the 5"-nucleotidase concentration, because ATPases and adenylate kinase remove the nucleotidase inhibitors ATP and ADP spontanously.	Adenosine Diphosphate	186-189	5'-nucleotidase ecto	Homo sapiens	75-90
4217190-0	1974	[Effect of Mg++ ion on 5-nucleotidase activity].	Magnesium	11-15	5'-nucleotidase ecto	Homo sapiens	23-37
5775689-0	1969	Inhibition of 5"-nucleotidase from Ehrlich ascites-tumour cells by nucleoside triphosphates.	nucleoside triphosphates	67-91	5'-nucleotidase ecto	Homo sapiens	14-29
4331335-0	1971	Resistance of uridine 5"-fluorophosphate to alkaline phosphatase and its sensitivity to 5"-nucleotidase.	uridine 5"-fluorophosphate	14-40	5'-nucleotidase ecto	Homo sapiens	88-103
5535709-0	1970	Comparison of sodium  -glycerophosphate and disodium phenyl phosphate as inhibitors of alkaline phosphatase in determination of 5"-nucleotidase activity of human serum.	alpha-glycerophosphoric acid	14-39	5'-nucleotidase ecto	Homo sapiens	128-143
5535709-0	1970	Comparison of sodium  -glycerophosphate and disodium phenyl phosphate as inhibitors of alkaline phosphatase in determination of 5"-nucleotidase activity of human serum.	phenylphosphate	44-69	5'-nucleotidase ecto	Homo sapiens	128-143
5775689-2	1969	5"-Nucleotidase activity was obtained in a soluble form after treatment of a particulate fraction from Ehrlich ascites-tumour cells with deoxycholate.	Deoxycholic Acid	137-149	5'-nucleotidase ecto	Homo sapiens	0-15
5775689-14	1969	After fractionation on Sephadex G-200 columns a single peak of 5"-nucleotidase activity (particle weight 120000-125000) was obtained with AMP, IMP and GMP as substrates.	sephadex	23-31	5'-nucleotidase ecto	Homo sapiens	63-78
5775689-14	1969	After fractionation on Sephadex G-200 columns a single peak of 5"-nucleotidase activity (particle weight 120000-125000) was obtained with AMP, IMP and GMP as substrates.	Adenosine Monophosphate	138-141	5'-nucleotidase ecto	Homo sapiens	63-78
5775689-14	1969	After fractionation on Sephadex G-200 columns a single peak of 5"-nucleotidase activity (particle weight 120000-125000) was obtained with AMP, IMP and GMP as substrates.	Inosine Monophosphate	143-146	5'-nucleotidase ecto	Homo sapiens	63-78
5775689-14	1969	After fractionation on Sephadex G-200 columns a single peak of 5"-nucleotidase activity (particle weight 120000-125000) was obtained with AMP, IMP and GMP as substrates.	guanosine 5'-monophosphorothioate	151-154	5'-nucleotidase ecto	Homo sapiens	63-78
13634080-0	1959	Localization of 5-nucleotidase and non-specific alkaline phosphatase by starch gel electrophoresis.	Starch	72-78	5'-nucleotidase ecto	Homo sapiens	16-30
13753593-0	1960	[Inhibition of 5-nucleotidase activity by the decomposition products of brain homogenates and lecithin digested with snake venom].	Lecithins	94-102	5'-nucleotidase ecto	Homo sapiens	15-29
5776544-0	1969	Activation of serum 5" nucleotidase by magnesium ions and its diagnostic applications.	Magnesium	39-48	5'-nucleotidase ecto	Homo sapiens	20-35
13354429-0	1956	The activity in situ of 5"-nucleotidase, phosphomonoesterase and thiamine pyrophosphatase in vitamin B1 deficient brain tissue.	Thiamine	93-103	5'-nucleotidase ecto	Homo sapiens	24-39
13941819-2	1963	Deletion of a 5"-nucleotidase in a 6-mercaptopurine-resistant subline of the Ehrlich ascites carcinoma.	Mercaptopurine	35-51	5'-nucleotidase ecto	Homo sapiens	14-29
13610905-0	1959	At 5"-nucleotidase activated by ferrous iron.	Iron	32-44	5'-nucleotidase ecto	Homo sapiens	3-18
33745072-9	2021	In summary, only MTX increased the expression of CD73 in GBM cells decreasing cells viability by mechanisms independent of the adenosinergic system.	Methotrexate	17-20	5'-nucleotidase ecto	Homo sapiens	49-53
33433704-13	2021	We also conclude that loss of stromal CD73 expression, due to its effect on the extracellular ATP/adenosine balance, may contribute to the pathogenesis of this rare form of endometriosis.	Adenosine Triphosphate	94-97	5'-nucleotidase ecto	Homo sapiens	38-42
33433704-13	2021	We also conclude that loss of stromal CD73 expression, due to its effect on the extracellular ATP/adenosine balance, may contribute to the pathogenesis of this rare form of endometriosis.	Adenosine	98-107	5'-nucleotidase ecto	Homo sapiens	38-42
34031899-2	2021	The ectoenzyme CD73, encoded by the NT5E gene, which catalyses the hydrolysis of AMP into adenosine, has been associated to an immunosuppressive tumour microenvironment, tumour cell adhesion and migration.	Adenosine Monophosphate	81-84	5'-nucleotidase ecto	Homo sapiens	15-19
33745072-0	2021	Influence of NSAIDs and methotrexate on CD73 expression and glioma cell growth.	Methotrexate	24-36	5'-nucleotidase ecto	Homo sapiens	40-44
33745072-2	2021	GBM cells overexpress the CD73 enzyme, which controls the level of extracellular adenosine, an immunosuppressive molecule.	Adenosine	81-90	5'-nucleotidase ecto	Homo sapiens	26-30
33745072-3	2021	Studies have shown that some nonsteroidal anti-inflammatory drugs (NSAIDs) and methotrexate (MTX) have antiproliferative and modulatory effects on CD73 in vitro and in vivo.	Methotrexate	79-91	5'-nucleotidase ecto	Homo sapiens	147-151
33745072-3	2021	Studies have shown that some nonsteroidal anti-inflammatory drugs (NSAIDs) and methotrexate (MTX) have antiproliferative and modulatory effects on CD73 in vitro and in vivo.	Methotrexate	93-96	5'-nucleotidase ecto	Homo sapiens	147-151
33745072-4	2021	However, it remains unclear whether the antiproliferative effects of MTX and NSAIDS in GBM cells are mediated by increases in CD73 expression and adenosine formation.	Methotrexate	69-72	5'-nucleotidase ecto	Homo sapiens	126-130
33745072-6	2021	In addition, we sought to understand whether the effects of MTX may be mediated by CD73 expression and activity.	Methotrexate	60-63	5'-nucleotidase ecto	Homo sapiens	83-87
33640831-11	2021	CONCLUSION: In conclusion, the DEGs related to cell-cell or cell-extracellular matrix interaction (ITGA5, SPP1, LUM, VCAN, APP), placenta metabolic or oxidative stress (CCR7, NT5E, CYBB) were predicted to be newly potential crucial genes that may play significant roles in the pathogenesis of early-onset PE.	alpha-amino-2-ethylbutanoic acid	31-35	5'-nucleotidase ecto	Homo sapiens	175-179
34031899-2	2021	The ectoenzyme CD73, encoded by the NT5E gene, which catalyses the hydrolysis of AMP into adenosine, has been associated to an immunosuppressive tumour microenvironment, tumour cell adhesion and migration.	Adenosine Monophosphate	81-84	5'-nucleotidase ecto	Homo sapiens	36-40
34031899-2	2021	The ectoenzyme CD73, encoded by the NT5E gene, which catalyses the hydrolysis of AMP into adenosine, has been associated to an immunosuppressive tumour microenvironment, tumour cell adhesion and migration.	Adenosine	90-99	5'-nucleotidase ecto	Homo sapiens	15-19
34031899-2	2021	The ectoenzyme CD73, encoded by the NT5E gene, which catalyses the hydrolysis of AMP into adenosine, has been associated to an immunosuppressive tumour microenvironment, tumour cell adhesion and migration.	Adenosine	90-99	5'-nucleotidase ecto	Homo sapiens	36-40
33909515-1	2021	INTRODUCTION: Hydrolysis of AMP to adenosine and inorganic phosphate is catalyzed by 5 -ectonucleotidase, e5NT, alias CD73, a metalloenzyme incorporating two zinc ions at its active site.	Adenosine Monophosphate	28-31	5'-nucleotidase ecto	Homo sapiens	106-110
34019179-1	2021	CD73 converts AMP to adenosine, an immunosuppressive metabolite that promotes tumorigenesis.	Adenosine Monophosphate	14-17	5'-nucleotidase ecto	Homo sapiens	0-4
34019179-1	2021	CD73 converts AMP to adenosine, an immunosuppressive metabolite that promotes tumorigenesis.	Adenosine	21-30	5'-nucleotidase ecto	Homo sapiens	0-4
33993290-2	2021	The ectonucleotidases ENTPD1 and NT5E degrade ATP and have been reported in rodent testicular peritubular cells.	Adenosine Triphosphate	46-49	5'-nucleotidase ecto	Homo sapiens	33-37
34016786-8	2021	Then ruxolitinib was selected to perform molecular docking simulations with ANGPT2, FGF7, NT5E, CSF3R, JAK1, JAK2, JAK3, TYK2.	ruxolitinib	5-16	5'-nucleotidase ecto	Homo sapiens	90-94
33909515-1	2021	INTRODUCTION: Hydrolysis of AMP to adenosine and inorganic phosphate is catalyzed by 5 -ectonucleotidase, e5NT, alias CD73, a metalloenzyme incorporating two zinc ions at its active site.	Adenosine Monophosphate	28-31	5'-nucleotidase ecto	Homo sapiens	118-122
33909515-1	2021	INTRODUCTION: Hydrolysis of AMP to adenosine and inorganic phosphate is catalyzed by 5 -ectonucleotidase, e5NT, alias CD73, a metalloenzyme incorporating two zinc ions at its active site.	Adenosine	35-44	5'-nucleotidase ecto	Homo sapiens	106-110
33909515-1	2021	INTRODUCTION: Hydrolysis of AMP to adenosine and inorganic phosphate is catalyzed by 5 -ectonucleotidase, e5NT, alias CD73, a metalloenzyme incorporating two zinc ions at its active site.	Adenosine	35-44	5'-nucleotidase ecto	Homo sapiens	118-122
33909515-1	2021	INTRODUCTION: Hydrolysis of AMP to adenosine and inorganic phosphate is catalyzed by 5 -ectonucleotidase, e5NT, alias CD73, a metalloenzyme incorporating two zinc ions at its active site.	Phosphates	49-68	5'-nucleotidase ecto	Homo sapiens	106-110
33986285-7	2021	Ex vivo expansion of Tregs from patients with PD restored and enhanced their suppressive functions while expanded Tregs displayed increased expression of foxp3, il2ra (CD25), nt5e (CD73), il10, il13, ctla4, pdcd1 (PD1), and gzmb.	tregs	114-119	5'-nucleotidase ecto	Homo sapiens	175-179
33909515-1	2021	INTRODUCTION: Hydrolysis of AMP to adenosine and inorganic phosphate is catalyzed by 5 -ectonucleotidase, e5NT, alias CD73, a metalloenzyme incorporating two zinc ions at its active site.	Phosphates	49-68	5'-nucleotidase ecto	Homo sapiens	118-122
33986285-7	2021	Ex vivo expansion of Tregs from patients with PD restored and enhanced their suppressive functions while expanded Tregs displayed increased expression of foxp3, il2ra (CD25), nt5e (CD73), il10, il13, ctla4, pdcd1 (PD1), and gzmb.	tregs	114-119	5'-nucleotidase ecto	Homo sapiens	181-185
33909515-6	2021	EXPERT OPINION: : Considerable advances have been reported in the design of nucleotide/nucleoside-based CD73 inhibitors, after the X-ray crystal structure of the enzyme in complex with the non-hydrolyzable ADP analog, adenosine (alpha,beta)-methylene diphosphate (AMPCP), was reported.	Nucleosides	87-97	5'-nucleotidase ecto	Homo sapiens	104-108
33909515-6	2021	EXPERT OPINION: : Considerable advances have been reported in the design of nucleotide/nucleoside-based CD73 inhibitors, after the X-ray crystal structure of the enzyme in complex with the non-hydrolyzable ADP analog, adenosine (alpha,beta)-methylene diphosphate (AMPCP), was reported.	Adenosine Diphosphate	206-209	5'-nucleotidase ecto	Homo sapiens	104-108
33909515-6	2021	EXPERT OPINION: : Considerable advances have been reported in the design of nucleotide/nucleoside-based CD73 inhibitors, after the X-ray crystal structure of the enzyme in complex with the non-hydrolyzable ADP analog, adenosine (alpha,beta)-methylene diphosphate (AMPCP), was reported.	Adenosine	218-227	5'-nucleotidase ecto	Homo sapiens	104-108
33909515-6	2021	EXPERT OPINION: : Considerable advances have been reported in the design of nucleotide/nucleoside-based CD73 inhibitors, after the X-ray crystal structure of the enzyme in complex with the non-hydrolyzable ADP analog, adenosine (alpha,beta)-methylene diphosphate (AMPCP), was reported.	alpha,beta-methyleneadenosine 5'-diphosphate	264-269	5'-nucleotidase ecto	Homo sapiens	104-108
33909515-9	2021	A highly potent small molecule CD73 inhibitor, AB680, is presently in early phase clinical trials as immunotherapeutic agents against various types of cancer.	AB-680	47-52	5'-nucleotidase ecto	Homo sapiens	31-35
33340515-5	2021	Along with the "canonical route" of ATP breakdown to adenosine via sequential ecto-nucleoside triphosphate diphosphohydrolase-1 (NTPDase1/CD39) and ecto-5"-nucleotidase/CD73 activities, it has now become clear that purine metabolism is the result of concerted effort between ATP release, its metabolism through redundant nucleotide-inactivating and counteracting ATP-regenerating ectoenzymatic pathways, as well as cellular nucleoside uptake and phosphorylation of adenosine to ATP through complex phosphotransfer reactions.	Adenosine	53-62	5'-nucleotidase ecto	Homo sapiens	148-168
33161021-2	2021	ATP is released from cells under physiologic and pathophysiologic condition; extracellular ATP is rapidly degraded to adenosine 5"-diphosphate (ADP) and adenosine by ecto-enzymes (mainly, CD39 and CD73).	Adenosine Triphosphate	0-3	5'-nucleotidase ecto	Homo sapiens	197-201
33161021-2	2021	ATP is released from cells under physiologic and pathophysiologic condition; extracellular ATP is rapidly degraded to adenosine 5"-diphosphate (ADP) and adenosine by ecto-enzymes (mainly, CD39 and CD73).	Adenosine Triphosphate	91-94	5'-nucleotidase ecto	Homo sapiens	197-201
33161021-2	2021	ATP is released from cells under physiologic and pathophysiologic condition; extracellular ATP is rapidly degraded to adenosine 5"-diphosphate (ADP) and adenosine by ecto-enzymes (mainly, CD39 and CD73).	Adenosine	118-127	5'-nucleotidase ecto	Homo sapiens	197-201
33340515-5	2021	Along with the "canonical route" of ATP breakdown to adenosine via sequential ecto-nucleoside triphosphate diphosphohydrolase-1 (NTPDase1/CD39) and ecto-5"-nucleotidase/CD73 activities, it has now become clear that purine metabolism is the result of concerted effort between ATP release, its metabolism through redundant nucleotide-inactivating and counteracting ATP-regenerating ectoenzymatic pathways, as well as cellular nucleoside uptake and phosphorylation of adenosine to ATP through complex phosphotransfer reactions.	Adenosine	53-62	5'-nucleotidase ecto	Homo sapiens	169-173
33161021-2	2021	ATP is released from cells under physiologic and pathophysiologic condition; extracellular ATP is rapidly degraded to adenosine 5"-diphosphate (ADP) and adenosine by ecto-enzymes (mainly, CD39 and CD73).	Adenosine Diphosphate	144-147	5'-nucleotidase ecto	Homo sapiens	197-201
33161021-2	2021	ATP is released from cells under physiologic and pathophysiologic condition; extracellular ATP is rapidly degraded to adenosine 5"-diphosphate (ADP) and adenosine by ecto-enzymes (mainly, CD39 and CD73).	Adenosine	153-162	5'-nucleotidase ecto	Homo sapiens	197-201
33340515-5	2021	Along with the "canonical route" of ATP breakdown to adenosine via sequential ecto-nucleoside triphosphate diphosphohydrolase-1 (NTPDase1/CD39) and ecto-5"-nucleotidase/CD73 activities, it has now become clear that purine metabolism is the result of concerted effort between ATP release, its metabolism through redundant nucleotide-inactivating and counteracting ATP-regenerating ectoenzymatic pathways, as well as cellular nucleoside uptake and phosphorylation of adenosine to ATP through complex phosphotransfer reactions.	Adenosine	465-474	5'-nucleotidase ecto	Homo sapiens	148-168
33434633-1	2021	BACKGROUND: Cytosolic 5"-nucleotidase II (cN-II) and ecto-5"-nucleotidase (CD73) are enzymes involved in the nucleotide metabolism by dephosphorylating nucleoside monophosphates.	dephosphorylating nucleoside monophosphates	134-177	5'-nucleotidase ecto	Homo sapiens	53-73
33434633-1	2021	BACKGROUND: Cytosolic 5"-nucleotidase II (cN-II) and ecto-5"-nucleotidase (CD73) are enzymes involved in the nucleotide metabolism by dephosphorylating nucleoside monophosphates.	dephosphorylating nucleoside monophosphates	134-177	5'-nucleotidase ecto	Homo sapiens	75-79
33460629-1	2021	CD39 and CD73 control cell immunity by hydrolyzing proinflammatory ATP and ADP (CD39) into AMP, subsequently converted into anti-inflammatory adenosine (CD73).	Adenosine	142-151	5'-nucleotidase ecto	Homo sapiens	9-13
33434633-6	2021	Furthermore, our results show that CD73-deficiency is associated with increased apoptosis in response to 1600 muM adenosine, decreased sensitivity to mitomycin and enhanced sensitivity to vincristine.	Adenosine	114-123	5'-nucleotidase ecto	Homo sapiens	35-39
33434633-6	2021	Furthermore, our results show that CD73-deficiency is associated with increased apoptosis in response to 1600 muM adenosine, decreased sensitivity to mitomycin and enhanced sensitivity to vincristine.	Mitomycin	150-159	5'-nucleotidase ecto	Homo sapiens	35-39
33434633-6	2021	Furthermore, our results show that CD73-deficiency is associated with increased apoptosis in response to 1600 muM adenosine, decreased sensitivity to mitomycin and enhanced sensitivity to vincristine.	Vincristine	188-199	5'-nucleotidase ecto	Homo sapiens	35-39
33460629-1	2021	CD39 and CD73 control cell immunity by hydrolyzing proinflammatory ATP and ADP (CD39) into AMP, subsequently converted into anti-inflammatory adenosine (CD73).	Adenosine Triphosphate	67-70	5'-nucleotidase ecto	Homo sapiens	9-13
33460629-1	2021	CD39 and CD73 control cell immunity by hydrolyzing proinflammatory ATP and ADP (CD39) into AMP, subsequently converted into anti-inflammatory adenosine (CD73).	Adenosine Triphosphate	67-70	5'-nucleotidase ecto	Homo sapiens	153-157
33460629-1	2021	CD39 and CD73 control cell immunity by hydrolyzing proinflammatory ATP and ADP (CD39) into AMP, subsequently converted into anti-inflammatory adenosine (CD73).	Adenosine	142-151	5'-nucleotidase ecto	Homo sapiens	153-157
33460629-1	2021	CD39 and CD73 control cell immunity by hydrolyzing proinflammatory ATP and ADP (CD39) into AMP, subsequently converted into anti-inflammatory adenosine (CD73).	Adenosine Diphosphate	75-78	5'-nucleotidase ecto	Homo sapiens	9-13
33460629-1	2021	CD39 and CD73 control cell immunity by hydrolyzing proinflammatory ATP and ADP (CD39) into AMP, subsequently converted into anti-inflammatory adenosine (CD73).	Adenosine Diphosphate	75-78	5'-nucleotidase ecto	Homo sapiens	153-157
33460629-1	2021	CD39 and CD73 control cell immunity by hydrolyzing proinflammatory ATP and ADP (CD39) into AMP, subsequently converted into anti-inflammatory adenosine (CD73).	Adenosine Monophosphate	91-94	5'-nucleotidase ecto	Homo sapiens	9-13
33460629-1	2021	CD39 and CD73 control cell immunity by hydrolyzing proinflammatory ATP and ADP (CD39) into AMP, subsequently converted into anti-inflammatory adenosine (CD73).	Adenosine Monophosphate	91-94	5'-nucleotidase ecto	Homo sapiens	153-157
33482152-9	2021	The net- resulting phenotype of adenosine derivatives in bone (including the ratio of ATP to Adenosine) is highly dependent on CD39 and CD73 enzymes together with the expression and activity of the specific receptors.	Adenosine	32-41	5'-nucleotidase ecto	Homo sapiens	136-140
33482152-9	2021	The net- resulting phenotype of adenosine derivatives in bone (including the ratio of ATP to Adenosine) is highly dependent on CD39 and CD73 enzymes together with the expression and activity of the specific receptors.	Adenosine Triphosphate	86-89	5'-nucleotidase ecto	Homo sapiens	136-140
33482152-9	2021	The net- resulting phenotype of adenosine derivatives in bone (including the ratio of ATP to Adenosine) is highly dependent on CD39 and CD73 enzymes together with the expression and activity of the specific receptors.	Adenosine	93-102	5'-nucleotidase ecto	Homo sapiens	136-140
33918053-3	2021	Quercetin has been also reported to modulate the activity of some members of the multidrug-resistance transporters family, such as P-gp, ABCC1, ABCC2, and ABCG2, and the activity of ecto-5"-nucleotidase (NT5E/CD73), a key regulator in some tumor processes such as invasion, migration, and metastasis.	Quercetin	0-9	5'-nucleotidase ecto	Homo sapiens	182-202
33928082-1	2021	Ecto-5"-nucleotidase (CD73) is an enzyme present on the surface of tumor cells whose primary described function is the production of extracellular adenosine.	Adenosine	147-156	5'-nucleotidase ecto	Homo sapiens	0-20
33928082-1	2021	Ecto-5"-nucleotidase (CD73) is an enzyme present on the surface of tumor cells whose primary described function is the production of extracellular adenosine.	Adenosine	147-156	5'-nucleotidase ecto	Homo sapiens	22-26
33928082-2	2021	Due to the immunosuppressive properties of adenosine, CD73 is being investigated as a target for new antitumor therapies.	Adenosine	43-52	5'-nucleotidase ecto	Homo sapiens	54-58
33579783-1	2021	[Abstract:] A recently reported clinical trial yielded positive results for a CD73 inhibitor that reduces production of immunosuppressive adenosine in patients with pancreatic cancer.	Adenosine	138-147	5'-nucleotidase ecto	Homo sapiens	78-82
33609609-1	2021	In many tumors, CD73 (NT5E), a rate-limiting enzyme in adenosine biosynthesis, is upregulated by TGF-beta and drives tumor progression.	Adenosine	55-64	5'-nucleotidase ecto	Homo sapiens	16-20
33609609-1	2021	In many tumors, CD73 (NT5E), a rate-limiting enzyme in adenosine biosynthesis, is upregulated by TGF-beta and drives tumor progression.	Adenosine	55-64	5'-nucleotidase ecto	Homo sapiens	22-26
33913070-2	2021	Neutrophil recruitment and migration to injured tissues is guided by purinergic receptor sensitization, mostly induced by extracellular adenosine triphosphate (ATP) and its hydrolysis product, adenosine (ADO), which is primarily produced by the CD39-CD73 axis located at the neutrophil cell surface.	Adenosine	136-145	5'-nucleotidase ecto	Homo sapiens	250-254
33913070-2	2021	Neutrophil recruitment and migration to injured tissues is guided by purinergic receptor sensitization, mostly induced by extracellular adenosine triphosphate (ATP) and its hydrolysis product, adenosine (ADO), which is primarily produced by the CD39-CD73 axis located at the neutrophil cell surface.	Adenosine Triphosphate	160-163	5'-nucleotidase ecto	Homo sapiens	250-254
33913070-2	2021	Neutrophil recruitment and migration to injured tissues is guided by purinergic receptor sensitization, mostly induced by extracellular adenosine triphosphate (ATP) and its hydrolysis product, adenosine (ADO), which is primarily produced by the CD39-CD73 axis located at the neutrophil cell surface.	Adenosine	193-202	5'-nucleotidase ecto	Homo sapiens	250-254
33913070-2	2021	Neutrophil recruitment and migration to injured tissues is guided by purinergic receptor sensitization, mostly induced by extracellular adenosine triphosphate (ATP) and its hydrolysis product, adenosine (ADO), which is primarily produced by the CD39-CD73 axis located at the neutrophil cell surface.	Adenosine	204-207	5'-nucleotidase ecto	Homo sapiens	250-254
33925516-1	2021	Recently, we found that the expressions of adenosine (ADO) receptors A2AR and A2BR and the ectonucleotidase CD73 which is needed for the conversion of adenosine triphosphate (ATP) to adenosine diphosphate (ADP) and the extracellular ADO level are increased in TNBC MDA-MB-231 cells and RT-R-MDA-MB-231 cells compared to normal cells or non-TNBC cells.	Adenosine	151-160	5'-nucleotidase ecto	Homo sapiens	108-112
33925516-1	2021	Recently, we found that the expressions of adenosine (ADO) receptors A2AR and A2BR and the ectonucleotidase CD73 which is needed for the conversion of adenosine triphosphate (ATP) to adenosine diphosphate (ADP) and the extracellular ADO level are increased in TNBC MDA-MB-231 cells and RT-R-MDA-MB-231 cells compared to normal cells or non-TNBC cells.	Adenosine Triphosphate	175-178	5'-nucleotidase ecto	Homo sapiens	108-112
33925516-1	2021	Recently, we found that the expressions of adenosine (ADO) receptors A2AR and A2BR and the ectonucleotidase CD73 which is needed for the conversion of adenosine triphosphate (ATP) to adenosine diphosphate (ADP) and the extracellular ADO level are increased in TNBC MDA-MB-231 cells and RT-R-MDA-MB-231 cells compared to normal cells or non-TNBC cells.	Adenosine	151-160	5'-nucleotidase ecto	Homo sapiens	108-112
33925516-1	2021	Recently, we found that the expressions of adenosine (ADO) receptors A2AR and A2BR and the ectonucleotidase CD73 which is needed for the conversion of adenosine triphosphate (ATP) to adenosine diphosphate (ADP) and the extracellular ADO level are increased in TNBC MDA-MB-231 cells and RT-R-MDA-MB-231 cells compared to normal cells or non-TNBC cells.	Adenosine Diphosphate	206-209	5'-nucleotidase ecto	Homo sapiens	108-112
33925516-1	2021	Recently, we found that the expressions of adenosine (ADO) receptors A2AR and A2BR and the ectonucleotidase CD73 which is needed for the conversion of adenosine triphosphate (ATP) to adenosine diphosphate (ADP) and the extracellular ADO level are increased in TNBC MDA-MB-231 cells and RT-R-MDA-MB-231 cells compared to normal cells or non-TNBC cells.	Adenosine	233-236	5'-nucleotidase ecto	Homo sapiens	108-112
33918053-3	2021	Quercetin has been also reported to modulate the activity of some members of the multidrug-resistance transporters family, such as P-gp, ABCC1, ABCC2, and ABCG2, and the activity of ecto-5"-nucleotidase (NT5E/CD73), a key regulator in some tumor processes such as invasion, migration, and metastasis.	Quercetin	0-9	5'-nucleotidase ecto	Homo sapiens	204-208
33430239-2	2021	One such regulatory molecule is the cell surface ectoenzyme ecto-5"-nucleotidase that hydrolyzes the conversion of extracellular adenosine monophosphate to adenosine (eADO).	Adenosine	129-138	5'-nucleotidase ecto	Homo sapiens	60-80
33656342-0	2021	Identification of Phelligridin-Based Compounds as Novel Human CD73 Inhibitors.	phelligridin	18-30	5'-nucleotidase ecto	Homo sapiens	62-66
33656342-10	2021	The identified inhibitors have a molecular weight of approximately 500 Dal and are predicted to form primarily hydrogen bonds with CD73 in addition to hydrophobic stacking interactions.	Hydrogen	111-119	5'-nucleotidase ecto	Homo sapiens	131-135
33656342-11	2021	In conclusion, novel inhibitors with satisfactory drug properties may serve as lead compounds for the development of CD73-targeting drugs, and the binding modes may provide insight for phelligridin-based drug design.	phelligridin	185-197	5'-nucleotidase ecto	Homo sapiens	117-121
33727591-4	2021	This was done by inhibiting CD73 with adenosine 5"-(alpha, beta-methylene) diphosphate (APCP) in MDA-MB-231 or 4T1 TNBC cells or through shRNA-silencing (sh-CD73).	Adenosine	38-47	5'-nucleotidase ecto	Homo sapiens	28-32
33727591-4	2021	This was done by inhibiting CD73 with adenosine 5"-(alpha, beta-methylene) diphosphate (APCP) in MDA-MB-231 or 4T1 TNBC cells or through shRNA-silencing (sh-CD73).	adenylyl(3'-5')cytidine-3'-phosphate	88-92	5'-nucleotidase ecto	Homo sapiens	28-32
33564128-12	2021	IMPACT: Immune effector cells, that is, monocytes, T cells and MDSCs from cord blood express ectonucleotidases CD39 and CD73 and may thus serve as a source for adenosine as an immunomodulatory metabolite.	Adenosine	160-169	5'-nucleotidase ecto	Homo sapiens	120-124
33268695-3	2021	Here, we show that CD73, which generates extracellular adenosine from ATP, and A2B receptor, which is activated by adenosine, are involved in the gamma-radiation-induced DDR and the enhanced migration ability of human glioblastoma cell line A172.	Adenosine	55-64	5'-nucleotidase ecto	Homo sapiens	19-23
33268695-3	2021	Here, we show that CD73, which generates extracellular adenosine from ATP, and A2B receptor, which is activated by adenosine, are involved in the gamma-radiation-induced DDR and the enhanced migration ability of human glioblastoma cell line A172.	Adenosine Triphosphate	70-73	5'-nucleotidase ecto	Homo sapiens	19-23
33268695-3	2021	Here, we show that CD73, which generates extracellular adenosine from ATP, and A2B receptor, which is activated by adenosine, are involved in the gamma-radiation-induced DDR and the enhanced migration ability of human glioblastoma cell line A172.	Adenosine	115-124	5'-nucleotidase ecto	Homo sapiens	19-23
33268695-3	2021	Here, we show that CD73, which generates extracellular adenosine from ATP, and A2B receptor, which is activated by adenosine, are involved in the gamma-radiation-induced DDR and the enhanced migration ability of human glioblastoma cell line A172.	ddr	170-173	5'-nucleotidase ecto	Homo sapiens	19-23
33268695-6	2021	These results suggest that activation of A2B receptor by extracellular adenosine generated via CD73 promotes gamma-radiation-induced DDR, leading to recovery from DNA damage, and also enhances cell migration and actin remodeling.	Adenosine	71-80	5'-nucleotidase ecto	Homo sapiens	95-99
32970317-0	2021	Enhanced migration of breast and lung cancer cells deficient for cN-II and CD73 via COX-2/PGE2/AKT axis regulation.	Dinoprostone	90-94	5'-nucleotidase ecto	Homo sapiens	75-79
32970317-1	2021	PURPOSE: Purine metabolism involves various intracellular and extracellular enzymes, including cN-II and CD73 that dephosphorylate intracellular and extracellular nucleoside monophosphates into their corresponding nucleosides.	purine	9-15	5'-nucleotidase ecto	Homo sapiens	105-109
32970317-1	2021	PURPOSE: Purine metabolism involves various intracellular and extracellular enzymes, including cN-II and CD73 that dephosphorylate intracellular and extracellular nucleoside monophosphates into their corresponding nucleosides.	nucleoside monophosphates	163-188	5'-nucleotidase ecto	Homo sapiens	105-109
32970317-1	2021	PURPOSE: Purine metabolism involves various intracellular and extracellular enzymes, including cN-II and CD73 that dephosphorylate intracellular and extracellular nucleoside monophosphates into their corresponding nucleosides.	Nucleosides	214-225	5'-nucleotidase ecto	Homo sapiens	105-109
33399453-6	2021	We have developed a series of potent and selective methylenephosphonic acid CD73 inhibitors via a structure-based design.	methylenephosphonic acid	51-75	5'-nucleotidase ecto	Homo sapiens	76-80
33399453-7	2021	Key binding interactions of the known inhibitor adenosine-5"-(alpha,beta-methylene)diphosphate (AMPCP) with hCD73 provided the foundation for our early designs.	Adenosine	48-57	5'-nucleotidase ecto	Homo sapiens	108-113
33399453-7	2021	Key binding interactions of the known inhibitor adenosine-5"-(alpha,beta-methylene)diphosphate (AMPCP) with hCD73 provided the foundation for our early designs.	alpha,beta-methyleneadenosine 5'-diphosphate	96-101	5'-nucleotidase ecto	Homo sapiens	108-113
33416944-1	2021	INTRODUCTION: CD73 is a membrane-bound enzyme crucial in adenosine generation.	Adenosine	57-66	5'-nucleotidase ecto	Homo sapiens	14-18
33416944-5	2021	Total CD73 (T +) was calculated as the average of luminal (L +) and basolateral (BL +) percentage membrane expression scores for each LUAD and was used to classify tumors into three groups based on the extent of T CD73 expression (high, low, and negative).	Phenobarbital	50-57	5'-nucleotidase ecto	Homo sapiens	6-10
33610376-4	2021	Studies of the past decade have demonstrated the role of Tregs and ectonucleotidases CD39 and CD73 in the generation of immunosuppressive extracellular adenosine.	Adenosine	152-161	5'-nucleotidase ecto	Homo sapiens	94-98
33610376-6	2021	Here we review the latest data on issues regarding the role of extracellular adenosine and its receptors in antitumor immune response, adenosine generation mechanisms involving Tregs and the membrane proteins CD39 and CD73.	Adenosine	135-144	5'-nucleotidase ecto	Homo sapiens	218-222
33740184-6	2021	The possible role of ectonucleotidases, such as CD39 and CD73, which have the function of dephosphorylating ATP in an immunosuppressive component, adenosine, are also covered in detail.	Adenosine Triphosphate	108-111	5'-nucleotidase ecto	Homo sapiens	57-61
33740184-6	2021	The possible role of ectonucleotidases, such as CD39 and CD73, which have the function of dephosphorylating ATP in an immunosuppressive component, adenosine, are also covered in detail.	Adenosine	147-156	5'-nucleotidase ecto	Homo sapiens	57-61
33450542-0	2021	4-Substituted-1,2,3-triazolo nucleotide analogues as CD73 inhibitors, their synthesis, in vitro screening, kinetic and in silico studies.	4-substituted-1,2,3-triazolo nucleotide	0-39	5'-nucleotidase ecto	Homo sapiens	53-57
33450542-5	2021	The beta-hydroxyphosphonylphosphonate ribonucleosides (series 2) were found to be potent inhibitors of CD73 using both purified recombinant protein and cell-based assays.	beta-hydroxyphosphonylphosphonate ribonucleosides	4-53	5'-nucleotidase ecto	Homo sapiens	103-107
32648591-0	2021	The role of the CD39-CD73-adenosine pathway in liver disease.	Adenosine	26-35	5'-nucleotidase ecto	Homo sapiens	21-25
32648591-2	2021	The ectonucleotidases CD39/ectonucleoside triphosphate diphosphohydrolase-1 and CD73/ecto-5"-nucleotidase are cell-surface enzymes that breakdown extracellular ATP into adenosine.	Adenosine Triphosphate	160-163	5'-nucleotidase ecto	Homo sapiens	80-84
32648591-2	2021	The ectonucleotidases CD39/ectonucleoside triphosphate diphosphohydrolase-1 and CD73/ecto-5"-nucleotidase are cell-surface enzymes that breakdown extracellular ATP into adenosine.	Adenosine Triphosphate	160-163	5'-nucleotidase ecto	Homo sapiens	85-105
32648591-2	2021	The ectonucleotidases CD39/ectonucleoside triphosphate diphosphohydrolase-1 and CD73/ecto-5"-nucleotidase are cell-surface enzymes that breakdown extracellular ATP into adenosine.	Adenosine	169-178	5'-nucleotidase ecto	Homo sapiens	80-84
32648591-2	2021	The ectonucleotidases CD39/ectonucleoside triphosphate diphosphohydrolase-1 and CD73/ecto-5"-nucleotidase are cell-surface enzymes that breakdown extracellular ATP into adenosine.	Adenosine	169-178	5'-nucleotidase ecto	Homo sapiens	85-105
32648591-4	2021	The CD39-CD73-adenosine pathway changes dynamically with the pathophysiological context in which it is embedded.	Adenosine	14-23	5'-nucleotidase ecto	Homo sapiens	9-13
32648591-6	2021	Recent studies have shown that the modification of the CD39-CD73-adenosine pathway alters the liver"s response to injury.	Adenosine	65-74	5'-nucleotidase ecto	Homo sapiens	60-64
32648591-8	2021	In this review, we aim to describe the role of the CD39-CD73-adenosine pathway and adenosine receptors in liver disease, highlighting potential therapeutic targets in this pathway, which will facilitate the development of therapeutic strategies for the treatment of liver disease.	Adenosine	61-70	5'-nucleotidase ecto	Homo sapiens	56-60
33584346-9	2021	In vivo experiments also showed that double knockout CD73 and ADORA2B remarkably improved CS-induced lung injury by activating PKC alpha, reducing the inflammatory cell number in bronchoalveolar lavage fluid and the production of inflammatory mediator IL-6, inhibiting the fibrosis-like lesions and decreasing collagen deposition surrounding bronchioles.	Cesium	90-92	5'-nucleotidase ecto	Homo sapiens	53-57
33553158-2	2020	Regulatory/effector cell balance is governed by the CD39 ectonucleotidase, the prototype member of the NTPDase family that hydrolyzes ATP and ADP into AMP, subsequently converted into adenosine by CD73.	Adenosine Triphosphate	134-137	5'-nucleotidase ecto	Homo sapiens	197-201
33553158-2	2020	Regulatory/effector cell balance is governed by the CD39 ectonucleotidase, the prototype member of the NTPDase family that hydrolyzes ATP and ADP into AMP, subsequently converted into adenosine by CD73.	Adenosine Diphosphate	142-145	5'-nucleotidase ecto	Homo sapiens	197-201
33553158-2	2020	Regulatory/effector cell balance is governed by the CD39 ectonucleotidase, the prototype member of the NTPDase family that hydrolyzes ATP and ADP into AMP, subsequently converted into adenosine by CD73.	Adenosine Monophosphate	151-154	5'-nucleotidase ecto	Homo sapiens	197-201
33553158-2	2020	Regulatory/effector cell balance is governed by the CD39 ectonucleotidase, the prototype member of the NTPDase family that hydrolyzes ATP and ADP into AMP, subsequently converted into adenosine by CD73.	Adenosine	184-193	5'-nucleotidase ecto	Homo sapiens	197-201
33399453-0	2021	Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors.	methylenephosphonic acid	34-58	5'-nucleotidase ecto	Homo sapiens	59-63
33399453-3	2021	The ectonucleotidase CD73 catalyzes the conversion of AMP to adenosine.	Adenosine Monophosphate	54-57	5'-nucleotidase ecto	Homo sapiens	21-25
33399453-3	2021	The ectonucleotidase CD73 catalyzes the conversion of AMP to adenosine.	Adenosine	61-70	5'-nucleotidase ecto	Homo sapiens	21-25
33399453-5	2021	CD73 inhibition is anticipated to restore immune function by skirting this major mechanism of adenosine generation.	Adenosine	94-103	5'-nucleotidase ecto	Homo sapiens	0-4
33098857-2	2021	In inflammatory microenvironments, exogenous ATP (eATP) is hydrolyzed to adenosine, which exerts immunosuppressive effects, by the consecutive action of the ectonucleotidases CD39 and CD73.	Adenosine Triphosphate	45-48	5'-nucleotidase ecto	Homo sapiens	184-188
33416944-9	2021	Immune profiling demonstrated that T-cell inflammation and adenosine signatures were significantly higher in CD73-expressing lung adenocarcinomas relative to those lacking CD73.	Adenosine	59-68	5'-nucleotidase ecto	Homo sapiens	109-113
33416945-2	2021	However, we do not know whether the adenosine pathway (CD39/CD73/A2AR) plays a role in renal cell carcinoma (RCC).	Adenosine	36-45	5'-nucleotidase ecto	Homo sapiens	60-64
33098857-2	2021	In inflammatory microenvironments, exogenous ATP (eATP) is hydrolyzed to adenosine, which exerts immunosuppressive effects, by the consecutive action of the ectonucleotidases CD39 and CD73.	eatp	50-54	5'-nucleotidase ecto	Homo sapiens	184-188
33430239-2	2021	One such regulatory molecule is the cell surface ectoenzyme ecto-5"-nucleotidase that hydrolyzes the conversion of extracellular adenosine monophosphate to adenosine (eADO).	Adenosine	156-165	5'-nucleotidase ecto	Homo sapiens	60-80
33098857-2	2021	In inflammatory microenvironments, exogenous ATP (eATP) is hydrolyzed to adenosine, which exerts immunosuppressive effects, by the consecutive action of the ectonucleotidases CD39 and CD73.	Adenosine	73-82	5'-nucleotidase ecto	Homo sapiens	184-188
33430239-2	2021	One such regulatory molecule is the cell surface ectoenzyme ecto-5"-nucleotidase that hydrolyzes the conversion of extracellular adenosine monophosphate to adenosine (eADO).	eado	167-171	5'-nucleotidase ecto	Homo sapiens	60-80
33123998-1	2021	Adenosine, deriving from ATP released by dying cancer cells and then degradated in the tumor environment by CD39/CD73 enzyme axis, is linked to the generation of an immunosuppressed niche favoring the onset of neoplasia.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	113-117
33407870-5	2021	RESULTS: We found the combination of LLY-507 and AZD5153 was sufficient for high-efficiency CD73+CD90+CD105+CD31-CD34-CD45-HLA-DR- MSC induction from both hESCs and hiPSCs with stemness (POU5F1/SOX2/NANOG).	Lysine	37-40	5'-nucleotidase ecto	Homo sapiens	92-96
33407870-5	2021	RESULTS: We found the combination of LLY-507 and AZD5153 was sufficient for high-efficiency CD73+CD90+CD105+CD31-CD34-CD45-HLA-DR- MSC induction from both hESCs and hiPSCs with stemness (POU5F1/SOX2/NANOG).	AZD5153	49-56	5'-nucleotidase ecto	Homo sapiens	92-96
33123998-1	2021	Adenosine, deriving from ATP released by dying cancer cells and then degradated in the tumor environment by CD39/CD73 enzyme axis, is linked to the generation of an immunosuppressed niche favoring the onset of neoplasia.	Adenosine Triphosphate	25-28	5'-nucleotidase ecto	Homo sapiens	113-117
33975446-9	2021	Flow cytometry revealed that 90% of the DMC subpopulation are HLA-G+, CD44+, CD73+, CD29+, CD105+, CD90+, and HLA-DR-.	dmc	40-43	5'-nucleotidase ecto	Homo sapiens	77-81
33052071-3	2021	Further degradation of the monophosphate nucleoside end products occurs by surface ecto-5"-nucleotidase (NMPase) or CD73.	monophosphate nucleoside	27-51	5'-nucleotidase ecto	Homo sapiens	83-103
33052071-3	2021	Further degradation of the monophosphate nucleoside end products occurs by surface ecto-5"-nucleotidase (NMPase) or CD73.	monophosphate nucleoside	27-51	5'-nucleotidase ecto	Homo sapiens	116-120
33052071-9	2021	Chimeric CD39-CD73-ECD proteins were superior in converting triphosphate and diphosphate nucleotides into nucleosides when compared with ALP-ECD and HAP-ECD.	triphosphoric acid	60-72	5'-nucleotidase ecto	Homo sapiens	14-18
33052071-9	2021	Chimeric CD39-CD73-ECD proteins were superior in converting triphosphate and diphosphate nucleotides into nucleosides when compared with ALP-ECD and HAP-ECD.	diphosphate nucleotides	77-100	5'-nucleotidase ecto	Homo sapiens	14-18
33052071-9	2021	Chimeric CD39-CD73-ECD proteins were superior in converting triphosphate and diphosphate nucleotides into nucleosides when compared with ALP-ECD and HAP-ECD.	Nucleosides	106-117	5'-nucleotidase ecto	Homo sapiens	14-18
32970335-1	2021	CD73 is an important ectoenzyme responsible for the production of extracellular adenosine.	Adenosine	80-89	5'-nucleotidase ecto	Homo sapiens	0-4
33322215-8	2020	In contrast to in vitro studies, specific upregulation of ADO-related enzymes CD73 and CD39 in GLUT-1high tumor regions was never observed.	Adenosine	58-61	5'-nucleotidase ecto	Homo sapiens	78-82
33130525-0	2021	Combined inhibition of CD73 and ZEB1 by Arg-Gly-Asp (RGD)-targeted nanoparticles inhibits tumor growth.	arginyl-glycyl-aspartic acid	40-51	5'-nucleotidase ecto	Homo sapiens	23-27
33130525-0	2021	Combined inhibition of CD73 and ZEB1 by Arg-Gly-Asp (RGD)-targeted nanoparticles inhibits tumor growth.	arginyl-glycyl-aspartic acid	53-56	5'-nucleotidase ecto	Homo sapiens	23-27
33130525-3	2021	In this study, we decided to inhibit the expression of these factors in the tumor site by using RGD-conjugated chitosan lactate (RGD-CL) nanoparticles (NPs) encapsulating CD73/ZEB-1 siRNA molecules, in vitro and in vivo.	chitosan lactate	111-127	5'-nucleotidase ecto	Homo sapiens	171-175
33130525-3	2021	In this study, we decided to inhibit the expression of these factors in the tumor site by using RGD-conjugated chitosan lactate (RGD-CL) nanoparticles (NPs) encapsulating CD73/ZEB-1 siRNA molecules, in vitro and in vivo.	rgd-cl	129-135	5'-nucleotidase ecto	Homo sapiens	171-175
32961376-4	2021	This immune privilege depends on cell-surface ectoenzymes CD39 and CD73 on niche Tregs, which generate extracellular adenosine, a nucleotide known to suppress immunity and potentiate Tregs.	tregs	81-86	5'-nucleotidase ecto	Homo sapiens	67-71
32961376-4	2021	This immune privilege depends on cell-surface ectoenzymes CD39 and CD73 on niche Tregs, which generate extracellular adenosine, a nucleotide known to suppress immunity and potentiate Tregs.	Adenosine	117-126	5'-nucleotidase ecto	Homo sapiens	67-71
32961376-4	2021	This immune privilege depends on cell-surface ectoenzymes CD39 and CD73 on niche Tregs, which generate extracellular adenosine, a nucleotide known to suppress immunity and potentiate Tregs.	tregs	183-188	5'-nucleotidase ecto	Homo sapiens	67-71
33122192-1	2020	The dimeric ectonucleotidase CD73 catalyzes the hydrolysis of AMP at the cell surface to form adenosine, a potent suppressor of the immune response.	Adenosine Monophosphate	62-65	5'-nucleotidase ecto	Homo sapiens	29-33
33122192-1	2020	The dimeric ectonucleotidase CD73 catalyzes the hydrolysis of AMP at the cell surface to form adenosine, a potent suppressor of the immune response.	Adenosine	94-103	5'-nucleotidase ecto	Homo sapiens	29-33
33122192-9	2020	A separate structure of CD73 with a Fab (TB38) which complements TB19 in a particularly potent biparatopic shows its binding to a non-overlapping site on the CD73 N-terminal domain.	tb19	65-69	5'-nucleotidase ecto	Homo sapiens	24-28
33122192-9	2020	A separate structure of CD73 with a Fab (TB38) which complements TB19 in a particularly potent biparatopic shows its binding to a non-overlapping site on the CD73 N-terminal domain.	tb19	65-69	5'-nucleotidase ecto	Homo sapiens	158-162
32203145-4	2021	CD39 and CD73 convert extracellular adenosine triphosphate (ATP) into adenosine, a key player in Tregs" immunosuppression.	Adenosine	36-45	5'-nucleotidase ecto	Homo sapiens	9-13
32203145-4	2021	CD39 and CD73 convert extracellular adenosine triphosphate (ATP) into adenosine, a key player in Tregs" immunosuppression.	Adenosine Triphosphate	60-63	5'-nucleotidase ecto	Homo sapiens	9-13
32203145-4	2021	CD39 and CD73 convert extracellular adenosine triphosphate (ATP) into adenosine, a key player in Tregs" immunosuppression.	Adenosine	70-79	5'-nucleotidase ecto	Homo sapiens	9-13
33488292-10	2020	These results suggest that persistent infection by HR-HPV and the concomitant production of TGF-beta promote the expression of CD39 and CD73 to favor CC progression through Ado generation.	Adenosine	173-176	5'-nucleotidase ecto	Homo sapiens	136-140
33325366-3	2020	On the other hand, it plays an anti-inflammatory role through conversion to adenosine by CD39 and CD73 on the cell surface and acting via adenosine receptor (P1 purinergic receptor).	Adenosine	76-85	5'-nucleotidase ecto	Homo sapiens	98-102
33488292-3	2020	To determine whether CD39 and CD73, which participate in the production of immunosuppressive adenosine (Ado), are involved in the progression of CC, we compared the concentrations and hydrolytic activity of these ectonucleotidases in platelet-free plasma (PFP) samples between patients with low-grade squamous intraepithelial lesions (LSILs) (n = 18), high-grade squamous intraepithelial lesions (HSILs) (n = 12), and CC (n = 19) and normal donors (NDs) (n = 15).	Adenosine	93-102	5'-nucleotidase ecto	Homo sapiens	30-34
33488292-3	2020	To determine whether CD39 and CD73, which participate in the production of immunosuppressive adenosine (Ado), are involved in the progression of CC, we compared the concentrations and hydrolytic activity of these ectonucleotidases in platelet-free plasma (PFP) samples between patients with low-grade squamous intraepithelial lesions (LSILs) (n = 18), high-grade squamous intraepithelial lesions (HSILs) (n = 12), and CC (n = 19) and normal donors (NDs) (n = 15).	Adenosine	104-107	5'-nucleotidase ecto	Homo sapiens	30-34
33045579-2	2020	CD39 can hydrolyze eATP into adenosine monophosphate (AMP), while CD73 can convert AMP into the immunosuppressive nucleoside adenosine (ADO).	Adenosine Monophosphate	83-86	5'-nucleotidase ecto	Homo sapiens	66-70
33045579-2	2020	CD39 can hydrolyze eATP into adenosine monophosphate (AMP), while CD73 can convert AMP into the immunosuppressive nucleoside adenosine (ADO).	Adenosine	125-134	5'-nucleotidase ecto	Homo sapiens	66-70
33045579-2	2020	CD39 can hydrolyze eATP into adenosine monophosphate (AMP), while CD73 can convert AMP into the immunosuppressive nucleoside adenosine (ADO).	Adenosine	136-139	5'-nucleotidase ecto	Homo sapiens	66-70
32548862-2	2020	We describe expression of CD73, an enzyme critical to the generation of adenosine from extracellular AMP, in T cells and other cell types within human head and neck tumors.	Adenosine	72-81	5'-nucleotidase ecto	Homo sapiens	26-30
32548862-2	2020	We describe expression of CD73, an enzyme critical to the generation of adenosine from extracellular AMP, in T cells and other cell types within human head and neck tumors.	Adenosine Monophosphate	101-104	5'-nucleotidase ecto	Homo sapiens	26-30
32548862-6	2020	In vitro studies with peripheral blood T cells indicate that anti-CD3-stimulation causes loss of CD73 expression, especially among cells that undergo proliferation and that exogenous AMP can impair T cell proliferation, while sustaining CD73 expression.	Adenosine Monophosphate	183-186	5'-nucleotidase ecto	Homo sapiens	237-241
33179142-2	2020	The umbilical cords (UC) were investigated by the histomorphological method and the number of WJ-MSC were detected by flow-cytometry using the CD90, CD44, CD105, and CD73 markers in Wharton"s jelly (WJ) isolated from fresh umbilical cords.	wharton	182-189	5'-nucleotidase ecto	Homo sapiens	166-170
33325366-8	2020	In this review, we summarize that CD39/CD73 synergistically regulates the balance of extracellular ATP and adenosine, thus influencing immune cell functions through P2 receptor and P1 receptor signaling pathway.	Adenosine Triphosphate	99-102	5'-nucleotidase ecto	Homo sapiens	39-43
33325366-8	2020	In this review, we summarize that CD39/CD73 synergistically regulates the balance of extracellular ATP and adenosine, thus influencing immune cell functions through P2 receptor and P1 receptor signaling pathway.	Adenosine	107-116	5'-nucleotidase ecto	Homo sapiens	39-43
33187081-5	2020	Reduction of CD73 protein resulted in significant suppression of GSC viability, proliferation and clonogenicity, whereas CD73 enzymatic activity exhibited negative effects only on GSC invasion involving impaired downstream adenosine (ADO) signalling.	Adenosine	223-232	5'-nucleotidase ecto	Homo sapiens	121-125
33222670-4	2021	Adenosine nucleoside, which is a derivative of ATP, is highly elevated in the tumor microenvironment by CD39 and CD73 enzymatic activity.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	113-117
33222670-4	2021	Adenosine nucleoside, which is a derivative of ATP, is highly elevated in the tumor microenvironment by CD39 and CD73 enzymatic activity.	Adenosine Triphosphate	47-50	5'-nucleotidase ecto	Homo sapiens	113-117
33222670-5	2021	Recently, it is distinguished that cancer cellderived exosomes carry CD39 and CD73 on their surface and may contribute to rising adenosine levels in the tumor microenvironment.	Adenosine	129-138	5'-nucleotidase ecto	Homo sapiens	78-82
33198064-1	2020	Cluster of differentiation (CD) 73, which is encoded by the NT5E gene, regulates production of immunosuppressive adenosine and is an emerging checkpoint in cancer immunotherapy.	Adenosine	113-122	5'-nucleotidase ecto	Homo sapiens	0-34
33198064-1	2020	Cluster of differentiation (CD) 73, which is encoded by the NT5E gene, regulates production of immunosuppressive adenosine and is an emerging checkpoint in cancer immunotherapy.	Adenosine	113-122	5'-nucleotidase ecto	Homo sapiens	60-64
32786396-2	2020	Blocking adenosine production by inhibiting nucleotide-metabolizing enzymes, such as ecto-nucleotidases CD73 and CD39, represents a promising therapeutic strategy that may synergize with other immuno-oncology mechanisms and chemotherapies.	Adenosine	9-18	5'-nucleotidase ecto	Homo sapiens	104-108
32786396-4	2020	This Perspective will outline challenges, strategies and recent advancements in targeting this class with small-molecule inhibitors, including AB680, the first small-molecule CD73 inhibitor to enter clinical development.	AB-680	143-148	5'-nucleotidase ecto	Homo sapiens	175-179
33187081-5	2020	Reduction of CD73 protein resulted in significant suppression of GSC viability, proliferation and clonogenicity, whereas CD73 enzymatic activity exhibited negative effects only on GSC invasion involving impaired downstream adenosine (ADO) signalling.	Adenosine	234-237	5'-nucleotidase ecto	Homo sapiens	121-125
33187081-6	2020	Furthermore, application of phosphodiesterase inhibitor pentoxifylline, a potent immunomodulator, effectively inhibited ZEB1 and CD73 expression and significantly decreased viability, clonogenicity, and invasion of GSC in vitro cultures.	Pentoxifylline	56-70	5'-nucleotidase ecto	Homo sapiens	129-133
33087577-6	2020	Signal transduction was strictly polarized to the serosal side of the epithelium, dependent on the extracellular and sequential hydrolysis of CDNs to adenosine by the ectonucleosidases ENPP1 and CD73, and occurred via activation of A2B adenosine receptors.	cdns	142-146	5'-nucleotidase ecto	Homo sapiens	195-199
33168024-10	2020	We demonstrated that COP1/CD73 was involved in the downstream mechanism of the miR-340-5p/KMT5A axis involving ubiquitination.	mir-340-	79-87	5'-nucleotidase ecto	Homo sapiens	26-30
33168024-13	2020	CONCLUSIONS: MiR-340-5p promoted CD8+ T-TIL infiltration and antitumor function by regulating KMT5A and COP1 and further activating CD73 ubiquitination.	mir-340-5p	13-23	5'-nucleotidase ecto	Homo sapiens	132-136
32985862-1	2020	Extracellular adenosine, produced through the activity of the ecto-5"-nucleotidase CD73, elicits potent immune-suppressive effects and its upregulation in tumor cells as well as in stromal and immune cell subsets within the tumor microenvironment is hypothesized to represent an important resistance mechanism to current cancer immunotherapies.	Adenosine	14-23	5'-nucleotidase ecto	Homo sapiens	62-82
32985862-1	2020	Extracellular adenosine, produced through the activity of the ecto-5"-nucleotidase CD73, elicits potent immune-suppressive effects and its upregulation in tumor cells as well as in stromal and immune cell subsets within the tumor microenvironment is hypothesized to represent an important resistance mechanism to current cancer immunotherapies.	Adenosine	14-23	5'-nucleotidase ecto	Homo sapiens	83-87
33087577-6	2020	Signal transduction was strictly polarized to the serosal side of the epithelium, dependent on the extracellular and sequential hydrolysis of CDNs to adenosine by the ectonucleosidases ENPP1 and CD73, and occurred via activation of A2B adenosine receptors.	Adenosine	150-159	5'-nucleotidase ecto	Homo sapiens	195-199
32847938-0	2020	An IL6-Adenosine Positive Feedback Loop between CD73+ gammadeltaTregs and CAFs Promotes Tumor Progression in Human Breast Cancer.	Adenosine	7-16	5'-nucleotidase ecto	Homo sapiens	48-52
32419057-4	2020	Enzymatic activity of ectonucleotidases CD39/CD73 carried by TEX was measured by HPLC.	NSC643817	61-64	5'-nucleotidase ecto	Homo sapiens	45-49
32419057-11	2020	RESULTS: TEX carried enzymatically active CD39/CD73 and adenosine.	NSC643817	9-12	5'-nucleotidase ecto	Homo sapiens	47-51
33177176-1	2020	BACKGROUND: CD73-adenosine signaling in the tumor microenvironment is immunosuppressive and may be associated with aggressive renal cell carcinoma (RCC).	Adenosine	17-26	5'-nucleotidase ecto	Homo sapiens	12-16
33177176-16	2020	Our findings provide compelling support for targeting the immunosuppressive and proangiogenic CD73-adenosine pathway in RCC.	Adenosine	99-108	5'-nucleotidase ecto	Homo sapiens	94-98
32401115-11	2020	The mRNA expression of NT5E and ICAM1 were higher in group HP, while MAP3K7CL was lower than CON group (p < .05).Conclusion: This study provided a working list of lncRNAs that may be relevant to osteogenic differentiation, which presents a new insights into the mechanism of vascular calcification induced by high phosphorus in VSMCs.	Phosphorus	314-324	5'-nucleotidase ecto	Homo sapiens	23-27
33335662-0	2020	Synthesis, Characterization, and In Silico Studies of Novel Spirooxindole Derivatives as Ecto-5"-Nucleotidase Inhibitors.	Spirooxindole	60-73	5'-nucleotidase ecto	Homo sapiens	89-109
33335662-2	2020	Traditional efforts used to inhibit the ecto-5"-nucleotidase have involved antibody therapy or development of small molecule inhibitors that can mimic the acidic and ionizable structure of adenosine 5"-monophosphate (AMP).	Adenosine	189-198	5'-nucleotidase ecto	Homo sapiens	40-60
33335662-2	2020	Traditional efforts used to inhibit the ecto-5"-nucleotidase have involved antibody therapy or development of small molecule inhibitors that can mimic the acidic and ionizable structure of adenosine 5"-monophosphate (AMP).	Adenosine Monophosphate	217-220	5'-nucleotidase ecto	Homo sapiens	40-60
32614585-0	2020	Discovery of AB680: A Potent and Selective Inhibitor of CD73.	AB-680	13-18	5'-nucleotidase ecto	Homo sapiens	56-60
32614585-2	2020	Intratumoral generation of ADO depends on the sequential catabolism of ATP by two ecto-nucleotidases, CD39 (ATP   AMP) and CD73 (AMP   ADO).	Adenosine	27-30	5'-nucleotidase ecto	Homo sapiens	123-127
32614585-2	2020	Intratumoral generation of ADO depends on the sequential catabolism of ATP by two ecto-nucleotidases, CD39 (ATP   AMP) and CD73 (AMP   ADO).	Adenosine Triphosphate	71-74	5'-nucleotidase ecto	Homo sapiens	123-127
32614585-2	2020	Intratumoral generation of ADO depends on the sequential catabolism of ATP by two ecto-nucleotidases, CD39 (ATP   AMP) and CD73 (AMP   ADO).	Adenosine	135-138	5'-nucleotidase ecto	Homo sapiens	123-127
32614585-3	2020	Inhibition of CD73 eliminates a major pathway of ADO production in the TME and can reverse ADO-mediated immune suppression.	Adenosine	49-52	5'-nucleotidase ecto	Homo sapiens	14-18
32614585-3	2020	Inhibition of CD73 eliminates a major pathway of ADO production in the TME and can reverse ADO-mediated immune suppression.	Adenosine	91-94	5'-nucleotidase ecto	Homo sapiens	14-18
32614585-4	2020	Extensive interrogation of structure-activity relationships (SARs), structure-based drug design, and optimization of pharmacokinetic properties culminated in the discovery of AB680, a highly potent (Ki = 5 pM), reversible, and selective inhibitor of CD73.	AB-680	175-180	5'-nucleotidase ecto	Homo sapiens	250-254
33123122-5	2020	We show here in primary tumors from non-small cell lung cancer (NSCLC) patients that MICs express higher levels of immunoregulatory molecules compared to tumor bulk, namely PD-L1 and CD73, an ectoenzyme that catalyzes the production of immunosuppressive adenosine, suggesting an enhanced ability of MICs to escape immune responses.	Adenosine	254-263	5'-nucleotidase ecto	Homo sapiens	183-187
32847938-0	2020	An IL6-Adenosine Positive Feedback Loop between CD73+ gammadeltaTregs and CAFs Promotes Tumor Progression in Human Breast Cancer.	gammadeltatregs	54-69	5'-nucleotidase ecto	Homo sapiens	48-52
32847938-2	2020	In this study, we documented that tumor-infiltrating CD73+ gammadeltaTregs were the predominant Tregs in human breast cancer and exerted more potent immunosuppressive activity than CD4+ or CD8+ Tregs.	tregs	69-74	5'-nucleotidase ecto	Homo sapiens	53-57
32847938-4	2020	CD73+ gammadeltaTregs could in turn promote IL6 secretion by CAFs through adenosine/A2BR/p38MAPK signaling, thereby forming an IL6-adenosine positive feedback loop.	gammadeltatregs	6-21	5'-nucleotidase ecto	Homo sapiens	0-4
32847938-4	2020	CD73+ gammadeltaTregs could in turn promote IL6 secretion by CAFs through adenosine/A2BR/p38MAPK signaling, thereby forming an IL6-adenosine positive feedback loop.	Adenosine	74-83	5'-nucleotidase ecto	Homo sapiens	0-4
32847938-4	2020	CD73+ gammadeltaTregs could in turn promote IL6 secretion by CAFs through adenosine/A2BR/p38MAPK signaling, thereby forming an IL6-adenosine positive feedback loop.	Adenosine	131-140	5'-nucleotidase ecto	Homo sapiens	0-4
32847938-5	2020	CD73+ gammadeltaTreg infiltration also impaired the tumoricidal functions of CD8+ T cells and significantly correlated with worse prognosis of patients.	gammadeltatreg	6-20	5'-nucleotidase ecto	Homo sapiens	0-4
32847938-6	2020	The data indicate that the IL6-adenosine loop between CD73+ gammadeltaTregs and CAFs is important to promote immunosuppression and tumor progression in human breast cancer, which may be critical for tumor immunotherapy.	Adenosine	31-40	5'-nucleotidase ecto	Homo sapiens	54-58
32755765-2	2020	Elevated expression of CD73 and CD39 is correlated with the over-production of adenosine in the tumor region.	Adenosine	79-88	5'-nucleotidase ecto	Homo sapiens	23-27
32717399-7	2020	ATP is metabolized to its derivatives by ectonucleotidases such as CD39 and CD73; ATP and its metabolites modulate neuronal and immune mechanisms through P1 and P2 purinergic receptors that are involved in pathophysiological mechanisms of neuroinfections.	Adenosine Triphosphate	0-3	5'-nucleotidase ecto	Homo sapiens	76-80
32717399-7	2020	ATP is metabolized to its derivatives by ectonucleotidases such as CD39 and CD73; ATP and its metabolites modulate neuronal and immune mechanisms through P1 and P2 purinergic receptors that are involved in pathophysiological mechanisms of neuroinfections.	Adenosine Triphosphate	82-85	5'-nucleotidase ecto	Homo sapiens	76-80
32865411-0	2020	Orally Bioavailable Small Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression Through Blockade of Adenosine Production.	Adenosine	107-116	5'-nucleotidase ecto	Homo sapiens	35-39
32865411-2	2020	In this pathway, ecto-5-nucleotidase CD73 has the unique function of regulating production of immunosuppressive adenosine (ADO) through the hydrolysis of AMP.	Adenosine	112-121	5'-nucleotidase ecto	Homo sapiens	17-36
32865411-2	2020	In this pathway, ecto-5-nucleotidase CD73 has the unique function of regulating production of immunosuppressive adenosine (ADO) through the hydrolysis of AMP.	Adenosine	112-121	5'-nucleotidase ecto	Homo sapiens	37-41
32865411-2	2020	In this pathway, ecto-5-nucleotidase CD73 has the unique function of regulating production of immunosuppressive adenosine (ADO) through the hydrolysis of AMP.	Adenosine	123-126	5'-nucleotidase ecto	Homo sapiens	17-36
32865411-2	2020	In this pathway, ecto-5-nucleotidase CD73 has the unique function of regulating production of immunosuppressive adenosine (ADO) through the hydrolysis of AMP.	Adenosine	123-126	5'-nucleotidase ecto	Homo sapiens	37-41
32865411-2	2020	In this pathway, ecto-5-nucleotidase CD73 has the unique function of regulating production of immunosuppressive adenosine (ADO) through the hydrolysis of AMP.	Adenosine Monophosphate	154-157	5'-nucleotidase ecto	Homo sapiens	17-36
32865411-2	2020	In this pathway, ecto-5-nucleotidase CD73 has the unique function of regulating production of immunosuppressive adenosine (ADO) through the hydrolysis of AMP.	Adenosine Monophosphate	154-157	5'-nucleotidase ecto	Homo sapiens	37-41
32865411-3	2020	CD73 is overexpressed in many cancers, resulting in elevated levels of ADO that corresponds to poor patient prognosis.	Adenosine	71-74	5'-nucleotidase ecto	Homo sapiens	0-4
32865411-4	2020	Therefore, reducing the level of ADO via inhibition of CD73 is a potential strategy for treating cancers.	Adenosine	33-36	5'-nucleotidase ecto	Homo sapiens	55-59
32865411-5	2020	Based on the binding mode of adenosine 5"-( , -methylene)diphosphate (AOPCP) with human CD73, we designed a series of novel monophosphonate small molecule CD73 inhibitors.	Adenosine	29-38	5'-nucleotidase ecto	Homo sapiens	88-92
32981507-1	2021	AIMS: The present study was conducted to examine the inhibitory effects of synthesized sulfonylhydrazones on the expression of CD73 (ecto-5"-NT).	sulfonylhydrazones	87-105	5'-nucleotidase ecto	Homo sapiens	127-131
32981507-2	2021	BACKGROUND: CD73 (ecto-5"-NT) represents the most significant class of ecto-nucleotidases which are mainly responsible for dephosphorylation of adenosine monophosphate to adenosine.	Adenosine	144-153	5'-nucleotidase ecto	Homo sapiens	12-16
32981507-2	2021	BACKGROUND: CD73 (ecto-5"-NT) represents the most significant class of ecto-nucleotidases which are mainly responsible for dephosphorylation of adenosine monophosphate to adenosine.	Adenosine	171-180	5'-nucleotidase ecto	Homo sapiens	12-16
32981507-5	2021	METHODS: All sulfonylhydrazones (3a-3i) were evaluated for their inhibitory activity towards CD73 (ecto-5"-NT) by the malachite green assay and their cytotoxic effect was investigated on HeLa cell line using MTT assay.	sulfonylhydrazones	13-31	5'-nucleotidase ecto	Homo sapiens	93-97
32981507-12	2021	Additionally, compound 3h was further investigated for its effect on expression of CD73 using qRT-PCR and western blot.	Tritium	23-25	5'-nucleotidase ecto	Homo sapiens	83-87
33072107-1	2020	The ectoenzymes CD39 and CD73 play a major role in controlling tissue inflammation by regulating the balance between adenosine triphosphate (ATP) and adenosine.	Adenosine	117-126	5'-nucleotidase ecto	Homo sapiens	25-29
33072107-1	2020	The ectoenzymes CD39 and CD73 play a major role in controlling tissue inflammation by regulating the balance between adenosine triphosphate (ATP) and adenosine.	Adenosine Triphosphate	141-144	5'-nucleotidase ecto	Homo sapiens	25-29
33072107-1	2020	The ectoenzymes CD39 and CD73 play a major role in controlling tissue inflammation by regulating the balance between adenosine triphosphate (ATP) and adenosine.	Adenosine	150-159	5'-nucleotidase ecto	Homo sapiens	25-29
32865411-5	2020	Based on the binding mode of adenosine 5"-( , -methylene)diphosphate (AOPCP) with human CD73, we designed a series of novel monophosphonate small molecule CD73 inhibitors.	Adenosine	29-38	5'-nucleotidase ecto	Homo sapiens	155-159
32865411-5	2020	Based on the binding mode of adenosine 5"-( , -methylene)diphosphate (AOPCP) with human CD73, we designed a series of novel monophosphonate small molecule CD73 inhibitors.	alpha,beta-methyleneadenosine 5'-diphosphate	70-75	5'-nucleotidase ecto	Homo sapiens	88-92
32865411-5	2020	Based on the binding mode of adenosine 5"-( , -methylene)diphosphate (AOPCP) with human CD73, we designed a series of novel monophosphonate small molecule CD73 inhibitors.	alpha,beta-methyleneadenosine 5'-diphosphate	70-75	5'-nucleotidase ecto	Homo sapiens	155-159
32865411-5	2020	Based on the binding mode of adenosine 5"-( , -methylene)diphosphate (AOPCP) with human CD73, we designed a series of novel monophosphonate small molecule CD73 inhibitors.	monophosphonate	124-139	5'-nucleotidase ecto	Homo sapiens	88-92
32865411-5	2020	Based on the binding mode of adenosine 5"-( , -methylene)diphosphate (AOPCP) with human CD73, we designed a series of novel monophosphonate small molecule CD73 inhibitors.	monophosphonate	124-139	5'-nucleotidase ecto	Homo sapiens	155-159
33013365-0	2020	Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors.	6-N,N-diethyl-beta,gamma-dibromomethylene-D-ATP	18-26	5'-nucleotidase ecto	Homo sapiens	89-93
32574672-3	2020	Herein, a delivery system was developed for silencing CD73 and HIF-1alpha gene using siRNA-loaded Superparamagnetic iron oxide (SPION) nanocarriers for cancer treatment.	ferric oxide	116-126	5'-nucleotidase ecto	Homo sapiens	54-58
32574672-7	2020	TAT-conjugated TMC-TC-SPIONs containing siRNAs could significantly reduce the HIF-1alpha and CD73 expression levels in cancer cells.	tmc-tc-spions	15-28	5'-nucleotidase ecto	Homo sapiens	93-97
32943546-4	2020	We developed two novel series of CD73 antibody Ab001/Ab002 and humanized version Hu001/Hu0002, which demonstrated high CD73 binding affinity, potent enzyme inhibition and efficiently protected effector T lymphocyte function from adenosine/cancer-imposed toxicity.	Adenosine	229-238	5'-nucleotidase ecto	Homo sapiens	33-37
33013365-2	2020	They increase the extracellular concentration of immunostimulatory ATP and reduce the formation of AMP, which can be further hydrolyzed by ecto-5"-nucleotidase (CD73) to immunosuppressive, cancer-promoting adenosine.	Adenosine Triphosphate	67-70	5'-nucleotidase ecto	Homo sapiens	161-165
33013365-2	2020	They increase the extracellular concentration of immunostimulatory ATP and reduce the formation of AMP, which can be further hydrolyzed by ecto-5"-nucleotidase (CD73) to immunosuppressive, cancer-promoting adenosine.	Adenosine Monophosphate	99-102	5'-nucleotidase ecto	Homo sapiens	139-159
33013365-2	2020	They increase the extracellular concentration of immunostimulatory ATP and reduce the formation of AMP, which can be further hydrolyzed by ecto-5"-nucleotidase (CD73) to immunosuppressive, cancer-promoting adenosine.	Adenosine Monophosphate	99-102	5'-nucleotidase ecto	Homo sapiens	161-165
33013365-2	2020	They increase the extracellular concentration of immunostimulatory ATP and reduce the formation of AMP, which can be further hydrolyzed by ecto-5"-nucleotidase (CD73) to immunosuppressive, cancer-promoting adenosine.	Adenosine	206-215	5'-nucleotidase ecto	Homo sapiens	139-159
33013365-2	2020	They increase the extracellular concentration of immunostimulatory ATP and reduce the formation of AMP, which can be further hydrolyzed by ecto-5"-nucleotidase (CD73) to immunosuppressive, cancer-promoting adenosine.	Adenosine	206-215	5'-nucleotidase ecto	Homo sapiens	161-165
33013365-10	2020	The present study provides a full characterization of the frequently applied CD39 inhibitor ARL67156, presents structure-activity relationships, and provides a basis for future optimization towards selective CD39 and dual CD39/CD73 inhibitors.	6-N,N-diethyl-beta,gamma-dibromomethylene-D-ATP	92-100	5'-nucleotidase ecto	Homo sapiens	227-231
33214837-1	2020	Ecto-5"-nucleotidase (CD73) catalyzes the hydrolysis of AMP to anti-inflammatory, immunosuppressive adenosine.	Adenosine Monophosphate	56-59	5'-nucleotidase ecto	Homo sapiens	0-20
33214837-1	2020	Ecto-5"-nucleotidase (CD73) catalyzes the hydrolysis of AMP to anti-inflammatory, immunosuppressive adenosine.	Adenosine Monophosphate	56-59	5'-nucleotidase ecto	Homo sapiens	22-26
33214837-1	2020	Ecto-5"-nucleotidase (CD73) catalyzes the hydrolysis of AMP to anti-inflammatory, immunosuppressive adenosine.	Adenosine	100-109	5'-nucleotidase ecto	Homo sapiens	0-20
33214837-1	2020	Ecto-5"-nucleotidase (CD73) catalyzes the hydrolysis of AMP to anti-inflammatory, immunosuppressive adenosine.	Adenosine	100-109	5'-nucleotidase ecto	Homo sapiens	22-26
33214837-3	2020	In the present study we designed and synthesized fluorescent-labeled CD73 inhibitors with low nanomolar affinity and high selectivity based on N 6 -benzyl-alpha,beta-methylene-ADP (PSB-12379) as a lead structure.	n 6 -benzyl-alpha,beta-methylene-adp	143-179	5'-nucleotidase ecto	Homo sapiens	69-73
33214837-3	2020	In the present study we designed and synthesized fluorescent-labeled CD73 inhibitors with low nanomolar affinity and high selectivity based on N 6 -benzyl-alpha,beta-methylene-ADP (PSB-12379) as a lead structure.	PSB-12379	181-190	5'-nucleotidase ecto	Homo sapiens	69-73
33214837-4	2020	Fluorescein was attached to the benzyl residue via different linkers resulting in PSB-19416 (14b, K i 12.6 nM) and PSB-18332 (14a, K i 2.98 nM) as fluorescent high-affinity probes for CD73.	Fluorescein	0-11	5'-nucleotidase ecto	Homo sapiens	184-188
32721947-6	2020	RESULTS: In glioma patients, the adenosine-CD73-CD39 immune suppressive pathway was most frequently expressed, followed by PD-1.	Adenosine	33-42	5'-nucleotidase ecto	Homo sapiens	43-47
32739778-0	2020	Preventing ATP Degradation by ASO-Mediated Knockdown of CD39 and CD73 Results in A2aR-Independent Rescue of T Cell Proliferation.	Adenosine Triphosphate	11-14	5'-nucleotidase ecto	Homo sapiens	65-69
32739778-0	2020	Preventing ATP Degradation by ASO-Mediated Knockdown of CD39 and CD73 Results in A2aR-Independent Rescue of T Cell Proliferation.	Oligonucleotides, Antisense	30-33	5'-nucleotidase ecto	Homo sapiens	65-69
32721947-7	2020	CD73 expression was upregulated on immune cells by 2-hydroxygluterate in IDH1 mutant glioma patients.	2-hydroxygluterate	51-69	5'-nucleotidase ecto	Homo sapiens	0-4
32739778-2	2020	The ectonucleotidase CD39 degrades extracellular adenosine triphosphate (ATP) to adenosine monophosphate (AMP), which is degraded to adenosine by CD73.	Adenosine	49-58	5'-nucleotidase ecto	Homo sapiens	146-150
32739778-2	2020	The ectonucleotidase CD39 degrades extracellular adenosine triphosphate (ATP) to adenosine monophosphate (AMP), which is degraded to adenosine by CD73.	Adenosine Triphosphate	73-76	5'-nucleotidase ecto	Homo sapiens	146-150
32585229-0	2020	The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma.	Adenosine	61-70	5'-nucleotidase ecto	Homo sapiens	48-52
32739778-2	2020	The ectonucleotidase CD39 degrades extracellular adenosine triphosphate (ATP) to adenosine monophosphate (AMP), which is degraded to adenosine by CD73.	Adenosine	81-90	5'-nucleotidase ecto	Homo sapiens	146-150
32739778-2	2020	The ectonucleotidase CD39 degrades extracellular adenosine triphosphate (ATP) to adenosine monophosphate (AMP), which is degraded to adenosine by CD73.	Adenosine Monophosphate	106-109	5'-nucleotidase ecto	Homo sapiens	146-150
32739778-2	2020	The ectonucleotidase CD39 degrades extracellular adenosine triphosphate (ATP) to adenosine monophosphate (AMP), which is degraded to adenosine by CD73.	Adenosine	81-90	5'-nucleotidase ecto	Homo sapiens	146-150
32739778-5	2020	CD39 and CD73 expression were suppressed using antisense oligonucleotides (ASOs), and A2aR was blocked using small molecules.	Oligonucleotides	57-73	5'-nucleotidase ecto	Homo sapiens	9-13
32739778-5	2020	CD39 and CD73 expression were suppressed using antisense oligonucleotides (ASOs), and A2aR was blocked using small molecules.	Oligonucleotides, Antisense	75-79	5'-nucleotidase ecto	Homo sapiens	9-13
32739778-11	2020	Therefore, inhibition of CD39 and/or CD73 has evident advantages over A2aR blockade to fully revert suppression of antitumor immune responses by the adenosine axis.	Adenosine	149-158	5'-nucleotidase ecto	Homo sapiens	37-41
32585229-3	2020	Overaccumulation of CD73-derived adenosine through interaction with its four G coupled receptors (A1AR, A2AAR, A2BAR, and A3AR) mediate tumor growth, immune suppression, angiogenesis, and metastasis.	Adenosine	33-42	5'-nucleotidase ecto	Homo sapiens	20-24
32585229-6	2020	Then, we depict the metabolism and signaling of CD73-derived adenosine along with its progressive role in development of melanoma.	Adenosine	61-70	5'-nucleotidase ecto	Homo sapiens	48-52
32585229-7	2020	Furthermore, the therapeutic potentials of CD73 -adenosine axis targeting is assessed in both preclinical and clinical studies.	Adenosine	49-58	5'-nucleotidase ecto	Homo sapiens	43-47
32585229-8	2020	Targeting CD73-derived adenosine via small molecule inhibitor or monoclonal antibodies studies especially in combination with immune checkpoint blockers including PD-1 and CTLA-4 have shown desirable results for management of melanoma in preclinical studies and several clinical trials have recently been started to evaluate the therapeutic potential of CD73-derived adenosine targeting in solid tumors.	Adenosine	23-32	5'-nucleotidase ecto	Homo sapiens	10-14
32585229-8	2020	Targeting CD73-derived adenosine via small molecule inhibitor or monoclonal antibodies studies especially in combination with immune checkpoint blockers including PD-1 and CTLA-4 have shown desirable results for management of melanoma in preclinical studies and several clinical trials have recently been started to evaluate the therapeutic potential of CD73-derived adenosine targeting in solid tumors.	Adenosine	23-32	5'-nucleotidase ecto	Homo sapiens	354-358
32585229-8	2020	Targeting CD73-derived adenosine via small molecule inhibitor or monoclonal antibodies studies especially in combination with immune checkpoint blockers including PD-1 and CTLA-4 have shown desirable results for management of melanoma in preclinical studies and several clinical trials have recently been started to evaluate the therapeutic potential of CD73-derived adenosine targeting in solid tumors.	Adenosine	367-376	5'-nucleotidase ecto	Homo sapiens	10-14
32585229-9	2020	Indeed, targeting of CD73-derived adenosine signaling could be considered as a new therapeutic target in melanoma.	Adenosine	34-43	5'-nucleotidase ecto	Homo sapiens	21-25
32641760-3	2020	The functional activities of ectonucleotidases such as CD39 and CD73, which hydrolyse pro-inflammatory ATP to generate immunosuppressive adenosine, are therefore pivotal in acute inflammation.	Adenosine Triphosphate	103-106	5'-nucleotidase ecto	Homo sapiens	64-68
32641760-3	2020	The functional activities of ectonucleotidases such as CD39 and CD73, which hydrolyse pro-inflammatory ATP to generate immunosuppressive adenosine, are therefore pivotal in acute inflammation.	Adenosine	137-146	5'-nucleotidase ecto	Homo sapiens	64-68
32973513-2	2020	The products are subsequently hydrolyzed by ecto-5"-nucleotidase (ecto-5"-NT) to nucleosides.	Nucleosides	81-92	5'-nucleotidase ecto	Homo sapiens	44-64
33747526-11	2021	Regulation of the CD39/CD73/adenosine pathway using metformin may represent a therapeutic option to reverse HBV-induced immune pathogenesis.	Metformin	52-61	5'-nucleotidase ecto	Homo sapiens	23-27
32856128-4	2020	Insights from other mineralization disorders suggest that local and systemic phosphate metabolism pathways involving the ABCC6, ENPP1, and NT5E genes play a critical role in regulation of ectopic calcification.	Phosphates	77-86	5'-nucleotidase ecto	Homo sapiens	139-143
33747526-0	2021	Skewed CD39/CD73/adenosine pathway contributes to B-cell hyperactivation and disease progression in patients with chronic hepatitis B.	Adenosine	17-26	5'-nucleotidase ecto	Homo sapiens	12-16
33747526-8	2021	In vitro, B-cells from CHB patients showed a markedly reduced capacity to generate CD39/CD73-dependent extracellular adenosine and expressed increased levels of activation markers after adenosine-production blockade.	Adenosine	117-126	5'-nucleotidase ecto	Homo sapiens	88-92
33747526-10	2021	Conclusions: The skewed CD39 and CD73 expression on B-cells was associated with a high viral burden, liver inflammation, and antiviral efficacy in CHB patients, and the skewed CD39/CD73/adenosine pathway contributed to B-cell hyperactivation.	Adenosine	186-195	5'-nucleotidase ecto	Homo sapiens	33-37
32760402-4	2020	Indeed, besides immune checkpoint receptors and their ligands, other mechanisms inducing immunosuppression and including adenosine produced by ecto-nucleotidases CD39 and CD73 contribute to lung tumorigenesis and progression.	Adenosine	121-130	5'-nucleotidase ecto	Homo sapiens	171-175
32824670-8	2020	While in mesenchymal GSCs, both CD73 and Prostatic Acid Phosphatase (PAP) contribute to the AMP (adenosine monophosphate) hydrolysis.	Adenosine Monophosphate	92-95	5'-nucleotidase ecto	Homo sapiens	32-36
32824670-8	2020	While in mesenchymal GSCs, both CD73 and Prostatic Acid Phosphatase (PAP) contribute to the AMP (adenosine monophosphate) hydrolysis.	Adenosine	97-106	5'-nucleotidase ecto	Homo sapiens	32-36
32643277-1	2020	CD73 is a glycosylphosphatidylinositol (GPI)-anchored protein that attenuates tumour immunity via cooperating with CD39 to generate immunosuppressive adenosine.	Adenosine	150-159	5'-nucleotidase ecto	Homo sapiens	0-4
32643277-6	2020	Then, Metascape analysis and GSEA showed that CD73 may play an important role in PC progression and immune regulations.	gsea	29-33	5'-nucleotidase ecto	Homo sapiens	46-50
32556945-7	2020	Immortalized cells upregulated the CD39/NTPDase1 enzyme and downregulated CD73/NT5E and adenosine deaminase (ADA), which had a direct impact on their nucleotide/nucleoside metabolism profile.	Nucleosides	161-171	5'-nucleotidase ecto	Homo sapiens	79-83
32402802-5	2020	Further, the chromen-2-one based molecule 5a showed excellent activity against h-ecto 5"-NT (human ecto-5"-nucleotidase) with IC50 value of 0.29 +- 0.004 microM compared to standard, sulfamic acid (IC50 = 42.1 +- 7.8 microM).	coumarin	13-26	5'-nucleotidase ecto	Homo sapiens	99-119
32289379-3	2020	We evaluated the role of TGF-beta on NT5E gene expression coding for the ecto-5`-nucleotidase CD73, the limiting enzyme in extracellular adenosine production.	Adenosine	137-146	5'-nucleotidase ecto	Homo sapiens	37-41
32289379-3	2020	We evaluated the role of TGF-beta on NT5E gene expression coding for the ecto-5`-nucleotidase CD73, the limiting enzyme in extracellular adenosine production.	Adenosine	137-146	5'-nucleotidase ecto	Homo sapiens	73-93
32289379-3	2020	We evaluated the role of TGF-beta on NT5E gene expression coding for the ecto-5`-nucleotidase CD73, the limiting enzyme in extracellular adenosine production.	Adenosine	137-146	5'-nucleotidase ecto	Homo sapiens	94-98
32289379-4	2020	We showed that high d-glucose may predispose HK-2 cells towards active transcription of the proximal promoter region of the NT5E gene while additional TGF-beta results in full activation.	Glucose	22-29	5'-nucleotidase ecto	Homo sapiens	124-128
32402802-5	2020	Further, the chromen-2-one based molecule 5a showed excellent activity against h-ecto 5"-NT (human ecto-5"-nucleotidase) with IC50 value of 0.29 +- 0.004 microM compared to standard, sulfamic acid (IC50 = 42.1 +- 7.8 microM).	sulfamic acid	183-196	5'-nucleotidase ecto	Homo sapiens	99-119
32402802-5	2020	Further, the chromen-2-one based molecule 5a showed excellent activity against h-ecto 5"-NT (human ecto-5"-nucleotidase) with IC50 value of 0.29 +- 0.004 microM compared to standard, sulfamic acid (IC50 = 42.1 +- 7.8 microM).	h-ecto 5"-nt	79-91	5'-nucleotidase ecto	Homo sapiens	99-119
32313990-7	2020	By contrast, the ecto-phosphodiesterase inhibitor DPSPX (1,3-dipropyl-8-sulfophenylxanthine) and the CD73 ecto-5"-nucleotidase inhibitor AMP-CP (adenosine 5"-(alpha,beta-methylene)diphosphate) were not protective.	alpha,beta-methyleneadenosine 5'-diphosphate	137-143	5'-nucleotidase ecto	Homo sapiens	101-105
32115260-6	2020	Furthermore, treatment of LPS-DCs with quercetin resulted in a reduced production of the pro-inflammatory cytokine IL-12p70 and in an increased expression of the immunoregulatory molecules disabled adaptor protein (Dab) 2, immunoglobulin-like transcript (ILT)-3, ILT4, ILT5 as well as ectonucleotidases CD39 and CD73, thereby inducing a tolerogenic phenotype in quercetin-treated maturing DCs.	Quercetin	39-48	5'-nucleotidase ecto	Homo sapiens	312-316
32266820-1	2020	CD73 is a membrane-bound enzyme that catalyzes the extracellular conversion of adenosine monophosphate to adenosine.	Adenosine Monophosphate	79-102	5'-nucleotidase ecto	Homo sapiens	0-4
32313990-7	2020	By contrast, the ecto-phosphodiesterase inhibitor DPSPX (1,3-dipropyl-8-sulfophenylxanthine) and the CD73 ecto-5"-nucleotidase inhibitor AMP-CP (adenosine 5"-(alpha,beta-methylene)diphosphate) were not protective.	alpha,beta-methyleneadenosine 5'-diphosphate	137-143	5'-nucleotidase ecto	Homo sapiens	106-126
32266820-1	2020	CD73 is a membrane-bound enzyme that catalyzes the extracellular conversion of adenosine monophosphate to adenosine.	Adenosine	79-88	5'-nucleotidase ecto	Homo sapiens	0-4
32313990-7	2020	By contrast, the ecto-phosphodiesterase inhibitor DPSPX (1,3-dipropyl-8-sulfophenylxanthine) and the CD73 ecto-5"-nucleotidase inhibitor AMP-CP (adenosine 5"-(alpha,beta-methylene)diphosphate) were not protective.	Adenosine	145-154	5'-nucleotidase ecto	Homo sapiens	101-105
32604028-8	2020	In the second case, we built a trajectory file for the ecto-5"-nucleotidase using the LiGRO program to study the carbon alpha pincer angles, to define the secondary structure of the proteins and to analyze the Modevectors.	Carbon	113-119	5'-nucleotidase ecto	Homo sapiens	55-75
32417936-0	2020	CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model.	Temozolomide	28-40	5'-nucleotidase ecto	Homo sapiens	0-4
32312837-2	2020	We previously demonstrated that TGFbeta signaling on myeloid cells regulates expression of CD73, a key enzyme for production of adenosine, a pro-tumorigenic metabolite implicated in regulation of tumor cell behaviors, immune response, and angiogenesis.	Adenosine	128-137	5'-nucleotidase ecto	Homo sapiens	91-95
32312837-9	2020	This discovered crosstalk between TGFbeta/CD73 on myeloid cells and TGFbeta signaling on fibroblasts can contribute to ECM remodeling and pro-tumorigenic actions of CAF.	cafestol palmitate	165-168	5'-nucleotidase ecto	Homo sapiens	42-46
32417936-3	2020	CD73, an enzyme responsible for adenosine production, emerges as a target for glioblastoma treatment.	Adenosine	32-41	5'-nucleotidase ecto	Homo sapiens	0-4
32417936-4	2020	Indeed, adenosine causes tumor-promoting actions and CD73 inhibition increases sensitivity to TMZ in vitro.	Temozolomide	94-97	5'-nucleotidase ecto	Homo sapiens	53-57
32165041-0	2020	Structural investigation on thiazolo[5,4-d]pyrimidines to obtain dual-acting blockers of CD73 and adenosine A2A receptor as potential antitumor agents.	thiazolo[5,4-d]pyrimidines	28-54	5'-nucleotidase ecto	Homo sapiens	89-93
32489531-0	2020	CD73+ extracellular vesicles inhibit angiogenesis through adenosine A2B receptor signalling.	Adenosine	58-67	5'-nucleotidase ecto	Homo sapiens	0-4
32165041-1	2020	Adenosine pathway, including its generating enzyme (CD73) and its receptors represents a key target for cancer immunotherapy.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	52-56
32165041-3	2020	The design project was to combine in the same molecule the thiazolo[5,4-d]pyrimidine core, an essential pharmacophoric feature to block the A2A AR, with a benzenesulfonamide group which is a characteristic group of CD73 inhibitors.	benzenesulfonamide	155-173	5'-nucleotidase ecto	Homo sapiens	215-219
32409420-11	2020	A CD39 inhibitor, POM-1, and an anti-CD73 antibody inhibited adenosine production and reduced T-cell suppression in vitro in coculture of myeloma and stromal cells.	Adenosine	61-70	5'-nucleotidase ecto	Homo sapiens	37-41
31953314-1	2020	PURPOSE: There are several agents in early clinical trials targeting components of the adenosine pathway including A2AR and CD73.	Adenosine	87-96	5'-nucleotidase ecto	Homo sapiens	124-128
32141895-5	2020	RECENT FINDINGS: Initial studies showed that elevated soluble CD73 (sCD73, converts AMP to adenosine) results in increased circulating adenosine that activates the A2B adenosine receptor (ADORA2B).	Adenosine Monophosphate	84-87	5'-nucleotidase ecto	Homo sapiens	62-66
32141895-5	2020	RECENT FINDINGS: Initial studies showed that elevated soluble CD73 (sCD73, converts AMP to adenosine) results in increased circulating adenosine that activates the A2B adenosine receptor (ADORA2B).	Adenosine	91-100	5'-nucleotidase ecto	Homo sapiens	62-66
32141895-5	2020	RECENT FINDINGS: Initial studies showed that elevated soluble CD73 (sCD73, converts AMP to adenosine) results in increased circulating adenosine that activates the A2B adenosine receptor (ADORA2B).	Adenosine	135-144	5'-nucleotidase ecto	Homo sapiens	62-66
32409420-0	2020	Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.	Adenosine Triphosphate	14-17	5'-nucleotidase ecto	Homo sapiens	43-47
32409420-0	2020	Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.	Adenosine	21-30	5'-nucleotidase ecto	Homo sapiens	43-47
32409420-3	2020	CD39 and CD73 convert extracellular ATP to adenosine, which inhibits T-cell effector functions via the adenosine receptor A2A (A2AR).	Adenosine Triphosphate	36-39	5'-nucleotidase ecto	Homo sapiens	9-13
32409420-3	2020	CD39 and CD73 convert extracellular ATP to adenosine, which inhibits T-cell effector functions via the adenosine receptor A2A (A2AR).	Adenosine	43-52	5'-nucleotidase ecto	Homo sapiens	9-13
32363113-3	2020	We assessed whether CD73, the rate limiting enzyme that catalyzes the degradation of extracellular AMP into immunosuppressive adenosine, could be an immunological determinant of colorectal liver metastases (CRLMs).	Adenosine Monophosphate	99-102	5'-nucleotidase ecto	Homo sapiens	20-24
32344922-3	2020	One of the dominant pathways generating extracellular adenosine involves the dephosphorylation of ATP by ecto-nucleotidases CD39 and CD73, which efficiently hydrolyze extracellular ATP to adenosine.	Adenosine	54-63	5'-nucleotidase ecto	Homo sapiens	133-137
32344922-3	2020	One of the dominant pathways generating extracellular adenosine involves the dephosphorylation of ATP by ecto-nucleotidases CD39 and CD73, which efficiently hydrolyze extracellular ATP to adenosine.	Adenosine Triphosphate	98-101	5'-nucleotidase ecto	Homo sapiens	133-137
32344922-3	2020	One of the dominant pathways generating extracellular adenosine involves the dephosphorylation of ATP by ecto-nucleotidases CD39 and CD73, which efficiently hydrolyze extracellular ATP to adenosine.	Adenosine Triphosphate	181-184	5'-nucleotidase ecto	Homo sapiens	133-137
32344922-3	2020	One of the dominant pathways generating extracellular adenosine involves the dephosphorylation of ATP by ecto-nucleotidases CD39 and CD73, which efficiently hydrolyze extracellular ATP to adenosine.	Adenosine	188-197	5'-nucleotidase ecto	Homo sapiens	133-137
32345959-4	2020	In addition, CD73+gammadeltaT1 cells exert an immunosuppressive effect via adenosine generation.	Adenosine	75-84	5'-nucleotidase ecto	Homo sapiens	13-17
32212732-2	2020	When upregulated in the tumor microenvironment, CD73 has been implicated in the inhibition of immune function through overproduction of adenosine.	Adenosine	136-145	5'-nucleotidase ecto	Homo sapiens	48-52
32212732-3	2020	Traditional efforts to inhibit CD73 have involved antibody therapy or the development of small molecules, the most potent of which mimic the acidic and ionizable structure of the enzyme"s natural substrate, adenosine 5"-monophosphate (AMP).	adenosine 5"-monophosphate	207-233	5'-nucleotidase ecto	Homo sapiens	31-35
32212732-3	2020	Traditional efforts to inhibit CD73 have involved antibody therapy or the development of small molecules, the most potent of which mimic the acidic and ionizable structure of the enzyme"s natural substrate, adenosine 5"-monophosphate (AMP).	Adenosine Monophosphate	235-238	5'-nucleotidase ecto	Homo sapiens	31-35
32363113-3	2020	We assessed whether CD73, the rate limiting enzyme that catalyzes the degradation of extracellular AMP into immunosuppressive adenosine, could be an immunological determinant of colorectal liver metastases (CRLMs).	Adenosine	126-135	5'-nucleotidase ecto	Homo sapiens	20-24
32363113-10	2020	Our results suggested that CD73 in CRLMs may be prognostically informative and may help select patients more likely to respond to adenosine pathway blocking agents.	Adenosine	130-139	5'-nucleotidase ecto	Homo sapiens	27-31
32351498-1	2020	CD73, a cell surface 5"nucleotidase that generates adenosine, has emerged as an attractive therapeutic target for reprogramming cancer cells and the tumor microenvironment to dampen antitumor immune cell evasion.	Adenosine	51-60	5'-nucleotidase ecto	Homo sapiens	0-4
33457090-1	2020	Synthesis of extracellular adenosine by the ectonucleotidases CD39 and CD73 represents an important pathway of immune suppression in the tumor microenvironment.	Adenosine	27-36	5'-nucleotidase ecto	Homo sapiens	71-75
32280302-2	2020	The concentrations of eATP and ADO in tumor microenvironment (TME) are controlled by ectonucleotidases, such as CD39 and CD73, the major ecto-enzymes expressed on immune cells, endothelial cells and cancer cells.	eatp	22-26	5'-nucleotidase ecto	Homo sapiens	121-125
32280302-2	2020	The concentrations of eATP and ADO in tumor microenvironment (TME) are controlled by ectonucleotidases, such as CD39 and CD73, the major ecto-enzymes expressed on immune cells, endothelial cells and cancer cells.	Adenosine	31-34	5'-nucleotidase ecto	Homo sapiens	121-125
32259773-2	2020	In this study, we analyzed the ability of CeCa cells to produce IL-10 through the CD73-adenosine pathway and its effect on the downregulation of HLA-I molecules to evade CTL-mediated immune recognition.	Adenosine	87-96	5'-nucleotidase ecto	Homo sapiens	82-86
32259773-4	2020	The silencing of CD73 or the blocking of A2BR with the specific antagonist MRS1754 reversed this effect.	N-(4-cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy)acetamide	75-82	5'-nucleotidase ecto	Homo sapiens	17-21
32205841-1	2020	Tumor microenvironment plays vital roles in shaping cancer diversity, and CD73 (ecto-5"-nucleotidase; NT5E) is an emerging immune checkpoint in modulating cancer progression via conversion of immunostimulatory ATP into immunosuppressive adenosine.	Adenosine Triphosphate	210-213	5'-nucleotidase ecto	Homo sapiens	74-78
32061060-1	2020	BACKGROUND: CD73 induces the dephosphorylation of adenosine monophosphate converting it to adenosine, enabling malignancies to escape from immune surveillance.	Adenosine Monophosphate	50-73	5'-nucleotidase ecto	Homo sapiens	12-16
32061060-1	2020	BACKGROUND: CD73 induces the dephosphorylation of adenosine monophosphate converting it to adenosine, enabling malignancies to escape from immune surveillance.	Adenosine	50-59	5'-nucleotidase ecto	Homo sapiens	12-16
32045236-0	2020	2-Substituted alpha,beta-Methylene-ADP Derivatives: Potent Competitive Ecto-5"-nucleotidase (CD73) Inhibitors with Variable Binding Modes.	2-substituted alpha,beta-methylene-adp	0-38	5'-nucleotidase ecto	Homo sapiens	71-91
32045236-0	2020	2-Substituted alpha,beta-Methylene-ADP Derivatives: Potent Competitive Ecto-5"-nucleotidase (CD73) Inhibitors with Variable Binding Modes.	2-substituted alpha,beta-methylene-adp	0-38	5'-nucleotidase ecto	Homo sapiens	93-97
32045236-2	2020	Here, we present the synthesis, structure-activity relationships, and cocrystal structures of novel derivatives of the competitive CD73 inhibitor alpha,beta-methylene-ADP (AOPCP) substituted in the 2-position.	alpha,beta-methyleneadenosine 5'-diphosphate	146-170	5'-nucleotidase ecto	Homo sapiens	131-135
32045236-2	2020	Here, we present the synthesis, structure-activity relationships, and cocrystal structures of novel derivatives of the competitive CD73 inhibitor alpha,beta-methylene-ADP (AOPCP) substituted in the 2-position.	alpha,beta-methyleneadenosine 5'-diphosphate	172-177	5'-nucleotidase ecto	Homo sapiens	131-135
32045236-3	2020	Small polar or lipophilic residues increased potency, 2-iodo- and 2-chloro-adenosine-5"-O-[(phosphonomethyl)phosphonic acid] (15, 16) being the most potent inhibitors with Ki values toward human CD73 of 3-6 nM.	2-iodo- and 2-chloro-adenosine-5"-o-[(phosphonomethyl)phosphonic acid]	54-124	5'-nucleotidase ecto	Homo sapiens	195-199
32045236-5	2020	Depending on the binding mode, large species differences were found, e.g., 2-piperazinyl-AOPCP (21) was >12-fold less potent against rat CD73 compared to human CD73.	2-piperazinyl-aopcp	75-94	5'-nucleotidase ecto	Homo sapiens	160-164
32225110-1	2020	BACKGROUND: CD73 is an ectonucleotidase regulating extracellular adenosine concentration and plays an important role in adenosine-mediated immunosuppressive pathways.	Adenosine	65-74	5'-nucleotidase ecto	Homo sapiens	12-16
32225110-1	2020	BACKGROUND: CD73 is an ectonucleotidase regulating extracellular adenosine concentration and plays an important role in adenosine-mediated immunosuppressive pathways.	Adenosine	120-129	5'-nucleotidase ecto	Homo sapiens	12-16
32225110-7	2020	RESULTS: 111In-labeled 067-213 bound to MIAPaCa-2 and A431 cells in a CD73-dependent manner and the affinity loss after 111In-labeling was limited.	Indium-111	9-14	5'-nucleotidase ecto	Homo sapiens	70-74
32225110-11	2020	CONCLUSIONS: 111In-labeled 067-213 showed CD73-expression-dependent tumor uptake and low uptake in normal organs and tissues.	Indium-111	13-18	5'-nucleotidase ecto	Homo sapiens	42-46
32205841-1	2020	Tumor microenvironment plays vital roles in shaping cancer diversity, and CD73 (ecto-5"-nucleotidase; NT5E) is an emerging immune checkpoint in modulating cancer progression via conversion of immunostimulatory ATP into immunosuppressive adenosine.	Adenosine Triphosphate	210-213	5'-nucleotidase ecto	Homo sapiens	80-100
32205841-1	2020	Tumor microenvironment plays vital roles in shaping cancer diversity, and CD73 (ecto-5"-nucleotidase; NT5E) is an emerging immune checkpoint in modulating cancer progression via conversion of immunostimulatory ATP into immunosuppressive adenosine.	Adenosine Triphosphate	210-213	5'-nucleotidase ecto	Homo sapiens	102-106
32205841-1	2020	Tumor microenvironment plays vital roles in shaping cancer diversity, and CD73 (ecto-5"-nucleotidase; NT5E) is an emerging immune checkpoint in modulating cancer progression via conversion of immunostimulatory ATP into immunosuppressive adenosine.	Adenosine	237-246	5'-nucleotidase ecto	Homo sapiens	74-78
32205841-1	2020	Tumor microenvironment plays vital roles in shaping cancer diversity, and CD73 (ecto-5"-nucleotidase; NT5E) is an emerging immune checkpoint in modulating cancer progression via conversion of immunostimulatory ATP into immunosuppressive adenosine.	Adenosine	237-246	5'-nucleotidase ecto	Homo sapiens	80-100
32205841-1	2020	Tumor microenvironment plays vital roles in shaping cancer diversity, and CD73 (ecto-5"-nucleotidase; NT5E) is an emerging immune checkpoint in modulating cancer progression via conversion of immunostimulatory ATP into immunosuppressive adenosine.	Adenosine	237-246	5'-nucleotidase ecto	Homo sapiens	102-106
32831246-4	2020	The average Te-O coordination number (NTe-O) for 5SrO-95TeO2 glass is 3.93 which decreases to 3.59 on increasing the SrO concentration to 10 mol.%.	sro	50-53	5'-nucleotidase ecto	Homo sapiens	38-41
32160899-3	2020	The aim of this study was to investigate the role of peripheral CD8+T cells expressing CD73, involved in the generation of the immune suppressive molecule adenosine, in predicting outcome after nivolumab treatment in advanced melanoma patients.	Adenosine	155-164	5'-nucleotidase ecto	Homo sapiens	87-91
31940246-6	2020	Zn chelator TPEN treatment reduced the expression of stem cell markers CD73, CD90 and CD105 and generated ROS in endometrial stromal cells.	N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine	12-16	5'-nucleotidase ecto	Homo sapiens	71-75
31868071-7	2020	To detect the production of adenosine by CD73, the Transcreener ADP2 Assay was coupled with adenosine kinase (AK); conversion of adenosine to AMP and adenosine diphosphate (ADP) by AK allows detection with ADP2 antibody.	Adenosine	28-37	5'-nucleotidase ecto	Homo sapiens	41-45
31714079-0	2020	Virtual Screening Approach for the Identification of Hydroxamic Acids as Novel Human Ecto-5"-Nucleotidase Inhibitors.	Hydroxamic Acids	53-69	5'-nucleotidase ecto	Homo sapiens	85-105
31714079-4	2020	Here, we aimed to search for hydroxamic acid-containing compounds as potential human ecto-5"-NT inhibitors, since this group is known to be a strong zinc chelator.	Hydroxamic Acids	29-44	5'-nucleotidase ecto	Homo sapiens	85-95
31714079-10	2020	Furthermore, to the best of our knowledge, they are the first hydroxamic acid-containing inhibitors of human ecto-5"-NT described so far.	Hydroxamic Acids	62-77	5'-nucleotidase ecto	Homo sapiens	109-119
32156055-3	2020	AMP (30 microM) was rapidly (t1/2 3 +- 1 min) dephosphorylated into adenosine by CD73/ecto-5"-nucleotidase.	Adenosine Monophosphate	0-3	5'-nucleotidase ecto	Homo sapiens	81-85
32156055-3	2020	AMP (30 microM) was rapidly (t1/2 3 +- 1 min) dephosphorylated into adenosine by CD73/ecto-5"-nucleotidase.	Adenosine Monophosphate	0-3	5'-nucleotidase ecto	Homo sapiens	86-106
32156055-3	2020	AMP (30 microM) was rapidly (t1/2 3 +- 1 min) dephosphorylated into adenosine by CD73/ecto-5"-nucleotidase.	Adenosine	68-77	5'-nucleotidase ecto	Homo sapiens	81-85
32156055-3	2020	AMP (30 microM) was rapidly (t1/2 3 +- 1 min) dephosphorylated into adenosine by CD73/ecto-5"-nucleotidase.	Adenosine	68-77	5'-nucleotidase ecto	Homo sapiens	86-106
31940246-6	2020	Zn chelator TPEN treatment reduced the expression of stem cell markers CD73, CD90 and CD105 and generated ROS in endometrial stromal cells.	Zinc	0-2	5'-nucleotidase ecto	Homo sapiens	71-75
32057736-7	2020	Recent findings have revealed that both ecto-nucleotidase CD39, a key enzyme hydrolyzing ATP, and CD73, an enzyme regulating adenosine turnover, are involved in the renal vascular injury in diabetes.	Adenosine	125-134	5'-nucleotidase ecto	Homo sapiens	98-102
31955347-4	2020	Considering the relationship between ATP and cancer, we aimed to evaluate the influence of imatinib mesylate on the expressions and functions of the NTPDase and ecto-5"-nucleotidase (CD73) enzymes in imatinib-sensitive and -resistant K-562 cell lines.	Adenosine Triphosphate	37-40	5'-nucleotidase ecto	Homo sapiens	183-187
31955347-4	2020	Considering the relationship between ATP and cancer, we aimed to evaluate the influence of imatinib mesylate on the expressions and functions of the NTPDase and ecto-5"-nucleotidase (CD73) enzymes in imatinib-sensitive and -resistant K-562 cell lines.	imatinib	91-108	5'-nucleotidase ecto	Homo sapiens	161-181
31955347-4	2020	Considering the relationship between ATP and cancer, we aimed to evaluate the influence of imatinib mesylate on the expressions and functions of the NTPDase and ecto-5"-nucleotidase (CD73) enzymes in imatinib-sensitive and -resistant K-562 cell lines.	imatinib	91-108	5'-nucleotidase ecto	Homo sapiens	183-187
31955347-4	2020	Considering the relationship between ATP and cancer, we aimed to evaluate the influence of imatinib mesylate on the expressions and functions of the NTPDase and ecto-5"-nucleotidase (CD73) enzymes in imatinib-sensitive and -resistant K-562 cell lines.	imatinib	91-99	5'-nucleotidase ecto	Homo sapiens	161-181
31955347-4	2020	Considering the relationship between ATP and cancer, we aimed to evaluate the influence of imatinib mesylate on the expressions and functions of the NTPDase and ecto-5"-nucleotidase (CD73) enzymes in imatinib-sensitive and -resistant K-562 cell lines.	imatinib	91-99	5'-nucleotidase ecto	Homo sapiens	183-187
31937477-8	2020	CD73 is an extrinsic protein involved in the generation of adenosine and is overexpressed in several tumors including glioblastoma.	Adenosine	59-68	5'-nucleotidase ecto	Homo sapiens	0-4
32831246-5	2020	The changes in NTe-O revealed that the glass network predominantly contains TeO4 units with a small amount of TeO3 units and there is a structural transformation TeO4   TeO3 with an increase in SrO concentration.	teo4   teo3	162-173	5'-nucleotidase ecto	Homo sapiens	15-18
32831246-5	2020	The changes in NTe-O revealed that the glass network predominantly contains TeO4 units with a small amount of TeO3 units and there is a structural transformation TeO4   TeO3 with an increase in SrO concentration.	sro	194-197	5'-nucleotidase ecto	Homo sapiens	15-18
32129745-0	2020	[A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response].	Adenosine	61-70	5'-nucleotidase ecto	Homo sapiens	56-60
31915882-2	2020	They have an innate and regulatory immune activity, and they are able to produce immunosuppressive adenosine (ADO) via their ectonucleotidases CD39 and CD73.	Adenosine	99-108	5'-nucleotidase ecto	Homo sapiens	152-156
31915882-2	2020	They have an innate and regulatory immune activity, and they are able to produce immunosuppressive adenosine (ADO) via their ectonucleotidases CD39 and CD73.	Adenosine	110-113	5'-nucleotidase ecto	Homo sapiens	152-156
31347162-0	2020	CD73-dependent adenosine dampens interleukin 1beta-induced CXCL8 production in gingival fibroblasts: Association with heme oxygenase-1 and adenosine monophosphate-activated protein kinase.	Adenosine	15-24	5'-nucleotidase ecto	Homo sapiens	0-4
31347162-1	2020	BACKGROUND: During inflammation, stressed or infected cells can release adenosine triphosphate (ATP) to the extracellular medium, which can be hydrolyzed to adenosine by ectonucleotidases such as ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and 5"-nucleotidase (CD73).	Adenosine Triphosphate	72-94	5'-nucleotidase ecto	Homo sapiens	273-277
31347162-1	2020	BACKGROUND: During inflammation, stressed or infected cells can release adenosine triphosphate (ATP) to the extracellular medium, which can be hydrolyzed to adenosine by ectonucleotidases such as ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and 5"-nucleotidase (CD73).	Adenosine Triphosphate	96-99	5'-nucleotidase ecto	Homo sapiens	273-277
31347162-1	2020	BACKGROUND: During inflammation, stressed or infected cells can release adenosine triphosphate (ATP) to the extracellular medium, which can be hydrolyzed to adenosine by ectonucleotidases such as ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and 5"-nucleotidase (CD73).	Adenosine	72-81	5'-nucleotidase ecto	Homo sapiens	273-277
31347162-3	2020	Here, we investigated whether CD73-mediated hydrolysis of extracellular ATP (eATP) could affect interleukin (IL)-1beta-induced CXCL8 secretion.	Adenosine Triphosphate	72-75	5'-nucleotidase ecto	Homo sapiens	30-34
31347162-10	2020	The inhibition of CD73 or the inhibition of adenosine receptors abrogated the ATP effect on CXCL8 secretion.	Adenosine Triphosphate	78-81	5'-nucleotidase ecto	Homo sapiens	18-22
31347162-11	2020	CONCLUSIONS: CD73-generated adenosine dampens IL-1beta-induced CXCL8 in HGFs and involves HO-1 and pAMPK signaling.	Adenosine	28-37	5'-nucleotidase ecto	Homo sapiens	13-17
31985456-16	2020	CONCLUSION: These results provide pharmacological evidence for a contribution of CD73 enzyme-dependent adenosine generation and signaling through ADORA2BR to IPC-mediated tissue protection.	Adenosine	103-112	5'-nucleotidase ecto	Homo sapiens	81-85
31980601-1	2020	CD73, an ecto-5"-nucleotidase (NT5E), serves as an immune checkpoint by generating adenosine (ADO), which suppresses immune activation through the A2A receptor.	Adenosine	83-92	5'-nucleotidase ecto	Homo sapiens	0-4
31980601-1	2020	CD73, an ecto-5"-nucleotidase (NT5E), serves as an immune checkpoint by generating adenosine (ADO), which suppresses immune activation through the A2A receptor.	Adenosine	83-92	5'-nucleotidase ecto	Homo sapiens	9-29
31980601-1	2020	CD73, an ecto-5"-nucleotidase (NT5E), serves as an immune checkpoint by generating adenosine (ADO), which suppresses immune activation through the A2A receptor.	Adenosine	83-92	5'-nucleotidase ecto	Homo sapiens	31-35
31980601-1	2020	CD73, an ecto-5"-nucleotidase (NT5E), serves as an immune checkpoint by generating adenosine (ADO), which suppresses immune activation through the A2A receptor.	Adenosine	94-97	5'-nucleotidase ecto	Homo sapiens	0-4
31980601-1	2020	CD73, an ecto-5"-nucleotidase (NT5E), serves as an immune checkpoint by generating adenosine (ADO), which suppresses immune activation through the A2A receptor.	Adenosine	94-97	5'-nucleotidase ecto	Homo sapiens	9-29
31980601-1	2020	CD73, an ecto-5"-nucleotidase (NT5E), serves as an immune checkpoint by generating adenosine (ADO), which suppresses immune activation through the A2A receptor.	Adenosine	94-97	5'-nucleotidase ecto	Homo sapiens	31-35
31959836-3	2020	The ecto-5"-nucleotidase CD73, an ectoenzyme highly expressed in cancer, is suggested to regulate intracellular NAD+ levels by processing NAD+ and its bio-precursor, nicotinamide mononucleotide (NMN), from tumor microenvironments, thereby enhancing tumor DNA repair capacity and chemotherapy resistance.	NAD	112-115	5'-nucleotidase ecto	Homo sapiens	4-24
31959836-3	2020	The ecto-5"-nucleotidase CD73, an ectoenzyme highly expressed in cancer, is suggested to regulate intracellular NAD+ levels by processing NAD+ and its bio-precursor, nicotinamide mononucleotide (NMN), from tumor microenvironments, thereby enhancing tumor DNA repair capacity and chemotherapy resistance.	NAD	112-115	5'-nucleotidase ecto	Homo sapiens	25-29
31959836-3	2020	The ecto-5"-nucleotidase CD73, an ectoenzyme highly expressed in cancer, is suggested to regulate intracellular NAD+ levels by processing NAD+ and its bio-precursor, nicotinamide mononucleotide (NMN), from tumor microenvironments, thereby enhancing tumor DNA repair capacity and chemotherapy resistance.	NAD	138-141	5'-nucleotidase ecto	Homo sapiens	4-24
31959836-3	2020	The ecto-5"-nucleotidase CD73, an ectoenzyme highly expressed in cancer, is suggested to regulate intracellular NAD+ levels by processing NAD+ and its bio-precursor, nicotinamide mononucleotide (NMN), from tumor microenvironments, thereby enhancing tumor DNA repair capacity and chemotherapy resistance.	NAD	138-141	5'-nucleotidase ecto	Homo sapiens	25-29
31959836-3	2020	The ecto-5"-nucleotidase CD73, an ectoenzyme highly expressed in cancer, is suggested to regulate intracellular NAD+ levels by processing NAD+ and its bio-precursor, nicotinamide mononucleotide (NMN), from tumor microenvironments, thereby enhancing tumor DNA repair capacity and chemotherapy resistance.	Nicotinamide Mononucleotide	166-193	5'-nucleotidase ecto	Homo sapiens	4-24
31959836-3	2020	The ecto-5"-nucleotidase CD73, an ectoenzyme highly expressed in cancer, is suggested to regulate intracellular NAD+ levels by processing NAD+ and its bio-precursor, nicotinamide mononucleotide (NMN), from tumor microenvironments, thereby enhancing tumor DNA repair capacity and chemotherapy resistance.	Nicotinamide Mononucleotide	166-193	5'-nucleotidase ecto	Homo sapiens	25-29
31959836-3	2020	The ecto-5"-nucleotidase CD73, an ectoenzyme highly expressed in cancer, is suggested to regulate intracellular NAD+ levels by processing NAD+ and its bio-precursor, nicotinamide mononucleotide (NMN), from tumor microenvironments, thereby enhancing tumor DNA repair capacity and chemotherapy resistance.	Nicotinamide Mononucleotide	195-198	5'-nucleotidase ecto	Homo sapiens	4-24
31959836-3	2020	The ecto-5"-nucleotidase CD73, an ectoenzyme highly expressed in cancer, is suggested to regulate intracellular NAD+ levels by processing NAD+ and its bio-precursor, nicotinamide mononucleotide (NMN), from tumor microenvironments, thereby enhancing tumor DNA repair capacity and chemotherapy resistance.	Nicotinamide Mononucleotide	195-198	5'-nucleotidase ecto	Homo sapiens	25-29
31959836-4	2020	We therefore investigated whether expression of CD73 impacts intracellular NAD+ content and NAD+-dependent DNA repair capacity.	NAD	75-78	5'-nucleotidase ecto	Homo sapiens	48-52
31959836-4	2020	We therefore investigated whether expression of CD73 impacts intracellular NAD+ content and NAD+-dependent DNA repair capacity.	NAD	92-95	5'-nucleotidase ecto	Homo sapiens	48-52
31959836-8	2020	In opposition to its proposed role in extracellular NAD+ bioprocessing, we found that recombinant human CD73 only poorly processes NMN but not NAD+.	NAD	52-55	5'-nucleotidase ecto	Homo sapiens	104-108
31959836-8	2020	In opposition to its proposed role in extracellular NAD+ bioprocessing, we found that recombinant human CD73 only poorly processes NMN but not NAD+.	Nicotinamide Mononucleotide	131-134	5'-nucleotidase ecto	Homo sapiens	104-108
31959836-8	2020	In opposition to its proposed role in extracellular NAD+ bioprocessing, we found that recombinant human CD73 only poorly processes NMN but not NAD+.	NAD	143-146	5'-nucleotidase ecto	Homo sapiens	104-108
31959836-9	2020	A positive correlation between CD73 expression and intracellular NAD+ content could not be made as CD73 knockout human cells were efficient in generating intracellular NAD+ when supplemented with NAD+ or NMN.	NAD	168-171	5'-nucleotidase ecto	Homo sapiens	99-103
31959836-9	2020	A positive correlation between CD73 expression and intracellular NAD+ content could not be made as CD73 knockout human cells were efficient in generating intracellular NAD+ when supplemented with NAD+ or NMN.	NAD	168-171	5'-nucleotidase ecto	Homo sapiens	99-103
33146056-3	2020	CD39 processes pro-inflammatory extracellular ATP to ADP and AMP, which is then processed by Ecto-5"-nucleotidase/CD73 to immunosuppressive adenosine.	Adenosine Triphosphate	46-49	5'-nucleotidase ecto	Homo sapiens	93-113
33146056-3	2020	CD39 processes pro-inflammatory extracellular ATP to ADP and AMP, which is then processed by Ecto-5"-nucleotidase/CD73 to immunosuppressive adenosine.	Adenosine Triphosphate	46-49	5'-nucleotidase ecto	Homo sapiens	114-118
33146056-3	2020	CD39 processes pro-inflammatory extracellular ATP to ADP and AMP, which is then processed by Ecto-5"-nucleotidase/CD73 to immunosuppressive adenosine.	Adenosine Diphosphate	53-56	5'-nucleotidase ecto	Homo sapiens	93-113
33146056-3	2020	CD39 processes pro-inflammatory extracellular ATP to ADP and AMP, which is then processed by Ecto-5"-nucleotidase/CD73 to immunosuppressive adenosine.	Adenosine Diphosphate	53-56	5'-nucleotidase ecto	Homo sapiens	114-118
33146056-3	2020	CD39 processes pro-inflammatory extracellular ATP to ADP and AMP, which is then processed by Ecto-5"-nucleotidase/CD73 to immunosuppressive adenosine.	Adenosine Monophosphate	61-64	5'-nucleotidase ecto	Homo sapiens	93-113
33146056-3	2020	CD39 processes pro-inflammatory extracellular ATP to ADP and AMP, which is then processed by Ecto-5"-nucleotidase/CD73 to immunosuppressive adenosine.	Adenosine Monophosphate	61-64	5'-nucleotidase ecto	Homo sapiens	114-118
33146056-3	2020	CD39 processes pro-inflammatory extracellular ATP to ADP and AMP, which is then processed by Ecto-5"-nucleotidase/CD73 to immunosuppressive adenosine.	Adenosine	140-149	5'-nucleotidase ecto	Homo sapiens	93-113
33146056-3	2020	CD39 processes pro-inflammatory extracellular ATP to ADP and AMP, which is then processed by Ecto-5"-nucleotidase/CD73 to immunosuppressive adenosine.	Adenosine	140-149	5'-nucleotidase ecto	Homo sapiens	114-118
31847204-4	2019	Other ectoenzymes, CD73 and CD203a, together with CD38, are also involved in the alternative axis of extracellular production of ADO, bypassing the canonical pathway mediated by CD39.	Adenosine	129-132	5'-nucleotidase ecto	Homo sapiens	19-23
31861118-2	2019	It has been recently described that pyrophosphate (a calcification inhibitor) deficiency could be the main cause of ectopic calcifications in this disease and in other genetic disorders associated to mutations of ENPP1 or CD73.	Diphosphates	36-49	5'-nucleotidase ecto	Homo sapiens	222-226
31461341-1	2019	Ecto-5"-nucleotidase [cluster of differentiation 73 (CD73)] is a ubiquitously expressed glycosylphosphatidylinositol-anchored glycoprotein that converts extracellular adenosine 5"-monophosphate to adenosine.	Adenosine	167-176	5'-nucleotidase ecto	Homo sapiens	0-20
31930120-1	2019	Background: Adenosine, derived from the degradation of ATP via ectonucleotidases CD39 and CD73, is a critical immunosuppressive metabolite in the hypoxic microenvironment of tumor tissue.	Adenosine	12-21	5'-nucleotidase ecto	Homo sapiens	90-94
31930120-1	2019	Background: Adenosine, derived from the degradation of ATP via ectonucleotidases CD39 and CD73, is a critical immunosuppressive metabolite in the hypoxic microenvironment of tumor tissue.	Adenosine Triphosphate	55-58	5'-nucleotidase ecto	Homo sapiens	90-94
31930120-11	2019	The process of Treg hydrolysis of ATP into adenosine was blocked by the antagonists of CD39 and CD73.	Adenosine Triphosphate	34-37	5'-nucleotidase ecto	Homo sapiens	96-100
31930120-11	2019	The process of Treg hydrolysis of ATP into adenosine was blocked by the antagonists of CD39 and CD73.	Adenosine	43-52	5'-nucleotidase ecto	Homo sapiens	96-100
31461341-1	2019	Ecto-5"-nucleotidase [cluster of differentiation 73 (CD73)] is a ubiquitously expressed glycosylphosphatidylinositol-anchored glycoprotein that converts extracellular adenosine 5"-monophosphate to adenosine.	Adenosine	197-206	5'-nucleotidase ecto	Homo sapiens	0-20
31401370-0	2019	The NT5E gene variant strongly affects the degradation rate of inosine 5"-monophosphate under postmortem conditions in Japanese Black beef.	inosine 5"-monophosphate	63-87	5'-nucleotidase ecto	Homo sapiens	4-8
31401370-2	2019	In a previous study, it was suggested that single nucleotide polymorphisms (SNPs) in the ecto-5"-nucleotidase (NT5E) gene affect the concentration of IMP under postmortem conditions by regulating NT5E enzymatic activity in Japanese Black beef.	Inosine Monophosphate	150-153	5'-nucleotidase ecto	Homo sapiens	89-109
31401370-2	2019	In a previous study, it was suggested that single nucleotide polymorphisms (SNPs) in the ecto-5"-nucleotidase (NT5E) gene affect the concentration of IMP under postmortem conditions by regulating NT5E enzymatic activity in Japanese Black beef.	Inosine Monophosphate	150-153	5'-nucleotidase ecto	Homo sapiens	111-115
31401370-2	2019	In a previous study, it was suggested that single nucleotide polymorphisms (SNPs) in the ecto-5"-nucleotidase (NT5E) gene affect the concentration of IMP under postmortem conditions by regulating NT5E enzymatic activity in Japanese Black beef.	Inosine Monophosphate	150-153	5'-nucleotidase ecto	Homo sapiens	196-200
31493676-5	2019	Further, we show that, similarly to activation by cancer cell contact, activation by EVs is dependent on the ecto enzyme CD73 that mediates extracellular formation of adenosine and on signaling by the A3 adenosine receptor.	Adenosine	167-176	5'-nucleotidase ecto	Homo sapiens	121-125
31520298-0	2019	The Inhibition of CD39 and CD73 Cell Surface Ectonucleotidases by Small Molecular Inhibitors Enhances the Mobilization of Bone Marrow Residing Stem Cells by Decreasing the Extracellular Level of Adenosine.	Adenosine	195-204	5'-nucleotidase ecto	Homo sapiens	27-31
31684171-0	2019	Methotrexate Restores CD73 Expression on Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis Patients and May Contribute to Its Anti-Inflammatory Effect through Ado Production.	Methotrexate	0-12	5'-nucleotidase ecto	Homo sapiens	22-26
31684171-4	2019	Because Methotrexate (MTX), used as first line treatment of RA and PsA, increases extracellular concentrations of AMP and immunosuppressive adenosine, we investigated the modulation of CD73 by MTX treatment on Teff in RA/PsA patients.	Methotrexate	193-196	5'-nucleotidase ecto	Homo sapiens	185-189
31684171-6	2019	RESULTS: We showed a decreased CD73 expression on Th1.17 and Th1 in untreated patients compared to healthy donors that was partly restored under MTX.	Methotrexate	145-148	5'-nucleotidase ecto	Homo sapiens	31-35
31684171-8	2019	CD73+ Teff remained functional under MTX treatment, but their CD73 re-expression may contribute to control their activation.	Methotrexate	37-40	5'-nucleotidase ecto	Homo sapiens	0-4
31641080-5	2019	Follicular B cells increased the abundance of the cell surface ectonucleotidase CD73, which coincided with adenosine 5"-monophosphate-activated protein kinase (AMPK) activation.	Adenosine Monophosphate	107-133	5'-nucleotidase ecto	Homo sapiens	80-84
31623231-9	2019	Adenosine is either released from stressed or injured cells or generated from extracellular adenine nucleotides by the concerted action of the ectoenzymes ectoapyrase (CD39) and 5" ectonucleotidase (NT5E, CD73) that catabolize ATP to adenosine.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	199-203
31652269-4	2019	The two main enzymes responsible for generating adenosine in the microenvironment are the ectonucleotidases CD39 and CD73, the former utilizes both ATP and ADP and produces AMP while the latter utilizes AMP and generates adenosine.	Adenosine	48-57	5'-nucleotidase ecto	Homo sapiens	117-121
31652269-4	2019	The two main enzymes responsible for generating adenosine in the microenvironment are the ectonucleotidases CD39 and CD73, the former utilizes both ATP and ADP and produces AMP while the latter utilizes AMP and generates adenosine.	Adenosine Triphosphate	148-151	5'-nucleotidase ecto	Homo sapiens	117-121
31652269-4	2019	The two main enzymes responsible for generating adenosine in the microenvironment are the ectonucleotidases CD39 and CD73, the former utilizes both ATP and ADP and produces AMP while the latter utilizes AMP and generates adenosine.	Adenosine Diphosphate	156-159	5'-nucleotidase ecto	Homo sapiens	117-121
31652269-4	2019	The two main enzymes responsible for generating adenosine in the microenvironment are the ectonucleotidases CD39 and CD73, the former utilizes both ATP and ADP and produces AMP while the latter utilizes AMP and generates adenosine.	Adenosine Monophosphate	173-176	5'-nucleotidase ecto	Homo sapiens	117-121
31652269-4	2019	The two main enzymes responsible for generating adenosine in the microenvironment are the ectonucleotidases CD39 and CD73, the former utilizes both ATP and ADP and produces AMP while the latter utilizes AMP and generates adenosine.	Adenosine Monophosphate	203-206	5'-nucleotidase ecto	Homo sapiens	117-121
31652269-4	2019	The two main enzymes responsible for generating adenosine in the microenvironment are the ectonucleotidases CD39 and CD73, the former utilizes both ATP and ADP and produces AMP while the latter utilizes AMP and generates adenosine.	Adenosine	221-230	5'-nucleotidase ecto	Homo sapiens	117-121
31634358-0	2019	Mutual role of ecto-5"-nucleotidase/CD73 and concentrative nucleoside transporter 3 in the intestinal uptake of dAMP.	2'-deoxy-5'-adenosine monophosphate	112-116	5'-nucleotidase ecto	Homo sapiens	15-35
31634358-8	2019	Further, [3H]dAMP uptake was greater in COS-7 cells expressing ecto-5"-nucleotidase/CD73 with CNT3 than in those expressing CNT3 alone.	Tritium	10-12	5'-nucleotidase ecto	Homo sapiens	63-83
31623231-9	2019	Adenosine is either released from stressed or injured cells or generated from extracellular adenine nucleotides by the concerted action of the ectoenzymes ectoapyrase (CD39) and 5" ectonucleotidase (NT5E, CD73) that catabolize ATP to adenosine.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	205-209
31634358-8	2019	Further, [3H]dAMP uptake was greater in COS-7 cells expressing ecto-5"-nucleotidase/CD73 with CNT3 than in those expressing CNT3 alone.	2'-deoxy-5'-adenosine monophosphate	13-17	5'-nucleotidase ecto	Homo sapiens	63-83
31623231-9	2019	Adenosine is either released from stressed or injured cells or generated from extracellular adenine nucleotides by the concerted action of the ectoenzymes ectoapyrase (CD39) and 5" ectonucleotidase (NT5E, CD73) that catabolize ATP to adenosine.	Adenine Nucleotides	92-111	5'-nucleotidase ecto	Homo sapiens	199-203
31623231-9	2019	Adenosine is either released from stressed or injured cells or generated from extracellular adenine nucleotides by the concerted action of the ectoenzymes ectoapyrase (CD39) and 5" ectonucleotidase (NT5E, CD73) that catabolize ATP to adenosine.	Adenine Nucleotides	92-111	5'-nucleotidase ecto	Homo sapiens	205-209
31623231-9	2019	Adenosine is either released from stressed or injured cells or generated from extracellular adenine nucleotides by the concerted action of the ectoenzymes ectoapyrase (CD39) and 5" ectonucleotidase (NT5E, CD73) that catabolize ATP to adenosine.	Adenosine Triphosphate	227-230	5'-nucleotidase ecto	Homo sapiens	199-203
31623231-9	2019	Adenosine is either released from stressed or injured cells or generated from extracellular adenine nucleotides by the concerted action of the ectoenzymes ectoapyrase (CD39) and 5" ectonucleotidase (NT5E, CD73) that catabolize ATP to adenosine.	Adenosine	234-243	5'-nucleotidase ecto	Homo sapiens	199-203
31623231-10	2019	Recent work revealed a role of the immunoregulatory CD73/adenosine system in radiation-induced fibrotic disease in normal tissues suggesting a potential use as novel therapeutic target for normal tissue protection.	Adenosine	57-66	5'-nucleotidase ecto	Homo sapiens	52-56
31623231-12	2019	However, expression and activity of the CD73/adenosine system in the tumor environment has also been linked to increased tumor growth and tumor immune escape, at least in preclinical models.	Adenosine	45-54	5'-nucleotidase ecto	Homo sapiens	40-44
31220343-3	2019	As ATP is a stress signal, we have tested if extracellular catabolism of adenine nucleotides into adenosine (through ecto-5"-nucleotidase or CD73) leads to A2A receptor over-activation in PD.	Adenine Nucleotides	73-92	5'-nucleotidase ecto	Homo sapiens	117-137
31636635-2	2019	There, high extracellular levels of nucleotides, mainly NAD+ and ATP, are catabolized by different ectonucleotidases, which can be divided in two families according to substrate specificity: on one side those that metabolize NAD+, including CD38, CD157, and CD203a; on the other, those that convert ATP, namely CD39 (and other ENTPDases) and CD73.	NAD	56-60	5'-nucleotidase ecto	Homo sapiens	342-346
31636635-2	2019	There, high extracellular levels of nucleotides, mainly NAD+ and ATP, are catabolized by different ectonucleotidases, which can be divided in two families according to substrate specificity: on one side those that metabolize NAD+, including CD38, CD157, and CD203a; on the other, those that convert ATP, namely CD39 (and other ENTPDases) and CD73.	Adenosine Triphosphate	65-68	5'-nucleotidase ecto	Homo sapiens	342-346
31636635-2	2019	There, high extracellular levels of nucleotides, mainly NAD+ and ATP, are catabolized by different ectonucleotidases, which can be divided in two families according to substrate specificity: on one side those that metabolize NAD+, including CD38, CD157, and CD203a; on the other, those that convert ATP, namely CD39 (and other ENTPDases) and CD73.	NAD	225-229	5'-nucleotidase ecto	Homo sapiens	342-346
31636635-2	2019	There, high extracellular levels of nucleotides, mainly NAD+ and ATP, are catabolized by different ectonucleotidases, which can be divided in two families according to substrate specificity: on one side those that metabolize NAD+, including CD38, CD157, and CD203a; on the other, those that convert ATP, namely CD39 (and other ENTPDases) and CD73.	Adenosine Triphosphate	299-302	5'-nucleotidase ecto	Homo sapiens	342-346
31547608-8	2019	Phenolic extracts derived from RB down-regulated the expression of four genes, ICAM1, CD39, CD73 and NOX4 and up-regulated the expression of another four genes, Nrf2, NQO1, HO1 and eNOS, indicating an antioxidant/ anti-inflammatory effect for RB against endothelial dysfunction.	phenolic acid	0-8	5'-nucleotidase ecto	Homo sapiens	92-96
31479688-6	2019	The breakdown of ATP through the CD39/CD73 axis produces adenosine, which mostly inhibits the inflammatory process through activation of specific P1 receptors.	Adenosine Triphosphate	17-20	5'-nucleotidase ecto	Homo sapiens	38-42
31479688-6	2019	The breakdown of ATP through the CD39/CD73 axis produces adenosine, which mostly inhibits the inflammatory process through activation of specific P1 receptors.	Adenosine	57-66	5'-nucleotidase ecto	Homo sapiens	38-42
31358663-5	2019	Compared to wildtype NT5C2, mutant proteins showed elevated 5"-nucleotidase activity with a stark preference of thiopurine metabolites over endogenous purine nucleotides, suggesting neomorphic effects specific to thiopurine metabolism.	purine	116-122	5'-nucleotidase ecto	Homo sapiens	60-75
31358663-5	2019	Compared to wildtype NT5C2, mutant proteins showed elevated 5"-nucleotidase activity with a stark preference of thiopurine metabolites over endogenous purine nucleotides, suggesting neomorphic effects specific to thiopurine metabolism.	2-mercaptopyrazine	213-223	5'-nucleotidase ecto	Homo sapiens	60-75
31547570-1	2019	CD73, a cell-surface protein encoded by the gene NT5E, is overexpressed in glioblastoma (GBM), where it contributes to the tumor"s pathophysiology via the generation of immunosuppressive adenosine.	Adenosine	187-196	5'-nucleotidase ecto	Homo sapiens	0-4
31547570-1	2019	CD73, a cell-surface protein encoded by the gene NT5E, is overexpressed in glioblastoma (GBM), where it contributes to the tumor"s pathophysiology via the generation of immunosuppressive adenosine.	Adenosine	187-196	5'-nucleotidase ecto	Homo sapiens	49-53
31220343-9	2019	CONCLUSION AND IMPLICATIONS: Our data indicate that increased ATP-derived adenosine formation is responsible for A2A receptor over-activation in PD, suggesting CD73 as a new target to manage PD.	Adenosine	74-83	5'-nucleotidase ecto	Homo sapiens	160-164
31220343-3	2019	As ATP is a stress signal, we have tested if extracellular catabolism of adenine nucleotides into adenosine (through ecto-5"-nucleotidase or CD73) leads to A2A receptor over-activation in PD.	Adenine Nucleotides	73-92	5'-nucleotidase ecto	Homo sapiens	141-145
31220343-3	2019	As ATP is a stress signal, we have tested if extracellular catabolism of adenine nucleotides into adenosine (through ecto-5"-nucleotidase or CD73) leads to A2A receptor over-activation in PD.	Adenosine	98-107	5'-nucleotidase ecto	Homo sapiens	117-137
31220343-3	2019	As ATP is a stress signal, we have tested if extracellular catabolism of adenine nucleotides into adenosine (through ecto-5"-nucleotidase or CD73) leads to A2A receptor over-activation in PD.	Adenosine	98-107	5'-nucleotidase ecto	Homo sapiens	141-145
31220343-5	2019	KEY RESULTS: 6-OHDA increased ATP release and extracellular conversion into adenosine through CD73 up-regulation in SH-SY5Y cells.	Oxidopamine	13-19	5'-nucleotidase ecto	Homo sapiens	94-98
31220343-5	2019	KEY RESULTS: 6-OHDA increased ATP release and extracellular conversion into adenosine through CD73 up-regulation in SH-SY5Y cells.	Adenosine	76-85	5'-nucleotidase ecto	Homo sapiens	94-98
31220343-7	2019	In vivo striatal exposure to 6-OHDA increased ATP release and extracellular formation of adenosine from adenosine nucleotides and up-regulated CD73 and A2A receptors in striatal synaptosomes.	Oxidopamine	29-35	5'-nucleotidase ecto	Homo sapiens	143-147
31220343-9	2019	CONCLUSION AND IMPLICATIONS: Our data indicate that increased ATP-derived adenosine formation is responsible for A2A receptor over-activation in PD, suggesting CD73 as a new target to manage PD.	Adenosine Triphosphate	62-65	5'-nucleotidase ecto	Homo sapiens	160-164
31592495-1	2019	CD73, a cell-surface N-linked glycoprotein that produces extracellular adenosine, is a novel target for cancer immunotherapy.	Adenosine	71-80	5'-nucleotidase ecto	Homo sapiens	0-4
31409424-3	2019	One, rapid immunosuppressive function of MSCs is through ectoenzyme expression of CD73 and CD39 which cooperatively hydrolyze inflammatory, extracellular adenosine triphosphate (ATP) to anti-inflammatory adenosine.	Adenosine Triphosphate	154-176	5'-nucleotidase ecto	Homo sapiens	82-86
31409424-3	2019	One, rapid immunosuppressive function of MSCs is through ectoenzyme expression of CD73 and CD39 which cooperatively hydrolyze inflammatory, extracellular adenosine triphosphate (ATP) to anti-inflammatory adenosine.	Adenosine Triphosphate	178-181	5'-nucleotidase ecto	Homo sapiens	82-86
31409424-3	2019	One, rapid immunosuppressive function of MSCs is through ectoenzyme expression of CD73 and CD39 which cooperatively hydrolyze inflammatory, extracellular adenosine triphosphate (ATP) to anti-inflammatory adenosine.	Adenosine	154-163	5'-nucleotidase ecto	Homo sapiens	82-86
31592495-8	2019	Biochemically, tumor-associated CD73 was deficient in hybrid and complex glycans specifically on residues N311 and N333 located in the C-terminal catalytic domain.	N(1),N(11)-diethylnorspermine	115-119	5'-nucleotidase ecto	Homo sapiens	32-36
31592495-9	2019	Blocking N311/N333 glycosylation by site-directed mutagenesis produced CD73 with significantly decreased 5"-nucleotidase activity in vitro, similar to the primary tumors.	N(1),N(11)-diethylnorspermine	14-18	5'-nucleotidase ecto	Homo sapiens	71-75
31592495-9	2019	Blocking N311/N333 glycosylation by site-directed mutagenesis produced CD73 with significantly decreased 5"-nucleotidase activity in vitro, similar to the primary tumors.	N(1),N(11)-diethylnorspermine	14-18	5'-nucleotidase ecto	Homo sapiens	105-120
31154474-4	2019	It degrades ATP to AMP and CD73 dephosphorylates AMP into adenosine.	Adenosine Monophosphate	49-52	5'-nucleotidase ecto	Homo sapiens	27-31
31264794-0	2019	Synthesis of Substituted 5"-Aminoadenosine Derivatives and Evaluation of Their Inhibitory Potential toward CD73.	5"-aminoadenosine	25-42	5'-nucleotidase ecto	Homo sapiens	107-111
31264794-5	2019	Among the new compounds, the most interesting candidates, 5 (5"-deoxy-5"-N-phosphonomethyladenosine) and 7 (5"-deoxy-5"-N-(ethoxyphosphorylacetate)adenosine), inhibited recombinant CD73 by 36 and 46 % and cellular CD73 by 61 and 45 % at 100 mum, respectively.	5 (5"-deoxy-5"-n-phosphonomethyladenosine	58-99	5'-nucleotidase ecto	Homo sapiens	181-185
31264794-5	2019	Among the new compounds, the most interesting candidates, 5 (5"-deoxy-5"-N-phosphonomethyladenosine) and 7 (5"-deoxy-5"-N-(ethoxyphosphorylacetate)adenosine), inhibited recombinant CD73 by 36 and 46 % and cellular CD73 by 61 and 45 % at 100 mum, respectively.	5 (5"-deoxy-5"-n-phosphonomethyladenosine	58-99	5'-nucleotidase ecto	Homo sapiens	214-218
31264794-5	2019	Among the new compounds, the most interesting candidates, 5 (5"-deoxy-5"-N-phosphonomethyladenosine) and 7 (5"-deoxy-5"-N-(ethoxyphosphorylacetate)adenosine), inhibited recombinant CD73 by 36 and 46 % and cellular CD73 by 61 and 45 % at 100 mum, respectively.	7 (5"-deoxy-5"-n-(ethoxyphosphorylacetate)adenosine	105-156	5'-nucleotidase ecto	Homo sapiens	181-185
31264794-5	2019	Among the new compounds, the most interesting candidates, 5 (5"-deoxy-5"-N-phosphonomethyladenosine) and 7 (5"-deoxy-5"-N-(ethoxyphosphorylacetate)adenosine), inhibited recombinant CD73 by 36 and 46 % and cellular CD73 by 61 and 45 % at 100 mum, respectively.	7 (5"-deoxy-5"-n-(ethoxyphosphorylacetate)adenosine	105-156	5'-nucleotidase ecto	Homo sapiens	214-218
31154474-4	2019	It degrades ATP to AMP and CD73 dephosphorylates AMP into adenosine.	Adenosine	58-67	5'-nucleotidase ecto	Homo sapiens	27-31
31404305-2	2019	The concerted action of ectonucleotidases CD39 and CD73 plays a major role in the local production of anti-inflammatory adenosine, but both ectonucleotidases are rarely co-expressed by human T cells.	Adenosine	120-129	5'-nucleotidase ecto	Homo sapiens	51-55
31223045-1	2019	CD73 is a novel immune checkpoint associated with adenosine metabolism that promotes tumor progression by suppressing antitumor immune response and promoting angiogenesis.	Adenosine	50-59	5'-nucleotidase ecto	Homo sapiens	0-4
31404305-5	2019	The possibility that CD73 could act in trans would resolve the conundrum of both enzymes being co-expressed for the degradation of ATP and the generation of adenosine.	Adenosine Triphosphate	131-134	5'-nucleotidase ecto	Homo sapiens	21-25
31404305-5	2019	The possibility that CD73 could act in trans would resolve the conundrum of both enzymes being co-expressed for the degradation of ATP and the generation of adenosine.	Adenosine	157-166	5'-nucleotidase ecto	Homo sapiens	21-25
31396523-4	2019	In addition, the hypoxia-driven activity of CD73 immunometabolically impairs NK cells in tumors, due to its catalytic role in the generation of the highly immunosuppressive metabolite adenosine.	Adenosine	184-193	5'-nucleotidase ecto	Homo sapiens	44-48
31404305-7	2019	It is not yet clear how CD73, a glycosylphosphatidylinositol (GPI)-anchored protein, is released from the cell membrane, but plausible mechanisms include cleavage by metalloproteinases and shedding mediated by cell-associated phospholipases.	Glycosylphosphatidylinositols	32-60	5'-nucleotidase ecto	Homo sapiens	24-28
31404305-7	2019	It is not yet clear how CD73, a glycosylphosphatidylinositol (GPI)-anchored protein, is released from the cell membrane, but plausible mechanisms include cleavage by metalloproteinases and shedding mediated by cell-associated phospholipases.	Glycosylphosphatidylinositols	62-65	5'-nucleotidase ecto	Homo sapiens	24-28
30907983-7	2019	Additionally, CD73 is a membrane bound ectonucleotidase expressed on mesenchymal stromal cells (MSCs) that allows manipulation of extracellular purines in tissues such as bone marrow.	Purines	144-151	5'-nucleotidase ecto	Homo sapiens	14-18
31379836-5	2019	It is then metabolized to adenosine monophosphate (AMP) via ectonucleoside triphosphate diphosphohydrolase-1 (CD39) and further hydrolyzed to adenosine via ecto-5"-nucleotidase (CD73).	Adenosine Monophosphate	26-49	5'-nucleotidase ecto	Homo sapiens	156-176
31379836-5	2019	It is then metabolized to adenosine monophosphate (AMP) via ectonucleoside triphosphate diphosphohydrolase-1 (CD39) and further hydrolyzed to adenosine via ecto-5"-nucleotidase (CD73).	Adenosine Monophosphate	26-49	5'-nucleotidase ecto	Homo sapiens	178-182
31379836-5	2019	It is then metabolized to adenosine monophosphate (AMP) via ectonucleoside triphosphate diphosphohydrolase-1 (CD39) and further hydrolyzed to adenosine via ecto-5"-nucleotidase (CD73).	Adenosine Monophosphate	51-54	5'-nucleotidase ecto	Homo sapiens	156-176
31379836-5	2019	It is then metabolized to adenosine monophosphate (AMP) via ectonucleoside triphosphate diphosphohydrolase-1 (CD39) and further hydrolyzed to adenosine via ecto-5"-nucleotidase (CD73).	Adenosine Monophosphate	51-54	5'-nucleotidase ecto	Homo sapiens	178-182
31379836-5	2019	It is then metabolized to adenosine monophosphate (AMP) via ectonucleoside triphosphate diphosphohydrolase-1 (CD39) and further hydrolyzed to adenosine via ecto-5"-nucleotidase (CD73).	Adenosine	26-35	5'-nucleotidase ecto	Homo sapiens	156-176
31379836-5	2019	It is then metabolized to adenosine monophosphate (AMP) via ectonucleoside triphosphate diphosphohydrolase-1 (CD39) and further hydrolyzed to adenosine via ecto-5"-nucleotidase (CD73).	Adenosine	26-35	5'-nucleotidase ecto	Homo sapiens	178-182
31237169-8	2019	Incubation of immune cells, obtained from post- CA subjects, with AMP , a substrate for CD 73, resulted in inhibition of tumor necrosis factor-alpha production and generation of reactive oxygen species.	Adenosine Monophosphate	66-69	5'-nucleotidase ecto	Homo sapiens	88-93
31237169-8	2019	Incubation of immune cells, obtained from post- CA subjects, with AMP , a substrate for CD 73, resulted in inhibition of tumor necrosis factor-alpha production and generation of reactive oxygen species.	Reactive Oxygen Species	178-201	5'-nucleotidase ecto	Homo sapiens	88-93
31237169-9	2019	This effect was blocked by adenosine 5"-(alpha, beta-methylene) diphosphate, a specific inhibitor of CD 73 and ZM 241385, an A2 adenosine receptor antagonist.	alpha,beta-methyleneadenosine 5'-diphosphate	27-75	5'-nucleotidase ecto	Homo sapiens	101-106
31237169-10	2019	We also found that AMP -dependent activation of CD 73 induces production of vascular endothelial growth factor.	Adenosine Monophosphate	19-22	5'-nucleotidase ecto	Homo sapiens	48-53
30941556-0	2019	Blockade pf CD73/adenosine axis improves the therapeutic efficacy of docetaxel in epithelial ovarian cancer.	Adenosine	17-26	5'-nucleotidase ecto	Homo sapiens	12-16
30941556-0	2019	Blockade pf CD73/adenosine axis improves the therapeutic efficacy of docetaxel in epithelial ovarian cancer.	Docetaxel	69-78	5'-nucleotidase ecto	Homo sapiens	12-16
30941556-7	2019	RESULTS: DTXL can increase both the CD73 expression and enzymatic activity in patient-derived epithelial cell and ID8 cell while causing immunosuppressive response which was reversed by anti-CD73 antibody (aCD73).	Docetaxel	9-13	5'-nucleotidase ecto	Homo sapiens	36-40
30941556-7	2019	RESULTS: DTXL can increase both the CD73 expression and enzymatic activity in patient-derived epithelial cell and ID8 cell while causing immunosuppressive response which was reversed by anti-CD73 antibody (aCD73).	Docetaxel	9-13	5'-nucleotidase ecto	Homo sapiens	191-195
30941556-9	2019	CONCLUSION: Blocking CD73/adenosine pathway could reverse the immunosuppression caused by DTXL, and a combination of DTXL with CD73 inhibitor or anti-CD73 antibody would be a more effective and promising therapy for EOC.	Docetaxel	90-94	5'-nucleotidase ecto	Homo sapiens	21-25
30725167-6	2019	After TPTD treatment, BMMNC positive cells for CD73, CD90 and CD105 increased from 6.5 to 37.5% (p &lt; 0.05); NANOG, SOX2 and OCT4 were upregulated, being statistically significant for NANOG (p &lt; 0.05), and cells increased proliferative capacity more than 50% at day 7 (p &lt; 0.05).	Teriparatide	6-10	5'-nucleotidase ecto	Homo sapiens	47-51
30301599-0	2019	Cervical cancer cells produce TGF-beta1 through the CD73-adenosine pathway and maintain CD73 expression through the autocrine activity of TGF-beta1.	Adenosine	57-66	5'-nucleotidase ecto	Homo sapiens	52-56
31014364-4	2019	The ectonucleotidase activity of CD73 catalyzes AMP to adenosine, which subsequently inhibits anti-tumor immune responses.	Adenosine Monophosphate	48-51	5'-nucleotidase ecto	Homo sapiens	33-37
30548323-5	2019	RESULTS: 1,25(OH)2 D3 decreased adenosine monophosphate hydrolysis via ecto-5"-nucleotidase/CD73 and expression of CD73, but did not change NTPDase1/CD39 activity; it increased the CD39 expression.	Adenosine Monophosphate	32-55	5'-nucleotidase ecto	Homo sapiens	71-91
30548323-5	2019	RESULTS: 1,25(OH)2 D3 decreased adenosine monophosphate hydrolysis via ecto-5"-nucleotidase/CD73 and expression of CD73, but did not change NTPDase1/CD39 activity; it increased the CD39 expression.	Adenosine Monophosphate	32-55	5'-nucleotidase ecto	Homo sapiens	92-96
31116985-3	2019	The production of adenosine via the sequential activity of CD39 and CD73 ectoenzymes participates to the generation of an immunosuppressive tumor microenvironment.	Adenosine	18-27	5'-nucleotidase ecto	Homo sapiens	68-72
31116985-4	2019	In order to disrupt the adenosine pathway, we generated two antibodies, IPH5201 and IPH5301, targeting human membrane-associated and soluble forms of CD39 and CD73, respectively, and efficiently blocking the hydrolysis of immunogenic ATP into immunosuppressive adenosine.	Adenosine	24-33	5'-nucleotidase ecto	Homo sapiens	159-163
31116985-4	2019	In order to disrupt the adenosine pathway, we generated two antibodies, IPH5201 and IPH5301, targeting human membrane-associated and soluble forms of CD39 and CD73, respectively, and efficiently blocking the hydrolysis of immunogenic ATP into immunosuppressive adenosine.	iph5201	72-79	5'-nucleotidase ecto	Homo sapiens	159-163
31116985-4	2019	In order to disrupt the adenosine pathway, we generated two antibodies, IPH5201 and IPH5301, targeting human membrane-associated and soluble forms of CD39 and CD73, respectively, and efficiently blocking the hydrolysis of immunogenic ATP into immunosuppressive adenosine.	iph5301	84-91	5'-nucleotidase ecto	Homo sapiens	159-163
30953394-14	2019	CONCLUSIONS: DPSCs and BMMSCs could depress NK cells" function by hydrolysing ATP to ADO using CD39 and CD73 enzymatic activity.	Adenosine Triphosphate	78-81	5'-nucleotidase ecto	Homo sapiens	104-108
30927045-6	2019	Further, miR-30a-5p overexpression significantly increased the cytotoxic effect of gemcitabine in pancreatic cancer by directly targeting CD73 messenger RNA (mRNA), suggesting that regulation of the miR-30a-5p/CD73 axis may play an important role in the development of gemcitabine resistance in pancreatic cancer.	mir-30a-5p	9-19	5'-nucleotidase ecto	Homo sapiens	138-142
30927045-6	2019	Further, miR-30a-5p overexpression significantly increased the cytotoxic effect of gemcitabine in pancreatic cancer by directly targeting CD73 messenger RNA (mRNA), suggesting that regulation of the miR-30a-5p/CD73 axis may play an important role in the development of gemcitabine resistance in pancreatic cancer.	mir-30a-5p	9-19	5'-nucleotidase ecto	Homo sapiens	210-214
30927045-6	2019	Further, miR-30a-5p overexpression significantly increased the cytotoxic effect of gemcitabine in pancreatic cancer by directly targeting CD73 messenger RNA (mRNA), suggesting that regulation of the miR-30a-5p/CD73 axis may play an important role in the development of gemcitabine resistance in pancreatic cancer.	gemcitabine	83-94	5'-nucleotidase ecto	Homo sapiens	138-142
30927045-6	2019	Further, miR-30a-5p overexpression significantly increased the cytotoxic effect of gemcitabine in pancreatic cancer by directly targeting CD73 messenger RNA (mRNA), suggesting that regulation of the miR-30a-5p/CD73 axis may play an important role in the development of gemcitabine resistance in pancreatic cancer.	gemcitabine	83-94	5'-nucleotidase ecto	Homo sapiens	210-214
30927045-6	2019	Further, miR-30a-5p overexpression significantly increased the cytotoxic effect of gemcitabine in pancreatic cancer by directly targeting CD73 messenger RNA (mRNA), suggesting that regulation of the miR-30a-5p/CD73 axis may play an important role in the development of gemcitabine resistance in pancreatic cancer.	gemcitabine	269-280	5'-nucleotidase ecto	Homo sapiens	138-142
30927045-6	2019	Further, miR-30a-5p overexpression significantly increased the cytotoxic effect of gemcitabine in pancreatic cancer by directly targeting CD73 messenger RNA (mRNA), suggesting that regulation of the miR-30a-5p/CD73 axis may play an important role in the development of gemcitabine resistance in pancreatic cancer.	gemcitabine	269-280	5'-nucleotidase ecto	Homo sapiens	210-214
31205451-3	2019	In this context, it is unknown whether ectonucleotidases CD39 and CD73, which are involved in the production of adenosine (Ado) that suppresses the specific antitumor immune response, are present in precursor lesions of CeCa.	Adenosine	112-121	5'-nucleotidase ecto	Homo sapiens	66-70
31205451-3	2019	In this context, it is unknown whether ectonucleotidases CD39 and CD73, which are involved in the production of adenosine (Ado) that suppresses the specific antitumor immune response, are present in precursor lesions of CeCa.	Adenosine	123-126	5'-nucleotidase ecto	Homo sapiens	66-70
31205451-6	2019	Interestingly, solubilized cervical mucus from these patients also showed higher contents of soluble CD39 and CD73, which were associated with a greater capacity to produce Ado from the hydrolysis of adenosine triphosphate (ATP) and adenosine monophosphate (AMP).	Adenosine	173-176	5'-nucleotidase ecto	Homo sapiens	110-114
31205451-6	2019	Interestingly, solubilized cervical mucus from these patients also showed higher contents of soluble CD39 and CD73, which were associated with a greater capacity to produce Ado from the hydrolysis of adenosine triphosphate (ATP) and adenosine monophosphate (AMP).	Adenosine Triphosphate	200-222	5'-nucleotidase ecto	Homo sapiens	110-114
31205451-6	2019	Interestingly, solubilized cervical mucus from these patients also showed higher contents of soluble CD39 and CD73, which were associated with a greater capacity to produce Ado from the hydrolysis of adenosine triphosphate (ATP) and adenosine monophosphate (AMP).	Adenosine Triphosphate	224-227	5'-nucleotidase ecto	Homo sapiens	110-114
31205451-6	2019	Interestingly, solubilized cervical mucus from these patients also showed higher contents of soluble CD39 and CD73, which were associated with a greater capacity to produce Ado from the hydrolysis of adenosine triphosphate (ATP) and adenosine monophosphate (AMP).	Adenosine Monophosphate	233-256	5'-nucleotidase ecto	Homo sapiens	110-114
31205451-6	2019	Interestingly, solubilized cervical mucus from these patients also showed higher contents of soluble CD39 and CD73, which were associated with a greater capacity to produce Ado from the hydrolysis of adenosine triphosphate (ATP) and adenosine monophosphate (AMP).	Adenosine Monophosphate	258-261	5'-nucleotidase ecto	Homo sapiens	110-114
31076346-8	2019	Blockade of CD39/CD73 or adenosine receptors has significantly abrogated the suppressive ability of GMSC in vitro and therapeutic effect of GMSC on bone erosion during CIA in vivo.	gmsc	100-104	5'-nucleotidase ecto	Homo sapiens	17-21
31076346-8	2019	Blockade of CD39/CD73 or adenosine receptors has significantly abrogated the suppressive ability of GMSC in vitro and therapeutic effect of GMSC on bone erosion during CIA in vivo.	gmsc	140-144	5'-nucleotidase ecto	Homo sapiens	17-21
31076346-9	2019	INTERPRETATION: GMSC inhibit osteoclast formation in vitro and in vivo partially via CD39-CD73-adenosine signals.	gmsc	16-20	5'-nucleotidase ecto	Homo sapiens	90-94
31076346-9	2019	INTERPRETATION: GMSC inhibit osteoclast formation in vitro and in vivo partially via CD39-CD73-adenosine signals.	Adenosine	95-104	5'-nucleotidase ecto	Homo sapiens	90-94
31413909-10	2019	Finally, we observed that Adora2a, Nt5e and Entpd1 gene expression positively correlated with Lyve1, Pdpn and Vegfc in several human cancers, thereby supporting the notion that adenosine production and A2a receptor activation might promote lymphangiogenesis in human tumors.	Adenosine	177-186	5'-nucleotidase ecto	Homo sapiens	35-39
31014364-4	2019	The ectonucleotidase activity of CD73 catalyzes AMP to adenosine, which subsequently inhibits anti-tumor immune responses.	Adenosine	55-64	5'-nucleotidase ecto	Homo sapiens	33-37
31014364-10	2019	RESULTS: In contrast to the long recognized immune suppressive effect of CD73-adenosine signaling in tumor tissue, we made a striking observation that in AML, CD73 expression on CD8 T cells associates with an increased immune response.	Adenosine	78-87	5'-nucleotidase ecto	Homo sapiens	73-77
31024543-2	2019	Adenosine is either released from stressed or injured cells or generated from extracellular adenine nucleotides by the concerted action of the ectoenzymes ectoapyrase (CD39) and 5" ectonucleotidase (CD73) that catabolize ATP to adenosine.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	199-203
30895781-0	2019	Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5"-Nucleotidase (CD73) Inhibitors.	purine	35-41	5'-nucleotidase ecto	Homo sapiens	72-92
30895781-0	2019	Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5"-Nucleotidase (CD73) Inhibitors.	Pyrimidine Nucleotides	46-68	5'-nucleotidase ecto	Homo sapiens	72-92
30689999-5	2019	Early data demonstrated a central role for cyclic AMP (cAMP) in the anti-inflammatory effect of nimesulide; more recently, we have shown the involvement of the pathway ecto-5"-nucleotidase/adenosine A2A receptor.	nimesulide	96-106	5'-nucleotidase ecto	Homo sapiens	168-188
31024543-2	2019	Adenosine is either released from stressed or injured cells or generated from extracellular adenine nucleotides by the concerted action of the ectoenzymes ectoapyrase (CD39) and 5" ectonucleotidase (CD73) that catabolize ATP to adenosine.	Adenine Nucleotides	92-111	5'-nucleotidase ecto	Homo sapiens	199-203
31024543-2	2019	Adenosine is either released from stressed or injured cells or generated from extracellular adenine nucleotides by the concerted action of the ectoenzymes ectoapyrase (CD39) and 5" ectonucleotidase (CD73) that catabolize ATP to adenosine.	Adenosine Triphosphate	221-224	5'-nucleotidase ecto	Homo sapiens	199-203
31024543-2	2019	Adenosine is either released from stressed or injured cells or generated from extracellular adenine nucleotides by the concerted action of the ectoenzymes ectoapyrase (CD39) and 5" ectonucleotidase (CD73) that catabolize ATP to adenosine.	Adenosine	228-237	5'-nucleotidase ecto	Homo sapiens	199-203
31024543-3	2019	An acute CD73-dependent increase of adenosine in normal tissues mostly exerts tissue protective functions whereas chronically increased adenosine-levels in tissues exposed to DNA damaging chemotherapy or radiotherapy promote pathologic remodeling processes and fibrosis for example in the skin and the lung.	Adenosine	36-45	5'-nucleotidase ecto	Homo sapiens	9-13
31024543-3	2019	An acute CD73-dependent increase of adenosine in normal tissues mostly exerts tissue protective functions whereas chronically increased adenosine-levels in tissues exposed to DNA damaging chemotherapy or radiotherapy promote pathologic remodeling processes and fibrosis for example in the skin and the lung.	Adenosine	136-145	5'-nucleotidase ecto	Homo sapiens	9-13
31604539-4	2019	In this review, we summarize past and recent research on the ecto-nucleotidases CD39 and CD73, conducted by our group and others, that recently lead to the development and clinical testing of adenosine targeting agents for cancer immunotherapy.	Adenosine	192-201	5'-nucleotidase ecto	Homo sapiens	89-93
30888380-2	2019	The local structure and lattice dynamic investigations reveal that the ZTE derives from the cooperation of the NTE of the inorganic Ba-O (or Pb-O) layer and the PTE of the squarate pillar.	pb-o	141-145	5'-nucleotidase ecto	Homo sapiens	111-114
30689733-0	2019	CD73-derived adenosine controls inflammation and neurodegeneration by modulating dopamine signalling.	Adenosine	13-22	5'-nucleotidase ecto	Homo sapiens	0-4
30957676-3	2019	However, besides immune checkpoints, other mechanisms including the adenosine produced by ectonucleotidases CD39 and CD73 contribute to the melanoma progression due to the immunosuppression induced by the tumour milieu.	Adenosine	68-77	5'-nucleotidase ecto	Homo sapiens	117-121
30770248-2	2019	Here, we showed that CD19+ extracellular vesicles (EVs) from B cells through CD39 and CD73 vesicle-incorporated proteins hydrolyzed ATP from chemotherapy-treated tumor cells into adenosine, thus impairing CD8+ T cell responses.	Adenosine Triphosphate	132-135	5'-nucleotidase ecto	Homo sapiens	86-90
30770248-2	2019	Here, we showed that CD19+ extracellular vesicles (EVs) from B cells through CD39 and CD73 vesicle-incorporated proteins hydrolyzed ATP from chemotherapy-treated tumor cells into adenosine, thus impairing CD8+ T cell responses.	Adenosine	179-188	5'-nucleotidase ecto	Homo sapiens	86-90
30395172-1	2019	CD73 is an adenosine-producing cell surface enzyme, which exerts strong anti-inflammatory and migration modulating effects in many cell types.	Adenosine	11-20	5'-nucleotidase ecto	Homo sapiens	0-4
30395172-8	2019	In multivariable models, CD73 negative epithelial cells in both BC types and CD73 negative endothelial cells in MIBC were independent factors predicting poor outcome.	4-METHYL-2-PENTANOL	112-116	5'-nucleotidase ecto	Homo sapiens	77-81
30689733-0	2019	CD73-derived adenosine controls inflammation and neurodegeneration by modulating dopamine signalling.	Dopamine	81-89	5'-nucleotidase ecto	Homo sapiens	0-4
30689733-3	2019	Here, we show that the ecto-5"-nucleotidase (CD73)-mediated adenosine formation provides an important input to activate A2AR, and upregulated CD73 and A2AR in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson"s disease models coordinatively contribute to the elevated adenosine signalling.	Adenosine	60-69	5'-nucleotidase ecto	Homo sapiens	23-43
30607549-1	2019	BACKGROUND: The tumor-expressed CD73 ectonucleotidase generates immune tolerance and promotes invasiveness via adenosine production from degradation of AMP.	Adenosine	111-120	5'-nucleotidase ecto	Homo sapiens	32-36
30607549-1	2019	BACKGROUND: The tumor-expressed CD73 ectonucleotidase generates immune tolerance and promotes invasiveness via adenosine production from degradation of AMP.	Adenosine Monophosphate	152-155	5'-nucleotidase ecto	Homo sapiens	32-36
30689733-3	2019	Here, we show that the ecto-5"-nucleotidase (CD73)-mediated adenosine formation provides an important input to activate A2AR, and upregulated CD73 and A2AR in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson"s disease models coordinatively contribute to the elevated adenosine signalling.	Adenosine	60-69	5'-nucleotidase ecto	Homo sapiens	45-49
30689733-3	2019	Here, we show that the ecto-5"-nucleotidase (CD73)-mediated adenosine formation provides an important input to activate A2AR, and upregulated CD73 and A2AR in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson"s disease models coordinatively contribute to the elevated adenosine signalling.	Adenosine	60-69	5'-nucleotidase ecto	Homo sapiens	142-146
30689733-3	2019	Here, we show that the ecto-5"-nucleotidase (CD73)-mediated adenosine formation provides an important input to activate A2AR, and upregulated CD73 and A2AR in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson"s disease models coordinatively contribute to the elevated adenosine signalling.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	163-207	5'-nucleotidase ecto	Homo sapiens	23-43
30689733-3	2019	Here, we show that the ecto-5"-nucleotidase (CD73)-mediated adenosine formation provides an important input to activate A2AR, and upregulated CD73 and A2AR in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson"s disease models coordinatively contribute to the elevated adenosine signalling.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	163-207	5'-nucleotidase ecto	Homo sapiens	45-49
30689733-3	2019	Here, we show that the ecto-5"-nucleotidase (CD73)-mediated adenosine formation provides an important input to activate A2AR, and upregulated CD73 and A2AR in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson"s disease models coordinatively contribute to the elevated adenosine signalling.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	163-207	5'-nucleotidase ecto	Homo sapiens	142-146
30689733-3	2019	Here, we show that the ecto-5"-nucleotidase (CD73)-mediated adenosine formation provides an important input to activate A2AR, and upregulated CD73 and A2AR in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson"s disease models coordinatively contribute to the elevated adenosine signalling.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	209-213	5'-nucleotidase ecto	Homo sapiens	23-43
30689733-3	2019	Here, we show that the ecto-5"-nucleotidase (CD73)-mediated adenosine formation provides an important input to activate A2AR, and upregulated CD73 and A2AR in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson"s disease models coordinatively contribute to the elevated adenosine signalling.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	209-213	5'-nucleotidase ecto	Homo sapiens	45-49
30689733-3	2019	Here, we show that the ecto-5"-nucleotidase (CD73)-mediated adenosine formation provides an important input to activate A2AR, and upregulated CD73 and A2AR in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson"s disease models coordinatively contribute to the elevated adenosine signalling.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	209-213	5'-nucleotidase ecto	Homo sapiens	142-146
30689733-3	2019	Here, we show that the ecto-5"-nucleotidase (CD73)-mediated adenosine formation provides an important input to activate A2AR, and upregulated CD73 and A2AR in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson"s disease models coordinatively contribute to the elevated adenosine signalling.	Adenosine	292-301	5'-nucleotidase ecto	Homo sapiens	23-43
30689733-3	2019	Here, we show that the ecto-5"-nucleotidase (CD73)-mediated adenosine formation provides an important input to activate A2AR, and upregulated CD73 and A2AR in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson"s disease models coordinatively contribute to the elevated adenosine signalling.	Adenosine	292-301	5'-nucleotidase ecto	Homo sapiens	45-49
30689733-3	2019	Here, we show that the ecto-5"-nucleotidase (CD73)-mediated adenosine formation provides an important input to activate A2AR, and upregulated CD73 and A2AR in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson"s disease models coordinatively contribute to the elevated adenosine signalling.	Adenosine	292-301	5'-nucleotidase ecto	Homo sapiens	142-146
30689733-4	2019	Importantly, we demonstrate that CD73-derived adenosine-A2AR signalling modulates microglial immunoresponses and morphological dynamics.	Adenosine	46-55	5'-nucleotidase ecto	Homo sapiens	33-37
30689733-5	2019	CD73 inactivation significantly attenuated lipopolysaccharide-induced pro-inflammatory responses in microglia, but enhanced microglia process extension, movement and morphological transformation in the laser injury and acute MPTP-induced Parkinson"s disease models.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	225-229	5'-nucleotidase ecto	Homo sapiens	0-4
30689733-6	2019	Limiting CD73-derived adenosine substantially suppressed microglia-mediated neuroinflammation and improved the viability of dopaminergic neurons and motor behaviours in Parkinson"s disease models.	Adenosine	22-31	5'-nucleotidase ecto	Homo sapiens	9-13
30689733-7	2019	Moreover, CD73 inactivation suppressed A2AR induction and A2AR-mediated pro-inflammatory responses, whereas replenishment of adenosine analogues restored these effects, suggesting that CD73 produces a self-regulating feed-forward adenosine formation to activate A2AR and promote neuroinflammation.	Adenosine	125-134	5'-nucleotidase ecto	Homo sapiens	185-189
30689733-7	2019	Moreover, CD73 inactivation suppressed A2AR induction and A2AR-mediated pro-inflammatory responses, whereas replenishment of adenosine analogues restored these effects, suggesting that CD73 produces a self-regulating feed-forward adenosine formation to activate A2AR and promote neuroinflammation.	Adenosine	230-239	5'-nucleotidase ecto	Homo sapiens	10-14
30689733-7	2019	Moreover, CD73 inactivation suppressed A2AR induction and A2AR-mediated pro-inflammatory responses, whereas replenishment of adenosine analogues restored these effects, suggesting that CD73 produces a self-regulating feed-forward adenosine formation to activate A2AR and promote neuroinflammation.	Adenosine	230-239	5'-nucleotidase ecto	Homo sapiens	185-189
30689733-9	2019	Our study thus reveals a novel role for CD73-mediated nucleotide metabolism in regulating neuroinflammation and provides the proof-of-principle that targeting nucleotide metabolic pathways to limit adenosine production and neuroinflammation in Parkinson"s disease might be a promising therapeutic strategy.	Adenosine	198-207	5'-nucleotidase ecto	Homo sapiens	40-44
30414410-7	2019	These three conditions, PXE, GACI, and ACDC, caused by mutations in ABCC6, ENPP1, and NT5E, respectively, are characterized by reduced levels of inorganic pyrophosphate (PPi) in plasma.	inorganic pyrophosphate	145-168	5'-nucleotidase ecto	Homo sapiens	86-90
30593827-6	2019	Melatonin induced alteration in differential expression patterns of mesenchymal stem cell antigens by reducing CD29, CD45, CD73, CD90 and CD105, but no changing CD34 expressing cells.	Melatonin	0-9	5'-nucleotidase ecto	Homo sapiens	123-127
30644036-10	2019	However, AMP hydrolysis was reduced by the CD73 inhibitor, APCP, and by levamisole, suggesting the action of a soluble form of CD73 and alkaline phosphatase.	Adenosine Monophosphate	9-12	5'-nucleotidase ecto	Homo sapiens	43-47
30644036-10	2019	However, AMP hydrolysis was reduced by the CD73 inhibitor, APCP, and by levamisole, suggesting the action of a soluble form of CD73 and alkaline phosphatase.	Adenosine Monophosphate	9-12	5'-nucleotidase ecto	Homo sapiens	127-131
30644036-10	2019	However, AMP hydrolysis was reduced by the CD73 inhibitor, APCP, and by levamisole, suggesting the action of a soluble form of CD73 and alkaline phosphatase.	Levamisole	72-82	5'-nucleotidase ecto	Homo sapiens	127-131
31069133-3	2019	Our working hypothesis is that adenosine (ADO), an immunosuppressive molecule along with the ectoenzymatic pathways (CD39-CD73 and CD38-CD203a/PC-1-CD73) controlling its production, are involved in the dynamics of NB cells in the BM.	Adenosine	31-40	5'-nucleotidase ecto	Homo sapiens	122-126
31069133-3	2019	Our working hypothesis is that adenosine (ADO), an immunosuppressive molecule along with the ectoenzymatic pathways (CD39-CD73 and CD38-CD203a/PC-1-CD73) controlling its production, are involved in the dynamics of NB cells in the BM.	Adenosine	42-45	5'-nucleotidase ecto	Homo sapiens	122-126
30293873-8	2019	CD73 rs2229523 and A2BR rs2015353 in the discovery cohort and CD39 rs2226163 in the validation cohort showed significant correlations with OS on univariate and multivariable analyses.	Osmium	139-141	5'-nucleotidase ecto	Homo sapiens	0-4
30909201-1	2019	CD73, also entitled as ecto-5"-nucleotidase (NT5E), is an ecto-nucleotidase that contributes in the breakage of extracellular ATP to adenosine and the preservation of immune balance.	Adenosine Triphosphate	126-129	5'-nucleotidase ecto	Homo sapiens	0-4
30556751-3	2019	Adenosine is a potent immune-modulating factor that can be generated through the degradation of ATP by cooperative action of NTPDase1 (CD39) and ecto-5"-nucleotidase (CD73) molecules.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	145-165
30556751-3	2019	Adenosine is a potent immune-modulating factor that can be generated through the degradation of ATP by cooperative action of NTPDase1 (CD39) and ecto-5"-nucleotidase (CD73) molecules.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	167-171
30556751-3	2019	Adenosine is a potent immune-modulating factor that can be generated through the degradation of ATP by cooperative action of NTPDase1 (CD39) and ecto-5"-nucleotidase (CD73) molecules.	Adenosine Triphosphate	96-99	5'-nucleotidase ecto	Homo sapiens	145-165
30556751-3	2019	Adenosine is a potent immune-modulating factor that can be generated through the degradation of ATP by cooperative action of NTPDase1 (CD39) and ecto-5"-nucleotidase (CD73) molecules.	Adenosine Triphosphate	96-99	5'-nucleotidase ecto	Homo sapiens	167-171
30556751-5	2019	Upregulation of CD73 is associated with the overproduction of adenosine; it suppresses antitumor immune responses and helps proliferation, angiogenesis, and metastasis.	Adenosine	62-71	5'-nucleotidase ecto	Homo sapiens	16-20
30587530-4	2019	The results obtained indicate that hAEC constitutively express a unique combination of functional ectoenzymes, driving the production of adenosine (ADO) via canonical (CD39, CD73) and alternative (CD38, CD203a/PC-1, CD73) pathways.	Adenosine	137-146	5'-nucleotidase ecto	Homo sapiens	174-178
30587530-4	2019	The results obtained indicate that hAEC constitutively express a unique combination of functional ectoenzymes, driving the production of adenosine (ADO) via canonical (CD39, CD73) and alternative (CD38, CD203a/PC-1, CD73) pathways.	Adenosine	137-146	5'-nucleotidase ecto	Homo sapiens	216-220
30587530-4	2019	The results obtained indicate that hAEC constitutively express a unique combination of functional ectoenzymes, driving the production of adenosine (ADO) via canonical (CD39, CD73) and alternative (CD38, CD203a/PC-1, CD73) pathways.	Adenosine	148-151	5'-nucleotidase ecto	Homo sapiens	174-178
30587530-4	2019	The results obtained indicate that hAEC constitutively express a unique combination of functional ectoenzymes, driving the production of adenosine (ADO) via canonical (CD39, CD73) and alternative (CD38, CD203a/PC-1, CD73) pathways.	Adenosine	148-151	5'-nucleotidase ecto	Homo sapiens	216-220
30281919-0	2019	NT5E inhibition suppresses the growth of sunitinib-resistant cells and EMT course and AKT/GSK-3beta signaling pathway in renal cell cancer.	Sunitinib	41-50	5'-nucleotidase ecto	Homo sapiens	0-4
30281919-2	2019	Microarray analysis, quantitative real time PCR (qRT-PCR), Western blot, and immunohistochemistry were used to detect Ecto-5"-nucleotidase (NT5E) expressions in sunitinib-resistant tissues in RCC.	Sunitinib	161-170	5'-nucleotidase ecto	Homo sapiens	118-138
30281919-2	2019	Microarray analysis, quantitative real time PCR (qRT-PCR), Western blot, and immunohistochemistry were used to detect Ecto-5"-nucleotidase (NT5E) expressions in sunitinib-resistant tissues in RCC.	Sunitinib	161-170	5'-nucleotidase ecto	Homo sapiens	140-144
30281919-5	2019	In vivo experiment was performed using NCr-nu/nu mice to explore the effects of NT5E on cell growth and EMT signal in sunitinib environment.	Sunitinib	118-127	5'-nucleotidase ecto	Homo sapiens	80-84
30281919-6	2019	NT5E expression was upregulated in sunitinib-resistant RCC tissues and cells.	Sunitinib	35-44	5'-nucleotidase ecto	Homo sapiens	0-4
30281919-8	2019	EMT course and AKT/GSK-3beta signal pathway both in vitro and in vivo in sunitinib environment was suppressed to varying degrees via NT5E inhibition.	Sunitinib	73-82	5'-nucleotidase ecto	Homo sapiens	133-137
30281919-9	2019	NT5E inhibition could suppress the growth of sunitinib-resistant RCC cells and restrain EMT course and AKT/GSK-3beta signal pathway in sunitinib environment in RCC.	Sunitinib	45-54	5'-nucleotidase ecto	Homo sapiens	0-4
30281919-9	2019	NT5E inhibition could suppress the growth of sunitinib-resistant RCC cells and restrain EMT course and AKT/GSK-3beta signal pathway in sunitinib environment in RCC.	Sunitinib	135-144	5'-nucleotidase ecto	Homo sapiens	0-4
30909201-1	2019	CD73, also entitled as ecto-5"-nucleotidase (NT5E), is an ecto-nucleotidase that contributes in the breakage of extracellular ATP to adenosine and the preservation of immune balance.	Adenosine Triphosphate	126-129	5'-nucleotidase ecto	Homo sapiens	23-43
30909201-1	2019	CD73, also entitled as ecto-5"-nucleotidase (NT5E), is an ecto-nucleotidase that contributes in the breakage of extracellular ATP to adenosine and the preservation of immune balance.	Adenosine Triphosphate	126-129	5'-nucleotidase ecto	Homo sapiens	45-49
30909201-1	2019	CD73, also entitled as ecto-5"-nucleotidase (NT5E), is an ecto-nucleotidase that contributes in the breakage of extracellular ATP to adenosine and the preservation of immune balance.	Adenosine	133-142	5'-nucleotidase ecto	Homo sapiens	0-4
30909201-1	2019	CD73, also entitled as ecto-5"-nucleotidase (NT5E), is an ecto-nucleotidase that contributes in the breakage of extracellular ATP to adenosine and the preservation of immune balance.	Adenosine	133-142	5'-nucleotidase ecto	Homo sapiens	23-43
30909201-1	2019	CD73, also entitled as ecto-5"-nucleotidase (NT5E), is an ecto-nucleotidase that contributes in the breakage of extracellular ATP to adenosine and the preservation of immune balance.	Adenosine	133-142	5'-nucleotidase ecto	Homo sapiens	45-49
29550257-6	2019	Both pathways converge to CD73, that fully degrades AMP to the final product ADO.	Adenosine Monophosphate	52-55	5'-nucleotidase ecto	Homo sapiens	26-30
29550257-6	2019	Both pathways converge to CD73, that fully degrades AMP to the final product ADO.	Adenosine	77-80	5'-nucleotidase ecto	Homo sapiens	26-30
29958894-3	2019	Among the host responses to the release of ATP, NAD+ and related small molecules is their breakdown on behalf of a panel of leukocyte ectonucleotidases - CD38, CD39, CD73, CD157, CD203a and CD203c -, whose activities are concatenated to form two nucleotide-catabolizing channels defined as the canonical and non-canonical adenosinergic pathways.	Adenosine Triphosphate	43-46	5'-nucleotidase ecto	Homo sapiens	166-170
29958894-3	2019	Among the host responses to the release of ATP, NAD+ and related small molecules is their breakdown on behalf of a panel of leukocyte ectonucleotidases - CD38, CD39, CD73, CD157, CD203a and CD203c -, whose activities are concatenated to form two nucleotide-catabolizing channels defined as the canonical and non-canonical adenosinergic pathways.	NAD	48-52	5'-nucleotidase ecto	Homo sapiens	166-170
30663435-0	2018	Adenosine Metabolism in COPD: A Study on Adenosine Levels, 5"-Nucleotidase, Adenosine Deaminase and Its Isoenzymes Activity in Serum, Lymphocytes and Erythrocytes.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	59-74
31727244-1	2019	CD73 is an ectonucleotidase able to catabolize 5"-adenosine monophosphate (AMP) into adenosine at the extracellular level.	Adenosine Monophosphate	47-73	5'-nucleotidase ecto	Homo sapiens	0-4
31727244-1	2019	CD73 is an ectonucleotidase able to catabolize 5"-adenosine monophosphate (AMP) into adenosine at the extracellular level.	Adenosine Monophosphate	75-78	5'-nucleotidase ecto	Homo sapiens	0-4
31727244-1	2019	CD73 is an ectonucleotidase able to catabolize 5"-adenosine monophosphate (AMP) into adenosine at the extracellular level.	Adenosine	50-59	5'-nucleotidase ecto	Homo sapiens	0-4
31727244-3	2019	In the context of cancer, the expression and activity of CD73, either in tissue and in biological fluids, is increased leading to high levels of adenosine that potently suppress T-cell mediated responses, promoting tumor progression through stimulation of adenosine receptors.	Adenosine	145-154	5'-nucleotidase ecto	Homo sapiens	57-61
31727244-3	2019	In the context of cancer, the expression and activity of CD73, either in tissue and in biological fluids, is increased leading to high levels of adenosine that potently suppress T-cell mediated responses, promoting tumor progression through stimulation of adenosine receptors.	Adenosine	256-265	5'-nucleotidase ecto	Homo sapiens	57-61
31727244-4	2019	Compelling evidence indicates that elevated levels of CD73-generating adenosine limit the efficacy of cancer immunotherapy.	Adenosine	70-79	5'-nucleotidase ecto	Homo sapiens	54-58
31727244-6	2019	Measurement of CD73 levels in serum of cancer patients is a promising approach that, although it needs to be validated, may help to select patients who will benefit from adenosine-targeting agents and predict response to immunotherapy.	Adenosine	170-179	5'-nucleotidase ecto	Homo sapiens	15-19
31727245-1	2019	CD73 is a membrane-anchored ectoenzyme that degrades extracellular AMP into adenosine, a potent immunosuppressive factor.	Adenosine Monophosphate	67-70	5'-nucleotidase ecto	Homo sapiens	0-4
31727245-1	2019	CD73 is a membrane-anchored ectoenzyme that degrades extracellular AMP into adenosine, a potent immunosuppressive factor.	Adenosine	76-85	5'-nucleotidase ecto	Homo sapiens	0-4
31727245-2	2019	In physiological conditions, induction of the CD73-adenosine pathway acts as natural feedback mechanism to prevent excessive immune reactions and subsequent tissue damage.	Adenosine	51-60	5'-nucleotidase ecto	Homo sapiens	46-50
31727245-3	2019	In the past few years, the CD73-adenosine pathway has emerged as a major immunosuppressive mechanism by which multiple types of cancer evade anti-tumor immunity.	Adenosine	32-41	5'-nucleotidase ecto	Homo sapiens	27-31
31727245-4	2019	Research from our group and others have established that blocking the CD73-adenosine pathway represents a promising approach to improve cancer immunotherapy.	Adenosine	75-84	5'-nucleotidase ecto	Homo sapiens	70-74
31727245-6	2019	Implementation of simple, rapid and HTS-compatible assays to evaluate CD73 enzymatic active is a critical step for any laboratory willing to study the CD73-adenosine pathway.	Adenosine	156-165	5'-nucleotidase ecto	Homo sapiens	70-74
31727245-6	2019	Implementation of simple, rapid and HTS-compatible assays to evaluate CD73 enzymatic active is a critical step for any laboratory willing to study the CD73-adenosine pathway.	Adenosine	156-165	5'-nucleotidase ecto	Homo sapiens	151-155
30513816-4	2018	The production of extracellular adenosine is mediated by the cell surface ectoenzymes CD73, CD39, and CD38 and therapeutic agents have been developed to target these as well as the downstream adenosine receptors (A1R, A2AR, A2BR, A3R) to enhance anti-tumor immune responses.	Adenosine	32-41	5'-nucleotidase ecto	Homo sapiens	86-90
30392016-1	2018	Physiologically, retinal pigment epithelium (RPE) expresses high levels of CD73 in their membrane, converting AMP to immune suppressive adenosine, mediates an anti-inflammatory effect.	Adenosine Monophosphate	110-113	5'-nucleotidase ecto	Homo sapiens	75-79
30560130-6	2018	During healthy aging, elderly lymph nodes adopted a regulatory profile, characterized by: (i) increased plasmacytoid DCs, (ii) increased expression of the adenosine-producing enzyme CD73 on CD11c+ cells, and (iii) increased expression of multiple regulatory markers (including CD73, the adenosine A2B receptor, CTLA-4, PD-1, ICOS, LAG-3, and IL-10) on CD8+ and CD4+ T cells, compared to lymph nodes from young mice.	Adenosine	155-164	5'-nucleotidase ecto	Homo sapiens	182-186
30392016-1	2018	Physiologically, retinal pigment epithelium (RPE) expresses high levels of CD73 in their membrane, converting AMP to immune suppressive adenosine, mediates an anti-inflammatory effect.	Adenosine	136-145	5'-nucleotidase ecto	Homo sapiens	75-79
30441833-3	2018	A lot of work has been done on extracellular 5"-nucleotidase and its involvement in the purinergic signaling, but also intracellular nucleotidases, which regulate the purine nucleotide homeostasis, play unexpected roles, not only in tumorigenesis but also in brain function.	Purine Nucleotides	167-184	5'-nucleotidase ecto	Homo sapiens	45-60
30467503-6	2018	Hypoxia also fuels the generation of adenosine from the cancer-associated ectoenzymes CD39 and CD73.	Adenosine	37-46	5'-nucleotidase ecto	Homo sapiens	95-99
30303204-1	2018	Ecto-nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39) is a major ectonucleotidase that hydrolyzes proinflammatory ATP via ADP to AMP, which is subsequently converted by ecto-5"-nucleotidase (CD73) to immunosuppressive adenosine.	Adenosine Triphosphate	126-129	5'-nucleotidase ecto	Homo sapiens	181-201
30473700-3	2018	In this sequence of events, the ectoenzyme CD39 degrades ATP into ADP and AMP, respectively, and CD73 catalyzes the last step leading to the production of Ado.	Adenosine	155-158	5'-nucleotidase ecto	Homo sapiens	97-101
30473700-6	2018	Thus, the balance of proinflammatory ATP and anti-inflammatory Ado that is regulated by CD39+/CD73+ immune cells, is important for decision making on whether tolerance or immunity ensues.	Adenosine Triphosphate	37-40	5'-nucleotidase ecto	Homo sapiens	94-98
30473700-7	2018	DCs express both ectoenzymes, enabling them to produce Ado from extracellular ATP by activity of CD73 and CD39 and thus allow dampening of the proinflammatory activity of adjacent leukocytes in the tissue.	Adenosine	55-58	5'-nucleotidase ecto	Homo sapiens	97-101
30473700-7	2018	DCs express both ectoenzymes, enabling them to produce Ado from extracellular ATP by activity of CD73 and CD39 and thus allow dampening of the proinflammatory activity of adjacent leukocytes in the tissue.	Adenosine Triphosphate	78-81	5'-nucleotidase ecto	Homo sapiens	97-101
30473700-2	2018	Ado can (i) actively be released by various cells into the tissue environment and can (ii) be produced through the degradation of extracellular ATP by the concerted action of CD39 and CD73.	Adenosine Triphosphate	144-147	5'-nucleotidase ecto	Homo sapiens	184-188
30303204-1	2018	Ecto-nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39) is a major ectonucleotidase that hydrolyzes proinflammatory ATP via ADP to AMP, which is subsequently converted by ecto-5"-nucleotidase (CD73) to immunosuppressive adenosine.	Adenosine Triphosphate	126-129	5'-nucleotidase ecto	Homo sapiens	203-207
30303204-1	2018	Ecto-nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39) is a major ectonucleotidase that hydrolyzes proinflammatory ATP via ADP to AMP, which is subsequently converted by ecto-5"-nucleotidase (CD73) to immunosuppressive adenosine.	Adenosine Diphosphate	134-137	5'-nucleotidase ecto	Homo sapiens	181-201
30303204-1	2018	Ecto-nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39) is a major ectonucleotidase that hydrolyzes proinflammatory ATP via ADP to AMP, which is subsequently converted by ecto-5"-nucleotidase (CD73) to immunosuppressive adenosine.	Adenosine Diphosphate	134-137	5'-nucleotidase ecto	Homo sapiens	203-207
30303204-1	2018	Ecto-nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39) is a major ectonucleotidase that hydrolyzes proinflammatory ATP via ADP to AMP, which is subsequently converted by ecto-5"-nucleotidase (CD73) to immunosuppressive adenosine.	Adenosine Monophosphate	141-144	5'-nucleotidase ecto	Homo sapiens	181-201
30303204-1	2018	Ecto-nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39) is a major ectonucleotidase that hydrolyzes proinflammatory ATP via ADP to AMP, which is subsequently converted by ecto-5"-nucleotidase (CD73) to immunosuppressive adenosine.	Adenosine Monophosphate	141-144	5'-nucleotidase ecto	Homo sapiens	203-207
30303204-1	2018	Ecto-nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39) is a major ectonucleotidase that hydrolyzes proinflammatory ATP via ADP to AMP, which is subsequently converted by ecto-5"-nucleotidase (CD73) to immunosuppressive adenosine.	Adenosine	230-239	5'-nucleotidase ecto	Homo sapiens	181-201
30303204-1	2018	Ecto-nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39) is a major ectonucleotidase that hydrolyzes proinflammatory ATP via ADP to AMP, which is subsequently converted by ecto-5"-nucleotidase (CD73) to immunosuppressive adenosine.	Adenosine	230-239	5'-nucleotidase ecto	Homo sapiens	203-207
29572822-0	2018	Methotrexate restores the function of peripheral blood regulatory T cells in psoriasis vulgaris via the CD73/AMPK/mTOR pathway.	Methotrexate	0-12	5'-nucleotidase ecto	Homo sapiens	104-108
29936438-9	2018	Use of CD73 blocking antibodies reversed MTX-induced tolerance.	Methotrexate	41-44	5'-nucleotidase ecto	Homo sapiens	7-11
30232037-3	2018	Suppression of adenosine signaling by inhibiting adenosine receptors or adenosine-generating enzymes (CD39 and CD73) on melanoma cells presents a novel therapeutic target for patients with melanoma.	Adenosine	15-24	5'-nucleotidase ecto	Homo sapiens	111-115
29572822-11	2018	CONCLUSIONS: We speculate that MTX can restore the immunosuppressive function of Tregs through upregulating CD73, activating AMPK and inactivating the mTOR pathway.	Methotrexate	31-34	5'-nucleotidase ecto	Homo sapiens	108-112
30176535-0	2018	CD73 inhibition by purine cytotoxic nucleoside analogue-based diphosphonates.	purine	19-25	5'-nucleotidase ecto	Homo sapiens	0-4
30319363-10	2018	Reduced expression of CD39 and CD73 suggests promotion of ATP-dependent pro-inflammatory and reduction of adenosine-mediated anti-inflammatory mechanisms in migraine.	Adenosine Triphosphate	58-61	5'-nucleotidase ecto	Homo sapiens	31-35
30319363-10	2018	Reduced expression of CD39 and CD73 suggests promotion of ATP-dependent pro-inflammatory and reduction of adenosine-mediated anti-inflammatory mechanisms in migraine.	Adenosine	106-115	5'-nucleotidase ecto	Homo sapiens	31-35
29663369-2	2018	CD73, an ecto-5-nucleotidase, is the ectoenzyme dephosphorylating extracellular AMP to adenosine.	Adenosine Monophosphate	80-83	5'-nucleotidase ecto	Homo sapiens	0-4
29663369-2	2018	CD73, an ecto-5-nucleotidase, is the ectoenzyme dephosphorylating extracellular AMP to adenosine.	Adenosine Monophosphate	80-83	5'-nucleotidase ecto	Homo sapiens	9-28
29663369-2	2018	CD73, an ecto-5-nucleotidase, is the ectoenzyme dephosphorylating extracellular AMP to adenosine.	Adenosine	87-96	5'-nucleotidase ecto	Homo sapiens	0-4
29663369-2	2018	CD73, an ecto-5-nucleotidase, is the ectoenzyme dephosphorylating extracellular AMP to adenosine.	Adenosine	87-96	5'-nucleotidase ecto	Homo sapiens	9-28
30839737-0	2018	Synthesis of novel (E)-1-(2-(2-(4(dimethylamino) benzylidene) hydrazinyl)-4-methylthiazol-5-yl)ethanone derivatives as ecto-5"-nucleotidase inhibitors.	(e)-1-(2-(2-(4(dimethylamino) benzylidene) hydrazinyl)-4-methylthiazol-5-yl)ethanone	19-103	5'-nucleotidase ecto	Homo sapiens	119-139
30075429-1	2018	Adenosine (ADO), generated by the ectonucleotidase CD39 and CD73 from ATP, interacts with its specific G protein-coupled receptors, which can impair anti-tumor immune responses inhibiting the infiltration and function of CD8+ T cell and natural killer cell.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	60-64
30075429-1	2018	Adenosine (ADO), generated by the ectonucleotidase CD39 and CD73 from ATP, interacts with its specific G protein-coupled receptors, which can impair anti-tumor immune responses inhibiting the infiltration and function of CD8+ T cell and natural killer cell.	Adenosine	11-14	5'-nucleotidase ecto	Homo sapiens	60-64
30075429-1	2018	Adenosine (ADO), generated by the ectonucleotidase CD39 and CD73 from ATP, interacts with its specific G protein-coupled receptors, which can impair anti-tumor immune responses inhibiting the infiltration and function of CD8+ T cell and natural killer cell.	Adenosine Triphosphate	70-73	5'-nucleotidase ecto	Homo sapiens	60-64
30176535-0	2018	CD73 inhibition by purine cytotoxic nucleoside analogue-based diphosphonates.	Nucleosides	36-46	5'-nucleotidase ecto	Homo sapiens	0-4
30176535-0	2018	CD73 inhibition by purine cytotoxic nucleoside analogue-based diphosphonates.	Diphosphonates	62-76	5'-nucleotidase ecto	Homo sapiens	0-4
30176535-2	2018	We describe new ADP analogues as CD73 inhibitors based on the replacement of the adenosine moiety, in the reference inhibitor APCP, by purine nucleoside analogues.	Adenosine Diphosphate	16-19	5'-nucleotidase ecto	Homo sapiens	33-37
30176535-2	2018	We describe new ADP analogues as CD73 inhibitors based on the replacement of the adenosine moiety, in the reference inhibitor APCP, by purine nucleoside analogues.	Adenosine	81-90	5'-nucleotidase ecto	Homo sapiens	33-37
30176535-2	2018	We describe new ADP analogues as CD73 inhibitors based on the replacement of the adenosine moiety, in the reference inhibitor APCP, by purine nucleoside analogues.	Purine Nucleosides	135-152	5'-nucleotidase ecto	Homo sapiens	33-37
30176535-4	2018	The clofarabine-containing compound (2) was shown to be more potent than APCP with IC50 values of 0.18 muM (vs. 3.8 muM) on purified protein and 0.24 muM (vs. 23.6 muM) on CD73 expressed on cells.	Clofarabine	4-15	5'-nucleotidase ecto	Homo sapiens	172-176
30155470-0	2018	Extracellular ATP Regulates CD73 and ABCC6 Expression in HepG2 Cells.	Adenosine Triphosphate	14-17	5'-nucleotidase ecto	Homo sapiens	28-32
29558203-7	2018	Inhibition of ATP hydrolyzing enzymes (CD39 and ENPP1) resulted in profound prodegenerative effects with a vigorous up-regulation of CD39, ENPP1, and CD73, as well as TGF-beta1 and osteopontin at the gene level.	Adenosine Triphosphate	14-17	5'-nucleotidase ecto	Homo sapiens	150-154
29977072-2	2018	We hypothesised that the expression of CD39 and CD73 would differ between propofol- and volatile anaesthetic-based anaesthesia in patients undergoing open heart surgery (OHS).	Propofol	74-82	5'-nucleotidase ecto	Homo sapiens	48-52
28560821-8	2018	The present study investigated whether ecto-5"-nucleotidase (CD73), an enzyme that generates adenosine, is functionally important in modifying CB sensory activity and cardiovascular respiratory responses to hypoxia.	Adenosine	93-102	5'-nucleotidase ecto	Homo sapiens	39-59
28560821-8	2018	The present study investigated whether ecto-5"-nucleotidase (CD73), an enzyme that generates adenosine, is functionally important in modifying CB sensory activity and cardiovascular respiratory responses to hypoxia.	Adenosine	93-102	5'-nucleotidase ecto	Homo sapiens	61-65
28560821-9	2018	Inhibition of CD73 by alpha,beta-methylene ADP (AOPCP) in the whole CB preparation in vitro reduced basal discharge frequency by 76 +- 5% and reduced sensory activity throughout graded hypoxia.	alpha,beta-methyleneadenosine 5'-diphosphate	22-46	5'-nucleotidase ecto	Homo sapiens	14-18
28560821-9	2018	Inhibition of CD73 by alpha,beta-methylene ADP (AOPCP) in the whole CB preparation in vitro reduced basal discharge frequency by 76 +- 5% and reduced sensory activity throughout graded hypoxia.	alpha,beta-methyleneadenosine 5'-diphosphate	48-53	5'-nucleotidase ecto	Homo sapiens	14-18
29977072-3	2018	The objective of this prospective randomized trial was to compare the changes in CD39 and CD73 levels in CD4+ T cells between propofol- and sevoflurane-based anaesthesia during OHS.	Propofol	126-134	5'-nucleotidase ecto	Homo sapiens	90-94
29977072-9	2018	The expression of CD39 and CD73 in the sevoflurane group was significantly lower than in the propofol group (P &lt; 0.001).	Sevoflurane	39-50	5'-nucleotidase ecto	Homo sapiens	27-31
29973267-0	2018	Human mesenchymal stromal cells inhibit platelet activation and aggregation involving CD73-converted adenosine.	Adenosine	101-110	5'-nucleotidase ecto	Homo sapiens	86-90
29977072-9	2018	The expression of CD39 and CD73 in the sevoflurane group was significantly lower than in the propofol group (P &lt; 0.001).	Propofol	93-101	5'-nucleotidase ecto	Homo sapiens	27-31
29973267-10	2018	Using inhibitors of the CD39-CD73-adenosine axis, we showed that adenosine produced by CD73 ectonucleotidase activity was largely responsible for the LA-MSC and BM-MSC platelet inhibitory action.	Adenosine	34-43	5'-nucleotidase ecto	Homo sapiens	87-91
29973267-10	2018	Using inhibitors of the CD39-CD73-adenosine axis, we showed that adenosine produced by CD73 ectonucleotidase activity was largely responsible for the LA-MSC and BM-MSC platelet inhibitory action.	Adenosine	65-74	5'-nucleotidase ecto	Homo sapiens	29-33
29973267-10	2018	Using inhibitors of the CD39-CD73-adenosine axis, we showed that adenosine produced by CD73 ectonucleotidase activity was largely responsible for the LA-MSC and BM-MSC platelet inhibitory action.	Adenosine	65-74	5'-nucleotidase ecto	Homo sapiens	87-91
29973267-13	2018	We now show that MSCs can, dependent on their tissue origin, inhibit platelet activation involving adenosine converted from adenosine monophosphate by CD73 ectonucleotidase activity.	Adenosine	99-108	5'-nucleotidase ecto	Homo sapiens	151-155
29973267-13	2018	We now show that MSCs can, dependent on their tissue origin, inhibit platelet activation involving adenosine converted from adenosine monophosphate by CD73 ectonucleotidase activity.	Adenosine Monophosphate	124-147	5'-nucleotidase ecto	Homo sapiens	151-155
29977072-11	2018	Propofol attenuated the decrease in CD39 and CD73 in circulating CD4+ T cells compared to sevoflurane-based anaesthesia during OHS.	Propofol	0-8	5'-nucleotidase ecto	Homo sapiens	45-49
29559470-0	2018	Autocrine Adenosine Regulates Tumor Polyfunctional CD73+CD4+ Effector T Cells Devoid of Immune Checkpoints.	Adenosine	10-19	5'-nucleotidase ecto	Homo sapiens	51-55
29559470-4	2018	CD39+ Tregs selectively targeted CD73+ Teffs through cooperative degradation of ATP into Ado inhibiting and restricting the ability of CD73+ Teffs to secrete IL17A.	Adenosine Triphosphate	80-83	5'-nucleotidase ecto	Homo sapiens	33-37
29455338-4	2018	Extracellular ATP is mainly hydrolyzed by NTPDase1/CD39 and NTPDase2/CD39L1, generating AMP, which is hydrolyzed by ecto-5"-nucleotidase (CD73) to adenosine, a possible promoter of tumor growth and metastasis.	Adenosine Triphosphate	14-17	5'-nucleotidase ecto	Homo sapiens	116-136
29914571-5	2018	Hypoxia, high cell turnover, and expression of CD39 and CD73 are important factors in adenosine production.	Adenosine	86-95	5'-nucleotidase ecto	Homo sapiens	56-60
29455338-10	2018	The higher expression of CD73 in PTC derived cells might favor the accumulation of extracellular adenosine in the tumor microenvironment, which could promote tumor progression.	Adenosine	97-106	5'-nucleotidase ecto	Homo sapiens	25-29
29455338-4	2018	Extracellular ATP is mainly hydrolyzed by NTPDase1/CD39 and NTPDase2/CD39L1, generating AMP, which is hydrolyzed by ecto-5"-nucleotidase (CD73) to adenosine, a possible promoter of tumor growth and metastasis.	Adenosine Triphosphate	14-17	5'-nucleotidase ecto	Homo sapiens	138-142
29455338-4	2018	Extracellular ATP is mainly hydrolyzed by NTPDase1/CD39 and NTPDase2/CD39L1, generating AMP, which is hydrolyzed by ecto-5"-nucleotidase (CD73) to adenosine, a possible promoter of tumor growth and metastasis.	Adenosine Monophosphate	88-91	5'-nucleotidase ecto	Homo sapiens	116-136
29455338-4	2018	Extracellular ATP is mainly hydrolyzed by NTPDase1/CD39 and NTPDase2/CD39L1, generating AMP, which is hydrolyzed by ecto-5"-nucleotidase (CD73) to adenosine, a possible promoter of tumor growth and metastasis.	Adenosine Monophosphate	88-91	5'-nucleotidase ecto	Homo sapiens	138-142
29455338-4	2018	Extracellular ATP is mainly hydrolyzed by NTPDase1/CD39 and NTPDase2/CD39L1, generating AMP, which is hydrolyzed by ecto-5"-nucleotidase (CD73) to adenosine, a possible promoter of tumor growth and metastasis.	Adenosine	147-156	5'-nucleotidase ecto	Homo sapiens	116-136
29455338-4	2018	Extracellular ATP is mainly hydrolyzed by NTPDase1/CD39 and NTPDase2/CD39L1, generating AMP, which is hydrolyzed by ecto-5"-nucleotidase (CD73) to adenosine, a possible promoter of tumor growth and metastasis.	Adenosine	147-156	5'-nucleotidase ecto	Homo sapiens	138-142
29455338-8	2018	In addition, adenosine induced an increase in proliferation and migration in PTC derived cells, whose effect was blocked by APCP, a non-hydrolysable ADP analogue, which is an inhibitor of CD73.	Adenosine	13-22	5'-nucleotidase ecto	Homo sapiens	188-192
29455338-8	2018	In addition, adenosine induced an increase in proliferation and migration in PTC derived cells, whose effect was blocked by APCP, a non-hydrolysable ADP analogue, which is an inhibitor of CD73.	Adenosine Diphosphate	149-152	5'-nucleotidase ecto	Homo sapiens	188-192
29759563-3	2018	High levels of extracellular adenosine (ADO) are detected in CLL as a consequence of expression of ecto-enzymes, such as CD39 and CD73.	Adenosine	29-38	5'-nucleotidase ecto	Homo sapiens	130-134
29759563-3	2018	High levels of extracellular adenosine (ADO) are detected in CLL as a consequence of expression of ecto-enzymes, such as CD39 and CD73.	Adenosine	40-43	5'-nucleotidase ecto	Homo sapiens	130-134
29928476-1	2018	Background: CD73 is an ectoenzyme involved in the production of adenosine.	Adenosine	64-73	5'-nucleotidase ecto	Homo sapiens	12-16
29928476-3	2018	Results: CD73 expression was detected in TC in 54% of melanoma metastases, involving &lt; 50% TC in the majority of the cases, with variable intensity.	Technetium	41-43	5'-nucleotidase ecto	Homo sapiens	9-13
29928476-3	2018	Results: CD73 expression was detected in TC in 54% of melanoma metastases, involving &lt; 50% TC in the majority of the cases, with variable intensity.	Technetium	94-96	5'-nucleotidase ecto	Homo sapiens	9-13
29928476-6	2018	Of the samples containing TIMC, 35% presented CD73+ TIMC.	timc	26-30	5'-nucleotidase ecto	Homo sapiens	46-50
29928476-10	2018	While CD73 expression in TC significantly correlated with decreased OS, CD73 expression in TIMC significantly associated with improved OS.	Technetium	25-27	5'-nucleotidase ecto	Homo sapiens	6-10
29928476-10	2018	While CD73 expression in TC significantly correlated with decreased OS, CD73 expression in TIMC significantly associated with improved OS.	Osmium	68-70	5'-nucleotidase ecto	Homo sapiens	6-10
29928476-10	2018	While CD73 expression in TC significantly correlated with decreased OS, CD73 expression in TIMC significantly associated with improved OS.	Osmium	135-137	5'-nucleotidase ecto	Homo sapiens	72-76
30221054-2	2018	Adenosine (ADO), an immunosuppressive molecule, is produced within MM patients" BM by adenosinergic ectoenzymes, starting from ATP (CD39/CD73) or NAD+ [CD38/CD203a(PC-1)/CD73].	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	137-141
29742141-1	2018	The ectoenzymes CD39 and CD73 degrade extracellular ATP to adenosine.	Adenosine Triphosphate	52-55	5'-nucleotidase ecto	Homo sapiens	25-29
29742141-1	2018	The ectoenzymes CD39 and CD73 degrade extracellular ATP to adenosine.	Adenosine	59-68	5'-nucleotidase ecto	Homo sapiens	25-29
30221054-2	2018	Adenosine (ADO), an immunosuppressive molecule, is produced within MM patients" BM by adenosinergic ectoenzymes, starting from ATP (CD39/CD73) or NAD+ [CD38/CD203a(PC-1)/CD73].	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	170-174
30221054-2	2018	Adenosine (ADO), an immunosuppressive molecule, is produced within MM patients" BM by adenosinergic ectoenzymes, starting from ATP (CD39/CD73) or NAD+ [CD38/CD203a(PC-1)/CD73].	Adenosine	11-14	5'-nucleotidase ecto	Homo sapiens	137-141
30221054-2	2018	Adenosine (ADO), an immunosuppressive molecule, is produced within MM patients" BM by adenosinergic ectoenzymes, starting from ATP (CD39/CD73) or NAD+ [CD38/CD203a(PC-1)/CD73].	Adenosine	11-14	5'-nucleotidase ecto	Homo sapiens	170-174
29278640-9	2018	Combined AP activity and CD73 concentration predicted adenosine production capacity (P&lt;0.0001).ConclusionsSerum CD73 increases following infant CPB.	Adenosine	54-63	5'-nucleotidase ecto	Homo sapiens	25-29
29731713-2	2018	Numerous studies have explored the role of CD38, CD39, CD203a/PC-1, and CD73 in generating extracellular adenosine (ADO) and thus in shaping the tumor niche in favor of proliferation.	Adenosine	105-114	5'-nucleotidase ecto	Homo sapiens	72-76
29731713-2	2018	Numerous studies have explored the role of CD38, CD39, CD203a/PC-1, and CD73 in generating extracellular adenosine (ADO) and thus in shaping the tumor niche in favor of proliferation.	Adenosine	116-119	5'-nucleotidase ecto	Homo sapiens	72-76
29731713-3	2018	The findings shown here reveal that CIK cells are able to produce extracellular ADO via traditional (CD39/CD73) and/or alternative (CD38/CD203a/CD73 or CD203a/CD73) pathways.	Adenosine	80-83	5'-nucleotidase ecto	Homo sapiens	106-110
29731713-3	2018	The findings shown here reveal that CIK cells are able to produce extracellular ADO via traditional (CD39/CD73) and/or alternative (CD38/CD203a/CD73 or CD203a/CD73) pathways.	Adenosine	80-83	5'-nucleotidase ecto	Homo sapiens	144-148
29731713-3	2018	The findings shown here reveal that CIK cells are able to produce extracellular ADO via traditional (CD39/CD73) and/or alternative (CD38/CD203a/CD73 or CD203a/CD73) pathways.	Adenosine	80-83	5'-nucleotidase ecto	Homo sapiens	144-148
29374065-0	2018	Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer.	Metformin	0-9	5'-nucleotidase ecto	Homo sapiens	40-44
29374065-2	2018	We show here that metformin treatment blocks the suppressive function of myeloid-derived suppressor cells (MDSC) in patients with ovarian cancer by downregulating the expression and ectoenzymatic activity of CD39 and CD73 on monocytic and polymononuclear MDSC subsets.	Metformin	18-27	5'-nucleotidase ecto	Homo sapiens	217-221
29374065-3	2018	Metformin triggered activation of AMP-activated protein kinase alpha and subsequently suppressed hypoxia-inducible factor alpha, which was critical for induction of CD39/CD73 expression in MDSC.	Metformin	0-9	5'-nucleotidase ecto	Homo sapiens	170-174
29374065-4	2018	Furthermore, metformin treatment correlated with longer overall survival in diabetic patients with ovarian cancer, which was accompanied by a metformin-induced reduction in the frequency of circulating CD39+CD73+ MDSC and a concomitant increase in the antitumor activities of circulating CD8+ T cells.	Metformin	13-22	5'-nucleotidase ecto	Homo sapiens	207-211
29374065-4	2018	Furthermore, metformin treatment correlated with longer overall survival in diabetic patients with ovarian cancer, which was accompanied by a metformin-induced reduction in the frequency of circulating CD39+CD73+ MDSC and a concomitant increase in the antitumor activities of circulating CD8+ T cells.	Metformin	142-151	5'-nucleotidase ecto	Homo sapiens	207-211
29374065-5	2018	Our results highlight a direct effect of metformin on MDSC and suggest that metformin may yield clinical benefit through improvement of antitumor T-cell immunity by dampening CD39/CD73-dependent MDSC immunosuppression in ovarian cancer patients.Significance: The antitumor activity of an antidiabetes drug is attributable to reduced immunosuppressive activity of myeloid-derived tumor suppressor cells.	Metformin	76-85	5'-nucleotidase ecto	Homo sapiens	180-184
28617999-4	2018	Suppression of adenosine signaling via inhibition of adenosine receptors or adenosine generating enzymes including CD39 and CD73 on ovarian or cervical cancer cells is a potentially novel therapeutic approach for gynecological cancer patients.	Adenosine	15-24	5'-nucleotidase ecto	Homo sapiens	124-128
29739946-3	2018	Here, using a chemically defined hPSC differentiation system combined with the use of DLL1-Fc and DAPT to manipulate NOTCH, we discover that NOTCH activation in hPSC-derived immature HE progenitors leads to formation of CD144+CD43-CD73-DLL4+Runx1 + 23-GFP+ arterial-type HE, which requires NOTCH signaling to undergo endothelial-to-hematopoietic transition and produce definitive lympho-myeloid and erythroid cells.	dapt	98-102	5'-nucleotidase ecto	Homo sapiens	231-235
29514048-4	2018	Exposure of HUVEC and VVEC to 1% O2 for 4-24 h triggered rather moderate activation of ATP breakdown into adenosine via the CD39-CD73 axis.	Oxygen	33-35	5'-nucleotidase ecto	Homo sapiens	129-133
29514048-4	2018	Exposure of HUVEC and VVEC to 1% O2 for 4-24 h triggered rather moderate activation of ATP breakdown into adenosine via the CD39-CD73 axis.	Adenosine Triphosphate	87-90	5'-nucleotidase ecto	Homo sapiens	129-133
29514048-4	2018	Exposure of HUVEC and VVEC to 1% O2 for 4-24 h triggered rather moderate activation of ATP breakdown into adenosine via the CD39-CD73 axis.	Adenosine	106-115	5'-nucleotidase ecto	Homo sapiens	129-133
29551673-8	2018	The biological function of CD73 in OCICs required its enzymatic activity and involved adenosine signaling.	Adenosine	86-95	5'-nucleotidase ecto	Homo sapiens	27-31
29145561-1	2018	Background: CD73 is an ecto-enzyme that promotes tumor immune escape through the production of immunosuppressive extracellular adenosine in the tumor microenvironment.	Adenosine	127-136	5'-nucleotidase ecto	Homo sapiens	12-16
29278640-9	2018	Combined AP activity and CD73 concentration predicted adenosine production capacity (P&lt;0.0001).ConclusionsSerum CD73 increases following infant CPB.	Adenosine	54-63	5'-nucleotidase ecto	Homo sapiens	115-119
29278640-11	2018	CD73 and AP together predict serum adenosine production capacity and may represent potential therapeutic targets to clear extracellular adenine nucleotides and improve outcomes following infant CPB.	Adenosine	35-44	5'-nucleotidase ecto	Homo sapiens	0-4
29278640-11	2018	CD73 and AP together predict serum adenosine production capacity and may represent potential therapeutic targets to clear extracellular adenine nucleotides and improve outcomes following infant CPB.	Adenine Nucleotides	136-155	5'-nucleotidase ecto	Homo sapiens	0-4
29769837-2	2018	ADO is produced from ATP through the enzymatic activities of CD39 and CD73.	Adenosine Triphosphate	21-24	5'-nucleotidase ecto	Homo sapiens	70-74
29306022-1	2018	T regulatory cells (Tregs), involved in tumour tolerance, can generate Adenosine by CD39/CD73 surface enzymes, which identify four Tregs subsets: CD39+CD73- nTregs, CD39+CD73+ iTregs, CD39-CD73+ oTregs and CD39-CD73- xTregs.	Adenosine	71-80	5'-nucleotidase ecto	Homo sapiens	89-93
29636685-2	2018	In the extracellular compartment ATP is converted by CD39, CD73, and other ecto-enzymes into metabolites that modulate the activity of T cells and macrophages.	Adenosine Triphosphate	33-36	5'-nucleotidase ecto	Homo sapiens	59-63
29769837-3	2018	Alternatively, ADO can be generated starting from NAD+, which is metabolized by the concerted action of CD38, CD203a/PC-1, and CD73.	Adenosine	15-18	5'-nucleotidase ecto	Homo sapiens	127-131
29769837-3	2018	Alternatively, ADO can be generated starting from NAD+, which is metabolized by the concerted action of CD38, CD203a/PC-1, and CD73.	NAD	50-54	5'-nucleotidase ecto	Homo sapiens	127-131
29273916-7	2018	CD73, together with alkaline phosphatase, also expressed apically in oviductal epithelium, complete the hydrolysis sequence by dephosphorylating AMP to adenosine.	Adenosine Monophosphate	145-148	5'-nucleotidase ecto	Homo sapiens	0-4
29514610-8	2018	Data from Oncomine validated that median CD73 expression level in tumor tissues was markedly higher than that in normal tissues in most kinds of cancers except cecum adenocarcinoma and ovarian cancer (P &lt; 0.05).	oncomine	10-18	5'-nucleotidase ecto	Homo sapiens	41-45
29273916-7	2018	CD73, together with alkaline phosphatase, also expressed apically in oviductal epithelium, complete the hydrolysis sequence by dephosphorylating AMP to adenosine.	Adenosine	152-161	5'-nucleotidase ecto	Homo sapiens	0-4
29047106-3	2018	The relationship between CD73 and AKT/GSK-3beta/beta-catenin pathway was assessed with adenosine, adenosine 2A receptor antagonist (SCH-58261), adenosine 2A receptor agonist (NECA), CD73 enzyme inhibitor (APCP) and Akt inhibitor (MK-2206).	Adenosine	87-96	5'-nucleotidase ecto	Homo sapiens	25-29
29047106-3	2018	The relationship between CD73 and AKT/GSK-3beta/beta-catenin pathway was assessed with adenosine, adenosine 2A receptor antagonist (SCH-58261), adenosine 2A receptor agonist (NECA), CD73 enzyme inhibitor (APCP) and Akt inhibitor (MK-2206).	5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine	132-141	5'-nucleotidase ecto	Homo sapiens	25-29
29662657-0	2018	5"-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer.	gemcitabine	75-86	5'-nucleotidase ecto	Homo sapiens	0-15
29545748-1	2018	CD73 is a bifunctional glycosylphosphatidylinositol (GPI)-anchored membrane protein which functions as ecto-5"-nucleotidase and a membrane receptor for extracellular matrix protein (ECM).	Glycosylphosphatidylinositols	23-51	5'-nucleotidase ecto	Homo sapiens	0-4
29545748-1	2018	CD73 is a bifunctional glycosylphosphatidylinositol (GPI)-anchored membrane protein which functions as ecto-5"-nucleotidase and a membrane receptor for extracellular matrix protein (ECM).	Glycosylphosphatidylinositols	23-51	5'-nucleotidase ecto	Homo sapiens	103-123
28233320-4	2018	Two cell surface expressed molecules including CD73 and CD39 catalyze the generation of adenosine from adenosine triphosphate (ATP).	Adenosine	88-97	5'-nucleotidase ecto	Homo sapiens	47-51
28233320-4	2018	Two cell surface expressed molecules including CD73 and CD39 catalyze the generation of adenosine from adenosine triphosphate (ATP).	Adenosine Triphosphate	103-125	5'-nucleotidase ecto	Homo sapiens	47-51
28233320-4	2018	Two cell surface expressed molecules including CD73 and CD39 catalyze the generation of adenosine from adenosine triphosphate (ATP).	Adenosine Triphosphate	127-130	5'-nucleotidase ecto	Homo sapiens	47-51
29545748-1	2018	CD73 is a bifunctional glycosylphosphatidylinositol (GPI)-anchored membrane protein which functions as ecto-5"-nucleotidase and a membrane receptor for extracellular matrix protein (ECM).	Glycosylphosphatidylinositols	53-56	5'-nucleotidase ecto	Homo sapiens	0-4
29545748-1	2018	CD73 is a bifunctional glycosylphosphatidylinositol (GPI)-anchored membrane protein which functions as ecto-5"-nucleotidase and a membrane receptor for extracellular matrix protein (ECM).	Glycosylphosphatidylinositols	53-56	5'-nucleotidase ecto	Homo sapiens	103-123
29336194-1	2018	CD73/Ecto-5"-nucleotidase is a membrane-tethered ecto-enzyme that works in tandem with CD39 to convert extracellular adenosine triphosphate (ATP) into adenosine.	Adenosine Triphosphate	117-139	5'-nucleotidase ecto	Homo sapiens	0-4
29336194-1	2018	CD73/Ecto-5"-nucleotidase is a membrane-tethered ecto-enzyme that works in tandem with CD39 to convert extracellular adenosine triphosphate (ATP) into adenosine.	Adenosine Triphosphate	117-139	5'-nucleotidase ecto	Homo sapiens	5-25
29336194-1	2018	CD73/Ecto-5"-nucleotidase is a membrane-tethered ecto-enzyme that works in tandem with CD39 to convert extracellular adenosine triphosphate (ATP) into adenosine.	Adenosine Triphosphate	141-144	5'-nucleotidase ecto	Homo sapiens	0-4
29336194-1	2018	CD73/Ecto-5"-nucleotidase is a membrane-tethered ecto-enzyme that works in tandem with CD39 to convert extracellular adenosine triphosphate (ATP) into adenosine.	Adenosine Triphosphate	141-144	5'-nucleotidase ecto	Homo sapiens	5-25
29336194-1	2018	CD73/Ecto-5"-nucleotidase is a membrane-tethered ecto-enzyme that works in tandem with CD39 to convert extracellular adenosine triphosphate (ATP) into adenosine.	Adenosine	117-126	5'-nucleotidase ecto	Homo sapiens	0-4
29336194-1	2018	CD73/Ecto-5"-nucleotidase is a membrane-tethered ecto-enzyme that works in tandem with CD39 to convert extracellular adenosine triphosphate (ATP) into adenosine.	Adenosine	117-126	5'-nucleotidase ecto	Homo sapiens	5-25
29336194-2	2018	CD73 is highly expressed on various types of cancer cells and on infiltrating suppressive immune cells, leading to an elevated concentration of adenosine in the tumor microenvironment, which elicits a strong immunosuppressive effect.	Adenosine	144-153	5'-nucleotidase ecto	Homo sapiens	0-4
29336194-4	2018	Despite initial studies using antibodies, inhibition of CD73 catalytic activity using small-molecule inhibitors may be more effective in lowering extracellular adenosine due to better tumor penetration and distribution.	Adenosine	160-169	5'-nucleotidase ecto	Homo sapiens	56-60
29662657-0	2018	5"-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer.	Platinum	87-95	5'-nucleotidase ecto	Homo sapiens	0-15
28938850-1	2018	INTRODUCTION: CD73 is an enzyme crucial in the metabolism of immunosuppressive adenosine.	Adenosine	79-88	5'-nucleotidase ecto	Homo sapiens	14-18
29303198-1	2018	Synthesis of pyrazolopyridines and benzofuropyridines and their optical and ecto-5"-nucleotidase inhibitory effects.	pyrazolopyridine	13-30	5'-nucleotidase ecto	Homo sapiens	76-96
29197225-0	2018	4-Aminopyridine based amide derivatives as dual inhibitors of tissue non-specific alkaline phosphatase and ecto-5"-nucleotidase with potential anticancer activity.	4-Aminopyridine	0-15	5'-nucleotidase ecto	Homo sapiens	107-127
29197225-0	2018	4-Aminopyridine based amide derivatives as dual inhibitors of tissue non-specific alkaline phosphatase and ecto-5"-nucleotidase with potential anticancer activity.	Amides	22-27	5'-nucleotidase ecto	Homo sapiens	107-127
29166791-0	2018	Evaluation of WO2017098421: GSK"s benzothiazine compounds as CD73 inhibitor filings.	benzothiazine	34-47	5'-nucleotidase ecto	Homo sapiens	61-65
29166791-2	2018	Areas covered: The application claims novel substituted benzothiadiazine derivatives as CD73 inhibitors for the treatment of cancer, precancerous syndromes, AIDS, autoimmune diseases, infections, atherosclerosis, and ischemia-reperfusion injury.	Benzothiadiazines	56-72	5'-nucleotidase ecto	Homo sapiens	88-92
29166791-4	2018	Expert Opinion: These benzothiadiazine derivatives provide good leads for the discovery of potent CD73 inhibitors for the treatment of cancer and other diseases mediated by adenosine and its action on adenosine receptors.	Benzothiadiazines	22-38	5'-nucleotidase ecto	Homo sapiens	98-102
29166791-4	2018	Expert Opinion: These benzothiadiazine derivatives provide good leads for the discovery of potent CD73 inhibitors for the treatment of cancer and other diseases mediated by adenosine and its action on adenosine receptors.	Adenosine	173-182	5'-nucleotidase ecto	Homo sapiens	98-102
29066254-7	2018	Furthermore Ci8 short affects CD4+/CD25high induced regulatory T cells (iTreg) subset selection which co-expressed the functional markers TGF-beta1/Latency Associated Protein (LAP) and CD39/CD73.	ci8	12-15	5'-nucleotidase ecto	Homo sapiens	190-194
29303198-1	2018	Synthesis of pyrazolopyridines and benzofuropyridines and their optical and ecto-5"-nucleotidase inhibitory effects.	benzofuropyridines	35-53	5'-nucleotidase ecto	Homo sapiens	76-96
29377887-1	2018	The ecto-5"-nucleotidase CD73 plays an important role in the production of immune-suppressive adenosine in tumor micro-environment, and has become a validated drug target in oncology.	Adenosine	94-103	5'-nucleotidase ecto	Homo sapiens	4-24
29377887-1	2018	The ecto-5"-nucleotidase CD73 plays an important role in the production of immune-suppressive adenosine in tumor micro-environment, and has become a validated drug target in oncology.	Adenosine	94-103	5'-nucleotidase ecto	Homo sapiens	25-29
29377887-3	2018	However, in the tumor micro-environment, two extracellular membrane-bound enzymes (CD39 and CD73) are overexpressed and hydrolyze efficiently ATP into AMP then further into immune-suppressive adenosine.	Adenosine Triphosphate	142-145	5'-nucleotidase ecto	Homo sapiens	92-96
29377887-3	2018	However, in the tumor micro-environment, two extracellular membrane-bound enzymes (CD39 and CD73) are overexpressed and hydrolyze efficiently ATP into AMP then further into immune-suppressive adenosine.	Adenosine Monophosphate	151-154	5'-nucleotidase ecto	Homo sapiens	92-96
29377887-3	2018	However, in the tumor micro-environment, two extracellular membrane-bound enzymes (CD39 and CD73) are overexpressed and hydrolyze efficiently ATP into AMP then further into immune-suppressive adenosine.	Adenosine	192-201	5'-nucleotidase ecto	Homo sapiens	92-96
29377887-4	2018	To circumvent the impact of CD73-generated adenosine, we applied an original bioinformatics approach to identify new allosteric inhibitors targeting the dimerization interface of CD73, which should impair the large dynamic motions required for its enzymatic function.	Adenosine	43-52	5'-nucleotidase ecto	Homo sapiens	28-32
29377887-4	2018	To circumvent the impact of CD73-generated adenosine, we applied an original bioinformatics approach to identify new allosteric inhibitors targeting the dimerization interface of CD73, which should impair the large dynamic motions required for its enzymatic function.	Adenosine	43-52	5'-nucleotidase ecto	Homo sapiens	179-183
29315226-1	2018	Ectonucleotidases CD39 and CD73, specific nucleotide metabolizing enzymes located on the surface of the host, can convert a pro-inflammatory environment driven by a danger molecule extracellular-ATP to an adenosine-mediated anti-inflammatory milieu.	Adenosine Triphosphate	195-198	5'-nucleotidase ecto	Homo sapiens	27-31
29315226-1	2018	Ectonucleotidases CD39 and CD73, specific nucleotide metabolizing enzymes located on the surface of the host, can convert a pro-inflammatory environment driven by a danger molecule extracellular-ATP to an adenosine-mediated anti-inflammatory milieu.	Adenosine	205-214	5'-nucleotidase ecto	Homo sapiens	27-31
28464260-9	2017	Pharmacological approaches strongly suggested that the effect of Apyrase involved the accumulation of extracellular adenosine; this notion was strengthened when the incubation of the SKOV-3 cell with alpha,beta-methylene ADP (CD73 inhibitor) or adenosine deaminase was sufficient to abolish the effect of apyrase on cell migration.	Adenosine	116-125	5'-nucleotidase ecto	Homo sapiens	226-230
29345574-1	2018	CD73, also known as ecto-5"-nucleotidase (eN, NT5E, EC3.13.5), is the ratelimiting enzyme for adenosine generation and is expressed on multiple cells.	Adenosine	94-103	5'-nucleotidase ecto	Homo sapiens	0-4
29345574-1	2018	CD73, also known as ecto-5"-nucleotidase (eN, NT5E, EC3.13.5), is the ratelimiting enzyme for adenosine generation and is expressed on multiple cells.	Adenosine	94-103	5'-nucleotidase ecto	Homo sapiens	20-40
29345574-1	2018	CD73, also known as ecto-5"-nucleotidase (eN, NT5E, EC3.13.5), is the ratelimiting enzyme for adenosine generation and is expressed on multiple cells.	Adenosine	94-103	5'-nucleotidase ecto	Homo sapiens	42-44
29345574-1	2018	CD73, also known as ecto-5"-nucleotidase (eN, NT5E, EC3.13.5), is the ratelimiting enzyme for adenosine generation and is expressed on multiple cells.	Adenosine	94-103	5'-nucleotidase ecto	Homo sapiens	46-50
29345574-5	2018	In addition, CD73 is expressed on Treg cells and mediates immune suppression through adenosine.	Adenosine	85-94	5'-nucleotidase ecto	Homo sapiens	13-17
30295112-2	2018	A potential histological differentiating mechanism is the use of immunohistochemical staining for the mesenchymal stem cell marker CD73, as a pilot study showed ITB but not CD granulomas stained positive for this marker.	ITB 301	161-164	5'-nucleotidase ecto	Homo sapiens	131-135
30295112-3	2018	The aim of this study was to assess the value of CD73 in differentiating ITB from CD granulomas in a South African cohort.	ITB 301	73-76	5'-nucleotidase ecto	Homo sapiens	49-53
29061643-5	2018	Motolimod plus cetuximab also decreased induction of Treg and reduced markers of suppression, including CTLA-4, CD73, and membrane-bound TGFbeta.	VTX-2337	0-9	5'-nucleotidase ecto	Homo sapiens	112-116
28464260-9	2017	Pharmacological approaches strongly suggested that the effect of Apyrase involved the accumulation of extracellular adenosine; this notion was strengthened when the incubation of the SKOV-3 cell with alpha,beta-methylene ADP (CD73 inhibitor) or adenosine deaminase was sufficient to abolish the effect of apyrase on cell migration.	methylene adp	211-224	5'-nucleotidase ecto	Homo sapiens	226-230
29127315-11	2017	Mechanismly, GMSCs could migrate to pancreas and local lymph node and function through CD39/CD73 pathway to regulate effector T cells.	gmscs	13-18	5'-nucleotidase ecto	Homo sapiens	92-96
29083399-4	2017	Mechanistically, apoptotic Treg cells release and convert a large amount of ATP to adenosine via CD39 and CD73, and mediate immunosuppression via the adenosine and A2A pathways.	Adenosine Triphosphate	76-79	5'-nucleotidase ecto	Homo sapiens	106-110
29209319-1	2017	The ectoenzymes CD39 and CD73 regulate the purinergic signaling through the hydrolysis of adenosine triphosphate (ATP)/ADP to AMP and to adenosine (Ado), respectively.	Adenosine Triphosphate	90-112	5'-nucleotidase ecto	Homo sapiens	25-29
29209319-1	2017	The ectoenzymes CD39 and CD73 regulate the purinergic signaling through the hydrolysis of adenosine triphosphate (ATP)/ADP to AMP and to adenosine (Ado), respectively.	Adenosine Triphosphate	114-117	5'-nucleotidase ecto	Homo sapiens	25-29
29209319-1	2017	The ectoenzymes CD39 and CD73 regulate the purinergic signaling through the hydrolysis of adenosine triphosphate (ATP)/ADP to AMP and to adenosine (Ado), respectively.	Adenosine Diphosphate	119-122	5'-nucleotidase ecto	Homo sapiens	25-29
29209319-1	2017	The ectoenzymes CD39 and CD73 regulate the purinergic signaling through the hydrolysis of adenosine triphosphate (ATP)/ADP to AMP and to adenosine (Ado), respectively.	Adenosine Monophosphate	126-129	5'-nucleotidase ecto	Homo sapiens	25-29
29209319-1	2017	The ectoenzymes CD39 and CD73 regulate the purinergic signaling through the hydrolysis of adenosine triphosphate (ATP)/ADP to AMP and to adenosine (Ado), respectively.	Adenosine	90-99	5'-nucleotidase ecto	Homo sapiens	25-29
29209319-1	2017	The ectoenzymes CD39 and CD73 regulate the purinergic signaling through the hydrolysis of adenosine triphosphate (ATP)/ADP to AMP and to adenosine (Ado), respectively.	Adenosine	148-151	5'-nucleotidase ecto	Homo sapiens	25-29
28950987-1	2017	BACKGROUND: The expression of CD73 in tumor cells plays a significant role in the production of adenosine (Ado) that suppresses antitumor effector cells.	Adenosine	96-105	5'-nucleotidase ecto	Homo sapiens	30-34
28950987-1	2017	BACKGROUND: The expression of CD73 in tumor cells plays a significant role in the production of adenosine (Ado) that suppresses antitumor effector cells.	Adenosine	107-110	5'-nucleotidase ecto	Homo sapiens	30-34
28950987-3	2017	RESULTS: HPV+ CeCa cells expressed significantly higher levels of CD73 in the membrane (p&lt;0.01) than HPV- CeCa cells and this expression was associated with the production of larger amounts of Ado (&gt;400muM) compared to HPV-CeCa cells (&lt;200muM) in the presence of AMP, as well asa stronger inhibition of (&gt;50%) proliferation, activation, and cytotoxic activity of CD8+ T cells via interaction with A2A adenosine receptor.	Adenosine Monophosphate	272-275	5'-nucleotidase ecto	Homo sapiens	66-70
28950987-3	2017	RESULTS: HPV+ CeCa cells expressed significantly higher levels of CD73 in the membrane (p&lt;0.01) than HPV- CeCa cells and this expression was associated with the production of larger amounts of Ado (&gt;400muM) compared to HPV-CeCa cells (&lt;200muM) in the presence of AMP, as well asa stronger inhibition of (&gt;50%) proliferation, activation, and cytotoxic activity of CD8+ T cells via interaction with A2A adenosine receptor.	Aspirin	285-288	5'-nucleotidase ecto	Homo sapiens	66-70
28950987-5	2017	CONCLUSION: This results suggest that HPV infection, which is associated with more than 99% of CeCa cases, may present an increased constitutive expression of CD73 in cervical neoplasia to contribute to the suppression of the immune response mediated by the production of large amounts of Ado.	Adenosine	289-292	5'-nucleotidase ecto	Homo sapiens	159-163
28959385-8	2017	We identified exosomal prostaglandin E2 (PGE2) as a potential driver of CD73 induction, as inhibition of PGE2 receptors significantly reduced exosome-dependent CD73 induction.	Dinoprostone	41-45	5'-nucleotidase ecto	Homo sapiens	72-76
28916770-0	2017	Changes in CD73, CD39 and CD26 expression on T-lymphocytes of ANCA-associated vasculitis patients suggest impairment in adenosine generation and turn-over.	Adenosine	120-129	5'-nucleotidase ecto	Homo sapiens	11-15
28916770-1	2017	Extracellular adenosine, generated via the concerted action of CD39 and CD73, contributes to T-cell differentiation and function.	Adenosine	14-23	5'-nucleotidase ecto	Homo sapiens	72-76
28959385-6	2017	CD8+ T cell responses were impaired via exosomal regulation of DC function; exosomes triggered the expression of CD73, an ecto-5-nucleotidase responsible for AMP to adenosine hydrolysis, on DC.	Adenosine Monophosphate	158-161	5'-nucleotidase ecto	Homo sapiens	113-117
28959385-6	2017	CD8+ T cell responses were impaired via exosomal regulation of DC function; exosomes triggered the expression of CD73, an ecto-5-nucleotidase responsible for AMP to adenosine hydrolysis, on DC.	Adenosine Monophosphate	158-161	5'-nucleotidase ecto	Homo sapiens	122-141
28959385-8	2017	We identified exosomal prostaglandin E2 (PGE2) as a potential driver of CD73 induction, as inhibition of PGE2 receptors significantly reduced exosome-dependent CD73 induction.	Dinoprostone	41-45	5'-nucleotidase ecto	Homo sapiens	160-164
28959385-6	2017	CD8+ T cell responses were impaired via exosomal regulation of DC function; exosomes triggered the expression of CD73, an ecto-5-nucleotidase responsible for AMP to adenosine hydrolysis, on DC.	Adenosine	165-174	5'-nucleotidase ecto	Homo sapiens	113-117
28747757-0	2017	TGFbeta-induced osteogenic potential of human amniotic fluid stem cells via CD73-generated adenosine production.	Adenosine	91-100	5'-nucleotidase ecto	Homo sapiens	76-80
28959385-6	2017	CD8+ T cell responses were impaired via exosomal regulation of DC function; exosomes triggered the expression of CD73, an ecto-5-nucleotidase responsible for AMP to adenosine hydrolysis, on DC.	Adenosine	165-174	5'-nucleotidase ecto	Homo sapiens	122-141
28959385-7	2017	CD73 induction on DC that constitutively express CD39 resulted in an ATP-dependent inhibition of TNFalpha- and IL-12-production.	Adenosine Triphosphate	69-72	5'-nucleotidase ecto	Homo sapiens	0-4
28959385-8	2017	We identified exosomal prostaglandin E2 (PGE2) as a potential driver of CD73 induction, as inhibition of PGE2 receptors significantly reduced exosome-dependent CD73 induction.	Dinoprostone	23-39	5'-nucleotidase ecto	Homo sapiens	72-76
28959385-8	2017	We identified exosomal prostaglandin E2 (PGE2) as a potential driver of CD73 induction, as inhibition of PGE2 receptors significantly reduced exosome-dependent CD73 induction.	Dinoprostone	23-39	5'-nucleotidase ecto	Homo sapiens	160-164
28775208-3	2017	Two lead therapies, regorafenib (Reg) and NU7441, were selected based on their ability to alter a variety of immunomodulatory proteins, including CD55, CD73, CD155, programmed death-ligand 1 (PD-L1), nerve growth factor receptor (NGFR), and HLA class I in a heterogeneous panel of melanomas.	regorafenib	20-31	5'-nucleotidase ecto	Homo sapiens	152-156
28547381-2	2017	High levels of extracellular ATP saturate the ATP hydrolysis enzymes CD39 and CD73 resulting in persistent high ATP levels despite the conversion to adenosine.	Adenosine Triphosphate	29-32	5'-nucleotidase ecto	Homo sapiens	78-82
28547381-2	2017	High levels of extracellular ATP saturate the ATP hydrolysis enzymes CD39 and CD73 resulting in persistent high ATP levels despite the conversion to adenosine.	Adenosine Triphosphate	46-49	5'-nucleotidase ecto	Homo sapiens	78-82
28547381-2	2017	High levels of extracellular ATP saturate the ATP hydrolysis enzymes CD39 and CD73 resulting in persistent high ATP levels despite the conversion to adenosine.	Adenosine Triphosphate	46-49	5'-nucleotidase ecto	Homo sapiens	78-82
28547381-2	2017	High levels of extracellular ATP saturate the ATP hydrolysis enzymes CD39 and CD73 resulting in persistent high ATP levels despite the conversion to adenosine.	Adenosine	149-158	5'-nucleotidase ecto	Homo sapiens	78-82
28547381-6	2017	The high levels of extracellular ATP and the upregulation of ecto-enzymes and soluble enzymes that hydrolyse ATP to adenosine (CD39 and CD73) increase the extracellular adenosine levels that inhibit the innate and adaptive immune responses rendering the host susceptible to infection by invading microorganisms.	Adenosine Triphosphate	33-36	5'-nucleotidase ecto	Homo sapiens	136-140
28547381-6	2017	The high levels of extracellular ATP and the upregulation of ecto-enzymes and soluble enzymes that hydrolyse ATP to adenosine (CD39 and CD73) increase the extracellular adenosine levels that inhibit the innate and adaptive immune responses rendering the host susceptible to infection by invading microorganisms.	Adenosine Triphosphate	109-112	5'-nucleotidase ecto	Homo sapiens	136-140
28547381-6	2017	The high levels of extracellular ATP and the upregulation of ecto-enzymes and soluble enzymes that hydrolyse ATP to adenosine (CD39 and CD73) increase the extracellular adenosine levels that inhibit the innate and adaptive immune responses rendering the host susceptible to infection by invading microorganisms.	Adenosine	116-125	5'-nucleotidase ecto	Homo sapiens	136-140
28547381-6	2017	The high levels of extracellular ATP and the upregulation of ecto-enzymes and soluble enzymes that hydrolyse ATP to adenosine (CD39 and CD73) increase the extracellular adenosine levels that inhibit the innate and adaptive immune responses rendering the host susceptible to infection by invading microorganisms.	Adenosine	169-178	5'-nucleotidase ecto	Homo sapiens	136-140
28652244-2	2017	In this study, we assessed whether the CD73-adenosinergic pathway is active in melanoma patients and whether adenosine restricts the efficacy of clinically approved targeted therapies for commonly mutated BRAFV600E melanoma.	Adenosine	44-53	5'-nucleotidase ecto	Homo sapiens	39-43
28652244-3	2017	In AJCC stage III melanoma patients, CD73 expression (the enzyme that generates adenosine) correlated significantly with patients presenting nodal metastatic melanoma, suggesting that targeting this pathway may be effective in advanced stage disease.	Adenosine	80-89	5'-nucleotidase ecto	Homo sapiens	37-41
28652244-4	2017	In addition, dabrafenib and trametinib treatment of CD73+ BRAFV600E-mutant melanomas caused profound CD73 downregulation in tumor cells.	dabrafenib	13-23	5'-nucleotidase ecto	Homo sapiens	52-56
28652244-4	2017	In addition, dabrafenib and trametinib treatment of CD73+ BRAFV600E-mutant melanomas caused profound CD73 downregulation in tumor cells.	dabrafenib	13-23	5'-nucleotidase ecto	Homo sapiens	101-105
28652244-4	2017	In addition, dabrafenib and trametinib treatment of CD73+ BRAFV600E-mutant melanomas caused profound CD73 downregulation in tumor cells.	trametinib	28-38	5'-nucleotidase ecto	Homo sapiens	52-56
28652244-4	2017	In addition, dabrafenib and trametinib treatment of CD73+ BRAFV600E-mutant melanomas caused profound CD73 downregulation in tumor cells.	trametinib	28-38	5'-nucleotidase ecto	Homo sapiens	101-105
28652246-2	2017	Here we found that induction of CD73, the enzyme that generates immunosuppressive adenosine, is linked to melanoma phenotype switching.	Adenosine	82-91	5'-nucleotidase ecto	Homo sapiens	32-36
27862653-2	2017	Central players in adenosine signaling are the ectonucleotidases CD39 and CD73, which convert ADP/ATP to AMP and AMP to adenosine, respectively.	Adenosine	19-28	5'-nucleotidase ecto	Homo sapiens	74-78
28461585-9	2017	CD73 mRNA, and alphabeta-methylene-ADP-inhibitable ecto-AMPase activity were elevated in the FADD-deficient cells.	fadd	93-97	5'-nucleotidase ecto	Homo sapiens	0-4
28399672-4	2017	Areas covered: This review focuses on cancer and explains how in the microenvironment, the ATP-adenosine balance shifts towards an excess of extracellular adenosine Expert commentary: The CD73-adenosine axis plays a key role in the inhibition of anti-tumor functions of immune effector cells.	ATP Adenosine	91-104	5'-nucleotidase ecto	Homo sapiens	188-192
28399672-4	2017	Areas covered: This review focuses on cancer and explains how in the microenvironment, the ATP-adenosine balance shifts towards an excess of extracellular adenosine Expert commentary: The CD73-adenosine axis plays a key role in the inhibition of anti-tumor functions of immune effector cells.	Adenosine	95-104	5'-nucleotidase ecto	Homo sapiens	188-192
28399672-4	2017	Areas covered: This review focuses on cancer and explains how in the microenvironment, the ATP-adenosine balance shifts towards an excess of extracellular adenosine Expert commentary: The CD73-adenosine axis plays a key role in the inhibition of anti-tumor functions of immune effector cells.	Adenosine	155-164	5'-nucleotidase ecto	Homo sapiens	188-192
28530470-0	2017	CD73 Controls Extracellular Adenosine Generation in the Trigeminal Nociceptive Nerves.	Adenosine	28-37	5'-nucleotidase ecto	Homo sapiens	0-4
28530470-8	2017	Our results indicate that CD73 might participate in nociceptive modulation by affecting extracellular adenosine generation in the trigeminal nociceptive pathway.	Adenosine	102-111	5'-nucleotidase ecto	Homo sapiens	26-30
28093236-5	2017	Extracellular ATP can be hydrolyzed into adenosine in a two-step enzymatic process involving the ectonucleotidases CD39 (ecto-apyrase) and CD73.	Adenosine Triphosphate	14-17	5'-nucleotidase ecto	Homo sapiens	139-143
28093236-5	2017	Extracellular ATP can be hydrolyzed into adenosine in a two-step enzymatic process involving the ectonucleotidases CD39 (ecto-apyrase) and CD73.	Adenosine	41-50	5'-nucleotidase ecto	Homo sapiens	139-143
28342985-5	2017	Stimulated ERK1/2 phosphorylation is strictly dependent on the ecto enzyme CD73 that mediates autocrine formation of adenosine, and is inhibited by knockdown of the A3 adenosine receptor (A3R) as well as by an A3R antagonist or by agonist-stimulated down-regulation of the A3R.	Adenosine	117-126	5'-nucleotidase ecto	Homo sapiens	75-79
28389406-0	2017	Simultaneous overexpression of human E5NT and ENTPD1 protects porcine endothelial cells against H2O2-induced oxidative stress and cytotoxicity in vitro.	Hydrogen Peroxide	96-100	5'-nucleotidase ecto	Homo sapiens	37-41
28389406-3	2017	We tested the potential protective effects derived by the co-expression of the two main vascular ectonucleotidases, ecto-5"-nucleotidase (E5NT) and ecto nucleoside triphosphate diphosphohydrolase 1 (ENTPD1), in an in vitro model of H2O2-induced oxidative stress and cytotoxicity.	Hydrogen Peroxide	232-236	5'-nucleotidase ecto	Homo sapiens	116-136
28389406-6	2017	Furthermore, such co-expression system led to the synergistic enzymatic activity of hE5NT and hENTPD1 as shown by the efficient catabolism of pro-inflammatory and pro-thrombotic extracellular adenine nucleotides along with the enhanced production of the anti-inflammatory molecule adenosine.	Adenine Nucleotides	192-211	5'-nucleotidase ecto	Homo sapiens	84-89
28389406-6	2017	Furthermore, such co-expression system led to the synergistic enzymatic activity of hE5NT and hENTPD1 as shown by the efficient catabolism of pro-inflammatory and pro-thrombotic extracellular adenine nucleotides along with the enhanced production of the anti-inflammatory molecule adenosine.	Adenosine	281-290	5'-nucleotidase ecto	Homo sapiens	84-89
28389406-7	2017	Interestingly, we found that the hE5NT/hENTPD1 co-expression system conferred protection to cells against H2O2-induced oxidative stress and cytotoxicity.	Hydrogen Peroxide	106-110	5'-nucleotidase ecto	Homo sapiens	33-38
28389406-8	2017	pCX-DI-2A-transfected cells showed reduced activation of caspase 3/7 and cytotoxicity than mock-, hE5NT- and hENTPD1-transfected cells.	pcx-di-2a	0-9	5'-nucleotidase ecto	Homo sapiens	98-103
27862653-2	2017	Central players in adenosine signaling are the ectonucleotidases CD39 and CD73, which convert ADP/ATP to AMP and AMP to adenosine, respectively.	Adenosine Diphosphate	94-97	5'-nucleotidase ecto	Homo sapiens	74-78
27862653-2	2017	Central players in adenosine signaling are the ectonucleotidases CD39 and CD73, which convert ADP/ATP to AMP and AMP to adenosine, respectively.	Adenosine Triphosphate	98-101	5'-nucleotidase ecto	Homo sapiens	74-78
27862653-2	2017	Central players in adenosine signaling are the ectonucleotidases CD39 and CD73, which convert ADP/ATP to AMP and AMP to adenosine, respectively.	Adenosine Monophosphate	105-108	5'-nucleotidase ecto	Homo sapiens	74-78
27862653-2	2017	Central players in adenosine signaling are the ectonucleotidases CD39 and CD73, which convert ADP/ATP to AMP and AMP to adenosine, respectively.	Adenosine Monophosphate	113-116	5'-nucleotidase ecto	Homo sapiens	74-78
27862653-2	2017	Central players in adenosine signaling are the ectonucleotidases CD39 and CD73, which convert ADP/ATP to AMP and AMP to adenosine, respectively.	Adenosine	120-129	5'-nucleotidase ecto	Homo sapiens	74-78
28399915-0	2017	Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73.	tiamulin	0-8	5'-nucleotidase ecto	Homo sapiens	94-98
28680754-1	2017	CD39/CD73-adenosine pathway has been recently defined as an important tumor-induced immunosuppressive mechanism.	Adenosine	10-19	5'-nucleotidase ecto	Homo sapiens	5-9
28529533-3	2017	Furthermore, cellular response to this nucleoside is highly dependent on its extracellular concentration that is regulated by ecto-enzymes such as CD39 and CD73.	Nucleosides	39-49	5'-nucleotidase ecto	Homo sapiens	156-160
28399915-5	2017	Here, we determined whether tiamulin, which was found to inhibit CD73, was able to suppress breast cancer development and explored the related mechanisms.	tiamulin	28-36	5'-nucleotidase ecto	Homo sapiens	65-69
28399915-6	2017	METHODS: We firstly measured the effect of tiamulin hydrogen fumarate (THF) on CD73 using high performance liquid chromatography (HPLC).	tiamulin	43-69	5'-nucleotidase ecto	Homo sapiens	79-83
28399915-6	2017	METHODS: We firstly measured the effect of tiamulin hydrogen fumarate (THF) on CD73 using high performance liquid chromatography (HPLC).	tiamulin	71-74	5'-nucleotidase ecto	Homo sapiens	79-83
28399915-9	2017	RESULTS: Our data demonstrated that THF inhibited CD73 by decreasing the activity instead of the expression of CD73.	tiamulin	36-39	5'-nucleotidase ecto	Homo sapiens	50-54
28399915-9	2017	RESULTS: Our data demonstrated that THF inhibited CD73 by decreasing the activity instead of the expression of CD73.	tiamulin	36-39	5'-nucleotidase ecto	Homo sapiens	111-115
28399915-12	2017	CONCLUSIONS: Our results indicate that THF inhibits growth and metastasis of breast cancer by blocking the activity of CD73, which may offer a promising treatment for breast cancer therapy.	tiamulin	39-42	5'-nucleotidase ecto	Homo sapiens	119-123
28373446-3	2017	In the present work, we evaluated the effect of alpha-bisabolol on ecto-5"-nucleotidase/CD73, the most well-characterized enzymatic source of adenosine, present in lipid rafts.	alpha-Bisabolol	48-63	5'-nucleotidase ecto	Homo sapiens	67-87
28373446-3	2017	In the present work, we evaluated the effect of alpha-bisabolol on ecto-5"-nucleotidase/CD73, the most well-characterized enzymatic source of adenosine, present in lipid rafts.	alpha-Bisabolol	48-63	5'-nucleotidase ecto	Homo sapiens	88-92
28373446-3	2017	In the present work, we evaluated the effect of alpha-bisabolol on ecto-5"-nucleotidase/CD73, the most well-characterized enzymatic source of adenosine, present in lipid rafts.	Adenosine	142-151	5'-nucleotidase ecto	Homo sapiens	67-87
28373446-3	2017	In the present work, we evaluated the effect of alpha-bisabolol on ecto-5"-nucleotidase/CD73, the most well-characterized enzymatic source of adenosine, present in lipid rafts.	Adenosine	142-151	5'-nucleotidase ecto	Homo sapiens	88-92
28373446-6	2017	RESULTS: Alpha-bisabolol led to a decrease in C6 and U138-MG glioma cells viability, accompanied by an increase in ecto-5"-NT/CD73 activity.	alpha-Bisabolol	9-24	5'-nucleotidase ecto	Homo sapiens	126-130
28373446-8	2017	CONCLUSION: Our data indicated the participation of ecto-5"-nucleotidase/CD73 and A3 receptor in the anti-proliferative effect of alpha-bisabolol on glioma cells.	alpha-Bisabolol	130-145	5'-nucleotidase ecto	Homo sapiens	52-72
28373446-8	2017	CONCLUSION: Our data indicated the participation of ecto-5"-nucleotidase/CD73 and A3 receptor in the anti-proliferative effect of alpha-bisabolol on glioma cells.	alpha-Bisabolol	130-145	5'-nucleotidase ecto	Homo sapiens	73-77
28174424-3	2017	Therefore, targeting adenosine-generating enzymes (CD39 and CD73) or adenosine receptors has emerged as a novel means to stimulate anti-tumor immunity.	Adenosine	21-30	5'-nucleotidase ecto	Homo sapiens	60-64
28373875-2	2017	One set of ectoenzymes-CD39, CD38, CD203a, and CD73-leads to the generation of adenosine (ADO) by metabolizing ATP and NAD+.	Adenosine	79-88	5'-nucleotidase ecto	Homo sapiens	47-51
27830476-4	2017	Human CD39 rapidly hydrolyzes ATP and ADP to AMP; AMP is hydrolyzed by ecto-5"-nucleotidase (CD73) to adenosine, an anti-thrombotic and cardiovascular protective mediator.	Adenosine Monophosphate	50-53	5'-nucleotidase ecto	Homo sapiens	71-91
27830476-4	2017	Human CD39 rapidly hydrolyzes ATP and ADP to AMP; AMP is hydrolyzed by ecto-5"-nucleotidase (CD73) to adenosine, an anti-thrombotic and cardiovascular protective mediator.	Adenosine Monophosphate	50-53	5'-nucleotidase ecto	Homo sapiens	93-97
27830476-4	2017	Human CD39 rapidly hydrolyzes ATP and ADP to AMP; AMP is hydrolyzed by ecto-5"-nucleotidase (CD73) to adenosine, an anti-thrombotic and cardiovascular protective mediator.	Adenosine	102-111	5'-nucleotidase ecto	Homo sapiens	71-91
27830476-4	2017	Human CD39 rapidly hydrolyzes ATP and ADP to AMP; AMP is hydrolyzed by ecto-5"-nucleotidase (CD73) to adenosine, an anti-thrombotic and cardiovascular protective mediator.	Adenosine	102-111	5'-nucleotidase ecto	Homo sapiens	93-97
28373875-2	2017	One set of ectoenzymes-CD39, CD38, CD203a, and CD73-leads to the generation of adenosine (ADO) by metabolizing ATP and NAD+.	Adenosine	90-93	5'-nucleotidase ecto	Homo sapiens	47-51
28373875-2	2017	One set of ectoenzymes-CD39, CD38, CD203a, and CD73-leads to the generation of adenosine (ADO) by metabolizing ATP and NAD+.	Adenosine Triphosphate	111-114	5'-nucleotidase ecto	Homo sapiens	47-51
28373875-2	2017	One set of ectoenzymes-CD39, CD38, CD203a, and CD73-leads to the generation of adenosine (ADO) by metabolizing ATP and NAD+.	NAD	119-123	5'-nucleotidase ecto	Homo sapiens	47-51
28210258-0	2017	Human Gingiva-Derived Mesenchymal Stem Cells Inhibit Xeno-Graft-versus-Host Disease via CD39-CD73-Adenosine and IDO Signals.	Adenosine	98-107	5'-nucleotidase ecto	Homo sapiens	93-97
28288184-1	2017	CD73 works together with CD39 to convert extracellular ATP to immunoregulatory adenosine, thus inhibiting inflammation.	Adenosine Triphosphate	55-58	5'-nucleotidase ecto	Homo sapiens	0-4
28288184-1	2017	CD73 works together with CD39 to convert extracellular ATP to immunoregulatory adenosine, thus inhibiting inflammation.	Adenosine	79-88	5'-nucleotidase ecto	Homo sapiens	0-4
28258700-4	2017	Extracellular adenosine generated by the ectonucleotidases CD39 and CD73 is a newly recognized "immune checkpoint mediator" that interferes with anti-tumor immune responses.	Adenosine	14-23	5'-nucleotidase ecto	Homo sapiens	68-72
28202050-2	2017	As a nucleotidase, CD73 plays its enzymatic function by catalyzing the hydrolysis of AMP into adenosine and phosphate.	Adenosine Monophosphate	85-88	5'-nucleotidase ecto	Homo sapiens	19-23
28202050-2	2017	As a nucleotidase, CD73 plays its enzymatic function by catalyzing the hydrolysis of AMP into adenosine and phosphate.	Adenosine	94-103	5'-nucleotidase ecto	Homo sapiens	19-23
28202050-2	2017	As a nucleotidase, CD73 plays its enzymatic function by catalyzing the hydrolysis of AMP into adenosine and phosphate.	Phosphates	108-117	5'-nucleotidase ecto	Homo sapiens	19-23
28202050-12	2017	These results demonstrated that the promotive effect of CD73 on cervical cancer cells proliferation and migration in vitro was independent from its enzymatic activity (i.e. production of adenosine).	Adenosine	187-196	5'-nucleotidase ecto	Homo sapiens	56-60
28210258-7	2017	Moreover, we demonstrated that GMSCs inhibited human PBMC-initiated xenogenic responses via CD39/CD73/adenosine and IDO signals.	gmscs	31-36	5'-nucleotidase ecto	Homo sapiens	97-101
28344879-1	2017	CD39 and CD73 are surface-expressed ectonucleotidases that hydrolyze ATP in a highly regulated, serial manner into ADP, AMP and adenosine.	Adenosine Triphosphate	69-72	5'-nucleotidase ecto	Homo sapiens	9-13
27638339-4	2017	We have identified soluble enzymes ecto-5"-nucleotidase/CD73, adenylate kinase-1, and nucleoside diphosphate kinase in the vitreous fluid that control active cycling between pro-inflammatory ATP and anti-inflammatory adenosine.	Adenosine Triphosphate	191-194	5'-nucleotidase ecto	Homo sapiens	35-55
27638339-4	2017	We have identified soluble enzymes ecto-5"-nucleotidase/CD73, adenylate kinase-1, and nucleoside diphosphate kinase in the vitreous fluid that control active cycling between pro-inflammatory ATP and anti-inflammatory adenosine.	Adenosine Triphosphate	191-194	5'-nucleotidase ecto	Homo sapiens	56-60
27638339-4	2017	We have identified soluble enzymes ecto-5"-nucleotidase/CD73, adenylate kinase-1, and nucleoside diphosphate kinase in the vitreous fluid that control active cycling between pro-inflammatory ATP and anti-inflammatory adenosine.	Adenosine	217-226	5'-nucleotidase ecto	Homo sapiens	35-55
27638339-4	2017	We have identified soluble enzymes ecto-5"-nucleotidase/CD73, adenylate kinase-1, and nucleoside diphosphate kinase in the vitreous fluid that control active cycling between pro-inflammatory ATP and anti-inflammatory adenosine.	Adenosine	217-226	5'-nucleotidase ecto	Homo sapiens	56-60
28060732-1	2017	In immune cells, CD73 dephosphorylates and converts extracellular AMP into adenosine, which binds the A2A adenosine receptor (A2AR).	Adenosine Monophosphate	66-69	5'-nucleotidase ecto	Homo sapiens	17-21
28060732-1	2017	In immune cells, CD73 dephosphorylates and converts extracellular AMP into adenosine, which binds the A2A adenosine receptor (A2AR).	Adenosine	75-84	5'-nucleotidase ecto	Homo sapiens	17-21
27321181-4	2017	Sequential hydrolysis of extracellular ATP catalyzed by CD39 and CD73 is the main pathway for the generation of adenosine in the tumor interstitium.	Adenosine Triphosphate	39-42	5'-nucleotidase ecto	Homo sapiens	65-69
27321181-4	2017	Sequential hydrolysis of extracellular ATP catalyzed by CD39 and CD73 is the main pathway for the generation of adenosine in the tumor interstitium.	Adenosine	112-121	5'-nucleotidase ecto	Homo sapiens	65-69
27321181-8	2017	Preclinical data show that targeting the adenosine-generating pathway (that is, CD73) or adenosinergic receptors (that is, A2A) relieves immunosuppresion and potently inhibits tumor growth.	Adenosine	41-50	5'-nucleotidase ecto	Homo sapiens	80-84
26898925-7	2017	Production of immunosuppressive adenosine (ADO) by functionally active ectonucleotidases, CD39 and CD73, was determined by luminescence and mass spectrometry.	Adenosine	32-41	5'-nucleotidase ecto	Homo sapiens	99-103
26898925-7	2017	Production of immunosuppressive adenosine (ADO) by functionally active ectonucleotidases, CD39 and CD73, was determined by luminescence and mass spectrometry.	Adenosine	43-46	5'-nucleotidase ecto	Homo sapiens	99-103
26898925-11	2017	Expression of ectonucleotidases, CD39 and CD73, was decreased in tMSC as compared to corresponding cMSC, which correlated with decreased ATP metabolism in mass spectrometry.	Adenosine Triphosphate	137-140	5'-nucleotidase ecto	Homo sapiens	42-46
28344879-1	2017	CD39 and CD73 are surface-expressed ectonucleotidases that hydrolyze ATP in a highly regulated, serial manner into ADP, AMP and adenosine.	Adenosine Diphosphate	115-118	5'-nucleotidase ecto	Homo sapiens	9-13
28344879-1	2017	CD39 and CD73 are surface-expressed ectonucleotidases that hydrolyze ATP in a highly regulated, serial manner into ADP, AMP and adenosine.	Adenosine Monophosphate	120-123	5'-nucleotidase ecto	Homo sapiens	9-13
27965423-1	2016	ACDC (arterial calcification due to deficiency of CD73) is an autosomal recessive disease resulting from loss-of-function mutations in NT5E, which encodes CD73, a 5"-ectonucleotidase that converts extracellular adenosine monophosphate to adenosine.	Adenosine Monophosphate	211-234	5'-nucleotidase ecto	Homo sapiens	135-139
28344879-1	2017	CD39 and CD73 are surface-expressed ectonucleotidases that hydrolyze ATP in a highly regulated, serial manner into ADP, AMP and adenosine.	Adenosine	128-137	5'-nucleotidase ecto	Homo sapiens	9-13
27965423-1	2016	ACDC (arterial calcification due to deficiency of CD73) is an autosomal recessive disease resulting from loss-of-function mutations in NT5E, which encodes CD73, a 5"-ectonucleotidase that converts extracellular adenosine monophosphate to adenosine.	Adenosine Monophosphate	211-234	5'-nucleotidase ecto	Homo sapiens	50-54
28344879-7	2017	CD73 expression was inducible on CD14+ cells with sPE, cyclic-AMP (cAMP)-inducers (forskolin and prostaglandin-E2 (PGE2)) and adenosine.	Cyclic AMP	55-65	5'-nucleotidase ecto	Homo sapiens	0-4
27965423-1	2016	ACDC (arterial calcification due to deficiency of CD73) is an autosomal recessive disease resulting from loss-of-function mutations in NT5E, which encodes CD73, a 5"-ectonucleotidase that converts extracellular adenosine monophosphate to adenosine.	Adenosine	211-220	5'-nucleotidase ecto	Homo sapiens	135-139
27965423-1	2016	ACDC (arterial calcification due to deficiency of CD73) is an autosomal recessive disease resulting from loss-of-function mutations in NT5E, which encodes CD73, a 5"-ectonucleotidase that converts extracellular adenosine monophosphate to adenosine.	Adenosine	211-220	5'-nucleotidase ecto	Homo sapiens	50-54
28344879-7	2017	CD73 expression was inducible on CD14+ cells with sPE, cyclic-AMP (cAMP)-inducers (forskolin and prostaglandin-E2 (PGE2)) and adenosine.	Cyclic AMP	67-71	5'-nucleotidase ecto	Homo sapiens	0-4
28344879-7	2017	CD73 expression was inducible on CD14+ cells with sPE, cyclic-AMP (cAMP)-inducers (forskolin and prostaglandin-E2 (PGE2)) and adenosine.	Colforsin	83-92	5'-nucleotidase ecto	Homo sapiens	0-4
28344879-7	2017	CD73 expression was inducible on CD14+ cells with sPE, cyclic-AMP (cAMP)-inducers (forskolin and prostaglandin-E2 (PGE2)) and adenosine.	Dinoprostone	97-113	5'-nucleotidase ecto	Homo sapiens	0-4
28344879-7	2017	CD73 expression was inducible on CD14+ cells with sPE, cyclic-AMP (cAMP)-inducers (forskolin and prostaglandin-E2 (PGE2)) and adenosine.	Dinoprostone	115-119	5'-nucleotidase ecto	Homo sapiens	0-4
28344879-7	2017	CD73 expression was inducible on CD14+ cells with sPE, cyclic-AMP (cAMP)-inducers (forskolin and prostaglandin-E2 (PGE2)) and adenosine.	Adenosine	126-135	5'-nucleotidase ecto	Homo sapiens	0-4
28344879-11	2017	TNFalpha production by CD73+ CD14+ cells was significantly impaired in the presence of AMP, confirming immunosuppressive function.	Adenosine Monophosphate	87-90	5'-nucleotidase ecto	Homo sapiens	23-27
28344879-12	2017	Taken together, CD73 expression can be induced by PGE2, cAMP or adenosine on human CD14+ cells.	Dinoprostone	50-54	5'-nucleotidase ecto	Homo sapiens	16-20
28344879-12	2017	Taken together, CD73 expression can be induced by PGE2, cAMP or adenosine on human CD14+ cells.	Cyclic AMP	56-60	5'-nucleotidase ecto	Homo sapiens	16-20
28344879-12	2017	Taken together, CD73 expression can be induced by PGE2, cAMP or adenosine on human CD14+ cells.	Adenosine	64-73	5'-nucleotidase ecto	Homo sapiens	16-20
27761584-4	2016	Within the niche, NAD+ is able to activate a discontinuous adenosinergic pathway that relies upon CD38, CD203a, and CD73 or TRACP, according to the environmental pH.	NAD	18-22	5'-nucleotidase ecto	Homo sapiens	116-120
27705752-4	2016	Four extracellular factors are necessary for the acquisition of SON expression and lineage plasticity in ePS cells: adenosine (which is produced by the 5" ecto-nucleotidase CD73 and activates in turn the PKA-dependent IL6/STAT3 pathway through the adenosine receptor ADORA2b), IL6, FGF2 and ACTIVIN A.	Adenosine	116-125	5'-nucleotidase ecto	Homo sapiens	173-177
27906627-2	2016	Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto-5"-nucleotidase (CD73) convert extracellular nucleotides in a sequential order: ATP to ADP, AMP, and then to adenosine.	Adenosine Triphosphate	145-148	5'-nucleotidase ecto	Homo sapiens	60-80
27906627-2	2016	Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto-5"-nucleotidase (CD73) convert extracellular nucleotides in a sequential order: ATP to ADP, AMP, and then to adenosine.	Adenosine Triphosphate	145-148	5'-nucleotidase ecto	Homo sapiens	82-86
27906612-1	2016	The 5"-nucleotidase cN-II has been shown to be associated with the sensitivity to nucleoside analogues, the survival of cytarabine treated leukemia patients and to cell proliferation.	Nucleosides	82-92	5'-nucleotidase ecto	Homo sapiens	4-19
27906627-2	2016	Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto-5"-nucleotidase (CD73) convert extracellular nucleotides in a sequential order: ATP to ADP, AMP, and then to adenosine.	Adenosine Diphosphate	152-155	5'-nucleotidase ecto	Homo sapiens	60-80
27906612-1	2016	The 5"-nucleotidase cN-II has been shown to be associated with the sensitivity to nucleoside analogues, the survival of cytarabine treated leukemia patients and to cell proliferation.	Cytarabine	120-130	5'-nucleotidase ecto	Homo sapiens	4-19
27906627-2	2016	Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto-5"-nucleotidase (CD73) convert extracellular nucleotides in a sequential order: ATP to ADP, AMP, and then to adenosine.	Adenosine Diphosphate	152-155	5'-nucleotidase ecto	Homo sapiens	82-86
27906615-1	2016	NT5E encodes ecto-5"-nucleotidase (e5NT, CD73) which hydrolyses extracellular AMP to adenosine.	Adenosine Monophosphate	78-81	5'-nucleotidase ecto	Homo sapiens	0-4
27906627-2	2016	Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto-5"-nucleotidase (CD73) convert extracellular nucleotides in a sequential order: ATP to ADP, AMP, and then to adenosine.	Adenosine Monophosphate	157-160	5'-nucleotidase ecto	Homo sapiens	60-80
27906615-1	2016	NT5E encodes ecto-5"-nucleotidase (e5NT, CD73) which hydrolyses extracellular AMP to adenosine.	Adenosine Monophosphate	78-81	5'-nucleotidase ecto	Homo sapiens	13-33
27906615-1	2016	NT5E encodes ecto-5"-nucleotidase (e5NT, CD73) which hydrolyses extracellular AMP to adenosine.	Adenosine Monophosphate	78-81	5'-nucleotidase ecto	Homo sapiens	35-39
27906627-2	2016	Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto-5"-nucleotidase (CD73) convert extracellular nucleotides in a sequential order: ATP to ADP, AMP, and then to adenosine.	Adenosine Monophosphate	157-160	5'-nucleotidase ecto	Homo sapiens	82-86
27906615-1	2016	NT5E encodes ecto-5"-nucleotidase (e5NT, CD73) which hydrolyses extracellular AMP to adenosine.	Adenosine Monophosphate	78-81	5'-nucleotidase ecto	Homo sapiens	41-45
27906627-2	2016	Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto-5"-nucleotidase (CD73) convert extracellular nucleotides in a sequential order: ATP to ADP, AMP, and then to adenosine.	Adenosine	174-183	5'-nucleotidase ecto	Homo sapiens	60-80
27906615-1	2016	NT5E encodes ecto-5"-nucleotidase (e5NT, CD73) which hydrolyses extracellular AMP to adenosine.	Adenosine	85-94	5'-nucleotidase ecto	Homo sapiens	0-4
27906615-1	2016	NT5E encodes ecto-5"-nucleotidase (e5NT, CD73) which hydrolyses extracellular AMP to adenosine.	Adenosine	85-94	5'-nucleotidase ecto	Homo sapiens	13-33
27906627-2	2016	Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto-5"-nucleotidase (CD73) convert extracellular nucleotides in a sequential order: ATP to ADP, AMP, and then to adenosine.	Adenosine	174-183	5'-nucleotidase ecto	Homo sapiens	82-86
27906615-1	2016	NT5E encodes ecto-5"-nucleotidase (e5NT, CD73) which hydrolyses extracellular AMP to adenosine.	Adenosine	85-94	5'-nucleotidase ecto	Homo sapiens	35-39
27906615-1	2016	NT5E encodes ecto-5"-nucleotidase (e5NT, CD73) which hydrolyses extracellular AMP to adenosine.	Adenosine	85-94	5'-nucleotidase ecto	Homo sapiens	41-45
27577957-4	2016	Compared to HMEC, MDA-MB-231 cells overexpress the ectonucleotidases ENPP1 and CD73, which convert extracellular ATP released by the cells to adenosine that stimulates A3 receptors and promotes cell migration with frequent directional changes.	Adenosine Triphosphate	113-116	5'-nucleotidase ecto	Homo sapiens	79-83
27906615-8	2016	Moreover, e5NT activity in aortic valves showed a trend toward lower levels in AVC patients with CC and TC genotypes than in those with the TT genotype.	Technetium	104-106	5'-nucleotidase ecto	Homo sapiens	10-14
27577957-4	2016	Compared to HMEC, MDA-MB-231 cells overexpress the ectonucleotidases ENPP1 and CD73, which convert extracellular ATP released by the cells to adenosine that stimulates A3 receptors and promotes cell migration with frequent directional changes.	Adenosine	142-151	5'-nucleotidase ecto	Homo sapiens	79-83
27732656-1	2016	BACKGROUND: CD73 dephosphorylates adenosine monophosphate to adenosine that is an anti-inflammatory molecule inhibiting immune activation and vascular leakage.	Adenosine Monophosphate	34-57	5'-nucleotidase ecto	Homo sapiens	12-16
27650530-4	2016	Here, we investigated changes in the expression and cellular localization of the A2A receptor and of the adenosine-generating enzyme, ecto-5"-nucleotidase/CD73, in the hippocampus of control individuals and MTLE human patients.	Adenosine	105-114	5'-nucleotidase ecto	Homo sapiens	134-154
27650530-4	2016	Here, we investigated changes in the expression and cellular localization of the A2A receptor and of the adenosine-generating enzyme, ecto-5"-nucleotidase/CD73, in the hippocampus of control individuals and MTLE human patients.	Adenosine	105-114	5'-nucleotidase ecto	Homo sapiens	155-159
27650530-9	2016	Given our data, we hypothesize that selective blockade of excessive activation of astrocytic A2A receptors and/or inhibition of surplus adenosine formation by membrane-bound ecto-5"-nucleotidase/CD73 may reduce neuronal excitability, thus providing a novel therapeutic target for drug-refractory seizures in MTLE patients.	Adenosine	136-145	5'-nucleotidase ecto	Homo sapiens	174-194
27650530-9	2016	Given our data, we hypothesize that selective blockade of excessive activation of astrocytic A2A receptors and/or inhibition of surplus adenosine formation by membrane-bound ecto-5"-nucleotidase/CD73 may reduce neuronal excitability, thus providing a novel therapeutic target for drug-refractory seizures in MTLE patients.	Adenosine	136-145	5'-nucleotidase ecto	Homo sapiens	195-199
27233214-7	2016	In contrast to RPMI1640, X-Vivo15 resulted in a significant down-regulation of the cell-surface-located ectonucleotidases CD39 (Ecto-Apyrase) and CD73 (Ecto-5"-Nucleotidase), critical for the extracellular nucleotides-hydrolysis to nucleosides, explaining the loss of inhibition mediated by dGTP and GTP, but not Guanosine.	Nucleosides	232-243	5'-nucleotidase ecto	Homo sapiens	152-172
27233214-7	2016	In contrast to RPMI1640, X-Vivo15 resulted in a significant down-regulation of the cell-surface-located ectonucleotidases CD39 (Ecto-Apyrase) and CD73 (Ecto-5"-Nucleotidase), critical for the extracellular nucleotides-hydrolysis to nucleosides, explaining the loss of inhibition mediated by dGTP and GTP, but not Guanosine.	deoxyguanosine triphosphate	291-295	5'-nucleotidase ecto	Homo sapiens	152-172
27233214-7	2016	In contrast to RPMI1640, X-Vivo15 resulted in a significant down-regulation of the cell-surface-located ectonucleotidases CD39 (Ecto-Apyrase) and CD73 (Ecto-5"-Nucleotidase), critical for the extracellular nucleotides-hydrolysis to nucleosides, explaining the loss of inhibition mediated by dGTP and GTP, but not Guanosine.	Guanosine Triphosphate	292-295	5'-nucleotidase ecto	Homo sapiens	152-172
27233214-7	2016	In contrast to RPMI1640, X-Vivo15 resulted in a significant down-regulation of the cell-surface-located ectonucleotidases CD39 (Ecto-Apyrase) and CD73 (Ecto-5"-Nucleotidase), critical for the extracellular nucleotides-hydrolysis to nucleosides, explaining the loss of inhibition mediated by dGTP and GTP, but not Guanosine.	Guanosine	313-322	5'-nucleotidase ecto	Homo sapiens	152-172
28915673-1	2017	CD73 is a glycosylphosphatidylinositol (GPI) anchored cell surface protein that is encoded by NT5E gene, plays multiple roles in tumor processes.	Glycosylphosphatidylinositols	10-38	5'-nucleotidase ecto	Homo sapiens	0-4
28915673-1	2017	CD73 is a glycosylphosphatidylinositol (GPI) anchored cell surface protein that is encoded by NT5E gene, plays multiple roles in tumor processes.	Glycosylphosphatidylinositols	10-38	5'-nucleotidase ecto	Homo sapiens	94-98
28915673-1	2017	CD73 is a glycosylphosphatidylinositol (GPI) anchored cell surface protein that is encoded by NT5E gene, plays multiple roles in tumor processes.	Glycosylphosphatidylinositols	40-43	5'-nucleotidase ecto	Homo sapiens	0-4
28915673-1	2017	CD73 is a glycosylphosphatidylinositol (GPI) anchored cell surface protein that is encoded by NT5E gene, plays multiple roles in tumor processes.	Glycosylphosphatidylinositols	40-43	5'-nucleotidase ecto	Homo sapiens	94-98
27732656-1	2016	BACKGROUND: CD73 dephosphorylates adenosine monophosphate to adenosine that is an anti-inflammatory molecule inhibiting immune activation and vascular leakage.	Adenosine	34-43	5'-nucleotidase ecto	Homo sapiens	12-16
27005321-5	2016	Under pathophysiological conditions, nucleotide-scavenging ectonucleotidases CD39 and CD73 hydrolyze ATP, ultimately, to the anti-inflammatory mediator adenosine.	Adenosine Triphosphate	101-104	5'-nucleotidase ecto	Homo sapiens	86-90
27005321-5	2016	Under pathophysiological conditions, nucleotide-scavenging ectonucleotidases CD39 and CD73 hydrolyze ATP, ultimately, to the anti-inflammatory mediator adenosine.	Adenosine	152-161	5'-nucleotidase ecto	Homo sapiens	86-90
27557512-5	2016	We also investigated the functional role of CD73 in vitro and demonstrated that CD73 promotes HNSCC migration and invasion through adenosine A3R stimulation and the activation of EGF/EGFR signaling.	adenosine a3r	131-144	5'-nucleotidase ecto	Homo sapiens	80-84
27417582-8	2016	However, the CD73 inhibitor alpha-beta-methylene-ADP nullified the prolongation in the time to thrombosis in human CD39 transgenic (hC39-Tg)/CD73-null mice.	alpha,beta-methyleneadenosine 5'-diphosphate	28-52	5'-nucleotidase ecto	Homo sapiens	13-17
27417582-8	2016	However, the CD73 inhibitor alpha-beta-methylene-ADP nullified the prolongation in the time to thrombosis in human CD39 transgenic (hC39-Tg)/CD73-null mice.	alpha,beta-methyleneadenosine 5'-diphosphate	28-52	5'-nucleotidase ecto	Homo sapiens	141-145
27557561-5	2016	RESULTS: Simvastatin decreased sputum IL-13, OPN and CD73, while increasing ADA expression, irrespective of inhaled corticosteroid treatment and smoking status in parallel to increased inosine levels.	Simvastatin	9-20	5'-nucleotidase ecto	Homo sapiens	53-57
28123924-3	2016	We revealed that CD73-generated adenosine induces a physiological response to protect epithelial integrity in well-differentiated, early stage endometrial carcinoma.	Adenosine	32-41	5'-nucleotidase ecto	Homo sapiens	17-21
28123924-4	2016	The ability of CD73-generated adenosine to protect the barrier is not so different from its ability to induce immunosuppression and other physiological responses in cancerous tissues.	Adenosine	30-39	5'-nucleotidase ecto	Homo sapiens	15-19
27429212-4	2016	We advocated (i) blocking immunosuppressive adenosine-A2AR-cAMP-mediated intracellular signaling by A2AR antagonists and (ii) weakening hypoxia-HIF-1alpha-mediated accumulation of extracellular adenosine by oxygenation agents that also inhibits CD39/CD73 adenosine-generating enzymes.	Cyclic AMP	59-63	5'-nucleotidase ecto	Homo sapiens	250-254
27209048-5	2016	Different groups have highlighted the therapeutic potential of blocking CD73-dependent adenosine-mediated immunosuppression to reinstate anti-tumor immunity.	Adenosine	87-96	5'-nucleotidase ecto	Homo sapiens	72-76
27236363-2	2016	CD39 generates AMP, which is in turn used by the ecto-5"-nucleotidase CD73 to synthesize adenosine.	Adenosine Monophosphate	15-18	5'-nucleotidase ecto	Homo sapiens	49-69
27236363-2	2016	CD39 generates AMP, which is in turn used by the ecto-5"-nucleotidase CD73 to synthesize adenosine.	Adenosine Monophosphate	15-18	5'-nucleotidase ecto	Homo sapiens	70-74
27236363-2	2016	CD39 generates AMP, which is in turn used by the ecto-5"-nucleotidase CD73 to synthesize adenosine.	Adenosine	89-98	5'-nucleotidase ecto	Homo sapiens	49-69
27236363-2	2016	CD39 generates AMP, which is in turn used by the ecto-5"-nucleotidase CD73 to synthesize adenosine.	Adenosine	89-98	5'-nucleotidase ecto	Homo sapiens	70-74
26961686-6	2016	RESULTS: Upon hypoxic stress, cancer cells release ATP into the extracellular space where nucleotides are converted into ADO by hypoxia-sensitive, membrane-bound ectoenzymes (CD39/CD73).	Adenosine Triphosphate	51-54	5'-nucleotidase ecto	Homo sapiens	180-184
26961686-6	2016	RESULTS: Upon hypoxic stress, cancer cells release ATP into the extracellular space where nucleotides are converted into ADO by hypoxia-sensitive, membrane-bound ectoenzymes (CD39/CD73).	Adenosine	121-124	5'-nucleotidase ecto	Homo sapiens	180-184
26510892-10	2016	Direct contact between NK cells and ELCs or WJ-MSCs decreased the level of NK-activating receptor natural-killer group 2, member D. Moreover, direct co-culturing with ELCs stimulates CD73 acquisition on NK cells, a mechanism which may induce adenosine secretion by the cells and lead to an immunosuppressive function.	Adenosine	242-251	5'-nucleotidase ecto	Homo sapiens	183-187
27066009-0	2016	Circulating Human Neonatal Naive B Cells are Deficient in CD73 Impairing Purine Salvage.	purine	73-79	5'-nucleotidase ecto	Homo sapiens	58-62
27066009-7	2016	Neonatal naive B cell deficiency of CD73 expression significantly impaired their capacity to acquire extracellular purines for purine salvage.	Purines	115-122	5'-nucleotidase ecto	Homo sapiens	36-40
27066009-7	2016	Neonatal naive B cell deficiency of CD73 expression significantly impaired their capacity to acquire extracellular purines for purine salvage.	purine	115-121	5'-nucleotidase ecto	Homo sapiens	36-40
27066009-8	2016	CONCLUSION: Human neonatal circulating naive B cells are selectively deficient in CD73, impairing extracellular purine acquisition and potentially contributing to impaired B cell responses in early life.	purine	112-118	5'-nucleotidase ecto	Homo sapiens	82-86
27014745-2	2016	In this context, CD73 is a key molecule, since via degradation of adenosine monophosphate into adenosine, endorses the generation of an immunosuppressed and pro-angiogenic niche within the tumor microenvironment that promotes the onset and progression of cancer.	Adenosine Monophosphate	66-89	5'-nucleotidase ecto	Homo sapiens	17-21
27014745-2	2016	In this context, CD73 is a key molecule, since via degradation of adenosine monophosphate into adenosine, endorses the generation of an immunosuppressed and pro-angiogenic niche within the tumor microenvironment that promotes the onset and progression of cancer.	Adenosine	66-75	5'-nucleotidase ecto	Homo sapiens	17-21
27467942-0	2016	CD73-adenosine reduces immune responses and survival in ovarian cancer patients.	Adenosine	5-14	5'-nucleotidase ecto	Homo sapiens	0-4
27467942-2	2016	Our results demonstrate that the CD73-adenosine pathway is a major immunosuppressive mechanism co-opted by ovarian tumors to escape antitumor immunity.	Adenosine	38-47	5'-nucleotidase ecto	Homo sapiens	33-37
26663722-6	2016	Importantly, DFMO impaired Gr1(+)CD11b(+) myeloid-derived suppressor cells (MDSCs) suppressive activity through at least two mechanisms, including reducing arginase expression and activity and inhibiting the CD39/CD73-mediated pathway.	Eflornithine	13-17	5'-nucleotidase ecto	Homo sapiens	213-217
26629888-0	2016	A Systems Oncology Approach Identifies NT5E as a Key Metabolic Regulator in Tumor Cells and Modulator of Platinum Sensitivity.	Platinum	105-113	5'-nucleotidase ecto	Homo sapiens	39-43
26629888-3	2016	NT5E expression and associated metabolome variations were also correlated with sensitivity to several chemotherapeutics including platinum-based treatment.	Platinum	130-138	5'-nucleotidase ecto	Homo sapiens	0-4
26629888-4	2016	NT5E mRNA levels were observed to be elevated in cells upon in vitro and in vivo acquisition of platinum resistance in ovarian cancer cells, and specific targeting of NT5E increased tumor cell sensitivity to platinum.	Platinum	96-104	5'-nucleotidase ecto	Homo sapiens	0-4
26629888-4	2016	NT5E mRNA levels were observed to be elevated in cells upon in vitro and in vivo acquisition of platinum resistance in ovarian cancer cells, and specific targeting of NT5E increased tumor cell sensitivity to platinum.	Platinum	208-216	5'-nucleotidase ecto	Homo sapiens	167-171
26629888-5	2016	We observed that tumor NT5E levels were prognostic for outcomes in ovarian cancer and were elevated after treatment with platinum, supporting the translational relevance of our findings.	Platinum	121-129	5'-nucleotidase ecto	Homo sapiens	23-27
26629888-7	2016	We experimentally validated the main findings of the NT5E gene being involved in both intrinsic and acquired resistance to platinum-based drugs.	Platinum	123-131	5'-nucleotidase ecto	Homo sapiens	53-57
26333425-6	2016	Cells release adenine nucleotides into the extracellular space, where these mediators are converted by CD39 and CD73 into ADO, which is anti-inflammatory in the short term but may also promote dermal, heart, liver, and lung fibrosis with repetitive signaling under defined circumstances.	Adenine Nucleotides	14-33	5'-nucleotidase ecto	Homo sapiens	112-116
26328528-7	2016	Two unique components are genetically combined in this molecule: 1) The ecto-nucleoside triphosphate diphosphohydrolase NTPDase CD39, which enzymatically degrades ATP and ADP to AMP, which is then further degraded to adenosine by the endothelially expressed CD73.	Adenosine Triphosphate	163-166	5'-nucleotidase ecto	Homo sapiens	258-262
26328528-7	2016	Two unique components are genetically combined in this molecule: 1) The ecto-nucleoside triphosphate diphosphohydrolase NTPDase CD39, which enzymatically degrades ATP and ADP to AMP, which is then further degraded to adenosine by the endothelially expressed CD73.	Adenosine Diphosphate	171-174	5'-nucleotidase ecto	Homo sapiens	258-262
26328528-7	2016	Two unique components are genetically combined in this molecule: 1) The ecto-nucleoside triphosphate diphosphohydrolase NTPDase CD39, which enzymatically degrades ATP and ADP to AMP, which is then further degraded to adenosine by the endothelially expressed CD73.	Adenosine Monophosphate	178-181	5'-nucleotidase ecto	Homo sapiens	258-262
26328528-7	2016	Two unique components are genetically combined in this molecule: 1) The ecto-nucleoside triphosphate diphosphohydrolase NTPDase CD39, which enzymatically degrades ATP and ADP to AMP, which is then further degraded to adenosine by the endothelially expressed CD73.	Adenosine	217-226	5'-nucleotidase ecto	Homo sapiens	258-262
27141365-1	2016	Adenosine, deriving from ATP released by dying cancer cells and then degradated in the tumor environment by CD39/CD73 enzyme axis, is linked to the generation of an immunosuppressed niche favoring the onset of neoplasia.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	113-117
27141365-1	2016	Adenosine, deriving from ATP released by dying cancer cells and then degradated in the tumor environment by CD39/CD73 enzyme axis, is linked to the generation of an immunosuppressed niche favoring the onset of neoplasia.	Adenosine Triphosphate	25-28	5'-nucleotidase ecto	Homo sapiens	113-117
27532024-0	2016	Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	170-174
27532024-0	2016	Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape.	Adenosine	89-98	5'-nucleotidase ecto	Homo sapiens	170-174
27532024-1	2016	BACKGROUND: Ovarian cancer (OvCA) tissues show abundant expression of the ectonucleotidases CD39 and CD73 which generate immunomodulatory adenosine, thereby inhibiting cytotoxic lymphocytes.	Adenosine	138-147	5'-nucleotidase ecto	Homo sapiens	101-105
27532024-17	2016	Accordingly, co-incubation with these TAMs suppressed CD4(+) T cell proliferation which could be rescued via blockade of CD39 or CD73.	Tamoxifen	38-42	5'-nucleotidase ecto	Homo sapiens	129-133
27793266-5	2016	The ability of the parasite to modulate the levels of extracellular ATP and adenosine either by directly acting on the levels of these molecules or by inducing the expression of CD39 and CD73 on the infected cell may influence the magnitude of the immune response against the parasite contributing to its growth and survival.	Adenosine Triphosphate	68-71	5'-nucleotidase ecto	Homo sapiens	187-191
27793266-5	2016	The ability of the parasite to modulate the levels of extracellular ATP and adenosine either by directly acting on the levels of these molecules or by inducing the expression of CD39 and CD73 on the infected cell may influence the magnitude of the immune response against the parasite contributing to its growth and survival.	Adenosine	76-85	5'-nucleotidase ecto	Homo sapiens	187-191
27757316-1	2016	The ecto-5"-nucleotidase/CD73 enzyme plays a pivotal role in generating an adenosine-enriched immunosuppressed and pro-angiogenic niche supporting cancer development.	Adenosine	75-84	5'-nucleotidase ecto	Homo sapiens	4-24
27757316-1	2016	The ecto-5"-nucleotidase/CD73 enzyme plays a pivotal role in generating an adenosine-enriched immunosuppressed and pro-angiogenic niche supporting cancer development.	Adenosine	75-84	5'-nucleotidase ecto	Homo sapiens	25-29
27054295-4	2016	The resulting 2-alkoxy-3-(sulfonylarylaminomethylene)-chroman-4-ones were found to be potent and selective inhibitors of ecto-5"-nucleotidase and alkaline phosphatases (TNAP and IAP).	2-alkoxy-3-(sulfonylarylaminomethylene)-chroman-4-ones	14-68	5'-nucleotidase ecto	Homo sapiens	121-141
27313580-7	2016	The second is the conversion of adenosine triphosphate into adenosine by the ectonucleases CD39 and CD73 present on the surface of Tregs.	Adenosine Triphosphate	32-54	5'-nucleotidase ecto	Homo sapiens	100-104
27313580-7	2016	The second is the conversion of adenosine triphosphate into adenosine by the ectonucleases CD39 and CD73 present on the surface of Tregs.	Adenosine	32-41	5'-nucleotidase ecto	Homo sapiens	100-104
27245613-8	2016	Furthermore, increased cAMP concentrations enhanced the expression of HIF target genes encoding CD39 and CD73, which are enzymes that convert extracellular adenosine 5"-triphosphate to adenosine, a molecule that enhances tumor immunosuppression and reduces heart rate and contractility.	Cyclic AMP	23-27	5'-nucleotidase ecto	Homo sapiens	105-109
27245613-8	2016	Furthermore, increased cAMP concentrations enhanced the expression of HIF target genes encoding CD39 and CD73, which are enzymes that convert extracellular adenosine 5"-triphosphate to adenosine, a molecule that enhances tumor immunosuppression and reduces heart rate and contractility.	Adenosine Triphosphate	156-181	5'-nucleotidase ecto	Homo sapiens	105-109
27245613-8	2016	Furthermore, increased cAMP concentrations enhanced the expression of HIF target genes encoding CD39 and CD73, which are enzymes that convert extracellular adenosine 5"-triphosphate to adenosine, a molecule that enhances tumor immunosuppression and reduces heart rate and contractility.	Adenosine	156-165	5'-nucleotidase ecto	Homo sapiens	105-109
27063086-12	2016	ATP would be rapidly transformed into adenosine by the ectonucleotidase activities such as NTPDase I (CD39), and NT5E (CD73).	Adenosine Triphosphate	0-3	5'-nucleotidase ecto	Homo sapiens	113-117
27063086-12	2016	ATP would be rapidly transformed into adenosine by the ectonucleotidase activities such as NTPDase I (CD39), and NT5E (CD73).	Adenosine Triphosphate	0-3	5'-nucleotidase ecto	Homo sapiens	119-123
27063086-12	2016	ATP would be rapidly transformed into adenosine by the ectonucleotidase activities such as NTPDase I (CD39), and NT5E (CD73).	Adenosine	38-47	5'-nucleotidase ecto	Homo sapiens	113-117
27063086-12	2016	ATP would be rapidly transformed into adenosine by the ectonucleotidase activities such as NTPDase I (CD39), and NT5E (CD73).	Adenosine	38-47	5'-nucleotidase ecto	Homo sapiens	119-123
26973651-7	2016	This purine nucleotide is rapidly hydrolyzed to adenosine by ectoenzymes on the macrophage surface, CD39 and CD73.	Purine Nucleotides	5-22	5'-nucleotidase ecto	Homo sapiens	109-113
26973651-7	2016	This purine nucleotide is rapidly hydrolyzed to adenosine by ectoenzymes on the macrophage surface, CD39 and CD73.	Adenosine	48-57	5'-nucleotidase ecto	Homo sapiens	109-113
26731338-4	2016	In this study, we demonstrate that adenosine is actively produced from adenosine 5"-monophosphate (AMP) by CD73 on MSCs and MSC-derived extracellular vesicles (EVs).	Adenosine	35-44	5'-nucleotidase ecto	Homo sapiens	107-111
26731338-4	2016	In this study, we demonstrate that adenosine is actively produced from adenosine 5"-monophosphate (AMP) by CD73 on MSCs and MSC-derived extracellular vesicles (EVs).	adenosine 5"-monophosphate	71-97	5'-nucleotidase ecto	Homo sapiens	107-111
26731338-4	2016	In this study, we demonstrate that adenosine is actively produced from adenosine 5"-monophosphate (AMP) by CD73 on MSCs and MSC-derived extracellular vesicles (EVs).	Adenosine Monophosphate	99-102	5'-nucleotidase ecto	Homo sapiens	107-111
26731338-5	2016	Our results indicate that although MSCs express CD39 at low level and it colocalizes with CD73 in bulge areas of membranes, the most efficient adenosine production from adenosine 5"-triphosphate (ATP) requires co-operation of MSCs and activated T cells.	Adenosine	143-152	5'-nucleotidase ecto	Homo sapiens	90-94
26731338-5	2016	Our results indicate that although MSCs express CD39 at low level and it colocalizes with CD73 in bulge areas of membranes, the most efficient adenosine production from adenosine 5"-triphosphate (ATP) requires co-operation of MSCs and activated T cells.	Adenosine Triphosphate	196-199	5'-nucleotidase ecto	Homo sapiens	90-94
26731338-6	2016	Highly CD39 expressing activated T cells produce AMP from ATP and MSCs produce adenosine from AMP via CD73 activity.	Adenosine	79-88	5'-nucleotidase ecto	Homo sapiens	102-106
26731338-6	2016	Highly CD39 expressing activated T cells produce AMP from ATP and MSCs produce adenosine from AMP via CD73 activity.	Adenosine Monophosphate	94-97	5'-nucleotidase ecto	Homo sapiens	102-106
26731338-9	2016	An efficient production of immunosuppressive adenosine is dependent on the concerted action of CD39-positive immune cells with CD73-positive cells such as MSCs or their EVs.	Adenosine	45-54	5'-nucleotidase ecto	Homo sapiens	127-131
27057473-1	2016	CD39 and CD73 are key enzymes in the adenosine (ADO) pathway.	Adenosine	37-46	5'-nucleotidase ecto	Homo sapiens	9-13
27057473-1	2016	CD39 and CD73 are key enzymes in the adenosine (ADO) pathway.	Adenosine	48-51	5'-nucleotidase ecto	Homo sapiens	9-13
26808918-0	2016	CD73-adenosine: a next-generation target in immuno-oncology.	Adenosine	5-14	5'-nucleotidase ecto	Homo sapiens	0-4
26808918-3	2016	The CD73-adenosine axis constitutes one of the most promising pathways in immuno-oncology.	Adenosine	9-18	5'-nucleotidase ecto	Homo sapiens	4-8
26808918-4	2016	We and others have demonstrated the immunosuppressive role of CD73-adenosine in cancer and established proof-of-concept that the targeted blockade of CD73 or adenosine receptors could effectively promote anti-tumor immunity and enhance the activity of first-generation immune checkpoint blockers.	Adenosine	67-76	5'-nucleotidase ecto	Homo sapiens	62-66
26808918-4	2016	We and others have demonstrated the immunosuppressive role of CD73-adenosine in cancer and established proof-of-concept that the targeted blockade of CD73 or adenosine receptors could effectively promote anti-tumor immunity and enhance the activity of first-generation immune checkpoint blockers.	Adenosine	67-76	5'-nucleotidase ecto	Homo sapiens	150-154
26658104-3	2016	Recently, we demonstrated that CD73 enables the utilization of extracellular NAD+/nicotinamide mononucleotide (NMN) by converting them to Nicotinamide riboside (NR), which can cross the plasmamembrane and fuel intracellular NAD+ biosynthesis in human cells.	NAD	77-81	5'-nucleotidase ecto	Homo sapiens	31-35
26658104-3	2016	Recently, we demonstrated that CD73 enables the utilization of extracellular NAD+/nicotinamide mononucleotide (NMN) by converting them to Nicotinamide riboside (NR), which can cross the plasmamembrane and fuel intracellular NAD+ biosynthesis in human cells.	Nicotinamide Mononucleotide	82-109	5'-nucleotidase ecto	Homo sapiens	31-35
26658104-3	2016	Recently, we demonstrated that CD73 enables the utilization of extracellular NAD+/nicotinamide mononucleotide (NMN) by converting them to Nicotinamide riboside (NR), which can cross the plasmamembrane and fuel intracellular NAD+ biosynthesis in human cells.	neuromedin N-125	111-114	5'-nucleotidase ecto	Homo sapiens	31-35
26658104-3	2016	Recently, we demonstrated that CD73 enables the utilization of extracellular NAD+/nicotinamide mononucleotide (NMN) by converting them to Nicotinamide riboside (NR), which can cross the plasmamembrane and fuel intracellular NAD+ biosynthesis in human cells.	nicotinamide-beta-riboside	138-159	5'-nucleotidase ecto	Homo sapiens	31-35
26658104-3	2016	Recently, we demonstrated that CD73 enables the utilization of extracellular NAD+/nicotinamide mononucleotide (NMN) by converting them to Nicotinamide riboside (NR), which can cross the plasmamembrane and fuel intracellular NAD+ biosynthesis in human cells.	NAD	224-228	5'-nucleotidase ecto	Homo sapiens	31-35
26854859-0	2016	Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action.	Adenosine Monophosphate	19-22	5'-nucleotidase ecto	Homo sapiens	14-18
27429212-4	2016	We advocated (i) blocking immunosuppressive adenosine-A2AR-cAMP-mediated intracellular signaling by A2AR antagonists and (ii) weakening hypoxia-HIF-1alpha-mediated accumulation of extracellular adenosine by oxygenation agents that also inhibits CD39/CD73 adenosine-generating enzymes.	Adenosine	44-53	5'-nucleotidase ecto	Homo sapiens	250-254
27429212-4	2016	We advocated (i) blocking immunosuppressive adenosine-A2AR-cAMP-mediated intracellular signaling by A2AR antagonists and (ii) weakening hypoxia-HIF-1alpha-mediated accumulation of extracellular adenosine by oxygenation agents that also inhibits CD39/CD73 adenosine-generating enzymes.	Adenosine	194-203	5'-nucleotidase ecto	Homo sapiens	250-254
25847308-5	2015	In contrast, LPS increased whereas glutamate decreased the extracellular catabolism of ATP into adenosine through ecto-nucleotidases and ecto-5"-nucleotidase.	Glutamic Acid	35-44	5'-nucleotidase ecto	Homo sapiens	137-157
26080748-5	2015	In the present study, we have explored the pattern of NTPDase1-3, NPP1-3, and eN expression by cultured cortical astrocytes challenged with 1 mmol/L ATP (eATP).	Adenosine Triphosphate	149-152	5'-nucleotidase ecto	Homo sapiens	78-80
26080748-8	2015	Our results suggest that eATP, by upregulating NTPDase2 and eN and altering the enzyme membrane topology, affects local kinetics of ATP metabolism and signal transduction that may have important roles in the process related to inflammation and reactive gliosis.	Adenosine Triphosphate	26-29	5'-nucleotidase ecto	Homo sapiens	60-62
26491983-1	2015	BACKGROUND: Ecto-5"-nucleotidase/CD73 (ecto-5"-NT) participates in extracellular ATP catabolism by converting adenosine monophosphate (AMP) into adenosine.	Adenosine	110-119	5'-nucleotidase ecto	Homo sapiens	12-32
26491983-1	2015	BACKGROUND: Ecto-5"-nucleotidase/CD73 (ecto-5"-NT) participates in extracellular ATP catabolism by converting adenosine monophosphate (AMP) into adenosine.	Adenosine	110-119	5'-nucleotidase ecto	Homo sapiens	33-37
26054707-8	2015	Treatment with MC-A not only decreased cancer cell viability and proliferation but also resulted in a decrease in the expression of pluripotency- and multipotency-associated markers such as NANOG, OCT-4, SOX-2, SSEA-4, TRA-1-60, CD90, CD73 and CD44.	myrtucommulone A	15-19	5'-nucleotidase ecto	Homo sapiens	235-239
26388774-8	2015	We hypothesize a cross-talk between Treg and bone-forming cells through the CD39-CD73-(adenosine)-adenosine receptor pathway, which might also potentiate the differentiation of MSCs, thus facilitating bone regeneration.	treg	36-40	5'-nucleotidase ecto	Homo sapiens	81-85
26431833-9	2015	The released ATP was sequentially dephosphorylated through ecto-nucleoside triphosphate diphosphohydrolase (NTPDase2) and ecto-5"-nucleotidase/CD73 reactions, with respective generation of adenosine diphosphate (ADP) and adenosine and their maintenance in the extracellular medium at basal levels.	Adenosine Triphosphate	13-16	5'-nucleotidase ecto	Homo sapiens	122-142
26431833-9	2015	The released ATP was sequentially dephosphorylated through ecto-nucleoside triphosphate diphosphohydrolase (NTPDase2) and ecto-5"-nucleotidase/CD73 reactions, with respective generation of adenosine diphosphate (ADP) and adenosine and their maintenance in the extracellular medium at basal levels.	Adenosine Triphosphate	13-16	5'-nucleotidase ecto	Homo sapiens	143-147
26431833-9	2015	The released ATP was sequentially dephosphorylated through ecto-nucleoside triphosphate diphosphohydrolase (NTPDase2) and ecto-5"-nucleotidase/CD73 reactions, with respective generation of adenosine diphosphate (ADP) and adenosine and their maintenance in the extracellular medium at basal levels.	Adenosine Diphosphate	189-210	5'-nucleotidase ecto	Homo sapiens	122-142
26431833-9	2015	The released ATP was sequentially dephosphorylated through ecto-nucleoside triphosphate diphosphohydrolase (NTPDase2) and ecto-5"-nucleotidase/CD73 reactions, with respective generation of adenosine diphosphate (ADP) and adenosine and their maintenance in the extracellular medium at basal levels.	Adenosine Diphosphate	189-210	5'-nucleotidase ecto	Homo sapiens	143-147
26431833-9	2015	The released ATP was sequentially dephosphorylated through ecto-nucleoside triphosphate diphosphohydrolase (NTPDase2) and ecto-5"-nucleotidase/CD73 reactions, with respective generation of adenosine diphosphate (ADP) and adenosine and their maintenance in the extracellular medium at basal levels.	Adenosine Diphosphate	212-215	5'-nucleotidase ecto	Homo sapiens	122-142
26431833-9	2015	The released ATP was sequentially dephosphorylated through ecto-nucleoside triphosphate diphosphohydrolase (NTPDase2) and ecto-5"-nucleotidase/CD73 reactions, with respective generation of adenosine diphosphate (ADP) and adenosine and their maintenance in the extracellular medium at basal levels.	Adenosine Diphosphate	212-215	5'-nucleotidase ecto	Homo sapiens	143-147
26431833-9	2015	The released ATP was sequentially dephosphorylated through ecto-nucleoside triphosphate diphosphohydrolase (NTPDase2) and ecto-5"-nucleotidase/CD73 reactions, with respective generation of adenosine diphosphate (ADP) and adenosine and their maintenance in the extracellular medium at basal levels.	Adenosine	189-198	5'-nucleotidase ecto	Homo sapiens	122-142
26431833-9	2015	The released ATP was sequentially dephosphorylated through ecto-nucleoside triphosphate diphosphohydrolase (NTPDase2) and ecto-5"-nucleotidase/CD73 reactions, with respective generation of adenosine diphosphate (ADP) and adenosine and their maintenance in the extracellular medium at basal levels.	Adenosine	189-198	5'-nucleotidase ecto	Homo sapiens	143-147
26226423-4	2015	CD39 and CD73 are two ectonucleotidases that cooperate in the generation of extracellular adenosine through ATP hydrolysis, thus tilting the balance towards immunosuppressive microenvironments.	Adenosine	90-99	5'-nucleotidase ecto	Homo sapiens	9-13
26226423-4	2015	CD39 and CD73 are two ectonucleotidases that cooperate in the generation of extracellular adenosine through ATP hydrolysis, thus tilting the balance towards immunosuppressive microenvironments.	Adenosine Triphosphate	108-111	5'-nucleotidase ecto	Homo sapiens	9-13
26226423-6	2015	In this review, we discuss evidence that supports a role of CD73 and CD39 ectonucleotidases in controlling naive T-cell homeostasis and memory cell survival through adenosine production.	Adenosine	165-174	5'-nucleotidase ecto	Homo sapiens	60-64
26251265-0	2015	1alpha,25-dihydroxyvitamin D3 acts via transforming growth factor-beta to up-regulate expression of immunosuppressive CD73 on human CD4+ Foxp3- T cells.	Calcitriol	0-29	5'-nucleotidase ecto	Homo sapiens	118-122
26491983-1	2015	BACKGROUND: Ecto-5"-nucleotidase/CD73 (ecto-5"-NT) participates in extracellular ATP catabolism by converting adenosine monophosphate (AMP) into adenosine.	ecto-5"-nt	39-49	5'-nucleotidase ecto	Homo sapiens	12-32
26491983-1	2015	BACKGROUND: Ecto-5"-nucleotidase/CD73 (ecto-5"-NT) participates in extracellular ATP catabolism by converting adenosine monophosphate (AMP) into adenosine.	ecto-5"-nt	39-49	5'-nucleotidase ecto	Homo sapiens	33-37
26491983-1	2015	BACKGROUND: Ecto-5"-nucleotidase/CD73 (ecto-5"-NT) participates in extracellular ATP catabolism by converting adenosine monophosphate (AMP) into adenosine.	Adenosine Triphosphate	81-84	5'-nucleotidase ecto	Homo sapiens	12-32
26491983-1	2015	BACKGROUND: Ecto-5"-nucleotidase/CD73 (ecto-5"-NT) participates in extracellular ATP catabolism by converting adenosine monophosphate (AMP) into adenosine.	Adenosine Triphosphate	81-84	5'-nucleotidase ecto	Homo sapiens	33-37
26491983-1	2015	BACKGROUND: Ecto-5"-nucleotidase/CD73 (ecto-5"-NT) participates in extracellular ATP catabolism by converting adenosine monophosphate (AMP) into adenosine.	Adenosine Monophosphate	110-133	5'-nucleotidase ecto	Homo sapiens	12-32
26491983-1	2015	BACKGROUND: Ecto-5"-nucleotidase/CD73 (ecto-5"-NT) participates in extracellular ATP catabolism by converting adenosine monophosphate (AMP) into adenosine.	Adenosine Monophosphate	110-133	5'-nucleotidase ecto	Homo sapiens	33-37
26491983-1	2015	BACKGROUND: Ecto-5"-nucleotidase/CD73 (ecto-5"-NT) participates in extracellular ATP catabolism by converting adenosine monophosphate (AMP) into adenosine.	Adenosine Monophosphate	135-138	5'-nucleotidase ecto	Homo sapiens	12-32
26491983-1	2015	BACKGROUND: Ecto-5"-nucleotidase/CD73 (ecto-5"-NT) participates in extracellular ATP catabolism by converting adenosine monophosphate (AMP) into adenosine.	Adenosine Monophosphate	135-138	5'-nucleotidase ecto	Homo sapiens	33-37
25847308-5	2015	In contrast, LPS increased whereas glutamate decreased the extracellular catabolism of ATP into adenosine through ecto-nucleotidases and ecto-5"-nucleotidase.	Adenosine Triphosphate	87-90	5'-nucleotidase ecto	Homo sapiens	137-157
25847308-5	2015	In contrast, LPS increased whereas glutamate decreased the extracellular catabolism of ATP into adenosine through ecto-nucleotidases and ecto-5"-nucleotidase.	Adenosine	96-105	5'-nucleotidase ecto	Homo sapiens	137-157
26009814-0	2015	Inhibition of Neutrophils by Hypertonic Saline Involves Pannexin-1, CD39, CD73, and Other Ectonucleotidases.	Sodium Chloride	40-46	5'-nucleotidase ecto	Homo sapiens	74-78
26059452-2	2015	CD39 has been reported to be a marker of regulatory immune cells and catalyzes extracellular hydrolysis of nucleotides to generate AMP and, in tandem with CD73, adenosine.	Adenosine	161-170	5'-nucleotidase ecto	Homo sapiens	155-159
26009814-10	2015	Inhibition of the ectonucleotidases CD39 and CD73 abolished the suppressive effect of HS on purified PMN cultures but only partially reduced the effect of HS in whole blood.	Sodium Chloride	86-88	5'-nucleotidase ecto	Homo sapiens	45-49
26009814-12	2015	We conclude that HS resuscitation exerts anti-inflammatory effects that involve panx1, CD39, CD73, and other ectonucleotidases, which produce the adenosine that blocks PMNs by stimulating their A2a receptors.	Adenosine	146-155	5'-nucleotidase ecto	Homo sapiens	93-97
25770019-8	2015	Meanwhile, CD73+ cells showed negative correlations with age, WHR, BMI, FPG, HbAc1, triglycerides and cholesterol.	Triglycerides	84-97	5'-nucleotidase ecto	Homo sapiens	11-15
26147331-0	2015	alpha,beta-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5"-Nucleotidase (CD73) Inhibitors.	alpha,beta-methyleneadenosine 5'-diphosphate	0-24	5'-nucleotidase ecto	Homo sapiens	96-116
26147331-0	2015	alpha,beta-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5"-Nucleotidase (CD73) Inhibitors.	alpha,beta-methyleneadenosine 5'-diphosphate	0-24	5'-nucleotidase ecto	Homo sapiens	118-122
26147331-0	2015	alpha,beta-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5"-Nucleotidase (CD73) Inhibitors.	alpha,beta-methyleneadenosine 5'-diphosphate	26-31	5'-nucleotidase ecto	Homo sapiens	96-116
26147331-0	2015	alpha,beta-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5"-Nucleotidase (CD73) Inhibitors.	alpha,beta-methyleneadenosine 5'-diphosphate	26-31	5'-nucleotidase ecto	Homo sapiens	118-122
26147331-1	2015	ecto-5"-Nucleotidase (eN, CD73) catalyzes the hydrolysis of extracellular AMP to adenosine.	Adenosine Monophosphate	74-77	5'-nucleotidase ecto	Homo sapiens	0-20
26147331-1	2015	ecto-5"-Nucleotidase (eN, CD73) catalyzes the hydrolysis of extracellular AMP to adenosine.	Adenosine Monophosphate	74-77	5'-nucleotidase ecto	Homo sapiens	22-24
26147331-1	2015	ecto-5"-Nucleotidase (eN, CD73) catalyzes the hydrolysis of extracellular AMP to adenosine.	Adenosine Monophosphate	74-77	5'-nucleotidase ecto	Homo sapiens	26-30
26147331-1	2015	ecto-5"-Nucleotidase (eN, CD73) catalyzes the hydrolysis of extracellular AMP to adenosine.	Adenosine	81-90	5'-nucleotidase ecto	Homo sapiens	0-20
26147331-1	2015	ecto-5"-Nucleotidase (eN, CD73) catalyzes the hydrolysis of extracellular AMP to adenosine.	Adenosine	81-90	5'-nucleotidase ecto	Homo sapiens	22-24
26147331-1	2015	ecto-5"-Nucleotidase (eN, CD73) catalyzes the hydrolysis of extracellular AMP to adenosine.	Adenosine	81-90	5'-nucleotidase ecto	Homo sapiens	26-30
26147331-3	2015	The eN inhibitor alpha,beta-methylene-ADP (AOPCP, adenosine-5"-O-[(phosphonomethyl)phosphonic acid]) was used as a lead structure, and derivatives modified in various positions were prepared.	alpha,beta-methyleneadenosine 5'-diphosphate	17-41	5'-nucleotidase ecto	Homo sapiens	4-6
26147331-3	2015	The eN inhibitor alpha,beta-methylene-ADP (AOPCP, adenosine-5"-O-[(phosphonomethyl)phosphonic acid]) was used as a lead structure, and derivatives modified in various positions were prepared.	alpha,beta-methyleneadenosine 5'-diphosphate	43-48	5'-nucleotidase ecto	Homo sapiens	4-6
26147331-3	2015	The eN inhibitor alpha,beta-methylene-ADP (AOPCP, adenosine-5"-O-[(phosphonomethyl)phosphonic acid]) was used as a lead structure, and derivatives modified in various positions were prepared.	adenosine-5"-o-[(phosphonomethyl)phosphonic acid	50-98	5'-nucleotidase ecto	Homo sapiens	4-6
25770019-8	2015	Meanwhile, CD73+ cells showed negative correlations with age, WHR, BMI, FPG, HbAc1, triglycerides and cholesterol.	Cholesterol	102-113	5'-nucleotidase ecto	Homo sapiens	11-15
25902928-4	2015	Levels of ecto-5"-nucleotidase (CD73), an enzyme that converts extracellular ATP into adenosine, are markedly different between regions and correlate with adenosine signalling and the efficacy of theta pulse stimulation in reversing long-term potentiation.	Adenosine Triphosphate	77-80	5'-nucleotidase ecto	Homo sapiens	10-30
25857773-1	2015	BACKGROUND: Type II cytosolic 5"-nucleotidase (cN-II) catalyzes the hydrolysis of purine and, to some extent, of pyrimidine monophosphates.	purine	82-88	5'-nucleotidase ecto	Homo sapiens	30-45
26321267-2	2015	CD73 converts AMP to adenosine that via specific subtypes of P1 receptor mediates cytoprotection involving diverse mechanisms such as vasodilatation, suppression of inflammation, inhibition of thrombosis and anti-adrenergic effect.	Adenosine Monophosphate	14-17	5'-nucleotidase ecto	Homo sapiens	0-4
26321267-2	2015	CD73 converts AMP to adenosine that via specific subtypes of P1 receptor mediates cytoprotection involving diverse mechanisms such as vasodilatation, suppression of inflammation, inhibition of thrombosis and anti-adrenergic effect.	Adenosine	21-30	5'-nucleotidase ecto	Homo sapiens	0-4
26321267-4	2015	Endothelium is a major site for both CD73 mediated production of adenosine and its cytoprotective effect.	Adenosine	65-74	5'-nucleotidase ecto	Homo sapiens	37-41
26321267-5	2015	Nucleotides (predominantly ATP or ADP) that could be released from different cells via controlled specific of unspecific mechanisms constitute a major source of substrate for adenosine production via CD73.	Adenosine Triphosphate	27-30	5'-nucleotidase ecto	Homo sapiens	200-204
26321267-5	2015	Nucleotides (predominantly ATP or ADP) that could be released from different cells via controlled specific of unspecific mechanisms constitute a major source of substrate for adenosine production via CD73.	Adenosine Diphosphate	34-37	5'-nucleotidase ecto	Homo sapiens	200-204
26321267-5	2015	Nucleotides (predominantly ATP or ADP) that could be released from different cells via controlled specific of unspecific mechanisms constitute a major source of substrate for adenosine production via CD73.	Adenosine	175-184	5'-nucleotidase ecto	Homo sapiens	200-204
26321267-7	2015	Retention of nucleotides and decreased adenosine production due to loss of CD73 function may have negative implications and could be important cause of various pathologies.	Adenosine	39-48	5'-nucleotidase ecto	Homo sapiens	75-79
25857773-1	2015	BACKGROUND: Type II cytosolic 5"-nucleotidase (cN-II) catalyzes the hydrolysis of purine and, to some extent, of pyrimidine monophosphates.	pyrimidine monophosphates	113-138	5'-nucleotidase ecto	Homo sapiens	30-45
26026888-8	2015	Furthermore, ZA or ZA + low doses of melatonin induced a decrease of expression of CD90/CD105/CD73 on BMMSCs, while a higher concentration recovered CD73 levels.	Melatonin	37-46	5'-nucleotidase ecto	Homo sapiens	94-98
26026888-8	2015	Furthermore, ZA or ZA + low doses of melatonin induced a decrease of expression of CD90/CD105/CD73 on BMMSCs, while a higher concentration recovered CD73 levels.	Melatonin	37-46	5'-nucleotidase ecto	Homo sapiens	149-153
25902928-4	2015	Levels of ecto-5"-nucleotidase (CD73), an enzyme that converts extracellular ATP into adenosine, are markedly different between regions and correlate with adenosine signalling and the efficacy of theta pulse stimulation in reversing long-term potentiation.	Adenosine Triphosphate	77-80	5'-nucleotidase ecto	Homo sapiens	32-36
25902928-4	2015	Levels of ecto-5"-nucleotidase (CD73), an enzyme that converts extracellular ATP into adenosine, are markedly different between regions and correlate with adenosine signalling and the efficacy of theta pulse stimulation in reversing long-term potentiation.	Adenosine	86-95	5'-nucleotidase ecto	Homo sapiens	10-30
25902928-4	2015	Levels of ecto-5"-nucleotidase (CD73), an enzyme that converts extracellular ATP into adenosine, are markedly different between regions and correlate with adenosine signalling and the efficacy of theta pulse stimulation in reversing long-term potentiation.	Adenosine	86-95	5'-nucleotidase ecto	Homo sapiens	32-36
25902928-4	2015	Levels of ecto-5"-nucleotidase (CD73), an enzyme that converts extracellular ATP into adenosine, are markedly different between regions and correlate with adenosine signalling and the efficacy of theta pulse stimulation in reversing long-term potentiation.	Adenosine	155-164	5'-nucleotidase ecto	Homo sapiens	10-30
25902928-4	2015	Levels of ecto-5"-nucleotidase (CD73), an enzyme that converts extracellular ATP into adenosine, are markedly different between regions and correlate with adenosine signalling and the efficacy of theta pulse stimulation in reversing long-term potentiation.	Adenosine	155-164	5'-nucleotidase ecto	Homo sapiens	32-36
25902928-11	2015	Input/output curves for two connections in the piriform cortex were similar to those for the LPP, whereas adenosine modulation again correlated with levels of CD73.	Adenosine	106-115	5'-nucleotidase ecto	Homo sapiens	159-163
25850771-1	2015	Ecto-5"-nucleotidase (ecto-5"-NT, 5"-NT, eN, CD73) is a membrane ecto-enzyme that is primarily responsible for the extracellular production of adenosine from AMP.	Polyamines	41-43	5'-nucleotidase ecto	Homo sapiens	0-20
26010187-3	2015	The deficiency of CD73 involves the extracellular adenosine metabolism that influences inorganic pyrophosphate and phosphate metabolism and leads to tissue calcification.	Adenosine	50-59	5'-nucleotidase ecto	Homo sapiens	18-22
26010187-3	2015	The deficiency of CD73 involves the extracellular adenosine metabolism that influences inorganic pyrophosphate and phosphate metabolism and leads to tissue calcification.	diphosphoric acid	97-110	5'-nucleotidase ecto	Homo sapiens	18-22
26010187-3	2015	The deficiency of CD73 involves the extracellular adenosine metabolism that influences inorganic pyrophosphate and phosphate metabolism and leads to tissue calcification.	Phosphates	101-110	5'-nucleotidase ecto	Homo sapiens	18-22
25677906-1	2015	The ectonucleotidase CD73 degrades adenosine triphosphate (ATP) to adenosine which potently inhibits host immune responses against cancer.	Adenosine Triphosphate	35-57	5'-nucleotidase ecto	Homo sapiens	21-25
25677906-1	2015	The ectonucleotidase CD73 degrades adenosine triphosphate (ATP) to adenosine which potently inhibits host immune responses against cancer.	Adenosine Triphosphate	59-62	5'-nucleotidase ecto	Homo sapiens	21-25
25677906-1	2015	The ectonucleotidase CD73 degrades adenosine triphosphate (ATP) to adenosine which potently inhibits host immune responses against cancer.	Adenosine	35-44	5'-nucleotidase ecto	Homo sapiens	21-25
25524006-4	2015	CD73 is an important cell surface enzyme which converts extracellular adenosine monophosphate (AMP) to adenosine.	Adenosine Monophosphate	70-93	5'-nucleotidase ecto	Homo sapiens	0-4
25524006-4	2015	CD73 is an important cell surface enzyme which converts extracellular adenosine monophosphate (AMP) to adenosine.	Adenosine Monophosphate	95-98	5'-nucleotidase ecto	Homo sapiens	0-4
25524006-4	2015	CD73 is an important cell surface enzyme which converts extracellular adenosine monophosphate (AMP) to adenosine.	Adenosine	70-79	5'-nucleotidase ecto	Homo sapiens	0-4
25850771-1	2015	Ecto-5"-nucleotidase (ecto-5"-NT, 5"-NT, eN, CD73) is a membrane ecto-enzyme that is primarily responsible for the extracellular production of adenosine from AMP.	Adenosine	143-152	5'-nucleotidase ecto	Homo sapiens	0-20
25850771-1	2015	Ecto-5"-nucleotidase (ecto-5"-NT, 5"-NT, eN, CD73) is a membrane ecto-enzyme that is primarily responsible for the extracellular production of adenosine from AMP.	Adenosine	143-152	5'-nucleotidase ecto	Homo sapiens	45-49
25850771-1	2015	Ecto-5"-nucleotidase (ecto-5"-NT, 5"-NT, eN, CD73) is a membrane ecto-enzyme that is primarily responsible for the extracellular production of adenosine from AMP.	Adenosine Monophosphate	158-161	5'-nucleotidase ecto	Homo sapiens	0-20
25850771-1	2015	Ecto-5"-nucleotidase (ecto-5"-NT, 5"-NT, eN, CD73) is a membrane ecto-enzyme that is primarily responsible for the extracellular production of adenosine from AMP.	Adenosine Monophosphate	158-161	5'-nucleotidase ecto	Homo sapiens	45-49
25720604-2	2015	A pre-defined stem-loop library, containing LNA in the forward primer region, was enriched with CD73 binding sequences through six rounds of SELEX with recombinant his-tagged CD73 immobilised on anti-his plates.	Histidine	164-167	5'-nucleotidase ecto	Homo sapiens	175-179
25672397-3	2015	The generation of adenosine by CD73 also suppresses antitumor immune responses through the activation of A2A receptors on T cells and natural killer (NK) cells.	Adenosine	18-27	5'-nucleotidase ecto	Homo sapiens	31-35
25532725-5	2015	BMSC recipients had increased serum CD73 expressing exosomes that promoted adenosine accumulation ex vivo.	Adenosine	75-84	5'-nucleotidase ecto	Homo sapiens	36-40
25717146-5	2015	The extracellular ATP concentration is regulated by an enzymatic process, in which CD39 converts ATP and ADP into AMP, and CD73 converts AMP into adenosine.	Adenosine Triphosphate	18-21	5'-nucleotidase ecto	Homo sapiens	123-127
25717146-5	2015	The extracellular ATP concentration is regulated by an enzymatic process, in which CD39 converts ATP and ADP into AMP, and CD73 converts AMP into adenosine.	Adenosine Monophosphate	137-140	5'-nucleotidase ecto	Homo sapiens	123-127
25717146-5	2015	The extracellular ATP concentration is regulated by an enzymatic process, in which CD39 converts ATP and ADP into AMP, and CD73 converts AMP into adenosine.	Adenosine	146-155	5'-nucleotidase ecto	Homo sapiens	123-127
25644539-3	2015	We hypothesized that expression of ectonucleotide pyrophosphatase/phosphodiesterase 1 (NPP1), which generates AMP, and 5"-nucleotidase (CD73), an enzyme using AMP as a substrate to produce adenosine, may co-regulate the mineralization of the aortic valve.	Adenosine Monophosphate	159-162	5'-nucleotidase ecto	Homo sapiens	136-140
25644539-3	2015	We hypothesized that expression of ectonucleotide pyrophosphatase/phosphodiesterase 1 (NPP1), which generates AMP, and 5"-nucleotidase (CD73), an enzyme using AMP as a substrate to produce adenosine, may co-regulate the mineralization of the aortic valve.	Adenosine	189-198	5'-nucleotidase ecto	Homo sapiens	136-140
25532725-7	2015	To investigate the potential clinical relevance of these mechanistic findings, patient serum samples collected pre- and post-BMSC treatment were studied for exosome content: CD73 expressing exosomes promoting adenosine accumulation were detected in post-BMSC samples.	Adenosine	209-218	5'-nucleotidase ecto	Homo sapiens	174-178
25403716-1	2015	The ectonucleotidases CD39 and CD73 hydrolyze extracellular adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to generate adenosine, which binds to adenosine receptors and inhibits T-cell and natural killer (NK)-cell responses, thereby suppressing the immune system.	Adenosine Triphosphate	60-82	5'-nucleotidase ecto	Homo sapiens	31-35
25403716-1	2015	The ectonucleotidases CD39 and CD73 hydrolyze extracellular adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to generate adenosine, which binds to adenosine receptors and inhibits T-cell and natural killer (NK)-cell responses, thereby suppressing the immune system.	Adenosine Triphosphate	84-87	5'-nucleotidase ecto	Homo sapiens	31-35
25403716-1	2015	The ectonucleotidases CD39 and CD73 hydrolyze extracellular adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to generate adenosine, which binds to adenosine receptors and inhibits T-cell and natural killer (NK)-cell responses, thereby suppressing the immune system.	Adenosine Diphosphate	93-114	5'-nucleotidase ecto	Homo sapiens	31-35
25403716-1	2015	The ectonucleotidases CD39 and CD73 hydrolyze extracellular adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to generate adenosine, which binds to adenosine receptors and inhibits T-cell and natural killer (NK)-cell responses, thereby suppressing the immune system.	Adenosine Diphosphate	116-119	5'-nucleotidase ecto	Homo sapiens	31-35
25403716-1	2015	The ectonucleotidases CD39 and CD73 hydrolyze extracellular adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to generate adenosine, which binds to adenosine receptors and inhibits T-cell and natural killer (NK)-cell responses, thereby suppressing the immune system.	Adenosine	60-69	5'-nucleotidase ecto	Homo sapiens	31-35
25403716-2	2015	The generation of adenosine via the CD39/CD73 pathway is recognized as a major mechanism of regulatory T cell (Treg) immunosuppressive function.	Adenosine	18-27	5'-nucleotidase ecto	Homo sapiens	41-45
25403716-8	2015	CD39 in cancer cells displays ATPase activity and, together with CD73, generates adenosine.	Adenosine	81-90	5'-nucleotidase ecto	Homo sapiens	65-69
25403716-9	2015	CD39+CD73+ cancer cells inhibited the proliferation of CD4 and CD8 T cells and the generation of cytotoxic effector CD8 T cells (CTL) in a CD39- and adenosine-dependent manner.	Adenosine	149-158	5'-nucleotidase ecto	Homo sapiens	5-9
26303492-4	2015	Pharmacological inhibition of ecto-5"-nucleotidase (CD73), a key enzyme required for extracellular generation of adenosine from ATP, using alpha,beta-methylene ADP, virtually abolished the basal normocapnic single fibre discharge frequency (superfusate PO(2) ~ 300 mmHg, PCO(2) ~ 40 mmHg) and diminished the chemoafferent response to hypercapnia (PCO(2) ~ 80 mmHg).	Adenosine	113-122	5'-nucleotidase ecto	Homo sapiens	30-50
25641680-1	2015	5"-Nucleotidase/CD73 is a key enzyme in the regulation of purinergic signaling, hydrolyzing extracellular AMP to produce adenosine, which is critical in the blood vascular system and in immunosuppression.	Adenosine Monophosphate	106-109	5'-nucleotidase ecto	Homo sapiens	0-15
25641680-1	2015	5"-Nucleotidase/CD73 is a key enzyme in the regulation of purinergic signaling, hydrolyzing extracellular AMP to produce adenosine, which is critical in the blood vascular system and in immunosuppression.	Adenosine Monophosphate	106-109	5'-nucleotidase ecto	Homo sapiens	16-20
25641680-1	2015	5"-Nucleotidase/CD73 is a key enzyme in the regulation of purinergic signaling, hydrolyzing extracellular AMP to produce adenosine, which is critical in the blood vascular system and in immunosuppression.	Adenosine	121-130	5'-nucleotidase ecto	Homo sapiens	0-15
25641680-1	2015	5"-Nucleotidase/CD73 is a key enzyme in the regulation of purinergic signaling, hydrolyzing extracellular AMP to produce adenosine, which is critical in the blood vascular system and in immunosuppression.	Adenosine	121-130	5'-nucleotidase ecto	Homo sapiens	16-20
25675517-7	2015	Tregs produce adenosine (ADO) through ATP degradation by sequential actions of two cell surface ectonucleotidases: CD39 and CD73.	Adenosine	14-23	5'-nucleotidase ecto	Homo sapiens	124-128
25675517-7	2015	Tregs produce adenosine (ADO) through ATP degradation by sequential actions of two cell surface ectonucleotidases: CD39 and CD73.	Adenosine	25-28	5'-nucleotidase ecto	Homo sapiens	124-128
25418634-0	2015	Correlation of low CD73 expression on synovial lymphocytes with reduced adenosine generation and higher disease severity in juvenile idiopathic arthritis.	Adenosine	72-81	5'-nucleotidase ecto	Homo sapiens	19-23
25418634-1	2015	OBJECTIVE: To investigate the expression and adenosine-generating activity of the ecto-5"-nucleotidase CD73 on synovial fluid mononuclear cells (SFMCs) and peripheral blood mononuclear cells (PBMCs) from children with juvenile idiopathic arthritis (JIA).	Adenosine	45-54	5'-nucleotidase ecto	Homo sapiens	82-102
25418634-1	2015	OBJECTIVE: To investigate the expression and adenosine-generating activity of the ecto-5"-nucleotidase CD73 on synovial fluid mononuclear cells (SFMCs) and peripheral blood mononuclear cells (PBMCs) from children with juvenile idiopathic arthritis (JIA).	Adenosine	45-54	5'-nucleotidase ecto	Homo sapiens	103-107
25418634-2	2015	METHODS: Given the role of CD73 protein in the production of antiinflammatory adenosine and its intersection with inflammatory biologic pathways, the expression of CD73 on SF and PB lymphocytes from patients with JIA and PB lymphocytes from healthy control subjects was determined by flow cytometry.	Adenosine	78-87	5'-nucleotidase ecto	Homo sapiens	27-31
25418634-11	2015	The decreased CD73 expression on SFMCs, in turn, results in reduced adenosine production, which leads to a decreased potential for antiinflammatory activity.	Adenosine	68-77	5'-nucleotidase ecto	Homo sapiens	14-18
25402681-3	2015	By comparing CD73 expression and function in mononuclear and endothelial cells (ECs) of blood and lymph, we show that extracellular purines and CD73 activity have differential effects in these two vascular systems.	Purines	132-139	5'-nucleotidase ecto	Homo sapiens	13-17
26303492-4	2015	Pharmacological inhibition of ecto-5"-nucleotidase (CD73), a key enzyme required for extracellular generation of adenosine from ATP, using alpha,beta-methylene ADP, virtually abolished the basal normocapnic single fibre discharge frequency (superfusate PO(2) ~ 300 mmHg, PCO(2) ~ 40 mmHg) and diminished the chemoafferent response to hypercapnia (PCO(2) ~ 80 mmHg).	Adenosine	113-122	5'-nucleotidase ecto	Homo sapiens	52-56
26303492-4	2015	Pharmacological inhibition of ecto-5"-nucleotidase (CD73), a key enzyme required for extracellular generation of adenosine from ATP, using alpha,beta-methylene ADP, virtually abolished the basal normocapnic single fibre discharge frequency (superfusate PO(2) ~ 300 mmHg, PCO(2) ~ 40 mmHg) and diminished the chemoafferent response to hypercapnia (PCO(2) ~ 80 mmHg).	Adenosine Triphosphate	128-131	5'-nucleotidase ecto	Homo sapiens	30-50
26303492-4	2015	Pharmacological inhibition of ecto-5"-nucleotidase (CD73), a key enzyme required for extracellular generation of adenosine from ATP, using alpha,beta-methylene ADP, virtually abolished the basal normocapnic single fibre discharge frequency (superfusate PO(2) ~ 300 mmHg, PCO(2) ~ 40 mmHg) and diminished the chemoafferent response to hypercapnia (PCO(2) ~ 80 mmHg).	Adenosine Triphosphate	128-131	5'-nucleotidase ecto	Homo sapiens	52-56
26303492-4	2015	Pharmacological inhibition of ecto-5"-nucleotidase (CD73), a key enzyme required for extracellular generation of adenosine from ATP, using alpha,beta-methylene ADP, virtually abolished the basal normocapnic single fibre discharge frequency (superfusate PO(2) ~ 300 mmHg, PCO(2) ~ 40 mmHg) and diminished the chemoafferent response to hypercapnia (PCO(2) ~ 80 mmHg).	methylene adp	150-163	5'-nucleotidase ecto	Homo sapiens	30-50
26303492-4	2015	Pharmacological inhibition of ecto-5"-nucleotidase (CD73), a key enzyme required for extracellular generation of adenosine from ATP, using alpha,beta-methylene ADP, virtually abolished the basal normocapnic single fibre discharge frequency (superfusate PO(2) ~ 300 mmHg, PCO(2) ~ 40 mmHg) and diminished the chemoafferent response to hypercapnia (PCO(2) ~ 80 mmHg).	methylene adp	150-163	5'-nucleotidase ecto	Homo sapiens	52-56
26303492-8	2015	These data therefore identify a functional role for CD73 derived adenosine and transmembrane adenylate cyclases, in modulating the basal chemoafferent discharge frequency and in priming the CB to hypercapnic stimulation.	Adenosine	65-74	5'-nucleotidase ecto	Homo sapiens	52-56
25352330-4	2014	Furthermore, ATP is rapidly degraded into adenosine by ectonucleotidases such as CD39 and CD73, and adenosine exerts additional regulatory effects through its own receptors.	Adenosine Triphosphate	13-16	5'-nucleotidase ecto	Homo sapiens	90-94
25048519-7	2015	Coadjuvant ectoenzymes include PC-1/CD203a, CD39, and CD73, which control the production of ADO.	Adenosine	92-95	5'-nucleotidase ecto	Homo sapiens	54-58
25298403-1	2014	Ecto-5"-nucleotidase (CD73), encoded by NT5E, is the major enzymatic source of extracellular adenosine.	Adenosine	93-102	5'-nucleotidase ecto	Homo sapiens	0-20
25298403-1	2014	Ecto-5"-nucleotidase (CD73), encoded by NT5E, is the major enzymatic source of extracellular adenosine.	Adenosine	93-102	5'-nucleotidase ecto	Homo sapiens	22-26
25298403-1	2014	Ecto-5"-nucleotidase (CD73), encoded by NT5E, is the major enzymatic source of extracellular adenosine.	Adenosine	93-102	5'-nucleotidase ecto	Homo sapiens	40-44
25490556-3	2014	Adenosine has previously been shown to suppress the proliferation and cytokine secretion of T-cells and recent evidence suggests that inhibition of CD73 has the potential to enhance T-cell directed therapies.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	148-152
25126879-2	2014	CD73/ecto-5"-nucleotidase is an enzyme that generates adenosine, which dampens inflammation and improves vascular barrier function in several disease models.	Adenosine	54-63	5'-nucleotidase ecto	Homo sapiens	0-4
25126879-2	2014	CD73/ecto-5"-nucleotidase is an enzyme that generates adenosine, which dampens inflammation and improves vascular barrier function in several disease models.	Adenosine	54-63	5'-nucleotidase ecto	Homo sapiens	5-25
25080434-5	2014	Extracellular nucleotides and adenosine were shown to be rapidly metabolized on tumor cell surfaces via sequential ecto-5"-nucleotidase (CD73/NT5E) and adenosine deaminase reactions with subsequent cellular uptake of nucleoside metabolites and their intracellular interconversion into ADP/ATP.	Adenosine	30-39	5'-nucleotidase ecto	Homo sapiens	115-135
25080434-5	2014	Extracellular nucleotides and adenosine were shown to be rapidly metabolized on tumor cell surfaces via sequential ecto-5"-nucleotidase (CD73/NT5E) and adenosine deaminase reactions with subsequent cellular uptake of nucleoside metabolites and their intracellular interconversion into ADP/ATP.	Adenosine	30-39	5'-nucleotidase ecto	Homo sapiens	137-141
25080434-5	2014	Extracellular nucleotides and adenosine were shown to be rapidly metabolized on tumor cell surfaces via sequential ecto-5"-nucleotidase (CD73/NT5E) and adenosine deaminase reactions with subsequent cellular uptake of nucleoside metabolites and their intracellular interconversion into ADP/ATP.	Adenosine	30-39	5'-nucleotidase ecto	Homo sapiens	142-146
25080434-5	2014	Extracellular nucleotides and adenosine were shown to be rapidly metabolized on tumor cell surfaces via sequential ecto-5"-nucleotidase (CD73/NT5E) and adenosine deaminase reactions with subsequent cellular uptake of nucleoside metabolites and their intracellular interconversion into ADP/ATP.	Nucleosides	217-227	5'-nucleotidase ecto	Homo sapiens	137-141
25080434-5	2014	Extracellular nucleotides and adenosine were shown to be rapidly metabolized on tumor cell surfaces via sequential ecto-5"-nucleotidase (CD73/NT5E) and adenosine deaminase reactions with subsequent cellular uptake of nucleoside metabolites and their intracellular interconversion into ADP/ATP.	Adenosine Diphosphate	285-288	5'-nucleotidase ecto	Homo sapiens	137-141
25080434-5	2014	Extracellular nucleotides and adenosine were shown to be rapidly metabolized on tumor cell surfaces via sequential ecto-5"-nucleotidase (CD73/NT5E) and adenosine deaminase reactions with subsequent cellular uptake of nucleoside metabolites and their intracellular interconversion into ADP/ATP.	Adenosine Triphosphate	289-292	5'-nucleotidase ecto	Homo sapiens	137-141
25352330-4	2014	Furthermore, ATP is rapidly degraded into adenosine by ectonucleotidases such as CD39 and CD73, and adenosine exerts additional regulatory effects through its own receptors.	Adenosine	42-51	5'-nucleotidase ecto	Homo sapiens	90-94
25221554-4	2014	The second mechanism is the metabolism of extracellular ATP to adenosine by the ectoenzymes CD39 and CD73.	Adenosine Triphosphate	56-59	5'-nucleotidase ecto	Homo sapiens	101-105
25675814-0	2014	[Immune regulation via the generation of extracellular adenosine by CD73].	Adenosine	55-64	5'-nucleotidase ecto	Homo sapiens	68-72
25127858-1	2014	There is growing evidence that generation of adenosine from ATP, which is mediated by the CD39/CD73 enzyme pair, predetermines immunosuppressive and proangiogenic properties of myeloid cells.	Adenosine	45-54	5'-nucleotidase ecto	Homo sapiens	95-99
25127858-1	2014	There is growing evidence that generation of adenosine from ATP, which is mediated by the CD39/CD73 enzyme pair, predetermines immunosuppressive and proangiogenic properties of myeloid cells.	Adenosine Triphosphate	60-63	5'-nucleotidase ecto	Homo sapiens	95-99
24958495-2	2014	In this context, a critical role of CD73, in calibrating the duration, magnitude and composition of adenosine signaling in cancer development and progression, has been identified.	Adenosine	100-109	5'-nucleotidase ecto	Homo sapiens	36-40
25221554-4	2014	The second mechanism is the metabolism of extracellular ATP to adenosine by the ectoenzymes CD39 and CD73.	Adenosine	63-72	5'-nucleotidase ecto	Homo sapiens	101-105
24749746-0	2014	Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.	Adenosine	44-53	5'-nucleotidase ecto	Homo sapiens	84-88
24749746-0	2014	Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.	Adenosine	44-53	5'-nucleotidase ecto	Homo sapiens	105-109
24749746-0	2014	Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.	Adenosine	44-53	5'-nucleotidase ecto	Homo sapiens	105-109
24749746-3	2014	Using mass spectrometry, we measured nucleoside production by subsets of human CD4(+) CD39(+) and CD4(+) CD39(-)CD73(+) T cells or CD19(+) B cells isolated from blood of 30 volunteers and 14 cancer patients.	Nucleosides	37-47	5'-nucleotidase ecto	Homo sapiens	112-116
24749746-9	2014	All these CD73(+) T cell subsets and B cells hydrolyzed 5"-AMP to ADO.	Adenosine Monophosphate	56-62	5'-nucleotidase ecto	Homo sapiens	10-14
24798880-6	2014	EXPERT OPINION: It was recently demonstrated that CD73 expression in TNBC is associated with worse clinical outcomes and increased resistance to anthracycline chemotherapy.	Anthracyclines	145-158	5'-nucleotidase ecto	Homo sapiens	50-54
25071765-2	2014	The immunosuppression by endogenously-produced adenosine is pathophysiologically significant since inactivation of A2A/A2B adenosine receptor (A2AR/A2BR) and adenosine-producing ecto-enzymes CD39/CD73 results in the higher intensity of immune response and exaggeration of inflammatory damage.	Adenosine	47-56	5'-nucleotidase ecto	Homo sapiens	196-200
25184735-6	2014	In this study we investigate the role of P2X7 channels and the ecto-5"-nucleotidase CD39 in ATP-triggered release of IL-1beta from LPS-treated mast cells.	Adenosine Triphosphate	92-95	5'-nucleotidase ecto	Homo sapiens	63-83
24652540-8	2014	The effects of extracellular cAMP on monocytes are mediated by CD73 ecto-5"-nucleotidase and A2A and A2B adenosine receptors, as selective antagonists could reverse its effects.	Cyclic AMP	29-33	5'-nucleotidase ecto	Homo sapiens	63-67
24990240-5	2014	Among the coadjuvants are (i) antagonists of A2AR, (ii) extracellular adenosine-degrading drugs, (iii) inhibitors of adenosine generation by CD39/CD73 ectoenzymes, and (iv) inhibitors of hypoxia-HIF-1alpha signaling.	Adenosine	117-126	5'-nucleotidase ecto	Homo sapiens	146-150
24859298-7	2014	Advances in medicinal chemistry have an accelerated pace toward clinical trials: Methotrexate and sulfasalazine, used to treat IBD, act by stimulating CD73-dependent adenosine production.	Methotrexate	81-93	5'-nucleotidase ecto	Homo sapiens	151-155
24859298-7	2014	Advances in medicinal chemistry have an accelerated pace toward clinical trials: Methotrexate and sulfasalazine, used to treat IBD, act by stimulating CD73-dependent adenosine production.	Sulfasalazine	98-111	5'-nucleotidase ecto	Homo sapiens	151-155
24859298-7	2014	Advances in medicinal chemistry have an accelerated pace toward clinical trials: Methotrexate and sulfasalazine, used to treat IBD, act by stimulating CD73-dependent adenosine production.	Adenosine	166-175	5'-nucleotidase ecto	Homo sapiens	151-155
24603684-0	2014	Crystal structures of the novel cytosolic 5"-nucleotidase IIIB explain its preference for m7GMP.	m(7)GMP	90-95	5'-nucleotidase ecto	Homo sapiens	42-57
24945528-4	2014	Clinically relevant concentrations of isoflurane induced CD73 activity and increased adenosine generation in cultured human umbilical vein or mouse glomerular endothelial cells.	Isoflurane	38-48	5'-nucleotidase ecto	Homo sapiens	57-61
24945528-9	2014	Supporting a critical role of CD73 in isoflurane-mediated endothelial protection, a selective CD73 inhibitor (APCP) prevented isoflurane-induced protection against human endothelial cell inflammation and apoptosis.	Isoflurane	38-48	5'-nucleotidase ecto	Homo sapiens	30-34
24945528-9	2014	Supporting a critical role of CD73 in isoflurane-mediated endothelial protection, a selective CD73 inhibitor (APCP) prevented isoflurane-induced protection against human endothelial cell inflammation and apoptosis.	Isoflurane	126-136	5'-nucleotidase ecto	Homo sapiens	30-34
24945528-9	2014	Supporting a critical role of CD73 in isoflurane-mediated endothelial protection, a selective CD73 inhibitor (APCP) prevented isoflurane-induced protection against human endothelial cell inflammation and apoptosis.	Isoflurane	126-136	5'-nucleotidase ecto	Homo sapiens	94-98
24357632-2	2014	Here we report that CD73, both a coactivator molecule of T cells and an immunosuppressive ecto-enzyme through adenosine production, is only weakly expressed by CD8+ T cells of HIV-infected patients and only partially restored after successful antiviral treatment.	Adenosine	110-119	5'-nucleotidase ecto	Homo sapiens	20-24
24748324-9	2014	Expression analysis in T cell subsets of the lung revealed ATP (Cd39, Cd73) and NAD (Cd38, Cd157, Cd296, Pc-1) degrading enzymes.	Adenosine Triphosphate	59-62	5'-nucleotidase ecto	Homo sapiens	70-74
24887587-1	2014	Ecto-5"-nucleotidase/CD73/NT5E, the product of the NT5E gene, is the dominant enzyme in the generation of adenosine from degradation of AMP in the extracellular environment.	Adenosine	106-115	5'-nucleotidase ecto	Homo sapiens	0-20
24887587-1	2014	Ecto-5"-nucleotidase/CD73/NT5E, the product of the NT5E gene, is the dominant enzyme in the generation of adenosine from degradation of AMP in the extracellular environment.	Adenosine	106-115	5'-nucleotidase ecto	Homo sapiens	21-25
24887587-1	2014	Ecto-5"-nucleotidase/CD73/NT5E, the product of the NT5E gene, is the dominant enzyme in the generation of adenosine from degradation of AMP in the extracellular environment.	Adenosine	106-115	5'-nucleotidase ecto	Homo sapiens	26-30
24887587-1	2014	Ecto-5"-nucleotidase/CD73/NT5E, the product of the NT5E gene, is the dominant enzyme in the generation of adenosine from degradation of AMP in the extracellular environment.	Adenosine	106-115	5'-nucleotidase ecto	Homo sapiens	51-55
24887587-1	2014	Ecto-5"-nucleotidase/CD73/NT5E, the product of the NT5E gene, is the dominant enzyme in the generation of adenosine from degradation of AMP in the extracellular environment.	Adenosine Monophosphate	136-139	5'-nucleotidase ecto	Homo sapiens	0-20
24887587-1	2014	Ecto-5"-nucleotidase/CD73/NT5E, the product of the NT5E gene, is the dominant enzyme in the generation of adenosine from degradation of AMP in the extracellular environment.	Adenosine Monophosphate	136-139	5'-nucleotidase ecto	Homo sapiens	21-25
24887587-1	2014	Ecto-5"-nucleotidase/CD73/NT5E, the product of the NT5E gene, is the dominant enzyme in the generation of adenosine from degradation of AMP in the extracellular environment.	Adenosine Monophosphate	136-139	5'-nucleotidase ecto	Homo sapiens	26-30
24887587-1	2014	Ecto-5"-nucleotidase/CD73/NT5E, the product of the NT5E gene, is the dominant enzyme in the generation of adenosine from degradation of AMP in the extracellular environment.	Adenosine Monophosphate	136-139	5'-nucleotidase ecto	Homo sapiens	51-55
24603684-11	2014	Analyzing the substrate specificities of cN-IIIB and the main pyrimidine 5"-nucleotidase cN-IIIA by mutagenesis studies, we show that cN-IIIA dephosphorylates the purine m7GMP as well, hence redefining its substrate spectrum.	purine	163-169	5'-nucleotidase ecto	Homo sapiens	73-88
24603684-11	2014	Analyzing the substrate specificities of cN-IIIB and the main pyrimidine 5"-nucleotidase cN-IIIA by mutagenesis studies, we show that cN-IIIA dephosphorylates the purine m7GMP as well, hence redefining its substrate spectrum.	m(7)GMP	170-175	5'-nucleotidase ecto	Homo sapiens	73-88
24462745-1	2014	In many vertebrate tissues CD39-like ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) act in concert with ecto-5"-nucleotidase (e5NT, CD73) to convert extracellular ATP to adenosine.	Adenosine Triphosphate	176-179	5'-nucleotidase ecto	Homo sapiens	117-137
24462745-1	2014	In many vertebrate tissues CD39-like ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) act in concert with ecto-5"-nucleotidase (e5NT, CD73) to convert extracellular ATP to adenosine.	Adenosine Triphosphate	176-179	5'-nucleotidase ecto	Homo sapiens	139-143
24462745-1	2014	In many vertebrate tissues CD39-like ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) act in concert with ecto-5"-nucleotidase (e5NT, CD73) to convert extracellular ATP to adenosine.	Adenosine Triphosphate	176-179	5'-nucleotidase ecto	Homo sapiens	145-149
24462745-1	2014	In many vertebrate tissues CD39-like ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) act in concert with ecto-5"-nucleotidase (e5NT, CD73) to convert extracellular ATP to adenosine.	Adenosine	183-192	5'-nucleotidase ecto	Homo sapiens	117-137
24462745-1	2014	In many vertebrate tissues CD39-like ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) act in concert with ecto-5"-nucleotidase (e5NT, CD73) to convert extracellular ATP to adenosine.	Adenosine	183-192	5'-nucleotidase ecto	Homo sapiens	139-143
24462745-1	2014	In many vertebrate tissues CD39-like ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) act in concert with ecto-5"-nucleotidase (e5NT, CD73) to convert extracellular ATP to adenosine.	Adenosine	183-192	5'-nucleotidase ecto	Homo sapiens	145-149
24600452-2	2014	Nucleotides such as adenosine triphosphate and adenosine diphosphate are release from injured and necrotic cells and hydrolyzed to adenosine monophosphate and adenosine by the concerted action of the ectonucleotidases CD39 and CD73.	Adenosine Triphosphate	20-42	5'-nucleotidase ecto	Homo sapiens	227-231
24429288-4	2014	Biochemical characterization of recombinant NudP revealed a Mn(2+)-dependent ecto-5"-nucleotidase activity on ribo- and deoxyribonucleoside 5"-mono- and 5"-diphosphates with a substrate specificity different from that of known orthologous enzymes.	ribo-	110-115	5'-nucleotidase ecto	Homo sapiens	77-97
24429288-4	2014	Biochemical characterization of recombinant NudP revealed a Mn(2+)-dependent ecto-5"-nucleotidase activity on ribo- and deoxyribonucleoside 5"-mono- and 5"-diphosphates with a substrate specificity different from that of known orthologous enzymes.	deoxyribonucleoside 5"-mono- and 5"-diphosphates	120-168	5'-nucleotidase ecto	Homo sapiens	77-97
24429288-6	2014	The NudP ecto-5"-nucleotidase activity is reminiscent of the reactions performed by the mammalian ectonucleotidases CD39 and CD73 involved in regulating the extracellular level of ATP and adenosine.	Adenosine Triphosphate	180-183	5'-nucleotidase ecto	Homo sapiens	9-29
24429288-6	2014	The NudP ecto-5"-nucleotidase activity is reminiscent of the reactions performed by the mammalian ectonucleotidases CD39 and CD73 involved in regulating the extracellular level of ATP and adenosine.	Adenosine Triphosphate	180-183	5'-nucleotidase ecto	Homo sapiens	125-129
24429288-6	2014	The NudP ecto-5"-nucleotidase activity is reminiscent of the reactions performed by the mammalian ectonucleotidases CD39 and CD73 involved in regulating the extracellular level of ATP and adenosine.	Adenosine	188-197	5'-nucleotidase ecto	Homo sapiens	9-29
24429288-6	2014	The NudP ecto-5"-nucleotidase activity is reminiscent of the reactions performed by the mammalian ectonucleotidases CD39 and CD73 involved in regulating the extracellular level of ATP and adenosine.	Adenosine	188-197	5'-nucleotidase ecto	Homo sapiens	125-129
24600452-2	2014	Nucleotides such as adenosine triphosphate and adenosine diphosphate are release from injured and necrotic cells and hydrolyzed to adenosine monophosphate and adenosine by the concerted action of the ectonucleotidases CD39 and CD73.	Adenosine Diphosphate	47-68	5'-nucleotidase ecto	Homo sapiens	227-231
24600452-2	2014	Nucleotides such as adenosine triphosphate and adenosine diphosphate are release from injured and necrotic cells and hydrolyzed to adenosine monophosphate and adenosine by the concerted action of the ectonucleotidases CD39 and CD73.	Adenosine Monophosphate	131-154	5'-nucleotidase ecto	Homo sapiens	227-231
24600452-2	2014	Nucleotides such as adenosine triphosphate and adenosine diphosphate are release from injured and necrotic cells and hydrolyzed to adenosine monophosphate and adenosine by the concerted action of the ectonucleotidases CD39 and CD73.	Adenosine	20-29	5'-nucleotidase ecto	Homo sapiens	227-231
24503265-3	2014	Production of anti-inflammatory adenosine by ecto-5"-nucleotidase (CD73) helps maintain endothelial barrier function.	Adenosine	32-41	5'-nucleotidase ecto	Homo sapiens	45-65
24503265-3	2014	Production of anti-inflammatory adenosine by ecto-5"-nucleotidase (CD73) helps maintain endothelial barrier function.	Adenosine	32-41	5'-nucleotidase ecto	Homo sapiens	67-71
24213679-5	2014	A subset of iTreg expressing ectonucleotidases, CD39 and CD73, is able to hydrolyze ATP to 5"-AMP and adenosine (ADO) and thus mediate suppression of those immune cells which express ADO receptors.	Adenosine Triphosphate	84-87	5'-nucleotidase ecto	Homo sapiens	57-61
25522227-9	2014	These enzymes, in cooperation with 5"-nucleotidase can significantly increase ecto-adenosine concentration.	ecto-adenosine	78-92	5'-nucleotidase ecto	Homo sapiens	35-50
24489992-0	2014	Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion.	Adenosine	101-110	5'-nucleotidase ecto	Homo sapiens	19-23
24489992-1	2014	The ectonucleotidases CD39 and CD73 degrade ATP to adenosine which inhibits immune responses via the A2A adenosine receptor (ADORA2A) on T and NK cells.	Adenosine Triphosphate	44-47	5'-nucleotidase ecto	Homo sapiens	31-35
24489992-1	2014	The ectonucleotidases CD39 and CD73 degrade ATP to adenosine which inhibits immune responses via the A2A adenosine receptor (ADORA2A) on T and NK cells.	Adenosine	51-60	5'-nucleotidase ecto	Homo sapiens	31-35
25126561-2	2014	Among the enzyme cascade, CD73, which catelyzes AMP breakdown to adenosine, has been found to be overexpressed in many types of cancer.	Adenosine Monophosphate	48-51	5'-nucleotidase ecto	Homo sapiens	26-30
25126561-2	2014	Among the enzyme cascade, CD73, which catelyzes AMP breakdown to adenosine, has been found to be overexpressed in many types of cancer.	Adenosine	65-74	5'-nucleotidase ecto	Homo sapiens	26-30
24213679-5	2014	A subset of iTreg expressing ectonucleotidases, CD39 and CD73, is able to hydrolyze ATP to 5"-AMP and adenosine (ADO) and thus mediate suppression of those immune cells which express ADO receptors.	Adenosine Monophosphate	91-97	5'-nucleotidase ecto	Homo sapiens	57-61
24213679-5	2014	A subset of iTreg expressing ectonucleotidases, CD39 and CD73, is able to hydrolyze ATP to 5"-AMP and adenosine (ADO) and thus mediate suppression of those immune cells which express ADO receptors.	Adenosine	102-111	5'-nucleotidase ecto	Homo sapiens	57-61
24213679-5	2014	A subset of iTreg expressing ectonucleotidases, CD39 and CD73, is able to hydrolyze ATP to 5"-AMP and adenosine (ADO) and thus mediate suppression of those immune cells which express ADO receptors.	Adenosine	113-116	5'-nucleotidase ecto	Homo sapiens	57-61
24940685-2	2014	Extracellular pathway that converts ATP and ADP to AMP, and AMP to adenosine mainly mediated by ecto-nucleoside triphosphate diphosphohydrolase 1, (ENTPD1 or CD39) and ecto-5"-nucleotidase (E5NT or CD73) respectively, is considered as important target for xenograft protection.	Adenosine Monophosphate	60-63	5'-nucleotidase ecto	Homo sapiens	168-188
24707115-4	2014	Two of these enzymes acting sequentially, CD39 and CD73, efficiently hydrolyze extracellular ATP to adenosine.	Adenosine Triphosphate	93-96	5'-nucleotidase ecto	Homo sapiens	51-55
24707115-4	2014	Two of these enzymes acting sequentially, CD39 and CD73, efficiently hydrolyze extracellular ATP to adenosine.	Adenosine	100-109	5'-nucleotidase ecto	Homo sapiens	51-55
25242869-1	2014	CD73, ecto-5"-nucleotidase, is the key enzyme catalyzing the conversion of extracellular AMP to adenosine that controls vascular permeability and immunosuppression.	Adenosine Monophosphate	89-92	5'-nucleotidase ecto	Homo sapiens	0-4
25242869-1	2014	CD73, ecto-5"-nucleotidase, is the key enzyme catalyzing the conversion of extracellular AMP to adenosine that controls vascular permeability and immunosuppression.	Adenosine Monophosphate	89-92	5'-nucleotidase ecto	Homo sapiens	6-26
25242869-1	2014	CD73, ecto-5"-nucleotidase, is the key enzyme catalyzing the conversion of extracellular AMP to adenosine that controls vascular permeability and immunosuppression.	Adenosine	96-105	5'-nucleotidase ecto	Homo sapiens	0-4
25242869-1	2014	CD73, ecto-5"-nucleotidase, is the key enzyme catalyzing the conversion of extracellular AMP to adenosine that controls vascular permeability and immunosuppression.	Adenosine	96-105	5'-nucleotidase ecto	Homo sapiens	6-26
25242873-4	2014	We first identified that HT-29 cells regulated adenosine and adenine nucleotide concentration at their surface by the expression of the ectoenzymes NTPDase2, ecto-5"-nucleotidase, and adenylate kinase.	Adenosine	47-56	5'-nucleotidase ecto	Homo sapiens	158-178
25242873-4	2014	We first identified that HT-29 cells regulated adenosine and adenine nucleotide concentration at their surface by the expression of the ectoenzymes NTPDase2, ecto-5"-nucleotidase, and adenylate kinase.	Adenine Nucleotides	61-79	5'-nucleotidase ecto	Homo sapiens	158-178
24940685-2	2014	Extracellular pathway that converts ATP and ADP to AMP, and AMP to adenosine mainly mediated by ecto-nucleoside triphosphate diphosphohydrolase 1, (ENTPD1 or CD39) and ecto-5"-nucleotidase (E5NT or CD73) respectively, is considered as important target for xenograft protection.	Adenosine Triphosphate	36-39	5'-nucleotidase ecto	Homo sapiens	168-188
24940685-2	2014	Extracellular pathway that converts ATP and ADP to AMP, and AMP to adenosine mainly mediated by ecto-nucleoside triphosphate diphosphohydrolase 1, (ENTPD1 or CD39) and ecto-5"-nucleotidase (E5NT or CD73) respectively, is considered as important target for xenograft protection.	Adenosine Triphosphate	36-39	5'-nucleotidase ecto	Homo sapiens	190-194
24940685-2	2014	Extracellular pathway that converts ATP and ADP to AMP, and AMP to adenosine mainly mediated by ecto-nucleoside triphosphate diphosphohydrolase 1, (ENTPD1 or CD39) and ecto-5"-nucleotidase (E5NT or CD73) respectively, is considered as important target for xenograft protection.	Adenosine Triphosphate	36-39	5'-nucleotidase ecto	Homo sapiens	198-202
24940685-2	2014	Extracellular pathway that converts ATP and ADP to AMP, and AMP to adenosine mainly mediated by ecto-nucleoside triphosphate diphosphohydrolase 1, (ENTPD1 or CD39) and ecto-5"-nucleotidase (E5NT or CD73) respectively, is considered as important target for xenograft protection.	Adenosine Diphosphate	44-47	5'-nucleotidase ecto	Homo sapiens	168-188
24940685-2	2014	Extracellular pathway that converts ATP and ADP to AMP, and AMP to adenosine mainly mediated by ecto-nucleoside triphosphate diphosphohydrolase 1, (ENTPD1 or CD39) and ecto-5"-nucleotidase (E5NT or CD73) respectively, is considered as important target for xenograft protection.	Adenosine Diphosphate	44-47	5'-nucleotidase ecto	Homo sapiens	190-194
24940685-2	2014	Extracellular pathway that converts ATP and ADP to AMP, and AMP to adenosine mainly mediated by ecto-nucleoside triphosphate diphosphohydrolase 1, (ENTPD1 or CD39) and ecto-5"-nucleotidase (E5NT or CD73) respectively, is considered as important target for xenograft protection.	Adenosine Diphosphate	44-47	5'-nucleotidase ecto	Homo sapiens	198-202
24940685-2	2014	Extracellular pathway that converts ATP and ADP to AMP, and AMP to adenosine mainly mediated by ecto-nucleoside triphosphate diphosphohydrolase 1, (ENTPD1 or CD39) and ecto-5"-nucleotidase (E5NT or CD73) respectively, is considered as important target for xenograft protection.	Adenosine Monophosphate	60-63	5'-nucleotidase ecto	Homo sapiens	190-194
24940685-2	2014	Extracellular pathway that converts ATP and ADP to AMP, and AMP to adenosine mainly mediated by ecto-nucleoside triphosphate diphosphohydrolase 1, (ENTPD1 or CD39) and ecto-5"-nucleotidase (E5NT or CD73) respectively, is considered as important target for xenograft protection.	Adenosine Monophosphate	60-63	5'-nucleotidase ecto	Homo sapiens	198-202
24940685-2	2014	Extracellular pathway that converts ATP and ADP to AMP, and AMP to adenosine mainly mediated by ecto-nucleoside triphosphate diphosphohydrolase 1, (ENTPD1 or CD39) and ecto-5"-nucleotidase (E5NT or CD73) respectively, is considered as important target for xenograft protection.	Adenosine	67-76	5'-nucleotidase ecto	Homo sapiens	168-188
24940685-2	2014	Extracellular pathway that converts ATP and ADP to AMP, and AMP to adenosine mainly mediated by ecto-nucleoside triphosphate diphosphohydrolase 1, (ENTPD1 or CD39) and ecto-5"-nucleotidase (E5NT or CD73) respectively, is considered as important target for xenograft protection.	Adenosine	67-76	5'-nucleotidase ecto	Homo sapiens	190-194
24940685-2	2014	Extracellular pathway that converts ATP and ADP to AMP, and AMP to adenosine mainly mediated by ecto-nucleoside triphosphate diphosphohydrolase 1, (ENTPD1 or CD39) and ecto-5"-nucleotidase (E5NT or CD73) respectively, is considered as important target for xenograft protection.	Adenosine	67-76	5'-nucleotidase ecto	Homo sapiens	198-202
24940685-8	2014	Following addition of AMP, production of adenosine in the medium of E5NT/ENTPD1- and E5NT- transfected cells increased to 14.2+-1.1 and 24.5+-3.4 muM respectively while it remained below 1 muM in controls and in ENTPD1-transfected cells.	Adenosine Monophosphate	22-25	5'-nucleotidase ecto	Homo sapiens	68-72
24940685-8	2014	Following addition of AMP, production of adenosine in the medium of E5NT/ENTPD1- and E5NT- transfected cells increased to 14.2+-1.1 and 24.5+-3.4 muM respectively while it remained below 1 muM in controls and in ENTPD1-transfected cells.	Adenosine Monophosphate	22-25	5'-nucleotidase ecto	Homo sapiens	85-89
24940685-8	2014	Following addition of AMP, production of adenosine in the medium of E5NT/ENTPD1- and E5NT- transfected cells increased to 14.2+-1.1 and 24.5+-3.4 muM respectively while it remained below 1 muM in controls and in ENTPD1-transfected cells.	Adenosine	41-50	5'-nucleotidase ecto	Homo sapiens	68-72
24940685-8	2014	Following addition of AMP, production of adenosine in the medium of E5NT/ENTPD1- and E5NT- transfected cells increased to 14.2+-1.1 and 24.5+-3.4 muM respectively while it remained below 1 muM in controls and in ENTPD1-transfected cells.	Adenosine	41-50	5'-nucleotidase ecto	Homo sapiens	85-89
24940685-9	2014	A marked increase of adenosine formation from ADP or ATP was observed only in E5NT/ENTPD1-transfected cells (11.7+-0.1 and 5.7+-2.2 muM respectively) but not in any other condition studied.	Adenosine	21-30	5'-nucleotidase ecto	Homo sapiens	78-82
24940685-9	2014	A marked increase of adenosine formation from ADP or ATP was observed only in E5NT/ENTPD1-transfected cells (11.7+-0.1 and 5.7+-2.2 muM respectively) but not in any other condition studied.	Adenosine Diphosphate	46-49	5'-nucleotidase ecto	Homo sapiens	78-82
24940685-9	2014	A marked increase of adenosine formation from ADP or ATP was observed only in E5NT/ENTPD1-transfected cells (11.7+-0.1 and 5.7+-2.2 muM respectively) but not in any other condition studied.	Adenosine Triphosphate	53-56	5'-nucleotidase ecto	Homo sapiens	78-82
24940691-5	2014	We found that e5N and ADA activities decreased by 20-40% after incubation for 20 or 60 minutes with 30 muM peroxynitrite.	Peroxynitrous Acid	107-120	5'-nucleotidase ecto	Homo sapiens	14-17
25274211-4	2014	Extracellular adenosine generated by CD73/ecto-5"-nucleotidase from ATP via AMP plays pleiotropic roles under physiological and pathological conditions by engaging four adenosine receptors.	Adenosine	14-23	5'-nucleotidase ecto	Homo sapiens	37-41
24043462-5	2014	The hBMSCs induced increased expression of the CD39 and CD73 on T cells correlated with the suppressive function of hBMSCs, which was accompanied by increased adenosine production.	Adenosine	159-168	5'-nucleotidase ecto	Homo sapiens	56-60
24043462-6	2014	Our data suggests that hBMSCs can effectively suppress immune responses of the Th17 cells via the CD39-CD73-mediated adenosine-producing pathway.	Adenosine	117-126	5'-nucleotidase ecto	Homo sapiens	103-107
25274211-4	2014	Extracellular adenosine generated by CD73/ecto-5"-nucleotidase from ATP via AMP plays pleiotropic roles under physiological and pathological conditions by engaging four adenosine receptors.	Adenosine	14-23	5'-nucleotidase ecto	Homo sapiens	42-62
25274211-4	2014	Extracellular adenosine generated by CD73/ecto-5"-nucleotidase from ATP via AMP plays pleiotropic roles under physiological and pathological conditions by engaging four adenosine receptors.	Adenosine Triphosphate	68-71	5'-nucleotidase ecto	Homo sapiens	37-41
25274211-4	2014	Extracellular adenosine generated by CD73/ecto-5"-nucleotidase from ATP via AMP plays pleiotropic roles under physiological and pathological conditions by engaging four adenosine receptors.	Adenosine Triphosphate	68-71	5'-nucleotidase ecto	Homo sapiens	42-62
25274211-4	2014	Extracellular adenosine generated by CD73/ecto-5"-nucleotidase from ATP via AMP plays pleiotropic roles under physiological and pathological conditions by engaging four adenosine receptors.	Adenosine Monophosphate	76-79	5'-nucleotidase ecto	Homo sapiens	37-41
25274211-4	2014	Extracellular adenosine generated by CD73/ecto-5"-nucleotidase from ATP via AMP plays pleiotropic roles under physiological and pathological conditions by engaging four adenosine receptors.	Adenosine Monophosphate	76-79	5'-nucleotidase ecto	Homo sapiens	42-62
25274211-9	2014	A competitive engraftment assay identified endogenous A2AAR signaling in donor T cells as part of a regulatory mechanism by CD73-generated adenosine.	Adenosine	139-148	5'-nucleotidase ecto	Homo sapiens	124-128
25274211-11	2014	Along with our findings, we herein introduce a novel concept that CD73-generated adenosine counteracts the ATP-evoked allogeneic immune reaction as a negative regulatory mechanism in GVHD.	Adenosine	81-90	5'-nucleotidase ecto	Homo sapiens	66-70
25274211-11	2014	Along with our findings, we herein introduce a novel concept that CD73-generated adenosine counteracts the ATP-evoked allogeneic immune reaction as a negative regulatory mechanism in GVHD.	Adenosine Triphosphate	107-110	5'-nucleotidase ecto	Homo sapiens	66-70
24012379-1	2013	The enzyme ecto-5"-nucleotidase (e5NT, CD73), a metallophosphoesterase, is a critical component of adenosine metabolism and signaling and implicated in different disease states.	Adenosine	99-108	5'-nucleotidase ecto	Homo sapiens	11-31
24575377-2	2013	We have recently demonstrated that targeting the immunosuppressive pathway mediated by CD73-derived adenosine through the blockade of A2A/A2B adenosine receptors significantly reduced the metastatic potential of CD73+ breast carcinomas and melanomas via both immunological and non-immunological mechanisms.	Adenosine	100-109	5'-nucleotidase ecto	Homo sapiens	87-91
24575377-2	2013	We have recently demonstrated that targeting the immunosuppressive pathway mediated by CD73-derived adenosine through the blockade of A2A/A2B adenosine receptors significantly reduced the metastatic potential of CD73+ breast carcinomas and melanomas via both immunological and non-immunological mechanisms.	Adenosine	100-109	5'-nucleotidase ecto	Homo sapiens	212-216
24012379-1	2013	The enzyme ecto-5"-nucleotidase (e5NT, CD73), a metallophosphoesterase, is a critical component of adenosine metabolism and signaling and implicated in different disease states.	Adenosine	99-108	5'-nucleotidase ecto	Homo sapiens	33-37
24012379-1	2013	The enzyme ecto-5"-nucleotidase (e5NT, CD73), a metallophosphoesterase, is a critical component of adenosine metabolism and signaling and implicated in different disease states.	Adenosine	99-108	5'-nucleotidase ecto	Homo sapiens	39-43
24012379-3	2013	For example, a virtual screening study using a molecular model of the enzyme has led to the identification of a new series of sulfonamide-containing e5NT inhibitors.	Sulfonamides	126-137	5'-nucleotidase ecto	Homo sapiens	149-153
24012379-8	2013	Taken together, the results rationalize the computer-aided discovery of sulfonamide inhibitors of e5NT and provide further support for the use of carefully built protein models for virtual screening.	Sulfonamides	72-83	5'-nucleotidase ecto	Homo sapiens	98-102
23941770-1	2013	Extracellular adenosine triphosphate (ATP) is sequentially dephosphorylated by two ectoenzymes: CD39/nucleotidase triphosphate dephosphorylase (ENTPD) and CD73/5"-ectonucleotidase (5"-NT).	Adenosine Triphosphate	14-36	5'-nucleotidase ecto	Homo sapiens	155-159
23941770-1	2013	Extracellular adenosine triphosphate (ATP) is sequentially dephosphorylated by two ectoenzymes: CD39/nucleotidase triphosphate dephosphorylase (ENTPD) and CD73/5"-ectonucleotidase (5"-NT).	Adenosine Triphosphate	38-41	5'-nucleotidase ecto	Homo sapiens	155-159
23941770-9	2013	ATP metabolites including adenosine 5"-diphosphate (ADP), adenosine 5"-monophosphate (AMP), and adenosine inhibited MMP-1 expression, but ADP-betaS, a stable ADP, did not, suggesting that adenosine converted from ATP by the action of CD39/ENTPD and CD73/5"-NT may contribute to MMP-1 inhibition.	Adenosine Triphosphate	0-3	5'-nucleotidase ecto	Homo sapiens	249-253
23653114-3	2013	CD73 (ecto-5"-nucleotidase) is a glycosylphosphatidylinositol (GPI)-linked 70-kDa cell surface enzyme.	Glycosylphosphatidylinositols	33-61	5'-nucleotidase ecto	Homo sapiens	0-4
24205323-6	2013	We found that TFV increases 5"-ecto-nucleotidase (NT5E) and inhibits mitochondrial nucleotidase (NT5M) gene expression and increases 5" nucleotidase activity in macrophages.	Tenofovir	14-17	5'-nucleotidase ecto	Homo sapiens	50-54
23653114-3	2013	CD73 (ecto-5"-nucleotidase) is a glycosylphosphatidylinositol (GPI)-linked 70-kDa cell surface enzyme.	Glycosylphosphatidylinositols	33-61	5'-nucleotidase ecto	Homo sapiens	6-26
23897810-4	2013	We demonstrate that soluble 5"-nucleotidase (5"-NT) and alkaline phosphatase (AP) mediate conversion of AMP to adenosine, whereas soluble adenosine deaminase (ADA) catabolizes adenosine to inosine.	Adenosine Monophosphate	104-107	5'-nucleotidase ecto	Homo sapiens	28-43
22137869-2	2013	Studies have revealed evidence of the involvement of the purinergic system in bladder tumorigenesis, particularly ecto-5"-NT/CD73, the enzyme responsible for AMP hydrolysis.	Adenosine Monophosphate	158-161	5'-nucleotidase ecto	Homo sapiens	125-129
22137869-4	2013	Here, we investigated the quercetin effect on the E-NTPDases and ecto-5"-nucleotidase/CD73, which catalyzes the introversion of the extracellular purine nucleotides in T24 human bladder cancer cells.	Quercetin	26-35	5'-nucleotidase ecto	Homo sapiens	65-85
22137869-4	2013	Here, we investigated the quercetin effect on the E-NTPDases and ecto-5"-nucleotidase/CD73, which catalyzes the introversion of the extracellular purine nucleotides in T24 human bladder cancer cells.	Quercetin	26-35	5'-nucleotidase ecto	Homo sapiens	86-90
22137869-4	2013	Here, we investigated the quercetin effect on the E-NTPDases and ecto-5"-nucleotidase/CD73, which catalyzes the introversion of the extracellular purine nucleotides in T24 human bladder cancer cells.	Purine Nucleotides	146-164	5'-nucleotidase ecto	Homo sapiens	65-85
22137869-4	2013	Here, we investigated the quercetin effect on the E-NTPDases and ecto-5"-nucleotidase/CD73, which catalyzes the introversion of the extracellular purine nucleotides in T24 human bladder cancer cells.	Purine Nucleotides	146-164	5'-nucleotidase ecto	Homo sapiens	86-90
22137869-5	2013	The results showed that this flavonoid was able to increase ADP hydrolysis and inhibit the ecto-5"-nucleotidase/CD73 activity, with no effect on protein expression.	Flavonoids	29-38	5'-nucleotidase ecto	Homo sapiens	91-111
22137869-5	2013	The results showed that this flavonoid was able to increase ADP hydrolysis and inhibit the ecto-5"-nucleotidase/CD73 activity, with no effect on protein expression.	Flavonoids	29-38	5'-nucleotidase ecto	Homo sapiens	112-116
22137869-6	2013	The treatment with APCP (alpha,beta-methyleneadenosine-5"-diphosphate), another ecto-5"-NT/CD73 inhibitor, led to a significant reduction in cell proliferation.	adenylyl(3'-5')cytidine-3'-phosphate	19-23	5'-nucleotidase ecto	Homo sapiens	91-95
22137869-6	2013	The treatment with APCP (alpha,beta-methyleneadenosine-5"-diphosphate), another ecto-5"-NT/CD73 inhibitor, led to a significant reduction in cell proliferation.	alpha,beta-methyleneadenosine 5'-diphosphate	25-69	5'-nucleotidase ecto	Homo sapiens	91-95
24015803-1	2013	Nucleoside beta-(S)-hydroxyphosphonate analogues have recently proven to be interesting bioactive compounds as 5"-nucleotidase inhibitors.	nucleoside beta-(s)-hydroxyphosphonate	0-38	5'-nucleotidase ecto	Homo sapiens	111-126
23897810-4	2013	We demonstrate that soluble 5"-nucleotidase (5"-NT) and alkaline phosphatase (AP) mediate conversion of AMP to adenosine, whereas soluble adenosine deaminase (ADA) catabolizes adenosine to inosine.	Adenosine	111-120	5'-nucleotidase ecto	Homo sapiens	28-43
23897810-4	2013	We demonstrate that soluble 5"-nucleotidase (5"-NT) and alkaline phosphatase (AP) mediate conversion of AMP to adenosine, whereas soluble adenosine deaminase (ADA) catabolizes adenosine to inosine.	Inosine	189-196	5'-nucleotidase ecto	Homo sapiens	28-43
23880765-7	2013	By specifically silencing or overexpressing CD38 and CD73, we demonstrated that endogenous CD73 enables, whereas CD38 impairs, the conversion of extracellular NMN to NR as a precursor for intracellular NAD(+) biosynthesis in human cells.	Nicotinamide Mononucleotide	159-162	5'-nucleotidase ecto	Homo sapiens	53-57
23880765-0	2013	CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.	NAD	67-71	5'-nucleotidase ecto	Homo sapiens	0-4
23880765-7	2013	By specifically silencing or overexpressing CD38 and CD73, we demonstrated that endogenous CD73 enables, whereas CD38 impairs, the conversion of extracellular NMN to NR as a precursor for intracellular NAD(+) biosynthesis in human cells.	Nicotinamide Mononucleotide	159-162	5'-nucleotidase ecto	Homo sapiens	91-95
23880765-0	2013	CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.	N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide	88-93	5'-nucleotidase ecto	Homo sapiens	0-4
23880765-7	2013	By specifically silencing or overexpressing CD38 and CD73, we demonstrated that endogenous CD73 enables, whereas CD38 impairs, the conversion of extracellular NMN to NR as a precursor for intracellular NAD(+) biosynthesis in human cells.	NAD	202-208	5'-nucleotidase ecto	Homo sapiens	91-95
23880765-8	2013	Moreover, cell viability in FK866-treated cells supplemented with extracellular NMN was strongly reduced in tumor cells, upon pharmacological inhibition or specific down-regulation of CD73.	N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide	28-33	5'-nucleotidase ecto	Homo sapiens	184-188
24015268-8	2013	Viral-induced ENS neurodysfunction influenced adenosine metabolism by increasing adenosine deaminase and CD73 levels in longitudinal muscle-myenteric plexus with no sign of frank inflammation.	Adenosine	46-55	5'-nucleotidase ecto	Homo sapiens	105-109
23749427-5	2013	Expression of the ecto-5-nucleotide enzyme CD73 by Treg cells has been shown to contribute to their suppressive function by converting extracellular adenosine-5-monophosphate to adenosine, which, following interaction with adenosine receptors expressed on target cells, leads to immune modulation.	ecto-5-nucleotide	18-35	5'-nucleotidase ecto	Homo sapiens	43-47
23749427-5	2013	Expression of the ecto-5-nucleotide enzyme CD73 by Treg cells has been shown to contribute to their suppressive function by converting extracellular adenosine-5-monophosphate to adenosine, which, following interaction with adenosine receptors expressed on target cells, leads to immune modulation.	Adenosine 5'-monophosphate monohydrate	149-174	5'-nucleotidase ecto	Homo sapiens	43-47
23749427-5	2013	Expression of the ecto-5-nucleotide enzyme CD73 by Treg cells has been shown to contribute to their suppressive function by converting extracellular adenosine-5-monophosphate to adenosine, which, following interaction with adenosine receptors expressed on target cells, leads to immune modulation.	Adenosine	149-158	5'-nucleotidase ecto	Homo sapiens	43-47
23749427-6	2013	CD73 was evident on Treg cell derived exosomes, accordingly when these exosomes were incubated in the presence of adenosine-5-monophosphate production of adenosine was observed.	Adenosine 5'-monophosphate monohydrate	114-139	5'-nucleotidase ecto	Homo sapiens	0-4
23749427-6	2013	CD73 was evident on Treg cell derived exosomes, accordingly when these exosomes were incubated in the presence of adenosine-5-monophosphate production of adenosine was observed.	Adenosine	114-123	5'-nucleotidase ecto	Homo sapiens	0-4
23749427-8	2013	Overall our findings demonstrate that CD73-expressing exosomes produced by Treg cells following activation contribute to their suppressive activity through the production of adenosine.	Adenosine	174-183	5'-nucleotidase ecto	Homo sapiens	38-42
23737488-7	2013	We demonstrated that increased suppression of responder CD4(+) T-cell proliferation suppression was induced by CD4(+)CD39(+) T cells in the presence of CD73(+) glioma cells, which could be alleviated by the CD39 inhibitor ARL67156, the CD73 inhibitor APCP, or the adenosine receptor A2aR antagonist SCH58261.	6-N,N-diethyl-beta,gamma-dibromomethylene-D-ATP	222-230	5'-nucleotidase ecto	Homo sapiens	152-156
23737488-7	2013	We demonstrated that increased suppression of responder CD4(+) T-cell proliferation suppression was induced by CD4(+)CD39(+) T cells in the presence of CD73(+) glioma cells, which could be alleviated by the CD39 inhibitor ARL67156, the CD73 inhibitor APCP, or the adenosine receptor A2aR antagonist SCH58261.	6-N,N-diethyl-beta,gamma-dibromomethylene-D-ATP	222-230	5'-nucleotidase ecto	Homo sapiens	236-240
23737488-7	2013	We demonstrated that increased suppression of responder CD4(+) T-cell proliferation suppression was induced by CD4(+)CD39(+) T cells in the presence of CD73(+) glioma cells, which could be alleviated by the CD39 inhibitor ARL67156, the CD73 inhibitor APCP, or the adenosine receptor A2aR antagonist SCH58261.	5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine	299-307	5'-nucleotidase ecto	Homo sapiens	152-156
23737488-7	2013	We demonstrated that increased suppression of responder CD4(+) T-cell proliferation suppression was induced by CD4(+)CD39(+) T cells in the presence of CD73(+) glioma cells, which could be alleviated by the CD39 inhibitor ARL67156, the CD73 inhibitor APCP, or the adenosine receptor A2aR antagonist SCH58261.	5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine	299-307	5'-nucleotidase ecto	Homo sapiens	236-240
23737488-9	2013	CONCLUSIONS: Our data indicate that glioma-derived CD73 contributes to local adenosine-mediated immunosuppression in synergy with CD39 from infiltrating CD4(+)CD39(+) T lymphocytes, which could become a potential therapeutic target for treatment of malignant glioma and other immunosuppressive diseases.	Adenosine	77-86	5'-nucleotidase ecto	Homo sapiens	51-55
23898333-5	2013	A subset of iTreg expressing ectonucleotidases CD39 and CD73 is able to hydrolyze ATP to 5"-AMP and adenosine (ADO) and thus mediate suppression of those immune cells which express ADO receptors.	Adenosine Triphosphate	82-85	5'-nucleotidase ecto	Homo sapiens	56-60
23677777-10	2013	These results suggest that piracetam-induced improvement of memory is associated with protection against oxidative stress and maintenance of NTPDase, 5"-nucleotidase and ADA activities, and suggest the purinergic system as a putative target of piracetam.	Piracetam	27-36	5'-nucleotidase ecto	Homo sapiens	150-165
23677777-0	2013	Piracetam prevents scopolamine-induced memory impairment and decrease of NTPDase, 5"-nucleotidase and adenosine deaminase activities.	Piracetam	0-9	5'-nucleotidase ecto	Homo sapiens	82-97
23677777-5	2013	Scopolamine also decreased the activity of 5"-nucleotidase (43 %) and ADA (91 %) in hippocampus.	Scopolamine	0-11	5'-nucleotidase ecto	Homo sapiens	43-58
23677777-7	2013	Piracetam fully prevented scopolamine-induced memory impairment and decrease of NTPDase, 5"-nucleotidase and adenosine deaminase activities in synaptosomes from cerebral cortex and hippocampus.	Piracetam	0-9	5'-nucleotidase ecto	Homo sapiens	89-104
23898333-5	2013	A subset of iTreg expressing ectonucleotidases CD39 and CD73 is able to hydrolyze ATP to 5"-AMP and adenosine (ADO) and thus mediate suppression of those immune cells which express ADO receptors.	Adenosine Monophosphate	89-95	5'-nucleotidase ecto	Homo sapiens	56-60
23898333-5	2013	A subset of iTreg expressing ectonucleotidases CD39 and CD73 is able to hydrolyze ATP to 5"-AMP and adenosine (ADO) and thus mediate suppression of those immune cells which express ADO receptors.	Adenosine	100-109	5'-nucleotidase ecto	Homo sapiens	56-60
23898333-5	2013	A subset of iTreg expressing ectonucleotidases CD39 and CD73 is able to hydrolyze ATP to 5"-AMP and adenosine (ADO) and thus mediate suppression of those immune cells which express ADO receptors.	Adenosine	111-114	5'-nucleotidase ecto	Homo sapiens	56-60
23776241-0	2013	CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.	Anthracyclines	14-27	5'-nucleotidase ecto	Homo sapiens	0-4
23776241-2	2013	Because anthracycline-based chemotherapy regimens are standard treatment for TNBC, we investigated the relationship between CD73 and anthracycline efficacy.	Anthracyclines	133-146	5'-nucleotidase ecto	Homo sapiens	124-128
23776241-3	2013	In TNBC patients treated with anthracycline-only preoperative chemotherapy, high CD73 gene expression was significantly associated with a lower rate of pathological complete response or the disappearance of invasive tumor at surgery.	Anthracyclines	30-43	5'-nucleotidase ecto	Homo sapiens	81-85
23685153-1	2013	The early activation of microglia that induces retinal inflammation in DR may serve as a target for therapeutic intervention of DR. Our demonstration that retinal inflammation is attenuated via adenosine receptor A(2A)AR supports the hypothesis that a mechanism to maintain extracellular concentrations of adenosine important in normal physiology is impaired in DR. Extracellular concentrations of adenosine are regulated by the interplay of equiliberative nucleoside transporter (ENT)s with enzymes of adenosine metabolism including adenosine deaminase-1 (ADA1), adenosine kinase (AK) and CD73.	Adenosine	194-203	5'-nucleotidase ecto	Homo sapiens	590-594
23685153-1	2013	The early activation of microglia that induces retinal inflammation in DR may serve as a target for therapeutic intervention of DR. Our demonstration that retinal inflammation is attenuated via adenosine receptor A(2A)AR supports the hypothesis that a mechanism to maintain extracellular concentrations of adenosine important in normal physiology is impaired in DR. Extracellular concentrations of adenosine are regulated by the interplay of equiliberative nucleoside transporter (ENT)s with enzymes of adenosine metabolism including adenosine deaminase-1 (ADA1), adenosine kinase (AK) and CD73.	Adenosine	306-315	5'-nucleotidase ecto	Homo sapiens	590-594
23685153-1	2013	The early activation of microglia that induces retinal inflammation in DR may serve as a target for therapeutic intervention of DR. Our demonstration that retinal inflammation is attenuated via adenosine receptor A(2A)AR supports the hypothesis that a mechanism to maintain extracellular concentrations of adenosine important in normal physiology is impaired in DR. Extracellular concentrations of adenosine are regulated by the interplay of equiliberative nucleoside transporter (ENT)s with enzymes of adenosine metabolism including adenosine deaminase-1 (ADA1), adenosine kinase (AK) and CD73.	Adenosine	306-315	5'-nucleotidase ecto	Homo sapiens	590-594
23584256-7	2013	These findings led us to further discover that elevated renal CD73 contributes to excess adenosine signaling via ADORA2B activation that directly stimulates endothelin-1 production in a hypoxia-inducible factor-alpha-dependent manner and underlies the pathogenesis of the disease.	Adenosine	89-98	5'-nucleotidase ecto	Homo sapiens	62-66
23271562-3	2013	Acute or chronic inflammatory conditions lead to the release of precursor adenine nucleotides (adenosine triphosphate (ATP), adenosien diphosphate (ADP) and adenosine monophosphate (AMP)) from cells, which are extracellularly catabolized into adenosine by extracellular ectonucleotidases, i.e., CD39 or nucleoside triphosphate dephosphorylase (NTPD) and CD73 or 5"-ectonucleotidase.	Adenine Nucleotides	74-93	5'-nucleotidase ecto	Homo sapiens	354-358
23271562-3	2013	Acute or chronic inflammatory conditions lead to the release of precursor adenine nucleotides (adenosine triphosphate (ATP), adenosien diphosphate (ADP) and adenosine monophosphate (AMP)) from cells, which are extracellularly catabolized into adenosine by extracellular ectonucleotidases, i.e., CD39 or nucleoside triphosphate dephosphorylase (NTPD) and CD73 or 5"-ectonucleotidase.	Adenosine Triphosphate	95-117	5'-nucleotidase ecto	Homo sapiens	354-358
23619528-2	2013	Ectonucleotidases (CD39 and CD73)-generated extracellular adenosine and cyclooxygenase-2 (COX2)-derived prostaglandin E2 (PGE2) are amongst the tumor microenvironmental factors that have emerged as attractive targets in this regard.	Dinoprostone	104-120	5'-nucleotidase ecto	Homo sapiens	28-32
23619528-2	2013	Ectonucleotidases (CD39 and CD73)-generated extracellular adenosine and cyclooxygenase-2 (COX2)-derived prostaglandin E2 (PGE2) are amongst the tumor microenvironmental factors that have emerged as attractive targets in this regard.	Dinoprostone	122-126	5'-nucleotidase ecto	Homo sapiens	28-32
23271562-3	2013	Acute or chronic inflammatory conditions lead to the release of precursor adenine nucleotides (adenosine triphosphate (ATP), adenosien diphosphate (ADP) and adenosine monophosphate (AMP)) from cells, which are extracellularly catabolized into adenosine by extracellular ectonucleotidases, i.e., CD39 or nucleoside triphosphate dephosphorylase (NTPD) and CD73 or 5"-ectonucleotidase.	Adenosine Monophosphate	182-185	5'-nucleotidase ecto	Homo sapiens	354-358
23271562-3	2013	Acute or chronic inflammatory conditions lead to the release of precursor adenine nucleotides (adenosine triphosphate (ATP), adenosien diphosphate (ADP) and adenosine monophosphate (AMP)) from cells, which are extracellularly catabolized into adenosine by extracellular ectonucleotidases, i.e., CD39 or nucleoside triphosphate dephosphorylase (NTPD) and CD73 or 5"-ectonucleotidase.	Adenosine	95-104	5'-nucleotidase ecto	Homo sapiens	354-358
23584256-9	2013	CONCLUSIONS: Overall, our studies reveal that angiotensin II-induced renal CD73 promotes the production of renal adenosine that is a prominent driver of hypertensive CKD by enhanced ADORA2B signaling-mediated endothelin-1 induction in a hypoxia-inducible factor-alpha-dependent manner.	Adenosine	113-122	5'-nucleotidase ecto	Homo sapiens	75-79
22751118-3	2013	Although Tregs mediate immunosuppression through multiple, non-redundant, cell-contact dependent and independent mechanisms, a growing body of evidence suggests an important role for the CD39-CD73-adenosine pathway.	Adenosine	197-206	5'-nucleotidase ecto	Homo sapiens	192-196
23601906-1	2013	The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, respectively.	Adenosine Diphosphate	197-200	5'-nucleotidase ecto	Homo sapiens	37-41
23601906-1	2013	The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, respectively.	Adenosine Triphosphate	201-204	5'-nucleotidase ecto	Homo sapiens	37-41
23601906-1	2013	The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, respectively.	Adenosine Monophosphate	208-211	5'-nucleotidase ecto	Homo sapiens	37-41
23601906-1	2013	The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, respectively.	Adenosine Monophosphate	216-219	5'-nucleotidase ecto	Homo sapiens	37-41
23601906-1	2013	The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, respectively.	Adenosine	223-232	5'-nucleotidase ecto	Homo sapiens	37-41
23341497-5	2013	Other prostasomal enzymes involved in ATP turnover were adenylate kinase, ATPase, 5"-nucleotidase, and hexose transporters.	Adenosine Triphosphate	38-41	5'-nucleotidase ecto	Homo sapiens	82-97
23830401-6	2013	To this aim, we analyzed the expression of CD39 (ectonucleoside triphosphate diphosphohydrolase 1, ENTPD1) and CD73 (ecto-5-nucleotidase, NT5E), the main pathway for adenosine generation, in samples obtained from women with RPL.	Adenosine	166-175	5'-nucleotidase ecto	Homo sapiens	117-136
23259837-7	2013	Furthermore, we demonstrated that ATP stimulated adipogenesis via its triphosphate form, while osteogenic differentiation was induced by the nucleoside adenosine, resulting from ATP degradation induced by CD39 and CD73 ectonucleotidases expressed on the MSC membrane.	nucleoside adenosine	141-161	5'-nucleotidase ecto	Homo sapiens	214-218
23199317-3	2013	The ecto-enzymes CD39 and CD73 can dephosphorylate extracellular ATP to adenosine, thereby controlling this important pathway of immune modulation.	Adenosine Triphosphate	65-68	5'-nucleotidase ecto	Homo sapiens	26-30
23288168-2	2013	Cell surface ecto-5"-nucleotidase (CD73) rapidly dephosphorylates extracellular adenosine 5"-monophosphate to adenosine.	Adenine Nucleotides	80-106	5'-nucleotidase ecto	Homo sapiens	13-33
23288168-2	2013	Cell surface ecto-5"-nucleotidase (CD73) rapidly dephosphorylates extracellular adenosine 5"-monophosphate to adenosine.	Adenine Nucleotides	80-106	5'-nucleotidase ecto	Homo sapiens	35-39
23288168-2	2013	Cell surface ecto-5"-nucleotidase (CD73) rapidly dephosphorylates extracellular adenosine 5"-monophosphate to adenosine.	Adenosine	80-89	5'-nucleotidase ecto	Homo sapiens	13-33
23288168-2	2013	Cell surface ecto-5"-nucleotidase (CD73) rapidly dephosphorylates extracellular adenosine 5"-monophosphate to adenosine.	Adenosine	80-89	5'-nucleotidase ecto	Homo sapiens	35-39
23288168-3	2013	We tested the hypothesis that coronary vasodilation to adenine nucleotides is mediated by an endothelial CD73-dependent, extracellular production of adenosine that acts as an endothelium-derived hyperpolarizing factor.	Adenine Nucleotides	55-74	5'-nucleotidase ecto	Homo sapiens	105-109
23288168-3	2013	We tested the hypothesis that coronary vasodilation to adenine nucleotides is mediated by an endothelial CD73-dependent, extracellular production of adenosine that acts as an endothelium-derived hyperpolarizing factor.	Adenosine	149-158	5'-nucleotidase ecto	Homo sapiens	105-109
23288168-4	2013	METHODS AND RESULTS: Videomicroscopy showed that adenine nucleotides, but not inosine, potently dilated and hyperpolarized human coronary arteries independent of nitric oxide, prostacyclin, and classical endothelium-derived hyperpolarizing factors, whereas endothelial denudation, adenosine receptor antagonism, adenosine deaminase, or CD73 blockers reduced vasodilations.	Adenine Nucleotides	49-68	5'-nucleotidase ecto	Homo sapiens	336-340
23288168-8	2013	CONCLUSIONS: Coronary vasodilation to adenine nucleotides is associated with endothelial CD73-dependent production of extracellular adenosine that acts as an endothelium-derived hyperpolarizing factor by relaxing and hyperpolarizing underlying vascular smooth muscle cells via activating adenosine receptors.	Adenine Nucleotides	38-57	5'-nucleotidase ecto	Homo sapiens	89-93
23288168-8	2013	CONCLUSIONS: Coronary vasodilation to adenine nucleotides is associated with endothelial CD73-dependent production of extracellular adenosine that acts as an endothelium-derived hyperpolarizing factor by relaxing and hyperpolarizing underlying vascular smooth muscle cells via activating adenosine receptors.	Adenosine	132-141	5'-nucleotidase ecto	Homo sapiens	89-93
23377281-3	2013	Using whole-exome sequencing, we identify mutations in the cytosolic 5"-nucleotidase II gene (NT5C2), which encodes a 5"-nucleotidase enzyme that is responsible for the inactivation of nucleoside-analog chemotherapy drugs, in 20/103 (19%) relapse T cell ALLs and 1/35 (3%) relapse B-precursor ALLs.	Nucleosides	185-195	5'-nucleotidase ecto	Homo sapiens	69-84
23377281-3	2013	Using whole-exome sequencing, we identify mutations in the cytosolic 5"-nucleotidase II gene (NT5C2), which encodes a 5"-nucleotidase enzyme that is responsible for the inactivation of nucleoside-analog chemotherapy drugs, in 20/103 (19%) relapse T cell ALLs and 1/35 (3%) relapse B-precursor ALLs.	Nucleosides	185-195	5'-nucleotidase ecto	Homo sapiens	118-133
23220537-1	2013	Clinical and preclinical observations have lead to the hypothesis that 5"-nucleotidase cN-II could constitute a therapeutic target in oncology, either per se or to increase the activity of cytotoxic nucleoside analogs.	Nucleosides	199-209	5'-nucleotidase ecto	Homo sapiens	71-86
23300031-3	2013	Cyclic-compressive loading of MSCs affects the expression of molecules involved in angiogenesis and matrix assembly, but also reduces the expression of CD73, an ecto-5"-nucleotidase, which plays a crucial role in extracellular adenosine generation.	Adenosine	227-236	5'-nucleotidase ecto	Homo sapiens	152-156
23300031-3	2013	Cyclic-compressive loading of MSCs affects the expression of molecules involved in angiogenesis and matrix assembly, but also reduces the expression of CD73, an ecto-5"-nucleotidase, which plays a crucial role in extracellular adenosine generation.	Adenosine	227-236	5'-nucleotidase ecto	Homo sapiens	161-181
23300031-7	2013	Through treatment with the CD73 inhibitor adenosine 5"-(alpha, beta-methylene) diphosphate, chondrogenic matrix deposition was further increased; in contrast, mineral matrix deposition and expression of osteogenic markers was reduced.	alpha,beta-methyleneadenosine 5'-diphosphate	42-90	5'-nucleotidase ecto	Homo sapiens	27-31
23300031-8	2013	One major signal transduction pathway, which is activated via CD73-mediated adenosine, is the adenosine receptor pathway.	Adenosine	76-85	5'-nucleotidase ecto	Homo sapiens	62-66
23737814-7	2013	Thus, TSA-generated Tregs showed increased suppressive activities, which could potentially be explained by a mechanism involving the ectonucleotidases CD39 and CD73.	trichostatin A	6-9	5'-nucleotidase ecto	Homo sapiens	160-164
23992315-11	2013	As for intracellular dephosphorylation of AMP, another intracellular 5"-nucleotidase, cN-I, is supposed to participate, because it hydrolyzes AMP more preferentially than IMP or GMP.	Adenosine Monophosphate	42-45	5'-nucleotidase ecto	Homo sapiens	69-84
23992315-11	2013	As for intracellular dephosphorylation of AMP, another intracellular 5"-nucleotidase, cN-I, is supposed to participate, because it hydrolyzes AMP more preferentially than IMP or GMP.	Adenosine Monophosphate	142-145	5'-nucleotidase ecto	Homo sapiens	69-84
23992315-11	2013	As for intracellular dephosphorylation of AMP, another intracellular 5"-nucleotidase, cN-I, is supposed to participate, because it hydrolyzes AMP more preferentially than IMP or GMP.	Inosine Monophosphate	171-174	5'-nucleotidase ecto	Homo sapiens	69-84
23992315-11	2013	As for intracellular dephosphorylation of AMP, another intracellular 5"-nucleotidase, cN-I, is supposed to participate, because it hydrolyzes AMP more preferentially than IMP or GMP.	guanosine 5'-monophosphorothioate	178-181	5'-nucleotidase ecto	Homo sapiens	69-84
23992316-5	2013	In districts, such as brain, which are dependent on salvage nucleotide synthesis, nucleosides are produced through the action of the ecto-5"-nucleotidase, the last component of a series of plasma-membrane bound enzyme proteins, catalyzing the successive dephosphorylation of released nucleoside-triphosphates.	Nucleosides	82-93	5'-nucleotidase ecto	Homo sapiens	133-153
23992316-5	2013	In districts, such as brain, which are dependent on salvage nucleotide synthesis, nucleosides are produced through the action of the ecto-5"-nucleotidase, the last component of a series of plasma-membrane bound enzyme proteins, catalyzing the successive dephosphorylation of released nucleoside-triphosphates.	nucleoside-triphosphates	284-308	5'-nucleotidase ecto	Homo sapiens	133-153
22833450-4	2013	Activity of the enzyme ecto-5"-nucleotidase (CD73) in tumor cells, which hydrolyses AMP to adenosine, has been linked to immunosuppression and prometastatic effects in breast cancer and to the proliferation of glioma cells.	Adenosine Monophosphate	84-87	5'-nucleotidase ecto	Homo sapiens	23-43
22833450-4	2013	Activity of the enzyme ecto-5"-nucleotidase (CD73) in tumor cells, which hydrolyses AMP to adenosine, has been linked to immunosuppression and prometastatic effects in breast cancer and to the proliferation of glioma cells.	Adenosine Monophosphate	84-87	5'-nucleotidase ecto	Homo sapiens	45-49
22833450-4	2013	Activity of the enzyme ecto-5"-nucleotidase (CD73) in tumor cells, which hydrolyses AMP to adenosine, has been linked to immunosuppression and prometastatic effects in breast cancer and to the proliferation of glioma cells.	Adenosine	91-100	5'-nucleotidase ecto	Homo sapiens	23-43
22833450-4	2013	Activity of the enzyme ecto-5"-nucleotidase (CD73) in tumor cells, which hydrolyses AMP to adenosine, has been linked to immunosuppression and prometastatic effects in breast cancer and to the proliferation of glioma cells.	Adenosine	91-100	5'-nucleotidase ecto	Homo sapiens	45-49
22833450-6	2013	In primary cultures of GBM, inhibition of CD73 activity or knocking down its expression by siRNA reversed the MDR phenotype and cell viability was decreased up to 60% on exposure to the antitumoral drug vincristine.	Vincristine	203-214	5'-nucleotidase ecto	Homo sapiens	42-46
22833450-9	2013	In conclusion, we have determined that the activity of CD73 to trigger adenosine signaling sustains chemoresistant phenotype in GBM cells.	Adenosine	71-80	5'-nucleotidase ecto	Homo sapiens	55-59
23988425-0	2013	Regulation of ecto-5 -nucleotidase by docosahexaenoic acid in human endothelial cells.	Docosahexaenoic Acids	38-58	5'-nucleotidase ecto	Homo sapiens	14-34
23988425-4	2013	mRNA level (real-time PCR), expression (western blot, flow cytometry) and activities (hydrolysis of etheno(epsilon)-purines and fluorescence HPLC) of CD73 (ecto-5 -nucleotidase) and CD39 (ecto-NTPDase-1) were quantified.	etheno(epsilon)-purines	100-123	5'-nucleotidase ecto	Homo sapiens	150-154
23988425-5	2013	RESULTS: DHA elevated total CD73 membrane protein expression concentration-dependently but CD73 mRNA level did not change.	Docosahexaenoic Acids	9-12	5'-nucleotidase ecto	Homo sapiens	28-32
23988425-10	2013	CONCLUSION: In human endothelial cells DHA caused 1) up-regulation of CD73 protein content and increased AMP hydrolysis at the cell membrane level, 2) increased cellular ATP release, and 3) decreased extracellular ATP/ADP hydrolysis.	Docosahexaenoic Acids	39-42	5'-nucleotidase ecto	Homo sapiens	70-74
23992312-1	2013	In mammals, cellular 5"-nucleotidase (5"-NT) activity (EC 3.1.3.5) encompasses a number of genetically and structurally distinct enzyme forms, either membrane-bound or soluble, mainly cytosolic, that are characterized by broad specificity towards nucleoside 5"-monophosphate substrates differing in base (purine/pyrimidine) and/or sugar (oxy/deoxy-ribose) moieties.	nucleoside 5"-monophosphate	247-274	5'-nucleotidase ecto	Homo sapiens	21-36
23992312-1	2013	In mammals, cellular 5"-nucleotidase (5"-NT) activity (EC 3.1.3.5) encompasses a number of genetically and structurally distinct enzyme forms, either membrane-bound or soluble, mainly cytosolic, that are characterized by broad specificity towards nucleoside 5"-monophosphate substrates differing in base (purine/pyrimidine) and/or sugar (oxy/deoxy-ribose) moieties.	purine	305-311	5'-nucleotidase ecto	Homo sapiens	21-36
23992312-1	2013	In mammals, cellular 5"-nucleotidase (5"-NT) activity (EC 3.1.3.5) encompasses a number of genetically and structurally distinct enzyme forms, either membrane-bound or soluble, mainly cytosolic, that are characterized by broad specificity towards nucleoside 5"-monophosphate substrates differing in base (purine/pyrimidine) and/or sugar (oxy/deoxy-ribose) moieties.	pyrimidine	312-322	5'-nucleotidase ecto	Homo sapiens	21-36
23992312-1	2013	In mammals, cellular 5"-nucleotidase (5"-NT) activity (EC 3.1.3.5) encompasses a number of genetically and structurally distinct enzyme forms, either membrane-bound or soluble, mainly cytosolic, that are characterized by broad specificity towards nucleoside 5"-monophosphate substrates differing in base (purine/pyrimidine) and/or sugar (oxy/deoxy-ribose) moieties.	Sugars	331-336	5'-nucleotidase ecto	Homo sapiens	21-36
23992312-1	2013	In mammals, cellular 5"-nucleotidase (5"-NT) activity (EC 3.1.3.5) encompasses a number of genetically and structurally distinct enzyme forms, either membrane-bound or soluble, mainly cytosolic, that are characterized by broad specificity towards nucleoside 5"-monophosphate substrates differing in base (purine/pyrimidine) and/or sugar (oxy/deoxy-ribose) moieties.	oxy/deoxy-ribose	338-354	5'-nucleotidase ecto	Homo sapiens	21-36
23199317-3	2013	The ecto-enzymes CD39 and CD73 can dephosphorylate extracellular ATP to adenosine, thereby controlling this important pathway of immune modulation.	Adenosine	72-81	5'-nucleotidase ecto	Homo sapiens	26-30
24215819-0	2013	Identification of sulfonic acids as efficient ecto-5"-nucleotidase inhibitors.	Sulfonic Acids	18-32	5'-nucleotidase ecto	Homo sapiens	46-66
24215819-5	2013	The most potent new sulfonic acid inhibitor 6-amino-4-hydroxynaphthalene-2-sulfonic acid (1) of ecto-5"-nucleotidase had an IC50 of 1.32 +- 0.09 muM for the human and 10.4 +- 3.3 muM for the rat enzyme.	Sulfonic Acids	20-33	5'-nucleotidase ecto	Homo sapiens	96-116
24215819-5	2013	The most potent new sulfonic acid inhibitor 6-amino-4-hydroxynaphthalene-2-sulfonic acid (1) of ecto-5"-nucleotidase had an IC50 of 1.32 +- 0.09 muM for the human and 10.4 +- 3.3 muM for the rat enzyme.	6-AMINO-4-HYDROXY-2-NAPHTHALENESULFONIC ACID	44-88	5'-nucleotidase ecto	Homo sapiens	96-116
22924692-8	2013	SSEA-4(+)hASCs cultured in alpha-MEM displayed fibroblastic-like morphology and exhibited a mesenchymal surface marker profile (&gt;90% CD90(+)/CD73(+)/CD105(+)).	alpha minimal essential medium	27-36	5'-nucleotidase ecto	Homo sapiens	144-148
23482243-0	2013	A delicate balance: CD73-generated adenosine limits the severity of graft vs. host disease but also constrains the allogeneic graft vs. tumor effect.	Adenosine	35-44	5'-nucleotidase ecto	Homo sapiens	20-24
23482243-2	2013	Studies involving the inhibition of CD73 by genetic or pharmacologic means suggest that the levels of CD73-generated adenosine may be manipulated to control GvHD, while maintaining the GvT effect.	Adenosine	117-126	5'-nucleotidase ecto	Homo sapiens	36-40
23482243-2	2013	Studies involving the inhibition of CD73 by genetic or pharmacologic means suggest that the levels of CD73-generated adenosine may be manipulated to control GvHD, while maintaining the GvT effect.	Adenosine	117-126	5'-nucleotidase ecto	Homo sapiens	102-106
23520507-1	2013	CD73 functions as an ecto-5"-nucleotidase to produce extracellular adenosine that has anti-inflammatory and immunosuppressive activity.	Adenosine	67-76	5'-nucleotidase ecto	Homo sapiens	0-4
23520507-1	2013	CD73 functions as an ecto-5"-nucleotidase to produce extracellular adenosine that has anti-inflammatory and immunosuppressive activity.	Adenosine	67-76	5'-nucleotidase ecto	Homo sapiens	21-41
23483072-3	2013	Specifically targeting CD73, the rate-limiting enzyme for the extracellular generation of adenosine, or the A3 receptor offers new therapeutic strategies to limit tumor progression.	Adenosine	90-99	5'-nucleotidase ecto	Homo sapiens	23-27
23658513-2	2013	A subpopulation of human Treg expresses the ectoenzyme CD39, which in association with CD73 converts ATP/ADP/AMP to adenosine.	Adenosine Triphosphate	101-104	5'-nucleotidase ecto	Homo sapiens	87-91
23658513-2	2013	A subpopulation of human Treg expresses the ectoenzyme CD39, which in association with CD73 converts ATP/ADP/AMP to adenosine.	Adenosine Diphosphate	105-108	5'-nucleotidase ecto	Homo sapiens	87-91
23658513-2	2013	A subpopulation of human Treg expresses the ectoenzyme CD39, which in association with CD73 converts ATP/ADP/AMP to adenosine.	Adenosine Monophosphate	109-112	5'-nucleotidase ecto	Homo sapiens	87-91
23658513-2	2013	A subpopulation of human Treg expresses the ectoenzyme CD39, which in association with CD73 converts ATP/ADP/AMP to adenosine.	Adenosine	116-125	5'-nucleotidase ecto	Homo sapiens	87-91
25474903-1	2013	We have shown that the decrease in oxygen tension in the culture medium of multipotent mesenchymal stromal cells (MMSCs) results in a short-term reduction in the proportion of CD73(+)-cells in the population, without effecting the number of cells expressing other constitutive surface markers (CD90 and CD105).	Oxygen	35-41	5'-nucleotidase ecto	Homo sapiens	176-180
22750273-1	2012	Ecto-5"-nucleotidase (e-5NT) is a cell-surface located, rate-limiting enzyme in the extracellular metabolism of ATP, catalyzing the final step of the conversion of AMP to adenosine.	Adenosine Triphosphate	112-115	5'-nucleotidase ecto	Homo sapiens	0-20
23192044-1	2012	Eukaryotic ecto-5"-nucleotidase (e5NT) catalyses the hydrolysis of extracellular AMP to adenosine and plays a pivotal role in switching on adenosine signalling via the P1 receptors of the purinergic signalling pathway.	Adenosine Monophosphate	81-84	5'-nucleotidase ecto	Homo sapiens	11-31
23192044-1	2012	Eukaryotic ecto-5"-nucleotidase (e5NT) catalyses the hydrolysis of extracellular AMP to adenosine and plays a pivotal role in switching on adenosine signalling via the P1 receptors of the purinergic signalling pathway.	Adenosine Monophosphate	81-84	5'-nucleotidase ecto	Homo sapiens	33-37
23192044-1	2012	Eukaryotic ecto-5"-nucleotidase (e5NT) catalyses the hydrolysis of extracellular AMP to adenosine and plays a pivotal role in switching on adenosine signalling via the P1 receptors of the purinergic signalling pathway.	Adenosine	88-97	5'-nucleotidase ecto	Homo sapiens	11-31
23192044-1	2012	Eukaryotic ecto-5"-nucleotidase (e5NT) catalyses the hydrolysis of extracellular AMP to adenosine and plays a pivotal role in switching on adenosine signalling via the P1 receptors of the purinergic signalling pathway.	Adenosine	88-97	5'-nucleotidase ecto	Homo sapiens	33-37
23192044-1	2012	Eukaryotic ecto-5"-nucleotidase (e5NT) catalyses the hydrolysis of extracellular AMP to adenosine and plays a pivotal role in switching on adenosine signalling via the P1 receptors of the purinergic signalling pathway.	Adenosine	139-148	5'-nucleotidase ecto	Homo sapiens	11-31
23192044-1	2012	Eukaryotic ecto-5"-nucleotidase (e5NT) catalyses the hydrolysis of extracellular AMP to adenosine and plays a pivotal role in switching on adenosine signalling via the P1 receptors of the purinergic signalling pathway.	Adenosine	139-148	5'-nucleotidase ecto	Homo sapiens	33-37
23192044-4	2012	Recombinant human e5NT comprising four asparagine-to-aspartate surface mutations targeting potential glycosylation sites was refolded from bacterial inclusion bodies.	Asparagine	39-49	5'-nucleotidase ecto	Homo sapiens	18-22
23192044-4	2012	Recombinant human e5NT comprising four asparagine-to-aspartate surface mutations targeting potential glycosylation sites was refolded from bacterial inclusion bodies.	Aspartic Acid	53-62	5'-nucleotidase ecto	Homo sapiens	18-22
23192044-8	2012	Structural comparisons with bacterial 5NT homologues showed that the human e5NT crystal structure has an open conformation in which the metal- and substrate-binding sites are distant from each other.	Metals	136-141	5'-nucleotidase ecto	Homo sapiens	75-79
22997138-2	2012	CD73 has important regulatory functions in the extracellular metabolism of certain nucleoside monophosphates, in particular adenosine monophosphate, and has been linked to a number of pathological conditions such as cancer and myocardial ischaemia.	nucleoside monophosphates	83-108	5'-nucleotidase ecto	Homo sapiens	0-4
22997138-2	2012	CD73 has important regulatory functions in the extracellular metabolism of certain nucleoside monophosphates, in particular adenosine monophosphate, and has been linked to a number of pathological conditions such as cancer and myocardial ischaemia.	Adenosine Monophosphate	124-147	5'-nucleotidase ecto	Homo sapiens	0-4
23086814-1	2012	CD73, an ecto-enzyme overexpressed in breast-cancer cells, catalyzes the dephosphorylation of adenosine monophosphates into adenosine.	Adenosine Monophosphate	94-118	5'-nucleotidase ecto	Homo sapiens	0-4
23086814-1	2012	CD73, an ecto-enzyme overexpressed in breast-cancer cells, catalyzes the dephosphorylation of adenosine monophosphates into adenosine.	Adenosine	94-103	5'-nucleotidase ecto	Homo sapiens	0-4
23086814-5	2012	EGFR expression can be decreased by suppressing CD73 with an inhibitor or small shRNA, and this effect was reversed by adenosine and NECA (adenosine A2 receptor agonist), which suggested that adenosine is involved in EGFR expression regulated by CD73 (P &lt; 0.01).	Adenosine	119-128	5'-nucleotidase ecto	Homo sapiens	246-250
22791337-5	2012	The mechanism by which the cAMPs increase cell proliferation entails 1) metabolism to their respective AMPs, 2) metabolism of their respective AMPs to adenosine (which for 5"-AMP in preglomerular vascular endothelial cells is mediated by CD73), and 3) activation of A(2B) receptors.	adenosine 5'-phosphorothioate	28-32	5'-nucleotidase ecto	Homo sapiens	238-242
22791337-5	2012	The mechanism by which the cAMPs increase cell proliferation entails 1) metabolism to their respective AMPs, 2) metabolism of their respective AMPs to adenosine (which for 5"-AMP in preglomerular vascular endothelial cells is mediated by CD73), and 3) activation of A(2B) receptors.	Adenosine	151-160	5'-nucleotidase ecto	Homo sapiens	238-242
22791337-5	2012	The mechanism by which the cAMPs increase cell proliferation entails 1) metabolism to their respective AMPs, 2) metabolism of their respective AMPs to adenosine (which for 5"-AMP in preglomerular vascular endothelial cells is mediated by CD73), and 3) activation of A(2B) receptors.	Adenosine Monophosphate	172-178	5'-nucleotidase ecto	Homo sapiens	238-242
23142347-1	2012	In vertebrates ecto-5"-nucleotidase (e5NT) catalyzes the hydrolysis of extracellular AMP to adenosine and represents the major control point for extracellular adenosine levels.	Adenosine Monophosphate	85-88	5'-nucleotidase ecto	Homo sapiens	15-35
23142347-1	2012	In vertebrates ecto-5"-nucleotidase (e5NT) catalyzes the hydrolysis of extracellular AMP to adenosine and represents the major control point for extracellular adenosine levels.	Adenosine Monophosphate	85-88	5'-nucleotidase ecto	Homo sapiens	37-41
23142347-1	2012	In vertebrates ecto-5"-nucleotidase (e5NT) catalyzes the hydrolysis of extracellular AMP to adenosine and represents the major control point for extracellular adenosine levels.	Adenosine	92-101	5'-nucleotidase ecto	Homo sapiens	15-35
23142347-1	2012	In vertebrates ecto-5"-nucleotidase (e5NT) catalyzes the hydrolysis of extracellular AMP to adenosine and represents the major control point for extracellular adenosine levels.	Adenosine	92-101	5'-nucleotidase ecto	Homo sapiens	37-41
23142347-1	2012	In vertebrates ecto-5"-nucleotidase (e5NT) catalyzes the hydrolysis of extracellular AMP to adenosine and represents the major control point for extracellular adenosine levels.	Adenosine	159-168	5'-nucleotidase ecto	Homo sapiens	15-35
23142347-1	2012	In vertebrates ecto-5"-nucleotidase (e5NT) catalyzes the hydrolysis of extracellular AMP to adenosine and represents the major control point for extracellular adenosine levels.	Adenosine	159-168	5'-nucleotidase ecto	Homo sapiens	37-41
22752606-7	2012	Results demonstrated an increase of 21 % in the E-NPP activity and 30 % in the E-5"-NT activity in IFCD group (P &lt; 0.05); however, a decrease of 34 % in the E-ADA activity was determined in the same group (P &lt; 0.001).	ifcd	99-103	5'-nucleotidase ecto	Homo sapiens	79-86
22612317-5	2012	Over a 20 day developmental period, the hEBs demonstrated increasing enrichment for cells expressing hMSC markers: CD29, CD44, CD63, CD56, CD71, CD73, CD105, CD106, and CD166 as revealed by immunohistochemical staining and flow cytometry (fluorescence-activated cell sorting) analysis.	hebs	40-44	5'-nucleotidase ecto	Homo sapiens	145-149
22741787-0	2012	Identification of small molecule sulfonic acids as ecto-5"-Nucleotidase inhibitors.	Sulfonic Acids	33-47	5'-nucleotidase ecto	Homo sapiens	51-71
22750273-1	2012	Ecto-5"-nucleotidase (e-5NT) is a cell-surface located, rate-limiting enzyme in the extracellular metabolism of ATP, catalyzing the final step of the conversion of AMP to adenosine.	Adenosine Triphosphate	112-115	5'-nucleotidase ecto	Homo sapiens	22-27
22750273-1	2012	Ecto-5"-nucleotidase (e-5NT) is a cell-surface located, rate-limiting enzyme in the extracellular metabolism of ATP, catalyzing the final step of the conversion of AMP to adenosine.	Adenosine Monophosphate	164-167	5'-nucleotidase ecto	Homo sapiens	0-20
22750273-1	2012	Ecto-5"-nucleotidase (e-5NT) is a cell-surface located, rate-limiting enzyme in the extracellular metabolism of ATP, catalyzing the final step of the conversion of AMP to adenosine.	Adenosine Monophosphate	164-167	5'-nucleotidase ecto	Homo sapiens	22-27
22750273-1	2012	Ecto-5"-nucleotidase (e-5NT) is a cell-surface located, rate-limiting enzyme in the extracellular metabolism of ATP, catalyzing the final step of the conversion of AMP to adenosine.	Adenosine	171-180	5'-nucleotidase ecto	Homo sapiens	0-20
22750273-1	2012	Ecto-5"-nucleotidase (e-5NT) is a cell-surface located, rate-limiting enzyme in the extracellular metabolism of ATP, catalyzing the final step of the conversion of AMP to adenosine.	Adenosine	171-180	5'-nucleotidase ecto	Homo sapiens	22-27
22772752-5	2012	Inducible enzymes such as CD73 and CD39 regulate adenosine formation and degradation in vivo.	Adenosine	49-58	5'-nucleotidase ecto	Homo sapiens	26-30
22406269-2	2012	Here, we showed that in vitro Th17 cells generated with the cytokines IL-6 and TGF-beta expressed CD39 and CD73 ectonucleotidases, leading to adenosine release and the subsequent suppression of CD4(+) and CD8(+) T cell effector functions.	Adenosine	142-151	5'-nucleotidase ecto	Homo sapiens	107-111
23122642-4	2012	Based on the similarities of GACI, PXE, CALJA, and IBGC, it can be speculated that the underlying disease genes-ENPP1, ABCC6, NT5E, and SLC20A2, respectively-drive a cohesive molecular pathophysiology system modulated by ATP metabolism, inorganic pyrophosphate, adenosine, and inorganic phosphate generation and functional activities.	Adenosine Triphosphate	221-224	5'-nucleotidase ecto	Homo sapiens	126-130
23122642-4	2012	Based on the similarities of GACI, PXE, CALJA, and IBGC, it can be speculated that the underlying disease genes-ENPP1, ABCC6, NT5E, and SLC20A2, respectively-drive a cohesive molecular pathophysiology system modulated by ATP metabolism, inorganic pyrophosphate, adenosine, and inorganic phosphate generation and functional activities.	diphosphoric acid	247-260	5'-nucleotidase ecto	Homo sapiens	126-130
23122642-4	2012	Based on the similarities of GACI, PXE, CALJA, and IBGC, it can be speculated that the underlying disease genes-ENPP1, ABCC6, NT5E, and SLC20A2, respectively-drive a cohesive molecular pathophysiology system modulated by ATP metabolism, inorganic pyrophosphate, adenosine, and inorganic phosphate generation and functional activities.	Adenosine	262-271	5'-nucleotidase ecto	Homo sapiens	126-130
23122642-4	2012	Based on the similarities of GACI, PXE, CALJA, and IBGC, it can be speculated that the underlying disease genes-ENPP1, ABCC6, NT5E, and SLC20A2, respectively-drive a cohesive molecular pathophysiology system modulated by ATP metabolism, inorganic pyrophosphate, adenosine, and inorganic phosphate generation and functional activities.	Phosphates	251-260	5'-nucleotidase ecto	Homo sapiens	126-130
22678911-8	2012	We propose that CD69 expression on CD39(+)  Treg cells enables them to interact with CD73-expressing CD8(+)  T cells to generate adenosine, thereby suppressing cytotoxicity.	Adenosine	129-138	5'-nucleotidase ecto	Homo sapiens	85-89
22423104-0	2012	Deletion of ecto-5"-nucleotidase (CD73) reveals direct action potential-dependent adenosine release.	Adenosine	82-91	5'-nucleotidase ecto	Homo sapiens	12-32
22423104-0	2012	Deletion of ecto-5"-nucleotidase (CD73) reveals direct action potential-dependent adenosine release.	Adenosine	82-91	5'-nucleotidase ecto	Homo sapiens	34-38
22731815-0	2012	Virtual screening identifies novel sulfonamide inhibitors of ecto-5"-nucleotidase.	Sulfonamides	35-46	5'-nucleotidase ecto	Homo sapiens	61-81
22526308-10	2012	In addition, formation of nucleoside metabolites was observed in primary hepatocytes, and ecto-5"-nucleotidase was able to dephosphorylate the monophosphate metabolites.	monophosphate	143-156	5'-nucleotidase ecto	Homo sapiens	90-110
22487321-3	2012	Adenosine within the tumor is generated by CD73, a membrane-bound nucleotidase that is expressed by tumor cells, suppressive immune subsets such as T regulatory cells (Tregs) and myeloid-derived suppressor cells and endothelial cells.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	43-47
22421436-4	2012	We report here that multiple enzymes degrade extracellular ATP in brain tissue, whereas only Nt5e degrades AMP to adenosine.	Adenosine Monophosphate	107-110	5'-nucleotidase ecto	Homo sapiens	93-97
22421436-4	2012	We report here that multiple enzymes degrade extracellular ATP in brain tissue, whereas only Nt5e degrades AMP to adenosine.	Adenosine	114-123	5'-nucleotidase ecto	Homo sapiens	93-97
22454080-6	2012	NT5E mRNA is downregulated by methylation-dependent transcriptional silencing in the melanoma cell lines SKMel2, SKMel23, WM35, Mel501, Mel505 and C81-61 and expression is reactivated by azacytidine.	Azacitidine	187-198	5'-nucleotidase ecto	Homo sapiens	0-4
21933152-0	2012	The high-resolution crystal structure of periplasmic Haemophilus influenzae NAD nucleotidase reveals a novel enzymatic function of human CD73 related to NAD metabolism.	NAD	76-79	5'-nucleotidase ecto	Homo sapiens	137-141
23162807-1	2012	Ecto-5"-nucleotidase (eN, CD73) mediates extracellular adenosine production from 5"-AMP.	Adenosine	55-64	5'-nucleotidase ecto	Homo sapiens	22-24
23162807-1	2012	Ecto-5"-nucleotidase (eN, CD73) mediates extracellular adenosine production from 5"-AMP.	Adenosine	55-64	5'-nucleotidase ecto	Homo sapiens	26-30
23162807-1	2012	Ecto-5"-nucleotidase (eN, CD73) mediates extracellular adenosine production from 5"-AMP.	Adenosine Monophosphate	81-87	5'-nucleotidase ecto	Homo sapiens	0-20
23162807-1	2012	Ecto-5"-nucleotidase (eN, CD73) mediates extracellular adenosine production from 5"-AMP.	Adenosine Monophosphate	81-87	5'-nucleotidase ecto	Homo sapiens	22-24
23162807-1	2012	Ecto-5"-nucleotidase (eN, CD73) mediates extracellular adenosine production from 5"-AMP.	Adenosine Monophosphate	81-87	5'-nucleotidase ecto	Homo sapiens	26-30
22553809-1	2012	Ecto-5"-nucleotidase (CD73) is a membrane-bound enzyme, which catalyzes the conversion of adenosine monophosphate to adenosine.	Adenosine Monophosphate	90-113	5'-nucleotidase ecto	Homo sapiens	0-20
22553809-1	2012	Ecto-5"-nucleotidase (CD73) is a membrane-bound enzyme, which catalyzes the conversion of adenosine monophosphate to adenosine.	Adenosine Monophosphate	90-113	5'-nucleotidase ecto	Homo sapiens	22-26
22553809-1	2012	Ecto-5"-nucleotidase (CD73) is a membrane-bound enzyme, which catalyzes the conversion of adenosine monophosphate to adenosine.	Adenosine	90-99	5'-nucleotidase ecto	Homo sapiens	0-20
22553809-1	2012	Ecto-5"-nucleotidase (CD73) is a membrane-bound enzyme, which catalyzes the conversion of adenosine monophosphate to adenosine.	Adenosine	90-99	5'-nucleotidase ecto	Homo sapiens	22-26
22553809-2	2012	CD73 has been postulated to play an important role in carcinogenesis, as adenosine promotes tumor progression and CD73-expressing cancer cell lines are more aggressive.	Adenosine	73-82	5'-nucleotidase ecto	Homo sapiens	0-4
22215671-3	2012	In contrast, AMP only activated the adenosine A(2B) receptor (A(2B)R) after hydrolysis to adenosine by ecto-5"-nucleotidase (NT5E, CD73) or prostatic acid phosphatase (PAP, ACPP).	Adenosine Monophosphate	13-16	5'-nucleotidase ecto	Homo sapiens	103-123
22215671-3	2012	In contrast, AMP only activated the adenosine A(2B) receptor (A(2B)R) after hydrolysis to adenosine by ecto-5"-nucleotidase (NT5E, CD73) or prostatic acid phosphatase (PAP, ACPP).	Adenosine Monophosphate	13-16	5'-nucleotidase ecto	Homo sapiens	131-135
22215671-3	2012	In contrast, AMP only activated the adenosine A(2B) receptor (A(2B)R) after hydrolysis to adenosine by ecto-5"-nucleotidase (NT5E, CD73) or prostatic acid phosphatase (PAP, ACPP).	Adenosine	36-45	5'-nucleotidase ecto	Homo sapiens	103-123
22215671-3	2012	In contrast, AMP only activated the adenosine A(2B) receptor (A(2B)R) after hydrolysis to adenosine by ecto-5"-nucleotidase (NT5E, CD73) or prostatic acid phosphatase (PAP, ACPP).	Adenosine	36-45	5'-nucleotidase ecto	Homo sapiens	131-135
22146892-3	2012	These Treg express CD39 and up-regulate CD73 ectonucleotidases, hydrolyze exogenous adenosine triphosphate (ATP) to AMP and adenosine and produce prostaglandin E(2) (PGE(2)).	Adenosine Triphosphate	84-106	5'-nucleotidase ecto	Homo sapiens	40-44
22146892-3	2012	These Treg express CD39 and up-regulate CD73 ectonucleotidases, hydrolyze exogenous adenosine triphosphate (ATP) to AMP and adenosine and produce prostaglandin E(2) (PGE(2)).	Adenosine Triphosphate	108-111	5'-nucleotidase ecto	Homo sapiens	40-44
22146892-3	2012	These Treg express CD39 and up-regulate CD73 ectonucleotidases, hydrolyze exogenous adenosine triphosphate (ATP) to AMP and adenosine and produce prostaglandin E(2) (PGE(2)).	Adenosine Monophosphate	116-119	5'-nucleotidase ecto	Homo sapiens	40-44
22146892-3	2012	These Treg express CD39 and up-regulate CD73 ectonucleotidases, hydrolyze exogenous adenosine triphosphate (ATP) to AMP and adenosine and produce prostaglandin E(2) (PGE(2)).	Adenosine	84-93	5'-nucleotidase ecto	Homo sapiens	40-44
22146892-3	2012	These Treg express CD39 and up-regulate CD73 ectonucleotidases, hydrolyze exogenous adenosine triphosphate (ATP) to AMP and adenosine and produce prostaglandin E(2) (PGE(2)).	Dinoprostone	146-164	5'-nucleotidase ecto	Homo sapiens	40-44
22146892-3	2012	These Treg express CD39 and up-regulate CD73 ectonucleotidases, hydrolyze exogenous adenosine triphosphate (ATP) to AMP and adenosine and produce prostaglandin E(2) (PGE(2)).	Prostaglandins E	166-169	5'-nucleotidase ecto	Homo sapiens	40-44
22219293-11	2012	Adenosine is generated during taste stimulation mainly by the action of the ecto-5"-nucleotidase, NT5E, and to a lesser extent, prostatic acid phosphatase.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	76-96
22219293-11	2012	Adenosine is generated during taste stimulation mainly by the action of the ecto-5"-nucleotidase, NT5E, and to a lesser extent, prostatic acid phosphatase.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	98-102
23162807-1	2012	Ecto-5"-nucleotidase (eN, CD73) mediates extracellular adenosine production from 5"-AMP.	Adenosine	55-64	5'-nucleotidase ecto	Homo sapiens	0-20
21933152-6	2012	Sequence and structural analysis of H. influenzae NadN led us to discover that human CD73 is capable of processing both NAD and NMN, therefore disclosing a possible novel function of human CD73 in systemic NAD metabolism.	nadn	50-54	5'-nucleotidase ecto	Homo sapiens	85-89
21933152-6	2012	Sequence and structural analysis of H. influenzae NadN led us to discover that human CD73 is capable of processing both NAD and NMN, therefore disclosing a possible novel function of human CD73 in systemic NAD metabolism.	nadn	50-54	5'-nucleotidase ecto	Homo sapiens	189-193
21933152-6	2012	Sequence and structural analysis of H. influenzae NadN led us to discover that human CD73 is capable of processing both NAD and NMN, therefore disclosing a possible novel function of human CD73 in systemic NAD metabolism.	NAD	120-123	5'-nucleotidase ecto	Homo sapiens	85-89
21933152-6	2012	Sequence and structural analysis of H. influenzae NadN led us to discover that human CD73 is capable of processing both NAD and NMN, therefore disclosing a possible novel function of human CD73 in systemic NAD metabolism.	NAD	120-123	5'-nucleotidase ecto	Homo sapiens	189-193
21933152-6	2012	Sequence and structural analysis of H. influenzae NadN led us to discover that human CD73 is capable of processing both NAD and NMN, therefore disclosing a possible novel function of human CD73 in systemic NAD metabolism.	NAD	206-209	5'-nucleotidase ecto	Homo sapiens	85-89
21933152-6	2012	Sequence and structural analysis of H. influenzae NadN led us to discover that human CD73 is capable of processing both NAD and NMN, therefore disclosing a possible novel function of human CD73 in systemic NAD metabolism.	NAD	206-209	5'-nucleotidase ecto	Homo sapiens	189-193
21306861-1	2011	NTPDase (EC 3.6.1.5) is an enzyme that hydrolyzes extracellular nucleoside tri- and/or diphoshates forming AMP that can serve as a substrate for an ecto-5"-nucleotidase (EC 3.1.3.5) with liberation of adenosine, a modulator of vascular tone and inhibitor of platelet aggregation.	Adenosine Monophosphate	107-110	5'-nucleotidase ecto	Homo sapiens	148-168
21885990-1	2012	Statins are known to have cholesterol-independent pleiotropic effects, such as upregulation of the enzyme ecto-5"-nucleotidase.	Cholesterol	26-37	5'-nucleotidase ecto	Homo sapiens	106-126
22920165-1	2012	BACKGROUND: The effectiveness of cladribine depends on the ratio of activating (deoxycytidine kinase) and inactivating (5-nucleotidase) enzymes.	Cladribine	33-43	5'-nucleotidase ecto	Homo sapiens	120-134
21858682-2	2012	The overexpression of ecto-5"-nucleotidase/CD73 (ecto-5"-NT/CD73), an adhesion molecule and the main enzymatic source of extracellular adenosine, has been reported in tumor cells, and it is emerging as a component of glioma progression.	Adenosine	135-144	5'-nucleotidase ecto	Homo sapiens	22-42
21858682-2	2012	The overexpression of ecto-5"-nucleotidase/CD73 (ecto-5"-NT/CD73), an adhesion molecule and the main enzymatic source of extracellular adenosine, has been reported in tumor cells, and it is emerging as a component of glioma progression.	Adenosine	135-144	5'-nucleotidase ecto	Homo sapiens	43-47
21858682-2	2012	The overexpression of ecto-5"-nucleotidase/CD73 (ecto-5"-NT/CD73), an adhesion molecule and the main enzymatic source of extracellular adenosine, has been reported in tumor cells, and it is emerging as a component of glioma progression.	Adenosine	135-144	5'-nucleotidase ecto	Homo sapiens	60-64
21858682-6	2012	The ECM protein laminin (lam) and chondroitin sulfate (ChS) modulated the ecto-5"-NT/CD73 activity and glioma adhesion in a parallel manner, suggesting the involvement of purinergic signaling in the effects mediated by the extracellular matrix.	Chondroitin Sulfates	34-53	5'-nucleotidase ecto	Homo sapiens	85-89
21858682-6	2012	The ECM protein laminin (lam) and chondroitin sulfate (ChS) modulated the ecto-5"-NT/CD73 activity and glioma adhesion in a parallel manner, suggesting the involvement of purinergic signaling in the effects mediated by the extracellular matrix.	Chondroitin Sulfates	55-58	5'-nucleotidase ecto	Homo sapiens	85-89
21858682-7	2012	Taken together, these results suggest that ecto-5"-NT/CD73, an important producer of extracellular adenosine, may modulate glioma cell adhesion and tumor cell-extracellular matrix interactions.	Adenosine	99-108	5'-nucleotidase ecto	Homo sapiens	54-58
23125525-0	2012	CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth.	Adenosine	15-24	5'-nucleotidase ecto	Homo sapiens	0-4
23125525-4	2012	One such immunosuppressive pathway is the production of extracellular adenosine by CD73, an ectonucleotidase overexpressed in various types of cancer.	Adenosine	70-79	5'-nucleotidase ecto	Homo sapiens	83-87
23133312-5	2012	The conversion of ATP into adenosine is mediated by ectonucleotidase molecules, namely, CD73 and CD39.	Adenosine Triphosphate	18-21	5'-nucleotidase ecto	Homo sapiens	88-92
23133312-5	2012	The conversion of ATP into adenosine is mediated by ectonucleotidase molecules, namely, CD73 and CD39.	Adenosine	27-36	5'-nucleotidase ecto	Homo sapiens	88-92
22839442-7	2012	Levels of CD133, CD34, CD73, and CD105 were significantly elevated in patients of paricalcitol (median 161, range 0-834 copies), calcitriol (163, 0-721), and diet (119, 0-401) groups, compared with the placebo group (0,0-41), p&lt;0.01.	paricalcitol	82-94	5'-nucleotidase ecto	Homo sapiens	23-27
22839442-7	2012	Levels of CD133, CD34, CD73, and CD105 were significantly elevated in patients of paricalcitol (median 161, range 0-834 copies), calcitriol (163, 0-721), and diet (119, 0-401) groups, compared with the placebo group (0,0-41), p&lt;0.01.	Calcitriol	129-139	5'-nucleotidase ecto	Homo sapiens	23-27
22720214-1	2012	Our recent data and that of others demonstrate that both tumor and host CD73-generated adenosine promote tumor growth and metastasis in a multifactorial manner.	Adenosine	87-96	5'-nucleotidase ecto	Homo sapiens	72-76
21306861-1	2011	NTPDase (EC 3.6.1.5) is an enzyme that hydrolyzes extracellular nucleoside tri- and/or diphoshates forming AMP that can serve as a substrate for an ecto-5"-nucleotidase (EC 3.1.3.5) with liberation of adenosine, a modulator of vascular tone and inhibitor of platelet aggregation.	Adenosine	201-210	5'-nucleotidase ecto	Homo sapiens	148-168
21622827-7	2011	In all cell types, 2"-AMP, 3"-AMP, and 5"-AMP increased adenosine levels, and inhibition of ecto-5"-nucleotidase blocked this effect of 5"-AMP but not that of 2"-AMP nor 3"-AMP.	Adenosine Monophosphate	136-142	5'-nucleotidase ecto	Homo sapiens	92-112
21998208-0	2011	CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death.	Adenosine	29-38	5'-nucleotidase ecto	Homo sapiens	0-4
21998208-1	2011	Extracellular adenosine (ADO), generated from ATP or ADP through the concerted action of the ectoenzymes CD39 and CD73, elicits autocrine and paracrine effects mediated by type 1 purinergic receptors.	Adenosine	14-23	5'-nucleotidase ecto	Homo sapiens	114-118
21998208-1	2011	Extracellular adenosine (ADO), generated from ATP or ADP through the concerted action of the ectoenzymes CD39 and CD73, elicits autocrine and paracrine effects mediated by type 1 purinergic receptors.	Adenosine	25-28	5'-nucleotidase ecto	Homo sapiens	114-118
21998208-1	2011	Extracellular adenosine (ADO), generated from ATP or ADP through the concerted action of the ectoenzymes CD39 and CD73, elicits autocrine and paracrine effects mediated by type 1 purinergic receptors.	Adenosine Diphosphate	53-56	5'-nucleotidase ecto	Homo sapiens	114-118
21998208-5	2011	CD39(+)/CD73(+) CLL cells generate ADO from ADP in a time- and concentration-dependent manner.	Adenosine	35-38	5'-nucleotidase ecto	Homo sapiens	8-12
21998208-5	2011	CD39(+)/CD73(+) CLL cells generate ADO from ADP in a time- and concentration-dependent manner.	Adenosine Diphosphate	44-47	5'-nucleotidase ecto	Homo sapiens	8-12
22035583-1	2011	BACKGROUND: Staphylococcus aureus is a human pathogen that produces extracellular adenosine to evade clearance by the host immune system, an activity attributed to the 5"-nucleotidase activity of adenosine synthase (AdsA).	Adenosine	82-91	5'-nucleotidase ecto	Homo sapiens	168-183
22035583-6	2011	Alanine substitution of two amino acids, aspartic acid 127 and histidine 196 within the 5"-nucleotidase signature sequence, leads to reduced AMP or ADP hydrolysis but does not affect the binding of these substrates.	Alanine	0-7	5'-nucleotidase ecto	Homo sapiens	88-103
22035583-6	2011	Alanine substitution of two amino acids, aspartic acid 127 and histidine 196 within the 5"-nucleotidase signature sequence, leads to reduced AMP or ADP hydrolysis but does not affect the binding of these substrates.	Aspartic Acid	41-54	5'-nucleotidase ecto	Homo sapiens	88-103
22035583-6	2011	Alanine substitution of two amino acids, aspartic acid 127 and histidine 196 within the 5"-nucleotidase signature sequence, leads to reduced AMP or ADP hydrolysis but does not affect the binding of these substrates.	Histidine	63-72	5'-nucleotidase ecto	Homo sapiens	88-103
22035583-6	2011	Alanine substitution of two amino acids, aspartic acid 127 and histidine 196 within the 5"-nucleotidase signature sequence, leads to reduced AMP or ADP hydrolysis but does not affect the binding of these substrates.	Adenosine Monophosphate	141-144	5'-nucleotidase ecto	Homo sapiens	88-103
22035583-6	2011	Alanine substitution of two amino acids, aspartic acid 127 and histidine 196 within the 5"-nucleotidase signature sequence, leads to reduced AMP or ADP hydrolysis but does not affect the binding of these substrates.	Adenosine Diphosphate	148-151	5'-nucleotidase ecto	Homo sapiens	88-103
21873433-1	2011	The 5"-nucleotidase (NT5) family of enzyme dephosphorylates non-cyclic nucleoside monophosphates to produce nucleosides and inorganic phosphates.	cyclic nucleoside monophosphates	64-96	5'-nucleotidase ecto	Homo sapiens	4-19
21873433-1	2011	The 5"-nucleotidase (NT5) family of enzyme dephosphorylates non-cyclic nucleoside monophosphates to produce nucleosides and inorganic phosphates.	cyclic nucleoside monophosphates	64-96	5'-nucleotidase ecto	Homo sapiens	21-24
21873433-1	2011	The 5"-nucleotidase (NT5) family of enzyme dephosphorylates non-cyclic nucleoside monophosphates to produce nucleosides and inorganic phosphates.	Nucleosides	108-119	5'-nucleotidase ecto	Homo sapiens	4-19
21873433-1	2011	The 5"-nucleotidase (NT5) family of enzyme dephosphorylates non-cyclic nucleoside monophosphates to produce nucleosides and inorganic phosphates.	Nucleosides	108-119	5'-nucleotidase ecto	Homo sapiens	21-24
21873433-1	2011	The 5"-nucleotidase (NT5) family of enzyme dephosphorylates non-cyclic nucleoside monophosphates to produce nucleosides and inorganic phosphates.	Phosphates	124-144	5'-nucleotidase ecto	Homo sapiens	4-19
21873433-1	2011	The 5"-nucleotidase (NT5) family of enzyme dephosphorylates non-cyclic nucleoside monophosphates to produce nucleosides and inorganic phosphates.	Phosphates	124-144	5'-nucleotidase ecto	Homo sapiens	21-24
21873433-2	2011	We hypothesized that gene silencing of NT5 enzymes to increase the intracellular availability of AMP would increase AMP-activated protein kinase (AMPK) activity and metabolism.	Adenosine Monophosphate	97-100	5'-nucleotidase ecto	Homo sapiens	39-42
21638125-0	2011	Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.	Adenosine	57-66	5'-nucleotidase ecto	Homo sapiens	27-31
21638125-1	2011	The ectonucleotidases CD39 and CD73 degrade immune stimulatory ATP to adenosine that inhibits T and NK cell responses via the A(2A) adenosine receptor (ADORA2A).	Adenosine Triphosphate	63-66	5'-nucleotidase ecto	Homo sapiens	31-35
21638125-1	2011	The ectonucleotidases CD39 and CD73 degrade immune stimulatory ATP to adenosine that inhibits T and NK cell responses via the A(2A) adenosine receptor (ADORA2A).	Adenosine	70-79	5'-nucleotidase ecto	Homo sapiens	31-35
21638125-7	2011	In vitro, human OvCA cell lines SK-OV-3 and OaW42 as well as 11/15 ascites-derived primary OvCA cell cultures expressed both functional CD39 and CD73 leading to more efficient depletion of extracellular ATP and enhanced generation of adenosine as compared to activated T(reg).	Adenosine Triphosphate	203-206	5'-nucleotidase ecto	Homo sapiens	145-149
22039302-7	2011	We further demonstrated that the ability of granulocytic MDSCs to suppress CD3/CD28-induced T cell proliferation was significantly facilitated in the presence of the ecto-5"-nucleotidase substrate 5"-AMP.	Adenosine Monophosphate	197-203	5'-nucleotidase ecto	Homo sapiens	166-186
22039302-8	2011	We propose that generation of adenosine by CD73 expressed at high levels on granulocytic MDSCs may promote their expansion and facilitate their immunosuppressive activity.	Adenosine	30-39	5'-nucleotidase ecto	Homo sapiens	43-47
21729107-4	2011	The extracellular adenosine-producing pathway comprises two major enzymes CD39 (ATP   ADP   AMP) and CD73 (AMP   Adenosine).	Adenosine	18-27	5'-nucleotidase ecto	Homo sapiens	101-105
21729107-4	2011	The extracellular adenosine-producing pathway comprises two major enzymes CD39 (ATP   ADP   AMP) and CD73 (AMP   Adenosine).	amp   adenosine	107-122	5'-nucleotidase ecto	Homo sapiens	101-105
21729107-6	2011	Our study shows high concentration of adenosine in diseased condition, varying expression of enzyme involved in adenosine-producing (CD73 ) and adenosine-degrading (ADA ) pathways.	Adenosine	38-47	5'-nucleotidase ecto	Homo sapiens	133-137
21729107-6	2011	Our study shows high concentration of adenosine in diseased condition, varying expression of enzyme involved in adenosine-producing (CD73 ) and adenosine-degrading (ADA ) pathways.	Adenosine	112-121	5'-nucleotidase ecto	Homo sapiens	133-137
21729107-6	2011	Our study shows high concentration of adenosine in diseased condition, varying expression of enzyme involved in adenosine-producing (CD73 ) and adenosine-degrading (ADA ) pathways.	Adenosine	112-121	5'-nucleotidase ecto	Homo sapiens	133-137
21638125-7	2011	In vitro, human OvCA cell lines SK-OV-3 and OaW42 as well as 11/15 ascites-derived primary OvCA cell cultures expressed both functional CD39 and CD73 leading to more efficient depletion of extracellular ATP and enhanced generation of adenosine as compared to activated T(reg).	Adenosine	234-243	5'-nucleotidase ecto	Homo sapiens	145-149
21638125-8	2011	Functional assays using siRNAs against CD39 and CD73 or pharmacological inhibitors of CD39, CD73 and ADORA2A revealed that tumour-derived adenosine inhibits the proliferation of allogeneic human CD4(+) T cells in co-culture with OvCA cells as well as cytotoxic T cell priming and NK cell cytotoxicity against SK-OV3 or OAW42 cells.	Adenosine	138-147	5'-nucleotidase ecto	Homo sapiens	48-52
21638125-8	2011	Functional assays using siRNAs against CD39 and CD73 or pharmacological inhibitors of CD39, CD73 and ADORA2A revealed that tumour-derived adenosine inhibits the proliferation of allogeneic human CD4(+) T cells in co-culture with OvCA cells as well as cytotoxic T cell priming and NK cell cytotoxicity against SK-OV3 or OAW42 cells.	Adenosine	138-147	5'-nucleotidase ecto	Homo sapiens	92-96
21777245-8	2011	Inhibitor studies indicated that the conversion of 2",3"-cAMP to 2"-AMP was mediated by a different ecto-enzyme than that involved in the metabolism of 2",3"-cAMP to 3"-AMP and that although CD73 mediates the conversion of 5"-AMP to adenosine, an alternative ecto-enzyme metabolizes 2"- or 3"-AMP to adenosine.	2",3"-camp	51-61	5'-nucleotidase ecto	Homo sapiens	191-195
21777245-8	2011	Inhibitor studies indicated that the conversion of 2",3"-cAMP to 2"-AMP was mediated by a different ecto-enzyme than that involved in the metabolism of 2",3"-cAMP to 3"-AMP and that although CD73 mediates the conversion of 5"-AMP to adenosine, an alternative ecto-enzyme metabolizes 2"- or 3"-AMP to adenosine.	Adenosine Monophosphate	65-71	5'-nucleotidase ecto	Homo sapiens	191-195
21295025-4	2011	Very recently, microvesicles have been shown (i) to harbor the glycosylphosphatidylinositol-anchored (c)AMP-degrading phosphodiesterase Gce1 and the 5"-nuceotidase CD73, (ii) to be released (preferably) from large adipocytes, (iii) to interact (preferably) with small adipocytes and (iv) to transfer Gce1 and CD73 to plasma membranes and lipid droplets of the small adipocytes where they degrade (c)AMP.	Adenosine Monophosphate	104-107	5'-nucleotidase ecto	Homo sapiens	164-168
20732359-5	2011	HIF-1 is also required for ischemic preconditioning and this effect may be due in part to its induction of CD73, the enzyme that produces adenosine.	Adenosine	138-147	5'-nucleotidase ecto	Homo sapiens	107-111
21750674-3	2011	Here, we show that HIV-1 positive patients have a significant increase of Treg-associated expression of CD39/ENTPD1, an ectoenzyme which in concert with CD73 generates adenosine.	Adenosine	168-177	5'-nucleotidase ecto	Homo sapiens	153-157
21677139-0	2011	Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production.	Adenosine	70-79	5'-nucleotidase ecto	Homo sapiens	33-37
21953104-8	2011	In addition, residues either side of the P5 residue (P5 + 1 and P5 - 1), the side-chains of which are directed away from the subunit groove, also modulate the rates of DSE, most likely by aiding the docking of the Nte into the P5 pocket on the accepting subunit prior to DSE.	nabam	168-171	5'-nucleotidase ecto	Homo sapiens	214-217
21953104-8	2011	In addition, residues either side of the P5 residue (P5 + 1 and P5 - 1), the side-chains of which are directed away from the subunit groove, also modulate the rates of DSE, most likely by aiding the docking of the Nte into the P5 pocket on the accepting subunit prior to DSE.	nabam	271-274	5'-nucleotidase ecto	Homo sapiens	214-217
21546330-3	2011	Extracellular adenosine levels are a net result of its production (mediated by CD39 and CD73), and of its conversion into inosine by Adenosine Deaminase (ADA).	Adenosine	14-23	5'-nucleotidase ecto	Homo sapiens	88-92
21484089-5	2011	Utilizing the hCMEC/D3 cell line, we determined that these cells express CD73, the cell surface enzyme that converts extracellular AMP to adenosine.	Adenosine Monophosphate	131-134	5'-nucleotidase ecto	Homo sapiens	73-77
21484089-5	2011	Utilizing the hCMEC/D3 cell line, we determined that these cells express CD73, the cell surface enzyme that converts extracellular AMP to adenosine.	Adenosine	138-147	5'-nucleotidase ecto	Homo sapiens	73-77
21295025-4	2011	Very recently, microvesicles have been shown (i) to harbor the glycosylphosphatidylinositol-anchored (c)AMP-degrading phosphodiesterase Gce1 and the 5"-nuceotidase CD73, (ii) to be released (preferably) from large adipocytes, (iii) to interact (preferably) with small adipocytes and (iv) to transfer Gce1 and CD73 to plasma membranes and lipid droplets of the small adipocytes where they degrade (c)AMP.	Adenosine Monophosphate	104-107	5'-nucleotidase ecto	Homo sapiens	309-313
21295025-4	2011	Very recently, microvesicles have been shown (i) to harbor the glycosylphosphatidylinositol-anchored (c)AMP-degrading phosphodiesterase Gce1 and the 5"-nuceotidase CD73, (ii) to be released (preferably) from large adipocytes, (iii) to interact (preferably) with small adipocytes and (iv) to transfer Gce1 and CD73 to plasma membranes and lipid droplets of the small adipocytes where they degrade (c)AMP.	Adenosine Monophosphate	399-402	5'-nucleotidase ecto	Homo sapiens	164-168
20224928-3	2011	Oligonucleotide microarray analysis identified 28 genes (MAPK13, ATP2C1, ANKRD57, MT1G, RGL4, C12orf49, EXOC6, RAB4A, TM9SF3, IFNGR1, DMD, HCG9, KIFC3, SYNGR3, NDRG4, NT5E, EOMES, SMC4, LANCL1, SCHIP1, and 8 ESTs) whose expression correlated with the combined effect of paclitaxel and SAHA.	Oligonucleotides	0-15	5'-nucleotidase ecto	Homo sapiens	167-171
21459887-6	2011	Very recently, microvesicles have been shown (i) to harbour the glycosylphosphatidylinositol-anchored (c)AMP-degrading phosphodiesterase Gce1 and 5"-nucleotidase CD73, (ii) to be released from large adipocytes, (iii) to interact with small adipocytes, and (iv) to transfer Gce1 and CD73 to plasma membranes and LDs of small adipocytes where they degrade (c)AMP.	Adenosine Monophosphate	105-108	5'-nucleotidase ecto	Homo sapiens	162-166
21459887-6	2011	Very recently, microvesicles have been shown (i) to harbour the glycosylphosphatidylinositol-anchored (c)AMP-degrading phosphodiesterase Gce1 and 5"-nucleotidase CD73, (ii) to be released from large adipocytes, (iii) to interact with small adipocytes, and (iv) to transfer Gce1 and CD73 to plasma membranes and LDs of small adipocytes where they degrade (c)AMP.	Adenosine Monophosphate	105-108	5'-nucleotidase ecto	Homo sapiens	282-286
21459887-6	2011	Very recently, microvesicles have been shown (i) to harbour the glycosylphosphatidylinositol-anchored (c)AMP-degrading phosphodiesterase Gce1 and 5"-nucleotidase CD73, (ii) to be released from large adipocytes, (iii) to interact with small adipocytes, and (iv) to transfer Gce1 and CD73 to plasma membranes and LDs of small adipocytes where they degrade (c)AMP.	Adenosine Monophosphate	357-360	5'-nucleotidase ecto	Homo sapiens	162-166
21288095-6	2011	Affected members of Family 1 shared a single 22.4-Mb region of homozygosity on chromosome 6 and had a homozygous nonsense mutation (c.662C A, p.S221X) in NT5E, encoding CD73, which converts AMP to adenosine.	Adenosine Monophosphate	190-193	5'-nucleotidase ecto	Homo sapiens	154-158
21288095-6	2011	Affected members of Family 1 shared a single 22.4-Mb region of homozygosity on chromosome 6 and had a homozygous nonsense mutation (c.662C A, p.S221X) in NT5E, encoding CD73, which converts AMP to adenosine.	Adenosine Monophosphate	190-193	5'-nucleotidase ecto	Homo sapiens	169-173
21288095-6	2011	Affected members of Family 1 shared a single 22.4-Mb region of homozygosity on chromosome 6 and had a homozygous nonsense mutation (c.662C A, p.S221X) in NT5E, encoding CD73, which converts AMP to adenosine.	Adenosine	197-206	5'-nucleotidase ecto	Homo sapiens	154-158
21288095-6	2011	Affected members of Family 1 shared a single 22.4-Mb region of homozygosity on chromosome 6 and had a homozygous nonsense mutation (c.662C A, p.S221X) in NT5E, encoding CD73, which converts AMP to adenosine.	Adenosine	197-206	5'-nucleotidase ecto	Homo sapiens	169-173
21288095-13	2011	This gene encodes CD73, which converts AMP to adenosine, supporting a role for this metabolic pathway in inhibiting ectopic tissue calcification.	Adenosine Monophosphate	39-42	5'-nucleotidase ecto	Homo sapiens	18-22
21288095-13	2011	This gene encodes CD73, which converts AMP to adenosine, supporting a role for this metabolic pathway in inhibiting ectopic tissue calcification.	Adenosine	46-55	5'-nucleotidase ecto	Homo sapiens	18-22
20224928-5	2011	SAHA induced NT5E mRNA expression in paclitaxel-resistant YCC-B1 cell.	Vorinostat	0-4	5'-nucleotidase ecto	Homo sapiens	13-17
20224928-5	2011	SAHA induced NT5E mRNA expression in paclitaxel-resistant YCC-B1 cell.	Paclitaxel	37-47	5'-nucleotidase ecto	Homo sapiens	13-17
21869566-0	2011	Inactivation of membrane surface ecto-5"-nucleotidase by sodium nitroprusside in C6 glioma cells.	Nitroprusside	57-77	5'-nucleotidase ecto	Homo sapiens	33-53
21869566-1	2011	Ecto-5"-nucleotidase (NT5E), a predominant enzyme that produces extracellular adenosine from AMP, plays an important role in a variety of physiological and pathophysiological processes.	Adenosine	78-87	5'-nucleotidase ecto	Homo sapiens	0-20
21869566-1	2011	Ecto-5"-nucleotidase (NT5E), a predominant enzyme that produces extracellular adenosine from AMP, plays an important role in a variety of physiological and pathophysiological processes.	Adenosine Monophosphate	93-96	5'-nucleotidase ecto	Homo sapiens	22-26
21869566-3	2011	When cells were incubated with sodium nitroprusside (SNP), phorbol 12-myristate 13-acetate, forskolin, lipopolysaccharide, or interferon-gamma, only SNP inhibited NT5E activity in a time- and concentration-dependent manner (IC(50) = 1.2 microM).	Nitroprusside	31-51	5'-nucleotidase ecto	Homo sapiens	163-167
21869566-1	2011	Ecto-5"-nucleotidase (NT5E), a predominant enzyme that produces extracellular adenosine from AMP, plays an important role in a variety of physiological and pathophysiological processes.	Adenosine	78-87	5'-nucleotidase ecto	Homo sapiens	22-26
21869566-3	2011	When cells were incubated with sodium nitroprusside (SNP), phorbol 12-myristate 13-acetate, forskolin, lipopolysaccharide, or interferon-gamma, only SNP inhibited NT5E activity in a time- and concentration-dependent manner (IC(50) = 1.2 microM).	Tetradecanoylphorbol Acetate	59-90	5'-nucleotidase ecto	Homo sapiens	163-167
21869566-1	2011	Ecto-5"-nucleotidase (NT5E), a predominant enzyme that produces extracellular adenosine from AMP, plays an important role in a variety of physiological and pathophysiological processes.	Adenosine Monophosphate	93-96	5'-nucleotidase ecto	Homo sapiens	0-20
21869566-6	2011	Similar to SNP, Fe(2+) inhibited NT5E activity, but to a lesser extent.	ammonium ferrous sulfate	16-22	5'-nucleotidase ecto	Homo sapiens	33-37
21560043-6	2011	In addition, they provide AMP for the activity of ecto 5"-nucleotidase (ecto 5"-NT; CD73), which produces the P1 receptor agonist: adenosine (ADO).	Adenosine	131-140	5'-nucleotidase ecto	Homo sapiens	50-70
21869566-8	2011	In contrast, addition of Zn(2+), an essential metal co-factor of NT5E activity, prevented SNP from inhibiting NT5E.	Zinc	25-27	5'-nucleotidase ecto	Homo sapiens	65-69
21869566-8	2011	In contrast, addition of Zn(2+), an essential metal co-factor of NT5E activity, prevented SNP from inhibiting NT5E.	Zinc	25-27	5'-nucleotidase ecto	Homo sapiens	110-114
21869566-9	2011	These results suggest that SNP disrupts a critical Zn(2+)-dependent enzyme activity and might be useful as a pharmacological tool for inhibiting NT5E.	Zinc	51-53	5'-nucleotidase ecto	Homo sapiens	145-149
21560043-6	2011	In addition, they provide AMP for the activity of ecto 5"-nucleotidase (ecto 5"-NT; CD73), which produces the P1 receptor agonist: adenosine (ADO).	Adenosine Monophosphate	26-29	5'-nucleotidase ecto	Homo sapiens	50-70
21560043-6	2011	In addition, they provide AMP for the activity of ecto 5"-nucleotidase (ecto 5"-NT; CD73), which produces the P1 receptor agonist: adenosine (ADO).	Adenosine Monophosphate	26-29	5'-nucleotidase ecto	Homo sapiens	72-82
21560043-6	2011	In addition, they provide AMP for the activity of ecto 5"-nucleotidase (ecto 5"-NT; CD73), which produces the P1 receptor agonist: adenosine (ADO).	Adenosine Monophosphate	26-29	5'-nucleotidase ecto	Homo sapiens	84-88
22235655-6	2011	This degradation terminates the nucleotide signaling process and also produces other signaling molecules like ADP, and with 5"-nucleotidase, adenosine.	Adenosine	141-150	5'-nucleotidase ecto	Homo sapiens	124-139
21560043-6	2011	In addition, they provide AMP for the activity of ecto 5"-nucleotidase (ecto 5"-NT; CD73), which produces the P1 receptor agonist: adenosine (ADO).	Adenosine	131-140	5'-nucleotidase ecto	Homo sapiens	72-82
21560043-6	2011	In addition, they provide AMP for the activity of ecto 5"-nucleotidase (ecto 5"-NT; CD73), which produces the P1 receptor agonist: adenosine (ADO).	Adenosine	131-140	5'-nucleotidase ecto	Homo sapiens	84-88
21560043-6	2011	In addition, they provide AMP for the activity of ecto 5"-nucleotidase (ecto 5"-NT; CD73), which produces the P1 receptor agonist: adenosine (ADO).	Adenosine	142-145	5'-nucleotidase ecto	Homo sapiens	50-70
21560043-6	2011	In addition, they provide AMP for the activity of ecto 5"-nucleotidase (ecto 5"-NT; CD73), which produces the P1 receptor agonist: adenosine (ADO).	Adenosine	142-145	5'-nucleotidase ecto	Homo sapiens	72-82
21560043-6	2011	In addition, they provide AMP for the activity of ecto 5"-nucleotidase (ecto 5"-NT; CD73), which produces the P1 receptor agonist: adenosine (ADO).	Adenosine	142-145	5'-nucleotidase ecto	Homo sapiens	84-88
21166885-8	2010	F12:Dulbecco"s modified eagle medium was the best medium for short term storage at 4  C. hAECs expressed CD9, CD44, CD73 and CD90, and negligibly expressed CD31, CD34, CD45 and CD117.	dulbecco"s modified eagle medium	4-36	5'-nucleotidase ecto	Homo sapiens	116-120
20874842-1	2010	Ecto-5"-nucleotidase (CD73), a cell surface protein that hydrolyzes extracellular AMP into adenosine and phosphate, is overexpressed in many solid tumors.	Adenosine Monophosphate	82-85	5'-nucleotidase ecto	Homo sapiens	0-20
20874842-1	2010	Ecto-5"-nucleotidase (CD73), a cell surface protein that hydrolyzes extracellular AMP into adenosine and phosphate, is overexpressed in many solid tumors.	Adenosine Monophosphate	82-85	5'-nucleotidase ecto	Homo sapiens	22-26
20874842-1	2010	Ecto-5"-nucleotidase (CD73), a cell surface protein that hydrolyzes extracellular AMP into adenosine and phosphate, is overexpressed in many solid tumors.	Adenosine	91-100	5'-nucleotidase ecto	Homo sapiens	0-20
20874842-1	2010	Ecto-5"-nucleotidase (CD73), a cell surface protein that hydrolyzes extracellular AMP into adenosine and phosphate, is overexpressed in many solid tumors.	Adenosine	91-100	5'-nucleotidase ecto	Homo sapiens	22-26
20874842-1	2010	Ecto-5"-nucleotidase (CD73), a cell surface protein that hydrolyzes extracellular AMP into adenosine and phosphate, is overexpressed in many solid tumors.	Phosphates	105-114	5'-nucleotidase ecto	Homo sapiens	0-20
20874842-1	2010	Ecto-5"-nucleotidase (CD73), a cell surface protein that hydrolyzes extracellular AMP into adenosine and phosphate, is overexpressed in many solid tumors.	Phosphates	105-114	5'-nucleotidase ecto	Homo sapiens	22-26
20874842-6	2010	CD73 inhibitor alpha,beta-methylene adenosine-5"-disphosphate (APCP) functioned similarly with RNAi-mediated CD73 suppression.	alpha,beta-methylene adenosine-5"-disphosphate	15-61	5'-nucleotidase ecto	Homo sapiens	0-4
20874842-6	2010	CD73 inhibitor alpha,beta-methylene adenosine-5"-disphosphate (APCP) functioned similarly with RNAi-mediated CD73 suppression.	adenylyl(3'-5')cytidine-3'-phosphate	63-67	5'-nucleotidase ecto	Homo sapiens	0-4
20977463-2	2010	Concentrations of nucleotides such as ADP, the physiological agonist at platelet P2Y1 and P2Y12 receptors, are regulated by vascular ectonucleotidases, mainly nucleoside triphosphate diphosphohydrolase (NTPDase)1 and ecto-5"-nucleotidase.	Adenosine Diphosphate	38-41	5'-nucleotidase ecto	Homo sapiens	217-237
20855458-4	2010	Those observations suggested the possible existence of a "thiopurine cellular circulation" involving nucleotide efflux by ABCC4, hydrolysis of thiopurine nucleotide monophosphates outside of the cell by NT5E, and subsequent transport of thiopurine nucleosides back into the cell by nucleoside transporters.	2-mercaptopyrazine	58-68	5'-nucleotidase ecto	Homo sapiens	203-207
21057730-1	2010	The ecto-5"-nucleotidase, CD73, catalyzes the rate-limiting step in the phosphohydrolysis of ATP to adenosine, and is a critical regulator of the balance between adenosine and its nucleotide precursors.	Adenosine Triphosphate	93-96	5'-nucleotidase ecto	Homo sapiens	4-24
21057730-1	2010	The ecto-5"-nucleotidase, CD73, catalyzes the rate-limiting step in the phosphohydrolysis of ATP to adenosine, and is a critical regulator of the balance between adenosine and its nucleotide precursors.	Adenosine Triphosphate	93-96	5'-nucleotidase ecto	Homo sapiens	26-30
21057730-1	2010	The ecto-5"-nucleotidase, CD73, catalyzes the rate-limiting step in the phosphohydrolysis of ATP to adenosine, and is a critical regulator of the balance between adenosine and its nucleotide precursors.	Adenosine	100-109	5'-nucleotidase ecto	Homo sapiens	4-24
21057730-1	2010	The ecto-5"-nucleotidase, CD73, catalyzes the rate-limiting step in the phosphohydrolysis of ATP to adenosine, and is a critical regulator of the balance between adenosine and its nucleotide precursors.	Adenosine	100-109	5'-nucleotidase ecto	Homo sapiens	26-30
21057730-1	2010	The ecto-5"-nucleotidase, CD73, catalyzes the rate-limiting step in the phosphohydrolysis of ATP to adenosine, and is a critical regulator of the balance between adenosine and its nucleotide precursors.	Adenosine	162-171	5'-nucleotidase ecto	Homo sapiens	4-24
21057730-1	2010	The ecto-5"-nucleotidase, CD73, catalyzes the rate-limiting step in the phosphohydrolysis of ATP to adenosine, and is a critical regulator of the balance between adenosine and its nucleotide precursors.	Adenosine	162-171	5'-nucleotidase ecto	Homo sapiens	26-30
21057730-3	2010	CD73 activity is primarily regulated at the level of transcription in response to the oxygen-sensing transcription factor HIF1, and its tissue-specific expression correlates negatively with oxygen tension.	Oxygen	86-92	5'-nucleotidase ecto	Homo sapiens	0-4
21057730-3	2010	CD73 activity is primarily regulated at the level of transcription in response to the oxygen-sensing transcription factor HIF1, and its tissue-specific expression correlates negatively with oxygen tension.	Oxygen	190-196	5'-nucleotidase ecto	Homo sapiens	0-4
21057730-5	2010	These beneficial effects of CD73 have largely been attributed to downstream adenosine signaling through its tissue-specific receptors.	Adenosine	76-85	5'-nucleotidase ecto	Homo sapiens	28-32
20679180-0	2010	Upregulation of ecto-5"-nucleotidase by rosuvastatin increases the vasodilator response to ischemia.	Rosuvastatin Calcium	40-52	5'-nucleotidase ecto	Homo sapiens	16-36
20679180-3	2010	In preclinical studies, increased ecto-5"-nucleotidase activity, the key enzyme in extracellular adenosine formation, plays an important role in these effects.	Adenosine	97-106	5'-nucleotidase ecto	Homo sapiens	34-54
20679180-10	2010	Rosuvastatin increases extracellular formation of adenosine in humans in vivo probably by enhancing ecto-5"-nucleotidase activity.	Rosuvastatin Calcium	0-12	5'-nucleotidase ecto	Homo sapiens	100-120
20679180-10	2010	Rosuvastatin increases extracellular formation of adenosine in humans in vivo probably by enhancing ecto-5"-nucleotidase activity.	Adenosine	50-59	5'-nucleotidase ecto	Homo sapiens	100-120
20682793-2	2010	Recent findings show a tumor-induced immunosuppressive mechanism, whereby tumor-derived CD73 functions as an ecto-enzyme to produce extracellular adenosine, which promotes tumor growth by limiting antitumor T-cell immunity via adenosine receptor signaling.	Adenosine	146-155	5'-nucleotidase ecto	Homo sapiens	88-92
20661219-3	2010	The conversion of extracellular ATP to adenosine, in contrast, essentially through the enzymatic activity of the ecto-nucleotidases CD39 and CD73, acts as a negative-feedback mechanism to prevent excessive immune responses.	Adenosine Triphosphate	32-35	5'-nucleotidase ecto	Homo sapiens	141-145
20661219-3	2010	The conversion of extracellular ATP to adenosine, in contrast, essentially through the enzymatic activity of the ecto-nucleotidases CD39 and CD73, acts as a negative-feedback mechanism to prevent excessive immune responses.	Adenosine	39-48	5'-nucleotidase ecto	Homo sapiens	141-145
20515260-3	2010	Here the stimulation of esterification and inhibition of lipolysis by synthetic phosphoinositolglycans (PIGs), such as PIG37, which represents the glycan component of the GPI anchor, are shown to be correlated to translocation from DIGs to LD and release into adiposomes of Gce1 and CD73.	Polysaccharides	95-101	5'-nucleotidase ecto	Homo sapiens	283-287
20814078-7	2010	Inclusion of alpha,alpha-methyleneadenosine 5"-diphosphate, a selective inhibitor of ecto-5"-nucleotidase in the incubation medium resulted in a significant decrease (7-fold) the adenosine concentration.	alpha,alpha-methyleneadenosine 5"-diphosphate	13-58	5'-nucleotidase ecto	Homo sapiens	85-105
20814078-7	2010	Inclusion of alpha,alpha-methyleneadenosine 5"-diphosphate, a selective inhibitor of ecto-5"-nucleotidase in the incubation medium resulted in a significant decrease (7-fold) the adenosine concentration.	Adenosine	34-43	5'-nucleotidase ecto	Homo sapiens	85-105
20515260-3	2010	Here the stimulation of esterification and inhibition of lipolysis by synthetic phosphoinositolglycans (PIGs), such as PIG37, which represents the glycan component of the GPI anchor, are shown to be correlated to translocation from DIGs to LD and release into adiposomes of Gce1 and CD73.	digs	232-236	5'-nucleotidase ecto	Homo sapiens	283-287
20515260-3	2010	Here the stimulation of esterification and inhibition of lipolysis by synthetic phosphoinositolglycans (PIGs), such as PIG37, which represents the glycan component of the GPI anchor, are shown to be correlated to translocation from DIGs to LD and release into adiposomes of Gce1 and CD73.	Glycosylphosphatidylinositols	171-174	5'-nucleotidase ecto	Homo sapiens	283-287
20415603-10	2010	Risperidone moderated the effect of change in 5"-nucleotidase, a marker of zinc status, for which decrease was associated with improvement only with risperidone, not with placebo.	Risperidone	0-11	5'-nucleotidase ecto	Homo sapiens	46-61
22966321-0	2010	Reduced CD73 expression and its association with altered purine nucleotide metabolism in colorectal cancer cells robustly causing liver metastases.	purine	57-63	5'-nucleotidase ecto	Homo sapiens	8-12
20516392-6	2010	3-Isobutyl-1-methylxanthine (phosphodiesterase inhibitor) and 1,3-dipropyl-8-p-sulfophenylxanthine (ecto-phosphodiesterase inhibitor) blocked conversion of 3",5"-cAMP to 5"-AMP and adenosine, and alpha,beta-methylene-adenosine-5"-diphosphate (CD73 inhibitor) blocked conversion of 5"-AMP to adenosine.	1-Methyl-3-isobutylxanthine	0-27	5'-nucleotidase ecto	Homo sapiens	243-247
20516392-6	2010	3-Isobutyl-1-methylxanthine (phosphodiesterase inhibitor) and 1,3-dipropyl-8-p-sulfophenylxanthine (ecto-phosphodiesterase inhibitor) blocked conversion of 3",5"-cAMP to 5"-AMP and adenosine, and alpha,beta-methylene-adenosine-5"-diphosphate (CD73 inhibitor) blocked conversion of 5"-AMP to adenosine.	1,3-dipropyl-8-(4-sulfophenyl)xanthine	62-98	5'-nucleotidase ecto	Homo sapiens	243-247
20516392-6	2010	3-Isobutyl-1-methylxanthine (phosphodiesterase inhibitor) and 1,3-dipropyl-8-p-sulfophenylxanthine (ecto-phosphodiesterase inhibitor) blocked conversion of 3",5"-cAMP to 5"-AMP and adenosine, and alpha,beta-methylene-adenosine-5"-diphosphate (CD73 inhibitor) blocked conversion of 5"-AMP to adenosine.	adenosine-3',5'-cyclic phosphorothioate	156-166	5'-nucleotidase ecto	Homo sapiens	243-247
20398264-2	2010	Since adenosine has antinociceptive effects in rodents and humans, we hypothesized that NT5E, an enzyme that generates adenosine, might also have antinociceptive effects in vivo.	Adenosine	6-15	5'-nucleotidase ecto	Homo sapiens	88-92
20398264-2	2010	Since adenosine has antinociceptive effects in rodents and humans, we hypothesized that NT5E, an enzyme that generates adenosine, might also have antinociceptive effects in vivo.	Adenosine	119-128	5'-nucleotidase ecto	Homo sapiens	88-92
20227555-8	2010	The activity of acrosome enzymes was reduced, and significant release of 5"-nucleotidase (a plasma membrane marker) into the surrounding medium was noted after treatment with 0.1 g/mL hexane fraction, indicating that the hexane fraction affected the cytoarchitecture of the sperm plasma membrane.	Hexanes	184-190	5'-nucleotidase ecto	Homo sapiens	73-88
20227555-8	2010	The activity of acrosome enzymes was reduced, and significant release of 5"-nucleotidase (a plasma membrane marker) into the surrounding medium was noted after treatment with 0.1 g/mL hexane fraction, indicating that the hexane fraction affected the cytoarchitecture of the sperm plasma membrane.	Hexanes	221-227	5'-nucleotidase ecto	Homo sapiens	73-88
20415603-10	2010	Risperidone moderated the effect of change in 5"-nucleotidase, a marker of zinc status, for which decrease was associated with improvement only with risperidone, not with placebo.	Risperidone	149-160	5'-nucleotidase ecto	Homo sapiens	46-61
19917691-5	2009	The mechanism of suppression by CD39(+) Treg cells appears to require cell contact and can be duplicated by adenosine, which is produced from ATP by the ectonucleotidases CD39 and CD73.	Adenosine	108-117	5'-nucleotidase ecto	Homo sapiens	180-184
19858205-4	2010	Human CD4(+)CD25(high)FOXP3(+) Treg overexpress CD39 and CD73, ectonucleotidases sequentially converting ATP into AMP and adenosine, which then binds to A(2a) receptors on effector T cells, suppressing their functions.	Adenosine Triphosphate	105-108	5'-nucleotidase ecto	Homo sapiens	57-61
19858205-4	2010	Human CD4(+)CD25(high)FOXP3(+) Treg overexpress CD39 and CD73, ectonucleotidases sequentially converting ATP into AMP and adenosine, which then binds to A(2a) receptors on effector T cells, suppressing their functions.	Adenosine Monophosphate	114-117	5'-nucleotidase ecto	Homo sapiens	57-61
19858205-4	2010	Human CD4(+)CD25(high)FOXP3(+) Treg overexpress CD39 and CD73, ectonucleotidases sequentially converting ATP into AMP and adenosine, which then binds to A(2a) receptors on effector T cells, suppressing their functions.	Adenosine	122-131	5'-nucleotidase ecto	Homo sapiens	57-61
20169073-4	2010	Changes include an up-regulation of CD73, the major enzyme of adenosine production and down-regulation of adenosine deaminase (ADA), the major enzyme for adenosine metabolism.	Adenosine	62-71	5'-nucleotidase ecto	Homo sapiens	36-40
20181103-1	2010	BACKGROUND: CD73 is a 5"-ectonucleotidase that produces extracellular adenosine, which then acts on G protein-coupled purigenic receptors to induce cellular responses.	Adenosine	70-79	5'-nucleotidase ecto	Homo sapiens	12-16
20181103-5	2010	RESULTS: CD73 depletion resulted in a strong reduction in adenosine production, indicating that CD73 is the major source of extracellular adenosine in HUVECs.	Adenosine	58-67	5'-nucleotidase ecto	Homo sapiens	9-13
20181103-5	2010	RESULTS: CD73 depletion resulted in a strong reduction in adenosine production, indicating that CD73 is the major source of extracellular adenosine in HUVECs.	Adenosine	58-67	5'-nucleotidase ecto	Homo sapiens	96-100
20181103-5	2010	RESULTS: CD73 depletion resulted in a strong reduction in adenosine production, indicating that CD73 is the major source of extracellular adenosine in HUVECs.	Adenosine	138-147	5'-nucleotidase ecto	Homo sapiens	9-13
20181103-5	2010	RESULTS: CD73 depletion resulted in a strong reduction in adenosine production, indicating that CD73 is the major source of extracellular adenosine in HUVECs.	Adenosine	138-147	5'-nucleotidase ecto	Homo sapiens	96-100
20476579-0	2010	[Role of PKC in regulation of CD73 by lysophosphatidylcholine in human endothelial cells].	Lysophosphatidylcholines	38-61	5'-nucleotidase ecto	Homo sapiens	30-34
20476579-1	2010	OBJECTIVE: To discuss the effect of protein kinase C (PKC) on regulation of ecto-5"-nucleotidase activity by lysophosphatidylcholine(LPC) in human umbilical endothelial cells (HUVEC).	Lysophosphatidylcholines	109-132	5'-nucleotidase ecto	Homo sapiens	76-96
20476579-1	2010	OBJECTIVE: To discuss the effect of protein kinase C (PKC) on regulation of ecto-5"-nucleotidase activity by lysophosphatidylcholine(LPC) in human umbilical endothelial cells (HUVEC).	lpc	133-136	5'-nucleotidase ecto	Homo sapiens	76-96
20476579-6	2010	CD73 inhibitor AOPCP significantly decreased the etheno-adenosine production compared to the other three groups (P &lt; 0.01).	etheno-adenosine	49-65	5'-nucleotidase ecto	Homo sapiens	0-4
19917691-5	2009	The mechanism of suppression by CD39(+) Treg cells appears to require cell contact and can be duplicated by adenosine, which is produced from ATP by the ectonucleotidases CD39 and CD73.	Adenosine Triphosphate	142-145	5'-nucleotidase ecto	Homo sapiens	180-184
19359665-1	2009	OBJECTIVE: Statins may increase extracellular adenosine formation from adenosine monophosphate by enhancing ecto-5"-nucleotidase activity.	Adenosine	46-55	5'-nucleotidase ecto	Homo sapiens	108-128
19253308-4	2009	Dysregulation occurs in 59% of purine genes in IBD including ADORA3, CD73, ADORA2A, ADORA2B, ADAR, AMPD2, AMPD3, DPP4, P2RY5, P2RY6, P2RY13, P2RY14, and P2RX5.	purine	31-37	5'-nucleotidase ecto	Homo sapiens	69-73
19253308-8	2009	Ingenuity Pathway Analysis (IPA) revealed significant associations between alterations in the expression of CD73 (upregulation) or ADORA3 (downregulation) and inflammatory or purine genes (&lt;or=10% of 57 genes) as well as G-protein coupled receptors, cAMP-dependent, and inflammatory pathways; IPA distinguishes CD from UC.	purine	175-181	5'-nucleotidase ecto	Homo sapiens	108-112
19253308-8	2009	Ingenuity Pathway Analysis (IPA) revealed significant associations between alterations in the expression of CD73 (upregulation) or ADORA3 (downregulation) and inflammatory or purine genes (&lt;or=10% of 57 genes) as well as G-protein coupled receptors, cAMP-dependent, and inflammatory pathways; IPA distinguishes CD from UC.	Cyclic AMP	253-257	5'-nucleotidase ecto	Homo sapiens	108-112
19825957-3	2009	The ectonucleotidases CD39 and CD73 are expressed in Treg and convert ATP into immunosuppressive adenosine.	Adenosine Triphosphate	70-73	5'-nucleotidase ecto	Homo sapiens	31-35
19825957-3	2009	The ectonucleotidases CD39 and CD73 are expressed in Treg and convert ATP into immunosuppressive adenosine.	Adenosine	97-106	5'-nucleotidase ecto	Homo sapiens	31-35
19464286-2	2009	The synthesis of adenosine involves the catabolism of adenine nucleotides (ATP, ADP and AMP) by the action of extracellular ectonucleotidases i.e. CD39 or nucleoside triphosphate dephosphorylase (NTPD) and CD73 or 5"-ectonucleotidase.	Adenosine	17-26	5'-nucleotidase ecto	Homo sapiens	206-210
19464286-2	2009	The synthesis of adenosine involves the catabolism of adenine nucleotides (ATP, ADP and AMP) by the action of extracellular ectonucleotidases i.e. CD39 or nucleoside triphosphate dephosphorylase (NTPD) and CD73 or 5"-ectonucleotidase.	Adenine Nucleotides	54-73	5'-nucleotidase ecto	Homo sapiens	206-210
19464286-2	2009	The synthesis of adenosine involves the catabolism of adenine nucleotides (ATP, ADP and AMP) by the action of extracellular ectonucleotidases i.e. CD39 or nucleoside triphosphate dephosphorylase (NTPD) and CD73 or 5"-ectonucleotidase.	Adenosine Triphosphate	75-78	5'-nucleotidase ecto	Homo sapiens	206-210
19464286-2	2009	The synthesis of adenosine involves the catabolism of adenine nucleotides (ATP, ADP and AMP) by the action of extracellular ectonucleotidases i.e. CD39 or nucleoside triphosphate dephosphorylase (NTPD) and CD73 or 5"-ectonucleotidase.	Adenosine Monophosphate	88-91	5'-nucleotidase ecto	Homo sapiens	206-210
19359665-1	2009	OBJECTIVE: Statins may increase extracellular adenosine formation from adenosine monophosphate by enhancing ecto-5"-nucleotidase activity.	Adenosine Monophosphate	71-94	5'-nucleotidase ecto	Homo sapiens	108-128
19763276-5	2009	Neither of the two electromagnetic field affected the activities of the purine metabolism enzymes ecto-5"-nucleotidase, adenosine deaminase, and adenosine kinase.	purine	72-78	5'-nucleotidase ecto	Homo sapiens	98-118
20020657-4	2009	We were the first to demonstrate that endothelial cell incubation was followed by increase in 5"-nucleotidase activity in the presence of sutent while celecoxib did not produce such effect.	Sunitinib	138-144	5'-nucleotidase ecto	Homo sapiens	94-109
19729987-1	2009	AIMS: Extracellular ATP may be metabolized to AMP and adenosine by the ectonucleotidases CD39 and CD73 and, in this study, we characterized the pathways for adenosine formation in human urinary tract epithelial cells.	Adenosine Triphosphate	20-23	5'-nucleotidase ecto	Homo sapiens	98-102
19729987-1	2009	AIMS: Extracellular ATP may be metabolized to AMP and adenosine by the ectonucleotidases CD39 and CD73 and, in this study, we characterized the pathways for adenosine formation in human urinary tract epithelial cells.	Adenosine Monophosphate	46-49	5'-nucleotidase ecto	Homo sapiens	98-102
19729987-1	2009	AIMS: Extracellular ATP may be metabolized to AMP and adenosine by the ectonucleotidases CD39 and CD73 and, in this study, we characterized the pathways for adenosine formation in human urinary tract epithelial cells.	Adenosine	54-63	5'-nucleotidase ecto	Homo sapiens	98-102
19729987-1	2009	AIMS: Extracellular ATP may be metabolized to AMP and adenosine by the ectonucleotidases CD39 and CD73 and, in this study, we characterized the pathways for adenosine formation in human urinary tract epithelial cells.	Adenosine	157-166	5'-nucleotidase ecto	Homo sapiens	98-102
19729987-5	2009	Adenosine was produced when the cells were exposed to 5"-AMP (substrate for CD73), but not when exposed to 5"-ATP (substrate for CD39).	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	76-80
19729987-5	2009	Adenosine was produced when the cells were exposed to 5"-AMP (substrate for CD73), but not when exposed to 5"-ATP (substrate for CD39).	Adenosine Monophosphate	54-60	5'-nucleotidase ecto	Homo sapiens	76-80
19729987-6	2009	A pronounced inhibition of 5"-AMP-induced adenosine formation by the CD73 inhibitor AMP-CP confirmed the involvement of CD73.	Adenosine Monophosphate	27-33	5'-nucleotidase ecto	Homo sapiens	69-73
19729987-6	2009	A pronounced inhibition of 5"-AMP-induced adenosine formation by the CD73 inhibitor AMP-CP confirmed the involvement of CD73.	Adenosine Monophosphate	27-33	5'-nucleotidase ecto	Homo sapiens	120-124
19729987-6	2009	A pronounced inhibition of 5"-AMP-induced adenosine formation by the CD73 inhibitor AMP-CP confirmed the involvement of CD73.	Adenosine	42-51	5'-nucleotidase ecto	Homo sapiens	69-73
19729987-6	2009	A pronounced inhibition of 5"-AMP-induced adenosine formation by the CD73 inhibitor AMP-CP confirmed the involvement of CD73.	alpha,beta-methyleneadenosine 5'-diphosphate	84-90	5'-nucleotidase ecto	Homo sapiens	69-73
20020657-5	2009	It may be suggested that elevated 5"-nucleotidase concentration at the membranes of endothelial cells might in turn contribute to the pool of extracellular adenosine to stimulate antiinflammatory effect.	Adenosine	156-165	5'-nucleotidase ecto	Homo sapiens	34-49
18924612-7	2008	The translocated platelets were found to release large quantities of ATP, which was metabolized to adenosine via a 2-step enzymatic reaction mediated by ecto-nucleotidases, including CD73 and ecto-nucleoside triphosphate diphosphohydrolases (ecto-NTPDases), expressed on the apical membrane of the intestinal epithelial cells.	Adenosine Triphosphate	69-72	5'-nucleotidase ecto	Homo sapiens	183-187
18636315-6	2008	Ecto-5"-nucleotidase/CD73 may regulate the extracellular adenosine 5"-monophosphate (AMP) and adenosine levels.	adenosine 5"-monophosphate	57-83	5'-nucleotidase ecto	Homo sapiens	0-20
18636315-6	2008	Ecto-5"-nucleotidase/CD73 may regulate the extracellular adenosine 5"-monophosphate (AMP) and adenosine levels.	adenosine 5"-monophosphate	57-83	5'-nucleotidase ecto	Homo sapiens	21-25
18636315-6	2008	Ecto-5"-nucleotidase/CD73 may regulate the extracellular adenosine 5"-monophosphate (AMP) and adenosine levels.	Adenosine Monophosphate	85-88	5'-nucleotidase ecto	Homo sapiens	0-20
18636315-6	2008	Ecto-5"-nucleotidase/CD73 may regulate the extracellular adenosine 5"-monophosphate (AMP) and adenosine levels.	Adenosine Monophosphate	85-88	5'-nucleotidase ecto	Homo sapiens	21-25
18636315-6	2008	Ecto-5"-nucleotidase/CD73 may regulate the extracellular adenosine 5"-monophosphate (AMP) and adenosine levels.	Adenosine	57-66	5'-nucleotidase ecto	Homo sapiens	0-20
18636315-6	2008	Ecto-5"-nucleotidase/CD73 may regulate the extracellular adenosine 5"-monophosphate (AMP) and adenosine levels.	Adenosine	57-66	5'-nucleotidase ecto	Homo sapiens	21-25
18636315-7	2008	Treatment with 1 microM APCP, a competitive ecto-5"-NT/CD73 inhibitor, caused a significant reduction of 30% in glioma cell proliferation.	adenylyl(3'-5')cytidine-3'-phosphate	24-28	5'-nucleotidase ecto	Homo sapiens	55-59
18636315-11	2008	Taken together, these results suggest the participation of ecto-5"-NT/CD73 in cell proliferation and that this process is dependent upon the enzyme"s production of adenosine, a proliferative factor, and removal of AMP, a toxic molecule for gliomas.	Adenosine	164-173	5'-nucleotidase ecto	Homo sapiens	70-74
18636315-11	2008	Taken together, these results suggest the participation of ecto-5"-NT/CD73 in cell proliferation and that this process is dependent upon the enzyme"s production of adenosine, a proliferative factor, and removal of AMP, a toxic molecule for gliomas.	Adenosine Monophosphate	214-217	5'-nucleotidase ecto	Homo sapiens	70-74
18924612-7	2008	The translocated platelets were found to release large quantities of ATP, which was metabolized to adenosine via a 2-step enzymatic reaction mediated by ecto-nucleotidases, including CD73 and ecto-nucleoside triphosphate diphosphohydrolases (ecto-NTPDases), expressed on the apical membrane of the intestinal epithelial cells.	Adenosine	99-108	5'-nucleotidase ecto	Homo sapiens	183-187
18825744-5	2008	Importantly, this reduction can be reversed using alpha,beta-methyleneadenosine-5"-diphosphate, a specific inhibitor of ecto-5"-nucleotidase.	alpha,beta-methyleneadenosine 5'-diphosphate	50-94	5'-nucleotidase ecto	Homo sapiens	120-140
18794336-7	2008	Treatment of T reg cells in vitro with imiquimod inhibited their suppressive activity and reduced FOXP3, CD39, CD73, IL-10, and TGF-beta by indirect mechanisms.	Imiquimod	39-48	5'-nucleotidase ecto	Homo sapiens	111-115
18165923-1	2008	Background AMP-deaminase (EC 3.5.4.6) and 5"-nucleotidase (EC 3.1.3.5) are enzymes responsible for the maintenance of cellular adenine nucleotides pool.	Adenine Nucleotides	127-146	5'-nucleotidase ecto	Homo sapiens	42-57
18787389-1	2008	5"-Nucleotidase is involved in sperm capacitation via the cAMP-adenosine pathway and in sperm motility via direct adenosine production from AMP.	Cyclic AMP	58-62	5'-nucleotidase ecto	Homo sapiens	0-15
18787389-1	2008	5"-Nucleotidase is involved in sperm capacitation via the cAMP-adenosine pathway and in sperm motility via direct adenosine production from AMP.	Adenosine	63-72	5'-nucleotidase ecto	Homo sapiens	0-15
18787389-1	2008	5"-Nucleotidase is involved in sperm capacitation via the cAMP-adenosine pathway and in sperm motility via direct adenosine production from AMP.	Adenosine	114-123	5'-nucleotidase ecto	Homo sapiens	0-15
18787389-1	2008	5"-Nucleotidase is involved in sperm capacitation via the cAMP-adenosine pathway and in sperm motility via direct adenosine production from AMP.	Adenosine Monophosphate	59-62	5'-nucleotidase ecto	Homo sapiens	0-15
18511695-2	2008	Extracellular adenosine mainly stems from enzymatic phosphohydrolysis of precursor nucleotides via ecto-5"-nucleotidase.	Adenosine	14-23	5'-nucleotidase ecto	Homo sapiens	99-119
18514936-7	2008	CONCLUSIONS: These increases in ecto-5"-nucleotidase in the plasma and myocardium may contribute to increased plasma and cardiac adenosine levels.	Adenosine	129-138	5'-nucleotidase ecto	Homo sapiens	32-52
18600546-0	2008	Ecto-5"-nucleotidase (CD73)-mediated extracellular adenosine production plays a critical role in hepatic fibrosis.	Adenosine	51-60	5'-nucleotidase ecto	Homo sapiens	0-20
18600546-0	2008	Ecto-5"-nucleotidase (CD73)-mediated extracellular adenosine production plays a critical role in hepatic fibrosis.	Adenosine	51-60	5'-nucleotidase ecto	Homo sapiens	22-26
17671792-2	2008	The purpose of the present study was to evaluate the role of ecto-5"-nucleotidase (eN, ecto-5-NT, CD73) generated extracellular adenosine in biologically malignant behaviors of human breast cancer cell lines.	Adenosine	128-137	5'-nucleotidase ecto	Homo sapiens	61-81
18311159-3	2008	Adenosine is both released by hypoxic cells/tissues and is also generated from extracellular nucleotides by ecto-enzymes e.g. CD39 (ENTPD1) and CD73 that are expressed by the vasculature and immune cells, in particular by T regulatory cell.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	144-148
17671792-2	2008	The purpose of the present study was to evaluate the role of ecto-5"-nucleotidase (eN, ecto-5-NT, CD73) generated extracellular adenosine in biologically malignant behaviors of human breast cancer cell lines.	Adenosine	128-137	5'-nucleotidase ecto	Homo sapiens	83-85
17671792-2	2008	The purpose of the present study was to evaluate the role of ecto-5"-nucleotidase (eN, ecto-5-NT, CD73) generated extracellular adenosine in biologically malignant behaviors of human breast cancer cell lines.	Adenosine	128-137	5'-nucleotidase ecto	Homo sapiens	98-102
17671792-5	2008	The effects of specific CD73 inhibitor, alpha, ss-methylene ADP (APCP), were observed in MB-MDA-231 cells.	alpha, ss-methylene adp	40-63	5'-nucleotidase ecto	Homo sapiens	24-28
17671792-5	2008	The effects of specific CD73 inhibitor, alpha, ss-methylene ADP (APCP), were observed in MB-MDA-231 cells.	adenylyl(3'-5')cytidine-3'-phosphate	65-69	5'-nucleotidase ecto	Homo sapiens	24-28
17671792-10	2008	CONCLUSION: Taken together, our results indicated that CD73 may facilitate the adhesion, migration and invasion of human breast cancer cells through its enzyme activity of generating adenosine.	Adenosine	183-192	5'-nucleotidase ecto	Homo sapiens	55-59
18258482-3	2008	Novel studies now establish that, through the generation of the immunosuppressive factor adenosine, the ectoenzymes CD39 and CD73 are important contributors to the regulatory activity of Foxp3(+)CD4(+) T cells.	Adenosine	89-98	5'-nucleotidase ecto	Homo sapiens	125-129
18158588-5	2008	The activities of ATPase, ADPase and ecto-5"-nucleotidase (eN) in cell homogenates following Atorvastatin treatment were also increased while no change was observed in the lactate dehydrogenase activity.	Atorvastatin	93-105	5'-nucleotidase ecto	Homo sapiens	37-57
17980347-1	2008	Powerful capillary electrophoresis (CE) methods were developed for monitoring the reaction of ecto-5"-nucleotidase (ecto-5"-NT, CD73), a (patho)biochemically important enzyme that hydrolyzes nucleoside-5"-monophosphates to the corresponding nucleosides.	nucleoside-5"-monophosphates	191-219	5'-nucleotidase ecto	Homo sapiens	94-114
17980347-1	2008	Powerful capillary electrophoresis (CE) methods were developed for monitoring the reaction of ecto-5"-nucleotidase (ecto-5"-NT, CD73), a (patho)biochemically important enzyme that hydrolyzes nucleoside-5"-monophosphates to the corresponding nucleosides.	nucleoside-5"-monophosphates	191-219	5'-nucleotidase ecto	Homo sapiens	116-126
17980347-1	2008	Powerful capillary electrophoresis (CE) methods were developed for monitoring the reaction of ecto-5"-nucleotidase (ecto-5"-NT, CD73), a (patho)biochemically important enzyme that hydrolyzes nucleoside-5"-monophosphates to the corresponding nucleosides.	nucleoside-5"-monophosphates	191-219	5'-nucleotidase ecto	Homo sapiens	128-132
17980347-1	2008	Powerful capillary electrophoresis (CE) methods were developed for monitoring the reaction of ecto-5"-nucleotidase (ecto-5"-NT, CD73), a (patho)biochemically important enzyme that hydrolyzes nucleoside-5"-monophosphates to the corresponding nucleosides.	Nucleosides	241-252	5'-nucleotidase ecto	Homo sapiens	94-114
17980347-1	2008	Powerful capillary electrophoresis (CE) methods were developed for monitoring the reaction of ecto-5"-nucleotidase (ecto-5"-NT, CD73), a (patho)biochemically important enzyme that hydrolyzes nucleoside-5"-monophosphates to the corresponding nucleosides.	Nucleosides	241-252	5'-nucleotidase ecto	Homo sapiens	116-126
17980347-1	2008	Powerful capillary electrophoresis (CE) methods were developed for monitoring the reaction of ecto-5"-nucleotidase (ecto-5"-NT, CD73), a (patho)biochemically important enzyme that hydrolyzes nucleoside-5"-monophosphates to the corresponding nucleosides.	Nucleosides	241-252	5'-nucleotidase ecto	Homo sapiens	128-132
18062933-11	2008	These data suggest that eN is a novel and specific receptor for tenascin C and that the interaction between these proteins may influence cell adhesion and migration and also lead to decreased generation of local adenosine.	Adenosine	212-221	5'-nucleotidase ecto	Homo sapiens	24-26
17619144-4	2008	Nevertheless, researchers refer any AMP-dephosphorylating activity to as 5"-nucleotidase, lacking a more accurate identification.	Adenosine Monophosphate	36-39	5'-nucleotidase ecto	Homo sapiens	73-88
17911479-2	2007	CD73 (ecto-5"-nucleotidase) is an ectoenzyme, which produces adenosine from adenosine monophosphate (AMP) precursor by enzymatic dephosphorylation.	Adenosine	61-70	5'-nucleotidase ecto	Homo sapiens	0-4
17878054-2	2007	alpha,beta-methylene-ADP, an ecto-5"-nucleotidase inhibitor, suppressed the hydrolysis of AMP and reversed the inhibition of cell growth induced by AMP but not by adenosine.	alpha,beta-methyleneadenosine 5'-diphosphate	0-24	5'-nucleotidase ecto	Homo sapiens	29-49
17878054-2	2007	alpha,beta-methylene-ADP, an ecto-5"-nucleotidase inhibitor, suppressed the hydrolysis of AMP and reversed the inhibition of cell growth induced by AMP but not by adenosine.	Adenosine Monophosphate	90-93	5'-nucleotidase ecto	Homo sapiens	29-49
17878054-2	2007	alpha,beta-methylene-ADP, an ecto-5"-nucleotidase inhibitor, suppressed the hydrolysis of AMP and reversed the inhibition of cell growth induced by AMP but not by adenosine.	Adenosine Monophosphate	148-151	5'-nucleotidase ecto	Homo sapiens	29-49
17878054-9	2007	These results indicate that extracellular adenine nucleotides inhibit C6 cell growth via adenosine, which is produced by ecto-nucleotidases including CD73 at the extracellular space and then incorporated into cells by ENT2.	Adenine Nucleotides	42-61	5'-nucleotidase ecto	Homo sapiens	150-154
17878054-9	2007	These results indicate that extracellular adenine nucleotides inhibit C6 cell growth via adenosine, which is produced by ecto-nucleotidases including CD73 at the extracellular space and then incorporated into cells by ENT2.	Adenosine	89-98	5'-nucleotidase ecto	Homo sapiens	150-154
17557193-14	2007	AMP was used as substrate to determine the 5"-nucleotidase activities, which showed to be elevated in the groups P (45.0%, S.D.	Adenosine Monophosphate	0-3	5'-nucleotidase ecto	Homo sapiens	43-58
17619122-2	2007	The neurotoxicity induced by glutamate increases the ecto-5"-nucleotidase activity in neurons, which produces adenosine from AMP.	Glutamic Acid	29-38	5'-nucleotidase ecto	Homo sapiens	53-73
17619122-2	2007	The neurotoxicity induced by glutamate increases the ecto-5"-nucleotidase activity in neurons, which produces adenosine from AMP.	Adenosine	110-119	5'-nucleotidase ecto	Homo sapiens	53-73
17619122-2	2007	The neurotoxicity induced by glutamate increases the ecto-5"-nucleotidase activity in neurons, which produces adenosine from AMP.	Adenosine Monophosphate	125-128	5'-nucleotidase ecto	Homo sapiens	53-73
17911479-2	2007	CD73 (ecto-5"-nucleotidase) is an ectoenzyme, which produces adenosine from adenosine monophosphate (AMP) precursor by enzymatic dephosphorylation.	Adenosine	61-70	5'-nucleotidase ecto	Homo sapiens	6-26
17619122-5	2007	MK-801 and AP-5 prevented the L- and D-Asp-evoked activation of ecto-5"-nucleotidase.	Dizocilpine Maleate	0-6	5'-nucleotidase ecto	Homo sapiens	64-84
17911479-2	2007	CD73 (ecto-5"-nucleotidase) is an ectoenzyme, which produces adenosine from adenosine monophosphate (AMP) precursor by enzymatic dephosphorylation.	Adenosine Monophosphate	76-99	5'-nucleotidase ecto	Homo sapiens	0-4
17911479-2	2007	CD73 (ecto-5"-nucleotidase) is an ectoenzyme, which produces adenosine from adenosine monophosphate (AMP) precursor by enzymatic dephosphorylation.	Adenosine Monophosphate	76-99	5'-nucleotidase ecto	Homo sapiens	6-26
17619122-5	2007	MK-801 and AP-5 prevented the L- and D-Asp-evoked activation of ecto-5"-nucleotidase.	2-amino-5-phosphopentanoic acid	11-15	5'-nucleotidase ecto	Homo sapiens	64-84
17619122-5	2007	MK-801 and AP-5 prevented the L- and D-Asp-evoked activation of ecto-5"-nucleotidase.	D-Aspartic Acid	39-42	5'-nucleotidase ecto	Homo sapiens	64-84
17911479-2	2007	CD73 (ecto-5"-nucleotidase) is an ectoenzyme, which produces adenosine from adenosine monophosphate (AMP) precursor by enzymatic dephosphorylation.	Adenosine Monophosphate	101-104	5'-nucleotidase ecto	Homo sapiens	0-4
17911479-2	2007	CD73 (ecto-5"-nucleotidase) is an ectoenzyme, which produces adenosine from adenosine monophosphate (AMP) precursor by enzymatic dephosphorylation.	Adenosine Monophosphate	101-104	5'-nucleotidase ecto	Homo sapiens	6-26
17911479-3	2007	AMP is known to be abundantly present at sites of inflammation, and more importantly adenosine, the product of CD73, is known to possess both anti-inflammatory and neuroprotective activity.	Adenosine	85-94	5'-nucleotidase ecto	Homo sapiens	111-115
17643826-9	2007	We suggest that the inhibition of ecto-5"-NT/CD73 may result in a decrease in extracellular adenosine production with a consequent reduction in tumor progression.	Adenosine	92-101	5'-nucleotidase ecto	Homo sapiens	45-49
17643826-0	2007	Ecto-5"-nucleotidase/CD73 inhibition by quercetin in the human U138MG glioma cell line.	Quercetin	40-49	5'-nucleotidase ecto	Homo sapiens	0-20
17643826-0	2007	Ecto-5"-nucleotidase/CD73 inhibition by quercetin in the human U138MG glioma cell line.	Quercetin	40-49	5'-nucleotidase ecto	Homo sapiens	21-25
17643826-6	2007	The adenine products secreted by glioma cells were first characterized; extracellular AMP was efficiently metabolized by the glioma culture, demonstrating a very active ecto-5"-NT/CD73.	Adenine	4-11	5'-nucleotidase ecto	Homo sapiens	180-184
17643826-6	2007	The adenine products secreted by glioma cells were first characterized; extracellular AMP was efficiently metabolized by the glioma culture, demonstrating a very active ecto-5"-NT/CD73.	Adenosine Monophosphate	86-89	5'-nucleotidase ecto	Homo sapiens	180-184
17643826-7	2007	Quercetin was able to inhibit the ecto-5"-NT/CD73 activity and modulate its expression.	Quercetin	0-9	5'-nucleotidase ecto	Homo sapiens	45-49
17643826-8	2007	In addition, the cell treatment with APCP (alpha,beta-methyleneadenosine-5"-diphosphate), an ecto-5"-NT/CD73 inhibitor, led to a significant reduction in glioma cell proliferation.	adenylyl(3'-5')cytidine-3'-phosphate	37-41	5'-nucleotidase ecto	Homo sapiens	104-108
17643826-8	2007	In addition, the cell treatment with APCP (alpha,beta-methyleneadenosine-5"-diphosphate), an ecto-5"-NT/CD73 inhibitor, led to a significant reduction in glioma cell proliferation.	alpha,beta-methyleneadenosine 5'-diphosphate	43-87	5'-nucleotidase ecto	Homo sapiens	104-108
17603550-5	2007	The inhibition of the activity of NTPDases (using the following substrates: ATP, ADP, UTP), NPPs (pnp-TMP, Ap(3)A) and ecto-5"-nucleotidase (AMP) was measured by colorimetric or HPLC assays.	Adenosine Triphosphate	76-79	5'-nucleotidase ecto	Homo sapiens	119-139
17603550-5	2007	The inhibition of the activity of NTPDases (using the following substrates: ATP, ADP, UTP), NPPs (pnp-TMP, Ap(3)A) and ecto-5"-nucleotidase (AMP) was measured by colorimetric or HPLC assays.	Adenosine Monophosphate	141-144	5'-nucleotidase ecto	Homo sapiens	119-139
17619122-9	2007	The adenosine formed from ecto-5"-nucleotidase stimulation preferentially acted on adenosine A(2A) receptor which is probably co-operating with the neurotoxicity induced by amino acids.	Adenosine	4-13	5'-nucleotidase ecto	Homo sapiens	26-46
17487388-1	2007	Ecto-5"-nucleotidase (CD73) is an essential enzyme that generates adenosine, an essential molecule for cell growth.	Adenosine	66-75	5'-nucleotidase ecto	Homo sapiens	0-20
17568578-0	2007	Indomethacin stimulates activity and expression of ecto-5"-nucleotidase/CD73 in glioma cell lines.	Indomethacin	0-12	5'-nucleotidase ecto	Homo sapiens	51-71
17568578-0	2007	Indomethacin stimulates activity and expression of ecto-5"-nucleotidase/CD73 in glioma cell lines.	Indomethacin	0-12	5'-nucleotidase ecto	Homo sapiens	72-76
17568578-2	2007	Ecto-NTPDases and ecto-5"-nucleotidase/CD73 can control extracellular ATP/adenosine levels, which have been described as proliferation factors.	Adenosine Triphosphate	70-73	5'-nucleotidase ecto	Homo sapiens	18-38
17568578-2	2007	Ecto-NTPDases and ecto-5"-nucleotidase/CD73 can control extracellular ATP/adenosine levels, which have been described as proliferation factors.	Adenosine Triphosphate	70-73	5'-nucleotidase ecto	Homo sapiens	39-43
17568578-2	2007	Ecto-NTPDases and ecto-5"-nucleotidase/CD73 can control extracellular ATP/adenosine levels, which have been described as proliferation factors.	Adenosine	74-83	5'-nucleotidase ecto	Homo sapiens	18-38
17568578-2	2007	Ecto-NTPDases and ecto-5"-nucleotidase/CD73 can control extracellular ATP/adenosine levels, which have been described as proliferation factors.	Adenosine	74-83	5'-nucleotidase ecto	Homo sapiens	39-43
17568578-6	2007	Significant increase in ecto-5"-nucleotidase/CD73 mRNA and protein levels were observed after treatment with indomethacin.	Indomethacin	109-121	5'-nucleotidase ecto	Homo sapiens	24-44
17568578-6	2007	Significant increase in ecto-5"-nucleotidase/CD73 mRNA and protein levels were observed after treatment with indomethacin.	Indomethacin	109-121	5'-nucleotidase ecto	Homo sapiens	45-49
17568578-9	2007	In conclusion, our data indicate that adenosine A(3) receptors and the enzyme, ecto-5"-nucleotidase/CD73, are involved in the anti-proliferative effect of indomethacin in glioma cells.	Indomethacin	155-167	5'-nucleotidase ecto	Homo sapiens	79-99
17568578-9	2007	In conclusion, our data indicate that adenosine A(3) receptors and the enzyme, ecto-5"-nucleotidase/CD73, are involved in the anti-proliferative effect of indomethacin in glioma cells.	Indomethacin	155-167	5'-nucleotidase ecto	Homo sapiens	100-104
17487388-1	2007	Ecto-5"-nucleotidase (CD73) is an essential enzyme that generates adenosine, an essential molecule for cell growth.	Adenosine	66-75	5'-nucleotidase ecto	Homo sapiens	22-26
17487388-3	2007	In this study, alpha,beta-methylene adenosine-5"-diphosphate (APCP), a specific CD73 inhibitor was used to block the hydrolase"s activity.	alpha,beta-methyleneadenosine 5'-diphosphate	15-60	5'-nucleotidase ecto	Homo sapiens	80-84
17487388-3	2007	In this study, alpha,beta-methylene adenosine-5"-diphosphate (APCP), a specific CD73 inhibitor was used to block the hydrolase"s activity.	adenylyl(3'-5')cytidine-3'-phosphate	62-66	5'-nucleotidase ecto	Homo sapiens	80-84
17296311-2	2007	Gemcitabine enters the cell mostly via the human equilibrative nucleoside transporter-1 (hENT1), while drug metabolism occurs by phosphorylation by deoxycytidine kinase (dCK), 5"-nucleotidase (cN-II) and cytidine deaminase (CDA) are the main inactivating enzymes.	gemcitabine	0-11	5'-nucleotidase ecto	Homo sapiens	176-191
17308037-1	2007	In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to adenosine by ecto-5"-nucleotidase.	Adenosine	145-154	5'-nucleotidase ecto	Homo sapiens	158-178
18404437-3	2007	We suspected that ecto-5"-nucleotidase (CD73, an intestinal enzyme) was a critical enzyme involved in the conversion of AMP to adenosine and in the pathogenesis of EPEC diarrhea.	Adenosine Monophosphate	120-123	5'-nucleotidase ecto	Homo sapiens	18-38
18404437-3	2007	We suspected that ecto-5"-nucleotidase (CD73, an intestinal enzyme) was a critical enzyme involved in the conversion of AMP to adenosine and in the pathogenesis of EPEC diarrhea.	Adenosine	127-136	5'-nucleotidase ecto	Homo sapiens	18-38
18404437-4	2007	We developed a nonradioactive method for measuring ecto-5"-nucleotidase in cultured T84 cell monolayers based on the detection of phosphate release from 5"-AMP.	Phosphates	130-139	5'-nucleotidase ecto	Homo sapiens	51-71
18404437-4	2007	We developed a nonradioactive method for measuring ecto-5"-nucleotidase in cultured T84 cell monolayers based on the detection of phosphate release from 5"-AMP.	Adenosine Monophosphate	153-159	5'-nucleotidase ecto	Homo sapiens	51-71
18404437-7	2007	Ecto-5"-nucleotidase was susceptible to inhibition by zinc acetate and by alpha,beta-methylene-adenosine diphosphate (alpha,beta-methylene-ADP).	Zinc Acetate	54-66	5'-nucleotidase ecto	Homo sapiens	0-20
18404437-7	2007	Ecto-5"-nucleotidase was susceptible to inhibition by zinc acetate and by alpha,beta-methylene-adenosine diphosphate (alpha,beta-methylene-ADP).	alpha,beta-methyleneadenosine 5'-diphosphate	74-116	5'-nucleotidase ecto	Homo sapiens	0-20
18404437-7	2007	Ecto-5"-nucleotidase was susceptible to inhibition by zinc acetate and by alpha,beta-methylene-adenosine diphosphate (alpha,beta-methylene-ADP).	alpha,beta-methyleneadenosine 5'-diphosphate	118-142	5'-nucleotidase ecto	Homo sapiens	0-20
18404437-10	2007	Ecto-5"-nucleotidase appears to be the major enzyme responsible for generation of adenosine from adenine nucleotides in the T84 cell line, and inhibitors of ecto-5"-nucleotidase, such as alpha,beta-methylene-ADP and zinc, might be useful for treatment of the watery diarrhea produced by EPEC infection.	Adenosine	82-91	5'-nucleotidase ecto	Homo sapiens	0-20
18404437-10	2007	Ecto-5"-nucleotidase appears to be the major enzyme responsible for generation of adenosine from adenine nucleotides in the T84 cell line, and inhibitors of ecto-5"-nucleotidase, such as alpha,beta-methylene-ADP and zinc, might be useful for treatment of the watery diarrhea produced by EPEC infection.	Adenosine	82-91	5'-nucleotidase ecto	Homo sapiens	157-177
18404437-10	2007	Ecto-5"-nucleotidase appears to be the major enzyme responsible for generation of adenosine from adenine nucleotides in the T84 cell line, and inhibitors of ecto-5"-nucleotidase, such as alpha,beta-methylene-ADP and zinc, might be useful for treatment of the watery diarrhea produced by EPEC infection.	Adenine Nucleotides	97-116	5'-nucleotidase ecto	Homo sapiens	0-20
18404437-10	2007	Ecto-5"-nucleotidase appears to be the major enzyme responsible for generation of adenosine from adenine nucleotides in the T84 cell line, and inhibitors of ecto-5"-nucleotidase, such as alpha,beta-methylene-ADP and zinc, might be useful for treatment of the watery diarrhea produced by EPEC infection.	alpha,beta-methyleneadenosine 5'-diphosphate	187-211	5'-nucleotidase ecto	Homo sapiens	157-177
17471030-5	2007	Surface CD73 activity was assessed by quantifying the conversion of etheno-AMP to ethenoadenosine via HPLC.	etheno-AMP	68-78	5'-nucleotidase ecto	Homo sapiens	8-12
17471030-5	2007	Surface CD73 activity was assessed by quantifying the conversion of etheno-AMP to ethenoadenosine via HPLC.	ethenoadenosine	82-97	5'-nucleotidase ecto	Homo sapiens	8-12
17471030-8	2007	We demonstrated that abilities of migration, invasions and adhesion to ECM in pcDNA-NT5E transfected T-47D cells increased significantly, which can be blocked by CD73 inhibitor alpha, beta-methylene ADP(APCP).	beta-methylene adp	184-202	5'-nucleotidase ecto	Homo sapiens	84-88
17471030-8	2007	We demonstrated that abilities of migration, invasions and adhesion to ECM in pcDNA-NT5E transfected T-47D cells increased significantly, which can be blocked by CD73 inhibitor alpha, beta-methylene ADP(APCP).	beta-methylene adp	184-202	5'-nucleotidase ecto	Homo sapiens	162-166
17471030-12	2007	Our results suggest that up-regulated adenosine production, EGFR and IL-8 expression due to overexpressed CD73 may involved in CD73-promoted breast cancer metastasis.	Adenosine	38-47	5'-nucleotidase ecto	Homo sapiens	106-110
17471030-12	2007	Our results suggest that up-regulated adenosine production, EGFR and IL-8 expression due to overexpressed CD73 may involved in CD73-promoted breast cancer metastasis.	Adenosine	38-47	5'-nucleotidase ecto	Homo sapiens	127-131
18404487-3	2006	In other tissues, ecto-nucleotidases mediate the consecutive dephosphorylation of ATP to AMP, and AMP is converted to adenosine by ecto-5" nucleotidase (CD73).	Adenosine Triphosphate	82-85	5'-nucleotidase ecto	Homo sapiens	153-157
16942776-0	2006	Simultaneous determination of adenosine and its metabolites by capillary electrophoresis as a rapid monitoring tool for 5"-nucleotidase activity.	Adenosine	30-39	5'-nucleotidase ecto	Homo sapiens	120-135
17289263-3	2007	Schizophrenic patients treated either with typical antipsychotics or clozapine showed increased serum adenosine deaminase activity compared to controls (controls=18.96+/-4.61 U/l; typical=25.09+/-10.98 U/l; clozapine=30.32+/-10.83 U/l; p&lt;0.05, ANOVA) and 5"-nucleotidase activity was also increased in patients on clozapine.	Clozapine	69-78	5'-nucleotidase ecto	Homo sapiens	258-273
17174234-1	2006	BACKGROUND: Adenosine 5"-triphosphate is catabolized to adenosine 5"-monophosphate (AMP), which is further degraded by 2 pathways: deamination to inosine 5"-monophosphate and ammonia by AMP deaminase, or dephosphorylation to adenosine and inorganic phosphate by 5"-nucleotidase.	Adenosine Triphosphate	12-37	5'-nucleotidase ecto	Homo sapiens	262-277
17174234-1	2006	BACKGROUND: Adenosine 5"-triphosphate is catabolized to adenosine 5"-monophosphate (AMP), which is further degraded by 2 pathways: deamination to inosine 5"-monophosphate and ammonia by AMP deaminase, or dephosphorylation to adenosine and inorganic phosphate by 5"-nucleotidase.	Adenine Nucleotides	56-82	5'-nucleotidase ecto	Homo sapiens	262-277
17174234-1	2006	BACKGROUND: Adenosine 5"-triphosphate is catabolized to adenosine 5"-monophosphate (AMP), which is further degraded by 2 pathways: deamination to inosine 5"-monophosphate and ammonia by AMP deaminase, or dephosphorylation to adenosine and inorganic phosphate by 5"-nucleotidase.	Adenine Nucleotides	84-87	5'-nucleotidase ecto	Homo sapiens	262-277
17174234-1	2006	BACKGROUND: Adenosine 5"-triphosphate is catabolized to adenosine 5"-monophosphate (AMP), which is further degraded by 2 pathways: deamination to inosine 5"-monophosphate and ammonia by AMP deaminase, or dephosphorylation to adenosine and inorganic phosphate by 5"-nucleotidase.	Inosine Monophosphate	146-170	5'-nucleotidase ecto	Homo sapiens	262-277
17174234-1	2006	BACKGROUND: Adenosine 5"-triphosphate is catabolized to adenosine 5"-monophosphate (AMP), which is further degraded by 2 pathways: deamination to inosine 5"-monophosphate and ammonia by AMP deaminase, or dephosphorylation to adenosine and inorganic phosphate by 5"-nucleotidase.	Ammonia	175-182	5'-nucleotidase ecto	Homo sapiens	262-277
17174234-1	2006	BACKGROUND: Adenosine 5"-triphosphate is catabolized to adenosine 5"-monophosphate (AMP), which is further degraded by 2 pathways: deamination to inosine 5"-monophosphate and ammonia by AMP deaminase, or dephosphorylation to adenosine and inorganic phosphate by 5"-nucleotidase.	Adenosine	56-65	5'-nucleotidase ecto	Homo sapiens	262-277
17174234-1	2006	BACKGROUND: Adenosine 5"-triphosphate is catabolized to adenosine 5"-monophosphate (AMP), which is further degraded by 2 pathways: deamination to inosine 5"-monophosphate and ammonia by AMP deaminase, or dephosphorylation to adenosine and inorganic phosphate by 5"-nucleotidase.	Phosphates	239-258	5'-nucleotidase ecto	Homo sapiens	262-277
16705150-0	2006	Regulation of ecto-5"-nucleotidase by NaCl and nitric oxide: potential roles in tubuloglomerular feedback and adaptation.	Sodium Chloride	38-42	5'-nucleotidase ecto	Homo sapiens	14-34
16705150-0	2006	Regulation of ecto-5"-nucleotidase by NaCl and nitric oxide: potential roles in tubuloglomerular feedback and adaptation.	Nitric Oxide	47-59	5'-nucleotidase ecto	Homo sapiens	14-34
16705150-6	2006	In isolated glomerular preparations, we developed a system for evaluating the effects of changing dietary salt on ecto-5"-nucleotidase (ecto-5"-NT) activity, the final enzyme in the conversion of ATP to adenosine.	Salts	106-110	5'-nucleotidase ecto	Homo sapiens	114-134
16705150-6	2006	In isolated glomerular preparations, we developed a system for evaluating the effects of changing dietary salt on ecto-5"-nucleotidase (ecto-5"-NT) activity, the final enzyme in the conversion of ATP to adenosine.	Salts	106-110	5'-nucleotidase ecto	Homo sapiens	136-146
16705150-6	2006	In isolated glomerular preparations, we developed a system for evaluating the effects of changing dietary salt on ecto-5"-nucleotidase (ecto-5"-NT) activity, the final enzyme in the conversion of ATP to adenosine.	Adenosine Triphosphate	196-199	5'-nucleotidase ecto	Homo sapiens	114-134
16705150-6	2006	In isolated glomerular preparations, we developed a system for evaluating the effects of changing dietary salt on ecto-5"-nucleotidase (ecto-5"-NT) activity, the final enzyme in the conversion of ATP to adenosine.	Adenosine Triphosphate	196-199	5'-nucleotidase ecto	Homo sapiens	136-146
16705150-6	2006	In isolated glomerular preparations, we developed a system for evaluating the effects of changing dietary salt on ecto-5"-nucleotidase (ecto-5"-NT) activity, the final enzyme in the conversion of ATP to adenosine.	Adenosine	203-212	5'-nucleotidase ecto	Homo sapiens	114-134
16705150-6	2006	In isolated glomerular preparations, we developed a system for evaluating the effects of changing dietary salt on ecto-5"-nucleotidase (ecto-5"-NT) activity, the final enzyme in the conversion of ATP to adenosine.	Adenosine	203-212	5'-nucleotidase ecto	Homo sapiens	136-146
16705150-7	2006	We found observable ecto-5"-NT activity in isolated glomeruli and that this activity can be regulated by dietary salt, with high salt increasing activity.	Salts	113-117	5'-nucleotidase ecto	Homo sapiens	20-30
16705150-7	2006	We found observable ecto-5"-NT activity in isolated glomeruli and that this activity can be regulated by dietary salt, with high salt increasing activity.	Salts	129-133	5'-nucleotidase ecto	Homo sapiens	20-30
16705150-9	2006	Moreover, NO inhibition of ecto-5"-NT activity is suppressed in the presence of dithiothreitol, suggesting nitrosylation as a reversible, oxidative stress-sensitive mechanism.	Dithiothreitol	80-94	5'-nucleotidase ecto	Homo sapiens	27-37
16705150-10	2006	The salt-induced activation of ecto-5"-NT correlates with high salt resetting of TGF.	Salts	4-8	5'-nucleotidase ecto	Homo sapiens	31-41
16705150-10	2006	The salt-induced activation of ecto-5"-NT correlates with high salt resetting of TGF.	Salts	63-67	5'-nucleotidase ecto	Homo sapiens	31-41
16718378-2	2006	The levels of these molecules are controlled by ecto-NTPDases and ecto-5"-nucleotidase/CD73 (ecto-5"-NT/CD73) actions, which are responsible for the complete ATP degradation to adenosine.	ecto-5"-nt	93-103	5'-nucleotidase ecto	Homo sapiens	66-86
16718378-2	2006	The levels of these molecules are controlled by ecto-NTPDases and ecto-5"-nucleotidase/CD73 (ecto-5"-NT/CD73) actions, which are responsible for the complete ATP degradation to adenosine.	ecto-5"-nt	93-103	5'-nucleotidase ecto	Homo sapiens	87-91
16718378-2	2006	The levels of these molecules are controlled by ecto-NTPDases and ecto-5"-nucleotidase/CD73 (ecto-5"-NT/CD73) actions, which are responsible for the complete ATP degradation to adenosine.	ecto-5"-nt	93-103	5'-nucleotidase ecto	Homo sapiens	104-108
16718378-2	2006	The levels of these molecules are controlled by ecto-NTPDases and ecto-5"-nucleotidase/CD73 (ecto-5"-NT/CD73) actions, which are responsible for the complete ATP degradation to adenosine.	Adenosine Triphosphate	158-161	5'-nucleotidase ecto	Homo sapiens	66-86
16718378-2	2006	The levels of these molecules are controlled by ecto-NTPDases and ecto-5"-nucleotidase/CD73 (ecto-5"-NT/CD73) actions, which are responsible for the complete ATP degradation to adenosine.	Adenosine Triphosphate	158-161	5'-nucleotidase ecto	Homo sapiens	87-91
16718378-2	2006	The levels of these molecules are controlled by ecto-NTPDases and ecto-5"-nucleotidase/CD73 (ecto-5"-NT/CD73) actions, which are responsible for the complete ATP degradation to adenosine.	Adenosine Triphosphate	158-161	5'-nucleotidase ecto	Homo sapiens	104-108
16718378-2	2006	The levels of these molecules are controlled by ecto-NTPDases and ecto-5"-nucleotidase/CD73 (ecto-5"-NT/CD73) actions, which are responsible for the complete ATP degradation to adenosine.	Adenosine	177-186	5'-nucleotidase ecto	Homo sapiens	66-86
16718378-2	2006	The levels of these molecules are controlled by ecto-NTPDases and ecto-5"-nucleotidase/CD73 (ecto-5"-NT/CD73) actions, which are responsible for the complete ATP degradation to adenosine.	Adenosine	177-186	5'-nucleotidase ecto	Homo sapiens	87-91
16718378-2	2006	The levels of these molecules are controlled by ecto-NTPDases and ecto-5"-nucleotidase/CD73 (ecto-5"-NT/CD73) actions, which are responsible for the complete ATP degradation to adenosine.	Adenosine	177-186	5'-nucleotidase ecto	Homo sapiens	104-108
18404487-3	2006	In other tissues, ecto-nucleotidases mediate the consecutive dephosphorylation of ATP to AMP, and AMP is converted to adenosine by ecto-5" nucleotidase (CD73).	Adenosine Monophosphate	98-101	5'-nucleotidase ecto	Homo sapiens	131-151
18404487-3	2006	In other tissues, ecto-nucleotidases mediate the consecutive dephosphorylation of ATP to AMP, and AMP is converted to adenosine by ecto-5" nucleotidase (CD73).	Adenosine Monophosphate	98-101	5'-nucleotidase ecto	Homo sapiens	153-157
18404487-3	2006	In other tissues, ecto-nucleotidases mediate the consecutive dephosphorylation of ATP to AMP, and AMP is converted to adenosine by ecto-5" nucleotidase (CD73).	Adenosine	118-127	5'-nucleotidase ecto	Homo sapiens	131-151
18404487-3	2006	In other tissues, ecto-nucleotidases mediate the consecutive dephosphorylation of ATP to AMP, and AMP is converted to adenosine by ecto-5" nucleotidase (CD73).	Adenosine	118-127	5'-nucleotidase ecto	Homo sapiens	153-157
18404475-3	2006	The formation of extracellular adenosine from adenosine 5"-monophosphate is accomplished primarily through ecto-5"-nucleotidase (CD73), a glycosyl phosphatidylinositol-linked membrane protein found on the surface of a variety of cell types.	Adenosine	31-40	5'-nucleotidase ecto	Homo sapiens	107-127
16709165-4	2006	Glycosylphosphatidylinositol-anchored 5"-nucleotidase is an extracellular, raft-associated enzyme responsible for conversion of extracellular ATP into adenosine.	Glycosylphosphatidylinositols	0-28	5'-nucleotidase ecto	Homo sapiens	38-53
16709165-4	2006	Glycosylphosphatidylinositol-anchored 5"-nucleotidase is an extracellular, raft-associated enzyme responsible for conversion of extracellular ATP into adenosine.	Adenosine Triphosphate	142-145	5'-nucleotidase ecto	Homo sapiens	38-53
16709165-4	2006	Glycosylphosphatidylinositol-anchored 5"-nucleotidase is an extracellular, raft-associated enzyme responsible for conversion of extracellular ATP into adenosine.	Adenosine	151-160	5'-nucleotidase ecto	Homo sapiens	38-53
16527902-1	2006	The "extracellular cAMP-adenosine pathway" refers to the conversion of cAMP to AMP by ecto-phosphodiesterase, followed by metabolism of AMP to adenosine by ecto-5"-nucleotidase, with all the steps occurring in the extracellular compartment.	Cyclic AMP	19-23	5'-nucleotidase ecto	Homo sapiens	156-176
16527902-1	2006	The "extracellular cAMP-adenosine pathway" refers to the conversion of cAMP to AMP by ecto-phosphodiesterase, followed by metabolism of AMP to adenosine by ecto-5"-nucleotidase, with all the steps occurring in the extracellular compartment.	Adenosine	24-33	5'-nucleotidase ecto	Homo sapiens	156-176
16527902-1	2006	The "extracellular cAMP-adenosine pathway" refers to the conversion of cAMP to AMP by ecto-phosphodiesterase, followed by metabolism of AMP to adenosine by ecto-5"-nucleotidase, with all the steps occurring in the extracellular compartment.	Adenosine Monophosphate	20-23	5'-nucleotidase ecto	Homo sapiens	156-176
16527902-1	2006	The "extracellular cAMP-adenosine pathway" refers to the conversion of cAMP to AMP by ecto-phosphodiesterase, followed by metabolism of AMP to adenosine by ecto-5"-nucleotidase, with all the steps occurring in the extracellular compartment.	Adenosine	143-152	5'-nucleotidase ecto	Homo sapiens	156-176
16468051-0	2006	Adenosine produced via the CD73/ecto-5"-nucleotidase pathway has no impact on erythropoietin production but is associated with reduced kidney weight.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	27-31
16468051-0	2006	Adenosine produced via the CD73/ecto-5"-nucleotidase pathway has no impact on erythropoietin production but is associated with reduced kidney weight.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	32-52
16468051-1	2006	CD73/ecto-5"-nucleotidase, which catalyzes the conversion of adenosine monophosphate to adenosine, has been implicated in vascular homeostasis.	Adenosine Monophosphate	61-84	5'-nucleotidase ecto	Homo sapiens	0-4
16468051-1	2006	CD73/ecto-5"-nucleotidase, which catalyzes the conversion of adenosine monophosphate to adenosine, has been implicated in vascular homeostasis.	Adenosine Monophosphate	61-84	5'-nucleotidase ecto	Homo sapiens	5-25
16468051-1	2006	CD73/ecto-5"-nucleotidase, which catalyzes the conversion of adenosine monophosphate to adenosine, has been implicated in vascular homeostasis.	Adenosine	61-70	5'-nucleotidase ecto	Homo sapiens	0-4
16468051-1	2006	CD73/ecto-5"-nucleotidase, which catalyzes the conversion of adenosine monophosphate to adenosine, has been implicated in vascular homeostasis.	Adenosine	61-70	5'-nucleotidase ecto	Homo sapiens	5-25
16468051-8	2006	We conclude that adenosine derived by the extracellular CD73 pathway has no impact on EPO production under basal conditions and after hypoxic challenge but may determine kidney weight.	Adenosine	17-26	5'-nucleotidase ecto	Homo sapiens	56-60
16861292-1	2006	CD73 (ecto-5"-nucleotidase) on human gingival fibroblasts plays a role in the regulation of intracellular cAMP levels through the generation of adenosine, which subsequently activates adenosine receptors.	Cyclic AMP	106-110	5'-nucleotidase ecto	Homo sapiens	0-4
16861292-1	2006	CD73 (ecto-5"-nucleotidase) on human gingival fibroblasts plays a role in the regulation of intracellular cAMP levels through the generation of adenosine, which subsequently activates adenosine receptors.	Cyclic AMP	106-110	5'-nucleotidase ecto	Homo sapiens	6-26
16861292-1	2006	CD73 (ecto-5"-nucleotidase) on human gingival fibroblasts plays a role in the regulation of intracellular cAMP levels through the generation of adenosine, which subsequently activates adenosine receptors.	Adenosine	144-153	5'-nucleotidase ecto	Homo sapiens	0-4
16861292-1	2006	CD73 (ecto-5"-nucleotidase) on human gingival fibroblasts plays a role in the regulation of intracellular cAMP levels through the generation of adenosine, which subsequently activates adenosine receptors.	Adenosine	144-153	5'-nucleotidase ecto	Homo sapiens	6-26
16861292-2	2006	In this study, we examined the involvement of ecto-adenosine deaminase, which can be anchored to CD26 on human gingival fibroblasts, in metabolizing adenosine generated by CD73, and thus attenuating adenosine receptor activation.	Adenosine	51-60	5'-nucleotidase ecto	Homo sapiens	172-176
16861292-4	2006	Interestingly, the cAMP response to adenosine generated from 5"-AMP via CD73 and the ability of 5"-AMP to induce hyaluronan synthase 1 mRNA were significantly decreased by the pre-treatment of fibroblasts with Jurkat cell lysate.	Cyclic AMP	19-23	5'-nucleotidase ecto	Homo sapiens	72-76
16861292-4	2006	Interestingly, the cAMP response to adenosine generated from 5"-AMP via CD73 and the ability of 5"-AMP to induce hyaluronan synthase 1 mRNA were significantly decreased by the pre-treatment of fibroblasts with Jurkat cell lysate.	Adenosine	36-45	5'-nucleotidase ecto	Homo sapiens	72-76
16861292-4	2006	Interestingly, the cAMP response to adenosine generated from 5"-AMP via CD73 and the ability of 5"-AMP to induce hyaluronan synthase 1 mRNA were significantly decreased by the pre-treatment of fibroblasts with Jurkat cell lysate.	Adenosine Monophosphate	61-67	5'-nucleotidase ecto	Homo sapiens	72-76
16861292-6	2006	These results suggest that ecto-adenosine deaminase metabolizes CD73-generated adenosine and regulates adenosine receptor activation.	Adenosine	32-41	5'-nucleotidase ecto	Homo sapiens	64-68
16718268-1	2006	Ecto-5"-nucleotidase is a GPI-anchored enzyme localized in cell membrane lipid rafts.	Glycosylphosphatidylinositols	26-29	5'-nucleotidase ecto	Homo sapiens	0-20
16718268-10	2006	As ConA-induced clustering may reflect the interactions of membrane proteins with extracellular matrix, we also analysed the effect of several extracellular matrix proteins on the in-situ activity of ecto-5"-nucleotidase in WM9 cells and found that tenascin C strongly inhibited ecto-5"-nucleotidase activity and adenosine generation from AMP.	Adenosine	313-322	5'-nucleotidase ecto	Homo sapiens	200-220
16718268-10	2006	As ConA-induced clustering may reflect the interactions of membrane proteins with extracellular matrix, we also analysed the effect of several extracellular matrix proteins on the in-situ activity of ecto-5"-nucleotidase in WM9 cells and found that tenascin C strongly inhibited ecto-5"-nucleotidase activity and adenosine generation from AMP.	Adenosine Monophosphate	339-342	5'-nucleotidase ecto	Homo sapiens	200-220
18404475-3	2006	The formation of extracellular adenosine from adenosine 5"-monophosphate is accomplished primarily through ecto-5"-nucleotidase (CD73), a glycosyl phosphatidylinositol-linked membrane protein found on the surface of a variety of cell types.	Adenosine	31-40	5'-nucleotidase ecto	Homo sapiens	129-133
18404475-3	2006	The formation of extracellular adenosine from adenosine 5"-monophosphate is accomplished primarily through ecto-5"-nucleotidase (CD73), a glycosyl phosphatidylinositol-linked membrane protein found on the surface of a variety of cell types.	adenosine 5"-monophosphate	46-72	5'-nucleotidase ecto	Homo sapiens	107-127
18404475-3	2006	The formation of extracellular adenosine from adenosine 5"-monophosphate is accomplished primarily through ecto-5"-nucleotidase (CD73), a glycosyl phosphatidylinositol-linked membrane protein found on the surface of a variety of cell types.	adenosine 5"-monophosphate	46-72	5'-nucleotidase ecto	Homo sapiens	129-133
16644754-5	2006	R-phycoerythrin-conjugated mouse antihuman monoclonal antibody to human CD73 was used for immunophenotyping.	r-phycoerythrin	0-15	5'-nucleotidase ecto	Homo sapiens	72-76
16807468-11	2006	Also, 5"-nucleotidase opposes the action of nucleoside kinases by catalysing the conversion of nucleotides back to nucleosides.	Nucleosides	115-126	5'-nucleotidase ecto	Homo sapiens	6-21
16644754-9	2006	However, preexposure of SKOV-3 cells to dipyridamole, an equilibrative nucleoside transporter inhibitor; APCP, a CD73 (ecto-5"-nucleotidase) inhibitor; or cold adenosine significantly inhibited cellular uptake of (3)H-AMP.	Dipyridamole	40-52	5'-nucleotidase ecto	Homo sapiens	119-139
16644754-9	2006	However, preexposure of SKOV-3 cells to dipyridamole, an equilibrative nucleoside transporter inhibitor; APCP, a CD73 (ecto-5"-nucleotidase) inhibitor; or cold adenosine significantly inhibited cellular uptake of (3)H-AMP.	Adenosine	160-169	5'-nucleotidase ecto	Homo sapiens	119-139
16644754-17	2006	The mechanism of intracellular uptake depends predominantly on equilibrative nucleoside transporters after conversion of AMP to adenosine by CD73 in SKOV-3, SCC-15, and U251 cells.	Adenosine Monophosphate	121-124	5'-nucleotidase ecto	Homo sapiens	141-145
16644754-17	2006	The mechanism of intracellular uptake depends predominantly on equilibrative nucleoside transporters after conversion of AMP to adenosine by CD73 in SKOV-3, SCC-15, and U251 cells.	Adenosine	128-137	5'-nucleotidase ecto	Homo sapiens	141-145
16735966-0	2006	Lymphocyte ecto-5"-nucleotidase in obese type 2 diabetic patients treated with gliclazide.	Gliclazide	79-89	5'-nucleotidase ecto	Homo sapiens	11-31
16735966-5	2006	RESULTS: 5"-nucleotidase activity in diabetic patients before treatment with gliclazide was 1.61 +/- 0.16 nmol/min/10(6) lymphocytes, and was significantly (P &lt; 0.01) increased compared with the level in healthy controls.	Gliclazide	77-87	5'-nucleotidase ecto	Homo sapiens	9-24
16735966-1	2006	OBJECTIVE: Lymphocyte 5"-nucleotidase is sensitive to superoxide anion, and is an indicator of oxidative stress in humans.	Superoxides	54-70	5'-nucleotidase ecto	Homo sapiens	22-37
16735966-6	2006	After three months of gliclazide treatment, ecto-5"-nucleotidase activity fell significantly by 47.39% and 36% in unstimulated Con A- and PMA-stimulated lymphocytes, respectively.	Gliclazide	22-32	5'-nucleotidase ecto	Homo sapiens	44-64
16735966-10	2006	CONCLUSION: These results show that gliclazide treatment inhibits the activity of lymphocyte ecto-5"-nucleotidase and presumably de-creases the concentration of adenosine at the cell surface.	Gliclazide	36-46	5'-nucleotidase ecto	Homo sapiens	93-113
16735966-2	2006	The aim of this study was to assess the effect of the sulfonylurea drugs gliclazide and glibenclamide on lymphocyte ecto-5"-nucleotidase of type 2 diabetic patients.	Gliclazide	73-83	5'-nucleotidase ecto	Homo sapiens	116-136
16735966-2	2006	The aim of this study was to assess the effect of the sulfonylurea drugs gliclazide and glibenclamide on lymphocyte ecto-5"-nucleotidase of type 2 diabetic patients.	Glyburide	88-101	5'-nucleotidase ecto	Homo sapiens	116-136
16418778-8	2006	Ecto-5"-nucleotidase (CD73) expression and activity was determined by RT-PCR, immunocytochemistry, and the cleavage of etheno-AMP to ethenoadenosine.	etheno-AMP	119-129	5'-nucleotidase ecto	Homo sapiens	0-20
16497986-4	2006	HUVEC express NTPDases, as well as 5"-nucleotidase; hence, nucleotides can be metabolized to adenosine.	Adenosine	93-102	5'-nucleotidase ecto	Homo sapiens	35-50
16418778-8	2006	Ecto-5"-nucleotidase (CD73) expression and activity was determined by RT-PCR, immunocytochemistry, and the cleavage of etheno-AMP to ethenoadenosine.	etheno-AMP	119-129	5'-nucleotidase ecto	Homo sapiens	22-26
16770441-6	2006	The adenosine-producing system in vertebrates involves a cascade dephosphorylating ATP and ending with 5"-nucleotidase (EC 3.1.3.5) localized either on the membrane or inside the cell.	Adenosine	4-13	5'-nucleotidase ecto	Homo sapiens	103-118
16418778-8	2006	Ecto-5"-nucleotidase (CD73) expression and activity was determined by RT-PCR, immunocytochemistry, and the cleavage of etheno-AMP to ethenoadenosine.	ethenoadenosine	133-148	5'-nucleotidase ecto	Homo sapiens	0-20
16418778-8	2006	Ecto-5"-nucleotidase (CD73) expression and activity was determined by RT-PCR, immunocytochemistry, and the cleavage of etheno-AMP to ethenoadenosine.	ethenoadenosine	133-148	5'-nucleotidase ecto	Homo sapiens	22-26
16770441-8	2006	The role of AMP-selective 5"-nucleotidase (cN-I) in the heart, skeletal muscle and brain is highlighted.	Adenosine Monophosphate	12-15	5'-nucleotidase ecto	Homo sapiens	26-41
15990089-0	2005	Role of 5"-nucleotidase in thiopurine metabolism: enzyme kinetic profile and association with thio-GMP levels in patients with acute lymphoblastic leukemia during 6-mercaptopurine treatment.	2-mercaptopyrazine	27-37	5'-nucleotidase ecto	Homo sapiens	8-23
16426349-1	2006	BACKGROUND: Pentoxifylline (Ptx) decreases necessity of cell energy and inflammatory reactions via inhibition of 5"-nucleotidase (5"-NT).	Pentoxifylline	12-26	5'-nucleotidase ecto	Homo sapiens	113-128
16426349-1	2006	BACKGROUND: Pentoxifylline (Ptx) decreases necessity of cell energy and inflammatory reactions via inhibition of 5"-nucleotidase (5"-NT).	Pentoxifylline	28-31	5'-nucleotidase ecto	Homo sapiens	113-128
17065104-9	2006	AICA riboside, which can be generated from the ribotide (an intermediate of the purine de novo synthesis) by the action of the ubiquitous cytosolic 5"-nucleotidase (cN-II), may accumulate in those individuals in which an inborn error of purine metabolism causes both a building up of intermediates and/or an increase of the rate of de novo synthesis, and/or an overexpression of cN-II.	acadesine	0-13	5'-nucleotidase ecto	Homo sapiens	148-163
17065104-9	2006	AICA riboside, which can be generated from the ribotide (an intermediate of the purine de novo synthesis) by the action of the ubiquitous cytosolic 5"-nucleotidase (cN-II), may accumulate in those individuals in which an inborn error of purine metabolism causes both a building up of intermediates and/or an increase of the rate of de novo synthesis, and/or an overexpression of cN-II.	ribotide	47-55	5'-nucleotidase ecto	Homo sapiens	148-163
17065104-9	2006	AICA riboside, which can be generated from the ribotide (an intermediate of the purine de novo synthesis) by the action of the ubiquitous cytosolic 5"-nucleotidase (cN-II), may accumulate in those individuals in which an inborn error of purine metabolism causes both a building up of intermediates and/or an increase of the rate of de novo synthesis, and/or an overexpression of cN-II.	purine	80-86	5'-nucleotidase ecto	Homo sapiens	148-163
16799190-5	2006	ATP and AMP are metabolized by endothelial cell-surface enzymes, the ecto-apyrase (CD39, metabolizes ATP to AMP) and the 5"-ecto-nucleotidase (CD73, metabolizes AMP to adenosine).	Adenosine Triphosphate	0-3	5'-nucleotidase ecto	Homo sapiens	143-147
16799190-5	2006	ATP and AMP are metabolized by endothelial cell-surface enzymes, the ecto-apyrase (CD39, metabolizes ATP to AMP) and the 5"-ecto-nucleotidase (CD73, metabolizes AMP to adenosine).	Adenosine Monophosphate	8-11	5'-nucleotidase ecto	Homo sapiens	143-147
16799190-5	2006	ATP and AMP are metabolized by endothelial cell-surface enzymes, the ecto-apyrase (CD39, metabolizes ATP to AMP) and the 5"-ecto-nucleotidase (CD73, metabolizes AMP to adenosine).	Adenosine	168-177	5'-nucleotidase ecto	Homo sapiens	143-147
15990089-0	2005	Role of 5"-nucleotidase in thiopurine metabolism: enzyme kinetic profile and association with thio-GMP levels in patients with acute lymphoblastic leukemia during 6-mercaptopurine treatment.	thio-gmp	94-102	5'-nucleotidase ecto	Homo sapiens	8-23
15990089-0	2005	Role of 5"-nucleotidase in thiopurine metabolism: enzyme kinetic profile and association with thio-GMP levels in patients with acute lymphoblastic leukemia during 6-mercaptopurine treatment.	Mercaptopurine	163-179	5'-nucleotidase ecto	Homo sapiens	8-23
15990089-3	2005	The 6-thiopurine mononucleotides 6-thio-IMP (thio-IMP), 6-thio-GMP (thio-GMP) and methylthio-IMP can be catabolized by purine 5"-nucleotidase.	6-thiopurine mononucleotides	4-32	5'-nucleotidase ecto	Homo sapiens	126-141
15990089-3	2005	The 6-thiopurine mononucleotides 6-thio-IMP (thio-IMP), 6-thio-GMP (thio-GMP) and methylthio-IMP can be catabolized by purine 5"-nucleotidase.	thioinosinic acid	33-43	5'-nucleotidase ecto	Homo sapiens	126-141
15990089-3	2005	The 6-thiopurine mononucleotides 6-thio-IMP (thio-IMP), 6-thio-GMP (thio-GMP) and methylthio-IMP can be catabolized by purine 5"-nucleotidase.	Thioinosinic acid	35-43	5'-nucleotidase ecto	Homo sapiens	126-141
15990089-3	2005	The 6-thiopurine mononucleotides 6-thio-IMP (thio-IMP), 6-thio-GMP (thio-GMP) and methylthio-IMP can be catabolized by purine 5"-nucleotidase.	6-thioguanylic acid	56-66	5'-nucleotidase ecto	Homo sapiens	126-141
15990089-3	2005	The 6-thiopurine mononucleotides 6-thio-IMP (thio-IMP), 6-thio-GMP (thio-GMP) and methylthio-IMP can be catabolized by purine 5"-nucleotidase.	thio-gmp	58-66	5'-nucleotidase ecto	Homo sapiens	126-141
15990089-3	2005	The 6-thiopurine mononucleotides 6-thio-IMP (thio-IMP), 6-thio-GMP (thio-GMP) and methylthio-IMP can be catabolized by purine 5"-nucleotidase.	methylthio-imp	82-96	5'-nucleotidase ecto	Homo sapiens	126-141
15863835-6	2005	Ceramide-induced cholesterol depletion increased the association of 5"-nucleotidase and ATP synthase beta-subunit with the CEMs but had a minimal effect on changing the abundance of other lipid raft proteins, such as flotillin-1 and G-proteins.	Ceramides	0-8	5'-nucleotidase ecto	Homo sapiens	68-83
16052215-5	2005	Moreover, fluvastatin administration significantly increases the expression of the deoxycytidine kinase, the enzyme required for the activation of gemcitabine, and simultaneously reduces the 5"-nucleotidase, responsible for deactivation of gemcitabine, suggesting a possible additional role of these enzymes in the enhanced cytotoxic activity of gemcitabine.	Fluvastatin	10-21	5'-nucleotidase ecto	Homo sapiens	191-206
16052215-5	2005	Moreover, fluvastatin administration significantly increases the expression of the deoxycytidine kinase, the enzyme required for the activation of gemcitabine, and simultaneously reduces the 5"-nucleotidase, responsible for deactivation of gemcitabine, suggesting a possible additional role of these enzymes in the enhanced cytotoxic activity of gemcitabine.	gemcitabine	240-251	5'-nucleotidase ecto	Homo sapiens	191-206
16052215-5	2005	Moreover, fluvastatin administration significantly increases the expression of the deoxycytidine kinase, the enzyme required for the activation of gemcitabine, and simultaneously reduces the 5"-nucleotidase, responsible for deactivation of gemcitabine, suggesting a possible additional role of these enzymes in the enhanced cytotoxic activity of gemcitabine.	gemcitabine	240-251	5'-nucleotidase ecto	Homo sapiens	191-206
16014444-6	2005	The following feedback control hypothesis is proposed: AMP is dephosphorylated by ecto-5"-nucleotidase, producing adenosine under hypoxic conditions in the extracellular space adjacent to a parenchymal cell (e.g., cardiomyocyte, skeletal muscle fiber, hepatocyte, etc.).	Adenosine Monophosphate	55-58	5'-nucleotidase ecto	Homo sapiens	82-102
16014444-6	2005	The following feedback control hypothesis is proposed: AMP is dephosphorylated by ecto-5"-nucleotidase, producing adenosine under hypoxic conditions in the extracellular space adjacent to a parenchymal cell (e.g., cardiomyocyte, skeletal muscle fiber, hepatocyte, etc.).	Adenosine	114-123	5'-nucleotidase ecto	Homo sapiens	82-102
16200394-0	2005	Modulation of ecto-5"-nucleotidase by phospholipids in human umbilical vein endothelial cells (HUVEC).	Phospholipids	38-51	5'-nucleotidase ecto	Homo sapiens	14-34
16200394-1	2005	Ecto-5"-nucleotidase, the major enzyme controlling extracellular adenosine production, can be activated by phospholipids, e.g. lysophosphatidylcholine (LPC).	Adenosine	65-74	5'-nucleotidase ecto	Homo sapiens	0-20
16200394-1	2005	Ecto-5"-nucleotidase, the major enzyme controlling extracellular adenosine production, can be activated by phospholipids, e.g. lysophosphatidylcholine (LPC).	Phospholipids	107-120	5'-nucleotidase ecto	Homo sapiens	0-20
16200394-1	2005	Ecto-5"-nucleotidase, the major enzyme controlling extracellular adenosine production, can be activated by phospholipids, e.g. lysophosphatidylcholine (LPC).	Lysophosphatidylcholines	127-150	5'-nucleotidase ecto	Homo sapiens	0-20
16200394-1	2005	Ecto-5"-nucleotidase, the major enzyme controlling extracellular adenosine production, can be activated by phospholipids, e.g. lysophosphatidylcholine (LPC).	Lysophosphatidylcholines	152-155	5'-nucleotidase ecto	Homo sapiens	0-20
16200394-2	2005	This study examined the structural requirements of phospholipids to evoke this enzyme activation and figured out two new activators of ecto-5"-nucleotidase: platelet activating factor (PAF) and sphingosylphosphorylcholine (SPC).	Phospholipids	51-64	5'-nucleotidase ecto	Homo sapiens	135-155
16200394-2	2005	This study examined the structural requirements of phospholipids to evoke this enzyme activation and figured out two new activators of ecto-5"-nucleotidase: platelet activating factor (PAF) and sphingosylphosphorylcholine (SPC).	sphingosine phosphorylcholine	194-221	5'-nucleotidase ecto	Homo sapiens	135-155
16200394-2	2005	This study examined the structural requirements of phospholipids to evoke this enzyme activation and figured out two new activators of ecto-5"-nucleotidase: platelet activating factor (PAF) and sphingosylphosphorylcholine (SPC).	sphingosine phosphorylcholine	223-226	5'-nucleotidase ecto	Homo sapiens	135-155
16200394-6	2005	Out of these ten structurally related phospholipids only lysophosphatidylcholine, sphingosylphosphatidylcholine and platelet activating factor dose-dependently increased the activity of ecto-5"-nucleotidase.	Phospholipids	38-51	5'-nucleotidase ecto	Homo sapiens	186-206
16200394-6	2005	Out of these ten structurally related phospholipids only lysophosphatidylcholine, sphingosylphosphatidylcholine and platelet activating factor dose-dependently increased the activity of ecto-5"-nucleotidase.	Lysophosphatidylcholines	57-80	5'-nucleotidase ecto	Homo sapiens	186-206
16200394-6	2005	Out of these ten structurally related phospholipids only lysophosphatidylcholine, sphingosylphosphatidylcholine and platelet activating factor dose-dependently increased the activity of ecto-5"-nucleotidase.	sphingosylphosphatidylcholine	82-111	5'-nucleotidase ecto	Homo sapiens	186-206
16200394-8	2005	Thus, using information on the known molecular structures of tested phospholipids, a phosphatidylcholine residue in alpha-position and a short chain length fatty acid esterified in beta-position seem essential for activation of ecto-5"-nucleotidase by glycerophospholipids.	Phospholipids	68-81	5'-nucleotidase ecto	Homo sapiens	228-248
16200394-8	2005	Thus, using information on the known molecular structures of tested phospholipids, a phosphatidylcholine residue in alpha-position and a short chain length fatty acid esterified in beta-position seem essential for activation of ecto-5"-nucleotidase by glycerophospholipids.	Phosphatidylcholines	85-104	5'-nucleotidase ecto	Homo sapiens	228-248
16200394-8	2005	Thus, using information on the known molecular structures of tested phospholipids, a phosphatidylcholine residue in alpha-position and a short chain length fatty acid esterified in beta-position seem essential for activation of ecto-5"-nucleotidase by glycerophospholipids.	Fatty Acids	156-166	5'-nucleotidase ecto	Homo sapiens	228-248
16200394-8	2005	Thus, using information on the known molecular structures of tested phospholipids, a phosphatidylcholine residue in alpha-position and a short chain length fatty acid esterified in beta-position seem essential for activation of ecto-5"-nucleotidase by glycerophospholipids.	Glycerophospholipids	252-272	5'-nucleotidase ecto	Homo sapiens	228-248
15863835-6	2005	Ceramide-induced cholesterol depletion increased the association of 5"-nucleotidase and ATP synthase beta-subunit with the CEMs but had a minimal effect on changing the abundance of other lipid raft proteins, such as flotillin-1 and G-proteins.	Cholesterol	17-28	5'-nucleotidase ecto	Homo sapiens	68-83
15955461-1	2005	The endothelial cell surface expression of ecto-5"-nucleotidase (E5"N, CD73) is thought to be essential for the extracellular formation of cytoprotective, anti-thrombotic and immunosuppressive adenosine.	Adenosine	193-202	5'-nucleotidase ecto	Homo sapiens	43-63
16028070-2	2005	These extracellular nucleotides are rapidly converted to adenosine by ectonucleotidases, mainly ectonucleoside triphosphate diphosphohydrolase1 (NTPDase1/CD39) and CD73.	Adenosine	57-66	5'-nucleotidase ecto	Homo sapiens	164-168
15955461-1	2005	The endothelial cell surface expression of ecto-5"-nucleotidase (E5"N, CD73) is thought to be essential for the extracellular formation of cytoprotective, anti-thrombotic and immunosuppressive adenosine.	Adenosine	193-202	5'-nucleotidase ecto	Homo sapiens	71-75
15888028-0	2005	Expression of human ecto-5"-nucleotidase in pig endothelium increases adenosine production and protects from NK cell-mediated lysis.	Adenosine	70-79	5'-nucleotidase ecto	Homo sapiens	20-40
15632039-9	2005	Experiments were performed under baseline conditions and in the presence of thymidine (competitive substrate) or fludarabine (in vitro inhibitor of 5"-nucleotidase).	fludarabine	113-124	5'-nucleotidase ecto	Homo sapiens	148-163
16566130-0	2005	[Effect of nitric oxide on 5"-nucleotidase activity of the membrane rafts in the smooth muscle cells].	Nitric Oxide	11-23	5'-nucleotidase ecto	Homo sapiens	27-42
16566130-1	2005	We investigated the effect of nitric oxide on the catalytic activity of 5"-nucleotidase associated with insoluble membrane domains (rafts) of pig stomach smooth muscle.	Nitric Oxide	30-42	5'-nucleotidase ecto	Homo sapiens	72-87
16566130-2	2005	The low concentration (0.1-10.0 microM) of nitric oxide donor sodium nitroprusside led to essential increase of catalytic activity of 5"-nucleotidase.	Nitric Oxide	43-55	5'-nucleotidase ecto	Homo sapiens	134-149
16566130-2	2005	The low concentration (0.1-10.0 microM) of nitric oxide donor sodium nitroprusside led to essential increase of catalytic activity of 5"-nucleotidase.	Nitroprusside	62-82	5'-nucleotidase ecto	Homo sapiens	134-149
16566130-5	2005	The catalytic activity of 5"-nucleotidase was also increased at presence of NaNO2, but only at high concentration (10 mM).	Sodium Nitrite	76-81	5'-nucleotidase ecto	Homo sapiens	26-41
16566130-7	2005	Our data shows that nitric oxide changes the AMP-ase activity of 5"-nucleotidase, that is thought to be due to direct effect of this substance on protein.	Nitric Oxide	20-32	5'-nucleotidase ecto	Homo sapiens	65-80
15699053-0	2005	Evidence for the involvement of cytosolic 5"-nucleotidase (cN-II) in the synthesis of guanine nucleotides from xanthosine.	Guanine Nucleotides	86-105	5'-nucleotidase ecto	Homo sapiens	42-57
15699053-0	2005	Evidence for the involvement of cytosolic 5"-nucleotidase (cN-II) in the synthesis of guanine nucleotides from xanthosine.	xanthosine	111-121	5'-nucleotidase ecto	Homo sapiens	42-57
15699053-2	2005	In rat brain extracts and in intact LoVo cells, xanthosine is salvaged to XMP via the phosphotransferase activity of cytosolic 5"-nucleotidase.	xanthosine	48-58	5'-nucleotidase ecto	Homo sapiens	127-142
15699053-2	2005	In rat brain extracts and in intact LoVo cells, xanthosine is salvaged to XMP via the phosphotransferase activity of cytosolic 5"-nucleotidase.	xanthosine monophosphate	74-77	5'-nucleotidase ecto	Homo sapiens	127-142
15699053-6	2005	Thus, phosphorylation of xanthosine by cytosolic 5"-nucleotidase circumvents the activity of IMP dehydrogenase, a rate-limiting enzyme, catalyzing the NAD(+)-dependent conversion of IMP to XMP at the branch point of de novo nucleotide synthesis, thus leading to the generation of guanine nucleotides.	xanthosine	25-35	5'-nucleotidase ecto	Homo sapiens	49-64
15699053-6	2005	Thus, phosphorylation of xanthosine by cytosolic 5"-nucleotidase circumvents the activity of IMP dehydrogenase, a rate-limiting enzyme, catalyzing the NAD(+)-dependent conversion of IMP to XMP at the branch point of de novo nucleotide synthesis, thus leading to the generation of guanine nucleotides.	NAD	151-157	5'-nucleotidase ecto	Homo sapiens	49-64
15699053-6	2005	Thus, phosphorylation of xanthosine by cytosolic 5"-nucleotidase circumvents the activity of IMP dehydrogenase, a rate-limiting enzyme, catalyzing the NAD(+)-dependent conversion of IMP to XMP at the branch point of de novo nucleotide synthesis, thus leading to the generation of guanine nucleotides.	Inosine Monophosphate	93-96	5'-nucleotidase ecto	Homo sapiens	49-64
15699053-6	2005	Thus, phosphorylation of xanthosine by cytosolic 5"-nucleotidase circumvents the activity of IMP dehydrogenase, a rate-limiting enzyme, catalyzing the NAD(+)-dependent conversion of IMP to XMP at the branch point of de novo nucleotide synthesis, thus leading to the generation of guanine nucleotides.	xanthosine monophosphate	189-192	5'-nucleotidase ecto	Homo sapiens	49-64
15699053-6	2005	Thus, phosphorylation of xanthosine by cytosolic 5"-nucleotidase circumvents the activity of IMP dehydrogenase, a rate-limiting enzyme, catalyzing the NAD(+)-dependent conversion of IMP to XMP at the branch point of de novo nucleotide synthesis, thus leading to the generation of guanine nucleotides.	Guanine Nucleotides	280-299	5'-nucleotidase ecto	Homo sapiens	49-64
15893296-7	2005	Inhibition of the enzymatic conversion of ATP to adenosine using a combination of a potent ecto-5"-nucleotidase inhibitor, alpha,beta-methylene adenosine 5"-diphosphate (AMP-CP), and a competitive substrate for ecto-5"-nucleotidase (guanosine monophosphate, GMP) did not affect basal VP release.	Adenosine Triphosphate	42-45	5'-nucleotidase ecto	Homo sapiens	91-111
15893296-7	2005	Inhibition of the enzymatic conversion of ATP to adenosine using a combination of a potent ecto-5"-nucleotidase inhibitor, alpha,beta-methylene adenosine 5"-diphosphate (AMP-CP), and a competitive substrate for ecto-5"-nucleotidase (guanosine monophosphate, GMP) did not affect basal VP release.	Adenosine Triphosphate	42-45	5'-nucleotidase ecto	Homo sapiens	211-231
15893296-7	2005	Inhibition of the enzymatic conversion of ATP to adenosine using a combination of a potent ecto-5"-nucleotidase inhibitor, alpha,beta-methylene adenosine 5"-diphosphate (AMP-CP), and a competitive substrate for ecto-5"-nucleotidase (guanosine monophosphate, GMP) did not affect basal VP release.	Adenosine	49-58	5'-nucleotidase ecto	Homo sapiens	91-111
15893296-7	2005	Inhibition of the enzymatic conversion of ATP to adenosine using a combination of a potent ecto-5"-nucleotidase inhibitor, alpha,beta-methylene adenosine 5"-diphosphate (AMP-CP), and a competitive substrate for ecto-5"-nucleotidase (guanosine monophosphate, GMP) did not affect basal VP release.	Adenosine	49-58	5'-nucleotidase ecto	Homo sapiens	211-231
15893296-7	2005	Inhibition of the enzymatic conversion of ATP to adenosine using a combination of a potent ecto-5"-nucleotidase inhibitor, alpha,beta-methylene adenosine 5"-diphosphate (AMP-CP), and a competitive substrate for ecto-5"-nucleotidase (guanosine monophosphate, GMP) did not affect basal VP release.	alpha,beta-methyleneadenosine 5'-diphosphate	170-176	5'-nucleotidase ecto	Homo sapiens	211-231
18404504-9	2005	Various NTPDases may also distinctly affect formation of extracellular adenosine and therefore adenosine receptor-mediated responses, since they generate different amounts of the substrate (AMP) and inhibitor (ADP) of ecto-5"-nucleotidase, the rate limiting enzyme in the production of adenosine.	Adenosine	71-80	5'-nucleotidase ecto	Homo sapiens	218-238
18404504-9	2005	Various NTPDases may also distinctly affect formation of extracellular adenosine and therefore adenosine receptor-mediated responses, since they generate different amounts of the substrate (AMP) and inhibitor (ADP) of ecto-5"-nucleotidase, the rate limiting enzyme in the production of adenosine.	Adenosine Monophosphate	190-193	5'-nucleotidase ecto	Homo sapiens	218-238
18404504-9	2005	Various NTPDases may also distinctly affect formation of extracellular adenosine and therefore adenosine receptor-mediated responses, since they generate different amounts of the substrate (AMP) and inhibitor (ADP) of ecto-5"-nucleotidase, the rate limiting enzyme in the production of adenosine.	Adenosine Diphosphate	210-213	5'-nucleotidase ecto	Homo sapiens	218-238
18404504-9	2005	Various NTPDases may also distinctly affect formation of extracellular adenosine and therefore adenosine receptor-mediated responses, since they generate different amounts of the substrate (AMP) and inhibitor (ADP) of ecto-5"-nucleotidase, the rate limiting enzyme in the production of adenosine.	Adenosine	95-104	5'-nucleotidase ecto	Homo sapiens	218-238
15319286-4	2004	Intravascular nucleotides released by inflammatory cells undergo phosphohydrolysis via hypoxia-induced CD39 ectoapyrase (CD39 converts adenosine triphosphate/adenosine diphosphate [ATP/ADP] to adenosine monophosphate [AMP]) and CD73 ecto-5"-nucleotidase (CD73 converts AMP to adenosine).	Adenosine Diphosphate	185-188	5'-nucleotidase ecto	Homo sapiens	228-232
16021917-0	2005	Expression of human ecto 5" nucleotidase in pig endothelial cells and its implication for adenosine production and xenotransplantation.	Adenosine	90-99	5'-nucleotidase ecto	Homo sapiens	20-40
15319286-4	2004	Intravascular nucleotides released by inflammatory cells undergo phosphohydrolysis via hypoxia-induced CD39 ectoapyrase (CD39 converts adenosine triphosphate/adenosine diphosphate [ATP/ADP] to adenosine monophosphate [AMP]) and CD73 ecto-5"-nucleotidase (CD73 converts AMP to adenosine).	Adenosine Diphosphate	185-188	5'-nucleotidase ecto	Homo sapiens	255-259
15319286-4	2004	Intravascular nucleotides released by inflammatory cells undergo phosphohydrolysis via hypoxia-induced CD39 ectoapyrase (CD39 converts adenosine triphosphate/adenosine diphosphate [ATP/ADP] to adenosine monophosphate [AMP]) and CD73 ecto-5"-nucleotidase (CD73 converts AMP to adenosine).	Adenosine Monophosphate	269-272	5'-nucleotidase ecto	Homo sapiens	255-259
15319286-4	2004	Intravascular nucleotides released by inflammatory cells undergo phosphohydrolysis via hypoxia-induced CD39 ectoapyrase (CD39 converts adenosine triphosphate/adenosine diphosphate [ATP/ADP] to adenosine monophosphate [AMP]) and CD73 ecto-5"-nucleotidase (CD73 converts AMP to adenosine).	Adenosine	135-144	5'-nucleotidase ecto	Homo sapiens	228-232
15319286-4	2004	Intravascular nucleotides released by inflammatory cells undergo phosphohydrolysis via hypoxia-induced CD39 ectoapyrase (CD39 converts adenosine triphosphate/adenosine diphosphate [ATP/ADP] to adenosine monophosphate [AMP]) and CD73 ecto-5"-nucleotidase (CD73 converts AMP to adenosine).	Adenosine Monophosphate	193-216	5'-nucleotidase ecto	Homo sapiens	228-232
15319286-4	2004	Intravascular nucleotides released by inflammatory cells undergo phosphohydrolysis via hypoxia-induced CD39 ectoapyrase (CD39 converts adenosine triphosphate/adenosine diphosphate [ATP/ADP] to adenosine monophosphate [AMP]) and CD73 ecto-5"-nucleotidase (CD73 converts AMP to adenosine).	Adenosine	135-144	5'-nucleotidase ecto	Homo sapiens	255-259
15319286-5	2004	Extensions of our in vitro findings using cd39- and cd73-null animals revealed that extracellular adenosine produced through adenine nucleotide metabolism during hypoxia is a potent anti-inflammatory signal for PMNs in vivo.	Adenosine	98-107	5'-nucleotidase ecto	Homo sapiens	52-56
15319286-4	2004	Intravascular nucleotides released by inflammatory cells undergo phosphohydrolysis via hypoxia-induced CD39 ectoapyrase (CD39 converts adenosine triphosphate/adenosine diphosphate [ATP/ADP] to adenosine monophosphate [AMP]) and CD73 ecto-5"-nucleotidase (CD73 converts AMP to adenosine).	Adenosine Monophosphate	193-216	5'-nucleotidase ecto	Homo sapiens	255-259
15319286-5	2004	Extensions of our in vitro findings using cd39- and cd73-null animals revealed that extracellular adenosine produced through adenine nucleotide metabolism during hypoxia is a potent anti-inflammatory signal for PMNs in vivo.	Adenine Nucleotides	125-143	5'-nucleotidase ecto	Homo sapiens	52-56
15319286-4	2004	Intravascular nucleotides released by inflammatory cells undergo phosphohydrolysis via hypoxia-induced CD39 ectoapyrase (CD39 converts adenosine triphosphate/adenosine diphosphate [ATP/ADP] to adenosine monophosphate [AMP]) and CD73 ecto-5"-nucleotidase (CD73 converts AMP to adenosine).	Adenosine Monophosphate	218-221	5'-nucleotidase ecto	Homo sapiens	228-232
15319286-6	2004	These findings identify CD39 and CD73 as critical control points for endogenous adenosine generation and implicate this pathway as an innate mechanism to attenuate excessive tissue PMN accumulation.	Adenosine	80-89	5'-nucleotidase ecto	Homo sapiens	33-37
15319286-4	2004	Intravascular nucleotides released by inflammatory cells undergo phosphohydrolysis via hypoxia-induced CD39 ectoapyrase (CD39 converts adenosine triphosphate/adenosine diphosphate [ATP/ADP] to adenosine monophosphate [AMP]) and CD73 ecto-5"-nucleotidase (CD73 converts AMP to adenosine).	Adenosine Monophosphate	218-221	5'-nucleotidase ecto	Homo sapiens	255-259
15319286-4	2004	Intravascular nucleotides released by inflammatory cells undergo phosphohydrolysis via hypoxia-induced CD39 ectoapyrase (CD39 converts adenosine triphosphate/adenosine diphosphate [ATP/ADP] to adenosine monophosphate [AMP]) and CD73 ecto-5"-nucleotidase (CD73 converts AMP to adenosine).	Adenosine Monophosphate	269-272	5'-nucleotidase ecto	Homo sapiens	228-232
15450953-10	2004	Our study demonstrated that 5"-nucleotidase, GMP kinase, creatine kinase, and NDP kinase could be responsible for the activation of DXG in vivo.	dioxolane guanosine	132-135	5'-nucleotidase ecto	Homo sapiens	28-43
15240122-5	2004	This is in agreement with the observation that 5"-nucleotidase/deoxycytidine kinase ratio might be an important factor in predicting resistance to NAs.	Nucleosides	147-150	5'-nucleotidase ecto	Homo sapiens	47-62
15202025-1	2004	Pre-treatment with bryostatin 1 (bryo) has been shown to potentiate the efficacy of (2-chloro-2-deoxyadenosine, cladribine, 2-CdA) in B-cell chronic lymphocytic leukemia (B-CLL) by increasing the ratio of deoxycytidine kinase (dCK) to 5"-nucleotidase (5"-NT) activity.	bryostatin 1	19-31	5'-nucleotidase ecto	Homo sapiens	235-250
15202025-1	2004	Pre-treatment with bryostatin 1 (bryo) has been shown to potentiate the efficacy of (2-chloro-2-deoxyadenosine, cladribine, 2-CdA) in B-cell chronic lymphocytic leukemia (B-CLL) by increasing the ratio of deoxycytidine kinase (dCK) to 5"-nucleotidase (5"-NT) activity.	bryostatin 1	19-23	5'-nucleotidase ecto	Homo sapiens	235-250
15148268-5	2004	Carvedilol reduced the infarct size (15.0+/-2.8% versus 40.9+/-4.2% in controls), and this effect was completely reversed by the nonselective adenosine receptor antagonist 8-sulfophenyltheophylline (45.2+/-5.4%) or by an inhibitor of ecto-5"-nucleotidase (44.4+/-3.6%).	Carvedilol	0-10	5'-nucleotidase ecto	Homo sapiens	234-254
15148268-9	2004	In human umbilical vein endothelial cells cultured with or without xanthine and xanthine oxidase, carvedilol caused an increase of ecto-5"-nucleotidase activity.	Xanthine	67-75	5'-nucleotidase ecto	Homo sapiens	131-151
15148268-9	2004	In human umbilical vein endothelial cells cultured with or without xanthine and xanthine oxidase, carvedilol caused an increase of ecto-5"-nucleotidase activity.	Carvedilol	98-108	5'-nucleotidase ecto	Homo sapiens	131-151
14687222-9	2004	The CD73/5"-NT expression was increased upon stimulation with gamma-interferon, but not other stimulants such as tumor necrosis factor-alpha, IL-4, lipopolysaccharide from Porphyromonas gingivalis and Escherichia coli, and fimbriae from P. gingivalis, and this increase was correlated with the enhanced GM-CSF inhibition by 5"-AMP but not adenosine.	Adenosine Monophosphate	324-330	5'-nucleotidase ecto	Homo sapiens	4-8
14734746-8	2004	Overall, these results suggest that IFN-alpha is a relevant in vivo regulator of CD73 in the endothelial-leukocyte microenvironment in infections/inflammations, and thus has a fundamental role in controlling the extent of inflammation via CD73-dependent adenosine production.	Adenosine	254-263	5'-nucleotidase ecto	Homo sapiens	81-85
14734746-8	2004	Overall, these results suggest that IFN-alpha is a relevant in vivo regulator of CD73 in the endothelial-leukocyte microenvironment in infections/inflammations, and thus has a fundamental role in controlling the extent of inflammation via CD73-dependent adenosine production.	Adenosine	254-263	5'-nucleotidase ecto	Homo sapiens	239-243
15044076-8	2004	Intracerebroventricular treatment with 960 nmol GMP prevented 80% of seizures and the 5"-nucleotidase inhibitor alpha-beta-methyleneadenosine 5"-diphosphate (AOPCP), when injected 3 min before, reduced this anticonvulsant effect to 30% protection as well as significantly decreased the conversion of GMP into guanosine measured in the CSF.	Guanosine Monophosphate	48-51	5'-nucleotidase ecto	Homo sapiens	86-101
15044076-8	2004	Intracerebroventricular treatment with 960 nmol GMP prevented 80% of seizures and the 5"-nucleotidase inhibitor alpha-beta-methyleneadenosine 5"-diphosphate (AOPCP), when injected 3 min before, reduced this anticonvulsant effect to 30% protection as well as significantly decreased the conversion of GMP into guanosine measured in the CSF.	alpha,beta-methyleneadenosine 5'-diphosphate	112-156	5'-nucleotidase ecto	Homo sapiens	86-101
15044076-8	2004	Intracerebroventricular treatment with 960 nmol GMP prevented 80% of seizures and the 5"-nucleotidase inhibitor alpha-beta-methyleneadenosine 5"-diphosphate (AOPCP), when injected 3 min before, reduced this anticonvulsant effect to 30% protection as well as significantly decreased the conversion of GMP into guanosine measured in the CSF.	alpha,beta-methyleneadenosine 5'-diphosphate	158-163	5'-nucleotidase ecto	Homo sapiens	86-101
15044076-8	2004	Intracerebroventricular treatment with 960 nmol GMP prevented 80% of seizures and the 5"-nucleotidase inhibitor alpha-beta-methyleneadenosine 5"-diphosphate (AOPCP), when injected 3 min before, reduced this anticonvulsant effect to 30% protection as well as significantly decreased the conversion of GMP into guanosine measured in the CSF.	Guanosine Monophosphate	300-303	5'-nucleotidase ecto	Homo sapiens	86-101
15044076-8	2004	Intracerebroventricular treatment with 960 nmol GMP prevented 80% of seizures and the 5"-nucleotidase inhibitor alpha-beta-methyleneadenosine 5"-diphosphate (AOPCP), when injected 3 min before, reduced this anticonvulsant effect to 30% protection as well as significantly decreased the conversion of GMP into guanosine measured in the CSF.	Guanosine	309-318	5'-nucleotidase ecto	Homo sapiens	86-101
15044076-9	2004	This study shows that the previously reported effect of GMP as an anticonvulsant seems to be related to its ability to generate guanosine through the action of ecto-5"-nucleotidase.	Guanosine Monophosphate	56-59	5'-nucleotidase ecto	Homo sapiens	160-180
15044076-9	2004	This study shows that the previously reported effect of GMP as an anticonvulsant seems to be related to its ability to generate guanosine through the action of ecto-5"-nucleotidase.	Guanosine	128-137	5'-nucleotidase ecto	Homo sapiens	160-180
14687222-9	2004	The CD73/5"-NT expression was increased upon stimulation with gamma-interferon, but not other stimulants such as tumor necrosis factor-alpha, IL-4, lipopolysaccharide from Porphyromonas gingivalis and Escherichia coli, and fimbriae from P. gingivalis, and this increase was correlated with the enhanced GM-CSF inhibition by 5"-AMP but not adenosine.	Adenosine	339-348	5'-nucleotidase ecto	Homo sapiens	4-8
14687222-10	2004	CONCLUSIONS: These findings suggested that CD73/5"-NT on hGF exerts an anti-inflammatory effects in periodontal disease by conversion from 5"-AMP to adenosine.	5"-nt	48-53	5'-nucleotidase ecto	Homo sapiens	43-47
14687222-10	2004	CONCLUSIONS: These findings suggested that CD73/5"-NT on hGF exerts an anti-inflammatory effects in periodontal disease by conversion from 5"-AMP to adenosine.	Adenosine Monophosphate	139-145	5'-nucleotidase ecto	Homo sapiens	43-47
14687222-10	2004	CONCLUSIONS: These findings suggested that CD73/5"-NT on hGF exerts an anti-inflammatory effects in periodontal disease by conversion from 5"-AMP to adenosine.	Adenosine	149-158	5'-nucleotidase ecto	Homo sapiens	43-47
14760094-1	2004	PURPOSE: The purpose is to understand the expression of ecto-5"-nucleotidase (eN), an adenosine producing enzyme with potential roles in angiogenesis, growth, and immunosuppression, in estrogen receptor (ER)-negative and -positive breast cancer.	Adenosine	86-95	5'-nucleotidase ecto	Homo sapiens	56-76
14734746-0	2004	IFN-alpha induced adenosine production on the endothelium: a mechanism mediated by CD73 (ecto-5"-nucleotidase) up-regulation.	Adenosine	18-27	5'-nucleotidase ecto	Homo sapiens	83-87
14734746-0	2004	IFN-alpha induced adenosine production on the endothelium: a mechanism mediated by CD73 (ecto-5"-nucleotidase) up-regulation.	Adenosine	18-27	5'-nucleotidase ecto	Homo sapiens	89-109
14734746-1	2004	CD73 (ecto-5"-nucleotidase; EC 3.1.3.5) participates in lymphocyte binding to endothelial cells and converts extracellular AMP into a potent anti-inflammatory substance adenosine.	Adenosine Monophosphate	123-126	5'-nucleotidase ecto	Homo sapiens	0-4
14734746-1	2004	CD73 (ecto-5"-nucleotidase; EC 3.1.3.5) participates in lymphocyte binding to endothelial cells and converts extracellular AMP into a potent anti-inflammatory substance adenosine.	Adenosine Monophosphate	123-126	5'-nucleotidase ecto	Homo sapiens	6-26
14734746-1	2004	CD73 (ecto-5"-nucleotidase; EC 3.1.3.5) participates in lymphocyte binding to endothelial cells and converts extracellular AMP into a potent anti-inflammatory substance adenosine.	Adenosine	169-178	5'-nucleotidase ecto	Homo sapiens	0-4
14734746-1	2004	CD73 (ecto-5"-nucleotidase; EC 3.1.3.5) participates in lymphocyte binding to endothelial cells and converts extracellular AMP into a potent anti-inflammatory substance adenosine.	Adenosine	169-178	5'-nucleotidase ecto	Homo sapiens	6-26
14734746-4	2004	Moreover, CD73-mediated production of adenosine is increased after IFN-alpha treatment on endothelial cells, resulting in a decrease in the permeability of these cells.	Adenosine	38-47	5'-nucleotidase ecto	Homo sapiens	10-14
14978343-4	2004	Ecto-5"-nucleotidase (E-5"-NT) has been considered to play a principal role in conversion of AMP to adenosine.	Adenosine Monophosphate	93-96	5'-nucleotidase ecto	Homo sapiens	0-20
14978343-4	2004	Ecto-5"-nucleotidase (E-5"-NT) has been considered to play a principal role in conversion of AMP to adenosine.	Adenosine Monophosphate	93-96	5'-nucleotidase ecto	Homo sapiens	22-29
14978343-4	2004	Ecto-5"-nucleotidase (E-5"-NT) has been considered to play a principal role in conversion of AMP to adenosine.	Adenosine	100-109	5'-nucleotidase ecto	Homo sapiens	0-20
14978343-4	2004	Ecto-5"-nucleotidase (E-5"-NT) has been considered to play a principal role in conversion of AMP to adenosine.	Adenosine	100-109	5'-nucleotidase ecto	Homo sapiens	22-29
14760094-1	2004	PURPOSE: The purpose is to understand the expression of ecto-5"-nucleotidase (eN), an adenosine producing enzyme with potential roles in angiogenesis, growth, and immunosuppression, in estrogen receptor (ER)-negative and -positive breast cancer.	Adenosine	86-95	5'-nucleotidase ecto	Homo sapiens	78-80
14760094-5	2004	Estradiol and antiestrogen treatments confirm that eN mRNA and protein expression and adenosine generation are negatively regulated through the ER.	Estradiol	0-9	5'-nucleotidase ecto	Homo sapiens	51-53
14760094-6	2004	Endogenous expression of eN in ER- cells transfected with ERalpha and phorbol ester-induced eN expression in ER+ cells was strongly suppressed by estradiol, suggesting a dominant function of ER.	Phorbol Esters	70-83	5'-nucleotidase ecto	Homo sapiens	25-27
14760094-6	2004	Endogenous expression of eN in ER- cells transfected with ERalpha and phorbol ester-induced eN expression in ER+ cells was strongly suppressed by estradiol, suggesting a dominant function of ER.	Phorbol Esters	70-83	5'-nucleotidase ecto	Homo sapiens	92-94
14760094-6	2004	Endogenous expression of eN in ER- cells transfected with ERalpha and phorbol ester-induced eN expression in ER+ cells was strongly suppressed by estradiol, suggesting a dominant function of ER.	Estradiol	146-155	5'-nucleotidase ecto	Homo sapiens	25-27
14760094-6	2004	Endogenous expression of eN in ER- cells transfected with ERalpha and phorbol ester-induced eN expression in ER+ cells was strongly suppressed by estradiol, suggesting a dominant function of ER.	Estradiol	146-155	5'-nucleotidase ecto	Homo sapiens	92-94
14760094-9	2004	CONCLUSIONS: Our results show for the first time that eN is negatively regulated by ERalpha in dominant fashion and suggests that eN expression and its generation of adenosine may relate to breast cancer progression.	Adenosine	166-175	5'-nucleotidase ecto	Homo sapiens	54-56
14760094-9	2004	CONCLUSIONS: Our results show for the first time that eN is negatively regulated by ERalpha in dominant fashion and suggests that eN expression and its generation of adenosine may relate to breast cancer progression.	Adenosine	166-175	5'-nucleotidase ecto	Homo sapiens	130-132
14578500-0	2003	Involvement of CD73 (ecto-5"-nucleotidase) in adenosine generation by human gingival fibroblasts.	Adenosine	46-55	5'-nucleotidase ecto	Homo sapiens	15-19
14977414-4	2004	Extracellular cAMP is then converted to adenosine by the serial actions of ecto-phosphodiesterase and ecto-5"-nucleotidase.	Cyclic AMP	14-18	5'-nucleotidase ecto	Homo sapiens	102-122
15299191-4	2004	Adenosine is produced from AMP by the action of 5"-nucleotidase (5"-NT) and is converted back into AMP by adenosine kinase (AK) or into inosine by adenosine deaminase (ADA).	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	48-63
15299191-4	2004	Adenosine is produced from AMP by the action of 5"-nucleotidase (5"-NT) and is converted back into AMP by adenosine kinase (AK) or into inosine by adenosine deaminase (ADA).	Adenosine Monophosphate	27-30	5'-nucleotidase ecto	Homo sapiens	48-63
14609743-6	2003	It was found that mRNA levels of human equilibrative nucleoside transporter-1 nucleoside transporter were higher whereas deoxycytidine kinase and IMP/GMP selective 5"-nucleotidase mRNA levels were lower in CD4(+) cells.	guanosine 5'-monophosphorothioate	150-153	5'-nucleotidase ecto	Homo sapiens	164-179
14560043-2	2003	The extracellular cAMP-adenosine pathway refers to the conversion of cAMP to AMP by ectophosphodiesterase, followed by metabolism of AMP to adenosine by ecto-5"-nucleotidase, with all steps occurring in the extracellular compartment.	Adenosine	23-32	5'-nucleotidase ecto	Homo sapiens	153-173
14560043-2	2003	The extracellular cAMP-adenosine pathway refers to the conversion of cAMP to AMP by ectophosphodiesterase, followed by metabolism of AMP to adenosine by ecto-5"-nucleotidase, with all steps occurring in the extracellular compartment.	Adenosine Monophosphate	19-22	5'-nucleotidase ecto	Homo sapiens	153-173
14560043-2	2003	The extracellular cAMP-adenosine pathway refers to the conversion of cAMP to AMP by ectophosphodiesterase, followed by metabolism of AMP to adenosine by ecto-5"-nucleotidase, with all steps occurring in the extracellular compartment.	Adenosine	140-149	5'-nucleotidase ecto	Homo sapiens	153-173
14578500-0	2003	Involvement of CD73 (ecto-5"-nucleotidase) in adenosine generation by human gingival fibroblasts.	Adenosine	46-55	5'-nucleotidase ecto	Homo sapiens	21-41
14578500-3	2003	In this study, we examined the involvement of CD73 (ecto-5"-nucleotidase) in adenosine generation by HGF.	Adenosine	77-86	5'-nucleotidase ecto	Homo sapiens	46-50
14578500-3	2003	In this study, we examined the involvement of CD73 (ecto-5"-nucleotidase) in adenosine generation by HGF.	Adenosine	77-86	5'-nucleotidase ecto	Homo sapiens	52-72
14578500-5	2003	Adenosine production was observed following the addition of 5"-AMP, the substrate of CD73-associated ecto-5"-nucleotidase.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	85-89
14977414-4	2004	Extracellular cAMP is then converted to adenosine by the serial actions of ecto-phosphodiesterase and ecto-5"-nucleotidase.	Adenosine	40-49	5'-nucleotidase ecto	Homo sapiens	102-122
15500070-1	2003	We studied the effect of four conjugated synthetic derivatives of estrone and ethynylestradiol and bis-beta-chloroethylamine-containing substance on activity of plasma membrane enzymes 5"-nucleotidase and N+-K+-ATPase.	Estrone	66-73	5'-nucleotidase ecto	Homo sapiens	185-200
15500070-1	2003	We studied the effect of four conjugated synthetic derivatives of estrone and ethynylestradiol and bis-beta-chloroethylamine-containing substance on activity of plasma membrane enzymes 5"-nucleotidase and N+-K+-ATPase.	Ethinyl Estradiol	78-94	5'-nucleotidase ecto	Homo sapiens	185-200
15500070-1	2003	We studied the effect of four conjugated synthetic derivatives of estrone and ethynylestradiol and bis-beta-chloroethylamine-containing substance on activity of plasma membrane enzymes 5"-nucleotidase and N+-K+-ATPase.	nornitrogen mustard	99-124	5'-nucleotidase ecto	Homo sapiens	185-200
14560043-2	2003	The extracellular cAMP-adenosine pathway refers to the conversion of cAMP to AMP by ectophosphodiesterase, followed by metabolism of AMP to adenosine by ecto-5"-nucleotidase, with all steps occurring in the extracellular compartment.	Cyclic AMP	18-22	5'-nucleotidase ecto	Homo sapiens	153-173
14578500-5	2003	Adenosine production was observed following the addition of 5"-AMP, the substrate of CD73-associated ecto-5"-nucleotidase.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	101-121
14578500-5	2003	Adenosine production was observed following the addition of 5"-AMP, the substrate of CD73-associated ecto-5"-nucleotidase.	Adenosine Monophosphate	60-66	5'-nucleotidase ecto	Homo sapiens	85-89
14692522-7	2003	5"-Nucleotidase (5"-NT) dephosphorylates cladribine-MP and the accumulation of cladribine-TP depends on the ratio of dCK and 5"-NT in the cells.	cladribine-tp	79-92	5'-nucleotidase ecto	Homo sapiens	0-15
14578500-5	2003	Adenosine production was observed following the addition of 5"-AMP, the substrate of CD73-associated ecto-5"-nucleotidase.	Adenosine Monophosphate	60-66	5'-nucleotidase ecto	Homo sapiens	101-121
14578500-7	2003	The 5"-AMP-induced increase in intracellular cAMP level was inhibited markedly by xanthine amine congener, an adenosine receptor antagonist, and partially by alpha,beta-methylene adenosine 5"-diphosphate, an ecto-5"-nucleotidase inhibitor.	Adenosine Monophosphate	4-10	5'-nucleotidase ecto	Homo sapiens	208-228
14578500-7	2003	The 5"-AMP-induced increase in intracellular cAMP level was inhibited markedly by xanthine amine congener, an adenosine receptor antagonist, and partially by alpha,beta-methylene adenosine 5"-diphosphate, an ecto-5"-nucleotidase inhibitor.	Cyclic AMP	45-49	5'-nucleotidase ecto	Homo sapiens	208-228
14578500-7	2003	The 5"-AMP-induced increase in intracellular cAMP level was inhibited markedly by xanthine amine congener, an adenosine receptor antagonist, and partially by alpha,beta-methylene adenosine 5"-diphosphate, an ecto-5"-nucleotidase inhibitor.	xanthine amine	82-96	5'-nucleotidase ecto	Homo sapiens	208-228
14578500-7	2003	The 5"-AMP-induced increase in intracellular cAMP level was inhibited markedly by xanthine amine congener, an adenosine receptor antagonist, and partially by alpha,beta-methylene adenosine 5"-diphosphate, an ecto-5"-nucleotidase inhibitor.	alpha,beta-methyleneadenosine 5'-diphosphate	158-203	5'-nucleotidase ecto	Homo sapiens	208-228
14578500-8	2003	These results suggest that CD73 on HGF is a critical enzyme responsible for the generation of adenosine, an immunomodulator that activates adenosine receptors.	Adenosine	94-103	5'-nucleotidase ecto	Homo sapiens	27-31
14692522-7	2003	5"-Nucleotidase (5"-NT) dephosphorylates cladribine-MP and the accumulation of cladribine-TP depends on the ratio of dCK and 5"-NT in the cells.	cladribine-mp	41-54	5'-nucleotidase ecto	Homo sapiens	0-15
12707258-0	2003	Adherent leukocytes prevent adenosine formation and impair endothelial barrier function by Ecto-5"-nucleotidase/CD73-dependent mechanism.	Adenosine	28-37	5'-nucleotidase ecto	Homo sapiens	91-111
12707258-4	2003	Upon adhesion, lymphocytes suppress endothelial purine metabolism via (i) inhibition of ecto-5"-nucleotidase/CD73-mediated AMP hydrolysis, (ii) rapid deamination of the remaining adenosine, and (iii) maintenance of the sustained pericellular ATP level through continuous nucleotide release and phosphotransfer reactions.	Adenosine Triphosphate	242-245	5'-nucleotidase ecto	Homo sapiens	109-113
12707258-0	2003	Adherent leukocytes prevent adenosine formation and impair endothelial barrier function by Ecto-5"-nucleotidase/CD73-dependent mechanism.	Adenosine	28-37	5'-nucleotidase ecto	Homo sapiens	112-116
12707258-4	2003	Upon adhesion, lymphocytes suppress endothelial purine metabolism via (i) inhibition of ecto-5"-nucleotidase/CD73-mediated AMP hydrolysis, (ii) rapid deamination of the remaining adenosine, and (iii) maintenance of the sustained pericellular ATP level through continuous nucleotide release and phosphotransfer reactions.	purine	48-54	5'-nucleotidase ecto	Homo sapiens	88-108
12707258-4	2003	Upon adhesion, lymphocytes suppress endothelial purine metabolism via (i) inhibition of ecto-5"-nucleotidase/CD73-mediated AMP hydrolysis, (ii) rapid deamination of the remaining adenosine, and (iii) maintenance of the sustained pericellular ATP level through continuous nucleotide release and phosphotransfer reactions.	purine	48-54	5'-nucleotidase ecto	Homo sapiens	109-113
12707258-4	2003	Upon adhesion, lymphocytes suppress endothelial purine metabolism via (i) inhibition of ecto-5"-nucleotidase/CD73-mediated AMP hydrolysis, (ii) rapid deamination of the remaining adenosine, and (iii) maintenance of the sustained pericellular ATP level through continuous nucleotide release and phosphotransfer reactions.	Adenosine Monophosphate	123-126	5'-nucleotidase ecto	Homo sapiens	88-108
12707258-4	2003	Upon adhesion, lymphocytes suppress endothelial purine metabolism via (i) inhibition of ecto-5"-nucleotidase/CD73-mediated AMP hydrolysis, (ii) rapid deamination of the remaining adenosine, and (iii) maintenance of the sustained pericellular ATP level through continuous nucleotide release and phosphotransfer reactions.	Adenosine Monophosphate	123-126	5'-nucleotidase ecto	Homo sapiens	109-113
12663485-1	2003	Extracellular adenosine production by the glycosyl-phosphatidyl-inositol-anchored Ecto-5"-Nucleotidase plays an important role in the defense against hypoxia, particularly in the intravascular space.	Adenosine	14-23	5'-nucleotidase ecto	Homo sapiens	82-102
12711081-7	2003	Addition of an ecto-5"-nucleotidase inhibitor abolished GMP-stimulatory effect on glutamate uptake, without affecting GUO action.	Glutamic Acid	82-91	5'-nucleotidase ecto	Homo sapiens	15-35
12759341-4	2003	Based on substrate-specificity and competitive studies, we identified three purine-inactivating enzymes in human serum, nucleotide pyrophosphatase (EC 3.6.1.9), 5"-nucleotidase (EC 3.1.3.5), and adenosine deaminase (EC 3.5.4.4), whereas an opposite ATP-generating pathway is represented by adenylate kinase (EC 2.7.4.3) and NDP kinase (EC 2.7.4.6).	purine	76-82	5'-nucleotidase ecto	Homo sapiens	161-176
12663485-1	2003	Extracellular adenosine production by the glycosyl-phosphatidyl-inositol-anchored Ecto-5"-Nucleotidase plays an important role in the defense against hypoxia, particularly in the intravascular space.	Glycosylphosphatidylinositols	42-72	5'-nucleotidase ecto	Homo sapiens	82-102
12663485-4	2003	Hypoxia (0% O2 for 18 hours) induced a 2-fold increase of Ecto-5"-Nucleotidase activity (Vmax 19.78+/-0.53 versus 8.82+/-1.12 nmol/mg protein per min), whereas mRNA abundance and total amount of the protein were unmodified.	Oxygen	12-14	5'-nucleotidase ecto	Homo sapiens	58-78
12663485-8	2003	Incubation of normoxic cells with palmitic acid enhanced Ecto-5"-Nucleotidase activity and cell surface expression.	Palmitic Acid	34-47	5'-nucleotidase ecto	Homo sapiens	57-77
12663485-10	2003	This effect could be supported by a decrease of Ecto-5"-Nucleotidase endocytosis through modification of plasma membrane fatty acid composition.	Fatty Acids	121-131	5'-nucleotidase ecto	Homo sapiens	48-68
12560324-9	2003	We identified two ectonucleotidases that mediated the conversion of AMP to adenosine: ecto 5"-nucleotidase (ecto 5"-NT, CD73) and alkaline phosphatase (AP).	Adenosine Monophosphate	68-71	5'-nucleotidase ecto	Homo sapiens	86-106
12560324-9	2003	We identified two ectonucleotidases that mediated the conversion of AMP to adenosine: ecto 5"-nucleotidase (ecto 5"-NT, CD73) and alkaline phosphatase (AP).	Adenosine Monophosphate	68-71	5'-nucleotidase ecto	Homo sapiens	108-118
12560324-9	2003	We identified two ectonucleotidases that mediated the conversion of AMP to adenosine: ecto 5"-nucleotidase (ecto 5"-NT, CD73) and alkaline phosphatase (AP).	Adenosine Monophosphate	68-71	5'-nucleotidase ecto	Homo sapiens	120-124
12560324-11	2003	In bronchial cultures and tissues, ecto 5"-NT accounted for &gt;80% of total activity toward 0.01 mm AMP, compared with &lt;15% for 5 mm AMP.	Adenosine Monophosphate	101-104	5'-nucleotidase ecto	Homo sapiens	35-45
12560324-14	2003	Collectively, these experiments support a major role for extracellular nucleotide catalysis and for ecto 5"-NT and NS AP in the regulation of adenosine concentrations on airway surfaces.	Adenosine	142-151	5'-nucleotidase ecto	Homo sapiens	100-110
12556361-15	2003	Adenosine generated by the action of 5"-nucleotidase may elicit further effects on ion transport, often opposite those of ATP.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	37-52
12787573-13	2003	ATP is released both spinally and peripherally following inflammation or injury, and may be converted to adenosine by ecto-5"-nucleotidase contributing an additional source of adenosine.	Adenosine Triphosphate	0-3	5'-nucleotidase ecto	Homo sapiens	118-138
12787573-13	2003	ATP is released both spinally and peripherally following inflammation or injury, and may be converted to adenosine by ecto-5"-nucleotidase contributing an additional source of adenosine.	Adenosine	105-114	5'-nucleotidase ecto	Homo sapiens	118-138
12787573-13	2003	ATP is released both spinally and peripherally following inflammation or injury, and may be converted to adenosine by ecto-5"-nucleotidase contributing an additional source of adenosine.	Adenosine	176-185	5'-nucleotidase ecto	Homo sapiens	118-138
12715899-5	2003	With up-regulated CD73 and A2a, cells also respond to 5"-AMP with increased cyclic AMP formation.	Adenosine Monophosphate	54-60	5'-nucleotidase ecto	Homo sapiens	18-22
12715899-5	2003	With up-regulated CD73 and A2a, cells also respond to 5"-AMP with increased cyclic AMP formation.	Cyclic AMP	76-86	5'-nucleotidase ecto	Homo sapiens	18-22
12556361-15	2003	Adenosine generated by the action of 5"-nucleotidase may elicit further effects on ion transport, often opposite those of ATP.	Adenosine Triphosphate	122-125	5'-nucleotidase ecto	Homo sapiens	37-52
12654334-8	2003	AICA riboside, derived from the hydrolysis of the ribotide, an intermediate of purine de novo synthesis, is absent in normal healthy cells; however it may accumulate in those individuals in which an inborn error of purine metabolism causes an increase in the rate of de novo synthesis and/or an overexpression of cytosolic 5"-nucleotidase, that appears to be the enzyme responsible for AICA ribotide hydrolysis.	riboside	5-13	5'-nucleotidase ecto	Homo sapiens	323-338
12654334-8	2003	AICA riboside, derived from the hydrolysis of the ribotide, an intermediate of purine de novo synthesis, is absent in normal healthy cells; however it may accumulate in those individuals in which an inborn error of purine metabolism causes an increase in the rate of de novo synthesis and/or an overexpression of cytosolic 5"-nucleotidase, that appears to be the enzyme responsible for AICA ribotide hydrolysis.	ribotide	50-58	5'-nucleotidase ecto	Homo sapiens	323-338
12493585-1	2002	OBJECTIVES: To investigate plasma activities of 5"-nucleotidase, a key enzyme in the production of adenosine and evaluate the relationship between changes in 5"-nucleotidase activities and pregnancy-related hormones, estrogen, progesterone and human chorionic gonadotropin (hCG) in women with hyperemesis gravidarum.	Adenosine	99-108	5'-nucleotidase ecto	Homo sapiens	48-63
12482826-3	2002	The activity of endothelial ectonucleotidases was assessed by the production of inorganic phosphate from ADP, which was decreased by chronic depolarization by 25% (n=6, P&lt;0.05) and the amount of AMP derived from ADP in the presence of the 5"-nucleotidase inhibitor alpha,beta-methylene-5"-diphosphate (100 micromol/L).	Phosphates	80-99	5'-nucleotidase ecto	Homo sapiens	242-257
12482826-3	2002	The activity of endothelial ectonucleotidases was assessed by the production of inorganic phosphate from ADP, which was decreased by chronic depolarization by 25% (n=6, P&lt;0.05) and the amount of AMP derived from ADP in the presence of the 5"-nucleotidase inhibitor alpha,beta-methylene-5"-diphosphate (100 micromol/L).	Adenosine Diphosphate	105-108	5'-nucleotidase ecto	Homo sapiens	242-257
12493585-4	2002	The increases in plasma 5"-nucleotidase activities were accompanied by elevations of plasma estradiol, progesterone and hCG levels.	Estradiol	92-101	5'-nucleotidase ecto	Homo sapiens	24-39
12493585-4	2002	The increases in plasma 5"-nucleotidase activities were accompanied by elevations of plasma estradiol, progesterone and hCG levels.	Progesterone	103-115	5'-nucleotidase ecto	Homo sapiens	24-39
12493585-5	2002	CONCLUSIONS: The increase of plasma 5"-nucleotidase activities may be at least partly attributed to elevations of pregnancy-related hormones, suggesting changes in purine metabolism in women with hyperemesis gravidarum.	purine	164-170	5'-nucleotidase ecto	Homo sapiens	36-51
12187107-1	2002	It has been demonstrated in anti-Thy1 glomerulonephritis that extracellular adenine nucleotides have a significant pro-inflammatory activity, however, glomerular ATP/ADPase, which in concert with 5"-nucleotidase converts ATP/ADP, and AMP to anti-inflammatory adenosine had an anti-inflammatory role.	Adenosine Triphosphate	162-165	5'-nucleotidase ecto	Homo sapiens	196-211
12187107-1	2002	It has been demonstrated in anti-Thy1 glomerulonephritis that extracellular adenine nucleotides have a significant pro-inflammatory activity, however, glomerular ATP/ADPase, which in concert with 5"-nucleotidase converts ATP/ADP, and AMP to anti-inflammatory adenosine had an anti-inflammatory role.	Adenosine Diphosphate	166-169	5'-nucleotidase ecto	Homo sapiens	196-211
12187107-1	2002	It has been demonstrated in anti-Thy1 glomerulonephritis that extracellular adenine nucleotides have a significant pro-inflammatory activity, however, glomerular ATP/ADPase, which in concert with 5"-nucleotidase converts ATP/ADP, and AMP to anti-inflammatory adenosine had an anti-inflammatory role.	Adenine Nucleotides	76-95	5'-nucleotidase ecto	Homo sapiens	196-211
12187107-1	2002	It has been demonstrated in anti-Thy1 glomerulonephritis that extracellular adenine nucleotides have a significant pro-inflammatory activity, however, glomerular ATP/ADPase, which in concert with 5"-nucleotidase converts ATP/ADP, and AMP to anti-inflammatory adenosine had an anti-inflammatory role.	Adenosine Monophosphate	234-237	5'-nucleotidase ecto	Homo sapiens	196-211
12187107-1	2002	It has been demonstrated in anti-Thy1 glomerulonephritis that extracellular adenine nucleotides have a significant pro-inflammatory activity, however, glomerular ATP/ADPase, which in concert with 5"-nucleotidase converts ATP/ADP, and AMP to anti-inflammatory adenosine had an anti-inflammatory role.	Adenosine	259-268	5'-nucleotidase ecto	Homo sapiens	196-211
12571440-1	2002	The present study investigated plasma activity of 5"-nucleotidase, a key enzyme in the production of adenosine, in pre-eclampsia, and evaluated the relationship between changes in 5"-nucleotidase activity, and levels of uric acid, endproduct of the purine metabolism, and the severity of pre-eclampsia.	Adenosine	101-110	5'-nucleotidase ecto	Homo sapiens	50-65
11738231-5	2002	Purine generation from endogenous precursors in the prey explains the presence of many hitherto unexplained enzyme activities in snake venoms: 5"-nucleotidase, endonucleases (including ribonuclease), phosphodiesterase, ATPase, ADPase, phosphomonoesterase, and NADase.	purine	0-6	5'-nucleotidase ecto	Homo sapiens	143-158
11884371-0	2002	Lovastatin enhances ecto-5"-nucleotidase activity and cell surface expression in endothelial cells: implication of rho-family GTPases.	Lovastatin	0-10	5'-nucleotidase ecto	Homo sapiens	20-40
11884371-1	2002	Extracellular adenosine production by the GPI-anchored Ecto-5"-Nucleotidase (Ecto-5"-Nu) plays an important role in the cardiovascular system, notably in defense against hypoxia.	Adenosine	14-23	5'-nucleotidase ecto	Homo sapiens	55-75
11884371-1	2002	Extracellular adenosine production by the GPI-anchored Ecto-5"-Nucleotidase (Ecto-5"-Nu) plays an important role in the cardiovascular system, notably in defense against hypoxia.	Adenosine	14-23	5'-nucleotidase ecto	Homo sapiens	55-65
11884371-1	2002	Extracellular adenosine production by the GPI-anchored Ecto-5"-Nucleotidase (Ecto-5"-Nu) plays an important role in the cardiovascular system, notably in defense against hypoxia.	Glycosylphosphatidylinositols	42-45	5'-nucleotidase ecto	Homo sapiens	55-75
11884371-1	2002	Extracellular adenosine production by the GPI-anchored Ecto-5"-Nucleotidase (Ecto-5"-Nu) plays an important role in the cardiovascular system, notably in defense against hypoxia.	Glycosylphosphatidylinositols	42-45	5'-nucleotidase ecto	Homo sapiens	55-65
11884371-4	2002	Lovastatin enhanced Ecto-5"-Nu activity in a dose-dependent manner.	Lovastatin	0-10	5'-nucleotidase ecto	Homo sapiens	20-30
11884371-6	2002	By contrast, lovastatin enhanced cell surface expression of Ecto-5"-Nu and decreased endocytosis of Ecto-5"-Nu, as evidenced by immunostaining.	Lovastatin	13-23	5'-nucleotidase ecto	Homo sapiens	60-70
11884371-6	2002	By contrast, lovastatin enhanced cell surface expression of Ecto-5"-Nu and decreased endocytosis of Ecto-5"-Nu, as evidenced by immunostaining.	Lovastatin	13-23	5'-nucleotidase ecto	Homo sapiens	100-110
11884371-10	2002	In conclusion, lovastatin enhances Ecto-5"-Nu activity and membrane expression in endothelial cells.	Lovastatin	15-25	5'-nucleotidase ecto	Homo sapiens	35-45
11896543-1	2002	The relative levels of the deoxycytidine kinase (dCK), deoxyguanosine kinase (dGK), and the 5"-nucleotidase (5"-NT) are of importance for the effect of many nucleoside analogues used in the treatment of hematological malignancies.	Nucleosides	157-167	5'-nucleotidase ecto	Homo sapiens	92-107
12571440-4	2002	Plasma 5"-nucleotidase activity increased according to increases in uric acid levels and the severity of pre-eclampsia.	Uric Acid	68-77	5'-nucleotidase ecto	Homo sapiens	7-22
12571440-5	2002	These results suggest that increased plasma 5"-nucleotidase activity may, at least in part, be related to changes in purine metabolism in pre-eclampsia.	purine	117-123	5'-nucleotidase ecto	Homo sapiens	44-59
11046060-0	2000	Regulation of endothelial CD73 by adenosine: paracrine pathway for enhanced endothelial barrier function.	Adenosine	34-43	5'-nucleotidase ecto	Homo sapiens	26-30
11705765-2	2001	activate 5"-nucleotidase (5"-ND), thereby increasing the production of renal adenosine and regulating renal function.	Adenosine	77-86	5'-nucleotidase ecto	Homo sapiens	9-24
11553506-5	2001	The extracellular cAMP-adenosine pathway is defined as the egress of cAMP from cells during activation of adenylyl cyclase, followed by the extracellular conversion of cAMP to adenosine by the serial actions of ecto-phosphodiesterase and ecto-5"-nucleotidase.	Cyclic AMP	18-22	5'-nucleotidase ecto	Homo sapiens	238-258
11553506-5	2001	The extracellular cAMP-adenosine pathway is defined as the egress of cAMP from cells during activation of adenylyl cyclase, followed by the extracellular conversion of cAMP to adenosine by the serial actions of ecto-phosphodiesterase and ecto-5"-nucleotidase.	Adenosine	23-32	5'-nucleotidase ecto	Homo sapiens	238-258
11553506-5	2001	The extracellular cAMP-adenosine pathway is defined as the egress of cAMP from cells during activation of adenylyl cyclase, followed by the extracellular conversion of cAMP to adenosine by the serial actions of ecto-phosphodiesterase and ecto-5"-nucleotidase.	Adenosine	176-185	5'-nucleotidase ecto	Homo sapiens	238-258
11124602-0	2000	Cyclosporin A stimulates ecto-5"-nucleotidase activity in mesangial cells.	Cyclosporine	0-13	5'-nucleotidase ecto	Homo sapiens	25-45
11535530-2	2001	Cytoplasmic 5"-nucleotidase (5NT) dephosphorylates ara-CMP, a key intermediate, preventing accumulation of ara-CTP and may reduce cellular sensitivity to the cytotoxic activity of ara-C.	1-beta-D-arabinofuranosylcytosine 5'-monophosphate	51-58	5'-nucleotidase ecto	Homo sapiens	12-27
11535530-2	2001	Cytoplasmic 5"-nucleotidase (5NT) dephosphorylates ara-CMP, a key intermediate, preventing accumulation of ara-CTP and may reduce cellular sensitivity to the cytotoxic activity of ara-C.	1-beta-D-arabinofuranosylcytosine 5'-monophosphate	51-58	5'-nucleotidase ecto	Homo sapiens	29-32
11535530-2	2001	Cytoplasmic 5"-nucleotidase (5NT) dephosphorylates ara-CMP, a key intermediate, preventing accumulation of ara-CTP and may reduce cellular sensitivity to the cytotoxic activity of ara-C.	Arabinofuranosylcytosine Triphosphate	107-114	5'-nucleotidase ecto	Homo sapiens	12-27
11535530-2	2001	Cytoplasmic 5"-nucleotidase (5NT) dephosphorylates ara-CMP, a key intermediate, preventing accumulation of ara-CTP and may reduce cellular sensitivity to the cytotoxic activity of ara-C.	Arabinofuranosylcytosine Triphosphate	107-114	5'-nucleotidase ecto	Homo sapiens	29-32
11535530-2	2001	Cytoplasmic 5"-nucleotidase (5NT) dephosphorylates ara-CMP, a key intermediate, preventing accumulation of ara-CTP and may reduce cellular sensitivity to the cytotoxic activity of ara-C.	Cytarabine	51-56	5'-nucleotidase ecto	Homo sapiens	12-27
11535530-2	2001	Cytoplasmic 5"-nucleotidase (5NT) dephosphorylates ara-CMP, a key intermediate, preventing accumulation of ara-CTP and may reduce cellular sensitivity to the cytotoxic activity of ara-C.	Cytarabine	51-56	5'-nucleotidase ecto	Homo sapiens	29-32
11509639-8	2001	Because ecto 5" nucleotidase inhibitor (alpha,beta-methylene adenosine-5"-diphosphate) blocked the effect of MTX, adenosine mimicked the effect of MTX, and adenosine A2b receptor antagonist (3,7-dimethyl-1-propargylxanthine) reversed the inhibitory effect of MTX, we suggest that MTX suppresses NF-kappaB activation by releasing adenosine.	alpha,beta-methyleneadenosine 5'-diphosphate	40-85	5'-nucleotidase ecto	Homo sapiens	8-28
11509639-8	2001	Because ecto 5" nucleotidase inhibitor (alpha,beta-methylene adenosine-5"-diphosphate) blocked the effect of MTX, adenosine mimicked the effect of MTX, and adenosine A2b receptor antagonist (3,7-dimethyl-1-propargylxanthine) reversed the inhibitory effect of MTX, we suggest that MTX suppresses NF-kappaB activation by releasing adenosine.	Methotrexate	109-112	5'-nucleotidase ecto	Homo sapiens	8-28
11509639-8	2001	Because ecto 5" nucleotidase inhibitor (alpha,beta-methylene adenosine-5"-diphosphate) blocked the effect of MTX, adenosine mimicked the effect of MTX, and adenosine A2b receptor antagonist (3,7-dimethyl-1-propargylxanthine) reversed the inhibitory effect of MTX, we suggest that MTX suppresses NF-kappaB activation by releasing adenosine.	Adenosine	61-70	5'-nucleotidase ecto	Homo sapiens	8-28
11493444-0	2001	The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5"-nucleotidase.	mononucleotide	4-18	5'-nucleotidase ecto	Homo sapiens	151-171
11493444-0	2001	The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5"-nucleotidase.	Phosphorothioate Oligonucleotides	85-118	5'-nucleotidase ecto	Homo sapiens	151-171
11493444-4	2001	The results indicate that differences in cytotoxicity of dNMPs or dNMPSs in these cells depend upon different activity of an ecto-5"-nucleotidase.	dnmps	57-62	5'-nucleotidase ecto	Homo sapiens	125-145
11493444-4	2001	The results indicate that differences in cytotoxicity of dNMPs or dNMPSs in these cells depend upon different activity of an ecto-5"-nucleotidase.	dnmpss	66-72	5'-nucleotidase ecto	Homo sapiens	125-145
11433002-19	2001	Phagocytosis of fluorescent beads was inhibited by ATP, but the ecto-5"-nucleotidase inhibitor alpha, beta-methylene ADP prevented this, suggesting that inhibition was mediated by extracellular conversion of ATP to adenosine.	beta-methylene adp	102-120	5'-nucleotidase ecto	Homo sapiens	64-84
11433002-19	2001	Phagocytosis of fluorescent beads was inhibited by ATP, but the ecto-5"-nucleotidase inhibitor alpha, beta-methylene ADP prevented this, suggesting that inhibition was mediated by extracellular conversion of ATP to adenosine.	Adenosine Triphosphate	208-211	5'-nucleotidase ecto	Homo sapiens	64-84
11433002-19	2001	Phagocytosis of fluorescent beads was inhibited by ATP, but the ecto-5"-nucleotidase inhibitor alpha, beta-methylene ADP prevented this, suggesting that inhibition was mediated by extracellular conversion of ATP to adenosine.	Adenosine	215-224	5'-nucleotidase ecto	Homo sapiens	64-84
11491293-0	2001	Mechanism of hydrolysis of phosphate esters by the dimetal center of 5"-nucleotidase based on crystal structures.	phosphate esters	27-43	5'-nucleotidase ecto	Homo sapiens	69-84
11491293-4	2001	In addition, a complex of the open form of 5"-nucleotidase with ATP was analyzed at a resolution of 1.7 A.	Adenosine Triphosphate	64-67	5'-nucleotidase ecto	Homo sapiens	43-58
11264476-3	2001	Nucleotides are rapidly converted to adenosine by a family of ecto-nucleotidases including CD39 and CD73.	Adenosine	37-46	5'-nucleotidase ecto	Homo sapiens	100-104
11067892-1	2000	CD73 is a GPI-anchored lymphocyte adhesion molecule possessing an ecto-5"-nucleotidase enzyme activity.	Glycosylphosphatidylinositols	10-13	5'-nucleotidase ecto	Homo sapiens	0-4
11067892-1	2000	CD73 is a GPI-anchored lymphocyte adhesion molecule possessing an ecto-5"-nucleotidase enzyme activity.	Glycosylphosphatidylinositols	10-13	5'-nucleotidase ecto	Homo sapiens	66-86
11046060-3	2000	Extracellular 5"-AMP is metabolized to adenosine by surface-expressed 5"-ectonucleotidase (CD73).	Adenosine Monophosphate	14-20	5'-nucleotidase ecto	Homo sapiens	91-95
11046060-3	2000	Extracellular 5"-AMP is metabolized to adenosine by surface-expressed 5"-ectonucleotidase (CD73).	Adenosine	39-48	5'-nucleotidase ecto	Homo sapiens	91-95
11046060-5	2000	We hypothesized that adenosine signaling to endothelia provides a paracrine loop for regulated expression of CD73 and enhanced endothelial barrier function.	Adenosine	21-30	5'-nucleotidase ecto	Homo sapiens	109-113
11046060-7	2000	Initial experiments revealed that adenosine and adenosine analogues induce CD73 mRNA (RT-PCR), surface expression (immunoprecipitation of surface biotinylated CD73), and function (HPLC analysis of etheno-AMP conversion to ethenoadenosine) in a time- and concentration-dependent fashion.	Adenosine	34-43	5'-nucleotidase ecto	Homo sapiens	75-79
11046060-7	2000	Initial experiments revealed that adenosine and adenosine analogues induce CD73 mRNA (RT-PCR), surface expression (immunoprecipitation of surface biotinylated CD73), and function (HPLC analysis of etheno-AMP conversion to ethenoadenosine) in a time- and concentration-dependent fashion.	Adenosine	34-43	5'-nucleotidase ecto	Homo sapiens	159-163
11046060-7	2000	Initial experiments revealed that adenosine and adenosine analogues induce CD73 mRNA (RT-PCR), surface expression (immunoprecipitation of surface biotinylated CD73), and function (HPLC analysis of etheno-AMP conversion to ethenoadenosine) in a time- and concentration-dependent fashion.	Adenosine	48-57	5'-nucleotidase ecto	Homo sapiens	75-79
11046060-7	2000	Initial experiments revealed that adenosine and adenosine analogues induce CD73 mRNA (RT-PCR), surface expression (immunoprecipitation of surface biotinylated CD73), and function (HPLC analysis of etheno-AMP conversion to ethenoadenosine) in a time- and concentration-dependent fashion.	Adenosine	48-57	5'-nucleotidase ecto	Homo sapiens	159-163
11046060-9	2000	Analysis of DNA-binding activity by EMSA identified a functional role for CD73 cAMP response element and, moreover, indicated that multiple cAMP agonists induce transcriptional activation of functional CD73.	Cyclic AMP	79-83	5'-nucleotidase ecto	Homo sapiens	74-78
11046060-9	2000	Analysis of DNA-binding activity by EMSA identified a functional role for CD73 cAMP response element and, moreover, indicated that multiple cAMP agonists induce transcriptional activation of functional CD73.	Cyclic AMP	79-83	5'-nucleotidase ecto	Homo sapiens	202-206
11046060-9	2000	Analysis of DNA-binding activity by EMSA identified a functional role for CD73 cAMP response element and, moreover, indicated that multiple cAMP agonists induce transcriptional activation of functional CD73.	Cyclic AMP	140-144	5'-nucleotidase ecto	Homo sapiens	74-78
11046060-9	2000	Analysis of DNA-binding activity by EMSA identified a functional role for CD73 cAMP response element and, moreover, indicated that multiple cAMP agonists induce transcriptional activation of functional CD73.	Cyclic AMP	140-144	5'-nucleotidase ecto	Homo sapiens	202-206
11046060-10	2000	Induced CD73 functioned to enhance 5"-AMP-mediated promotion of endothelial barrier (measured as a paracellular flux of 70-kDa FITC-labeled tracer).	Adenosine Monophosphate	35-41	5'-nucleotidase ecto	Homo sapiens	8-12
11046060-10	2000	Induced CD73 functioned to enhance 5"-AMP-mediated promotion of endothelial barrier (measured as a paracellular flux of 70-kDa FITC-labeled tracer).	Fluorescein-5-isothiocyanate	127-131	5'-nucleotidase ecto	Homo sapiens	8-12
11046060-11	2000	These results provide an example of transcriptional induction of enzyme (CD73) by enzymatic product (adenosine) and define a paracrine pathway for the regulated expression of vascular endothelial CD73 and barrier function.	Adenosine	101-110	5'-nucleotidase ecto	Homo sapiens	73-77
11046060-11	2000	These results provide an example of transcriptional induction of enzyme (CD73) by enzymatic product (adenosine) and define a paracrine pathway for the regulated expression of vascular endothelial CD73 and barrier function.	Adenosine	101-110	5'-nucleotidase ecto	Homo sapiens	196-200
10931179-1	2000	The structure of ecto-5"-nucleotidase from bull seminal plasma, containing a glycosyl-phosphatidylinositol anchor, was studied using mass spectrometry.	Glycosylphosphatidylinositols	77-106	5'-nucleotidase ecto	Homo sapiens	17-37
10979961-1	2000	We studied the role of adenosine (Ado), which is generated from adenine nucleotides via the activity of ecto-5"-nucleotidase (ecto-5"-NT), in the inhibition of platelet aggregation by endothelial cells (ECs).	Adenosine	23-32	5'-nucleotidase ecto	Homo sapiens	104-124
10979961-1	2000	We studied the role of adenosine (Ado), which is generated from adenine nucleotides via the activity of ecto-5"-nucleotidase (ecto-5"-NT), in the inhibition of platelet aggregation by endothelial cells (ECs).	Adenosine	34-37	5'-nucleotidase ecto	Homo sapiens	104-124
10988261-1	2000	The extracellular "cAMP-adenosine pathway" refers to the local production of adenosine mediated by cAMP egress into the extracellular space, conversion of cAMP to AMP by ectophosphodiesterase, and the metabolism of AMP to adenosine by ecto-5"-nucleotidase.	Cyclic AMP	19-23	5'-nucleotidase ecto	Homo sapiens	235-255
10988261-1	2000	The extracellular "cAMP-adenosine pathway" refers to the local production of adenosine mediated by cAMP egress into the extracellular space, conversion of cAMP to AMP by ectophosphodiesterase, and the metabolism of AMP to adenosine by ecto-5"-nucleotidase.	Adenosine	24-33	5'-nucleotidase ecto	Homo sapiens	235-255
10988261-1	2000	The extracellular "cAMP-adenosine pathway" refers to the local production of adenosine mediated by cAMP egress into the extracellular space, conversion of cAMP to AMP by ectophosphodiesterase, and the metabolism of AMP to adenosine by ecto-5"-nucleotidase.	Adenosine	77-86	5'-nucleotidase ecto	Homo sapiens	235-255
10988261-1	2000	The extracellular "cAMP-adenosine pathway" refers to the local production of adenosine mediated by cAMP egress into the extracellular space, conversion of cAMP to AMP by ectophosphodiesterase, and the metabolism of AMP to adenosine by ecto-5"-nucleotidase.	Cyclic AMP	99-103	5'-nucleotidase ecto	Homo sapiens	235-255
10988261-1	2000	The extracellular "cAMP-adenosine pathway" refers to the local production of adenosine mediated by cAMP egress into the extracellular space, conversion of cAMP to AMP by ectophosphodiesterase, and the metabolism of AMP to adenosine by ecto-5"-nucleotidase.	Cyclic AMP	99-103	5'-nucleotidase ecto	Homo sapiens	235-255
10988261-1	2000	The extracellular "cAMP-adenosine pathway" refers to the local production of adenosine mediated by cAMP egress into the extracellular space, conversion of cAMP to AMP by ectophosphodiesterase, and the metabolism of AMP to adenosine by ecto-5"-nucleotidase.	Adenosine Monophosphate	20-23	5'-nucleotidase ecto	Homo sapiens	235-255
10988261-1	2000	The extracellular "cAMP-adenosine pathway" refers to the local production of adenosine mediated by cAMP egress into the extracellular space, conversion of cAMP to AMP by ectophosphodiesterase, and the metabolism of AMP to adenosine by ecto-5"-nucleotidase.	Adenosine	77-86	5'-nucleotidase ecto	Homo sapiens	235-255
10931179-11	2000	This work resolves details of the structure of ecto-5"-nucleotidase, with particular regard to the localization and composition of the glycidic moiety, number and localization of the disulfide bridges and characterization of the glycosyl-phosphatidylinositol anchor.	Glycosylphosphatidylinositols	229-258	5'-nucleotidase ecto	Homo sapiens	47-67
10931179-11	2000	This work resolves details of the structure of ecto-5"-nucleotidase, with particular regard to the localization and composition of the glycidic moiety, number and localization of the disulfide bridges and characterization of the glycosyl-phosphatidylinositol anchor.	glycidic	135-143	5'-nucleotidase ecto	Homo sapiens	47-67
10931179-11	2000	This work resolves details of the structure of ecto-5"-nucleotidase, with particular regard to the localization and composition of the glycidic moiety, number and localization of the disulfide bridges and characterization of the glycosyl-phosphatidylinositol anchor.	Disulfides	183-192	5'-nucleotidase ecto	Homo sapiens	47-67
11007996-10	2000	The relevance of cellular mediators, such as 5"-nucleotidase, to generate adenosine for preconditioning is controversial.	Adenosine	74-83	5'-nucleotidase ecto	Homo sapiens	45-60
10696091-5	2000	When shear stress was applied after removal of ecto-5"-nucleotidase by phosphatidylinositol-specific phospholipase C, the release of 5"-nucleotidase was drastically reduced.	Phosphatidylinositols	71-91	5'-nucleotidase ecto	Homo sapiens	52-67
10801967-6	2000	A 3-wk supplementation with zinc (30 mg/d as glycine-chelate) raised initially low plasma zinc values to above normal values and increased plasma activities of 5"-nucleotidase.	Glycine	45-52	5'-nucleotidase ecto	Homo sapiens	160-175
10762436-1	2000	5"-nucleotidase, an adenosine producing enzyme with a glycosylphosphatidylinositol-anchored structure, was localized in human ejaculated spermatozoa.	Adenosine	20-29	5'-nucleotidase ecto	Homo sapiens	0-15
10762436-1	2000	5"-nucleotidase, an adenosine producing enzyme with a glycosylphosphatidylinositol-anchored structure, was localized in human ejaculated spermatozoa.	Glycosylphosphatidylinositols	54-82	5'-nucleotidase ecto	Homo sapiens	0-15
10757505-2	2000	Ecto-5"-nucleotidase produces adenosine from AMP.	Adenosine	30-39	5'-nucleotidase ecto	Homo sapiens	0-20
10757505-2	2000	Ecto-5"-nucleotidase produces adenosine from AMP.	Adenosine Monophosphate	45-48	5'-nucleotidase ecto	Homo sapiens	0-20
10825541-0	2000	The ecto-5"-nucleotidase subunits in dimers are not linked by disulfide bridges but by non-covalent bonds.	Disulfides	62-71	5'-nucleotidase ecto	Homo sapiens	4-24
10825541-1	2000	It has long been considered that ecto-5"-nucleotidase (eNT) dimers consist of subunits linked by disulfide bonds.	Disulfides	97-106	5'-nucleotidase ecto	Homo sapiens	33-53
10825541-1	2000	It has long been considered that ecto-5"-nucleotidase (eNT) dimers consist of subunits linked by disulfide bonds.	Disulfides	97-106	5'-nucleotidase ecto	Homo sapiens	55-58
10825541-4	2000	2S) and amphiphilic (2.6S) eNT monomers were obtained after reduction of disulfide bonds in dimers.	Disulfides	73-82	5'-nucleotidase ecto	Homo sapiens	27-30
10825541-5	2000	The amphiphilic eNT dimers or monomers were converted into their hydrophilic variants with phosphatidylinositol-specific phospholipase C. SDS-PAGE plus Western blot showed 68 kDa subunits, regardless of the addition of beta-mercaptoethanol to the SDS mixture.	Phosphatidylinositols	91-111	5'-nucleotidase ecto	Homo sapiens	16-19
10825541-5	2000	The amphiphilic eNT dimers or monomers were converted into their hydrophilic variants with phosphatidylinositol-specific phospholipase C. SDS-PAGE plus Western blot showed 68 kDa subunits, regardless of the addition of beta-mercaptoethanol to the SDS mixture.	Sodium Dodecyl Sulfate	138-141	5'-nucleotidase ecto	Homo sapiens	16-19
10825541-5	2000	The amphiphilic eNT dimers or monomers were converted into their hydrophilic variants with phosphatidylinositol-specific phospholipase C. SDS-PAGE plus Western blot showed 68 kDa subunits, regardless of the addition of beta-mercaptoethanol to the SDS mixture.	Mercaptoethanol	219-239	5'-nucleotidase ecto	Homo sapiens	16-19
10825541-5	2000	The amphiphilic eNT dimers or monomers were converted into their hydrophilic variants with phosphatidylinositol-specific phospholipase C. SDS-PAGE plus Western blot showed 68 kDa subunits, regardless of the addition of beta-mercaptoethanol to the SDS mixture.	Sodium Dodecyl Sulfate	247-250	5'-nucleotidase ecto	Homo sapiens	16-19
10825541-6	2000	Active eNT monomers were obtained by addition of 1 M guanidinium chloride (Gdn) to dimers, and unfolded subunits by addition of 4 M Gdn.	Guanidine	53-73	5'-nucleotidase ecto	Homo sapiens	7-10
10825541-6	2000	Active eNT monomers were obtained by addition of 1 M guanidinium chloride (Gdn) to dimers, and unfolded subunits by addition of 4 M Gdn.	Guanidine	75-78	5'-nucleotidase ecto	Homo sapiens	7-10
10825541-7	2000	The results unambiguously demonstrate that the subunits in eNT dimers are not linked by disulfide bridges, but by non-covalent bonds, and that dissociation precedes inactivation and unfolding.	Disulfides	88-97	5'-nucleotidase ecto	Homo sapiens	59-62
10819858-2	2000	STUDY DESIGN: We measured plasma adenosine levels, the platelet activation markers beta-thromboglobulin and platelet factor 4, and 5"-nucleotidase activity, which catalyzes dephosphorylation from adenosine monophosphate to adenosine, in 34 nonpregnant women and 34 women with normal pregnancies in the third trimester.	Adenosine Monophosphate	196-219	5'-nucleotidase ecto	Homo sapiens	131-146
10819858-2	2000	STUDY DESIGN: We measured plasma adenosine levels, the platelet activation markers beta-thromboglobulin and platelet factor 4, and 5"-nucleotidase activity, which catalyzes dephosphorylation from adenosine monophosphate to adenosine, in 34 nonpregnant women and 34 women with normal pregnancies in the third trimester.	Adenosine	196-205	5'-nucleotidase ecto	Homo sapiens	131-146
10819858-5	2000	CONCLUSION: The increase of plasma adenosine may be attributed at least in part to platelet activation and an increase of 5"-nucleotidase activity during normal pregnancy.	Adenosine	35-44	5'-nucleotidase ecto	Homo sapiens	122-137
10696091-5	2000	When shear stress was applied after removal of ecto-5"-nucleotidase by phosphatidylinositol-specific phospholipase C, the release of 5"-nucleotidase was drastically reduced.	Phosphatidylinositols	71-91	5'-nucleotidase ecto	Homo sapiens	133-148
10506947-5	1999	In general, 5"-nucleotidase has been considered as a marker enzyme for the plasma membrane, and is considered to be a key enzyme in the generation of adenosine, a potential vasodilator.	Adenosine	150-159	5'-nucleotidase ecto	Homo sapiens	12-27
10567326-5	1999	Outcome measurements included troponin I and creatine kinase-MB isoenzyme (until the third postoperative day) levels and the activity of ecto-5"-nucleotidase, which contributes to adenosine production and is considered to be a reporter of protein kinase C activation, as assessed in right atrial biopsy samples taken before bypass and at the end of the preconditioning protocol (or after 15 minutes of bypass in control patients).	Adenosine	180-189	5'-nucleotidase ecto	Homo sapiens	137-157
10229870-2	1999	The aim of this study was 2-fold: first, to characterize the mechanisms by which CD38 regulates CD73 expression; and second, to determine whether surface-induced CD73 modulates CBTC responses.	cbtc	177-181	5'-nucleotidase ecto	Homo sapiens	162-166
10399192-0	1999	In vitro effects of selected flavonoids on the 5"-nucleotidase activity.	Flavonoids	29-39	5'-nucleotidase ecto	Homo sapiens	47-62
10352024-3	1999	Treatment of hepatocytes or WIF-B cells with phosphoinositide 3-kinase inhibitors, wortmannin or LY294002, led to accumulation of the apical plasma membrane proteins, 5"-nucleotidase and aminopeptidase N in lysosomal vacuoles.	Wortmannin	83-93	5'-nucleotidase ecto	Homo sapiens	167-182
10352024-3	1999	Treatment of hepatocytes or WIF-B cells with phosphoinositide 3-kinase inhibitors, wortmannin or LY294002, led to accumulation of the apical plasma membrane proteins, 5"-nucleotidase and aminopeptidase N in lysosomal vacuoles.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	97-105	5'-nucleotidase ecto	Homo sapiens	167-182
10229870-4	1999	The induction of CD73 was blocked by wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase (PI3-K).	Wortmannin	37-47	5'-nucleotidase ecto	Homo sapiens	17-21
10229870-7	1999	Highly CBTC, totally unresponsive to mitogenic concentrations of plastic-immobilized CD3 mAb, proliferated vigorously when exposed to the combination of plastic-immobilized CD3 and CD73 mAbs.	cbtc	7-11	5'-nucleotidase ecto	Homo sapiens	181-185
10383080-1	1999	OBJECTIVE: Erythrocyte pyrimidine 5"-nucleotidase (Pyr-5"-N) is highly sensitive to heavy metal inactivation in vitro and in vivo, and a number of studies have verified its usefulness as a biomarker of acute and chronic lead exposures.	Metals	90-95	5'-nucleotidase ecto	Homo sapiens	34-49
10475769-5	1999	We found that ischemic preconditioning activates the enzyme responsible for adenosine release, ie, ecto-5"-nucleotidase.	Adenosine	76-85	5'-nucleotidase ecto	Homo sapiens	99-119
10475769-8	1999	Protein kinase C phosphorylated the serine and threonine residues of ecto-5"-nucleotidase.	Serine	36-42	5'-nucleotidase ecto	Homo sapiens	69-89
10475769-8	1999	Protein kinase C phosphorylated the serine and threonine residues of ecto-5"-nucleotidase.	Threonine	47-56	5'-nucleotidase ecto	Homo sapiens	69-89
10475769-9	1999	Therefore, we suggest that adenosine produced via ecto-5"-nucleotidase gives cardioprotection against ischemia and reperfusion injury.	Adenosine	27-36	5'-nucleotidase ecto	Homo sapiens	50-70
10475769-11	1999	Ecto-5"-nucleotidase activity increased in the blood and the myocardium in patients with chronic heart failure, which may explain the increases in adenosine levels in the plasma and the myocardium.	Adenosine	147-156	5'-nucleotidase ecto	Homo sapiens	0-20
10092873-2	1999	IMP-specific, High Km 5"-nucleotidase (EC 3.1.3.5) is an ubiquitous enzyme, the activity of which is highly regulated by substrate, ATP, and inorganic phosphate.	Adenosine Triphosphate	132-135	5'-nucleotidase ecto	Homo sapiens	22-37
9950763-7	1999	Metabolic conversion of ADO nucleotides by surface ecto-5"-nucleotidase to more active (less phosphorylated) forms contributes to anion transport activation in these cells.	ado nucleotides	24-39	5'-nucleotidase ecto	Homo sapiens	51-71
10092873-0	1999	ATP and phosphate reciprocally affect subunit association of human recombinant High Km 5"-nucleotidase.	Adenosine Triphosphate	0-3	5'-nucleotidase ecto	Homo sapiens	87-102
10092873-0	1999	ATP and phosphate reciprocally affect subunit association of human recombinant High Km 5"-nucleotidase.	Phosphates	8-17	5'-nucleotidase ecto	Homo sapiens	87-102
10065327-5	1999	An increase in interstitial adenosine during preconditioning is thought to be derived primarily from hydrolysis of 5"-AMP in the myocyte by cytosolic 5"-nucleotidase, although a contribution of ectosolic 5"-nucleotidase remains controversial.	Adenosine	28-37	5'-nucleotidase ecto	Homo sapiens	150-165
10065327-5	1999	An increase in interstitial adenosine during preconditioning is thought to be derived primarily from hydrolysis of 5"-AMP in the myocyte by cytosolic 5"-nucleotidase, although a contribution of ectosolic 5"-nucleotidase remains controversial.	Adenosine	28-37	5'-nucleotidase ecto	Homo sapiens	204-219
10092873-2	1999	IMP-specific, High Km 5"-nucleotidase (EC 3.1.3.5) is an ubiquitous enzyme, the activity of which is highly regulated by substrate, ATP, and inorganic phosphate.	Phosphates	151-160	5'-nucleotidase ecto	Homo sapiens	22-37
10092873-12	1999	These data suggest an important function of the polyglutamic acid tract in the process of association and dissociation of 5"-nucleotidase subunits.	Polyglutamic Acid	48-65	5'-nucleotidase ecto	Homo sapiens	122-137
9973547-0	1999	Activity of IMP- and AMP-preferring isoforms of 5"-nucleotidase from human seminal plasma with AMP analogues.	Adenosine Monophosphate	21-24	5'-nucleotidase ecto	Homo sapiens	48-63
9920798-4	1999	Further application of EB in the presence of suramin, a blocker of P2-purinergic receptor, or AOPCP, an inhibitor of 5"-nucleotidase, still increased IK.	Evans Blue	23-25	5'-nucleotidase ecto	Homo sapiens	117-132
9973547-0	1999	Activity of IMP- and AMP-preferring isoforms of 5"-nucleotidase from human seminal plasma with AMP analogues.	Adenosine Monophosphate	95-98	5'-nucleotidase ecto	Homo sapiens	48-63
9973547-1	1999	AMP analogues modified at various positions of the molecule were checked as substrates for the two soluble isoforms of 5"-nucleotidase from human seminal plasma.	Adenosine Monophosphate	0-3	5'-nucleotidase ecto	Homo sapiens	119-134
9885947-0	1998	Upregulation of ecto-5"-nucleotidase in human neuroblastoma SH-SY5Y cells on differentiation by retinoic acid or phorbolester.	Tretinoin	96-109	5'-nucleotidase ecto	Homo sapiens	16-36
9845378-0	1998	Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5"-nucleotidase activity.	Cytarabine	46-56	5'-nucleotidase ecto	Homo sapiens	106-121
9845378-0	1998	Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5"-nucleotidase activity.	Cladribine	60-70	5'-nucleotidase ecto	Homo sapiens	106-121
9613962-2	1998	The slow recovery of ATP may reflect a lack of purine metabolic precursors and/or increased activity of purine catabolic enzymes such as 5"-nucleotidase (5"-NT, EC 3.1.3.5) and adenosine deaminase (ADA, EC 3.5.4.4).	Adenosine Triphosphate	21-24	5'-nucleotidase ecto	Homo sapiens	137-152
9782120-0	1998	Neutrophil-derived 5"-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation.	Adenosine Monophosphate	19-45	5'-nucleotidase ecto	Homo sapiens	88-92
9782120-0	1998	Neutrophil-derived 5"-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation.	Adenosine	22-31	5'-nucleotidase ecto	Homo sapiens	88-92
9782120-8	1998	5"-AMP bioactivity required endothelial CD73-mediated conversion of 5"-AMP to adenosine via its 5"-ectonucleotidase activity.	5"-amp	0-6	5'-nucleotidase ecto	Homo sapiens	40-44
9782120-8	1998	5"-AMP bioactivity required endothelial CD73-mediated conversion of 5"-AMP to adenosine via its 5"-ectonucleotidase activity.	5"-amp	68-74	5'-nucleotidase ecto	Homo sapiens	40-44
9782120-8	1998	5"-AMP bioactivity required endothelial CD73-mediated conversion of 5"-AMP to adenosine via its 5"-ectonucleotidase activity.	Adenosine	78-87	5'-nucleotidase ecto	Homo sapiens	40-44
9788749-3	1998	A membrane-bound 5"-nucleotidase from BCS-TC2 cells has been purified to homogeneity with a high specific activity (130 U/mg), yielding a single 72-kDa band on SDS-PAGE.	Sodium Dodecyl Sulfate	160-163	5'-nucleotidase ecto	Homo sapiens	17-32
9675011-1	1998	Human 5"-nucleotidase (5"-NT, EC 3.1.3.5) is an enzyme that hydrolyzes nucleotides such as AMP or IMP (inosine 5"-monophosphate) into inorganic phosphate and the respective nucleoside.	Adenosine Monophosphate	91-94	5'-nucleotidase ecto	Homo sapiens	6-21
9675011-1	1998	Human 5"-nucleotidase (5"-NT, EC 3.1.3.5) is an enzyme that hydrolyzes nucleotides such as AMP or IMP (inosine 5"-monophosphate) into inorganic phosphate and the respective nucleoside.	Inosine Monophosphate	98-101	5'-nucleotidase ecto	Homo sapiens	6-21
9675011-1	1998	Human 5"-nucleotidase (5"-NT, EC 3.1.3.5) is an enzyme that hydrolyzes nucleotides such as AMP or IMP (inosine 5"-monophosphate) into inorganic phosphate and the respective nucleoside.	Inosine Monophosphate	103-127	5'-nucleotidase ecto	Homo sapiens	6-21
9675011-1	1998	Human 5"-nucleotidase (5"-NT, EC 3.1.3.5) is an enzyme that hydrolyzes nucleotides such as AMP or IMP (inosine 5"-monophosphate) into inorganic phosphate and the respective nucleoside.	inorganic	134-143	5'-nucleotidase ecto	Homo sapiens	6-21
9675011-1	1998	Human 5"-nucleotidase (5"-NT, EC 3.1.3.5) is an enzyme that hydrolyzes nucleotides such as AMP or IMP (inosine 5"-monophosphate) into inorganic phosphate and the respective nucleoside.	Phosphates	118-127	5'-nucleotidase ecto	Homo sapiens	6-21
9675011-1	1998	Human 5"-nucleotidase (5"-NT, EC 3.1.3.5) is an enzyme that hydrolyzes nucleotides such as AMP or IMP (inosine 5"-monophosphate) into inorganic phosphate and the respective nucleoside.	Nucleosides	173-183	5'-nucleotidase ecto	Homo sapiens	6-21
9636049-10	1998	The nucleoside analogue was also greater than 1000-fold more potent against c-N-I than the membrane ecto-5"-nucleotidase (e-N).	Nucleosides	4-14	5'-nucleotidase ecto	Homo sapiens	100-120
9636049-10	1998	The nucleoside analogue was also greater than 1000-fold more potent against c-N-I than the membrane ecto-5"-nucleotidase (e-N).	Nucleosides	4-14	5'-nucleotidase ecto	Homo sapiens	122-125
9636049-11	1998	Because the phosphonate analogues measurably inhibited e-N (apparent Ki values of 6-12 microM), the selectivity of the phosphonates for c-N-I versus e-N was less (40-200-fold).	Organophosphonates	12-23	5'-nucleotidase ecto	Homo sapiens	55-58
9636049-11	1998	Because the phosphonate analogues measurably inhibited e-N (apparent Ki values of 6-12 microM), the selectivity of the phosphonates for c-N-I versus e-N was less (40-200-fold).	Organophosphonates	119-131	5'-nucleotidase ecto	Homo sapiens	149-152
9808167-1	1998	CD73 is a glycosyl phosphatidylinositol-anchored protein with both ecto-enzyme activity (ecto-5"-nucleotidase) and signal transducing capabilities for human T lymphocytes.	Glycosylphosphatidylinositols	10-39	5'-nucleotidase ecto	Homo sapiens	0-4
9808167-1	1998	CD73 is a glycosyl phosphatidylinositol-anchored protein with both ecto-enzyme activity (ecto-5"-nucleotidase) and signal transducing capabilities for human T lymphocytes.	Glycosylphosphatidylinositols	10-39	5'-nucleotidase ecto	Homo sapiens	67-109
9690876-17	1998	Superfusion of the slices with 5"-nucleotidase also prevented the inhibitory activity of ATP on epileptiform discharges.	Adenosine Triphosphate	89-92	5'-nucleotidase ecto	Homo sapiens	31-46
9593124-0	1998	Metabolism in human cells of the D and L enantiomers of the carbocyclic analog of 2"-deoxyguanosine: substrate activity with deoxycytidine kinase, mitochondrial deoxyguanosine kinase, and 5"-nucleotidase.	Deoxyguanosine	82-99	5'-nucleotidase ecto	Homo sapiens	188-203
9593124-4	1998	Both enantiomers of CdG were substrates for deoxycytidine kinase (EC 2.7.1.74) from MOLT-4 cells, 5"-nucleotidase (EC 3.1.3.5) from HEp-2 cells, and mitochondrial deoxyguanosine kinase (EC 2.7.1.113) from human platelets and CEM cells.	cdg	20-23	5'-nucleotidase ecto	Homo sapiens	98-113
9593124-8	1998	The fact that the phosphorylation of D-CdG was stimulated by mycophenolic acid and was not affected by deoxycytidine suggested that 5"-nucleotidase was the enzyme primarily responsible for its metabolism in virally infected cells.	2-Amino-9-((1'R,3'S,4'R)-3-hydroxy-4-(hydroxymethyl)cyclopentyl)-1,9-dihydro-6H-purin-6-one	37-42	5'-nucleotidase ecto	Homo sapiens	132-147
9593124-8	1998	The fact that the phosphorylation of D-CdG was stimulated by mycophenolic acid and was not affected by deoxycytidine suggested that 5"-nucleotidase was the enzyme primarily responsible for its metabolism in virally infected cells.	Mycophenolic Acid	61-78	5'-nucleotidase ecto	Homo sapiens	132-147
9613962-2	1998	The slow recovery of ATP may reflect a lack of purine metabolic precursors and/or increased activity of purine catabolic enzymes such as 5"-nucleotidase (5"-NT, EC 3.1.3.5) and adenosine deaminase (ADA, EC 3.5.4.4).	purine	104-110	5'-nucleotidase ecto	Homo sapiens	137-152
9553767-3	1998	As an enzyme that produces adenosine, CD73 can also regulate adenosine receptor engagement in many tissues.	Adenosine	27-36	5'-nucleotidase ecto	Homo sapiens	38-42
9553767-1	1998	CD73 or ecto-5"-nucleotidase (5"-NT) is a widely expressed ecto-enzyme which catalyzes the dephosphorylation of AMP and other nucleoside monophosphates.	Adenosine Monophosphate	112-115	5'-nucleotidase ecto	Homo sapiens	0-4
9435300-0	1998	Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5"-nucleotidase-mediated conversion of adenine nucleotides.	Methotrexate	0-12	5'-nucleotidase ecto	Homo sapiens	86-106
9553767-1	1998	CD73 or ecto-5"-nucleotidase (5"-NT) is a widely expressed ecto-enzyme which catalyzes the dephosphorylation of AMP and other nucleoside monophosphates.	Adenosine Monophosphate	112-115	5'-nucleotidase ecto	Homo sapiens	8-28
9553767-1	1998	CD73 or ecto-5"-nucleotidase (5"-NT) is a widely expressed ecto-enzyme which catalyzes the dephosphorylation of AMP and other nucleoside monophosphates.	nucleoside monophosphates	126-151	5'-nucleotidase ecto	Homo sapiens	0-4
9553767-1	1998	CD73 or ecto-5"-nucleotidase (5"-NT) is a widely expressed ecto-enzyme which catalyzes the dephosphorylation of AMP and other nucleoside monophosphates.	nucleoside monophosphates	126-151	5'-nucleotidase ecto	Homo sapiens	8-28
9553767-2	1998	CD73 participates in purine salvage through this enzymatic activity, supplying cells with precursors for energy metabolism and nucleic acid biosynthesis.	purine	21-27	5'-nucleotidase ecto	Homo sapiens	0-4
9435300-0	1998	Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5"-nucleotidase-mediated conversion of adenine nucleotides.	Sulfasalazine	17-30	5'-nucleotidase ecto	Homo sapiens	86-106
9435300-0	1998	Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5"-nucleotidase-mediated conversion of adenine nucleotides.	Adenosine	39-48	5'-nucleotidase ecto	Homo sapiens	86-106
9435300-0	1998	Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5"-nucleotidase-mediated conversion of adenine nucleotides.	Adenine Nucleotides	130-149	5'-nucleotidase ecto	Homo sapiens	86-106
9435300-2	1998	The results of the experiments reported here provide three distinct lines of evidence that adenosine results from the ecto-5"-nucleotidase- mediated conversion of adenine nucleotides to adenosine.	Adenosine	91-100	5'-nucleotidase ecto	Homo sapiens	118-138
9435300-2	1998	The results of the experiments reported here provide three distinct lines of evidence that adenosine results from the ecto-5"-nucleotidase- mediated conversion of adenine nucleotides to adenosine.	Adenine Nucleotides	163-182	5'-nucleotidase ecto	Homo sapiens	118-138
9435300-2	1998	The results of the experiments reported here provide three distinct lines of evidence that adenosine results from the ecto-5"-nucleotidase- mediated conversion of adenine nucleotides to adenosine.	Adenosine	186-195	5'-nucleotidase ecto	Homo sapiens	118-138
9435300-3	1998	First, pretreatment of a human microvascular endothelial cell line (HMEC-1) with methotrexate increases extracellular adenosine after exposure of the pretreated cells to activated neutrophils; the ecto-5"-nucleotidase inhibitor alpha, beta-methylene adenosine-5"-diphosphate (APCP) abrogates completely the increase in extracellular adenosine.	Methotrexate	81-93	5'-nucleotidase ecto	Homo sapiens	197-217
9435300-3	1998	First, pretreatment of a human microvascular endothelial cell line (HMEC-1) with methotrexate increases extracellular adenosine after exposure of the pretreated cells to activated neutrophils; the ecto-5"-nucleotidase inhibitor alpha, beta-methylene adenosine-5"-diphosphate (APCP) abrogates completely the increase in extracellular adenosine.	alpha,beta-methyleneadenosine 5'-diphosphate	228-274	5'-nucleotidase ecto	Homo sapiens	197-217
9435300-3	1998	First, pretreatment of a human microvascular endothelial cell line (HMEC-1) with methotrexate increases extracellular adenosine after exposure of the pretreated cells to activated neutrophils; the ecto-5"-nucleotidase inhibitor alpha, beta-methylene adenosine-5"-diphosphate (APCP) abrogates completely the increase in extracellular adenosine.	adenylyl(3'-5')cytidine-3'-phosphate	276-280	5'-nucleotidase ecto	Homo sapiens	197-217
9435300-3	1998	First, pretreatment of a human microvascular endothelial cell line (HMEC-1) with methotrexate increases extracellular adenosine after exposure of the pretreated cells to activated neutrophils; the ecto-5"-nucleotidase inhibitor alpha, beta-methylene adenosine-5"-diphosphate (APCP) abrogates completely the increase in extracellular adenosine.	Adenosine	250-259	5'-nucleotidase ecto	Homo sapiens	197-217
9435300-6	1998	These results not only show that ecto-5"-nucleotidase activity is a critical mediator of methotrexate- and sulfasalazine-induced antiinflammatory activity in vitro and in vivo but also indicate that adenine nucleotides, released from cells, are the source of extracellular adenosine.	Methotrexate	89-101	5'-nucleotidase ecto	Homo sapiens	33-53
9435300-6	1998	These results not only show that ecto-5"-nucleotidase activity is a critical mediator of methotrexate- and sulfasalazine-induced antiinflammatory activity in vitro and in vivo but also indicate that adenine nucleotides, released from cells, are the source of extracellular adenosine.	Sulfasalazine	107-120	5'-nucleotidase ecto	Homo sapiens	33-53
9435300-6	1998	These results not only show that ecto-5"-nucleotidase activity is a critical mediator of methotrexate- and sulfasalazine-induced antiinflammatory activity in vitro and in vivo but also indicate that adenine nucleotides, released from cells, are the source of extracellular adenosine.	Adenine Nucleotides	199-218	5'-nucleotidase ecto	Homo sapiens	33-53
9435300-6	1998	These results not only show that ecto-5"-nucleotidase activity is a critical mediator of methotrexate- and sulfasalazine-induced antiinflammatory activity in vitro and in vivo but also indicate that adenine nucleotides, released from cells, are the source of extracellular adenosine.	Adenosine	273-282	5'-nucleotidase ecto	Homo sapiens	33-53
9315551-5	1997	Treatment of cultured human coronary arterial endothelial cells (HCAECs) with L-NAME for 30 minutes increased ecto-5"-nucleotidase activity, which was inhibited by either GF109203X or calphostin C. NO releasers decreased both ecto-5"-nucleotidase and PKC activities in HCAECs.	NG-Nitroarginine Methyl Ester	78-84	5'-nucleotidase ecto	Homo sapiens	110-130
9315551-4	1997	The intracoronary administration of alpha,beta-methyleneadenosine 5"-diphosphate, an inhibitor of ecto-5"-nucleotidase, or GF109203X or calphostin C, both of which are PKC inhibitors, attenuated the L-NAME-induced increases in adenosine levels and ecto-5"-nucleotidase activity.	alpha,beta-methyleneadenosine 5'-diphosphate	36-80	5'-nucleotidase ecto	Homo sapiens	98-118
9598042-0	1998	Purification and some molecular properties of pigeon heart AMP-selective 5"-nucleotidase.	Adenosine Monophosphate	59-62	5'-nucleotidase ecto	Homo sapiens	73-88
9498326-2	1998	We hypothesize that the mutation affects the cell Zn content, which subsequently affects the activity of various zinc-dependent enzymes, such as 5"-nucleotidase.	Zinc	50-52	5'-nucleotidase ecto	Homo sapiens	145-160
9498326-5	1998	The activity of 5"-nucleotidase in the AE fibroblasts grown in 16 micromol/L Zn or 1.5 micromol/L Zn medium was also significantly lower than in normal fibroblasts.	Zinc	77-79	5'-nucleotidase ecto	Homo sapiens	16-31
9498326-5	1998	The activity of 5"-nucleotidase in the AE fibroblasts grown in 16 micromol/L Zn or 1.5 micromol/L Zn medium was also significantly lower than in normal fibroblasts.	zn medium	98-107	5'-nucleotidase ecto	Homo sapiens	16-31
9498326-7	1998	Cells grown in 200 micromol/L Zn medium exhibited threefold greater 5"-nucleotidase activity in AE fibroblasts, but had no affect on enzyme activity in normal cells.	Zinc	30-32	5'-nucleotidase ecto	Homo sapiens	68-83
9498326-9	1998	However, AE fibroblasts grown in 200 micromol/L Zn medium exhibited recovery of their 5"-nucleotidase activity to normal levels.	zn medium	48-57	5'-nucleotidase ecto	Homo sapiens	86-101
9498326-11	1998	The lower cell Zn content subsequently affects the activity of 5"-nucleotidase.	Zinc	15-17	5'-nucleotidase ecto	Homo sapiens	63-78
9851317-5	1998	In contrast, genistein (10 mg x ml(-1)), an inhibitor of tyrosine kinase, prevented EGF-dependent stimulation of aminopeptidase N and 5"-nucleotidase, suggesting that protein phosphorylation was involved in the signaling mechanism.	Genistein	13-22	5'-nucleotidase ecto	Homo sapiens	134-149
9851317-7	1998	These results demonstrate that EGF, via the control of 5"-nucleotidase and aminopeptidase N, which are implied in adenosine formation and peptide processing, respectively, could play a role in human cultured mesangial cell contractility and proliferation.	Adenosine	114-123	5'-nucleotidase ecto	Homo sapiens	55-70
9316413-7	1997	High-performance liquid chromatography analysis reveals that the ecto-enzyme hydrolyzes epsilon-(ApnA) to give epsilon-adenosine-5"(n-1)-phosphate and epsilon-AMP, which are then further catabolized up to epsilon-adenosine via the membrane-bound nucleotidase system ecto-ATPase, ecto-ADPase (or apyrase), and ecto-5"-nucleotidase.	epsilon-adenosine-5"(n-1)-phosphate	111-146	5'-nucleotidase ecto	Homo sapiens	309-329
9316413-7	1997	High-performance liquid chromatography analysis reveals that the ecto-enzyme hydrolyzes epsilon-(ApnA) to give epsilon-adenosine-5"(n-1)-phosphate and epsilon-AMP, which are then further catabolized up to epsilon-adenosine via the membrane-bound nucleotidase system ecto-ATPase, ecto-ADPase (or apyrase), and ecto-5"-nucleotidase.	etheno-AMP	151-162	5'-nucleotidase ecto	Homo sapiens	309-329
9316413-7	1997	High-performance liquid chromatography analysis reveals that the ecto-enzyme hydrolyzes epsilon-(ApnA) to give epsilon-adenosine-5"(n-1)-phosphate and epsilon-AMP, which are then further catabolized up to epsilon-adenosine via the membrane-bound nucleotidase system ecto-ATPase, ecto-ADPase (or apyrase), and ecto-5"-nucleotidase.	epsilon-adenosine	111-128	5'-nucleotidase ecto	Homo sapiens	309-329
9315551-4	1997	The intracoronary administration of alpha,beta-methyleneadenosine 5"-diphosphate, an inhibitor of ecto-5"-nucleotidase, or GF109203X or calphostin C, both of which are PKC inhibitors, attenuated the L-NAME-induced increases in adenosine levels and ecto-5"-nucleotidase activity.	alpha,beta-methyleneadenosine 5'-diphosphate	36-80	5'-nucleotidase ecto	Homo sapiens	248-268
9315551-5	1997	Treatment of cultured human coronary arterial endothelial cells (HCAECs) with L-NAME for 30 minutes increased ecto-5"-nucleotidase activity, which was inhibited by either GF109203X or calphostin C. NO releasers decreased both ecto-5"-nucleotidase and PKC activities in HCAECs.	NG-Nitroarginine Methyl Ester	78-84	5'-nucleotidase ecto	Homo sapiens	226-246
9315551-7	1997	CONCLUSIONS: These results indicate that the inhibition of NO synthesis increases both adenosine production and ecto5"-nucleotidase activity through the activation of PKC and that NO modulates ecto-5"-nucleotidase via cGMP-independent mechanisms.	Adenosine	87-96	5'-nucleotidase ecto	Homo sapiens	193-213
9315551-7	1997	CONCLUSIONS: These results indicate that the inhibition of NO synthesis increases both adenosine production and ecto5"-nucleotidase activity through the activation of PKC and that NO modulates ecto-5"-nucleotidase via cGMP-independent mechanisms.	Cyclic GMP	218-222	5'-nucleotidase ecto	Homo sapiens	112-131
9315551-7	1997	CONCLUSIONS: These results indicate that the inhibition of NO synthesis increases both adenosine production and ecto5"-nucleotidase activity through the activation of PKC and that NO modulates ecto-5"-nucleotidase via cGMP-independent mechanisms.	Cyclic GMP	218-222	5'-nucleotidase ecto	Homo sapiens	193-213
9264340-7	1997	The 5"-Nase-positive lymphatic vessels were seen predominantly in the capsule and interlobular connective tissue but sometimes in the immediate vicinity of the PVS around the PCV, when a discrete opening in the lymphatic wall next to the PVS was found.	penciclovir	175-178	5'-nucleotidase ecto	Homo sapiens	4-11
9211192-3	1997	These normally undetectable succinylpurines are the products of the dephosphorylation, by cytosolic 5"-nucleotidase, of the two substrates of adenylosuccinase.	succinylpurines	28-43	5'-nucleotidase ecto	Homo sapiens	100-115
9263751-0	1997	Differentiation of BCS-TC2 human colon adenocarcinoma cells by sodium butyrate: increase in 5"-nucleotidase activity.	Butyric Acid	63-78	5'-nucleotidase ecto	Homo sapiens	92-107
9232203-0	1997	Human seminal plasma soluble 5"-nucleotidase: regulatory aspects of the dephosphorylation of nucleoside 5"-monophosphates.	nucleoside 5"-monophosphates	93-121	5'-nucleotidase ecto	Homo sapiens	29-44
9169488-10	1997	An inhibitor of the ecto-5"-nucleotidase CD73, alpha, beta-methylene ADP (AOPCP), inhibited epithelial Cl- secretory responses to 5"-AMP, but not to authentic adenosine.	alpha,beta-methyleneadenosine 5'-diphosphate	47-72	5'-nucleotidase ecto	Homo sapiens	20-40
9169488-10	1997	An inhibitor of the ecto-5"-nucleotidase CD73, alpha, beta-methylene ADP (AOPCP), inhibited epithelial Cl- secretory responses to 5"-AMP, but not to authentic adenosine.	alpha,beta-methyleneadenosine 5'-diphosphate	47-72	5'-nucleotidase ecto	Homo sapiens	41-45
9169488-10	1997	An inhibitor of the ecto-5"-nucleotidase CD73, alpha, beta-methylene ADP (AOPCP), inhibited epithelial Cl- secretory responses to 5"-AMP, but not to authentic adenosine.	alpha,beta-methyleneadenosine 5'-diphosphate	74-79	5'-nucleotidase ecto	Homo sapiens	20-40
9169488-10	1997	An inhibitor of the ecto-5"-nucleotidase CD73, alpha, beta-methylene ADP (AOPCP), inhibited epithelial Cl- secretory responses to 5"-AMP, but not to authentic adenosine.	alpha,beta-methyleneadenosine 5'-diphosphate	74-79	5'-nucleotidase ecto	Homo sapiens	41-45
9169488-10	1997	An inhibitor of the ecto-5"-nucleotidase CD73, alpha, beta-methylene ADP (AOPCP), inhibited epithelial Cl- secretory responses to 5"-AMP, but not to authentic adenosine.	Adenosine Monophosphate	130-136	5'-nucleotidase ecto	Homo sapiens	20-40
9169488-10	1997	An inhibitor of the ecto-5"-nucleotidase CD73, alpha, beta-methylene ADP (AOPCP), inhibited epithelial Cl- secretory responses to 5"-AMP, but not to authentic adenosine.	Adenosine Monophosphate	130-136	5'-nucleotidase ecto	Homo sapiens	41-45
9169488-10	1997	An inhibitor of the ecto-5"-nucleotidase CD73, alpha, beta-methylene ADP (AOPCP), inhibited epithelial Cl- secretory responses to 5"-AMP, but not to authentic adenosine.	Adenosine	159-168	5'-nucleotidase ecto	Homo sapiens	41-45
9169488-13	1997	Treatment with phosphotidylinositol specific-phospholipase C (PI-PLC) released 95% of apical CD73, indicating that the intestinal CD73 possesses a glycosylphosphatidylinositol (GPI) anchor.	Glycosylphosphatidylinositols	147-175	5'-nucleotidase ecto	Homo sapiens	130-134
9169488-13	1997	Treatment with phosphotidylinositol specific-phospholipase C (PI-PLC) released 95% of apical CD73, indicating that the intestinal CD73 possesses a glycosylphosphatidylinositol (GPI) anchor.	Glycosylphosphatidylinositols	177-180	5'-nucleotidase ecto	Homo sapiens	130-134
9169488-15	1997	The bulk of apical CD73 ( approximately 60%) was released from the cell surface by treatment with 1% Triton X-100 (TX-100) at 4 degrees C, but such release was not affected by pretreatment with ligand or by prior, antibody-mediated cross-linking of CD73.	Octoxynol	101-113	5'-nucleotidase ecto	Homo sapiens	19-23
9169488-15	1997	The bulk of apical CD73 ( approximately 60%) was released from the cell surface by treatment with 1% Triton X-100 (TX-100) at 4 degrees C, but such release was not affected by pretreatment with ligand or by prior, antibody-mediated cross-linking of CD73.	Octoxynol	115-121	5'-nucleotidase ecto	Homo sapiens	19-23
9169488-16	1997	Subsequent analyses showed that the subpool of CD73 released by TX-100 at 4 degrees C was not truly solubilized, but rather represented TX-100-induced release of CD73-containing membrane fragments.	Octoxynol	64-70	5'-nucleotidase ecto	Homo sapiens	47-51
9169488-16	1997	Subsequent analyses showed that the subpool of CD73 released by TX-100 at 4 degrees C was not truly solubilized, but rather represented TX-100-induced release of CD73-containing membrane fragments.	Octoxynol	64-70	5'-nucleotidase ecto	Homo sapiens	162-166
9169488-16	1997	Subsequent analyses showed that the subpool of CD73 released by TX-100 at 4 degrees C was not truly solubilized, but rather represented TX-100-induced release of CD73-containing membrane fragments.	Octoxynol	136-142	5'-nucleotidase ecto	Homo sapiens	47-51
9169488-16	1997	Subsequent analyses showed that the subpool of CD73 released by TX-100 at 4 degrees C was not truly solubilized, but rather represented TX-100-induced release of CD73-containing membrane fragments.	Octoxynol	136-142	5'-nucleotidase ecto	Homo sapiens	162-166
9169488-18	1997	These data indicate that human intestinal epithelia express CD73, which is apically polarized and targeted to microdomains with DIGs/caveolae characteristics.	digs	128-132	5'-nucleotidase ecto	Homo sapiens	60-64
9169488-19	1997	CD73 likely participates in translating paracrine, PMN-derived 5"-AMP signals to the authentic effector adenosine.	Adenosine Monophosphate	63-69	5'-nucleotidase ecto	Homo sapiens	0-4
9169488-19	1997	CD73 likely participates in translating paracrine, PMN-derived 5"-AMP signals to the authentic effector adenosine.	Adenosine	104-113	5'-nucleotidase ecto	Homo sapiens	0-4
9113412-1	1997	CD73 (ecto-5"-nucleotidase), a glycosyl phosphatidylinositol (GPI) anchored purine salvage enzyme expressed on the surface of human T and B lymphocytes, catalyzes the conversion of purine and pyrimidine ribo- and deoxyribonucleoside monophosphates to the corresponding nucleosides.	Glycosylphosphatidylinositols	31-60	5'-nucleotidase ecto	Homo sapiens	0-4
9113412-6	1997	CD73 generated adenosine functions in cell signalling in many physiologic systems, including intestinal epithelium, ischemic myocardium, and cholinergic synapses.	Adenosine	15-24	5'-nucleotidase ecto	Homo sapiens	0-4
9113412-7	1997	The hypothesis that CD73 produces adenosine that is important for T cell development is presented.	Adenosine	34-43	5'-nucleotidase ecto	Homo sapiens	20-24
9113412-1	1997	CD73 (ecto-5"-nucleotidase), a glycosyl phosphatidylinositol (GPI) anchored purine salvage enzyme expressed on the surface of human T and B lymphocytes, catalyzes the conversion of purine and pyrimidine ribo- and deoxyribonucleoside monophosphates to the corresponding nucleosides.	Glycosylphosphatidylinositols	31-60	5'-nucleotidase ecto	Homo sapiens	6-26
9113412-1	1997	CD73 (ecto-5"-nucleotidase), a glycosyl phosphatidylinositol (GPI) anchored purine salvage enzyme expressed on the surface of human T and B lymphocytes, catalyzes the conversion of purine and pyrimidine ribo- and deoxyribonucleoside monophosphates to the corresponding nucleosides.	Glycosylphosphatidylinositols	62-65	5'-nucleotidase ecto	Homo sapiens	0-4
9113412-1	1997	CD73 (ecto-5"-nucleotidase), a glycosyl phosphatidylinositol (GPI) anchored purine salvage enzyme expressed on the surface of human T and B lymphocytes, catalyzes the conversion of purine and pyrimidine ribo- and deoxyribonucleoside monophosphates to the corresponding nucleosides.	Glycosylphosphatidylinositols	62-65	5'-nucleotidase ecto	Homo sapiens	6-26
9113412-1	1997	CD73 (ecto-5"-nucleotidase), a glycosyl phosphatidylinositol (GPI) anchored purine salvage enzyme expressed on the surface of human T and B lymphocytes, catalyzes the conversion of purine and pyrimidine ribo- and deoxyribonucleoside monophosphates to the corresponding nucleosides.	purine	76-82	5'-nucleotidase ecto	Homo sapiens	0-4
9113412-1	1997	CD73 (ecto-5"-nucleotidase), a glycosyl phosphatidylinositol (GPI) anchored purine salvage enzyme expressed on the surface of human T and B lymphocytes, catalyzes the conversion of purine and pyrimidine ribo- and deoxyribonucleoside monophosphates to the corresponding nucleosides.	purine	76-82	5'-nucleotidase ecto	Homo sapiens	6-26
9113412-1	1997	CD73 (ecto-5"-nucleotidase), a glycosyl phosphatidylinositol (GPI) anchored purine salvage enzyme expressed on the surface of human T and B lymphocytes, catalyzes the conversion of purine and pyrimidine ribo- and deoxyribonucleoside monophosphates to the corresponding nucleosides.	purine	181-187	5'-nucleotidase ecto	Homo sapiens	0-4
9113412-1	1997	CD73 (ecto-5"-nucleotidase), a glycosyl phosphatidylinositol (GPI) anchored purine salvage enzyme expressed on the surface of human T and B lymphocytes, catalyzes the conversion of purine and pyrimidine ribo- and deoxyribonucleoside monophosphates to the corresponding nucleosides.	purine	181-187	5'-nucleotidase ecto	Homo sapiens	6-26
9113412-1	1997	CD73 (ecto-5"-nucleotidase), a glycosyl phosphatidylinositol (GPI) anchored purine salvage enzyme expressed on the surface of human T and B lymphocytes, catalyzes the conversion of purine and pyrimidine ribo- and deoxyribonucleoside monophosphates to the corresponding nucleosides.	pyrimidine	192-202	5'-nucleotidase ecto	Homo sapiens	0-4
9113412-1	1997	CD73 (ecto-5"-nucleotidase), a glycosyl phosphatidylinositol (GPI) anchored purine salvage enzyme expressed on the surface of human T and B lymphocytes, catalyzes the conversion of purine and pyrimidine ribo- and deoxyribonucleoside monophosphates to the corresponding nucleosides.	pyrimidine	192-202	5'-nucleotidase ecto	Homo sapiens	6-26
9113412-1	1997	CD73 (ecto-5"-nucleotidase), a glycosyl phosphatidylinositol (GPI) anchored purine salvage enzyme expressed on the surface of human T and B lymphocytes, catalyzes the conversion of purine and pyrimidine ribo- and deoxyribonucleoside monophosphates to the corresponding nucleosides.	monophosphates	233-247	5'-nucleotidase ecto	Homo sapiens	0-4
9113412-1	1997	CD73 (ecto-5"-nucleotidase), a glycosyl phosphatidylinositol (GPI) anchored purine salvage enzyme expressed on the surface of human T and B lymphocytes, catalyzes the conversion of purine and pyrimidine ribo- and deoxyribonucleoside monophosphates to the corresponding nucleosides.	monophosphates	233-247	5'-nucleotidase ecto	Homo sapiens	6-26
9113412-1	1997	CD73 (ecto-5"-nucleotidase), a glycosyl phosphatidylinositol (GPI) anchored purine salvage enzyme expressed on the surface of human T and B lymphocytes, catalyzes the conversion of purine and pyrimidine ribo- and deoxyribonucleoside monophosphates to the corresponding nucleosides.	Nucleosides	269-280	5'-nucleotidase ecto	Homo sapiens	0-4
9113412-1	1997	CD73 (ecto-5"-nucleotidase), a glycosyl phosphatidylinositol (GPI) anchored purine salvage enzyme expressed on the surface of human T and B lymphocytes, catalyzes the conversion of purine and pyrimidine ribo- and deoxyribonucleoside monophosphates to the corresponding nucleosides.	Nucleosides	269-280	5'-nucleotidase ecto	Homo sapiens	6-26
9015312-0	1997	Differential regulation and function of CD73, a glycosyl-phosphatidylinositol-linked 70-kD adhesion molecule, on lymphocytes and endothelial cells.	Glycosylphosphatidylinositols	48-77	5'-nucleotidase ecto	Homo sapiens	40-44
9015312-6	1997	Lymphocyte CD73 is susceptible to phosphatidylinositol phospholipase, whereas only a small portion of CD73 on EC could be removed by this enzyme.	Phosphatidylinositols	34-54	5'-nucleotidase ecto	Homo sapiens	11-15
9015312-7	1997	Furthermore, CD73 on EC was unable to deliver a tyrosine phosphorylation inducing signal upon mAb triggering, whereas triggering of lymphocyte CD73 can induce tyrosine phosphorylation.	Tyrosine	159-167	5'-nucleotidase ecto	Homo sapiens	143-147
8645720-1	1996	Magnesium ion is an allosteric effector of 5"-nucleotidase and thus activates adenosine production from AMP.	Magnesium	0-9	5'-nucleotidase ecto	Homo sapiens	43-58
9408766-2	1997	Adenosine is the end product of 5"-nucleotidase activity.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	32-47
8906810-1	1996	CD73 is a glycosyl phosphatidylinositol (GPI)-anchored purine salvage enzyme (ecto-5"-nucleotidase (ecto-5"-NT), E.C.	Glycosylphosphatidylinositols	10-39	5'-nucleotidase ecto	Homo sapiens	0-4
8906810-1	1996	CD73 is a glycosyl phosphatidylinositol (GPI)-anchored purine salvage enzyme (ecto-5"-nucleotidase (ecto-5"-NT), E.C.	Glycosylphosphatidylinositols	10-39	5'-nucleotidase ecto	Homo sapiens	78-98
8906810-1	1996	CD73 is a glycosyl phosphatidylinositol (GPI)-anchored purine salvage enzyme (ecto-5"-nucleotidase (ecto-5"-NT), E.C.	Glycosylphosphatidylinositols	10-39	5'-nucleotidase ecto	Homo sapiens	100-110
8906810-1	1996	CD73 is a glycosyl phosphatidylinositol (GPI)-anchored purine salvage enzyme (ecto-5"-nucleotidase (ecto-5"-NT), E.C.	Glycosylphosphatidylinositols	41-44	5'-nucleotidase ecto	Homo sapiens	0-4
8906810-1	1996	CD73 is a glycosyl phosphatidylinositol (GPI)-anchored purine salvage enzyme (ecto-5"-nucleotidase (ecto-5"-NT), E.C.	Glycosylphosphatidylinositols	41-44	5'-nucleotidase ecto	Homo sapiens	78-98
8906810-1	1996	CD73 is a glycosyl phosphatidylinositol (GPI)-anchored purine salvage enzyme (ecto-5"-nucleotidase (ecto-5"-NT), E.C.	Glycosylphosphatidylinositols	41-44	5'-nucleotidase ecto	Homo sapiens	100-110
8906810-1	1996	CD73 is a glycosyl phosphatidylinositol (GPI)-anchored purine salvage enzyme (ecto-5"-nucleotidase (ecto-5"-NT), E.C.	purine	55-61	5'-nucleotidase ecto	Homo sapiens	0-4
8906810-1	1996	CD73 is a glycosyl phosphatidylinositol (GPI)-anchored purine salvage enzyme (ecto-5"-nucleotidase (ecto-5"-NT), E.C.	purine	55-61	5'-nucleotidase ecto	Homo sapiens	78-98
8906810-1	1996	CD73 is a glycosyl phosphatidylinositol (GPI)-anchored purine salvage enzyme (ecto-5"-nucleotidase (ecto-5"-NT), E.C.	purine	55-61	5'-nucleotidase ecto	Homo sapiens	100-110
8906810-10	1996	CD73 was not induced by other agents that activate T cells and CD73 was the only GPI-anchored molecule up-regulated by CD38 ligation out of six analyzed.	Glycosylphosphatidylinositols	81-84	5'-nucleotidase ecto	Homo sapiens	63-67
8906810-11	1996	These results document a novel pathway in human lymphocytes leading from CD38 ligation to CD73 expression, which may result in the rapid acquisition of new functions, including increased purine salvage, increased sensitivity to Ag-induced activation, and the generation of adenosine (Ado) for Ado receptor signaling.	purine	187-193	5'-nucleotidase ecto	Homo sapiens	90-94
8906810-11	1996	These results document a novel pathway in human lymphocytes leading from CD38 ligation to CD73 expression, which may result in the rapid acquisition of new functions, including increased purine salvage, increased sensitivity to Ag-induced activation, and the generation of adenosine (Ado) for Ado receptor signaling.	Adenosine	273-282	5'-nucleotidase ecto	Homo sapiens	90-94
8906810-11	1996	These results document a novel pathway in human lymphocytes leading from CD38 ligation to CD73 expression, which may result in the rapid acquisition of new functions, including increased purine salvage, increased sensitivity to Ag-induced activation, and the generation of adenosine (Ado) for Ado receptor signaling.	Adenosine	284-287	5'-nucleotidase ecto	Homo sapiens	90-94
8901821-5	1996	The conversion of cAMP to adenosine and inosine was inhibited by blockade of phosphodiesterase with IBMX, of ecto-phosphodiesterase with DPSPX, and of ecto-5"-nucleotidase with AMP-CP.	Cyclic AMP	18-22	5'-nucleotidase ecto	Homo sapiens	151-171
8901821-5	1996	The conversion of cAMP to adenosine and inosine was inhibited by blockade of phosphodiesterase with IBMX, of ecto-phosphodiesterase with DPSPX, and of ecto-5"-nucleotidase with AMP-CP.	Adenosine	26-35	5'-nucleotidase ecto	Homo sapiens	151-171
8901821-5	1996	The conversion of cAMP to adenosine and inosine was inhibited by blockade of phosphodiesterase with IBMX, of ecto-phosphodiesterase with DPSPX, and of ecto-5"-nucleotidase with AMP-CP.	Inosine	40-47	5'-nucleotidase ecto	Homo sapiens	151-171
8901821-5	1996	The conversion of cAMP to adenosine and inosine was inhibited by blockade of phosphodiesterase with IBMX, of ecto-phosphodiesterase with DPSPX, and of ecto-5"-nucleotidase with AMP-CP.	alpha,beta-methyleneadenosine 5'-diphosphate	177-183	5'-nucleotidase ecto	Homo sapiens	151-171
8901821-9	1996	These results indicate that vascular smooth muscle cells metabolize cAMP to adenosine via the sequential action of ecto-phosphodiesterase and ecto-5"-nucleotidase and provide the first evidence that cAMP-derived adenosine can inhibit vascular smooth muscle cell growth.	Cyclic AMP	68-72	5'-nucleotidase ecto	Homo sapiens	142-162
8901821-9	1996	These results indicate that vascular smooth muscle cells metabolize cAMP to adenosine via the sequential action of ecto-phosphodiesterase and ecto-5"-nucleotidase and provide the first evidence that cAMP-derived adenosine can inhibit vascular smooth muscle cell growth.	Adenosine	76-85	5'-nucleotidase ecto	Homo sapiens	142-162
8901821-9	1996	These results indicate that vascular smooth muscle cells metabolize cAMP to adenosine via the sequential action of ecto-phosphodiesterase and ecto-5"-nucleotidase and provide the first evidence that cAMP-derived adenosine can inhibit vascular smooth muscle cell growth.	Cyclic AMP	199-203	5'-nucleotidase ecto	Homo sapiens	142-162
8901821-9	1996	These results indicate that vascular smooth muscle cells metabolize cAMP to adenosine via the sequential action of ecto-phosphodiesterase and ecto-5"-nucleotidase and provide the first evidence that cAMP-derived adenosine can inhibit vascular smooth muscle cell growth.	Adenosine	212-221	5'-nucleotidase ecto	Homo sapiens	142-162
8812736-1	1996	Soluble broad spectrum 5"-nucleotidase from human seminal plasma was purified to homogeneity by a combination of (NH4)2SO4 precipitation, affinity chromatography, and gel filtration.	Ammonium Sulfate	113-122	5'-nucleotidase ecto	Homo sapiens	23-38
8912394-8	1996	The hydrolysis of nucleoside 5"-monophosphates is catalysed by 5"-nucleotidase whose biochemical properties and molecular structure have been studied in detail.	nucleoside 5"-monophosphates	18-46	5'-nucleotidase ecto	Homo sapiens	63-78
8912394-12	1996	Whereas in adult mammalian brain activity for hydrolysis of ATP and ADP may be associated with nerve cells or glial cells 5"-nucleotidase appears to have a preferential glial allocation in the adult mammal.	Adenosine Triphosphate	60-63	5'-nucleotidase ecto	Homo sapiens	122-137
8912394-12	1996	Whereas in adult mammalian brain activity for hydrolysis of ATP and ADP may be associated with nerve cells or glial cells 5"-nucleotidase appears to have a preferential glial allocation in the adult mammal.	Adenosine Diphosphate	68-71	5'-nucleotidase ecto	Homo sapiens	122-137
8693293-2	1996	CD73 is a bifunctional glycosyl phosphatidylinositol anchored leucocyte differentiation antigen which has specific ecto-5"-nucleotidase (ecto-5"-NT) activity and is an accessory T-lymphocyte activation molecule.	Glycosylphosphatidylinositols	23-52	5'-nucleotidase ecto	Homo sapiens	0-4
8693293-2	1996	CD73 is a bifunctional glycosyl phosphatidylinositol anchored leucocyte differentiation antigen which has specific ecto-5"-nucleotidase (ecto-5"-NT) activity and is an accessory T-lymphocyte activation molecule.	Glycosylphosphatidylinositols	23-52	5'-nucleotidase ecto	Homo sapiens	115-135
8693293-2	1996	CD73 is a bifunctional glycosyl phosphatidylinositol anchored leucocyte differentiation antigen which has specific ecto-5"-nucleotidase (ecto-5"-NT) activity and is an accessory T-lymphocyte activation molecule.	Glycosylphosphatidylinositols	23-52	5'-nucleotidase ecto	Homo sapiens	137-147
8693293-4	1996	This group of patients had both significantly decreased levels of ecto-5"-NT on BMC (P = 0.002) and decreased numbers of CD73 molecules per CD73+ lymphocyte (P = 0.01).	bmc	80-83	5'-nucleotidase ecto	Homo sapiens	66-76
8693293-9	1996	In addition, a positive correlation was found between ability to proliferate and level of ecto-5"-NT on BMC (rs = 0.53, P &lt; 0.05).	bmc	104-107	5'-nucleotidase ecto	Homo sapiens	90-100
8693293-10	1996	Furthermore the ability of BMC to synthesize ecto-5"-NT was studied.	bmc	27-30	5'-nucleotidase ecto	Homo sapiens	45-55
8693293-11	1996	During 2 days culture ecto-5"-NT activity increased markedly on BMC from both patients and healthy donors.	bmc	64-67	5'-nucleotidase ecto	Homo sapiens	22-32
8693293-13	1996	This shows that the decreased levels of ecto-5"-NT found on freshly isolated BMC from patients with IGD is due to defective regulation of the enzyme activity in vivo.	bmc	77-80	5'-nucleotidase ecto	Homo sapiens	40-50
9361795-12	1997	2.5"-Nucleotidase (5"-NT) is an enzyme that hydrolyzes nucleotides such as AMP or IMP into inorganic phosphate and the respective nucleoside.	Adenosine Monophosphate	75-78	5'-nucleotidase ecto	Homo sapiens	2-17
9361795-12	1997	2.5"-Nucleotidase (5"-NT) is an enzyme that hydrolyzes nucleotides such as AMP or IMP into inorganic phosphate and the respective nucleoside.	Phosphates	101-110	5'-nucleotidase ecto	Homo sapiens	2-17
9361795-12	1997	2.5"-Nucleotidase (5"-NT) is an enzyme that hydrolyzes nucleotides such as AMP or IMP into inorganic phosphate and the respective nucleoside.	Nucleosides	130-140	5'-nucleotidase ecto	Homo sapiens	2-17
9615614-3	1997	For n-butanol extracts containing oil red, 5"-nucleotidase, or alkaline phosphatase, the hydrophobic molecules and Triton X-114 were retained in the aqueous phase during incubations at 30 degrees C. The n-butanol interference was concentration-dependent and was reduced by lowering the final n-butanol concentration of the sample to 1.5% (v/v) or less.	1-Butanol	4-13	5'-nucleotidase ecto	Homo sapiens	43-58
9615614-3	1997	For n-butanol extracts containing oil red, 5"-nucleotidase, or alkaline phosphatase, the hydrophobic molecules and Triton X-114 were retained in the aqueous phase during incubations at 30 degrees C. The n-butanol interference was concentration-dependent and was reduced by lowering the final n-butanol concentration of the sample to 1.5% (v/v) or less.	Nonidet P-40	115-127	5'-nucleotidase ecto	Homo sapiens	43-58
9615614-3	1997	For n-butanol extracts containing oil red, 5"-nucleotidase, or alkaline phosphatase, the hydrophobic molecules and Triton X-114 were retained in the aqueous phase during incubations at 30 degrees C. The n-butanol interference was concentration-dependent and was reduced by lowering the final n-butanol concentration of the sample to 1.5% (v/v) or less.	1-Butanol	203-212	5'-nucleotidase ecto	Homo sapiens	43-58
9615614-3	1997	For n-butanol extracts containing oil red, 5"-nucleotidase, or alkaline phosphatase, the hydrophobic molecules and Triton X-114 were retained in the aqueous phase during incubations at 30 degrees C. The n-butanol interference was concentration-dependent and was reduced by lowering the final n-butanol concentration of the sample to 1.5% (v/v) or less.	1-Butanol	203-212	5'-nucleotidase ecto	Homo sapiens	43-58
9615614-4	1997	The results demonstrate how buffer-diluted n-butanol extracts of 5"-nucleotidase and alkaline phosphatase can be successfully employed for subsequent Triton X-114 fractionation of the enzymes.	1-Butanol	43-52	5'-nucleotidase ecto	Homo sapiens	65-80
9615614-4	1997	The results demonstrate how buffer-diluted n-butanol extracts of 5"-nucleotidase and alkaline phosphatase can be successfully employed for subsequent Triton X-114 fractionation of the enzymes.	Nonidet P-40	150-162	5'-nucleotidase ecto	Homo sapiens	65-80
9110121-3	1997	Regulation of the enzyme producing adenosine (i.e., 5"-nucleotidase) has been reported during preconditioning but, because its activity does not seem to be associated with infarct size, it is unlikely that the hydrolase plays a pivotal role.	Adenosine	35-44	5'-nucleotidase ecto	Homo sapiens	52-67
9131425-11	1996	Ecto-5"-nucleotidase is a GPI-anchored glycoprotein and catalyses the formation of AMP to adenosine.	Adenosine Monophosphate	83-86	5'-nucleotidase ecto	Homo sapiens	0-20
9131425-11	1996	Ecto-5"-nucleotidase is a GPI-anchored glycoprotein and catalyses the formation of AMP to adenosine.	Adenosine	90-99	5'-nucleotidase ecto	Homo sapiens	0-20
8759717-4	1996	Two other nucleotide-hydrolyzing activities were induced on the T cell surface concomitantly with CD38: the human PC-1 molecule, a nucleotide phosphodiesterase/pyrophosphatase that produces AMP from NAD or ADP-ribose, and a nucleotidase that produces adenosine from AMP, but which may be distinct from the CD73 5"-nucleotidase.	Adenosine Monophosphate	190-193	5'-nucleotidase ecto	Homo sapiens	306-310
8759717-4	1996	Two other nucleotide-hydrolyzing activities were induced on the T cell surface concomitantly with CD38: the human PC-1 molecule, a nucleotide phosphodiesterase/pyrophosphatase that produces AMP from NAD or ADP-ribose, and a nucleotidase that produces adenosine from AMP, but which may be distinct from the CD73 5"-nucleotidase.	NAD	199-202	5'-nucleotidase ecto	Homo sapiens	306-310
8645720-15	1996	A simplified model of compartmentalized adenosine metabolism is proposed in which magnesium ion-activated cardiac purine release originates predominantly from the ecto 5"-nucleotidase; magnesium ion stimulation of metabolic flux through the cytosolic isoforms was constrained by concomitant reductions in intracellular AMP substrate and allosteric activator ADP.	Adenosine	40-49	5'-nucleotidase ecto	Homo sapiens	163-183
8645720-15	1996	A simplified model of compartmentalized adenosine metabolism is proposed in which magnesium ion-activated cardiac purine release originates predominantly from the ecto 5"-nucleotidase; magnesium ion stimulation of metabolic flux through the cytosolic isoforms was constrained by concomitant reductions in intracellular AMP substrate and allosteric activator ADP.	Magnesium	82-91	5'-nucleotidase ecto	Homo sapiens	163-183
8645720-16	1996	Magnesium ion-enhanced adenosine formation by 5"-nucleotidase could contribute to the known cardioprotective effects of this clinically used cation.	Magnesium	0-9	5'-nucleotidase ecto	Homo sapiens	46-61
8645720-16	1996	Magnesium ion-enhanced adenosine formation by 5"-nucleotidase could contribute to the known cardioprotective effects of this clinically used cation.	Adenosine	23-32	5'-nucleotidase ecto	Homo sapiens	46-61
8645720-1	1996	Magnesium ion is an allosteric effector of 5"-nucleotidase and thus activates adenosine production from AMP.	Adenosine	78-87	5'-nucleotidase ecto	Homo sapiens	43-58
8645720-1	1996	Magnesium ion is an allosteric effector of 5"-nucleotidase and thus activates adenosine production from AMP.	Adenosine Monophosphate	104-107	5'-nucleotidase ecto	Homo sapiens	43-58
8645720-9	1996	50 microM, alpha,beta-methylene adenosine 5"-diphosphate (AOPCP), a selective inhibitor of ecto 5"-nucleotidase, elevated interstitial AMP concentration tenfold, did not attenuate basal nucleoside release, but completely inhibited Mg2+-stimulated coronary venous purine nucleoside release and blunted Mg2+-stimulated interstitial purine nucleoside formation by 69%.	alpha,beta-methyleneadenosine 5'-diphosphate	11-56	5'-nucleotidase ecto	Homo sapiens	91-111
8645720-9	1996	50 microM, alpha,beta-methylene adenosine 5"-diphosphate (AOPCP), a selective inhibitor of ecto 5"-nucleotidase, elevated interstitial AMP concentration tenfold, did not attenuate basal nucleoside release, but completely inhibited Mg2+-stimulated coronary venous purine nucleoside release and blunted Mg2+-stimulated interstitial purine nucleoside formation by 69%.	alpha,beta-methyleneadenosine 5'-diphosphate	58-63	5'-nucleotidase ecto	Homo sapiens	91-111
8645720-9	1996	50 microM, alpha,beta-methylene adenosine 5"-diphosphate (AOPCP), a selective inhibitor of ecto 5"-nucleotidase, elevated interstitial AMP concentration tenfold, did not attenuate basal nucleoside release, but completely inhibited Mg2+-stimulated coronary venous purine nucleoside release and blunted Mg2+-stimulated interstitial purine nucleoside formation by 69%.	Adenosine Monophosphate	135-138	5'-nucleotidase ecto	Homo sapiens	91-111
8779965-6	1996	Addition of alpha, beta-methyleneadenosine 5"-diphosphate (50 microM) to inhibit 5"-nucleotidase activity increased AMP concentrations two- to threefold.	alpha,beta-methyleneadenosine 5'-diphosphate	12-57	5'-nucleotidase ecto	Homo sapiens	81-96
8617729-0	1996	Inhibition of ecto-5"-nucleotidase by nitric oxide donors.	Nitric Oxide	38-50	5'-nucleotidase ecto	Homo sapiens	14-34
8617729-2	1996	We evaluated, in renal epithelial cells with a proximal tubule phenotype, the effect of nitric oxide (NO) on ecto-5 -nucleotidase (5"-N U), the underlying mechanism and its functional consequence.	Nitric Oxide	88-100	5'-nucleotidase ecto	Homo sapiens	109-129
9238677-7	1996	All of the post-testicularly acquired GPI-anchored proteins identified thus far have also been found on cells of the immune system (CD62, CD55, CD59, CD73), and we speculate that they may have a role in protecting spermatozoa from immune attack in the male and female reproductive tracts.	Glycosylphosphatidylinositols	38-41	5'-nucleotidase ecto	Homo sapiens	150-154
8619914-3	1996	The aim of the present study was to elucidate whether specific ecto-5"-NT activity on blood mononuclear cells (BMC) was correlated with CD73 expression measured by flow cytometry.	bmc	111-114	5'-nucleotidase ecto	Homo sapiens	63-73
8619914-3	1996	The aim of the present study was to elucidate whether specific ecto-5"-NT activity on blood mononuclear cells (BMC) was correlated with CD73 expression measured by flow cytometry.	bmc	111-114	5'-nucleotidase ecto	Homo sapiens	136-140
8619914-7	1996	The ecto-5"-NT activity increased significantly (p&lt;0.02) during culture of unseparated BMC, whereas the number of anti-CD73 binding sites did not change.	bmc	90-93	5'-nucleotidase ecto	Homo sapiens	4-14
8619914-11	1996	Treatment of BMC with phosphatidylinositol-specific phospholipase-C released 57% (51%-75%) of the ecto-5"-NT activity into the supernatants, without a detectable decrease in CD73 expression.	bmc	13-16	5'-nucleotidase ecto	Homo sapiens	98-108
8619914-11	1996	Treatment of BMC with phosphatidylinositol-specific phospholipase-C released 57% (51%-75%) of the ecto-5"-NT activity into the supernatants, without a detectable decrease in CD73 expression.	bmc	13-16	5'-nucleotidase ecto	Homo sapiens	174-178
8619914-11	1996	Treatment of BMC with phosphatidylinositol-specific phospholipase-C released 57% (51%-75%) of the ecto-5"-NT activity into the supernatants, without a detectable decrease in CD73 expression.	Phosphatidylinositols	22-42	5'-nucleotidase ecto	Homo sapiens	98-108
8619914-11	1996	Treatment of BMC with phosphatidylinositol-specific phospholipase-C released 57% (51%-75%) of the ecto-5"-NT activity into the supernatants, without a detectable decrease in CD73 expression.	Phosphatidylinositols	22-42	5'-nucleotidase ecto	Homo sapiens	174-178
8619914-13	1996	The results of this study indicate that CD73 exists on BMC in isoforms with distinct capacities to bind mouse monoclonal anti-CD73.	bmc	55-58	5'-nucleotidase ecto	Homo sapiens	40-44
8619914-13	1996	The results of this study indicate that CD73 exists on BMC in isoforms with distinct capacities to bind mouse monoclonal anti-CD73.	bmc	55-58	5'-nucleotidase ecto	Homo sapiens	126-130
8645738-1	1996	Cytosolic 5"-nucleotidase, acting preferentially on IMP, GMP and their deoxyderivatives, can also behave as a phosphotransferase, operating a transfer of phosphate from a nucleoside monophosphate donor to a nucleoside acceptor which, besides a natural nucleoside, can be also an analog.	guanosine 5'-monophosphorothioate	57-60	5'-nucleotidase ecto	Homo sapiens	10-25
8645738-1	1996	Cytosolic 5"-nucleotidase, acting preferentially on IMP, GMP and their deoxyderivatives, can also behave as a phosphotransferase, operating a transfer of phosphate from a nucleoside monophosphate donor to a nucleoside acceptor which, besides a natural nucleoside, can be also an analog.	Phosphates	154-163	5'-nucleotidase ecto	Homo sapiens	10-25
8645738-1	1996	Cytosolic 5"-nucleotidase, acting preferentially on IMP, GMP and their deoxyderivatives, can also behave as a phosphotransferase, operating a transfer of phosphate from a nucleoside monophosphate donor to a nucleoside acceptor which, besides a natural nucleoside, can be also an analog.	nucleoside monophosphate	171-195	5'-nucleotidase ecto	Homo sapiens	10-25
8645738-1	1996	Cytosolic 5"-nucleotidase, acting preferentially on IMP, GMP and their deoxyderivatives, can also behave as a phosphotransferase, operating a transfer of phosphate from a nucleoside monophosphate donor to a nucleoside acceptor which, besides a natural nucleoside, can be also an analog.	Nucleosides	171-181	5'-nucleotidase ecto	Homo sapiens	10-25
8645738-1	1996	Cytosolic 5"-nucleotidase, acting preferentially on IMP, GMP and their deoxyderivatives, can also behave as a phosphotransferase, operating a transfer of phosphate from a nucleoside monophosphate donor to a nucleoside acceptor which, besides a natural nucleoside, can be also an analog.	Nucleosides	207-217	5'-nucleotidase ecto	Homo sapiens	10-25
8645738-6	1996	The observation that BPG favors the phosphotransferase more than the hydrolase activity of 5"-nucleotidase stands for a key role of this metabolite in the regulation of the processes of activation of purine pro-drugs, in which this enzyme is involved.	purine	200-206	5'-nucleotidase ecto	Homo sapiens	91-106
8967393-11	1996	Nevertheless, cytosolic 5"-nucleotidase activity in human heart can easily account for adenosine formation during ischemia.	Adenosine	87-96	5'-nucleotidase ecto	Homo sapiens	24-39
8726403-3	1996	Cell lines deficient in deoxycytidine kinase were shown to be resistant to CdA and a high deoxycytidine kinase level in combination with low 5"-nucleotidase has been proposed to partly explain the selectivity in CdA toxicity for lymphoid cells.	Cladribine	212-215	5'-nucleotidase ecto	Homo sapiens	141-156
8779965-6	1996	Addition of alpha, beta-methyleneadenosine 5"-diphosphate (50 microM) to inhibit 5"-nucleotidase activity increased AMP concentrations two- to threefold.	Adenosine Monophosphate	116-119	5'-nucleotidase ecto	Homo sapiens	81-96
8717492-3	1996	Since AMPDA competes with 5"-nucleotidase for AMP, it is responsible for regulation of a physiologically important active product of purine nucleotide metabolism, such as adenosine.	purine	133-139	5'-nucleotidase ecto	Homo sapiens	26-41
8717492-3	1996	Since AMPDA competes with 5"-nucleotidase for AMP, it is responsible for regulation of a physiologically important active product of purine nucleotide metabolism, such as adenosine.	Adenosine	171-180	5'-nucleotidase ecto	Homo sapiens	26-41
8790720-6	1996	Alternative routes for phosphorylation of nucleoside analogs are also reviewed, such as the phosphotransfer capacity of 5"-nucleotidase and protein kinases.	Nucleosides	42-52	5'-nucleotidase ecto	Homo sapiens	120-135
8778740-6	1995	However, in most cases the inhibitory effect of this adenine nucleotide depends upon its hydrolysis into adenosine by a cascade of ectoenzymes, the last step being mediated by ecto-5"-nucleotidase.	Adenine Nucleotides	53-71	5'-nucleotidase ecto	Homo sapiens	176-196
19927594-0	1996	The phosphotransferase activity of cytosolic 5"-nucleotidase; a purine analog phosphorylating enzyme.	purine	64-70	5'-nucleotidase ecto	Homo sapiens	45-60
19927594-1	1996	Cytosolic 5"-nucleotidase is involved in the phosphorylation of several purine nucleoside analogs,used as antiviral and chemotherapeutic agents.	Purine Nucleosides	72-89	5'-nucleotidase ecto	Homo sapiens	10-25
19927594-6	1996	This is the first report of deoxycoformycin phosphorylation catalyzed by a 5"-nucleotidase purified from eukaryotic cells.	Pentostatin	28-43	5'-nucleotidase ecto	Homo sapiens	75-90
19927594-8	1996	Finally, the presence of a suitable substrate for the phosphotransferase activity of cytosolic 5"-nucleotidase caused a stimulation of the rate of formation of the nucleoside.	Nucleosides	164-174	5'-nucleotidase ecto	Homo sapiens	95-110
7595232-3	1995	Protein sequencing of tryptic peptides from immunoaffinity-purified L-VAP-2 revealed sequence identity between L-VAP-2 and CD73 (ecto-5"-nucleotidase, E.C.3.1.3.5), and COS cells transfected with a CD73 cDNA were positively stained with the mAb 4G4, which recognizes L-VAP-2.	Peptides	30-38	5'-nucleotidase ecto	Homo sapiens	123-127
8566797-1	1995	Ecto-5"-nucleotidase (NT, CD73) is a purine salvage-pathway enzyme located on the surface of various cell types, including subsets of human lymphocytes and certain leukemias and lymphomas.	purine	37-43	5'-nucleotidase ecto	Homo sapiens	0-20
8566797-1	1995	Ecto-5"-nucleotidase (NT, CD73) is a purine salvage-pathway enzyme located on the surface of various cell types, including subsets of human lymphocytes and certain leukemias and lymphomas.	purine	37-43	5'-nucleotidase ecto	Homo sapiens	26-30
7595232-7	1995	Adhesion experiments showed significantly increased binding of freshly isolated lymphocytes to COS cells transfected with a CD73 cDNA, as compared to mock-transfected COS cells, and binding of lymphocytes to CD73-expressing COS cells was inhibited by the presence of mAb 4G4 in the adhesion assay.	carbonyl sulfide	95-98	5'-nucleotidase ecto	Homo sapiens	124-128
7595232-8	1995	CD73 is a glycosyl phosphatidylinositol-linked molecule previously shown to have a cosignalling role in T lymphocyte proliferation.	Glycosylphosphatidylinositols	10-39	5'-nucleotidase ecto	Homo sapiens	0-4
8778740-6	1995	However, in most cases the inhibitory effect of this adenine nucleotide depends upon its hydrolysis into adenosine by a cascade of ectoenzymes, the last step being mediated by ecto-5"-nucleotidase.	Adenosine	105-114	5'-nucleotidase ecto	Homo sapiens	176-196
7729503-3	1995	Adenosine agonists increased 5"-nucleotidase activity via A2 receptor stimulation.	Adenosine	0-9	5'-nucleotidase ecto	Homo sapiens	29-44
7532359-5	1995	An inhibitor of 5"-nucleotidase, alpha,beta-methyleneadenosine 5"-diphosphate, blocked most of the response to luminal ATP.	alpha,beta-methyleneadenosine 5'-diphosphate	33-77	5'-nucleotidase ecto	Homo sapiens	16-31
7532359-5	1995	An inhibitor of 5"-nucleotidase, alpha,beta-methyleneadenosine 5"-diphosphate, blocked most of the response to luminal ATP.	Adenosine Triphosphate	119-122	5'-nucleotidase ecto	Homo sapiens	16-31
8027539-1	1994	Ecto-5"-nucleotidase (5"-NT,) CD73 is a glycosyl phosphatidylinositol (GPI)-anchored differentiation Ag and purine salvage enzyme expressed on the surface of subsets of human lymphocytes.	Glycosylphosphatidylinositols	40-69	5'-nucleotidase ecto	Homo sapiens	0-20
7494863-7	1995	Finally, alternative pathways for nucleoside analogue phosphorylation are surveyed, such as the phosphotransfer capacity of 5"-nucleotidase.	Nucleosides	34-44	5'-nucleotidase ecto	Homo sapiens	124-139
7969062-6	1994	This decrease in ddAdo and 2"-beta-F-ddAdo phosphorylation with higher levels of the inhibitor appears to result from intracellular penetration of 2"-dCF and consequent inhibition of intracellular deamination, a critical step in the activation of both agents through the 5"-nucleotidase pathway.	Dideoxyadenosine	17-22	5'-nucleotidase ecto	Homo sapiens	271-286
7969062-6	1994	This decrease in ddAdo and 2"-beta-F-ddAdo phosphorylation with higher levels of the inhibitor appears to result from intracellular penetration of 2"-dCF and consequent inhibition of intracellular deamination, a critical step in the activation of both agents through the 5"-nucleotidase pathway.	2"-beta-f-ddado	27-42	5'-nucleotidase ecto	Homo sapiens	271-286
7969062-6	1994	This decrease in ddAdo and 2"-beta-F-ddAdo phosphorylation with higher levels of the inhibitor appears to result from intracellular penetration of 2"-dCF and consequent inhibition of intracellular deamination, a critical step in the activation of both agents through the 5"-nucleotidase pathway.	Pentostatin	147-153	5'-nucleotidase ecto	Homo sapiens	271-286
7927909-0	1994	Ecto-5"-nucleotidase (CD73) in multidrug-resistant cell lines generated by doxorubicin.	Doxorubicin	75-86	5'-nucleotidase ecto	Homo sapiens	0-20
7927909-0	1994	Ecto-5"-nucleotidase (CD73) in multidrug-resistant cell lines generated by doxorubicin.	Doxorubicin	75-86	5'-nucleotidase ecto	Homo sapiens	22-26
7707350-1	1994	Seminal plasma separated from freshly ejaculated bull semen contains vesicles with a 5"-nucleotidase activity incorporated as an ectoenzyme anchored by glycosyl phosphatidylinositol (GPI).	Glycosylphosphatidylinositols	152-181	5'-nucleotidase ecto	Homo sapiens	85-100
7707350-1	1994	Seminal plasma separated from freshly ejaculated bull semen contains vesicles with a 5"-nucleotidase activity incorporated as an ectoenzyme anchored by glycosyl phosphatidylinositol (GPI).	Glycosylphosphatidylinositols	183-186	5'-nucleotidase ecto	Homo sapiens	85-100
7707350-6	1994	Furthermore, the spectral parameters obtained before and after treatment of 5"-nucleotidase-containing liposomes with phosphatidylinositol-specific phospholipase C (PI-PLC) indicated that the liposome membrane bilayer did not contain protein segments.	Phosphatidylinositols	118-138	5'-nucleotidase ecto	Homo sapiens	76-91
7957770-0	1994	Effect of dipyridamole on glomerular mesangial cell ecto-5"-nucleotidase expression.	Dipyridamole	10-22	5'-nucleotidase ecto	Homo sapiens	52-72
7957770-2	1994	Cultured mesangial cells were treated with dipyridamole 1-100 microM from 6-72 h. Ecto-5"-nucleotidase activity approximately doubled (from 115 +/- 11 to 226 +/- 14 nmol/min/mg) after treatment with 100 microM dipyridamole for 72 h. This effect was concentration- and time-dependent.	dipyridamole 1	43-57	5'-nucleotidase ecto	Homo sapiens	82-102
7957770-2	1994	Cultured mesangial cells were treated with dipyridamole 1-100 microM from 6-72 h. Ecto-5"-nucleotidase activity approximately doubled (from 115 +/- 11 to 226 +/- 14 nmol/min/mg) after treatment with 100 microM dipyridamole for 72 h. This effect was concentration- and time-dependent.	Dipyridamole	43-55	5'-nucleotidase ecto	Homo sapiens	82-102
7957770-6	1994	Addition of dipyridamole or NBTI to the adenosine-treated mesangial cells produced an additive increase in ecto-5"-nucleotidase activity.	Dipyridamole	12-24	5'-nucleotidase ecto	Homo sapiens	107-127
7957770-6	1994	Addition of dipyridamole or NBTI to the adenosine-treated mesangial cells produced an additive increase in ecto-5"-nucleotidase activity.	4-nitrobenzylthioinosine	28-32	5'-nucleotidase ecto	Homo sapiens	107-127
7957770-6	1994	Addition of dipyridamole or NBTI to the adenosine-treated mesangial cells produced an additive increase in ecto-5"-nucleotidase activity.	Adenosine	40-49	5'-nucleotidase ecto	Homo sapiens	107-127
7957770-7	1994	Dipyridamole, through its effect on extracellular adenosine and ecto-5"-nucleotidase, may have an influence upon regulation of the glomerular microcirculation.	Dipyridamole	0-12	5'-nucleotidase ecto	Homo sapiens	64-84
8027539-1	1994	Ecto-5"-nucleotidase (5"-NT,) CD73 is a glycosyl phosphatidylinositol (GPI)-anchored differentiation Ag and purine salvage enzyme expressed on the surface of subsets of human lymphocytes.	Glycosylphosphatidylinositols	40-69	5'-nucleotidase ecto	Homo sapiens	30-34
8027539-1	1994	Ecto-5"-nucleotidase (5"-NT,) CD73 is a glycosyl phosphatidylinositol (GPI)-anchored differentiation Ag and purine salvage enzyme expressed on the surface of subsets of human lymphocytes.	Glycosylphosphatidylinositols	71-74	5'-nucleotidase ecto	Homo sapiens	0-20
8027539-1	1994	Ecto-5"-nucleotidase (5"-NT,) CD73 is a glycosyl phosphatidylinositol (GPI)-anchored differentiation Ag and purine salvage enzyme expressed on the surface of subsets of human lymphocytes.	Glycosylphosphatidylinositols	71-74	5'-nucleotidase ecto	Homo sapiens	30-34
8027539-1	1994	Ecto-5"-nucleotidase (5"-NT,) CD73 is a glycosyl phosphatidylinositol (GPI)-anchored differentiation Ag and purine salvage enzyme expressed on the surface of subsets of human lymphocytes.	purine	108-114	5'-nucleotidase ecto	Homo sapiens	0-20
8027539-1	1994	Ecto-5"-nucleotidase (5"-NT,) CD73 is a glycosyl phosphatidylinositol (GPI)-anchored differentiation Ag and purine salvage enzyme expressed on the surface of subsets of human lymphocytes.	purine	108-114	5'-nucleotidase ecto	Homo sapiens	30-34
8031149-3	1994	This phosphorylating activity has drawn the attention of several research groups because the cytosolic 5"-nucleotidase represents the only cellular enzyme able to phosphorylate inosine and guanosine analogs, which are not substrates of known cellular nucleoside kinases.	Inosine	177-184	5'-nucleotidase ecto	Homo sapiens	103-118
8031149-3	1994	This phosphorylating activity has drawn the attention of several research groups because the cytosolic 5"-nucleotidase represents the only cellular enzyme able to phosphorylate inosine and guanosine analogs, which are not substrates of known cellular nucleoside kinases.	Guanosine	189-198	5'-nucleotidase ecto	Homo sapiens	103-118
8405663-0	1993	Effects of adenine nucleotides on low Km 5" nucleotidase from human seminal plasma.	Adenine Nucleotides	11-30	5'-nucleotidase ecto	Homo sapiens	41-56
8000038-0	1994	Effect of dopamine on ecto-5"-nucleotidase expression in human glomerular mesangial cells.	Dopamine	10-18	5'-nucleotidase ecto	Homo sapiens	22-42
8000038-1	1994	Ecto-5"-nucleotidase (5"-ribonucleotide phosphohydrolase, EC 3.1.3.5) of mesangial cells may be the main source of adenosine within the glomerulus, and thus essential in the regulation of glomerular microcirculation.	Adenosine	115-124	5'-nucleotidase ecto	Homo sapiens	0-20
8000038-2	1994	c-AMP and c-AMP-stimulating agents were found to induce ecto-5"-nucleotidase of mesangial cells.	c-amp	0-5	5'-nucleotidase ecto	Homo sapiens	56-76
8000038-2	1994	c-AMP and c-AMP-stimulating agents were found to induce ecto-5"-nucleotidase of mesangial cells.	c-amp	10-15	5'-nucleotidase ecto	Homo sapiens	56-76
8000038-4	1994	We have studied the effect of dopamine on ecto-5"-nucleotidase expression and DNA synthesis of glomerular mesangial cells in culture.	Dopamine	30-38	5'-nucleotidase ecto	Homo sapiens	42-62
8000038-5	1994	Human mesangial cells were exposed to dopamine in the concentration range from 0.1 microM- to 1 mM, for 6-72 h. Ecto-5"-nucleotidase activity of human mesangial cells increased from 118.6 +/- 7.7 to 171 +/- 12 nmol/min/mg in a 72 h culture.	Dopamine	38-46	5'-nucleotidase ecto	Homo sapiens	112-132
8000038-8	1994	DNA synthesis of human mesangial cells, studied after exposure of these cells to the same concentrations of dopamine used in the 5"-nucleotidase stimulation, was inhibited, being also dose dependent.	Dopamine	108-116	5'-nucleotidase ecto	Homo sapiens	129-144
8000038-9	1994	These results indicate that dopamine induces ecto-5"-nucleotidase and inhibits DNA synthesis of cultured human mesangial cells.	Dopamine	28-36	5'-nucleotidase ecto	Homo sapiens	45-65
7910373-1	1994	We have undertaken to characterize the role of cytoplasmic 5"-nucleotidase (EC 3.1.3.5) in the phosphorylation of the anti-herpes simplex virus and anti-human cytomegalovirus agent ganciclovir (GCV) in MOLT-4 cells, a human T cell line adapted to grow in suspension culture.	Ganciclovir	181-192	5'-nucleotidase ecto	Homo sapiens	59-74
7910373-1	1994	We have undertaken to characterize the role of cytoplasmic 5"-nucleotidase (EC 3.1.3.5) in the phosphorylation of the anti-herpes simplex virus and anti-human cytomegalovirus agent ganciclovir (GCV) in MOLT-4 cells, a human T cell line adapted to grow in suspension culture.	Ganciclovir	194-197	5'-nucleotidase ecto	Homo sapiens	59-74
7910373-5	1994	Thus, agents that enhance 5"-nucleotidase-catalyzed phosphorylation of GCV in uninfected cells do not play a similar role in HStk-transfected cells, a consequence of the quantitative predominance of the viral thymidine kinase-catalyzed reaction over that attributable to endogenous cytoplasmic 5"-nucleotidase.	Ganciclovir	71-74	5'-nucleotidase ecto	Homo sapiens	26-41
7510010-2	1993	Like 5"-nucleotidase (which hydrolyzes 5"-adenosine monophosphate to adenosine), and adenylate cyclase (which converts adenosine triphosphate to cyclic AMP), guanylate cyclase selectively stains positive for lymphatic capillaries and therefore may be another useful histochemical marker to differentiate dermal lymph from blood capillaries.	Adenosine Monophosphate	39-65	5'-nucleotidase ecto	Homo sapiens	5-20
7510010-2	1993	Like 5"-nucleotidase (which hydrolyzes 5"-adenosine monophosphate to adenosine), and adenylate cyclase (which converts adenosine triphosphate to cyclic AMP), guanylate cyclase selectively stains positive for lymphatic capillaries and therefore may be another useful histochemical marker to differentiate dermal lymph from blood capillaries.	Adenosine	42-51	5'-nucleotidase ecto	Homo sapiens	5-20
8255734-4	1993	Removal of ecto-5"-nucleotidase inhibition shows that the catabolism of adenine nucleotides released during stimulation contributes in about 50% to the amount of endogenous extracellular adenosine.	Adenine Nucleotides	72-91	5'-nucleotidase ecto	Homo sapiens	11-31
8255734-4	1993	Removal of ecto-5"-nucleotidase inhibition shows that the catabolism of adenine nucleotides released during stimulation contributes in about 50% to the amount of endogenous extracellular adenosine.	Adenosine	187-196	5'-nucleotidase ecto	Homo sapiens	11-31
8255734-5	1993	When only one of the enzymes catabolizing AMP (ecto-5"-nucleotidase or exo-AMP deaminase) was inhibited, the evoked release of adenine nucleotides was undetectable, suggesting that each enzyme is able to catabolize all the AMP formed from adenine nucleotides released upon stimulation.	Adenine Nucleotides	127-146	5'-nucleotidase ecto	Homo sapiens	47-67
8255734-5	1993	When only one of the enzymes catabolizing AMP (ecto-5"-nucleotidase or exo-AMP deaminase) was inhibited, the evoked release of adenine nucleotides was undetectable, suggesting that each enzyme is able to catabolize all the AMP formed from adenine nucleotides released upon stimulation.	Adenine Nucleotides	239-258	5'-nucleotidase ecto	Homo sapiens	47-67
8255734-6	1993	It is concluded that the concentration of endogenous extracellular adenosine is under the control of the relative activities of exo-AMP deaminase and ecto-5"-nucleotidase.	Adenosine	67-76	5'-nucleotidase ecto	Homo sapiens	150-170
8228257-9	1993	Inhibition of epithelial apical membrane ecto-5"-nucleotidase ablated the conversion to adenosine.	Adenosine	88-97	5'-nucleotidase ecto	Homo sapiens	41-61
7691935-8	1993	A phosphotyrosine analysis by Western blotting showed that cross-linking of CD73 induced the phosphorylation of two proteins with a molecular mass of approximately 28 and 100 kDa respectively, whereas ligation of CD3 induced phosphorylation of many substrates.	Phosphotyrosine	2-17	5'-nucleotidase ecto	Homo sapiens	76-80
7691935-10	1993	Because CD73 is linked to the cell surface by a GPI anchor, the transduction of this signal is probably mediated by a lateral interaction with transmembrane molecules.	Glycosylphosphatidylinositols	48-51	5'-nucleotidase ecto	Homo sapiens	8-12
7691935-11	1993	This hypothesis was assessed by cocapping, which showed that CD73 associates strongly with CD45RC, moderately with CD8, and weakly with CD3.	cd45rc	91-97	5'-nucleotidase ecto	Homo sapiens	61-65
8348695-5	1993	In accordance with the decreases in ecto-5"-nucleotidase activity, release of adenosine was attenuated in the FMLP-pretreated and complement C5a-pretreated polymorphonuclear leukocytes, which were restored by concomitant administration of superoxide dismutase.	Adenosine	78-87	5'-nucleotidase ecto	Homo sapiens	36-56
8405663-2	1993	Low Km 5" nucleotidase purified from human seminal plasma has been used in this study to investigate the response of the enzyme ot adenine nucleoside di- and triphosphates in the presence of AMP and IMP as substrates.	adenine nucleoside di- and triphosphates	131-171	5'-nucleotidase ecto	Homo sapiens	7-22
8405663-2	1993	Low Km 5" nucleotidase purified from human seminal plasma has been used in this study to investigate the response of the enzyme ot adenine nucleoside di- and triphosphates in the presence of AMP and IMP as substrates.	Adenosine Monophosphate	191-194	5'-nucleotidase ecto	Homo sapiens	7-22
8405663-2	1993	Low Km 5" nucleotidase purified from human seminal plasma has been used in this study to investigate the response of the enzyme ot adenine nucleoside di- and triphosphates in the presence of AMP and IMP as substrates.	Inosine Monophosphate	199-202	5'-nucleotidase ecto	Homo sapiens	7-22
8222268-4	1993	The prostasome membrane-linked 5"-nucleotidase readily hydrolysed 5"-AMP.	Adenosine Monophosphate	66-72	5'-nucleotidase ecto	Homo sapiens	31-46
8043831-1	1993	The investigation reveals different influence of the plague microbe"s fraction 1 polysaccharide-protein complex and of it"s purified protein on the 5"-nucleotidase activity and on the chemiluminescence response of peritoneal macrophages.	Polysaccharides	81-95	5'-nucleotidase ecto	Homo sapiens	148-163
8485889-0	1993	Interferences of bilirubin, ascorbic acid, dipyrone, and D-penicillamine in two assays of 5"-nucleotidase.	Penicillamine	57-72	5'-nucleotidase ecto	Homo sapiens	90-105
8456972-8	1993	Inhibition of ecto-5"-nucleotidase by alpha,beta-methylene-ADP (5 x 10(-5) M) enhanced AN release from 2.6 to 8.2 pmol.min-1 x ml CV-1 and reduced ADO release by an equivalent extent.	alpha,beta-methyleneadenosine 5'-diphosphate	38-62	5'-nucleotidase ecto	Homo sapiens	14-34
8456951-0	1993	Distribution and regulation of renal ecto-5"-nucleotidase: implications for physiological functions of adenosine.	Adenosine	103-112	5'-nucleotidase ecto	Homo sapiens	37-57
8486793-4	1993	Additional studies suggested that neutrophil-derived 5"-AMP is subsequently converted to adenosine at the epithelial cell surface by ecto-5"-nucleotidase and that adenosine subsequently activates intestinal secretion through adenosine receptors on the apical membrane of target intestinal epithelial cells.	Adenosine Monophosphate	53-59	5'-nucleotidase ecto	Homo sapiens	133-153
8486793-4	1993	Additional studies suggested that neutrophil-derived 5"-AMP is subsequently converted to adenosine at the epithelial cell surface by ecto-5"-nucleotidase and that adenosine subsequently activates intestinal secretion through adenosine receptors on the apical membrane of target intestinal epithelial cells.	Adenosine	89-98	5'-nucleotidase ecto	Homo sapiens	133-153
8384443-10	1993	From studies with inhibitors of membrane 5"-nucleotidase and of S-adenosylhomocysteine hydrolase, it was deduced that adenosine is produced by the latter enzyme and by cytosolic 5"-nucleotidase in normoxia, and by cytosolic and membrane 5"-nucleotidases in anoxia.	Adenosine	118-127	5'-nucleotidase ecto	Homo sapiens	41-56
8384443-10	1993	From studies with inhibitors of membrane 5"-nucleotidase and of S-adenosylhomocysteine hydrolase, it was deduced that adenosine is produced by the latter enzyme and by cytosolic 5"-nucleotidase in normoxia, and by cytosolic and membrane 5"-nucleotidases in anoxia.	Adenosine	118-127	5'-nucleotidase ecto	Homo sapiens	178-193
8456951-6	1993	Then we focus on the ecto-5"-nucleotidase, which seems to represent the major source of extracellular adenosine in the kidney; that enzyme is present in tubular luminal membranes, in fibroblasts, and in mesangial cells.	Adenosine	102-111	5'-nucleotidase ecto	Homo sapiens	21-41
7678737-3	1993	Here we demonstrate that incubation of 3T3 adipocytes with the novel sulphonylurea, glimepiride, causes a time- and concentration-dependent release of the glycosylphosphatidylinositol (GPI)-anchored ecto-proteins, 5"-nucleotidase, lipoprotein lipase and a 62 kDa cyclic AMP (cAMP)-binding protein from the plasma membrane into the culture medium.	Sulfonylurea Compounds	69-82	5'-nucleotidase ecto	Homo sapiens	214-229
8261102-1	1993	The adenosine-producing ectoenzyme 5"-nucleotidase has recently been shown to undergo a marked redistribution during development of the cat visual cortex and to be involved in the remodelling of ocular dominance columns (Schoen et al., J. Comp.	Adenosine	4-13	5'-nucleotidase ecto	Homo sapiens	35-50
8450671-13	1993	We conclude that these differences plus a lower content of low Km 5"-nucleotidase in T-cells may account for the decreased ability of T-lymphoblasts to dephosphorylate nucleotides and may contribute to the selective cytotoxicity of deoxyribonucleosides for T-lymphoblasts as compared to B-lymphoblasts.	Deoxyribonucleosides	232-252	5'-nucleotidase ecto	Homo sapiens	66-81
8381105-3	1993	In the presence of an inhibitor of ecto-5"-nucleotidase [alpha, beta-methylene-adenosine 5"-diphosphate (ADP), 0.5 mM], exposure to xanthine oxidase and hypoxanthine resulted in the appearance of three times more nucleotides in the culture medium than in the absence of the inhibitor, but there was no change in medium nucleotides after H2O2 exposure.	SCHEMBL3677036	69-103	5'-nucleotidase ecto	Homo sapiens	35-55
8381105-3	1993	In the presence of an inhibitor of ecto-5"-nucleotidase [alpha, beta-methylene-adenosine 5"-diphosphate (ADP), 0.5 mM], exposure to xanthine oxidase and hypoxanthine resulted in the appearance of three times more nucleotides in the culture medium than in the absence of the inhibitor, but there was no change in medium nucleotides after H2O2 exposure.	Adenosine Diphosphate	105-108	5'-nucleotidase ecto	Homo sapiens	35-55
8381105-3	1993	In the presence of an inhibitor of ecto-5"-nucleotidase [alpha, beta-methylene-adenosine 5"-diphosphate (ADP), 0.5 mM], exposure to xanthine oxidase and hypoxanthine resulted in the appearance of three times more nucleotides in the culture medium than in the absence of the inhibitor, but there was no change in medium nucleotides after H2O2 exposure.	Hypoxanthine	153-165	5'-nucleotidase ecto	Homo sapiens	35-55
8381105-3	1993	In the presence of an inhibitor of ecto-5"-nucleotidase [alpha, beta-methylene-adenosine 5"-diphosphate (ADP), 0.5 mM], exposure to xanthine oxidase and hypoxanthine resulted in the appearance of three times more nucleotides in the culture medium than in the absence of the inhibitor, but there was no change in medium nucleotides after H2O2 exposure.	Hydrogen Peroxide	337-341	5'-nucleotidase ecto	Homo sapiens	35-55
7678737-3	1993	Here we demonstrate that incubation of 3T3 adipocytes with the novel sulphonylurea, glimepiride, causes a time- and concentration-dependent release of the glycosylphosphatidylinositol (GPI)-anchored ecto-proteins, 5"-nucleotidase, lipoprotein lipase and a 62 kDa cyclic AMP (cAMP)-binding protein from the plasma membrane into the culture medium.	glimepiride	84-95	5'-nucleotidase ecto	Homo sapiens	214-229
7678737-3	1993	Here we demonstrate that incubation of 3T3 adipocytes with the novel sulphonylurea, glimepiride, causes a time- and concentration-dependent release of the glycosylphosphatidylinositol (GPI)-anchored ecto-proteins, 5"-nucleotidase, lipoprotein lipase and a 62 kDa cyclic AMP (cAMP)-binding protein from the plasma membrane into the culture medium.	Glycosylphosphatidylinositols	185-188	5'-nucleotidase ecto	Homo sapiens	214-229
8417143-3	1993	The ecto-5"-nucleotidase (EC 3.1.3.5) had a Km of 21 microM, was inhibited by AMPPNP and alpha,beta-methylene ADP, and by a specific antiserum.	Adenylyl Imidodiphosphate	78-84	5'-nucleotidase ecto	Homo sapiens	4-24
8384527-2	1993	It is produced by the enzymatic dephosphorylation of 5"-AMP by 5"-nucleotidase and the hydrolysis of SAH by SAH-hydrolase.	Adenosine Monophosphate	53-59	5'-nucleotidase ecto	Homo sapiens	63-78
8384527-3	1993	5"-Nucleotidase is thought to contribute to adenosine production aside from the accumulation of 5"-AMP in the ischaemic myocardium, while the hydrolysis of SAH plays a major role in adenosine production in the normoxic myocardium.	Adenosine	44-53	5'-nucleotidase ecto	Homo sapiens	0-15
8384527-4	1993	5"-Nucleotidase activity is reported to increase adenosine production through accumulation of ATP, ADP, H+, Mg2+ and inorganic phosphate during ischaemia.	Adenosine	49-58	5'-nucleotidase ecto	Homo sapiens	0-15
8384527-4	1993	5"-Nucleotidase activity is reported to increase adenosine production through accumulation of ATP, ADP, H+, Mg2+ and inorganic phosphate during ischaemia.	Adenosine Triphosphate	94-97	5'-nucleotidase ecto	Homo sapiens	0-15
8384527-4	1993	5"-Nucleotidase activity is reported to increase adenosine production through accumulation of ATP, ADP, H+, Mg2+ and inorganic phosphate during ischaemia.	Adenosine Diphosphate	99-102	5'-nucleotidase ecto	Homo sapiens	0-15
8384527-4	1993	5"-Nucleotidase activity is reported to increase adenosine production through accumulation of ATP, ADP, H+, Mg2+ and inorganic phosphate during ischaemia.	magnesium ion	108-112	5'-nucleotidase ecto	Homo sapiens	0-15
8384527-4	1993	5"-Nucleotidase activity is reported to increase adenosine production through accumulation of ATP, ADP, H+, Mg2+ and inorganic phosphate during ischaemia.	Phosphates	117-136	5'-nucleotidase ecto	Homo sapiens	0-15
8417143-6	1993	The intraterminal 5"-nucleotidase enzyme, which amounted to 40% of the total 5"-nucleotidase activity, was inhibited by AMPPNP, alpha,beta-methylene ADP, and the antiserum, and also had the same kinetic properties as the ectoenzyme.	alpha,beta-methyleneadenosine 5'-diphosphate	128-152	5'-nucleotidase ecto	Homo sapiens	18-33
8417143-6	1993	The intraterminal 5"-nucleotidase enzyme, which amounted to 40% of the total 5"-nucleotidase activity, was inhibited by AMPPNP, alpha,beta-methylene ADP, and the antiserum, and also had the same kinetic properties as the ectoenzyme.	alpha,beta-methyleneadenosine 5'-diphosphate	128-152	5'-nucleotidase ecto	Homo sapiens	77-92
8417143-8	1993	The delay in adenosine production was proportional to the initial ATP concentration, was a consequence of feedforward inhibition of the ADPase and 5"-nucleotidase, and was inversely proportional to the ecto-5"-nucleotidase activity.	Adenosine	13-22	5'-nucleotidase ecto	Homo sapiens	147-162
8417143-3	1993	The ecto-5"-nucleotidase (EC 3.1.3.5) had a Km of 21 microM, was inhibited by AMPPNP and alpha,beta-methylene ADP, and by a specific antiserum.	alpha,beta-methyleneadenosine 5'-diphosphate	89-113	5'-nucleotidase ecto	Homo sapiens	4-24
8417143-8	1993	The delay in adenosine production was proportional to the initial ATP concentration, was a consequence of feedforward inhibition of the ADPase and 5"-nucleotidase, and was inversely proportional to the ecto-5"-nucleotidase activity.	Adenosine	13-22	5'-nucleotidase ecto	Homo sapiens	202-222
8417143-9	1993	The function and characteristics of this pathway and the central role of 5"-nucleotidase in the regulation of extraterminal adenosine concentrations are discussed.	Adenosine	124-133	5'-nucleotidase ecto	Homo sapiens	73-88
8417143-6	1993	The intraterminal 5"-nucleotidase enzyme, which amounted to 40% of the total 5"-nucleotidase activity, was inhibited by AMPPNP, alpha,beta-methylene ADP, and the antiserum, and also had the same kinetic properties as the ectoenzyme.	Adenylyl Imidodiphosphate	120-126	5'-nucleotidase ecto	Homo sapiens	18-33
8417143-6	1993	The intraterminal 5"-nucleotidase enzyme, which amounted to 40% of the total 5"-nucleotidase activity, was inhibited by AMPPNP, alpha,beta-methylene ADP, and the antiserum, and also had the same kinetic properties as the ectoenzyme.	Adenylyl Imidodiphosphate	120-126	5'-nucleotidase ecto	Homo sapiens	77-92
1445204-10	1992	The control patterns of these five fluxes indicate that, in the presence of extracellular adenosine and inosine, the intracellular metabolism of adenine derivatives would be highly dependent on the extracellular and intracellular concentrations of both nucleosides, on the ectoenzymes (5"-nucleotidase and adenosine deaminase) and on the transporter.	Nucleosides	253-264	5'-nucleotidase ecto	Homo sapiens	286-301
1445204-8	1992	Control analyses are reported which show that the fluxes towards intracellular adenine nucleosides are controlled by ecto-5"-nucleotidase in some circumstances and by the nucleoside transporters in others.	Adenosine	79-98	5'-nucleotidase ecto	Homo sapiens	117-137
1445204-10	1992	The control patterns of these five fluxes indicate that, in the presence of extracellular adenosine and inosine, the intracellular metabolism of adenine derivatives would be highly dependent on the extracellular and intracellular concentrations of both nucleosides, on the ectoenzymes (5"-nucleotidase and adenosine deaminase) and on the transporter.	Adenosine	90-99	5'-nucleotidase ecto	Homo sapiens	286-301
8093816-8	1993	A decrease in alpha-linolenic series acids in the membranes results in a 40% reduction in the Na-K-ATPase of nerve terminals and a 20% reduction in 5"-nucleotidase.	alpha-linolenic series acids	14-42	5'-nucleotidase ecto	Homo sapiens	148-163
1383219-2	1992	5"-Nucleotidase catalyzed the phosphorylation of (-)-carbovir, which is active against HIV (human immunodeficiency virus), but did not phosphorylate (+)-carbovir.	carbovir	49-61	5'-nucleotidase ecto	Homo sapiens	0-15
1318110-12	1992	Ecto-5"-nucleotidase activity results in the production of adenosine, which acts on mesangial cells through A1 and A2 receptors.	Adenosine	59-68	5'-nucleotidase ecto	Homo sapiens	0-20
1333499-6	1992	5"-nucleotidase activity was significantly elevated only after a 24-hour exposure to Triol, whereas there was no change in angiotensin-converting enzyme (ACE) activity in response to 20 microM Triol treatment at any time studied.	triol	85-90	5'-nucleotidase ecto	Homo sapiens	0-15
1430786-0	1992	A novel non-radioactive method for detection of nucleoside analog phosphorylation by 5"-nucleotidase.	Nucleosides	48-58	5'-nucleotidase ecto	Homo sapiens	85-100
1430786-1	1992	Cytosolic 5"-nucleotidase has been implicated in the phosphorylation of certain nucleosides of therapeutic interest.	Nucleosides	80-91	5'-nucleotidase ecto	Homo sapiens	10-25
1644065-4	1992	Furthermore, PTN108, PTN124, and PTN514 reduced the 5"-nucleotidase AMPase activity in contrast to PTN63 having no inhibitory effect.	ptn108	13-19	5'-nucleotidase ecto	Homo sapiens	52-67
1644065-4	1992	Furthermore, PTN108, PTN124, and PTN514 reduced the 5"-nucleotidase AMPase activity in contrast to PTN63 having no inhibitory effect.	ptn124	21-27	5'-nucleotidase ecto	Homo sapiens	52-67
1644065-4	1992	Furthermore, PTN108, PTN124, and PTN514 reduced the 5"-nucleotidase AMPase activity in contrast to PTN63 having no inhibitory effect.	ptn514	33-39	5'-nucleotidase ecto	Homo sapiens	52-67
1445204-10	1992	The control patterns of these five fluxes indicate that, in the presence of extracellular adenosine and inosine, the intracellular metabolism of adenine derivatives would be highly dependent on the extracellular and intracellular concentrations of both nucleosides, on the ectoenzymes (5"-nucleotidase and adenosine deaminase) and on the transporter.	Inosine	104-111	5'-nucleotidase ecto	Homo sapiens	286-301
1445204-10	1992	The control patterns of these five fluxes indicate that, in the presence of extracellular adenosine and inosine, the intracellular metabolism of adenine derivatives would be highly dependent on the extracellular and intracellular concentrations of both nucleosides, on the ectoenzymes (5"-nucleotidase and adenosine deaminase) and on the transporter.	Adenine	145-152	5'-nucleotidase ecto	Homo sapiens	286-301
1335121-1	1992	The hydrolysis of 5"-phosphonates of 2"-deoxythymidine and its 3"-modified analogs, inhibiting the HIV reproduction, by the E. coli alkaline, calf intestine and human placenta phosphatases as well as by the Crotalus atrox venom 5"-nucleotidase were studied.	5"-phosphonates	18-33	5'-nucleotidase ecto	Homo sapiens	228-243
1335121-1	1992	The hydrolysis of 5"-phosphonates of 2"-deoxythymidine and its 3"-modified analogs, inhibiting the HIV reproduction, by the E. coli alkaline, calf intestine and human placenta phosphatases as well as by the Crotalus atrox venom 5"-nucleotidase were studied.	Thymidine	37-54	5'-nucleotidase ecto	Homo sapiens	228-243
1335121-3	1992	The nucleotide derivatives modified at the phosphate residue were not hydrolyzed by any of the phosphatases studied except for the cobra venom 5"-nucleotidase, the effectiveness of the latter depended on the substitutes at both phosphate and sugar residues.	Sugars	242-247	5'-nucleotidase ecto	Homo sapiens	143-158
1430786-3	1992	Existing assays for nucleoside phosphorylation effected by 5"-nucleotidase require a radiolabeled nucleoside as the phosphate acceptor and separation of the substrate-nucleoside from product-nucleotide has been accomplished either by a filter binding method or HPLC.	Nucleosides	20-30	5'-nucleotidase ecto	Homo sapiens	59-74
1430786-3	1992	Existing assays for nucleoside phosphorylation effected by 5"-nucleotidase require a radiolabeled nucleoside as the phosphate acceptor and separation of the substrate-nucleoside from product-nucleotide has been accomplished either by a filter binding method or HPLC.	Nucleosides	98-108	5'-nucleotidase ecto	Homo sapiens	59-74
1430786-3	1992	Existing assays for nucleoside phosphorylation effected by 5"-nucleotidase require a radiolabeled nucleoside as the phosphate acceptor and separation of the substrate-nucleoside from product-nucleotide has been accomplished either by a filter binding method or HPLC.	Phosphates	116-125	5'-nucleotidase ecto	Homo sapiens	59-74
1430786-3	1992	Existing assays for nucleoside phosphorylation effected by 5"-nucleotidase require a radiolabeled nucleoside as the phosphate acceptor and separation of the substrate-nucleoside from product-nucleotide has been accomplished either by a filter binding method or HPLC.	Nucleosides	98-108	5'-nucleotidase ecto	Homo sapiens	59-74
1430786-6	1992	Using this procedure, a 5"-nucleotidase activity from the 100,000 x g supernatant fraction of human T-lymphoblasts deficient in adenosine kinase, hypoxanthine-guanine phosphoribosyltransferase, and deoxycytidine kinase, was characterized with regard to structure-activity relationships for certain inosine and guanosine analogs.	Inosine	298-305	5'-nucleotidase ecto	Homo sapiens	24-39
1430786-6	1992	Using this procedure, a 5"-nucleotidase activity from the 100,000 x g supernatant fraction of human T-lymphoblasts deficient in adenosine kinase, hypoxanthine-guanine phosphoribosyltransferase, and deoxycytidine kinase, was characterized with regard to structure-activity relationships for certain inosine and guanosine analogs.	Guanosine	310-319	5'-nucleotidase ecto	Homo sapiens	24-39
1330052-2	1992	This effect was maximal at physiological hormone concentrations, being 36% and 17% for 5"-nucleotidase and alkaline phosphatase respectively, and was fully mimicked by the phosphatidylinositol specific phospholipase C (PI-PLC), thus confirming the presence of a glycosylphosphatidylinositol anchoring-system for these exofacial enzymatic proteins.	Phosphatidylinositols	172-192	5'-nucleotidase ecto	Homo sapiens	87-102
1330052-2	1992	This effect was maximal at physiological hormone concentrations, being 36% and 17% for 5"-nucleotidase and alkaline phosphatase respectively, and was fully mimicked by the phosphatidylinositol specific phospholipase C (PI-PLC), thus confirming the presence of a glycosylphosphatidylinositol anchoring-system for these exofacial enzymatic proteins.	Glycosylphosphatidylinositols	262-290	5'-nucleotidase ecto	Homo sapiens	87-102
1557611-2	1992	Interleukin-4 (IL-4) and interferon-gamma (IFN-gamma) decreased the level of ecto-5"-NT activity on BMC whereas prostaglandin E2 (PGE2) increased the ecto-5"-NT level.	bmc	100-103	5'-nucleotidase ecto	Homo sapiens	77-87
1557611-2	1992	Interleukin-4 (IL-4) and interferon-gamma (IFN-gamma) decreased the level of ecto-5"-NT activity on BMC whereas prostaglandin E2 (PGE2) increased the ecto-5"-NT level.	Dinoprostone	112-128	5'-nucleotidase ecto	Homo sapiens	150-160
1535254-1	1992	Ecto-5"-nucleotidase (ecto-5"-NUC, EC 3.1.3.5., CD73) is a plasma membrane enzyme, which catalyzes the hydrolytic dephosphorylation of purine nucleotides to the corresponding nucleosides so that they can pass through the plasma membrane.	purine	135-141	5'-nucleotidase ecto	Homo sapiens	0-20
1557611-2	1992	Interleukin-4 (IL-4) and interferon-gamma (IFN-gamma) decreased the level of ecto-5"-NT activity on BMC whereas prostaglandin E2 (PGE2) increased the ecto-5"-NT level.	Dinoprostone	130-134	5'-nucleotidase ecto	Homo sapiens	150-160
1557611-6	1992	These data indicate that immunomodulators may also take part in the regulation of ecto-5"-NT activity on BMC in vivo.	bmc	105-108	5'-nucleotidase ecto	Homo sapiens	82-92
1557611-7	1992	BMC from 7 patients with different immunodeficiency syndromes showed decreased ecto-5"-NT activity on freshly isolated cells.	bmc	0-3	5'-nucleotidase ecto	Homo sapiens	79-89
1557611-8	1992	However, following culture ecto-5"-NT activity was increased above the level found on freshly isolated BMC from healthy persons.	bmc	103-106	5'-nucleotidase ecto	Homo sapiens	27-37
1557611-9	1992	On BMC from 3 patients with hypogammaglobulinaemia, the effect of IL-4 on the level of ecto-5"-NT activity was identical to that found on BMC from healthy donors, whereas PGE2 increased ecto-5"-NT activity on BMC from only 1 of the 3 patients investigated.	Dinoprostone	171-175	5'-nucleotidase ecto	Homo sapiens	186-196
1557611-10	1992	The decreased ecto-5"-NT activity of BMC from patients with immunodeficiency may thus be due to a defective regulation of ecto-5"-NT activity in vivo.	bmc	37-40	5'-nucleotidase ecto	Homo sapiens	14-24
1557611-10	1992	The decreased ecto-5"-NT activity of BMC from patients with immunodeficiency may thus be due to a defective regulation of ecto-5"-NT activity in vivo.	bmc	37-40	5'-nucleotidase ecto	Homo sapiens	122-132
1601953-1	1992	The enzyme 5"-nucleotidase (5"-ribonucleotide phosphohydrolase, EC 3.1.3.5) catalyzes a critical reaction in intermediary metabolism, the phosphohydrolysis of nucleoside 5"-monophosphates to their corresponding nucleosides.	nucleoside 5"-monophosphates	159-187	5'-nucleotidase ecto	Homo sapiens	11-26
1601953-1	1992	The enzyme 5"-nucleotidase (5"-ribonucleotide phosphohydrolase, EC 3.1.3.5) catalyzes a critical reaction in intermediary metabolism, the phosphohydrolysis of nucleoside 5"-monophosphates to their corresponding nucleosides.	Nucleosides	211-222	5'-nucleotidase ecto	Homo sapiens	11-26
1636491-10	1992	A decrease in alpha-linolenic series acids in the membranes results in a 40% reduction in the Na(+)-K(+)-ATPase of nerve terminals and a 20% reduction in 5"-nucleotidase.	alpha-linolenic series acids	14-42	5'-nucleotidase ecto	Homo sapiens	154-169
1535254-1	1992	Ecto-5"-nucleotidase (ecto-5"-NUC, EC 3.1.3.5., CD73) is a plasma membrane enzyme, which catalyzes the hydrolytic dephosphorylation of purine nucleotides to the corresponding nucleosides so that they can pass through the plasma membrane.	purine	135-141	5'-nucleotidase ecto	Homo sapiens	22-33
1535254-1	1992	Ecto-5"-nucleotidase (ecto-5"-NUC, EC 3.1.3.5., CD73) is a plasma membrane enzyme, which catalyzes the hydrolytic dephosphorylation of purine nucleotides to the corresponding nucleosides so that they can pass through the plasma membrane.	purine	135-141	5'-nucleotidase ecto	Homo sapiens	48-52
1535254-1	1992	Ecto-5"-nucleotidase (ecto-5"-NUC, EC 3.1.3.5., CD73) is a plasma membrane enzyme, which catalyzes the hydrolytic dephosphorylation of purine nucleotides to the corresponding nucleosides so that they can pass through the plasma membrane.	Nucleosides	175-186	5'-nucleotidase ecto	Homo sapiens	0-20
1535254-1	1992	Ecto-5"-nucleotidase (ecto-5"-NUC, EC 3.1.3.5., CD73) is a plasma membrane enzyme, which catalyzes the hydrolytic dephosphorylation of purine nucleotides to the corresponding nucleosides so that they can pass through the plasma membrane.	Nucleosides	175-186	5'-nucleotidase ecto	Homo sapiens	22-33
1535254-1	1992	Ecto-5"-nucleotidase (ecto-5"-NUC, EC 3.1.3.5., CD73) is a plasma membrane enzyme, which catalyzes the hydrolytic dephosphorylation of purine nucleotides to the corresponding nucleosides so that they can pass through the plasma membrane.	Nucleosides	175-186	5'-nucleotidase ecto	Homo sapiens	48-52
1659319-1	1991	A cytosolic 5"-nucleotidase, acting preferentially on IMP and GMP, has been isolated from human colon carcinoma extracts.	Inosine Monophosphate	54-57	5'-nucleotidase ecto	Homo sapiens	12-27
1765099-10	1991	5"-nucleotidase isolated from Torpedo electric organ hydrolyzes UDP-glucose at 8% of the rate of AMP hydrolysis.	Uridine Diphosphate Glucose	64-75	5'-nucleotidase ecto	Homo sapiens	0-15
1765099-10	1991	5"-nucleotidase isolated from Torpedo electric organ hydrolyzes UDP-glucose at 8% of the rate of AMP hydrolysis.	Adenosine Monophosphate	97-100	5'-nucleotidase ecto	Homo sapiens	0-15
1659319-1	1991	A cytosolic 5"-nucleotidase, acting preferentially on IMP and GMP, has been isolated from human colon carcinoma extracts.	guanosine 5'-monophosphorothioate	62-65	5'-nucleotidase ecto	Homo sapiens	12-27
1954233-3	1991	Sodium dodecyl sulphate polyacrylamide gel electrophoresis of purified low Km 5"-nucleotidase revealed a single polypeptide band of 40 +/- 7 kDa and a tetrameric structure of 160 +/- 10 kDa has been proposed for the native enzyme.	Sodium Dodecyl Sulfate	0-23	5'-nucleotidase ecto	Homo sapiens	78-93
1954233-3	1991	Sodium dodecyl sulphate polyacrylamide gel electrophoresis of purified low Km 5"-nucleotidase revealed a single polypeptide band of 40 +/- 7 kDa and a tetrameric structure of 160 +/- 10 kDa has been proposed for the native enzyme.	polyacrylamide	24-38	5'-nucleotidase ecto	Homo sapiens	78-93
1954233-4	1991	The kinetic properties of low Km 5"-nucleotidase have been determined and rather unique characteristics have been found for this soluble low Km 5"-nucleotidase: the substrate efficiency was slightly higher for IMP with an optimum pH at 7.5; the enzyme showed an absolute dependence on Mg2+ ions.	magnesium ion	285-289	5'-nucleotidase ecto	Homo sapiens	33-48
1954233-4	1991	The kinetic properties of low Km 5"-nucleotidase have been determined and rather unique characteristics have been found for this soluble low Km 5"-nucleotidase: the substrate efficiency was slightly higher for IMP with an optimum pH at 7.5; the enzyme showed an absolute dependence on Mg2+ ions.	magnesium ion	285-289	5'-nucleotidase ecto	Homo sapiens	144-159
1654107-13	1991	Finally, the AMPase activity of 5"-nucleotidase from human seminal plasma is not affected by dithiothreitol which, on the contrary, is a powerful inhibitor of the bovine enzyme causing the dissociation of its subunits which are held together by disulphide bridges (Fini, C., Minelli, A., Camici, M. and Floridi, A.	disulphide	245-255	5'-nucleotidase ecto	Homo sapiens	32-47
1832463-7	1991	In the presence of BWA1433U and a continuous intralobar infusion of the selective 5"-nucleotidase inhibitor, alpha,beta-methyleneadenosine-5"-diphosphate, ATP VC responses are significantly enhanced compared to those after BWA1433U.	BW A1433U	19-27	5'-nucleotidase ecto	Homo sapiens	82-97
1832463-7	1991	In the presence of BWA1433U and a continuous intralobar infusion of the selective 5"-nucleotidase inhibitor, alpha,beta-methyleneadenosine-5"-diphosphate, ATP VC responses are significantly enhanced compared to those after BWA1433U.	alpha,beta-methyleneadenosine 5'-diphosphate	109-153	5'-nucleotidase ecto	Homo sapiens	82-97
1832463-7	1991	In the presence of BWA1433U and a continuous intralobar infusion of the selective 5"-nucleotidase inhibitor, alpha,beta-methyleneadenosine-5"-diphosphate, ATP VC responses are significantly enhanced compared to those after BWA1433U.	BW A1433U	223-231	5'-nucleotidase ecto	Homo sapiens	82-97
1656202-6	1991	After phorbol myristate acetate (PMA)-cell stimulation, cytochrome b was mobilized to fractions showing respiratory burst activity and enriched in 5"-nucleotidase activity.	Tetradecanoylphorbol Acetate	33-36	5'-nucleotidase ecto	Homo sapiens	147-162
1776109-1	1991	5"-Nucleotidase is a degrading purine ectoenzyme acting at alkaline pH.	purine	31-37	5'-nucleotidase ecto	Homo sapiens	0-15
1867645-7	1991	5"-Nucleotidase activities with TMP as substrate were 428.9 +/- 37.8 and 255.9 +/- 28.7 pmol/mg protein/min in H9 and H9-AZT cells, respectively.	Thymidine Monophosphate	32-35	5'-nucleotidase ecto	Homo sapiens	0-15
2040089-1	1991	A procedure is proposed for the separation of multiple forms of 5"-nucleotidase (EC 3.1.3.5) by cellulose acetate electrophoresis.	acetylcellulose	96-113	5'-nucleotidase ecto	Homo sapiens	64-79
2040089-2	1991	The effects of various treatments (wheat-germ lectin, neuraminidase, n-butanol, papain, Triton X-100 and precipitation of LDL and VLDL) on the electrophoretic pattern of 5"-nucleotidase and alkaline phosphatase were studied.	1-Butanol	69-78	5'-nucleotidase ecto	Homo sapiens	170-185
2040089-2	1991	The effects of various treatments (wheat-germ lectin, neuraminidase, n-butanol, papain, Triton X-100 and precipitation of LDL and VLDL) on the electrophoretic pattern of 5"-nucleotidase and alkaline phosphatase were studied.	Octoxynol	88-100	5'-nucleotidase ecto	Homo sapiens	170-185
1781360-0	1991	Studies on the structure and biosynthesis of the phosphatidyl-inositol-glycan anchor and the carbohydrate side chains of human placental ecto-5"-nucleotidase.	Carbohydrates	93-105	5'-nucleotidase ecto	Homo sapiens	137-157
1998727-2	1991	Sodium dodecyl sulphate polyacrylamide gel electrophoresis of purified 5"-nucleotidase revealed a single polypeptide band of 67 kDa.	Sodium Dodecyl Sulfate	0-23	5'-nucleotidase ecto	Homo sapiens	71-86
1998727-2	1991	Sodium dodecyl sulphate polyacrylamide gel electrophoresis of purified 5"-nucleotidase revealed a single polypeptide band of 67 kDa.	polyacrylamide	24-38	5'-nucleotidase ecto	Homo sapiens	71-86
1998727-6	1991	Adenosine 5"-[alpha,beta-methylene]diphosphate is a competitive inhibitor of 5"-nucleotidase, whereas concanavalin A inhibits the enzymatic activity in a non-competitive manner.	alpha,beta-methyleneadenosine 5'-diphosphate	0-46	5'-nucleotidase ecto	Homo sapiens	77-92
1989648-1	1991	Ecto-5"-nucleotidase (ecto-5"-NT) is a phosphatidylinositol anchored membrane structure recently defined as the lymphocyte differentiation antigen CD73.	Phosphatidylinositols	39-59	5'-nucleotidase ecto	Homo sapiens	0-20
1989648-1	1991	Ecto-5"-nucleotidase (ecto-5"-NT) is a phosphatidylinositol anchored membrane structure recently defined as the lymphocyte differentiation antigen CD73.	Phosphatidylinositols	39-59	5'-nucleotidase ecto	Homo sapiens	147-151
1995064-0	1991	Deoxyadenosine-resistant human T lymphoblasts with elevated 5"-nucleotidase activity.	2'-deoxyadenosine	0-14	5'-nucleotidase ecto	Homo sapiens	60-75
1995064-3	1991	Compared to parental CEM cells, the variant had 4-fold elevated ATP-activated cytosolic 5"-nucleotidase activity.	Adenosine Triphosphate	64-67	5'-nucleotidase ecto	Homo sapiens	88-103
1995064-5	1991	In medium supplemented with the adenosine deaminase inhibitor deoxycoformycin, the T cells with increased 5"-nucleotidase accumulated less nucleotides from exogenously added deoxyadenosine, or 9-beta-D-arabinofuranosyladenine, than did parental T lymphocytes.	Pentostatin	62-77	5'-nucleotidase ecto	Homo sapiens	106-121
1995064-5	1991	In medium supplemented with the adenosine deaminase inhibitor deoxycoformycin, the T cells with increased 5"-nucleotidase accumulated less nucleotides from exogenously added deoxyadenosine, or 9-beta-D-arabinofuranosyladenine, than did parental T lymphocytes.	2'-deoxyadenosine	174-188	5'-nucleotidase ecto	Homo sapiens	106-121
1995064-7	1991	The T cells with elevated 5"-nucleotidase activity formed more 2",3"-dideoxyadenosine than did parental cells, in deoxycoformycin-supplemented medium.	Dideoxyadenosine	63-85	5'-nucleotidase ecto	Homo sapiens	26-41
1995064-7	1991	The T cells with elevated 5"-nucleotidase activity formed more 2",3"-dideoxyadenosine than did parental cells, in deoxycoformycin-supplemented medium.	Pentostatin	114-129	5'-nucleotidase ecto	Homo sapiens	26-41
1995064-9	1991	These data establish the importance of the cytosolic 5"-nucleotidase for the metabolism of purine 2"-deoxyribonucleosides, arabinonucleosides and 2",3"-dideoxyribonucleosides in T lymphoblasts.	purine	91-97	5'-nucleotidase ecto	Homo sapiens	53-68
1995064-9	1991	These data establish the importance of the cytosolic 5"-nucleotidase for the metabolism of purine 2"-deoxyribonucleosides, arabinonucleosides and 2",3"-dideoxyribonucleosides in T lymphoblasts.	2"-deoxyribonucleosides	98-121	5'-nucleotidase ecto	Homo sapiens	53-68
1995064-9	1991	These data establish the importance of the cytosolic 5"-nucleotidase for the metabolism of purine 2"-deoxyribonucleosides, arabinonucleosides and 2",3"-dideoxyribonucleosides in T lymphoblasts.	Arabinonucleosides	123-141	5'-nucleotidase ecto	Homo sapiens	53-68
1995064-9	1991	These data establish the importance of the cytosolic 5"-nucleotidase for the metabolism of purine 2"-deoxyribonucleosides, arabinonucleosides and 2",3"-dideoxyribonucleosides in T lymphoblasts.	2",3"-dideoxyribonucleosides	146-174	5'-nucleotidase ecto	Homo sapiens	53-68
27463204-2	1991	This occurs because of the accumulation of deoxyadenine nucleotides in cells with high deoxycytidine kinase and low 5"-nucleotidase activity.	Deoxyadenine Nucleotides	43-67	5'-nucleotidase ecto	Homo sapiens	116-131
1849846-0	1991	Determination of cytoplasmic 5"-nucleotidase which preferentially hydrolyses 6-hydroxypurine nucleotides in pig, rat and human tissues by immunotitration.	6-hydroxypurine nucleotides	77-104	5'-nucleotidase ecto	Homo sapiens	29-44
27463204-3	1991	2-Chlorodeoxyadenosine (2-CdA) resists the action of adenosine deaminase and accumulates in cells with high deoxycytidine kinase and low 5"-nucleotidase activity.	Cladribine	0-22	5'-nucleotidase ecto	Homo sapiens	137-152
2173922-1	1990	Three forms of 5"-nucleotidase purified from human placenta (two membrane-bound forms, one sensitive and one resistant to cleavage by phosphatidylinositol-specific phospholipase C, as well as a soluble form) had the same molecular weight before (73,000 Da) and after (56,000 Da) digestion with N-glycosidase F and showed similar amino acid compositions, N-terminal amino acid sequences, and KMs for IMP (9.6 to 11.9 microM).	Phosphatidylinositols	134-154	5'-nucleotidase ecto	Homo sapiens	15-30
1898656-8	1991	alpha, beta-Methyleneadenosine 5"-diphosphate (AMPCP, 2.5 mM), an inhibitor of membranous ecto-5"-nucleotidase, profoundly inhibited endogenous adenosine accumulation under all conditions.	alpha,beta-methyleneadenosine 5'-diphosphate	0-45	5'-nucleotidase ecto	Homo sapiens	90-110
1898656-8	1991	alpha, beta-Methyleneadenosine 5"-diphosphate (AMPCP, 2.5 mM), an inhibitor of membranous ecto-5"-nucleotidase, profoundly inhibited endogenous adenosine accumulation under all conditions.	alpha,beta-methyleneadenosine 5'-diphosphate	47-52	5'-nucleotidase ecto	Homo sapiens	90-110
1898656-8	1991	alpha, beta-Methyleneadenosine 5"-diphosphate (AMPCP, 2.5 mM), an inhibitor of membranous ecto-5"-nucleotidase, profoundly inhibited endogenous adenosine accumulation under all conditions.	Adenosine	21-30	5'-nucleotidase ecto	Homo sapiens	90-110
2173922-4	1990	Soluble 5"-nucleotidase contained a similar quantity of myo-inositol, suggesting that it was previously membrane-anchored via glycosyl phosphatidylinositol.	Inositol	56-68	5'-nucleotidase ecto	Homo sapiens	8-23
2173922-4	1990	Soluble 5"-nucleotidase contained a similar quantity of myo-inositol, suggesting that it was previously membrane-anchored via glycosyl phosphatidylinositol.	Glycosylphosphatidylinositols	126-155	5'-nucleotidase ecto	Homo sapiens	8-23
2173922-5	1990	The form resistant to phosphatidylinositol-specific phospholipase C contained less myo-inositol, leaving open the possibility of a third form of 5"-nucleotidase with a conventional transmembrane anchor.	Phosphatidylinositols	22-42	5'-nucleotidase ecto	Homo sapiens	145-160
2173922-5	1990	The form resistant to phosphatidylinositol-specific phospholipase C contained less myo-inositol, leaving open the possibility of a third form of 5"-nucleotidase with a conventional transmembrane anchor.	Inositol	83-95	5'-nucleotidase ecto	Homo sapiens	145-160
2271622-13	1990	36, 291-295] showed that a cytosolic 5"-nucleotidase catalyzes the activation of CBV to the monosphosphate.	carbovir	81-84	5'-nucleotidase ecto	Homo sapiens	37-52
2271622-13	1990	36, 291-295] showed that a cytosolic 5"-nucleotidase catalyzes the activation of CBV to the monosphosphate.	monosphosphate	92-106	5'-nucleotidase ecto	Homo sapiens	37-52
2271622-15	1990	The exact mechanism for this potentiation of CBV phosphorylation has not been elucidated but may be due to a modulating effect of intracellular nucleotides on 5"-nucleotidase activity.	carbovir	45-48	5'-nucleotidase ecto	Homo sapiens	159-174
1977386-4	1990	These results support the proposal that the initial phosphorylation of ddGuo is catalyzed by a phosphotransferase (5"-nucleotidase) which utilizes IMP as its phosphate donor (Johnson and Fridland, [1989] Molec.	2',3'-Dideoxyguanosine	71-76	5'-nucleotidase ecto	Homo sapiens	115-130
1975259-2	1990	Interaction of the glycosyl phosphatidylinositol-linked differentiation Ag CD73 (ecto-5"-nucleotidase) with the CD73-specific mAb 1E9 generates agonistic signals that strongly synergize with T cell activation induced by CD3 and CD2 mAb.	Glycosylphosphatidylinositols	19-48	5'-nucleotidase ecto	Homo sapiens	75-79
1975259-2	1990	Interaction of the glycosyl phosphatidylinositol-linked differentiation Ag CD73 (ecto-5"-nucleotidase) with the CD73-specific mAb 1E9 generates agonistic signals that strongly synergize with T cell activation induced by CD3 and CD2 mAb.	Glycosylphosphatidylinositols	19-48	5'-nucleotidase ecto	Homo sapiens	81-101
1975259-2	1990	Interaction of the glycosyl phosphatidylinositol-linked differentiation Ag CD73 (ecto-5"-nucleotidase) with the CD73-specific mAb 1E9 generates agonistic signals that strongly synergize with T cell activation induced by CD3 and CD2 mAb.	Glycosylphosphatidylinositols	19-48	5'-nucleotidase ecto	Homo sapiens	112-116
1975259-12	1990	Finally, the functional association between CD73 and integral membrane molecules like CD3 and CD2 suggests that GPI-anchored molecules may play a role in transmembrane signaling mediated by conventional second messenger systems.	Glycosylphosphatidylinositols	112-115	5'-nucleotidase ecto	Homo sapiens	44-48
1977386-4	1990	These results support the proposal that the initial phosphorylation of ddGuo is catalyzed by a phosphotransferase (5"-nucleotidase) which utilizes IMP as its phosphate donor (Johnson and Fridland, [1989] Molec.	Inosine Monophosphate	147-150	5'-nucleotidase ecto	Homo sapiens	115-130
1977386-4	1990	These results support the proposal that the initial phosphorylation of ddGuo is catalyzed by a phosphotransferase (5"-nucleotidase) which utilizes IMP as its phosphate donor (Johnson and Fridland, [1989] Molec.	Phosphates	158-167	5'-nucleotidase ecto	Homo sapiens	115-130
2128226-4	1990	A different level of 5"-nucleotidase activity has been found in two seminal plasmas: in bull 5"-nucleotidase represents 80% of the total AMP dephosphorylating enzymes while in man 5"-nucleotidase represents only 1.3% of the total AMP dephosphorylating activities.	Adenosine Monophosphate	230-233	5'-nucleotidase ecto	Homo sapiens	21-36
2129526-10	1990	Thus, it is concluded that the mature 5"-nucleotidase lacks the predicted COOH-terminal peptide extension (524-548), which has been replaced by the glycophospholipid functioning as the membrane anchor of 5"-nucleotidase.	glycophospholipid	148-165	5'-nucleotidase ecto	Homo sapiens	38-53
2129526-10	1990	Thus, it is concluded that the mature 5"-nucleotidase lacks the predicted COOH-terminal peptide extension (524-548), which has been replaced by the glycophospholipid functioning as the membrane anchor of 5"-nucleotidase.	glycophospholipid	148-165	5'-nucleotidase ecto	Homo sapiens	204-219
2231747-5	1990	This mainly lysosomal 5"-nucleotidase activity was 61% inhibited by the alpha,beta-methylene analog of ADP, indicating that although the latter has been considered specific to the plasma membrane enzyme, it also inhibits the lysosomal enzyme.	alpha,beta-methylene	72-92	5'-nucleotidase ecto	Homo sapiens	22-37
2231747-5	1990	This mainly lysosomal 5"-nucleotidase activity was 61% inhibited by the alpha,beta-methylene analog of ADP, indicating that although the latter has been considered specific to the plasma membrane enzyme, it also inhibits the lysosomal enzyme.	Adenosine Diphosphate	103-106	5'-nucleotidase ecto	Homo sapiens	22-37
2231747-6	1990	The intercellular distribution of 5"-nucleotidase was not studied, but the lack of this enzyme in the mitochondria indicate that the adenosine production observed during mitochondrial AMP production, e.g. during acetate oxidation in intact heart muscle, must involve AMP transport out from the mitochondria.	Adenosine	133-142	5'-nucleotidase ecto	Homo sapiens	34-49
2159757-6	1990	The phosphatidylinositol-specific phospholipase C released the ecto-5"-nucleotidase from the chromaffin cells in culture, thus suggesting an anchorage through phosphatidylinositol to plasma membranes.	Phosphatidylinositols	4-24	5'-nucleotidase ecto	Homo sapiens	63-83
2159757-6	1990	The phosphatidylinositol-specific phospholipase C released the ecto-5"-nucleotidase from the chromaffin cells in culture, thus suggesting an anchorage through phosphatidylinositol to plasma membranes.	chromaffin	93-103	5'-nucleotidase ecto	Homo sapiens	63-83
2159757-6	1990	The phosphatidylinositol-specific phospholipase C released the ecto-5"-nucleotidase from the chromaffin cells in culture, thus suggesting an anchorage through phosphatidylinositol to plasma membranes.	Phosphatidylinositols	159-179	5'-nucleotidase ecto	Homo sapiens	63-83
2140264-0	1990	Glycosylation and processing of carbohydrate side chains of ecto-5"-nucleotidase in cultured human chorionic cells.	Carbohydrates	32-44	5'-nucleotidase ecto	Homo sapiens	60-80
2140264-1	1990	Glycosylation and carbohydrate processing of ecto-5"-nucleotidase were studied in cultured human chorionic cells using metabolic labelling and immunoprecipitation with monoclonal antibodies.	Carbohydrates	18-30	5'-nucleotidase ecto	Homo sapiens	45-65
2140264-5	1990	It is calculated that, in addition to the phosphatidylinositol-glycan anchor structure, ecto-5"-nucleotidase of human chorionic cells should carry 4 oligosaccharide side chains per subunit, 3 of which should be of the complex and one of the high mannose type.	Oligosaccharides	149-164	5'-nucleotidase ecto	Homo sapiens	88-108
2140264-5	1990	It is calculated that, in addition to the phosphatidylinositol-glycan anchor structure, ecto-5"-nucleotidase of human chorionic cells should carry 4 oligosaccharide side chains per subunit, 3 of which should be of the complex and one of the high mannose type.	Mannose	246-253	5'-nucleotidase ecto	Homo sapiens	88-108
2130573-0	1990	Effect of phospholipids on thyroid 5"-nucleotidase.	Phospholipids	10-23	5'-nucleotidase ecto	Homo sapiens	35-50
2130573-3	1990	Arrhenius plot of the 5"-nucleotidase activity in native thyroid plasma membranes clearly exhibited a break at 28 degrees C. Biphasic nature of Arrhenius plot showed that the enzyme activity was influenced by physical state of membrane bilayer, although phospholipids were not obligatory cofactor for this enzyme.	Phospholipids	254-267	5'-nucleotidase ecto	Homo sapiens	22-37
2344353-0	1990	Partial purification and properties of an AMP-specific soluble 5"-nucleotidase from pigeon heart.	Adenosine Monophosphate	42-45	5'-nucleotidase ecto	Homo sapiens	63-78
2365589-4	1990	Incubations for NADH oxidase activity performed in the presence of exogenous catalase or in the absence of catalase or peroxidase inhibitors did not affect the staining intensity, whereas inhibitors of 5"-nucleotidase (EDTA) and non-specific alkaline phosphatase (levamisole) always did.	Edetic Acid	219-223	5'-nucleotidase ecto	Homo sapiens	202-217
2128226-4	1990	A different level of 5"-nucleotidase activity has been found in two seminal plasmas: in bull 5"-nucleotidase represents 80% of the total AMP dephosphorylating enzymes while in man 5"-nucleotidase represents only 1.3% of the total AMP dephosphorylating activities.	Adenosine Monophosphate	137-140	5'-nucleotidase ecto	Homo sapiens	21-36